Document

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

0001628280-18-014023.txt : 20181109 0001628280-18-014023.hdr.sgml : 20181109 20181108173847 ACCESSION NUMBER: 0001628280-18-014023 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181109 DATE AS OF CHANGE: 20181108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Regulus Therapeutics Inc. CENTRAL INDEX KEY: 0001505512 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264738379 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35670 FILM NUMBER: 181170824 BUSINESS ADDRESS: STREET 1: 10614 SCIENCE CENTER DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-202-6300 MAIL ADDRESS: STREET 1: 10614 SCIENCE CENTER DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 10-Q 1 rgls20180930-10q.htm 10-Q Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549



	FORM 10-Q

(Mark One)



x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2018



¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO

Commission file number: 001-35670



	Regulus Therapeutics Inc. (Exact name of registrant as specified in its charter)



Delaware		26-4738379
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

10614 Science Center Drive San Diego, CA		92121
(Address of Principal Executive Offices)		(Zip Code)

858-202-6300

(Registrant’s Telephone Number, Including Area Code)

___________________________________________________________

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No ý

As of November 2, 2018, the registrant had 8,750,343 shares of Common Stock ($0.001 par value) outstanding.

REGULUS THERAPEUTICS INC.

TABLE OF CONTENTS




PART I. FINANCIAL INFORMATION
Item 1. Financial Statements	3
Condensed Balance Sheets as of September 30, 2018 (Unaudited) and December 31, 2017	3
Condensed Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2018 and 2017 (Unaudited)	4
Condensed Statements of Cash Flows for the three and nine months ended September 30, 2018 and 2017 (Unaudited)	5
Notes to Condensed Financial Statements (Unaudited)	6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3. Quantitative and Qualitative Disclosures about Market Risk	25
Item 4. Controls and Procedures	25
PART II. OTHER INFORMATION
Item 1. Legal Proceedings	26
Item 1A. Risk Factors	26
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	52
Item 3. Defaults Upon Senior Securities	52
Item 4. Mine Safety Disclosures	52
Item 5. Other Information	52
Item 6. Exhibits	53

PART I. FINANCIAL INFORMATION


ITEM 1.	FINANCIAL STATEMENTS

Regulus Therapeutics Inc.

CONDENSED BALANCE SHEETS

(in thousands, except share and per share data)



	September 30, 2018			December 31, 2017
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	14,084		$	13,519
Short-term investments	6,433			46,555
Contract and other receivables	13			373
Prepaid materials, net	4,194			4,783
Prepaid expenses and other current assets	717			1,506
Total current assets	25,441			66,736
Property and equipment, net	8,324			9,708
Intangibles, net	676			775
Other assets	327			590
Total assets	$	34,768		$	77,809
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	1,235		$	5,743
Accrued liabilities	1,856			2,995
Accrued compensation	1,292			1,985
Current portion of term loan, less debt issuance costs	19,069			19,859
Current portion of contract liabilities	72			—
Other current liabilities	2,130			2,018
Total current liabilities	25,654			32,600
Contract liabilities, less current portion	24			1,921
Deferred rent, less current portion	7,139			8,072
Other long-term liabilities	373			—
Total liabilities	33,190			42,593
Commitments and Contingencies
Stockholders’ equity:
Common stock, $0.001 par value; 200,000,000 shares authorized, 8,750,343 and 8,662,435 shares issued and outstanding at September 30, 2018 (unaudited) and December 31, 2017, respectively	9			9
Additional paid-in capital	385,793			381,199
Accumulated other comprehensive loss	(63		)	(134		)
Accumulated deficit	(384,161		)	(345,858		)
Total stockholders’ equity	1,578			35,216
Total liabilities and stockholders’ equity	$	34,768		$	77,809

See accompanying notes to these condensed financial statements.

Regulus Therapeutics Inc.

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share data)



	Three months ended September 30,						Nine months ended September 30,
	2018			2017			2018			2017
	(Unaudited)
Revenues:
Revenue under strategic alliances and collaborations	$	18		$	18		$	54		$	54
Total revenues	18			18			54			54
Operating expenses:
Research and development	6,879			12,697			28,720			42,727
General and administrative	2,993			2,736			10,115			13,752
Total operating expenses	9,872			15,433			38,835			56,479
Loss from operations	(9,854		)	(15,415		)	(38,781		)	(56,425		)
Other income (expense):
Interest and other income	201			160			483			559
Interest and other expense	(620		)	(580		)	(1,848		)	(1,730		)
Loss before income taxes	(10,273		)	(15,835		)	(40,146		)	(57,596		)
Income tax benefit	—			7			—			139
Net loss	$	(10,273	)	$	(15,828	)	$	(40,146	)	$	(57,457	)
Other comprehensive loss:
Unrealized gain (loss) on short-term investments, net	16			(16		)	70			19
Comprehensive loss	$	(10,257	)	$	(15,844	)	$	(40,076	)	$	(57,438	)
Net loss per share, basic and diluted	$	(1.18	)	$	(2.11	)	$	(4.62	)	$	(10.52	)
Weighted average shares used to compute basic and diluted net loss per share	8,703,626			7,506,529			8,688,831			5,463,096

See accompanying notes to these condensed financial statements.

Regulus Therapeutics Inc.

CONDENSED STATEMENTS OF CASH FLOWS

(In thousands)



	Nine months ended September 30,
	2018			2017
	(Unaudited)
Operating activities
Net loss	$	(40,146	)	$	(57,457	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization expense	1,672			1,942
Stock-based compensation	4,374			6,531
Amortization of premium on investments, net	92			271
Other	182			206
Change in operating assets and liabilities:
Contracts and other receivables	360			1,124
Prepaid materials	589			(360		)
Prepaid expenses and other assets	1,050			2,405
Accounts payable	(4,509		)	(579		)
Accrued liabilities	(1,138		)	(652		)
Accrued compensation	(693		)	(631		)
Contract liabilities	(54		)	(54		)
Deferred rent and other liabilities	(1,035		)	(418		)
Net cash used in operating activities	(39,256		)	(47,672		)
Investing activities
Purchases of short-term investments	—			(48,539		)
Sales and maturities of short-term investments	40,101			58,310
Purchases of property and equipment	(22		)	(217		)
Acquisition of intangibles	—			(16		)
Net cash provided by investing activities	40,079			9,538
Financing activities
Proceeds from issuance of common stock, net	219			43,411
Proceeds from exercise of common stock options	2			4
Principal payments on other long-term obligations	(833		)	—
Proceeds from capital lease financing	354			—
Net cash used in financing activities	(258		)	43,415
Net increase in cash and cash equivalents	565			5,281
Cash and cash equivalents at beginning of period	13,519			14,941
Cash and cash equivalents at end of period	$	14,084		$	20,222
Supplemental disclosure of cash flow information
Interest paid	$	(1,573	)	$	(1,444	)
Income taxes paid	$	(1	)	$	(1	)
Supplemental disclosure of non-cash investing and financing activities
Non-cash acquisition of property and equipment	$	306		$	—

See accompanying notes to these condensed financial statements.

Regulus Therapeutics Inc.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

1. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented.

Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2017, from which the balance sheet information herein was derived.

In May 2017, we implemented a corporate restructuring to streamline our operations, reduce our operating expenses, extend our cash runway and focus our resources on our most promising programs. In connection with the restructuring, we reduced our total workforce by approximately 30%, to approximately 65 employees. We completed the workforce reduction in June 2017. In July 2018, we implemented a second corporate restructuring to further reduce operating expenses and focus our resources, which involved an additional reduction in our workforce of approximately 60%. The workforce reduction was substantially completed in July 2018. As of September 30, 2018, we had 25 employees.

On October 2, 2018 we filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation with the Secretary of State of the state of Delaware to effect a 1-for-12 reverse stock split of our issued and outstanding common stock. The reverse stock split became effective at 5:00 p.m. Eastern Time on October 3, 2018 and our common stock began trading on a split-adjusted basis on The Nasdaq Global Market on October 4, 2018. The accompanying condensed financial statements and notes thereto give retrospective effect to the reverse stock split for all periods presented. All issued and outstanding common stock, options exercisable for common stock, restricted stock units, and per share amounts contained in our condensed financial statements have been retrospectively adjusted.

Liquidity

The accompanying financial statements have been prepared on a basis which assumes we are a going concern, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from any uncertainty related to our ability to continue as a going concern. Through the date of the issuance of these financial statements, we have principally been financed through proceeds received from the sale of our common stock and other equity securities, debt financings, up-front payments and milestones received from collaboration agreements. As of September 30, 2018, we had approximately $20.5 million of cash, cash equivalents and short-term investments. Based on our operating plans, we believe our cash, cash equivalents and short-term investments may not be sufficient to fund our operations for the period one year following the issuance of these financial statements. As a result, there is substantial doubt about our ability to continue as a going concern. All amounts due under the Term Loan (see note 5) have been classified as a current liability as of September 30, 2018 and December 31, 2017 due to the considerations discussed above and the assessment that the material adverse change clause under the Term Loan is not within our control. We have not been notified of an event of default by the Lender as of the date of the filing of this Form 10-Q.

We intend to seek additional capital through equity and/or debt financings, collaborative or other funding arrangements with partners or through other sources of financing. Should we seek additional financing from outside sources, we may not be able to raise such financing on terms acceptable to us, or at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to scale back or discontinue the advancement of product candidates, reduce headcount, file for bankruptcy, reorganize, merge with another entity, or cease operations.

If we become unable to continue as a going concern, we may have to liquidate our assets, and might realize significantly less than the values at which they are carried on our financial statements, and stockholders may lose all or part of their investment in our common stock.

Use of Estimates

Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.

Revenue Recognition

Our revenues generally consist of upfront payments for licenses or options to obtain licenses in the future, milestone payments and payments for other research services under strategic alliance and collaboration agreements.

Effective January 1, 2018, we adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606) (“Topic 606”) using the modified retrospective method which consisted of applying and recognizing the cumulative effect of Topic 606 at the date of initial application. Topic 606 supersedes the revenue recognition requirements in Accounting Standards Codification (“ASC”) Topic 605, Revenue Recognition (“Topic 605”). All periods prior to the adoption date of Topic 606 have not been restated to reflect the impact of the adoption of Topic 606, but are accounted for and presented under Topic 605.

The following paragraphs in this section describe our revenue recognition accounting polices under Topic 606 upon adoption on January 1, 2018. Refer to Note 1 to the financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017 for revenue recognition accounting policies under Topic 605.

We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligation(s). At contract inception, we assess the goods or services promised within each contract, assess whether each promised good or service is distinct and identify those that are performance obligations. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Collaborative Arrangements

We enter into collaborative arrangements with partners that typically include payment to us of one of more of the following: (i) license fees; (ii) payments related to the achievement of developmental, regulatory, or commercial milestones; and (iii) royalties on net sales of licensed products. Where a portion of non-refundable up-front fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as contract liabilities and recognized as revenue when (or as) the underlying performance obligation is satisfied.

As part of the accounting for these arrangements, we must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation(s). The stand-alone selling price may include items such as forecasted revenues, development timelines, discount rates, and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time, or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.

License Fees

If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other performance obligations, we use judgment to assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.

Milestone Payments

At the inception of each arrangement that includes milestone payments (variable consideration), we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price. If it is probable that a milestone event would occur at the inception of an arrangement, the associated milestone value is included in the transaction price. Milestone payments that are contingent upon the achievement of events that are uncertain or not controllable, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received, and therefore not included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, we evaluate the probability of achievement of such milestones and any related constraint(s), and if necessary, may adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.

Royalties

For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of our collaborative arrangements.

Stock-Based Compensation

We account for stock-based compensation expense related to stock options granted to employees and members of our board of directors by estimating the fair value of each stock option on the date of grant using the Black-Scholes option pricing model. We recognize stock-based compensation expense using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award was in substance multiple awards, resulting in accelerated expense recognition over the vesting period. For performance-based awards granted to employees (i) the fair value of the award is determined on the grant date, (ii) we assess the probability of the individual milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.

We account for restricted stock units by determining the fair value of each restricted stock unit based on the closing market price of our common stock on the date of grant. We recognize stock-based compensation expense using the accelerated multiple-option approach over the requisite service periods of the awards.

Clinical Trial and Preclinical Study Accruals

We make estimates of our accrued expenses for clinical trial and preclinical study activities as of each balance sheet date in our financial statements based on the facts and circumstances known to us at that time. These accruals are based upon estimates of costs incurred and fees that may be associated with services provided by clinical trial investigational sites, clinical research organizations (“CROs”) and for other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If possible, we obtain information regarding unbilled services directly from these service providers. However, we may be required to estimate these services based on other information available to us. If we underestimate or overestimate the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, our estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in our accruals.

Prepaid Materials

We capitalize the purchase of certain raw materials and related supplies for use in the manufacturing of drug product in our clinical development programs, as we have determined that these materials have alternative future use. We can use these raw materials and related supplies in multiple clinical drug products, and therefore have future use independent of the development status of any particular drug program until it is utilized in the manufacturing process. We expense the cost of

materials when used. We periodically review these capitalized materials for continued alternative future use and write down the asset to its net realizable value in the period in which it is identified.

Recent Accounting Pronouncements

As disclosed above, effective January 1, 2018, we adopted Topic 606. Since ASU 2014-09 was issued, several additional ASUs have been issued and incorporated within Topic 606 to clarify various elements of the guidance. As part of our adoption efforts, we have completed the assessment of our collaboration and license agreements under Topic 606. We adopted Topic 606 in the first quarter of 2018 using the modified retrospective method which consists of applying and recognizing the cumulative effect of Topic 606 at the date of initial application and providing certain additional disclosures as defined per Topic 606. On January 1, 2018, we recorded a cumulative adjustment to decrease deferred revenue and accumulated deficit by approximately $1.8 million to reflect the impact of the adoption of Topic 606. The cumulative adjustment relates primarily to our agreement with Sanofi which is described further in Note 7.

Below is a summary of the affected line items of the condensed balance sheets upon adoption of Topic 606 (in thousands):



	Balance at December 31, 2017		Adjustments due to Topic 606		Balance at January 1, 2018
Balance Sheet
Deferred revenue (contract liabilities), non-current	1,921		(1,844	)	77
Accumulated deficit	(345,858	)	1,844		(344,014	)

There is no difference between what our revenue would have been in the three and nine months ended September 30, 2018, reported under Topic 606 or Topic 605.

In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities, which eliminates the requirement for public companies to disclose the method(s) and significant assumptions used to estimate the fair value for financial instruments measured at amortized cost on the balance sheet. Additionally, the standard requires public companies to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes. Furthermore, the standard requires presentation of financial assets and liabilities by measurement category and form of financial asset on the balance sheet or accompanying notes to the financial statements. The standard is effective for annual reporting periods beginning after December 15, 2017, including interim periods within those annual reporting periods. The adoption of this guidance had no impact on our financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases, which increases transparency and comparability among organizations by requiring recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements. Since ASU 2016-02 was issued, several additional ASUs have been issued to clarify various elements of the guidance. The standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual reporting periods. Early application is permitted. We are in the process of determining the impact the adoption will have on our financial statements and expect significant changes to the recognition of right-of-use assets and liabilities associated with our operating leases.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments, which addresses the presentation and classification of certain cash receipts and cash payments in the statement of cash flows under Accounting Standards Codification 230. The standard is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those annual reporting periods. The adoption of this guidance had no impact on our financial statements.

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows: Restricted Cash, which requires restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those annual reporting periods. The adoption of this guidance will have no impact on our financial statements.

In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation: Scope of Modification Accounting, which provides clarity and guidance around which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard is effective for annual reporting periods

beginning after December 15, 2017, and interim periods within those annual reporting periods. The adoption of this guidance had no impact on our financial statements and will continue to have no impact on our financial statements unless we have modification accounting in accordance with Topic 718.

In December 2017, The Tax Cuts and Jobs Act (the "Act") was signed into law and amended the Internal Revenue Code, or IRC, to reduce tax rates and modify policies, credits, and deductions for individuals and businesses. Due to uncertainties which currently exist in the interpretation of the provisions of the Act regarding IRC Section 162(m), as of September 30, 2018, we have not completed our evaluation of the potential impacts of IRC Section 162(m) as amended by the Act on our financial statements. In March 2018, the FASB issued ASU No. 2018-05, Income taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118, which provides guidance regarding the recording of tax impacts where uncertainty exists, in the period of adoption of the Act. To the extent that a company’s accounting for certain income tax effects of the Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the condensed financial statements. If a company cannot determine a provisional estimate to be included in the condensed financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Act. We have provisionally determined that there is no deferred tax benefit or expense with respect to the re-measurement of certain deferred tax assets and liabilities due to the full valuation allowance against net deferred tax assets. Additional analysis of the law and the impact to the company will be performed and any impact will be recorded in the respective quarter.

In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting, which aligns the measurement and classification guidance for share-based payment to non-employees with the guidance for share-based payments to employees. Under the new guidance, the measurement period for equity-classified non-employee awards will be fixed at the grant date. This update is effective for annual periods beginning after December 15, 2018, and interim periods within those periods and early adoption is permitted. The adoption of this guidance will have no impact on our financial statements.

In August 2018, the FASB issues ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement, which updates and modifies the disclosure requirements on fair value measurements in Topic 820, primarily in relation to Level 3 fair value measurements. This update is effective for annual periods beginning after December 15, 2019, and interim periods within those periods. Early adoption is permitted. The adoption of this guidance will have no impact on our financial statements.

2. Net Loss Per Share

Basic net loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of options outstanding under our stock option plans. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted net loss per share.

Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive consisted of zero and 575,256 shares attributable to common stock options and restricted stock units ("RSUs") for the three and nine months ended September 30, 2018, respectively, compared to 106,597 and 210,816 shares attributable to common stock options for the three and nine months ended September 30, 2017, respectively.

3. Investments

We invest our excess cash primarily in debt instruments of financial institutions, corporations, U.S. government-sponsored agencies and the U.S. Treasury. We generally hold our investments to maturity and do not sell our investments before we have recovered our amortized cost basis.

The following tables summarize our short-term investments (in thousands):



	Maturity (in years)	Amortized cost		Unrealized					Estimated fair value
	Maturity (in years)	Amortized cost		Gains		Losses			Estimated fair value
As of September 30, 2018
Certificates of deposit	1 or less	$	2,440	$	—	$	—		$	2,440
U.S. Treasury securities	1 or less	3,999		1		(7		)	3,993
Total		$	6,439	$	1	$	(7	)	$	6,433



	Maturity (in years)	Amortized cost		Unrealized					Estimated fair value
	Maturity (in years)	Amortized cost		Gains		Losses			Estimated fair value
As of December 31, 2017
Corporate debt securities	1 or less	$	32,922	$	—	$	(55	)	$	32,867
Certificates of deposit	1 or less	8,216		—		—			8,216
U.S. Treasury securities	1 or less	3,996		—		(18		)	3,978
Debt securities of U.S. government-sponsored agencies	1 or less	1,498		—		(4		)	1,494
Total		$	46,632	$	—	$	(77	)	$	46,555

4. Fair Value Measurements

We have certain financial assets recorded at fair value which have been classified as Level 1, 2, or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.

Accounting standards define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The accounting standards provide an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors that market participants would use in valuing the asset or liability. The accounting standards prioritize the inputs used in measuring the fair value into the following hierarchy:


•	Level 1 includes financial instruments for which quoted market prices for identical instruments are available in active markets.

•

Level 2 includes financial instruments for which there are inputs other than quoted prices included within Level 1 that are observable for the instrument such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets with insufficient volume or infrequent transactions (less active markets) or model-driven valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.


•	Level 3 includes financial instruments for which fair value is derived from valuation techniques in which one or more significant inputs are unobservable, including management’s own assumptions.

Financial Assets Measured at Fair Value

The following table presents our fair value hierarchy for assets measured at fair value on a recurring basis as of September 30, 2018 and December 31, 2017 (in thousands):



	Fair value as of September 30, 2018
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	13,631	$	13,631	$	—	$	—
Certificates of deposit	2,440		—		2,440		—
U.S. treasury securities	3,993		—		3,993		—
	$	20,064	$	13,631	$	6,433	$	—



	Fair value as of December 31, 2017
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	10,847	$	10,847	$	—	$	—
Corporate debt securities	32,867		—		32,867		—
Certificates of deposit	8,216		—		8,216		—
U.S. treasury securities	3,978		—		3,978		—
Debt securities of U.S. government-sponsored agencies	1,494		—		1,494		—
	$	57,402	$	10,847	$	46,555	$	—

We obtain pricing information from quoted market prices or quotes from brokers/dealers. We generally determine the fair value of our investment securities using standard observable inputs, including reported trades, broker/dealer quotes, bids and/or offers. Refer to Note 3 for information regarding our investments.

5. Term Loan

On June 17, 2016, we entered into a loan and security agreement (“Loan Agreement”) with Oxford Finance, LLC, (“Oxford” or sometimes referred to as the “Lender”), pursuant to which Oxford agreed to lend us up to $30.0 million, issuable in two separate term loans of $20.0 million (the “Term A Loan”) and $10.0 million (the “Term B Loan”). On June 22, 2016, we received $20.0 million in proceeds from the Term A Loan, net of debt issuance costs. The ability to borrow on the Term B Loan expired on March 31, 2017, and no amounts were borrowed under the Term B Loan. We refer to all amounts outstanding under the Loan Agreement as the Term Loan.

The outstanding Term Loan will mature on June 1, 2020 (the “Maturity Date”) and bears interest at a floating per annum rate equal to (i) 8.51% plus (ii) the greater of (a) the 30 day U.S. Dollar LIBOR rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue and (b) 0.44%. Under the original Loan Agreement, we were required to make interest-only payments through June 1, 2018, followed by 24 equal monthly payments of principal and unpaid accrued interest.

In March 2018, we and Oxford entered into an amendment to our Loan Agreement, providing for the modification of the loan amortization period from a 24-month period commencing on July 1, 2018 to a 15-month period commencing on April 1, 2019, subject to our receipt, following the date of the amendment, of unrestricted net cash proceeds of not less than $30.0 million on or prior to June 30, 2018. The ability to modify the loan amortization period under this amendment to the Loan Agreement expired on June 30, 2018, as we did not receive unrestricted net cash proceeds of not less than $30.0 million on or prior to June 30, 2018.

In August 2018, we and Oxford entered into an additional amendment to our Loan Agreement, providing for a modification of the loan amortization period. Under the terms of the amendment, principal amortization and repayment was deferred between August 2018 through October 2018, and during this period, we were required to make payments of interest-only. Amortization payments will recommence in November 2018. In addition, the amendment contained a minimum cash reserve covenant, whereby we will be required to maintain aggregate cash reserves of not less than 110% of the principal balance of the Term Loan that would be outstanding on such date that our then-held cash reserves would first be completely exhausted based on certain assumptions specified in the amendment. There were no changes to the maturity date of the Term Loan, which is June 2020. Pursuant to the amendment, we granted the Lender a security interest in our intellectual property as additional collateral for the repayment of the Term Loan.

We have the option to prepay all, but not less than all, of the borrowed amount, provided that we will be obligated to pay a prepayment fee equal to (i) 2% of the outstanding principal balance of the Term Loan if prepayment is made prior to the second anniversary of the funding date of the Term Loan, or (ii) 1% of the Term Loan prepaid thereafter and prior to the Maturity Date. We will be required to make a final payment of 5.5% of the principal balance outstanding, payable on the earlier of (i) the Maturity Date, (ii) acceleration of the Term Loan, or (iii) the prepayment of the Term Loan.

We may use the proceeds from the Term Loan solely for working capital and to fund our general business requirements. Our obligations under the Loan Agreement are secured by a first priority security interest in substantially all of our current and future assets, other than our intellectual property and certain assets under capital lease obligations. We have also agreed not to encumber our intellectual property assets, except as permitted by the Loan Agreement. The Loan Agreement includes customary events of default, including instances of a material adverse change in our operations, that may require prepayment of the outstanding Term Loan. All amounts due under the Term Loan have been classified as a current liability as of September 30, 2018 due to the considerations discussed in Note 1 and the assessment that the material adverse change clause under the Term Loan is not within our control. We have not been notified of an event of default by the Lender as of the date of the filing of this Form 10-Q.

As of September 30, 2018, we had a net liability of $19.1 million outstanding under the Term Loan. In connection with the Term Loan, the debt issuance costs have been recorded as a debt discount in our consolidated balance sheets, which are being accreted to interest expense over the life of the Term Loan using an effective interest rate of 8.98%. The exit fee is being accrued over the life of the Term Loan through interest expense.

As of September 30, 2018, we were in compliance with all covenants under the Loan Agreement.

As of September 30, 2018, future principal payments for the Term Loan due under the Loan Agreement are as follows (in thousands):



2018	$	1,917
2019	11,500
2020	5,750
	$	19,167

6. Stockholders’ Equity

Shares Reserved for Future Issuance

The following shares of common stock were reserved for future issuance as of September 30, 2018 (in thousands):



Common stock options outstanding	1,134
RSUs outstanding	66
Common stock available for future grant under 2012 Equity Incentive Plan	61
Common stock available for future grant under 2015 Inducement Plan	3
Employee Stock Purchase Plan	155
Total common shares reserved for future issuance	1,419

The following table summarizes our stock option and RSU activity (together Stock Awards) under all equity incentive plans for the nine months ended September 30, 2018 (shares in thousands):



	Number of options		Weighted average exercise price		Number of RSUs		Weighted average grant date fair value
Stock Awards outstanding at December 31, 2017	887		$	53.24	35		$	10.68
Granted	603		$	11.70	102		$	3.88
Exercised (options) or Vested (RSUs)	(1	)	$	4.56	(57	)	$	6.25
Canceled/forfeited/expired	(355	)	$	58.59	(8	)	$	7.57
Stock Awards outstanding at September 30, 2018	1,134				72

Stock-Based Compensation

The following table summarizes the weighted average assumptions used to estimate the fair value of stock options and performance stock awards granted to employees under our 2012 Equity Incentive Plan and 2015 Inducement Plan and the shares purchasable under our Employee Stock Purchase Plan during the periods presented:



	Three months ended September 30,				Nine months ended September 30,
	2018		2017		2018		2017
Stock options
Risk-free interest rate	2.9	%	1.9	%	2.7	%	2.0	%
Volatility	92.0	%	89.5	%	87.8	%	89.4	%
Dividend yield	—		—		—		—
Expected term (years)	6.1		6.1		6.1		6.1
Performance stock options
Risk-free interest rate	—		—		2.7	%	2.1	%
Volatility	—		—		87.4	%	89.9	%
Dividend yield	—		—		—		—
Expected term (years)	0.0		0.0		5.7		5.6
Employee stock purchase plan shares
Risk-free interest rate	2.0	%	1.0	%	1.8	%	0.8	%
Volatility	99.9	%	104.5	%	91.7	%	110.7	%
Dividend yield	—		—		—		—
Expected term (years)	0.5		0.5		0.5		0.5

The following table summarizes the allocation of our stock-based compensation expense for all stock awards during the periods presented (in thousands):



	Three months ended September 30,					Nine months ended September 30,
	2018			2017		2018			2017
Research and development	$	491		$	653	$	1,745		$	2,411
Research and development-restructuring related adjustments	31			—		31			(1,399		)
General and administrative	883			631		2,613			2,840
General and administrative-restructuring related adjustments	(15		)	—		(15		)	2,679
Total	$	1,390		$	1,284	$	4,374		$	6,531

7. Strategic Alliances and Collaborations

Revenue recognized from our strategic alliances and collaborations was less than $0.1 million for each of the three and nine months ended September 30, 2018 and 2017.

Sanofi

In July 2012, we amended and restated our collaboration and license agreement with Sanofi to expand the potential therapeutic applications of the microRNA alliance targets to be developed under such agreement. We determined that the elements within the strategic alliance agreement with Sanofi should be treated as a single unit of accounting because the delivered elements did not have stand-alone value to Sanofi. The following elements were delivered as part of the strategic alliance with Sanofi: (1) a license for up to four microRNA targets; and (2) a research license under our technology alliance.

In June 2013, the original research term expired, upon which we and Sanofi entered into an option agreement pursuant to which Sanofi was granted an exclusive right to negotiate the co-development and commercialization of certain of our unencumbered microRNA programs and we were granted the exclusive right to negotiate with Sanofi for co-development and commercialization of certain miR-21 anti-miRs in oncology and Alport syndrome. In July 2013, we received an upfront payment of $2.5 million, of which $1.25 million is creditable against future amounts payable by Sanofi to us under any future co-development and commercialization agreement we enter pursuant to the option agreement. Revenue associated with the creditable portion of this option payment was deferred as of December 31, 2017 and recorded as an adjustment to accumulated deficit upon our adoption of ASC 606 on January 1, 2018. The non-creditable portion of this payment, $1.25 million, was recognized as revenue over the option period from the effective date of the option agreement in June 2013 through the expiration of the option period in January 2014.

In February 2014, we and Sanofi entered into a second amended and restated collaboration and license agreement (the “2014 Sanofi Amendment”) to renew our strategic alliance to discover, develop and commercialize microRNA therapeutics to focus on specific orphan disease and oncology targets. Under the terms of our renewed alliance, Sanofi has opt-in rights to our clinical fibrosis program targeting miR-21 for the treatment of Alport syndrome, our preclinical program targeting miR-21 for oncology indications, and our preclinical program targeting miR-221/222 for hepatocellular carcinoma (“HCC”). We are responsible for developing each of these programs to proof-of-concept, at which time Sanofi has an exclusive option on each program. If Sanofi chooses to exercise its option on any of these programs, Sanofi will reimburse us for a significant portion of our preclinical and clinical development costs and will also pay us an option exercise fee for any such program, provided that $1.25 million of the $2.5 million upfront option fee paid to us by Sanofi in connection with the June 2013 option agreement will be creditable against such option exercise fee. We are eligible to receive royalties on microRNA therapeutic products commercialized by Sanofi and will have the right to co-promote these products.

In connection with the 2014 Sanofi Amendment, we entered into a Common Stock Purchase Agreement (the “Purchase Agreement”), pursuant to which we sold 1,303,780 shares of our common stock to Aventisub LLC (“Aventis”), an entity affiliated with Sanofi, in a private placement at a price per share of $7.67 for an aggregate purchase price of $10.0 million. Under the terms of the Purchase Agreement, Aventis was not permitted to sell, transfer, make any short sale of, or grant any option for the sale of any common stock for the 12-month period following its effective date. The Purchase Agreement and the 2014 Sanofi Amendment were negotiated concurrently and were therefore evaluated as a single agreement. Based upon restricted stock studies of similar duration and a Black-Scholes valuation to measure the discount for lack of marketability, approximately $0.4 million of the proceeds from the Purchase Agreement was attributed to the 2014 Sanofi Amendment, and represents consideration for the value of the program targeting miR-221/222 for HCC. We are recognizing the $0.4 million allocated consideration into revenue ratably over the estimated period of performance of the miR-221/222 program. As of September 30, 2018, contract liabilities associated with the Purchase Agreement and the 2014 Sanofi Amendment was $0.1 million, which we are expecting to recognize over the remaining estimated period of performance of approximately one year.

We are eligible to receive milestone payments of up to $101.8 million for proof-of-concept option exercise fees (net of $1.25 million creditable, as noted above), $15.0 million for clinical milestones and up to $300.0 million for regulatory and commercial milestones. In addition, we are entitled to receive royalties based on a percentage of net sales of any products from the miR-21 and miR-221/222 programs which, in the case of sales in the United States, will be in the middle of the 10 to 20% range, and, in the case of sales outside of the United States, will range from the low end to the middle of the 10 to 20% range, depending upon the volume of sales. If we exercise our option to co-promote a product, we will continue to be eligible to receive royalties on net sales of each product in the United States at the same rate, unless we elect to share a portion of Sanofi’s profits from sales of such product in the United States in lieu of royalties.

8. Related Party Transactions

We have entered into certain agreements with related parties in the ordinary course of business to license intellectual property and to procure research and development support services.

In September 2014, we entered into an agreement with Sanofi-Aventis Deutschland GmbH (“Sanofi Deutschland”), a contract manufacturing subsidiary of Sanofi, for the manufacture of certain drug substance requirements and other services to support our preclinical and clinical activities associated with the RG-012 program. Pursuant to this agreement, we engaged Sanofi Deutschland to manufacture RG-012 drug product and perform stability studies on our behalf. Expenses incurred under the agreement for services performed or out-of-pocket expenses were less than $0.1 million for each of the three and nine months ended September 30, 2018 and 2017.

9. Subsequent Events

Reverse Stock Split

On October 2, 2018, we filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation with the Secretary of State of the state of Delaware to effect a 1-for-12 reverse stock split of our issued and outstanding common stock. The primary purpose of the reverse stock split was to raise the per share trading price of our common stock to seek to maintain the listing of our common stock on The Nasdaq Global Market. At the effective time of the reverse stock split at 5:00 p.m. on October 3, 2018, each 12 shares of our issued and outstanding common stock were automatically combined and converted into one issued and outstanding share of common stock. All of our stock options and RSUs outstanding immediately prior to the reverse stock split were proportionately adjusted. All issued and outstanding common stock, options exercisable for common stock, restricted stock units, and per share amounts contained in our condensed financial statements have been retrospectively adjusted.

Tender Offer

On October 15, 2018, we filed a tender offer statement on Schedule TO with the Securities and Exchange Commission related to an offer by us to certain eligible optionholders, subject to specified conditions, to exchange some or all of their outstanding options to purchase shares of our common stock for new RSUs (the "Exchange Offer"). The Exchange Offer will expire at 5:00 p.m., U.S. Pacific Time, on November 11, 2018, unless extended.

An option holder will be eligible to exchange their options (an “Eligible Holder”) if:


•	on the date the Exchange Offer commences, either an optionholder is employed by us (each, an “Employee”) or is a non-employee member (each, a “Non-Employee Director”) of our board of directors and has not been notified by us that such optionholder’s employment or service relationship with us is being terminated; and


•	such optionholder continues to be an Employee or serve as a Non-Employee Director and has not submitted a notice of resignation or received a notice of termination, as of the first business day following the Expiration Time (as defined in the Exchange Offer).

An option will be eligible for exchange (an “Eligible Option”) if it:


•	is held by an Eligible Holder;


•	has an exercise price equal to or greater than $4.56 (and an exercise price greater than the closing price of our common stock on the last business day before the Expiration Time); and


•	was granted under our 2009 Equity Incentive Plan, 2012 Equity Incentive Plan or 2015 Inducement Plan.

The exchange ratio for each Eligible Option will be determined using the Black-Scholes option pricing model and will be based on, among other things, the fair market value of a share of our common stock, the volatility of our common stock, U.S. treasury rates, the exercise prices of the Eligible Options, the remaining terms of the Eligible Options and the term of the new RSUs. For purposes of determining the fair value of Eligible Options, the fair market value of a share of our common stock will be determined based on the trailing 20-day volume weighted average price (the “20-Day VWAP”). The 20-Day VWAP represents the simple arithmetic average of the daily VWAPs over the 20 consecutive trading days beginning on October 15, 2018 and ending on the last business day prior to the Expiration Time. For purposes of determining the fair value of the new RSUs, the fair market value of a share of our common stock will be determined based on the closing trading price of a share of our common stock on Nasdaq on the last business day prior to the Expiration Time. In no event will an Eligible Optionholder be eligible to receive more new RSUs than the number of shares underlying the number of Eligible Options.

The foregoing is only a summary of the Exchange Offer, does not purport to be complete and is qualified in its entirety by reference to the full text of the Schedule TO, which was filed with the Securities and Exchange Commission on October 15, 2018.

First Amendment to Second Amended and Restated Collaboration and License Agreement

On November 5, 2018, we entered into an amendment to the 2014 Sanofi Amendment with Sanofi to modify the parties’ rights and obligations with respect to our miR-21 programs, including our RG-012 program (the “2018 Sanofi Amendment”).

administration and expense of clinical trials and all other costs, including in-license royalties and other in-license payments, related to our miR-21 programs. Under the terms of the 2018 Sanofi Amendment, we have assigned to Sanofi certain agreements and all materials directed to miR-21 or to any miR-21 compound or product and are required to provide reasonable technical assistance to Sanofi for a period of 24 months after the date of the 2018 Sanofi Amendment.

Under the terms of the 2018 Sanofi Amendment, we are eligible to receive approximately $6.8 million in upfront payments and a payment for miR-21 program-related materials (collectively, the “Upfront Amendment Payments”). We are also eligible to receive up to $40.0 million in development milestone payments. In addition, Sanofi has agreed to reimburse us for certain out-of-pocket transition activities and assume our upstream license royalty obligations. We and Sanofi also agreed to a general release of claims against each other for any claims that arose at any time prior to the date of the 2018 Sanofi Amendment, or that thereafter could arise based on anything that occurred prior to the date of the 2018 Sanofi Amendment.

Fourth Amendment to Loan and Security Agreement

On November 5, 2018 and in connection with the 2018 Sanofi Amendment we entered into a fourth amendment to the Term Loan with the Lender (the "Fourth Amendment").

Under the terms of the Fourth Amendment, the Lender has consented to the 2018 Sanofi Amendment and our license, assignment and transfer to Sanofi of certain of our intellectual property, as required to be delivered to Sanofi under the 2018 Sanofi Amendment (the “Assigned Assets”), which previously served as collateral under the loan and security agreement, and has released its liens in the Assigned Assets, provided that the Lender will continue to have liens on all proceeds received by us pursuant to the Sanofi License. Under the terms of the Fourth Amendment, we now have the option to prepay part of the Term Loan at any time and in any amount after 10 days’ prior written notice. We are also required to prepay part of the Term Loan with 25% of certain payments we receive under the 2018 Sanofi Amendment, which payments consist of the Upfront Amendment Payments and the first development milestone payment in the amount of $10.0 million. We will be required to pay the applicable 5.5% final payment fee related to each such 2018 Sanofi Amendment prepayment. Under the Fourth Amendment, we are required to maintain cash in a collateral account controlled by the Lender of (i) $10.0 million, if we have not received net proceeds of at least $15.0 million from (a) the issuance and sale of our unsecured subordinated convertible debt and/or equity securities or (b) upfront or milestone payments in connection with a joint venture, collaboration or other partnering transaction, other than pursuant to the Sanofi License (the receipt of such net proceeds, a “Capital Event”), or (ii) $5.0 million if a Capital Event has occurred.

The maturity date of the Term Loan remains unchanged and the Term Loan is required to be paid in full on June 1, 2020.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The interim unaudited condensed financial statements and this Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2017 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, 2017, or Annual Report, filed with the Securities and Exchange Commission on March 8, 2018. Past operating results are not necessarily indicative of results that may occur in future periods.

FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For these forward-looking statements, we claim the protection of the Private Securities Litigation Reform Act of 1995. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth below under Part II, Item 1A, “Risk Factors” in this quarterly report on Form 10-Q. Except as required by law, we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise. These statements, which represent our current expectations or beliefs concerning various future events, may contain words such

as “may,” “will,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate” or other words indicating future results, though not all forward-looking statements necessarily contain these identifying words. Such statements may include, but are not limited to, statements concerning the following:


•	the initiation, cost, timing, progress and results of, and our expected ability to undertake certain activities and accomplish certain goals with respect to our research and development activities, preclinical studies and clinical trials;


•	our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate;


•	our ability to obtain funding for our operations;


•	our plans to research, develop and commercialize our product candidates;


•	the potential election of any strategic alliance or collaboration partner to pursue development and commercialization of any programs or product candidates that are subject to a collaboration with such partner;


•	our ability to attract collaborators with relevant development, regulatory and commercialization expertise;


•	future activities to be undertaken by our strategic alliance partners, collaborators and other third parties;


•	our ability to obtain and maintain intellectual property protection for our product candidates;


•	the size and growth potential of the markets for our product candidates, and our ability to serve those markets;


•	our ability to successfully commercialize, and our expectations regarding future therapeutic and commercial potential with respect to our product candidates;


•	the rate and degree of market acceptance of our product candidates;


•	our ability to develop sales and marketing capabilities, whether alone or with potential future collaborators;


•	regulatory developments in the United States and foreign countries;


•	the performance of our third-party suppliers and manufacturers;


•	the success of competing therapies that are or may become available;


•	the loss of key scientific or management personnel;


•	our ability to successfully secure and deploy capital;


•	our ability to satisfy our debt obligations;


•	the accuracy of our estimates regarding future expenses, future revenues, capital requirements and need for additional financing; and


•	the risks and other forward-looking statements described under the caption “Risk Factors” under Part II, Item 1A of this quarterly report on Form 10-Q.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

OVERVIEW

We are a clinical-stage biopharmaceutical company focused on discovering and developing first-in-class drugs targeting microRNAs to treat diseases with significant unmet medical need. We were formed in 2007 when Alnylam Pharmaceuticals, Inc., or Alnylam, and Ionis Pharmaceuticals, Inc., or Ionis, contributed significant intellectual property, know-how and financial and human capital to pursue the development of drugs targeting microRNAs pursuant to a license and collaboration agreement. Our most advanced product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease with no approved therapy available. In November 2018, we and Sanofi agreed to transition further development activities of our miR-21 programs, including our RG-012 program, to Sanofi, which will be responsible for all costs incurred in the development of our miR programs. RGLS4326 is an anti-miR targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease, or ADPKD. In addition to these clinical programs, we continue to develop a pipeline of preclinical drug product candidates.

microRNAs are naturally occurring ribonucleic acid, or RNA, molecules that play a critical role in regulating key biological pathways. Scientific research has shown that an imbalance, or dysregulation, of microRNAs is directly linked to many diseases. Furthermore, many different infectious pathogens interact and bind to host microRNA to survive. To date, over 500 microRNAs have been identified in humans, each of which can bind to multiple messenger RNAs that control key aspects of cell biology. Since many diseases are multi-factorial, involving multiple targets and pathways, the ability to modulate multiple pathways by targeting a single microRNA provides a new therapeutic approach for treating complex diseases.

RNA plays an essential role in the process used by cells to encode and translate genetic information from deoxyribonucleic acid, or DNA, to proteins. RNA is comprised of subunits called nucleotides and is synthesized from a DNA template by a process known as transcription. Transcription generates different types of RNA, including messenger RNAs that carry the information for proteins in the sequence of their nucleotides. In contrast, microRNAs are RNAs that do not code for proteins but rather are responsible for regulating gene expression by modulating the translation and decay of target messenger RNAs. By interacting with many messenger RNAs, a single microRNA can regulate the expression of multiple genes involved in the normal function of a biological pathway. Many pathogens, including viruses, bacteria and parasites, also use host microRNAs to regulate the cellular environment for survival. In some instances, the host microRNAs are essential for the replication and/or survival of the pathogen. For example, miR-122 is a microRNA expressed in human hepatocytes and is a key factor for the replication of the hepatitis C virus, or HCV.

We believe that microRNA therapeutics have the potential to become a new and major class of drugs with broad therapeutic application for the following reasons:


•	microRNAs play a critical role in regulating biological pathways by controlling the translation of many target genes;


•	microRNA therapeutics regulate disease pathways which may result in more effective treatment of complex multi-factorial diseases;


•	many human pathogens, including viruses, bacteria and parasites, use microRNAs (host and pathogen encoded) to enable their replication and suppression of host immune responses; and


•	microRNA therapeutics may be synergistic with other therapies because of their different mechanism of action.

We have assembled significant expertise in the microRNA field, including expertise in microRNA biology and oligonucleotide chemistry, a broad intellectual property estate, relationships with key opinion leaders and a disciplined drug discovery and development process. We are using our microRNA expertise to develop chemically modified, single-stranded oligonucleotides that we call anti-miRs to modulate microRNAs and address underlying disease. We believe microRNAs may play a critical role in complex disease and that targeting them with anti-miRs may become a source of a new and major class of drugs with broad therapeutic application, much like small molecules, biologics and monoclonal antibodies.

We believe that microRNA biomarkers may be used to select optimal patient segments in clinical trials and to monitor disease progression or relapse. We believe these microRNA biomarkers can be applied toward drugs that we develop and drugs developed by other companies with which we partner or collaborate.

Development Stage Pipeline

We currently have multiple programs in various stages of clinical development.

RG-012: In the third quarter of 2017, we initiated HERA, the Phase II randomized (1:1), double-blinded, placebo-controlled clinical trial evaluating the safety and efficacy of RG-012 in 40 Alport syndrome patients. In parallel, a renal biopsy study was also initiated in the third quarter of 2017 to evaluate RG-012 renal tissue pharmacokinetics, or PK, target engagement and downstream effects on genomic disease biomarkers. In December 2017, we concluded our global ATHENA natural history of disease study. In May 2017, we completed a Phase I multiple-ascending dose, or MAD, clinical trial in 24 healthy volunteers (six-week repeat dosing) to determine safety, tolerability and PK of RG-012 prior to chronic dosing in patients. In Phase I clinical trials to date, RG-012 was well-tolerated, and there were no serious adverse events, or SAEs, reported. Preliminary results from the first patients through the renal biopsy study are encouraging, with kidney tissue concentrations achieved that would be predictive of therapeutic benefit based on animal disease models. In addition, modulation of the target, miR-21, was observed. RG-012 has received orphan designation in both the United States and Europe. In July 2018, in connection with our corporate restructuring, we paused recruitment activities for our RG-012 clinical program in Alport syndrome while we engaged in discussions with Sanofi regarding the potential restructuring of our collaboration. In November 2018, we and Sanofi agreed to transition further development activities of our miR-21 programs, including our RG-012 program to Sanofi, which will be responsible for all costs incurred in the development of our miR-21 programs.

RGLS4326: RGLS4326 is a novel oligonucleotide designed to inhibit miR-17 using a unique chemistry designed to preferentially deliver to the kidney. Preclinical studies with RGLS4326 have demonstrated a reduction in kidney cyst formation, improved kidney weight/body weight ratio, decreased cyst cell proliferation and preserved kidney function in mouse models of ADPKD. In March 2018, we completed dose escalation of a Phase I single ascending dose, or SAD, clinical trial in healthy volunteers and found RGLS4326 was well tolerated and no SAEs were reported. In April 2018, we initiated a Phase I randomized, double-blind, placebo-controlled, MAD clinical trial in healthy volunteers designed to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of RGLS4326. In July 2018, we voluntarily paused this study due to unexpected observations in our 27-week mouse chronic toxicity study, which was designed to support the Phase II proof-of-concept clinical trial in ADPKD previously planned to start in mid-2019. The observations in the mouse chronic toxicity study were unexpected, given the favorable safety profile of RGLS4326 in previous 7-week non-GLP and GLP toxicity studies in mouse and non-human primates required for Phase I testing, which had no significant findings across similar dose levels and frequencies. In September 2018, we initiated a new mouse chronic toxicity study with several changes believed to address the unexpected findings in the earlier terminated chronic mouse toxicity study. Data from the new study are anticipated in the first quarter of 2019.

RG-125(AZD4076): In June 2017, AstraZeneca AB, or AstraZeneca, delivered written notice of their election to terminate the collaboration and license agreement. Effective upon the termination of the agreement, AstraZeneca’s rights with respect to RG-125(AZD4076) for the treatment of non-alcoholic steatohepatitis, or NASH, in Type 2 Diabetes/Pre-diabetes will revert to us. In May 2018, AstraZeneca requested to extend the Collaboration and License Agreement termination effective date by an additional 12 months to allow AstraZeneca to complete all activities involving AZD4076. By the end of this 12-month extension, the parties will complete the transfer activities contemplated by the agreement. The new termination effective date pursuant to the extension will be June 2019.

Preclinical Pipeline

A major focus of our preclinical research has historically targeted dysregulated microRNAs implicated in diseases of high unmet medical need where we know we can effectively deliver to the target tissue or organ, such as the liver and kidney. We also have early discovery programs investigating additional microRNA targets for infectious diseases, immunology and indications for which there is microRNA dysregulation or in disease settings where the host microRNAs are essential for the replication and/or survival of the pathogen.

We currently have multiple programs in various stages of preclinical development.

Hepatitis B virus program: We have determined that advancing our preclinical programs targeting the Hepatitis B virus ("HBV") represents an attractive opportunity in our pipeline for investment, affecting an estimated 350 million people worldwide. We have identified several microRNA targets that serve as host factors for the virus. Our lead compound directed to one of the host microRNAs has demonstrated sub-nanomolar potency against HBV DNA replication and more than 95% reduction in Hepatitis B surface antigen in in vitro studies. We believe that targeting a host factor in the liver represents a unique mechanism of action for treatment of the virus compared to other programs in development and holds the potential for achieving a functional cure. We currently expect to submit an investigational new drug application ("IND") to the U.S. Food and Drug Administration ("FDA") for the HBV program in the second half of 2019, with the potential of achieving human proof-of-concept in a Phase 1 clinical trial.

Glioblastoma multiforme program: Our lead anti-miR candidate targeting microRNA-10b demonstrated statistically significant improvements in survival as both a monotherapy as well as in combination with temozolamide (TMZ) in an orthotopic glioblastoma multiforme animal model. In combination with TMZ, the addition of a single dose of anti-mir-10b, delivered intracranially, led to a more than two-fold improvement in survival compared to TMZ alone. These, and additional survival data on our lead anti-miR candidate, will be presented in November 2018 at the Society for Neuro-Oncology Meeting in New Orleans, Louisiana. We expect to nominate a clinical candidate by year-end and plan to seek a partner to further advance its development.

Non-Alcoholic Steatohepatitis program: Across multiple animal models of NASH, our lead candidate has demonstrated improvement in key endpoints, including NAFLD Activity Score (NAS), liver transaminases, hyperglycemia, and disease-related gene expression. In the diet-induced NASH mouse model (Amylin model) after two to four weekly doses, early onset of improvement across multiple disease parameters including liver triglycerides and blood levels of transaminases was observed. After nine weeks of treatment, there was evidence of sustained benefit with significant improvement of liver fibrosis and hyperglycemia compared to control-treated animals. We believe that targeting dysregulated microRNA in a complex disease

like NASH may offer a unique mechanism of action from other programs in development. We plan to seek a partner to further advance its development.

FINANCIAL OPERATIONS OVERVIEW

Revenue

In the future, we may generate revenue from a combination of license fees and other upfront payments, payments for research and development services, milestone payments, product sales and royalties in connection with strategic alliances. We expect that any revenue we generate will fluctuate from quarter-to-quarter as a result of the timing of our achievement of preclinical, clinical, regulatory and commercialization milestones, if at all, the timing and amount of payments relating to such milestones and the extent to which any of our products are approved and successfully commercialized by us or our strategic alliance partners. If our current or future strategic alliance partners do not elect or otherwise agree to fund our development costs pursuant to our current or future strategic alliance agreement, or we or our strategic alliance partner fails to develop product candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenues, and our results of operations and financial position would be adversely affected.

Research and development expenses

Research and development expenses consist of costs associated with our research activities, including our drug discovery efforts and the development of our therapeutic programs. Our research and development expenses include:


•	employee-related expenses, including salaries, benefits, travel and stock-based compensation expense;


•	external research and development expenses incurred under arrangements with third parties, such as contract research organizations, or CROs, contract manufacturing organizations, or CMOs, other clinical trial related vendors, consultants and our scientific advisors;


•	license fees; and


•	facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment, and laboratory and other supplies.

We expense research and development costs as incurred. We account for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received. Certain of the raw materials used in the process of manufacturing drug product are capitalized upon their acquisition and expensed upon usage, as we have determined these materials have alternative future use.

To date, we have conducted research on many different microRNAs with the goal of understanding how they function and identifying those that might be targets for therapeutic modulation. At any given time we are working on multiple targets, primarily within our therapeutic areas of focus. Our organization is structured to allow the rapid deployment and shifting of resources to focus on the best known targets based on our ongoing research. As a result, in the early phase of our development programs, our research and development costs are not tied to any specific target. However, we are currently spending the vast majority of our research and development resources on our lead development programs.

Since our inception, we have spent a total of approximately $340.4 million in research and development expenses through September 30, 2018.

The process of conducting clinical trials and preclinical studies necessary to obtain regulatory approval is costly and time consuming. We, or our strategic alliance partners, may never succeed in achieving marketing approval for any of our product candidates. The probability of success for each product candidate may be affected by numerous factors, including preclinical data, clinical data, competition, manufacturing capability and commercial viability.

Successful development of future product candidates is highly uncertain and may not result in approved products. Completion dates and completion costs can vary significantly for each future product candidate and are difficult to predict. We anticipate we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to our ability to maintain or enter into new strategic alliances with respect to each program or potential product candidate, the scientific and clinical success of each future product candidate, as well as ongoing assessments

as to each future product candidate’s commercial potential. We will need to raise additional capital and may seek additional strategic alliances in the future in order to advance our various programs.

General and administrative expenses

General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development and support functions. Other general and administrative expenses include allocated facility-related costs not otherwise included in research and development expenses and professional fees for auditing, tax and legal services, some of which are incurred as a result of being a publicly-traded company.

Other income (expense), net

Other income (expense) consists primarily of interest income and expense and various income or expense items of a non-recurring nature. We earn interest income from interest-bearing accounts and money market funds for cash and cash equivalents and short-term investments, such as interest-bearing bonds, for our short-term investments. Interest expense is primarily attributable to interest charges associated with borrowings under our secured Term Loan.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

There have been no significant changes to our critical accounting policies since December 31, 2017, with the exception of changes made upon adoption of ASU No. 2014-09 and the related supplemental ASUs. For a description of critical accounting policies that affect our significant judgments and estimates used in the preparation of our consolidated financial statements, refer to Item 7 in Management’s Discussion and Analysis of Financial Condition and Results of Operations and Note 1 to our financial statements contained in our Annual Report and Note 1 to our condensed financial statements contained in this quarterly report on Form 10-Q. For a description of accounting policy changes resulting from the adoption of ASU No. 2014-09 and the related supplemental ASUs, refer to Note 1 to our condensed financial statements contained in this quarterly report on Form 10-Q.

RESULTS OF OPERATIONS

Comparison of the three and nine months ended September 30, 2018 and 2017

The following table summarizes our results of operations for the three and nine months ended September 30, 2018 and 2017 (in thousands):



	Three months ended September 30,						Nine months ended September 30,
	2018			2017			2018			2017
Revenue under strategic alliances and collaborations	$	18		$	18		$	54		$	54
Research and development expenses	6,879			12,697			28,720			42,727
General and administrative expenses	2,993			2,736			10,115			13,752
Interest and other expenses, net	(419		)	(420		)	(1,365		)	(1,171		)

Revenue under strategic alliances and collaborations

Our revenues are generated from ongoing strategic alliance and collaborations, and generally consist of upfront payments for licenses or options to obtain licenses in the future, milestone payments and payments for other research services. Revenue under our strategic alliance was less than $0.1 million for each of the three and nine months ended September 30, 2018 and 2017. As of September 30, 2018, we had $0.1 million of deferred revenue, which consisted of payments received through our strategic alliance that have not yet been recognized in accordance with our revenue recognition policies.

Upon adoption of ASU No 2014-09 and the related supplemental ASUs, we reclassified $1.8 million of contract liabilities into accumulated deficit through the modified retrospective method of adoption.

Research and development expenses

The following tables summarize the components of our research and development expenses for the periods indicated, together with year-over-year changes (dollars in thousands):



									Increase (decrease)
	Three months ended September 30, 2018		% of total		Three months ended September 30, 2017		% of total		$			%
Research and development
Personnel and internal expenses	$	4,597	67	%	$	4,526	36	%	$	71		2	%
Third-party and outsourced expenses	1,541		22	%	7,030		55	%	(5,489		)	(78	)%
Non-cash stock-based compensation	522		8	%	653		5	%	(131		)	(20	)%
Depreciation	219		3	%	488		4	%	(269		)	(55	)%
Total research and development expenses	$	6,879	100	%	$	12,697	100	%	$	(5,818	)	(46	)%



									Increase (decrease)
	Nine months ended September 30, 2018		% of total		Nine months ended September 30, 2017		% of total		$			%
Research and development
Personnel and internal expenses	$	13,340	47	%	$	17,227	40	%	$	(3,887	)	(23	)%
Third-party and outsourced expenses	12,932		45	%	22,857		54	%	(9,925		)	(43	)%
Non-cash stock-based compensation	1,776		6	%	1,012		2	%	764			75	%
Depreciation	672		2	%	1,631		4	%	(959		)	(59	)%
Total research and development expenses	$	28,720	100	%	$	42,727	100	%	$	(14,007	)	(33	)%

Research and development expenses were $6.9 million and $28.7 million for the three and nine months ended September 30, 2018, respectively, compared to $12.7 million and $42.7 million for the three and nine ended September 30, 2017, respectively. The aggregate decreases were driven by a $5.5 million and $9.9 million decrease in external development expenses during the three and nine month periods ended September 30, 2018, respectively, primarily attributable to the pausing of the RG-012 and RGLS4326 programs early in the third quarter of 2018 and the discontinuation of the RG-101 and RGLS5040 programs in 2017. Additionally, the decrease for the nine months ended September 30, 2018 as compared to the nine months ended September 30, 2017 was driven by a $3.9 million reduction in personnel and internal expenses, primarily attributable to a reduction in costs subsequent to our corporate restructurings.

General and administrative expenses

General and administrative expenses were $3.0 million and $10.1 million for the three and nine months ended September 30, 2018, respectively, compared to $2.7 million and $13.8 million for the three and nine months ended September 30, 2017, respectively. The increase for the three months ended September 30, 2018 as compared to the three months ended September 30, 2017 was driven by non-recurring severance charges of $0.3 million recorded in the third quarter of 2018 in connection with our July 2018 corporate restructuring. The decrease for the nine months ended September 30, 2018 as compared to the nine months ended September 30, 2017 was driven by non-recurring severance charges of $1.0 million and non-recurring, non-cash stock-based compensation charges of $2.7 million recorded in connection with our May 2017 corporate restructuring.

Interest and other expenses, net

Net interest and other expenses were $0.4 million and $1.4 million for the three and nine months ended September 30, 2018, respectively, compared to $0.4 million and $1.2 million for the three and nine months ended September 30, 2017, respectively, primarily related to interest charges associated with our outstanding Term Loan.

LIQUIDITY AND CAPITAL RESOURCES

Since our inception through September 30, 2018, we have received $85.1 million from our strategic alliances and collaborations, principally from upfront payments, research funding and preclinical and clinical milestones, $300.1 million from the sale of our equity and convertible debt securities and $19.8 million in net proceeds from our Term Loan. As of September 30, 2018, we had cash, cash equivalents and short-term investments of $20.5 million.

If we are unable to maintain sufficient financial resources, our business, financial condition and results of operations will be materially and adversely affected. There can be no assurance that we will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or debt financings may have a dilutive effect on the holdings of the Company’s existing stockholders. These factors raise substantial doubt about our ability to continue as a going concern.

Our future capital requirements are difficult to forecast and will depend on many factors, including:


•	whether and when we achieve any milestones under our strategic alliance agreement with Sanofi;


•	the terms and timing of any other strategic alliance, licensing and other arrangements that we may establish;


•	the initiation, progress, timing and completion of preclinical studies and clinical trials for our development programs and product candidates, and associated costs;


•	the number and characteristics of product candidates that we pursue;


•	the outcome, timing and cost of regulatory approvals;


•	delays that may be caused by changing regulatory requirements;


•	the cost and timing of hiring new employees to support our continued growth;


•	the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;


•	the costs and timing of procuring clinical and commercial supplies of our product candidates;


•	the costs and timing of establishing sales, marketing and distribution capabilities;


•	the extent to which we acquire or invest in businesses, products or technologies; and


•	payments under our Term Loan.

The following table shows a summary of our cash flows for the nine months ended September 30, 2018 and 2017 (in thousands):



	Nine months ended September 30,
	2018			2017
	(unaudited)
Net cash (used in) provided by:
Operating activities	$	(39,256	)	$	(47,672	)
Investing activities	40,079			9,538
Financing activities	(258		)	43,415
Total	$	565		$	5,281

Operating activities

Net cash used in operating activities was $39.3 million for the nine months ended September 30, 2018, compared to $47.7 million for the nine months ended September 30, 2017. The decrease in net cash used in operating activities was primarily attributable to a net loss of $40.1 million for the nine months ended September 30, 2018, compared to a net loss of $57.5 million for the nine months ended September 30, 2017. This decrease was partially offset by changes in working capital, resulting in a decrease in net cash used in operating activities of $5.4 million for the nine months ended September 30, 2018, compared to an increase in net cash used in operating activities of $0.8 million for the nine months ended September 30, 2017. Additionally, the decrease was partially offset by adjustments for non-cash charges, including stock-based compensation, resulting in decreases in net cash used in operating activities of $6.3 million for the nine months ended September 30, 2018, compared to decreases in net cash used in operating activities of $9.0 million for the nine months ended September 30, 2017.

Investing activities

Net cash provided by investing activities for the periods presented primarily related to the net of purchases, sales and maturities of investments used to fund our operations. We invest cash in excess of our immediate operating requirements in a way that maturity is staggered and designed to optimize our return on investment, while satisfying our liquidity needs. Net cash

provided by the net sales and maturities of short-term investments was $40.1 million for the nine months ended September 30, 2018, compared to $9.5 million for the nine months ended September 30, 2017.

Financing activities

Net cash used in financing activities was $0.3 million for the nine months ended September 30, 2018, compared to net cash provided by financing activities of $43.4 million for the nine months ended September 30, 2017. Net cash used in financing activities for the nine months ended September 30, 2018 was primarily attributable to the remittance of our first principal amortization payment due under our outstanding Term Loan, partially offset by proceeds from capital lease financing activities. Net cash provided by financing activities for the nine months ended September 30, 2017 was primarily attributable to $43.0 million in net proceeds received from our public offering in July 2017.

CONTRACTUAL OBLIGATIONS AND COMMITMENTS

As of September 30, 2018, there have been no material changes, outside of the ordinary course of business, in our outstanding contractual obligations from those disclosed within the contractual obligations table under “Management's Discussion and Analysis of Financial Condition and Results of Operations”, as contained in our Annual Report, other than the August 2018 amendment to our Loan Agreement (refer to Note 5 for information regarding our Loan Agreement).

Off-Balance Sheet Arrangements

As of September 30, 2018, we did not have any off-balance sheet arrangements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Some of the securities that we invest in have market risk where a change in prevailing interest rates may cause the principal amount of short-term investments to fluctuate. Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. We invest our excess cash primarily in debt instruments of financial institutions, corporations, U.S. government-sponsored agencies and the U.S. Treasury. The primary objectives of our investment activities are to ensure liquidity and to preserve principal while at the same time maximizing the income we receive from our short-term investments without significantly increasing risk. Additionally, we established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.

Because of the short-term maturities of our cash equivalents and short-term investments, we do not believe that an increase in market rates would have any significant impact on the realized value of our short-term investments. If a 10% change in interest rates were to have occurred on September 30, 2018, this change would not have had a material effect on the fair value of our investment portfolio as of that date.

We also have interest rate exposure as a result of our outstanding Term Loan. As of September 30, 2018, the outstanding principal amount of the Term Loan was $19.2 million. The Term Loan bears interest at a floating per annum rate equal to (i) 8.51% plus (ii) the greater of (a) the 30 day U.S. Dollar LIBOR rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue and (b) 0.44%. Changes in the U.S. Dollar LIBOR rate may therefore affect our interest expense associated with the Term Loan.

If a 10% change in interest rates were to have occurred on September 30, 2018, this change would not have had a material effect on our interest expense as of that date.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and our principal financial and accounting officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and

procedures. In addition, the design of any system of controls also is based, in part, upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

As of September 30, 2018, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and our principal financial and accounting officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Based on this evaluation, our principal executive officer and our principal financial and accounting officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2018.

Changes in Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Rule 13a-15(f) of the Exchange Act. An evaluation was also performed under the supervision and with the participation of our management, including our principal executive officer and our principal financial and accounting officer, of any change in our internal control over financial reporting that occurred during our last fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any change in our internal control over financial reporting that occurred during our latest fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

On January 31, 2017, a putative class action complaint was filed by Baran Polat in the United States District Court for the Southern District of California, or District Court, against us, Paul C. Grint (our former Chief Executive Officer), and Joseph P. Hagan (then our Chief Operating Officer and currently our President and Chief Executive Officer). The complaint includes claims asserted, on behalf of certain purchasers of our securities, under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended. In general, the complaint alleges that, between January 21, 2016, and June 27, 2016, the defendants violated the federal securities laws by making materially false and misleading statements regarding our business and the prospects for RG-101, thereby artificially inflating the price of our securities. The plaintiff seeks unspecified monetary damages and other relief. On February 10, 2017, a second putative class action complaint was filed by Li Jin in the District Court against the Company, Mr. Hagan, Dr. Grint, and Timothy Wright, the Company’s Chief Research and Development Officer. The Complaint alleges claims similar to those asserted by Mr. Polat. The actions have been related. On February 17, 2017, the District Court entered an order stating that defendants need not answer, or otherwise respond, until the District Court enters an order appointing, pursuant to the Private Securities Litigation Reform Act of 1995, lead plaintiff and lead counsel, and the parties then submit a schedule to the District Court for the filing of an amended or consolidated complaint and the timing of defendants’ answer or response. On April 3, 2017, two motions for consolidation of the two actions, appointment of lead plaintiff and approval of counsel were filed in the actions, or the Consolidation and Lead Plaintiff Motions. On October 26, 2017, the District Court entered an order consolidating the cases, appointing lead plaintiffs, and appointing lead counsel for lead plaintiffs. On December 22, 2017, lead plaintiffs filed a consolidated complaint against the Company, Dr. Grint, Mr. Hagan, and Michael Huang (our former Vice President of Clinical Development). The consolidated complaint alleges that between February 17, 2016 and June 12, 2017, the Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, by making materially false and misleading statements regarding RG-101. The consolidated complaint seeks unspecified monetary damages and an award of attorneys’ fees and costs. On February 6, 2018, defendants filed a Motion to Dismiss the Consolidated Complaint. On March 23, 2018, plaintiff filed their opposition to the motion and on April 24, 2018, defendants filed their response. No hearing date has been set. We intend to vigorously defend this matter.

ITEM 1A. RISK FACTORS

You should carefully consider the following risk factors, as well as the other information in this report, before deciding whether to purchase, hold or sell shares of our common stock. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all the factors described when evaluating our business. The risk factors set forth below that are marked with an asterisk (*) did not appear as separate risk factors in, or contain changes to the similarly titled risk factors included in,

Item 1A of our Annual Report. If any of the following risks actually occurs, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock would likely decline.

RISKS RELATED TO OUR FINANCIAL CONDITION AND NEED FOR ADDITIONAL CAPITAL

We will need to raise additional capital, and if we are unable to do so when needed, we will not be able to continue as a going concern. *

This Form 10-Q includes disclosures regarding management’s assessment of our ability to continue as a going concern and our Annual Report on Form 10-K for the year ended December 31, 2017 includes a report from our independent registered public accounting firm that contains an explanatory paragraph regarding going concern, as our current liquidity position and recurring losses from operations since inception and negative cash flows from operating activities raise substantial doubt about our ability to continue as a going concern. As of September 30, 2018, we had $20.5 million of cash, cash equivalents and short-term investments and we had $19.2 million of outstanding debt principal obligations under our Term Loan with Oxford. In addition, pursuant to the terms of the Fourth Amendment, we are required to maintain cash in a collateral account controlled by the Lender of (i) $10.0 million if a Capital Event has not occured, or (ii) $5.0 million if a Capital Event has occurred. We will need to raise additional capital to fund our operations, service our debt obligations and comply with the cash reserve covenant under our Loan Agreement with Oxford, and if we are unable to raise additional capital when needed, we will not be able to continue as a going concern.

Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. We expect our research and development expenses to substantially increase in connection with our ongoing activities, particularly as we advance our product candidates towards or through clinical trials. We will need to raise additional capital to fund our operations and such funding may not be available to us on acceptable terms, or at all.

As we move future lead compounds through toxicology and other preclinical studies, also referred to as nonclinical studies, required to file an IND, and as we conduct clinical development of RG-012, RGLS4326 and any other future product candidates, we may have adverse results requiring mitigation strategies that may cause us to consume additional capital. For example, in July 2018 we voluntarily paused our Phase I MAD clinical trial for RGLS4326 due to unexpected observations in our 27-week mouse chronic toxicity study, which was designed to support the Phase II proof-of-concept clinical trial in ADPKD previously planned to start in mid-2019. In consultation with the FDA, we initiated a new mouse chronic toxicity study in September 2018 with certain changes that are believed to address the unexpected observations. Additionally, our strategic alliance partners may not elect to pursue the development and commercialization of any of our microRNA product candidates that are subject to their respective strategic alliance agreements with us. Any of these events may increase our development costs more than we expect. For example, in June 2017, AstraZeneca terminated its development of RG-125(AZD4076). Upon the effective date of termination, in June 2019, AstraZeneca’s rights to the program will revert to us and we may decide to continue with its development but will then be responsible for any continuing costs of development. In November 2018, we and Sanofi agreed to transition further development activities of our miR-21 programs, including our RG-012 program, to Sanofi, which will be responsible for all costs incurred in the development of our miR-21 programs. As a result, we will not receive royalties in the event our miR-21 programs are eventually commercialized and will also receive significantly reduced milestones for these programs. We may need to raise additional capital or otherwise obtain funding through additional strategic alliances if we choose to initiate clinical trials for new product candidates other than programs currently partnered. In any event, we will require additional capital to obtain regulatory approval for, and to commercialize, future product candidates.

For the foreseeable future, we expect to rely primarily on equity and/or debt financings to fund our operations. Raising additional capital through the sale of securities could cause significant dilution to our stockholders. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. Our ability to raise additional funds will depend, in part, on the success of our preclinical studies and clinical trials and other product development activities, regulatory events, our ability to identify and enter into licensing or other strategic arrangements, and other events or conditions that may affect our value or prospects, as well as factors related to financial, economic and market conditions, many of which are beyond our control. There can be no assurances that sufficient funds will be available to us when required or on acceptable terms, if at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to:


•	significantly delay, scale back or discontinue the development or commercialization of any future product candidates;


•	seek strategic alliances, or amend existing alliances, for research and development programs at an earlier stage than otherwise would be desirable or for the development of programs that we otherwise would have sought to develop independently, or on terms that are less favorable than might otherwise be available;


•	dispose of technology assets, or relinquish or license on unfavorable terms, our rights to technologies or any future product candidates that we otherwise would seek to develop or commercialize ourselves;


•	pursue the sale of our company to a third party at a price that may result in a loss on investment for our stockholders; or


•	file for bankruptcy or cease operations altogether.

Any of these events could have a material adverse effect on our business, operating results and prospects.

We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. *

Since inception, our operations have been primarily limited to acquiring and in-licensing intellectual property rights, developing our microRNA product platform, undertaking basic research around microRNA targets and conducting preclinical and clinical studies for our initial programs. We have not yet obtained regulatory approval for any product candidates. Consequently, any predictions about our future success or viability, or any evaluation of our business and prospects, may not be accurate.

We have incurred losses in each year since our inception in September 2007. Our net losses were $10.3 million and $40.1 million for the three and nine months ended September 30, 2018, respectively, compared to $15.8 million and $57.5 million for the three and nine months ended September 30, 2017, respectively. As of September 30, 2018, we had an accumulated deficit of $384.2 million.

We have devoted most of our financial resources to research and development, including our preclinical and clinical development activities. To date, we have financed our operations primarily through the sale of equity securities and convertible debt, through our Term Loan and from revenue received from our strategic alliance partners. We have a strategic alliance with Sanofi relating to the development of our miR-21 programs for HCC and kidney fibrosis and our miR-221/222 program for oncology indications. Under our collaboration and license agreement with Sanofi, Sanofi has an option to obtain exclusive worldwide licenses for the development, manufacture and commercialization of our preclinical program targeting miR-221/222 for HCC. If Sanofi exercises its option, it will assume responsibility for funding and conducting further clinical development and commercialization activities for such product candidate. However, if Sanofi does not exercise its option, we will be responsible for funding further development of the applicable product candidate and may not have the resources to do so unless we are able to enter into another strategic alliance for such product candidate. In November 2018, we and Sanofi agreed to transition further development activities of our miR-21 programs, including our RG-012 program, to Sanofi, which will be responsible for all costs incurred in the development of our miR-21 programs. In June 2017, AstraZeneca provided notice to us of its election to discontinue the clinical development of RG-125(AZD4076) for NASH and terminated our collaboration and license agreement. Under the agreement with AstraZeneca, the termination was to become effective in June 2018. In May 2018, AstraZeneca requested to extend the agreement termination effective date by an additional 12 months to allow AstraZeneca to complete all activities involving AZD4076. By the end of this 12-month extension, the parties will complete the transfer activities contemplated by the agreement. The new termination effective date pursuant to the extension will be June 2019.

The size of our future net losses will depend, in part, on the rate of future expenditures and our ability to obtain funding through equity or debt financings, strategic alliances or grants. We initiated clinical development of RGLS4326 for the treatment of ADPKD. We have also initiated clinical development of RG-012, however, it will be several years, if ever, before we or our strategic alliance partners have a product candidate ready for commercialization. Even if we or our strategic alliance partners successfully obtain regulatory approval to market a product candidate, our revenues will also depend upon the size of any markets in which our product candidates have received market approval, and our ability to achieve sufficient market acceptance and adequate market share for our products.

We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that our expenses will increase substantially if and as we: continue our research and preclinical and clinical development of our product candidates, both independently and under our strategic alliance agreements; seek to identify additional microRNA targets and product candidates; acquire or in-license other products and technologies; continue with clinical development of our product candidates; seek marketing

approvals for our product candidates that successfully complete clinical trials; ultimately establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; maintain, expand and protect our intellectual property portfolio; hire additional clinical, regulatory, research and administrative personnel; and create additional infrastructure to support our operations and our product development and planned future commercialization efforts.

We have never generated any revenue from product sales and may never be profitable.

Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic alliance partners, to successfully complete the development of, obtain the necessary regulatory approvals for and commercialize product candidates. We do not anticipate generating revenues from sales of products for the foreseeable future, if ever. Our ability to generate future revenues from product sales depends heavily on our success in:


•	identifying and validating new microRNAs as therapeutic targets;


•	completing our research and preclinical development of product candidates;


•	initiating and completing clinical trials for product candidates;


•	seeking and obtaining marketing approvals for product candidates that successfully complete clinical trials;


•	establishing and maintaining supply and manufacturing relationships with third parties;


•	launching and commercializing product candidates for which we obtain marketing approval, with an alliance partner or, if launched independently, successfully establishing a sales force, marketing and distribution infrastructure;


•	maintaining, protecting and expanding our intellectual property portfolio; and


•	attracting, hiring and retaining qualified personnel.

Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to predict the timing or amount of increased expenses and when we will be able to achieve or maintain profitability, if ever. In addition, our expenses could increase beyond expectations if we are required by the FDA or foreign regulatory agencies to perform studies and trials in addition to those that we currently anticipate.

Even if one or more of the product candidates that we independently develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations.

Payments under the instruments governing our indebtedness may reduce our working capital. In addition, a default under our loan and security agreement could cause a material adverse effect on our financial position. *

In June 2016, we entered into a loan and security agreement with Oxford. Under the terms of the Loan Agreement, Oxford provided us with a Term Loan of $20.0 million. Our obligations under the Loan Agreement are secured by a first priority security interest in substantially all of our current and future assets, except for the Assigned Assets that were licensed, assigned and transferred to Sanofi pursuant to the 2018 Sanofi Amendment, provided that the Oxford will continue to have liens on all proceeds received by us pursuant to the Sanofi License. We have also agreed not to encumber our intellectual property assets, except as permitted by the Loan Agreement. Amounts outstanding under the Term Loan mature on June 1, 2020 and were interest-only through June 1, 2018. On August 6, 2018, we and Oxford entered into an amendment to the parties’ Loan Agreement. Under the terms of the amendment, we were required to make payments of interest-only for an additional three-month period, from August 2018 through October 2018. Amortization payments commence in November 2018. On November 5, 2018 and in connection with the 2018 Sanofi Amendment we entered into the Fourth Amendment with the Lender. Under the terms of the Fourth Amendment, we are required to prepay part of the Term Loan with 25% of certain payments we receive under the 2018 Sanofi Amendment, which payments consist of the Upfront Amendment Payments and the first development milestone payment in the amount of $10.0 million. We will also be required to pay the applicable 5.5% final payment fee related to each such 2018 Sanofi Amendment prepayment. In addition, we are required to maintain cash in a collateral account controlled by the Lender of (i) $10.0 million if a Capital Event has not occurred, or (ii) $5.0 million if a Capital Event has occurred. Payments under the Loan Agreement could result in a significant reduction of our assets.

The Loan Agreement requires us, and any debt arrangements we may enter into in the future may require us, to comply with various covenants that limit our ability to, among other things:


•	dispose of assets;


•	complete mergers or acquisitions;


•	incur indebtedness;


•	encumber assets;


•	pay dividends or make other distributions to holders of our capital stock;


•	make specified investments; and


•	engage in transactions with our affiliates.

These restrictions could inhibit our ability to pursue our business strategies. If we default under our obligations under the Loan Agreement, the lender could proceed against the collateral granted to it to secure our indebtedness or declare all obligation under the Loan Agreement to be due and payable. In certain circumstances, procedures by the lenders could result in a loss by us of all of our equipment and inventory, which are included in the collateral granted to the lenders. If any indebtedness under the Loan Agreement were to be accelerated, there can be no assurance that our assets would be sufficient to repay in full that indebtedness. In addition, upon any distribution of assets pursuant to any liquidation, insolvency, dissolution, reorganization or similar proceeding, the holders of secured indebtedness will be entitled to receive payment in full from the proceeds of the collateral securing our secured indebtedness before the holders of other indebtedness or our common stock will be entitled to receive any distribution with respect thereto.

We may incur additional indebtedness in the future. The debt instruments governing such indebtedness may contain provisions that are as, or more, restrictive than the provisions governing our existing indebtedness under the Loan Agreement. If we are unable to repay, refinance or restructure our indebtedness when payment is due, the lenders could proceed against the collateral or force us into bankruptcy or liquidation.

RISKS RELATED TO THE DISCOVERY AND DEVELOPMENT OF PRODUCT CANDIDATES

The approach we are taking to discover and develop drugs is novel and may never lead to marketable products.

We have concentrated our therapeutic product research and development efforts on microRNA technology, and our future success depends on the successful development of this technology and products based on our microRNA product platform. Neither we, nor any other company, has received regulatory approval to market therapeutics targeting microRNAs. The scientific discoveries that form the basis for our efforts to discover and develop product candidates are relatively new. The scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. If we do not successfully develop and commercialize product candidates based upon our technological approach, we may not become profitable and the value of our common stock may decline.

Further, our focus solely on microRNA technology for developing drugs as opposed to multiple, more proven technologies for drug development increases the risks associated with the ownership of our common stock. If we are not successful in developing any product candidates using microRNA technology, we may be required to change the scope and direction of our product development activities. In that case, we may not be able to identify and implement successfully an alternative product development strategy.

We may not be successful in our efforts to identify or discover potential product candidates.

The success of our business depends primarily upon our ability to identify, develop and commercialize microRNA therapeutics. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:


•	our research methodology or that of any strategic alliance partner may be unsuccessful in identifying potential product candidates;


•	potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval; or


•	our current or future strategic alliance partners may change their development profiles for potential product candidates or abandon a therapeutic area.

If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful.

Preclinical and clinical studies of our product candidates may not be successful. If we are unable to generate successful results from our preclinical and clinical studies of our product candidates, or experience significant delays in doing so, our business may be materially harmed.

We have invested a significant portion of our efforts and financial resources in the identification and development of product candidates that target microRNAs. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates.

The success of our product candidates will depend on several factors, including the following:


•	successfully designing preclinical studies which may be predictive of clinical outcomes;


•	successful results from preclinical and clinical studies;


•	receipt of marketing approvals from applicable regulatory authorities;


•	obtaining and maintaining patent and trade secret protection for future product candidates;


•	establishing and maintaining manufacturing relationships with third parties or establishing our own manufacturing capability; and


•	successfully commercializing our products, if and when approved, whether alone or in collaboration with others.

If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully complete the development of, or commercialize, our product candidates, which would materially harm our business.

If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates. *

Before obtaining marketing approval from regulatory authorities for the sale of product candidates, we or a strategic alliance partner must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. Clinical trials are expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for their products.

Events which may result in a delay or unsuccessful completion of clinical development include:


•	delays in reaching an agreement with the FDA or other regulatory authorities on final trial design;


•	imposition of a clinical hold of our clinical trial operations or trial sites by the FDA or other regulatory authorities;


•	delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites;


•	our inability to adhere to clinical trial requirements directly or with third parties such as CROs;


•	delays in obtaining required institutional review board approval at each clinical trial site;


•	delays in recruiting suitable patients to participate in a trial;


•	delays in the testing, validation, manufacturing and delivery of the product candidates to the clinical sites;


•	delays in having patients complete participation in a trial or return for post-treatment follow-up;


•	delays caused by patients dropping out of a trial due to protocol procedures or requirements, product side effects or disease progression;


•	clinical sites dropping out of a trial to the detriment of enrollment;


•	time required to add new clinical sites; or


•	delays by our contract manufacturers to produce and deliver sufficient supply of clinical trial materials.

For example, in June 2016, the FDA placed a full clinical hold on our RG-101 clinical program after a second patient experienced an SAE of jaundice, which ultimately led to our identification of a bilirubin transport mechanism as the likely cause for the cases of SAEs of jaundice and our decision to discontinue clinical development of RG-101. In July 2018, we voluntarily paused our Phase I MAD clinical trial for RGLS4326 due to unexpected observations in our 27-week mouse chronic toxicity study, which was designed to support the Phase II proof-of-concept clinical trial in ADPKD previously planned to start in mid-2019. The observations in the mouse chronic toxicity study were unexpected, given the favorable safety profile of RGLS4326 in previous non-GLP and GLP toxicity studies at the same or similar doses supporting the IND and Phase I clinical trial. In consultation with the FDA, we initiated a new mouse chronic toxicity study with certain changes that are believed to address the unexpected observations.

If we or our current or future strategic alliance partners are required to conduct additional clinical trials or other testing of any product candidates beyond those that are currently contemplated, are unable to successfully complete clinical trials of any such product candidates or other testing, or if the results of these trials or tests are not positive or are only moderately positive or if there are safety concerns, we or our current or future strategic alliance partners may:


•	be delayed in obtaining marketing approval for our future product candidates;


•	not obtain marketing approval at all;


•	obtain approval for indications or patient populations that are not as broad as originally intended or desired;


•	obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;


•	be subject to additional post-marketing testing requirements; or


•	have the product removed from the market after obtaining marketing approval.

Our product development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether any clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which would impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. Any inability to successfully complete preclinical and clinical development, whether independently or with a strategic alliance partner, could result in additional costs to us or impair our ability to generate revenues from product sales, regulatory and commercialization milestones and royalties.

Any of our product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label or market acceptance.

Adverse events, or AEs, caused by our product candidates could cause us, other reviewing entities, clinical trial sites or regulatory authorities to interrupt, delay or halt clinical trials and could result in the denial of regulatory approval. Certain oligonucleotide therapeutics have shown injection site reactions and pro-inflammatory effects and may also lead to impairment of kidney or liver function. There is a risk that our future product candidates may induce similar AEs.

If AEs are observed in any clinical trials of our product candidates, including those that a strategic alliance partner may develop under an agreement with us, our or our partners’ ability to obtain regulatory approval for product candidates may be negatively impacted.

Further, if any of our future products, if and when approved for commercial sale, cause serious or unexpected side effects, a number of potentially significant negative consequences could result, including:


•	regulatory authorities may withdraw their approval of the product or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy;


•	regulatory authorities may require the addition of labeling statements, such as warnings or contraindications;


•	we may be required to change the way the product is administered or conduct additional clinical trials;


•	we could be sued and held liable for harm caused to patients; or


•	our reputation may suffer.

Any of these events could prevent us or our partners from achieving or maintaining market acceptance of the affected product and could substantially increase the costs of commercializing our future products and impair our ability to generate revenues from the commercialization of these products either on our own or with a strategic alliance partner.

Even if we complete the necessary preclinical studies and clinical trials, we cannot predict whether or when we will obtain regulatory approval to commercialize a product candidate and we cannot, therefore, predict the timing of any revenue from a future product.

Neither we nor any strategic alliance partner can commercialize a product until the appropriate regulatory authorities, such as the FDA, have reviewed and approved the product candidate. The regulatory agencies may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee recommends restrictions on approval or recommends non-approval. In addition, we or a strategic alliance partner may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical trials and the review process.

Even if we obtain regulatory approval for a product candidate, we will still face extensive regulatory requirements and our products may face future development and regulatory difficulties.

Even if we obtain regulatory approval in the United States, the FDA may still impose significant restrictions on the indicated uses or marketing of our product candidates, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. The holder of an approved NDA is obligated to monitor and report AEs and any failure of a product to meet the specifications in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws.

In addition, drug product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, and adherence to commitments made in the NDA. If we or a regulatory agency discovers previously unknown problems with a product such as AEs of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.

If we or our partners fail to comply with applicable regulatory requirements following approval of any of our product candidates, a regulatory agency may:


•	issue a warning letter asserting that we are in violation of the law;


•	seek an injunction or impose civil or criminal penalties or monetary fines;


•	suspend or withdraw regulatory approval;


•	suspend any ongoing clinical trials;


•	refuse to approve a pending NDA or supplements to an NDA submitted by us;


•	seize product; or


•	refuse to allow us to enter into supply contracts, including government contracts.

Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our future products and generate revenues.

We may not be successful in obtaining or maintaining necessary rights to microRNA targets, drug compounds and processes for our development pipeline through acquisitions and in-licenses.

Presently we have rights to the intellectual property, through licenses from third parties and under patents that we own, to modulate only a subset of the known microRNA targets. Because our programs may involve a range of microRNA targets, including targets that require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. In addition, our product candidates may require specific

formulations to work effectively and efficiently and these rights may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.

For example, we may collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution’s rights in technology resulting from the collaboration. Regardless of such right of first negotiation for intellectual property, we may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.

In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party intellectual property rights, our business, financial condition and prospects for growth could suffer.

We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success. *

Because we have limited financial and human resources, our existing strategy is to pursue strategic alliance agreements for the development and commercialization of our programs and potential product candidates in indications with potentially large commercial markets such as HCC, fibrosis, HCV, and HBV, while focusing our internal development resources and any internal sales and marketing organization that we may establish on research programs and product candidates for selected markets, such as orphan diseases. As a result, we may forego or delay pursuit of opportunities with other programs or product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic alliance, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate, or we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement.

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.

We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.

Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.

RISKS RELATED TO OUR RELIANCE ON THIRD PARTIES

We will depend upon strategic alliances for the development and eventual commercialization of certain microRNA product candidates. If these strategic alliances are unsuccessful or are terminated, we may be unable to commercialize certain product candidates and we may be unable to generate revenues from our development programs. *

We are likely to depend upon third party strategic alliance partners for financial and scientific resources for the clinical development and commercialization of certain of our microRNA product candidates. These strategic alliances will likely provide us with limited control over the course of development of a microRNA product candidate, especially once a candidate has reached the stage of clinical development. For example, in our alliance with Sanofi, Sanofi has the option to obtain an exclusive worldwide license to develop, manufacture and commercialize our preclinical program targeting miR-221/222 for HCC upon the achievement of relevant endpoints in clinical trials. However, Sanofi is not under any obligation to exercise this option. While Sanofi has development obligations with respect to programs that it may elect to pursue under our agreement, our ability to ultimately recognize revenue from this and future relationships will depend upon the ability and willingness of our alliance partners to successfully meet their respective responsibilities under our agreements with them. In November 2018, we and Sanofi agreed to transition further development activities of our miR-21 programs, including our RG-012 program, to Sanofi, who will be responsible for all costs incurred in the development of our miR-21 program. As a result, we will not receive royalties in the event our miR-21 programs are eventually commercialized and will also receive significantly reduced milestones for these programs.

Our ability to recognize revenues from successful strategic alliances may be impaired by several factors including:


•	an alliance partner may shift its priorities and resources away from our programs due to a change in business strategies, or a merger, acquisition, sale or downsizing of its company or business unit;


•	an alliance partner may cease development in therapeutic areas which are the subject of our strategic alliances;


•	an alliance partner may change the success criteria for a particular program or potential product candidate thereby delaying or ceasing development of such program or candidate;


•	a significant delay in initiation of certain development activities by an alliance partner will also delay payment of milestones tied to such activities, thereby impacting our ability to fund our own activities;


•	an alliance partner could develop a product that competes, either directly or indirectly, with an alliance product;


•	an alliance partner with commercialization obligations may not commit sufficient financial or human resources to the marketing, distribution or sale of a product;


•	an alliance partner with manufacturing responsibilities may encounter regulatory, resource or quality issues and be unable to meet demand requirements;


•	an alliance partner may exercise its rights under the agreement to terminate a strategic alliance;


•	a dispute may arise between us and an alliance partner concerning the research, development or commercialization of a program or product candidate resulting in a delay in milestones, royalty payments or termination of a program and possibly resulting in costly litigation or arbitration which may divert management attention and resources; and


•	an alliance partner may use our proprietary information or intellectual property in such a way as to invite litigation from a third party or fail to maintain or prosecute intellectual property rights such that our rights in such property are jeopardized.

Specifically, with respect to termination rights, Sanofi may terminate the entire alliance or its current alliance target program for any or no reason upon 30 days’ written notice to us. The agreement with Sanofi may also be terminated by either party for material breach by the other party, including a failure to comply with such party’s diligence obligations that remains uncured after 120 days. Depending on the timing of any such termination, we may not be entitled to receive the option exercise fees or milestone payments, as these payments terminate with termination of the respective program or agreement. In June 2017, AstraZeneca provided notice to us of its election to terminate our collaboration and license agreement in its entirety, which termination was to become effective in June 2018. In May 2018, AstraZeneca requested to extend the collaboration and license agreement termination effective date by an additional 12 months to allow AstraZeneca to complete all activities involving AZD4076. By the end of this 12-month extension, the parties will complete the transfer activities contemplated by the agreement. The new termination effective date pursuant to the extension will be June 2019. We will be responsible for any further development costs at that time.

If any of our alliance partners do not elect to pursue the development and commercialization of our microRNA development candidates or if they terminate the strategic alliance, then, depending on the event:


•	in the case of Sanofi, under certain circumstances, we may owe Sanofi royalties with respect to product candidates covered by our agreement with Sanofi that we elect to continue to commercialize, depending upon the stage of development at which such product commercialization rights reverted back to us, or additional payments if we license such product candidates to third parties;


•	product candidates subject to the Sanofi agreement, as applicable, may be terminated or significantly delayed;


•	our cash expenditures could increase significantly if it is necessary for us to hire additional employees and allocate scarce resources to the development and commercialization of product candidates that were previously funded, or expected to be funded, by AstraZeneca or Sanofi, as applicable;

•

we would bear all of the risks and costs related to the further development and commercialization of product candidates that were previously the subject of the AstraZeneca agreement or the Sanofi agreement, as applicable, including the reimbursement of third parties; for example, upon expiration of the AstraZeneca termination period, we will be responsible for any further costs of development. In addition, we may owe AstraZeneca certain consideration for use of any intellectual property generated by AstraZeneca; and

•

in order to fund further development and commercialization, we may need to seek out and establish alternative strategic alliances with third-party partners; this may not be possible, or we may not be able to do so on terms which are acceptable to us, in which case it may be necessary for us to limit the size or scope of one or more of our programs or increase our expenditures and seek additional funding by other means.

Any of these events would have a material adverse effect on our results of operations and financial condition.

We rely on third parties to conduct some aspects of our compound formulation, research and preclinical studies, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such formulation, research or testing.

We do not expect to independently conduct all aspects of our drug discovery activities, compound formulation research or preclinical studies of product candidates. We currently rely and expect to continue to rely on third parties to conduct some aspects of our preclinical studies and formulation development.

Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it would delay our product development activities. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, for product candidates that we develop and commercialize on our own, we will remain responsible for ensuring that each of our IND-enabling studies and clinical trials are conducted in accordance with the study plan and protocols for the trial.

If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, we will not be able to complete, or may be delayed in completing, the necessary preclinical studies to enable us or our strategic alliance partners to select viable product candidates for IND submissions and will not be able to, or may be delayed in our efforts to, successfully develop and commercialize such product candidates.

We rely on third-party manufacturers to produce our preclinical and clinical product candidates, and we intend to rely on third parties to produce future clinical supplies of product candidates that we advance into clinical trials and commercial supplies of any approved product candidates.

Reliance on third-party manufacturers entails risks, including risks that we would not be subject to if we manufactured the product candidates ourselves, including:


•	the inability to meet any product specifications and quality requirements consistently;


•	a delay or inability to procure or expand sufficient manufacturing capacity;


•	manufacturing and product quality issues related to scale-up of manufacturing;


•	costs and validation of new equipment and facilities required for scale-up;


•	a failure to comply with cGMP and similar foreign standards;


•	the inability to negotiate manufacturing or supply agreements with third parties under commercially reasonable terms;


•	termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us;


•	the reliance on a limited number of sources, and in some cases, single sources for raw materials, such that if we are unable to secure a sufficient supply of these product components, we will be unable to manufacture and sell future product candidates in a timely fashion, in sufficient quantities or under acceptable terms;


•	the lack of qualified backup suppliers for any raw materials that are currently purchased from a single source supplier;


•	operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier;


•	carrier disruptions or increased costs that are beyond our control; and


•	the failure to deliver products under specified storage conditions and in a timely manner.

Any of these events could lead to clinical study delays or failure to obtain regulatory approval, or impact our ability to successfully commercialize future products. Some of these events could be the basis for FDA action, including injunction, recall, seizure or total or partial suspension of production.

We rely on limited sources of supply for the drug substance of product candidates and any disruption in the chain of supply may cause a delay in developing and commercializing these product candidates. *

We have established manufacturing relationships with a limited number of suppliers to manufacture raw materials and the drug substance of any product candidate for which we are responsible for preclinical or clinical development. Each supplier may require licenses to manufacture such components if such processes are not owned by the supplier or in the public domain. As part of any marketing approval, a manufacturer and its processes are required to be qualified by the FDA prior to commercialization. If supply from the approved vendor is interrupted, there could be a significant disruption in commercial supply. An alternative vendor would need to be qualified through an NDA supplement which could result in further delay. The FDA or other regulatory agencies outside of the United States may also require additional studies if a new supplier is relied upon for commercial production. Switching vendors may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.

In addition, if our alliance partners elect to pursue the development and commercialization of certain programs, we will lose control over the manufacturing of the product candidate subject to the agreement. For example, in November 2018, we and Sanofi agreed to transition further development activities of our miR-21 programs, including our RG-012 program, to Sanofi, who will be responsible for all costs incurred in the development of our miR-21 programs. As a result, we will no longer be involved in the development or commercialization of our miR-21 programs. Sanofi will be free to use a manufacturer of its own choosing or manufacture the product candidates in its own manufacturing facilities. In such a case, we will have no control over Sanofi’s processes or supply chains to ensure the timely manufacture and supply of the product candidates. In addition, we will not be able to ensure that the product candidates will be manufactured under the correct conditions to permit the product candidates to be used in such clinical trials.

These factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our product candidates, cause us to incur higher costs and prevent us from commercializing our products successfully. Furthermore, if our suppliers fail to deliver the required commercial quantities of active pharmaceutical ingredients on a timely basis and at commercially reasonable prices, and we are unable to secure one or more replacement suppliers capable of production in a timely manner at a substantially equivalent cost, our clinical trials may be delayed or we could lose potential revenue.

Manufacturing issues may arise that could increase product and regulatory approval costs or delay commercialization.

As we scale-up manufacturing of product candidates and conduct required stability testing, product, packaging, equipment and process-related issues may require refinement or resolution in order to proceed with any clinical trials and obtain regulatory approval for commercial marketing. We may identify significant impurities, which could result in increased scrutiny by the regulatory agencies, delays in clinical programs and regulatory approval, increases in our operating expenses, or failure to obtain or maintain approval for product candidates or any approved products.

We rely on third parties to conduct, supervise and monitor our clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.

We or our strategic alliance partners rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials. While we will have agreements governing their activities, we and our strategic alliance partners have limited influence over their actual performance. We control only certain aspects of our CROs’ activities. Nevertheless, we or our strategic alliance partners are responsible for ensuring that each of our clinical trials are conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities.

We, our alliance partners and our CROs are required to comply with the FDA’s or other regulatory agency’s good clinical practices, or GCPs, for conducting, recording and reporting the results of IND-enabling studies and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. The FDA and non-U.S. regulatory agencies enforce these GCPs through periodic inspections of trial sponsors, principal investigators and clinical trial sites. If we or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or applicable non-U.S. regulatory agency may require us to perform additional clinical trials before approving any marketing applications for the relevant jurisdiction. Upon inspection, the FDA or applicable non-U.S. regulatory agency may determine that our clinical trials did not comply with GCPs. In addition, our clinical trials will require a sufficiently large number of test subjects to evaluate the safety and effectiveness of a potential drug product. Accordingly, if our CROs fail to comply with these regulations or fail to recruit a sufficient number of patients, we may be required to repeat such clinical trials, which would delay the regulatory approval process.

Our CROs will not be our employees, and we will not be able to control whether or not they devote sufficient time and resources to our clinical and nonclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities which could harm our competitive position. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements, or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for such products and any product candidates that we develop would be harmed, our costs could increase, and our ability to generate revenues could be delayed.

We also rely on other third parties to store and distribute drug products for any clinical trials that we may conduct. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products, if approved, producing additional losses and depriving us of potential product revenue.

RISKS RELATED TO OUR INTELLECTUAL PROPERTY

If we are unable to obtain or protect intellectual property rights related to our future products and product candidates, we may not be able to compete effectively in our markets.

We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our future products and product candidates. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in patents with claims that cover the products in the United States or in other countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found; such prior art can invalidate a patent or prevent a patent from issuing based on a pending patent application. Even if patents do successfully issue, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims.

If the patent applications we hold or have in-licensed with respect to our programs or product candidates fail to issue or if their breadth or strength of protection is threatened, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize, future products. We cannot offer any assurances about which, if any, patents will issue or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. A patent may be challenged through one or more of several administrative proceedings including post-grant challenges, re-examination or opposition before the U.S. PTO or foreign patent offices. For example, re-examination of, or oppositions to, patents owned by or licensed to us have previously been initiated, and while we believe these concluded proceedings did not result in a commercially relevant impact on the individual patents, any successful challenge of patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we or our strategic alliance partners may develop.

Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we were the first to file any patent application related to a product candidate. Furthermore, in certain situations, if we and one or more third parties have filed patent applications in the United States and claiming the same subject matter, an administrative proceeding, known as an interference, can be initiated to determine which applicant is entitled to the patent on that subject matter. Such an interference proceeding provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications, or those of our alliance partners or licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of a patent or patent application in such a proceeding may not be successful and, even if successful, may result in substantial costs and distract our management and other employees.

In addition, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available however the life of a patent, and the protection it affords, is limited. Once the patent life has expired for a product, we may be open to competition from generic medications. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.

In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our drug discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Although each of our employees agrees to assign their inventions to us through an employee inventions agreement, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA’s disclosure policies may change in the future, if at all.

Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition.

Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.

Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our strategic alliance partners are pursuing development candidates. For example, we are aware that Roche Innovation Center Copenhagen has patents and patent applications in the microRNA therapeutics space, including patents and patent applications related to targeting microRNAs, such as miR-122, for the treatment of disease. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.

Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable

patents, or until such patents expire. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all.

Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.

If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.

We are a party to a number of intellectual property license agreements that are important to our business and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty and other obligations on us. For example, under our exclusive license agreement for Max-Planck-Innovation GmbH’s proprietary technology and know-how covering microRNA sequences, we are required to use commercially reasonable diligence to develop and commercialize a product and to satisfy specified payment obligations. If we fail to comply with our obligations under our agreement with Max-Planck-Innovation GmbH or our other license agreements, or we are subject to a bankruptcy, the licensor may have the right to terminate the license, in which event we, or our strategic alliance partners, would not be able to market products covered by the license. In addition, our exclusive license agreements with our founding companies, Alnylam and Ionis, provide us with rights to nucleotide technologies in the field of microRNA therapeutics based on oligonucleotides that modulate microRNAs. Some of these technologies, such as intellectual property relating to the chemical modification of oligonucleotides, are relevant to our product candidate development programs. If our license agreements with Alnylam or Ionis are terminated, or our business relationships with either of these companies or our other licensors are disrupted by events that may include the acquisition of either company, our access to critical intellectual property rights will be materially and adversely affected.

We may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our future products, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.

We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful.

Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.

Our defense in a litigation may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.

We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees’ former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.

RISKS RELATED TO COMMERCIALIZATION OF PRODUCT CANDIDATES

The commercial success of our programs that are part of our strategic alliance agreements with Sanofi or others will depend in large part on the development and marketing efforts of our alliance partners. If our alliance partners are unable or unwilling to perform in accordance with the terms of our agreements, our potential to generate future revenue from these programs would be significantly reduced and our business would be materially and adversely harmed.

In November 2018, we and Sanofi agreed to transition further development activities of our miR-21 programs, including our RG-012 program, to Sanofi, who will be responsible for all costs incurred in the development of our miR-21 programs. As a result, we will have no influence and/or control over their approaches to development and commercialization of our miR-21 programs. If Sanofi or any potential future strategic alliance partners do not perform in the manner that we expect or fail to fulfill their responsibilities in a timely manner, or at all, the clinical development, regulatory approval and commercialization efforts related to product candidates we have licensed to such strategic alliance partners could be delayed or terminated. If we terminate any of our strategic alliances or any program thereunder due to a material breach by Sanofi, and except in the case of RG-012, we have the right to assume the responsibility at our own expense for the development of the applicable microRNA product candidates. Assuming sole responsibility for further development will increase our expenditures and may mean we will need to limit the size and scope of one or more of our programs, seek additional funding and/or choose to stop work altogether on one or more of the affected product candidates. This could result in a limited potential to generate future revenue from such microRNA product candidates and our business could be materially and adversely affected. Further, under certain circumstances, we may owe Sanofi royalties on any product candidate that we may successfully commercialize.

We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.

The biotechnology and pharmaceutical industries are intensely competitive. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, biotechnology companies and universities and other research institutions. Our competitors may have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, drug products that are more effective or less costly than any product candidate that we may develop.

Most of our programs are targeted toward indications for which there are approved products on the market or product candidates in clinical development. We will face competition from other drugs currently approved or that will be approved in the future for the same therapeutic indications. Our ability to compete successfully will depend largely on our ability to leverage our experience in drug discovery and development to:


•	discover and develop therapeutics that are superior to other products in the market;


•	attract qualified scientific, product development and commercial personnel;


•	obtain patent and/or other proprietary protection for our microRNA product platform and future product candidates;


•	obtain required regulatory approvals; and


•	successfully collaborate with pharmaceutical companies in the discovery, development and commercialization of new therapeutics.

The availability of our competitors’ products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize. We will not achieve our business plan if the acceptance of any of these products is inhibited by price competition or the reluctance of physicians to switch from existing drug products to our products, or if physicians switch to other new drug products or choose to reserve our future products for use in limited circumstances. The inability to compete with existing or subsequently introduced drug products would have a material adverse impact on our business, financial condition and prospects.

Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make our product candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval or discovering, developing and commercializing product candidates before we do, which would have a material adverse impact on our business.

The commercial success of our product candidates will depend upon the acceptance of these product candidates by the medical community, including physicians, patients and healthcare payors.

The degree of market acceptance of any product candidates will depend on a number of factors, including:


•	demonstration of clinical safety and efficacy compared to other products;


•	the relative convenience, ease of administration and acceptance by physicians, patients and healthcare payors;


•	the prevalence and severity of any AEs;


•	limitations or warnings contained in the FDA-approved label for such products;


•	availability of alternative treatments;


•	pricing and cost-effectiveness;


•	the effectiveness of our or any collaborators’ sales and marketing strategies;


•	our ability to obtain hospital formulary approval;


•	our ability to obtain and maintain sufficient third party coverage or adequate reimbursement; and


•	the willingness of patients to pay out-of-pocket in the absence of third party coverage.

Unless other formulations are developed in the future, we expect our compounds to be formulated in an injectable form. Injectable medications may be disfavored by patients or their physicians in the event drugs which are easy to administer, such as oral medications, are available. If a product is approved, but does not achieve an adequate level of acceptance by physicians, patients and healthcare payors, we may not generate sufficient revenues from such product and we may not become or remain profitable. For example, several new antivirals and antiviral combinations have been approved for the treatment of the HCV since we commenced our HCV program. Such increased competition may decrease any future potential revenue for future product candidates due to increasing pressure for lower pricing and higher discounts in the commercialization of our product.

If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenues. *

We currently do not have an organization for the sales, marketing and distribution of pharmaceutical products and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any products that may be approved, we must build our sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. For example, in order to exercise our co-promotion rights with Sanofi with respect to our miR-221/222 program, we would need to build our sales, marketing, managerial and other non-technical capabilities in order to effectively carry out sales or co-promotion activities with respect to any approved products that are developed through these programs. With respect to certain of our current programs as well as future programs, we may rely completely on an alliance partner for sales and marketing. In addition, we intend to enter into strategic alliances with third parties to commercialize other product candidates, including in markets outside of the United States or for other large markets that are beyond our resources. Although we intend to establish a sales organization if we are able to obtain approval to market any product candidates for niche markets in the United States, we will also consider the option to enter into strategic alliances for future product candidates in the United States if commercialization requirements exceed our available resources. This will reduce the revenue generated from the sales of these products.

Our current and any future strategic alliance partners may not dedicate sufficient resources to the commercialization of our product candidates or may otherwise fail in their commercialization due to factors beyond our control. If we are unable to establish effective alliances to enable the sale of our product candidates to healthcare professionals and in geographical regions, including the United States, that will not be covered by our own marketing and sales force, or if our potential future strategic alliance partners do not successfully commercialize the product candidates, our ability to generate revenues from product sales will be adversely affected.

If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate sufficient product revenue and may not become profitable. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.

If we obtain approval to commercialize any approved products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business. *

If any product candidates that we develop are approved for commercialization, we may also enter into agreements with third parties to market them on a worldwide basis or in more limited geographical regions. We expect that we will be subject to additional risks related to entering into international business relationships, including:


•	different regulatory requirements for drug approvals in foreign countries;


•	reduced protection for intellectual property rights;


•	unexpected changes in tariffs, trade barriers and regulatory requirements;


•	economic weakness, including inflation, or political instability in particular foreign economies and markets;


•	compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;


•	foreign taxes, including withholding of payroll taxes;


•	foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;


•	workforce uncertainty in countries where labor unrest is more common than in the United States;


•	production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and


•	business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.

Coverage and adequate reimbursement may not be available for our product candidates, which could make it difficult for us to sell products profitably.

Market acceptance and sales of any product candidates that we develop will depend on coverage and reimbursement policies and may be affected by future healthcare reform measures. Government authorities and third party payors, such as private health insurers, government payors and health maintenance organizations, decide which drugs they will pay for and establish reimbursement levels. We cannot be sure that coverage and adequate reimbursement will be available for any future product candidates. Also, inadequate reimbursement amounts may reduce the demand for, or the price of, our future products. Further, one payor’s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. If reimbursement is not available, or is available only at limited levels, we may not be able to successfully commercialize product candidates that we develop.

In addition, we cannot be certain if and when we will obtain formulary approval to allow us to sell any products that we may develop and commercialize into our target markets. Obtaining formulary approval from hospitals and from payors can be an expensive and time-consuming process. Failure to obtain timely formulary approval will limit our commercial success.

There have been a number of legislative and regulatory proposals to change the healthcare system in the United States and in some foreign jurisdictions that could affect our ability to sell products profitably. These legislative and/or regulatory changes may negatively impact the reimbursement for drug products, following approval. The availability of numerous generic treatments may also substantially reduce the likelihood of reimbursement for our future products. The potential application of user fees to generic drug products may expedite the approval of additional generic drug treatments. We expect to experience

pricing pressures in connection with the sale of any products that we develop, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. If we fail to successfully secure and maintain reimbursement coverage for our future products or are significantly delayed in doing so, we will have difficulty achieving market acceptance of our future products and our business will be harmed.

In addition, in some non-U.S. jurisdictions, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the EU do not follow price structures of the U.S. and generally tend to be priced significantly lower.

RISKS RELATED TO OUR BUSINESS OPERATIONS AND INDUSTRY

Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.

We are highly dependent on principal members of our executive team, the loss of whose services may adversely impact the achievement of our objectives. While we have entered into employment agreements with each of our executive officers, any of them could leave our employment at any time, as all of our employees are “at will” employees. Recruiting and retaining other qualified employees for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of skilled executives in our industry, which is likely to continue. As a result, competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical companies for individuals with similar skill sets. In addition, failure to succeed in preclinical studies and clinical trials may make it more challenging to recruit and retain qualified personnel. The inability to recruit or loss of the services of any executive or key employee might impede the progress of our research, development and commercialization objectives.

We may need to expand our organization and may experience difficulties in managing this growth, which could disrupt our operations. *

In early July 2018, we implemented a corporate restructuring which involved a reduction in our total workforce by approximately 60%. The workforce reduction was substantially completed in July 2018. As of September 30, 2018, we had 25 employees. In the future, we may need to expand our organization.

Future growth would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Also, our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. Moreover, if our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.

Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.

We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with the regulations of the FDA and non-U.S. regulators, provide accurate information to the FDA and non-U.S. regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements.

Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.

We may undertake internal restructuring activities that could result in disruptions to our business or otherwise materially harm our results of operations or financial condition.*

From time to time we may undertake internal restructuring activities as we continue to evaluate and attempt to optimize our cost and operating structure in light of developments in our business strategy and long-term operating plans. For example, we initiated a corporate restructuring in May 2017 and in July 2018, each of which resulted in a reduction in our workforce. Any such restructuring activities may result in write-offs or other restructuring charges. There can be no assurance that any restructuring activities that we have undertaken or undertake in the future will achieve the cost savings, operating efficiencies or other benefits that we may initially expect. Restructuring activities may also result in a loss of continuity, accumulated knowledge and inefficiency during transitional periods and thereafter. In addition, internal restructurings can require a significant amount of time and focus from management and other employees, which may divert attention from commercial operations. If any internal restructuring activities we have undertaken or undertake in the future fail to achieve some or all of the expected benefits therefrom, our business, results of operations and financial condition could be materially and adversely affected.

Certain current and future relationships with customers and third party payors as well as certain of our business operations may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.

If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations may be directly, or indirectly through our customers, further subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act. These laws may impact, among other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation by the federal government and by the U.S. states and foreign jurisdictions in which we conduct our business. The healthcare laws and regulations that may affect our ability to operate include:

•

the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs;


•	federal civil and criminal false claims laws and civil monetary penalty laws, including the civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to the federal government, including Medicare or Medicaid, that are false or fraudulent;


•	the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;


•	HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their implementing regulations, which imposes certain requirements on certain types of individuals and entities relating to the privacy, security and transmission of individually identifiable health information;

•

the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare & Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians, and further

requires applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members; and

•

state and foreign law equivalents of each of the above federal laws, such as: anti-kickback and false claims laws which may apply to items or services reimbursed by any third party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.

If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, possible exclusion from Medicare, Medicaid and other government healthcare programs, disgorgement, imprisonment, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

Recent and future healthcare legislation may further impact our business operations.

The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.

For example, there have been judicial and Congressional challenges to certain aspects of the ACA, as well as recent efforts by the Trump administration to repeal or replace certain aspects of the ACA. Since January 2017, President Trump has signed two Executive Orders designed to delay the implementation of any certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate”. Additionally, on January 23, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain ACA-mandated fees, including the so-called “Cadillac” tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices. As a result, there is significant uncertainty regarding future healthcare reform and its impact on our operations.

Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, to encourage importation from other countries and bulk purchasing.

We expect that healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors.

We cannot predict what healthcare reform initiatives may be adopted in the future. Further federal, state and foreign legislative and regulatory developments are likely, and we expect ongoing initiatives to increase pressure on drug pricing. Such reforms could

have an adverse effect on anticipated revenues from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.

We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs.

The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. Certain oligonucleotide therapeutics have shown injection site reactions and pro-inflammatory effects and may also lead to impairment of kidney or liver function. There is a risk that our current and future product candidates may induce similar adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:


•	impairment of our business reputation;


•	withdrawal of clinical trial participants;


•	costs due to related litigation;


•	distraction of management’s attention from our primary business;


•	substantial monetary awards to patients or other claimants;


•	the inability to commercialize our product candidates; and


•	decreased demand for our product candidates, if approved for commercial sale.

We maintain product liability insurance relating to the use of our therapeutics in clinical trials. However, such insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.

Cybersecurity risks and the failure to maintain the confidentiality, integrity, and availability of our computer hardware, software, and Internet applications and related tools and functions could result in damage to our reputation and/or subject us to costs, fines or lawsuits.

Our business requires manipulating, analyzing and storing large amounts of data. In addition, we rely on a global enterprise software system to operate and manage our business. We also maintain personally identifiable information about our employees. Our business therefore depends on the continuous, effective, reliable, and secure operation of our computer hardware, software, networks, Internet servers, and related infrastructure. To the extent that our hardware or software malfunctions or access to our data by internal research personnel is interrupted, our business could suffer. The integrity and protection of our employee and company data is critical to our business and employees have a high expectation that we will adequately protect their personal information. The regulatory environment governing information, security and privacy laws is increasingly demanding and continues to evolve. Maintaining compliance with applicable security and privacy regulations may increase our operating costs. Although our computer and communications hardware is protected through physical and software safeguards, it is still vulnerable to fire, storm, flood, power loss, earthquakes, telecommunications failures, physical or software break-ins, software viruses, and similar events. These events could lead to the unauthorized access, disclosure and use of non-public information. The techniques used by criminal elements to attack computer systems are sophisticated, change frequently and may originate from less regulated and remote areas of the world. As a result, we may not be able to address these techniques proactively or implement adequate preventative measures. If our computer systems are compromised, we could be subject to fines, damages, litigation and enforcement actions, and we could lose trade secrets, the occurrence of which could harm our business. In addition, any sustained disruption in internet access provided by other companies could harm our business.

Business interruptions could delay us in the process of developing our future products.

Our headquarters are located in San Diego County. We are vulnerable to natural disasters such as earthquakes and wild fires, as well as other events that could disrupt our operations. We do not carry insurance for earthquakes or other natural disasters and we may not carry sufficient business interruption insurance to compensate us for losses that may occur. Any losses or damages we incur could have a material adverse effect on our business operations.

RISKS RELATED TO OUR COMMON STOCK

The market price of our common stock may be highly volatile.*

Since January 1, 2015 through November 2, 2018, the closing price of our common stock as reported on The Nasdaq Global Market has ranged from $1.75 to $253.56, as adjusted for our 1-for-12 reverse stock split that became effective on October 3, 2018.

Our stock price could be subject to wide fluctuations in response to a variety of factors, including the following:


•	adverse results or delays in preclinical studies or clinical trials;


•	inability to obtain additional funding;


•	any delay in filing an IND or NDA for any of our product candidates and any adverse development or perceived adverse development with respect to the FDA’s review of that IND or NDA;


•	failure to maintain our existing strategic alliances or enter into new alliances;


•	failure of our strategic alliance partners to elect to develop and commercialize product candidates under our alliance agreements or the termination of any programs under our alliance agreements;


•	failure by us or our licensors and strategic alliance partners to prosecute, maintain or enforce our intellectual property rights;


•	failure to successfully develop and commercialize our product candidates;


•	changes in laws or regulations applicable to our preclinical and clinical development activities, product candidates or future products;


•	inability to obtain adequate product supply for our product candidates or the inability to do so at acceptable prices;


•	adverse regulatory decisions;


•	introduction of new products, services or technologies by our competitors;


•	failure to meet or exceed financial projections we may provide to the public;


•	failure to meet or exceed the estimates and projections of the investment community;


•	the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;


•	announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic alliance partners or our competitors;


•	disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;


•	additions or departures of key scientific or management personnel;


•	significant lawsuits, including patent or stockholder litigation;


•	changes in the market valuations of similar companies;


•	sales of our common stock by us or our stockholders in the future; and


•	trading volume of our common stock.

In addition, companies trading in the stock market in general, and The Nasdaq Global Market in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.

The requirements of being a publicly traded company may strain our resources and divert management’s attention. *

As a publicly traded company, we have incurred, and will continue to incur, significant legal, accounting and other expenses. In addition, the Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC and The Nasdaq Global Market have imposed various requirements on public companies. In July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our management and other personnel have devoted and will need to continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly.

Changes or modifications in financial accounting standards, including those related to revenue recognition, may harm our results of operations. *

From time to time, the Financial Accounting Standards Board, or FASB, either alone or jointly with other organizations, promulgates new accounting principles that could have an adverse impact on our financial position, results of operations or reported cash flows. In May 2014, the FASB issued Accounting Standards Update, or ASU, No. 2014-09, Revenue from Contracts with Customers (Topic 606), which requires an entity to recognize the amount of revenue when promised goods or services are transferred to customers. The standard requires a company to recognize revenue to depict the transfer of goods or services to customers in the amount that reflects the consideration it expects to be entitled to receive in exchange for those goods or services. The FASB subsequently issued amendments to ASU No. 2014-09 that have the same effective date and transition date. These new standards became effective for us on January 1, 2018 and were adopted using the modified retrospective method through a cumulative-effect adjustment directly to accumulated deficit of $1.8 million.

Any difficulties in adopting or implementing any new accounting standard could result in our failure to meet our financial reporting obligations, which could result in regulatory discipline and harm investors’ confidence in us. Finally, if we were to change our critical accounting estimates, including those related to the recognition of collaboration revenue, our operating results could be significantly affected.

Sales of a substantial number of shares of our common stock in the public market by our existing stockholders could cause our stock price to fall.

Substantially all of our outstanding shares of common stock are available for public sale, subject in some cases to volume and other limitations. If our existing stockholders sell substantial amounts of our common stock in the public market, or the market perceives that such sales may occur, the trading price of our common stock could decline. In addition, shares of common stock that are either subject to outstanding options or reserved for future issuance under our employee benefit plans are or may become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule 144 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.

Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall. In addition, if eligible optionholders choose not to participate in the Exchange Offer, our employees and directors who hold such options may not be properly incentivized.*

We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, preferred stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time, any of which may result in material dilution to investors and/or our existing stockholders. New investors could also be issued securities with rights superior to those of our existing stockholders.

Pursuant to our 2012 Equity Incentive Plan (the "2012 Plan"), our management is authorized to grant stock options and other equity-based awards to our employees, directors and consultants. The number of shares available for future grant under the 2012 Plan will automatically increase each year by up to 4% of all shares of our capital stock outstanding as of December 31st of the preceding calendar year, subject to the ability of our board of directors to take action to reduce the size of the increase in any given year. In addition, we may grant or provide for the grant of rights to purchase shares of our common stock pursuant to our 2012 Employee Stock Purchase Plan ("the ESPP"). The number of shares of our common stock reserved for issuance under the ESPP will automatically increase on January 1 of each calendar year by the lessor of 1% of the total number of shares of our common stock outstanding on December 31st of the preceding calendar year and 500,000 shares, subject to the ability of our board of directors to take action to reduce the size of the increase in any given year. Any such

increase, of the maximum amount or a lesser amount, may cause our stockholders to experience additional dilution, which could cause our stock price to fall. Currently, we plan to register the increased number of shares available for issuance under the 2012 Plan and the ESPP each year.

In addition, we previously adopted an Inducement Plan in 2015 (the “Inducement Plan”) pursuant to which our management had the ability to grant stock options exercisable for up to an aggregate of 1,000,000 shares of our common stock to new employees as inducements material to such new employees entering into employment with us. The number of shares which may be granted under the Inducement Plan may be increased in the future by our board of directors. In the event we increase the number of shares which may be granted under the Inducement Plan, or adopt another inducement plan for which no stockholder approval is required under applicable rules and regulations, and grant options pursuant to such plan, our stockholders may experience additional dilution, which could cause our stock price to fall.

On October 15, 2018, we commenced the Exchange Offer pursuant to which certain eligible optionholders, subject to specified conditions, will be able exchange some or all of their outstanding options to purchase shares of our common stock for new RSUs. Shares of our common stock underlying eligible options granted under our 2009 Equity Incentive Plan or the 2012 Plan that are properly exchanged in the Exchange Offer will return to our 2012 Plan and become available for issuance under new stock award grants under our 2012 Plan, including the new RSUs. Shares of our common stock underlying eligible options granted under the Inducement Plan that are properly exchanged in the Exchange Offer will not become available for grant under the 2012 Plan or otherwise.

The purpose of the Exchange Offer is to revitalize the incentive value of our outstanding equity awards to retain and motivate employees and directors and recreate a personal stake in the long term financial success of our company, and thereby align their interests with those of our other stockholders. Equity awards are a critical component of our compensation philosophy, the focal point of which is to increase long-term stockholder value. During the past several fiscal years, our stock price has declined. As of October 15, 2018, 100% of our outstanding stock options were “underwater,” meaning the exercise price of each of those options is greater than our current stock price, with exercise prices ranging from $4.56 to over $200 per share; a significant portion of these options have been “underwater” for more than two years. Specifically, all stock options granted between February 2012 and October 2016 have been “underwater” in their entirety for more than two years. This means that our historically granted stock options may have little or no perceived value to those who hold them and therefore may no longer be effective as incentives to motivate and retain these individuals. If eligible optionholders choose not to participate in the Exchange Offer, our employees and directors who hold such options may not be properly incentivized.

We may be unable to comply with the applicable continued listing requirements of The Nasdaq Global Market. *

Our common stock is currently listed on The Nasdaq Global Market, or Nasdaq. In order to maintain this listing, we must satisfy minimum financial and other continued listing requirements and standards, including a minimum closing bid price requirement for our common stock of $1.00 per share. For example, in December 2017, we received a letter from The Nasdaq Stock Market advising us that for 30 consecutive trading days preceding the date of the letter, the bid price of our common stock had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Global Market, and therefore we could become subject to delisting if we did not regain compliance within the compliance period. In January 2018, we were notified by The Nasdaq Stock Market that for a period of 10 consecutive trading days, we had maintained a closing bid above $1.00 and therefore had regained compliance with Nasdaq listing rules. In April 2018, we again received a letter from The Nasdaq Stock Market advising us that for 30 consecutive trading days preceding the date of the letter, the bid price of our common stock had closed below the $1.00 per share minimum price required for continued listing on The Nasdaq Global Market, and therefore we could become subject to delisting if our common stock does not meet the $1.00 minimum bid price for 10 consecutive trading days within the 180-day period following the date of the letter. On October 2, 2018 we filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation with the Secretary of State of the state of Delaware to effect a 1-for-12 reverse stock split of our issued and outstanding common stock. The reverse stock split became effective at 5:00 p.m. Eastern Time on October 3, 2018 and our shares of common stock began trading on a split-adjusted basis on The Nasdaq Global Market on October 4, 2018. On October 18, 2018, we were notified by The Nasdaq Stock Market that as of October 17, 2018 we had maintained a closing bid above $1.00 for a period of 10 consecutive trading days and therefore had regained compliance with Nasdaq listing rules. There can be no assurance that we will continue to be in compliance with the $1.00 minimum bid price requirement or comply with Nasdaq's other continued listing standards in the future. If in the future we are not able to regain compliance with the minimum bid price requirement within the allotted 180-day period, our shares of common stock would be subject to delisting. In the event that our common stock is delisted from Nasdaq and is not eligible for quotation or listing on another market or exchange, trading of our common stock could be conducted only in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it could become more difficult to dispose of, or obtain accurate price quotations for our common stock and there would likely also be a reduction in our coverage by securities analysts and the news media, which could cause the

price of our common stock to decline further. In addition, the delisting of our common stock from The Nasdaq Global Market would constitute an event of default under our Loan Agreement with Oxford.

We are the subject of a putative securities class action lawsuit, and additional securities litigation may be brought against us in the future.*

In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. On January 31, 2017, a putative class action complaint was filed in the United States District Court for the Southern District of California against us, Paul C. Grint (our former Chief Executive Officer) and Joseph P. Hagan (then our Chief Operating Officer and currently our President and Chief Executive Officer). The complaint includes claims asserted, on behalf of certain purchasers of our securities, under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended. In general, the complaint alleges that between January 21, 2016, and June 27, 2016, the defendants violated the federal securities laws by making materially false and misleading statements regarding our business and the prospects for RG-101, thereby artificially inflating the price of our securities. A second action has subsequently been filed making the same allegations but extending the period of alleged violations to January 27, 2017 and also naming our Chief Research & Development Officer, Timothy M. Wright, as a defendant. These actions were consolidated and on December 22, 2017, lead plaintiffs filed a consolidated complaint against the Company, Dr. Grint, Mr. Hagan, and Michael Huang (our former Vice President of Clinical Development). The consolidated complaint alleges that between February 17, 2016 and June 12, 2017, the Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, by making materially false and misleading statements regarding RG-101. The consolidated complaint seeks unspecified monetary damages and an award of attorneys’ fees and costs. On February 6, 2018, defendants filed a Motion to Dismiss the consolidated complaint. On March 23, 2018, plaintiff filed their opposition to the motion and on April 24, 2018, defendants filed their response. No hearing date has been set. We are not able to predict or reasonably estimate the ultimate outcome or possible losses relating to these claims. It is possible that additional lawsuits will be filed, or allegations made by stockholders, with respect to these same or other matters and also naming us and/or our officers and directors as defendants. While we carry liability insurance, there is no assurance that any losses we incur in connection with the current lawsuits or any future lawsuits will be covered or that coverage, if any, will be sufficient. In addition, the current lawsuits and similar future litigation could result in substantial costs and a diversion of management’s attention and resources, which could harm our business.

Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

As of December 31, 2017, we had federal and state net operating loss carryforwards of $265.8 million and $146.3 million, respectively. The federal and state net operating loss carryforwards will begin to expire, if not utilized, in 2030 and 2031. These net operating loss carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under the newly enacted federal income tax law, federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. It is uncertain if and to what extent various states will conform to the newly enacted federal tax law. In addition, under Section 382 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an “ownership change,” which is generally defined as a greater than 50% change (by value) in its equity ownership over a three year period, the corporation’s ability to use its pre-change net operating loss carryforwards, or NOLs, and other pre-change tax attributes (such as research tax credits) to offset its post-change income may be limited. We triggered an “ownership change” limitation at the completion of our initial public offering in October 2012 and again in July 2015. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership some of which may be outside of our control. As a result, if we earn net taxable income, our ability to use our pre-ownership change net operating loss carryforwards to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.

We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.

We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, our ability to pay cash dividends is currently prohibited by the terms of our secured debt, and any future debt financing arrangement may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Any return to stockholders will therefore be limited to the appreciation of their stock.

Provisions in our amended and restated certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management.

Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management. These provisions include:


•	authorizing the issuance of “blank check” preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval;


•	prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;


•	eliminating the ability of stockholders to call a special meeting of stockholders;


•	establishing the state of Delaware as the sole forum for certain legal actions against the Company, its officers and directors; and


•	establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings.

In addition, we are subject to Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder, unless such transactions are approved by our board of directors. This provision could have the effect of delaying or preventing a change in control, whether or not it is desired by or beneficial to our stockholders. Further, other provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Recent Sales of Unregistered Securities

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

First Amendment to Second Amended and Restated Collaboration and License Agreement

On November 5, 2018, we entered into the 2018 Sanofi Amendment with Sanofi to modify the parties’ rights and obligations with respect to our miR-21 programs, including our RG-012 program.

Under the terms of the 2018 Sanofi Amendment, we have granted Sanofi a worldwide, royalty-free, fee-bearing, exclusive license, with the right to grant sublicenses, under our know-how and patents to develop and commercialize miR-21 compounds and products for all indications, including Alport Syndrome. Sanofi will control and will assume all responsibilities and obligations for developing and commercializing each of our miR-21 programs, including our obligations regarding the administration and expense of clinical trials and all other costs, including in-license royalties and other in-license payments, related to our miR-21 programs. Under the terms of the 2018 Sanofi Amendment, we have assigned to Sanofi certain agreements and all materials directed to miR-21 or to any miR-21 compound or product and are required to provide reasonable technical assistance to Sanofi for a period of 24 months after the date of the 2018 Sanofi Amendment.

Under the terms of the 2018 Sanofi Amendment, we are eligible to receive the Upfront Amendment Payments. We are also eligible to receive up to $40.0 million in development milestone payments. In addition, Sanofi has agreed to reimburse us for certain out-of-pocket transition activities and assume our upstream license royalty obligations. We and Sanofi also agreed to a general release of claims against each other for any claims that arose at any time prior to the date of the 2018 Sanofi Amendment, or that thereafter could arise based on anything that occurred prior to the date of the 2018 Sanofi Amendment.

Fourth Amendment to Loan and Security Agreement

On November 5, 2018 and in connection with the 2018 Sanofi Amendment we entered into the Fourth Amendment with the Lender. Under the terms of the Fourth Amendment, the Lender has consented to the 2018 Sanofi Amendment and our license, assignment and transfer to Sanofi of the Assigned Assets, which previously served as collateral under the loan and

security agreement, and has released its liens in the Assigned Assets, provided that the Lender will continue to have liens on all proceeds received by us pursuant to the Sanofi License. Under the terms of the Fourth Amendment, we now have the option to prepay part of the Term Loan at any time and in any amount after 10 days’ prior written notice. We are also required to prepay part of the Term Loan with 25% of certain payments we receive under the 2018 Sanofi Amendment, which payments consist of the Upfront Amendment Payments and the first development milestone payment in the amount of $10.0 million. We will be required to pay the applicable 5.5% final payment fee related to each such 2018 Sanofi Amendment prepayment. Under the Fourth Amendment, we are required to maintain cash in a collateral account controlled by the Lender of (i) $10.0 million if a Capital Event has not occurred, or (ii) $5.0 million if a Capital Event has occurred.

The maturity date of the Term Loan remains unchanged and the Term Loan is required to be paid in full on June 1, 2020.

The foregoing is only a summary of the material terms of the 2018 Sanofi Amendment and the Fourth Amendment, does not purport to be complete and is qualified in its entirety by reference to the full text of such amendments, which will be filed as exhibits to our Annual Report on Form 10-K for the fiscal year ending December 31, 2018.

ITEM 6. EXHIBITS



Exhibit Number	Description

3.1		Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-35670), filed with the SEC on August 3, 2016).

3.2		Certificate of Amendment of Amended and Restated Certificate of Incorporation of Regulus Therapeutics Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (file No. 001-35670), filed with the SEC on October 2, 2018).

3.3		Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-35670), filed with the SEC on June 8, 2016).

4.1		Reference is made to Exhibits 3.1, 3.2 and 3.3.

4.2		Form of common stock certificate of the Registrant.

10.1†		Third Amendment to Loan and Security Agreement, dated August 6, 2018, by and between the Registrant and Oxford Finance LLC.

31.1		Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.

31.2		Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.

32.1**		Certification of the Principal Executive Officer and the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document.

101.SCH		XBRL Taxonomy Extension Schema Document.

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB		XBRL Taxonomy Extension Label Linkbase Document.

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document.



†	We have requested confidential treatment for certain portions of this agreement, which have been omitted and filed separately with the SEC pursuant to Rue 24b-2 of the Securities Exchange Act of 1934, as amended.
*	Indicates management contract or compensatory plan.
**	These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



	Regulus Therapeutics Inc.
Date: November 8, 2018	By:	/s/ Joseph P. Hagan
		Joseph P. Hagan
		President and Chief Executive Officer
		(Principal Executive Officer)

Date: November 8, 2018	By:	/s/ Daniel R. Chevallard
		Daniel R. Chevallard
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-4.2 2 ex-42x20180930.htm EXHIBIT 4.2 Exhibit

EX-10.1 3 ex-101x20180930.htm EXHIBIT 10.1 Exhibit

Exhibit 10.1

***Text Omitted and Filed Separately

with the Securities and Exchange Commission.

Confidential Treatment Requested

Under 17 C.F.R. Sections 200.80(c) and Rule 24b-2 of the

Securities Exchange Act of 1934, as amended.

THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT

THIS THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is made effective as of August 6, 2018 (the “Third Amendment Date”) by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (in its individual capacity, “Oxford”; and in its capacity as Collateral Agent, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”) and REGULUS THERAPEUTICS INC., a Delaware corporation with offices located at 10614 Science Center Dr., San Diego, California 92121 (“Borrower”).

WHEREAS, Collateral Agent, Borrower and Lenders party thereto from time to time have entered into that certain Loan and Security Agreement, dated as of June 17, 2016 (as amended, supplemented or otherwise modified from time to time, the “Loan Agreement”), pursuant to which Lenders have provided to Borrower certain loans in accordance with the terms and conditions thereof;

WHEREAS, Borrower, Lenders and Collateral Agent desire to amend certain provisions of the Loan Agreement as provided herein and subject to the terms and conditions set forth herein; and

NOW, THEREFORE, in consideration of the promises, covenants and agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Borrower, Lenders and Collateral Agent hereby agree as follows:


1.	Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Loan Agreement.

Borrower hereby reaffirms the security interest granted by Borrower previously in Section 4.1 of the Loan Agreement with respect to the Collateral (prior to the date hereof) and hereby grants Collateral Agent, for the ratable benefit of the Lenders, to secure the payment and performance in full of all of the Obligations, a continuing security interest in, and pledges to Collateral Agent, for the ratable benefit of the Lenders, such part of the Collateral that was not pledged previously or in which security interest was not granted prior to the Third Amendment Date, wherever located, whether now owned or hereafter acquired or arising, and all proceeds and products thereof. Furthermore, Borrower hereby authorizes Collateral Agent to file financing statements or take any other action required to perfect Collateral Agent’s security interests in the Collateral, without notice to Borrower, with all appropriate jurisdictions to perfect or protect Collateral Agent’s interest or rights under the Loan Documents, including a notice that any disposition of the Collateral, except to the extent permitted by the terms of this Amendment, by Borrower, or any other Person, shall be deemed to violate the rights of Collateral Agent under the Code.


3.	Section 2.2(b) of the Loan Agreement is hereby amended and restated in its entirety as follows:

(b) Repayment. Borrower shall make monthly payments of interest only commencing on the first (1st) Payment Date following the Funding Date of each Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately preceding the Amortization Date. Borrower agrees to pay, on the Funding Date of each Term Loan, any initial partial monthly interest payment otherwise due for the period between the Funding Date of such Term Loan and the last day of the calendar month during which the Funding Date occurs. Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter, Borrower shall make consecutive equal monthly payments of principal, together with applicable interest, in arrears, to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon: (1) the amount of such Lender’s Term Loan, (2) the effective rate of interest, as determined in Section

2.3(a), and (3) a repayment schedule with respect to the Term Loans equal to (A) twenty-four (24) months. All unpaid principal and accrued and unpaid interest with respect to each Term Loan is due and payable in full on the Maturity Date. Each Term Loan may only be prepaid in accordance with Sections 2.2(c) and 2.2(d). Notwithstanding the foregoing, Borrower shall make monthly payments of interest only commencing on August 1, 2018, and continuing on the Payment Date of each successive two (2) months thereafter through and including the October 1, 2018. Thereafter, Borrower will resume making consecutive equal monthly payments of principal, together with applicable interest, in arrears, to each Lender in accordance with this Section 2.2(b).


4.	Section 2.2(d) of the Loan Agreement is hereby amended and restated in its entirety as follows:

(d) Permitted Prepayment of Term Loans.

(i)

Borrower shall have the option to prepay all, but not less than all, of the Term Loans advanced by the Lenders under this Agreement, provided Borrower (i) provides written notice to Collateral Agent of its election to prepay the Term Loans at least ten (10) days prior to such prepayment, and (ii) pays to the Lenders on the date of such prepayment, payable to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of (A) all outstanding principal of the Term Loans plus accrued and unpaid interest thereon through the prepayment date, (B) the Final Payment, (C) the Prepayment Fee, plus (D) all other Obligations that are due and payable, including Lenders’ Expenses and interest at the Default Rate with respect to any past due amounts.

(ii)

Notwithstanding anything herein to the contrary, Borrower shall also have the option to prepay part of Term Loans advanced by the Lenders under this Agreement on or before November 1, 2018, provided Borrower (i) provides written notice to Collateral Agent of its election to prepay the Term Loans at least ten (10) days prior to such prepayment, (ii) prepays such part of the Term Loans as would reduce the aggregate principal amount of the Term Loans then outstanding to Ten Million Dollars ($10,000,000.00) or less, and (iii) pays to the Lenders on the date of such prepayment, payable to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of (A) the portion of outstanding principal of such Term Loans plus all accrued and unpaid interest thereon through the prepayment date, (B) the applicable Final Payment, and and (C) all other Obligations that are then due and payable, including Lenders’ Expenses and interest at the Default Rate with respect to any past due amounts. For the purposes of clarity, any partial prepayment shall be applied pro-rata to all outstanding amounts under each Term Loan, and shall be applied pro-rata within each Term Loan tranche to reduce amortization payments under Section 2.2(b) on a pro-rata basis.


5.	Section 2.5 of the Loan Agreement is hereby amended by deleting the word “and” immediately following Section 2.5(f), replacing “.” at the end of Section 2.5(f) with “; and” and adding Section 2.5(g) thereto as follows:

(g) Third Amendment Fee. A fully earned and non-refundable third amendment fee in the amount of Twenty Five Thousand Dollars ($25,000.00), which shall become due and payable upon the earlier of: (i) the Maturity Date, (ii) the acceleration of any Term Loan, or (iii) the prepayment of a Term Loan pursuant to Section 2.2(c) or (d).


6.	Section 5.2(d) of the Loan Agreement is hereby amended and restated as follows:

(d) Borrower and each of its Subsidiaries is the sole owner of the Intellectual Property each respectively purports to own, free and clear of all Liens other than Permitted Liens. (i) Each of Borrower’s and its Subsidiaries’ Copyrights, Trademarks and issued Patents material to their business are valid and enforceable and no part of Borrower’s or its Subsidiaries’ Intellectual Property has been judged invalid or unenforceable, in whole or in part, and (ii) to the best of Borrower’s knowledge, no claim has been made that any part of the Intellectual Property or any practice by Borrower or its Subsidiaries violates the rights of any third party except to the extent such claim could not reasonably be expected to have a Material Adverse Change. Except as noted on the Perfection Certificates or the exhibits to the Third Amendment, neither Borrower nor any of its Subsidiaries is a party to, nor is bound by, any material license or other material agreement with respect to which Borrower or such Subsidiary is the licensee that (i) prohibits or otherwise restricts Borrower or its Subsidiaries from granting a security interest in Borrower’s or such Subsidiaries’ interest in such material license or material agreement or any other property except for customary anti-assignment provisions, or (ii) for which a default under or termination of could interfere with Collateral Agent’s or any Lender’s right to sell any Collateral. Borrower shall provide written notice to Collateral Agent and each Lender within ten (10) days of Borrower or any of its Subsidiaries entering into or becoming bound by any material license or material agreement

with respect to which Borrower or any Subsidiary is the licensee (other than over the counter software that is commercially available to the public).


7.	Section 6.2(a)(viii) of the Loan Agreement is hereby amended and restated in its entirety as follows:

(viii) prompt notice of (A) any material change in the composition of the Intellectual Property, (B) the registration of any copyright, including any subsequent ownership right of Borrower or any of its Subsidiaries in or to any copyright, patent or trademark, including a copy of any such registration, and (C) any event that could reasonably be expected to materially and adversely affect the value of the Intellectual Property;


8.	Section 6.7 of the Loan Agreement is hereby amended and restated in its entirety as follows:

6.7 Protection of Intellectual Property Rights. Borrower and each of its Subsidiaries shall: (a) use commercially reasonable efforts to protect, defend and maintain the validity and enforceability of its Intellectual Property that is material to Borrower’s business; (b) promptly advise Collateral Agent in writing of material infringement by a third party of its Intellectual Property; and (c) not allow any Intellectual Property material to Borrower’s business to be abandoned, forfeited or dedicated to the public without Collateral Agent’s prior written consent. If Borrower or any of its Subsidiaries (i) obtains any patent, registered trademark or servicemark, registered copyright, registered mask work, or any pending application for any of the foregoing, whether as owner, licensee or otherwise, or (ii) applies for any patent or the registration of any trademark or servicemark, then Borrower or such Subsidiary shall substantially contemporaneously provide written notice thereof to Collateral Agent and each Lender and shall execute such intellectual property security agreements and other documents and take such other actions as Collateral Agent shall reasonably request in its good faith business judgment to perfect and maintain a first priority perfected security interest in favor of Collateral Agent, for the ratable benefit of the Lenders, in such property. If Borrower or any of its Subsidiaries decides to register any copyrights or mask works in the United States Copyright Office, Borrower or such Subsidiary shall: (x) provide Collateral Agent and each Lender with at least ten (10) days prior written notice of Borrower’s or such Subsidiary’s intent to register such copyrights or mask works together with a copy of the application it intends to file with the United States Copyright Office (excluding exhibits thereto); (y) execute an intellectual property security agreement and such other documents and take such other actions as Collateral Agent may reasonably request in its good faith business judgment to perfect and maintain a first priority perfected security interest in favor of Collateral Agent, for the ratable benefit of the Lenders, in the copyrights or mask works intended to be registered with the United States Copyright Office; and (z) record such intellectual property security agreement with the United States Copyright Office contemporaneously with filing the copyright or mask work application(s) with the United States Copyright Office. Borrower or such Subsidiary shall promptly provide to Collateral Agent and each Lender with evidence of the recording of the intellectual property security agreement necessary for Collateral Agent to perfect and maintain a first priority perfected security interest in such property.


9.	The following new Section 7.12 is hereby added to the Loan Agreement:

7.12 Cash Covenant. Fail to maintain at all times cash in a Collateral Account subject to a Control Agreement in favor of Collateral Agent, an amount equal to One Hundred Ten Percent (110%) of the Cash Out Principal Loan Balance. In the monthly Compliance Certificate that Borrower is obligated to provide under Section 6.2(b), Borrower shall set forth the calculation of the Cash Out Principal Loan Balance and Cash Out Date. Borrower shall no longer be required to comply with the provisions of this Section 7.12 if the aggregate outstanding principal balance of the Term Loans is equal to or less than $10,000,000 on or before November 1, 2018.


10.	Section 13.1 of the Loan Agreement is hereby amended by adding the following definitions thereto in alphabetical order:

“Cash Out Date” is at any given time, the date on which Borrower’s then held cash reserves would first be completely exhausted assuming a continuing cash burn equal to the Operative Monthly Cash Burn (and accounting for making all of the interest and principal payments on the Term Loans during the period starting from the date on which the Cash Out Date is being calculated through the Cash Out Date). Cash Out Date shall be calculated at the end of each month.

“Cash Out Principal Loan Balance” is at any given time, the aggregate principal amount of the Term Loans that would be outstanding on the Cash Out Date.

“Third Amendment Date” means August 6, 2018.

“IP Agreement” is that certain Intellectual Property Security Agreement entered into by and between Borrower and Collateral Agent dated as of the Third Amendment Date, as such may be amended from time to time.

“Operative Monthly Cash Burn” is (i) at any given time on or prior to September 30, 2018, equal to (A) Projected Monthly Cash Burn, if at such time the Past Actual Monthly Cash Burn is not greater than or equal to 120% of the Projected Trailing Monthly Cash Burn or (B) Past Actual Monthly Cash Burn, if at such time the Past Actual Monthly Cash Burn is greater than 120% of the Projected Trailing Monthly Cash Burn, and (ii) at any given time on are after October 1, 2018, equal to (A) Projected Monthly Cash Burn, if at such time the Past Actual Monthly Cash Burn is not greater than or equal to 115% of the Projected Trailing Monthly Cash Burn or (B) Past Actual Monthly Cash Burn, if at such time the Past Actual Monthly Cash Burn is greater than 115% of the Projected Trailing Monthly Cash Burn.

“Past Actual Monthly Cash Burn” is, at any given time, the average monthly cash burn over the immediately preceding three-month period.

“Projected Monthly Cash Burn” is, at any given time, the projected average monthly cash burn through the Cash Out Date as reflected in the then applicable Annual Projections.

“Projected Trailing Monthly Cash Burn” is, at any given time, the projected average monthly cash burn as reflected in the then applicable Annual Projections for the immediately preceding three-month period.


11.	Section 13.1 of the Loan Agreement is hereby amended by amending and restating the following definition therein as follows:

“Loan Documents” are, collectively, this Agreement, the Perfection Certificates, each Compliance Certificate, each Disbursement Letter, the IP Agreement, any subordination agreements, any note, or notes or guaranties executed by Borrower or any other Person, and any other present or future agreement entered into by Borrower, any Guarantor or any other Person for the benefit of the Lenders and Collateral Agent in connection with this Agreement; all as amended, restated, or otherwise modified.


12.	Section 13.1 of the Loan Agreement is hereby further amended by deleting therefrom the definition of Equity Event.


13.	Exhibit A to the Loan Agreement is hereby amended and restated in its entirety as set forth on Exhibit A hereto.


14.	Borrower hereby represents and warrants that a complete and accurate list of its Intellectual Property as of the Third Amendment Date is attached hereto as Exhibit B.


15.	The form of the Compliance Certificate (Exhibit C to the Loan Agreement) is hereby amended and restated as set forth on Exhibit C attached hereto.


16.	The Amortization Table attached to the Disbursement Letter dated as of the Effective Date is hereby amended and restated as set forth on the Amortization Table attached as Exhibit D hereto.


17.	Limitation of Amendment.

The amendments and consents set forth above are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right, remedy or obligation which Lenders or Borrower may now have or may have in the future under or in connection with any Loan Document, as amended hereby.


b.	This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed and shall remain in full force and effect.


18.	To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and Lenders as follows:

Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing;


b.	Borrower has the power and due authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment;


c.	The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and updated pursuant to subsequent deliveries by the Borrower to the Collateral Agent, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect;

The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not and will not contravene (i) any law or regulation binding on or affecting Borrower, (ii) any contractual restriction with a Person binding on Borrower, (iii) any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (iv) the organizational documents of Borrower;

The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower, except as already has been obtained or made;


f.	This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’ rights; and

The Borrower hereby remises, releases, acquits, satisfies and forever discharges the Lenders and Collateral Agent, their agents, employees, officers, directors, predecessors, attorneys and all others acting or purporting to act on behalf of or at the direction of the Lenders and Collateral Agent (“Releasees”), of and from any and all manner of actions, causes of action, suit, debts, accounts, covenants, contracts, controversies, agreements, variances, damages, judgments, claims and demands whatsoever, in law or in equity, which any of such parties ever had, now has or, to the extent arising from or in connection with any act, omission or state of facts taken or existing on or prior to the date hereof, may have after the date hereof against the Releasees, for, upon or by reason of any matter, cause or thing whatsoever relating to or arising out of the Loan Agreement or the other Loan Documents on or prior to the date hereof through the date hereof. Without limiting the generality of the foregoing, the Borrower waives and affirmatively agrees not to allege or otherwise pursue any defenses, affirmative defenses, counterclaims, claims, causes of action, setoffs or other rights they do, shall or may have as of the date hereof, including the rights to contest: (a) the right of Collateral Agent and each Lender to exercise its rights and remedies described in the Loan Documents; (b) any provision of this Amendment or the Loan Documents; or (c) any conduct of the Lenders or other Releasees relating to or arising out of the Loan Agreement or the other Loan Documents on or prior to the date hereof.


19.	Except as expressly set forth herein, the Loan Agreement shall continue in full force and effect without alteration or amendment. This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.


20.	Borrower agrees to promptly pay (but in no event in less than 5 Business Days of invoice date) all unpaid Lenders’ Expenses incurred through the date hereof, which may be debited (or ACH’d) from any of Borrower’s accounts.


21.	This Amendment shall be deemed effective as of the Third Amendment Date upon (a) the due execution and delivery to Collateral Agent of this Amendment by each party hereto and the execution and delivery by Borrower of the IP Agreement.


22.	This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument.


23.	This Amendment and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of California.

[Balance of Page Intentionally Left Blank - Signature Pages to Follow]

IN WITNESS WHEREOF, the parties hereto have caused this Third Amendment to Loan and Security Agreement to be executed as of the date first set forth above.



BORROWER:

REGULUS THERAPEUTICS INC.

By /s/ Daniel Chevallard
Name: Daniel Chevallard
Title: Chief Financial Officer

COLLATERAL AGENT AND LENDER:

OXFORD FINANCE LLC

By /s/ Colette H. Featherly
Name: Colette H. Featherly
Title: Senior Vice President

EXHIBIT A

Exhibit A

Description of Collateral

The Collateral consists of all of Borrower’s right, title and interest in and to the following personal property:

All goods, Accounts (including health‑care receivables), Equipment, Inventory, contract rights or rights to payment of money, leases, license agreements, franchise agreements, General Intangibles (including all Intellectual Property), commercial tort claims, documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts and other Collateral Accounts, all certificates of deposit, fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), securities, and all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever located; and

All Borrower’s Books relating to the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing.

Notwithstanding the foregoing, the Collateral does not include (i) more than 65% of the total combined voting power of all classes of stock entitled to vote the shares of capital stock (the “Shares”) of any Foreign Subsidiary, if Borrower demonstrates to Collateral Agent’s reasonable satisfaction that a pledge of more than sixty five percent (65%) of the Shares of such Subsidiary creates a present and existing adverse tax consequence to Borrower under the U.S. Internal Revenue Code; (ii) any intent to use trademarks, and (iii) any license or contract, in each case if the granting of a Lien in such license or contract is prohibited by or would constitute a default under the agreement governing such license or contract (but (A) only to the extent such prohibition is enforceable under applicable law and (B) other than to the extent that any such term would be rendered ineffective pursuant to Sections 9-406, 9-408 or 9-409 (or any other Section) of Division 9 of the Code); provided that upon the termination, lapsing or expiration of any such prohibition, such license or contract, as applicable, shall automatically be subject to the security interest granted in favor of Collateral Agent hereunder and become part of the “Collateral.”

EXHIBIT B

Intellectual Property

Please see attached

EXHIBIT B-1

Patents

Regulus Patent

Portfolio July 26, 2018



Regulus Ref. (*see notes column)	Effective Filing Date	Priority Date	Title	CC	Status	Serial Number	Patent Number	Issue Date	Publication #	Publication Date	Notes
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]

***Confidential Treatment Requested

Page 1 of 13

Regulus Patent

Portfolio July 26, 2018



…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]

***Confidential Treatment Requested

Page 2 of 13

Regulus Patent

Portfolio July 26, 2018



[...***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]				[…***…]

***Confidential Treatment Requested

Page 3 of 13

Regulus Patent

Portfolio July 26, 2018



[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]				[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]

***Confidential Treatment Requested

Page 4 of 13

Regulus Patent

Portfolio July 26, 2018



[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]					[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]				[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]

***Confidential Treatment Requested

Page 5 of 13

Regulus Patent

Portfolio July 26, 2018



[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]				[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]				[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]

***Confidential Treatment Requested

Page 6 of 13

Regulus Patent

Portfolio July 26, 2018



[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]				[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]				[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]		[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]				[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]

***Confidential Treatment Requested

Page 7 of 13

Regulus Patent

Portfolio July 26, 2018



[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]				[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]				[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]

***Confidential Treatment Requested

Page 8 of 13

Regulus Patent

Portfolio July 26, 2018



[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]				[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]		[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]				[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]				[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]				[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]

***Confidential Treatment Requested

Page 9 of 13

Regulus Patent

Portfolio July 26, 2018



[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]				[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]

***Confidential Treatment Requested

Page 10 of 13

Regulus Patent

Portfolio July 26, 2018



[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]				[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]				[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]				[…***…]

***Confidential Treatment Requested

Page 11 of 13

Regulus Patent

Portfolio July 26, 2018



[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]			[…***…]	[…***…]

***Confidential Treatment Requested

Page 12 of 13

Regulus Patent

Portfolio July 26, 2018



[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]

***Confidential Treatment Requested

Page 13 of 13

EXHIBIT B-2

Trademarks



Thursday, April 26, 2018	Trademark List by Trademark	Page: 1



Trademark	Matter Number Country	Sub Case Case Type	Status Classes	Application Number/Date	Registration Number/Date
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]

[…***…]	[…***…]
[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]

[…***…]	[…***…]
[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]

[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]

[…***…]	[…***…]
[…***…]	[…***…]
[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]

[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]

***Confidential Treatment Requested



Thursday, April 26, 2018	Trademark List by Trademark	Page: 2



Trademark	Matter Number Country	Sub Case Case Type	Status Classes	Application Number/Date	Registration Number/Date

[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]

[…***…]	[…***…]
[…***…]	[…***…]
[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]

[…***…]	[…***…]
[…***…]	[…***…]
[…***…]	[…***…]
[…***…]	[…***…]	[…***…]	[…***…]	[…***…]	[…***…]

***Confidential Treatment Requested



[…***…]		[…***…]

***Confidential Treatment Requested

EXHIBIT B-3

Copyrights

COPYRIGHTS

Registered Copyrights - None

EXHIBIT C

Exhibit C

Compliance Certificate



TO:	OXFORD FINANCE LLC, as Collateral Agent and Lender
FROM:	REGULUS THERAPEUTICS INC.

The undersigned authorized officer (“Officer”) of REGULUS THERAPEUTICS INC. (“Borrower”), hereby certifies that in accordance with the terms and conditions of the Loan and Security Agreement by and among Borrower, Collateral Agent, and the Lenders from time to time party thereto (the “Loan Agreement;” capitalized terms used but not otherwise defined herein shall have the meanings given them in the Loan Agreement),

(a) Borrower is in complete compliance for the period ending _______________ with all required covenants in the Loan Agreement except as noted below;

(b) There are no Events of Default, except as noted below;

(c) Except as noted below, all representations and warranties of Borrower stated in the Loan Documents are true and correct in all material respects on this date and for the period described in (a), above; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date.

(d) Borrower, and each of Borrower’s Subsidiaries, has timely filed all required tax returns and reports or extensions therefor, Borrower, and each of Borrower’s Subsidiaries, has timely paid all foreign, federal, state, and local taxes, assessments, deposits and contributions owed by Borrower, or Subsidiary, except as otherwise permitted pursuant to the terms of Section 5.8 of the Loan Agreement;

(e) No Liens have been levied or claims made against Borrower or any of its Subsidiaries relating to unpaid employee payroll or benefits of which Borrower has not previously provided written notification to Collateral Agent and the Lenders.

Attached are the required documents, if any, supporting our certification(s). The Officer, on behalf of Borrower, further certifies that the attached financial statements are prepared in accordance with Generally Accepted Accounting Principles (GAAP) and are consistently applied from one period to the next except as explained in an accompanying letter or footnotes and except, in the case of unaudited financial statements, for the absence of footnotes and subject to year‑end audit adjustments as to the interim financial statements.

Please indicate compliance status since the last Compliance Certificate by circling Yes, No, or N/A under “Complies” column.



	Reporting Covenant	Requirement	Actual	Complies
1)	Financial statements - balance sheet and income statement	Monthly within 30 days		Yes	No	N/A
2)	Financial statements - cash flow statement	Quarterly within 45 days		Yes	No	N/A



3)	Annual (CPA Audited) statements	Within 120 days after FYE		Yes	No	N/A
4)	Annual Financial Projections/Budget (prepared on a monthly basis)	Annually (within 45 days of FYE), and when revised		Yes	No	N/A
5)	8‑K, 10‑K and 10‑Q Filings	If applicable, within 5 days of filing		Yes	No	N/A
6)	Compliance Certificate	Monthly within 30 days		Yes	No	N/A
7)	IP Report	When required		Yes	No	N/A
8)	Total amount of Borrower’s cash and cash equivalents at the last day of the measurement period		$________	Yes	No	N/A
9)	Total amount of Borrower’s Subsidiaries’ cash and cash equivalents at the last day of the measurement period		$________	Yes	No	N/A
10)	Updated Exhibit A to Landlord Waiver	Quarterly within 30 days, and in any month in which new Collateral in excess of $100,000 was delivered to 10614 Science Center Dr., San Diego, California 92121		Yes	No	N/A
11)	Cash Out Date:
12)	Operative Monthly Cash Burn		$________
13)	Past Actual Monthly Cash Burn		$________
14)	Projected Monthly Cash Burn		$________
15)	Projected Trailing Monthly Cash Burn		$________
16)	Cash Out Principal Loan Balance		$________


15)	110% of Cash Out Principal Loan Balance is less than the total amount of Borrower’s cash and cash equivalents at the last day of the measurement period?			Yes	No	N/A

Deposit and Securities Accounts

(Please list all accounts; attach separate sheet if additional space needed)



Institution Name	Account Number	Account Balance as of the date hereof	New Account?	Account Control Agreement in place?



1)	Yes	No	Yes	No
2)	Yes	No	Yes	No
3)	Yes	No	Yes	No
4)	Yes	No	Yes	No

Other Matters



1)	Have there been any changes in management since the last Compliance Certificate?	Yes	No

2)	Have there been any transfers/sales/disposals/retirement of Collateral or IP prohibited by the Loan Agreement?	Yes	No

3)	Have there been any new or pending claims or causes of action against Borrower that involve more than Two Hundred Fifty Thousand Dollars ($250,000.00)?	Yes	No
4)	Have there been any amendments of or other changes to the Borrower’s Operating Documents or any of its Subsidiaries’ Operating Documents? If the Borrower is no longer subject to Securities Exchange Act of 1934, as amended, have there been any material changes to the capitalization of Borrower? If yes, please provide copies of any such amendments or changes to the Operating Documents and capitalization table, as applicable, with this Compliance Certificate.	Yes	No

Exceptions

Please explain any exceptions with respect to the certification above: (If no exceptions exist, state “No exceptions.” Attach separate sheet if additional space needed.)

REGULUS THERAPEUTICS INC.



By: ______________________
Name: ____________________
Title: _____________________

Date:



LENDER USE ONLY

Received by:		Date:

Verified by:		Date:

Compliance Status:	Yes	No

Exhibit D

Amortization Table

Please see attached.

Oxford Finance LLC

Amortization Table

Regulus AA01

TOTAL



Start Date:	6/22/2016		Disclaimer:
Interest Rate:	8.97885%		THIS IS A STANDARD AMORTIZATION
Term:	47	23 IO + 24 PI	SCHEDULE. IT IS NOT INTENDED TO BE
Payment:	Varies		USED FOR PAYOFF PURPOSES.
Final Payment:	$1,100,000.00	5.50%
Amendment Fee:	$125,000.00
Amount:	20,000,000.00		THIS AMORTIZATION SCHEDULE REPRESENTS A
Interim Interest Days:	9		FLOATING INTEREST RATE LOAN. INTEREST RATE
Interim Interest:	$44,894.25		CHARGED MAY DIFFER FROM RATE PER THIS
			SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT



PMT No.	Payment Date	Beginning Balance	Monthly Payment	Interest	Principal	Ending Balance

	7/1/16		Interim Interest Due			$20,000,000.00
1	8/1/16	$20,000,000.00	$154,635.75	$154,635.75	$0.00	$20,000,000.00
2	9/1/16	$20,000,000.00	$154,635.75	$154,635.75	$0.00	$20,000,000.00
3	10/1/16	$20,000,000.00	$149,647.50	$149,647.50	$0.00	$20,000,000.00
4	11/1/16	$20,000,000.00	$154,635.75	$154,635.75	$0.00	$20,000,000.00
5	12/1/16	$20,000,000.00	$149,647.50	$149,647.50	$0.00	$20,000,000.00
6	1/1/17	$20,000,000.00	$154,635.75	$154,635.75	$0.00	$20,000,000.00
7	2/1/17	$20,000,000.00	$154,635.75	$154,635.75	$0.00	$20,000,000.00
8	3/1/17	$20,000,000.00	$139,671.00	$139,671.00	$0.00	$20,000,000.00
9	4/1/17	$20,000,000.00	$154,635.75	$154,635.75	$0.00	$20,000,000.00
10	5/1/17	$20,000,000.00	$149,647.50	$149,647.50	$0.00	$20,000,000.00
11	6/1/17	$20,000,000.00	$154,635.75	$154,635.75	$0.00	$20,000,000.00
12	7/1/17	$20,000,000.00	$149,647.50	$149,647.50	$0.00	$20,000,000.00
13	8/1/17	$20,000,000.00	$154,635.75	$154,635.75	$0.00	$20,000,000.00
14	9/1/17	$20,000,000.00	$154,635.75	$154,635.75	$0.00	$20,000,000.00
15	10/1/17	$20,000,000.00	$149,647.50	$149,647.50	$0.00	$20,000,000.00
16	11/1/17	$20,000,000.00	$154,635.75	$154,635.75	$0.00	$20,000,000.00
17	12/1/17	$20,000,000.00	$149,647.50	$149,647.50	$0.00	$20,000,000.00
18	1/1/18	$20,000,000.00	$154,635.75	$154,635.75	$0.00	$20,000,000.00
19	2/1/18	$20,000,000.00	$154,635.75	$154,635.75	$0.00	$20,000,000.00
20	3/1/18	$20,000,000.00	$139,671.00	$139,671.00	$0.00	$20,000,000.00
21	4/1/18	$20,000,000.00	$154,635.75	$154,635.75	$0.00	$20,000,000.00
22	5/1/18	$20,000,000.00	$149,647.50	$149,647.50	$0.00	$20,000,000.00
23	6/1/18	$20,000,000.00	$154,635.75	$154,635.75	$0.00	$20,000,000.00
24	7/1/18	$20,000,000.00	$982,980.83	$149,647.50	$833,333.33	$19,166,666.67
25	8/1/18	$19,166,666.67	$148,192.59	$148,192.59	$0.00	$19,166,666.67
26	9/1/18	$19,166,666.67	$148,192.59	$148,192.59	$0.00	$19,166,666.67
27	10/1/18	$19,166,666.67	$143,412.19	$143,412.19	$0.00	$19,166,666.67
28	11/1/18	$19,166,666.67	$1,106,525.93	$148,192.59	$958,333.33	$18,208,333.33
29	12/1/18	$18,208,333.33	$1,094,574.91	$136,241.58	$958,333.33	$17,250,000.00
30	1/1/19	$17,250,000.00	$1,091,706.67	$133,373.33	$958,333.33	$16,291,666.67
31	2/1/19	$16,291,666.67	$1,084,297.04	$125,963.70	$958,333.33	$15,333,333.33
32	3/1/19	$15,333,333.33	$1,065,414.43	$107,081.10	$958,333.33	$14,375,000.00
33	4/1/19	$14,375,000.00	$1,069,477.78	$111,144.45	$958,333.33	$13,416,666.67
34	5/1/19	$13,416,666.67	$1,058,721.86	$100,388.53	$958,333.33	$12,458,333.33
35	6/1/19	$12,458,333.33	$1,054,658.52	$96,325.19	$958,333.33	$11,500,000.00
36	7/1/19	$11,500,000.00	$1,044,380.65	$86,047.31	$958,333.33	$10,541,666.67
37	8/1/19	$10,541,666.67	$1,039,839.26	$81,505.93	$958,333.33	$9,583,333.33
38	9/1/19	$9,583,333.33	$1,032,429.63	$74,096.30	$958,333.33	$8,625,000.00
39	10/1/19	$8,625,000.00	$1,022,868.82	$64,535.48	$958,333.33	$7,666,666.67
40	11/1/19	$7,666,666.67	$1,017,610.37	$59,277.04	$958,333.33	$6,708,333.33
41	12/1/19	$6,708,333.33	$1,008,527.60	$50,194.27	$958,333.33	$5,750,000.00
42	1/1/20	$5,750,000.00	$1,002,791.11	$44,457.78	$958,333.33	$4,791,666.67
43	2/1/20	$4,791,666.67	$995,381.48	$37,048.15	$958,333.33	$3,833,333.33
44	3/1/20	$3,833,333.33	$986,059.69	$27,726.36	$958,333.33	$2,875,000.00
45	4/1/20	$2,875,000.00	$980,562.22	$22,228.89	$958,333.33	$1,916,666.67
46	5/1/20	$1,916,666.67	$972,674.55	$14,341.22	$958,333.33	$958,333.33
47	6/1/20	$958,333.33	$965,742.96	$7,409.63	$958,333.33	($0.00)
Final	6/1/20	Final Payment	$1,125,000.00	$1,125,000.00	$0.00

		Totals	$26,733,798.69	$6,733,798.69	$20,000,000.00

Note: Interest rate floats monthly (greater of 1 Month Libor + 8.51% or 8.95%).

8/6/2018

Oxford Finance LLC

Amortization Table

Regulus AA01a

OF ID: 216050



Start Date:	6/22/2016		Disclaimer:
Interest Rate:	8.97885%		THIS IS A STANDARD AMORTIZATION
Term:	47	23 IO + 24 PI	SCHEDULE. IT IS NOT INTENDED TO BE
Payment:	Varies		USED FOR PAYOFF PURPOSES.
Final Payment:	$385,000.00	5.5%
Amendment Fee:	$43,750.00
Amount:	7,000,000.00		THIS AMORTIZATION SCHEDULE REPRESENTS A
Interim Interest Days:	9		FLOATING INTEREST RATE LOAN. INTEREST RATE
Interim Interest:	$15,712.99		CHARGED MAY DIFFER FROM RATE PER THIS
			SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT



PMT No.	Payment Date	Beginning Balance	Monthly Payment	Interest	Principal	Ending Balance

	7/1/2016		Interim Interest Due			$7,000,000.00
1	8/1/2016	$7,000,000.00	$54,122.51	$54,122.51	$—	$7,000,000.00
2	9/1/2016	$7,000,000.00	$54,122.51	$54,122.51	$—	$7,000,000.00
3	10/1/2016	$7,000,000.00	$52,376.63	$52,376.63	$—	$7,000,000.00
4	11/1/2016	$7,000,000.00	$54,122.51	$54,122.51	$—	$7,000,000.00
5	12/1/2016	$7,000,000.00	$52,376.63	$52,376.63	$—	$7,000,000.00
6	1/1/2017	$7,000,000.00	$54,122.51	$54,122.51	$—	$7,000,000.00
7	2/1/2017	$7,000,000.00	$54,122.51	$54,122.51	$—	$7,000,000.00
8	3/1/2017	$7,000,000.00	$48,884.85	$48,884.85	$—	$7,000,000.00
9	4/1/2017	$7,000,000.00	$54,122.51	$54,122.51	$—	$7,000,000.00
10	5/1/2017	$7,000,000.00	$52,376.63	$52,376.63	$—	$7,000,000.00
11	6/1/2017	$7,000,000.00	$54,122.51	$54,122.51	$—	$7,000,000.00
12	7/1/2017	$7,000,000.00	$52,376.63	$52,376.63	$—	$7,000,000.00
13	8/1/2017	$7,000,000.00	$54,122.51	$54,122.51	$—	$7,000,000.00
14	9/1/2017	$7,000,000.00	$54,122.51	$54,122.51	$—	$7,000,000.00
15	10/1/2017	$7,000,000.00	$52,376.63	$52,376.63	$—	$7,000,000.00
16	11/1/2017	$7,000,000.00	$54,122.51	$54,122.51	$—	$7,000,000.00
17	12/1/2017	$7,000,000.00	$52,376.63	$52,376.63	$—	$7,000,000.00
18	1/1/2018	$7,000,000.00	$54,122.51	$54,122.51	$—	$7,000,000.00
19	2/1/2018	$7,000,000.00	$54,122.51	$54,122.51	$—	$7,000,000.00
20	3/1/2018	$7,000,000.00	$48,884.85	$48,884.85	$—	$7,000,000.00
21	4/1/2018	$7,000,000.00	$54,122.51	$54,122.51	$—	$7,000,000.00
22	5/1/2018	$7,000,000.00	$52,376.63	$52,376.63	$—	$7,000,000.00
23	6/1/2018	$7,000,000.00	$54,122.51	$54,122.51	$—	$7,000,000.00
24	7/1/2018	$7,000,000.00	$344,043.29	$52,376.63	$291,666.67	$6,708,333.33
25	8/1/2018	$6,708,333.33	$51,867.41	$51,867.41	$—	$6,708,333.33
26	9/1/2018	$6,708,333.33	$51,867.41	$51,867.41	$—	$6,708,333.33
27	10/1/2018	$6,708,333.33	$50,194.27	$50,194.27	$—	$6,708,333.33
28	11/1/2018	$6,708,333.33	$387,284.07	$51,867.41	$335,416.67	$6,372,916.67
29	12/1/2018	$6,372,916.67	$383,101.22	$47,684.55	$335,416.67	$6,037,500.00
30	1/1/2019	$6,037,500.00	$382,097.33	$46,680.67	$335,416.67	$5,702,083.33
31	2/1/2019	$5,702,083.33	$379,503.96	$44,087.30	$335,416.67	$5,366,666.67
32	3/1/2019	$5,366,666.67	$372,895.05	$37,478.39	$335,416.67	$5,031,250.00
33	4/1/2019	$5,031,250.00	$374,317.22	$38,900.56	$335,416.67	$4,695,833.33
34	5/1/2019	$4,695,833.33	$370,552.65	$35,135.99	$335,416.67	$4,360,416.67
35	6/1/2019	$4,360,416.67	$369,130.48	$33,713.82	$335,416.67	$4,025,000.00
36	7/1/2019	$4,025,000.00	$365,533.23	$30,116.56	$335,416.67	$3,689,583.33
37	8/1/2019	$3,689,583.33	$363,943.74	$28,527.07	$335,416.67	$3,354,166.67
38	9/1/2019	$3,354,166.67	$361,350.37	$25,933.70	$335,416.67	$3,018,750.00
39	10/1/2019	$3,018,750.00	$358,004.09	$22,587.42	$335,416.67	$2,683,333.33
40	11/1/2019	$2,683,333.33	$356,163.63	$20,746.96	$335,416.67	$2,347,916.67
41	12/1/2019	$2,347,916.67	$352,984.66	$17,567.99	$335,416.67	$2,012,500.00
42	1/1/2020	$2,012,500.00	$350,976.89	$15,560.22	$335,416.67	$1,677,083.33
43	2/1/2020	$1,677,083.33	$348,383.52	$12,966.85	$335,416.67	$1,341,666.67
44	3/1/2020	$1,341,666.67	$345,120.89	$9,704.22	$335,416.67	$1,006,250.00
45	4/1/2020	$1,006,250.00	$343,196.78	$7,780.11	$335,416.67	$670,833.33
46	5/1/2020	$670,833.33	$340,436.09	$5,019.43	$335,416.67	$335,416.67
47	6/1/2020	$335,416.67	$338,010.04	$2,593.37	$335,416.67	$—
Final	6/1/2020	Final Payment	$393,750.00	$393,750.00	$—

		Totals	$9,356,829.54	$2,356,829.54	$7,000,000.00

Note: Interest rate floats monthly (greater of 1 Month Libor + 8.51% or 8.95%).

8/6/2018

Oxford Finance LLC

Amortization Table

Regulus AA01b

OF ID: 216051



Start Date:	6/22/2016		Disclaimer:
Interest Rate:	8.97885%		THIS IS A STANDARD AMORTIZATION
Term:	47	23 IO + 24 PI	SCHEDULE. IT IS NOT INTENDED TO BE
Payment:	Varies		USED FOR PAYOFF PURPOSES.
Final Payment:	$275,000.00	5.5%
Amendment Fee:	$31,250.00
Amount:	5,000,000.00		THIS AMORTIZATION SCHEDULE REPRESENTS A
Interim Interest Days:	9		FLOATING INTEREST RATE LOAN. INTEREST RATE
Interim Interest:	$11,223.56		CHARGED MAY DIFFER FROM RATE PER THIS
			SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT



PMT No.	Payment Date	Beginning Balance	Monthly Payment	Interest	Principal	Ending Balance

	7/1/2016		Interim Interest Due			$5,000,000.00
1	8/1/2016	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
2	9/1/2016	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
3	10/1/2016	$5,000,000.00	$37,411.88	$37,411.88	$—	$5,000,000.00
4	11/1/2016	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
5	12/1/2016	$5,000,000.00	$37,411.88	$37,411.88	$—	$5,000,000.00
6	1/1/2017	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
7	2/1/2017	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
8	3/1/2017	$5,000,000.00	$34,917.75	$34,917.75	$—	$5,000,000.00
9	4/1/2017	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
10	5/1/2017	$5,000,000.00	$37,411.88	$37,411.88	$—	$5,000,000.00
11	6/1/2017	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
12	7/1/2017	$5,000,000.00	$37,411.88	$37,411.88	$—	$5,000,000.00
13	8/1/2017	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
14	9/1/2017	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
15	10/1/2017	$5,000,000.00	$37,411.88	$37,411.88	$—	$5,000,000.00
16	11/1/2017	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
17	12/1/2017	$5,000,000.00	$37,411.88	$37,411.88	$—	$5,000,000.00
18	1/1/2018	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
19	2/1/2018	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
20	3/1/2018	$5,000,000.00	$34,917.75	$34,917.75	$—	$5,000,000.00
21	4/1/2018	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
22	5/1/2018	$5,000,000.00	$37,411.88	$37,411.88	$—	$5,000,000.00
23	6/1/2018	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
24	7/1/2018	$5,000,000.00	$245,745.21	$37,411.88	$208,333.33	$4,791,666.67
25	8/1/2018	$4,791,666.67	$37,048.15	$37,048.15	$—	$4,791,666.67
26	9/1/2018	$4,791,666.67	$37,048.15	$37,048.15	$—	$4,791,666.67
27	10/1/2018	$4,791,666.67	$35,853.05	$35,853.05	$—	$4,791,666.67
28	11/1/2018	$4,791,666.67	$276,631.48	$37,048.15	$239,583.33	$4,552,083.33
29	12/1/2018	$4,552,083.33	$273,643.73	$34,060.39	$239,583.33	$4,312,500.00
30	1/1/2019	$4,312,500.00	$272,926.67	$33,343.33	$239,583.33	$4,072,916.67
31	2/1/2019	$4,072,916.67	$271,074.26	$31,490.93	$239,583.33	$3,833,333.33
32	3/1/2019	$3,833,333.33	$266,353.61	$26,770.28	$239,583.33	$3,593,750.00
33	4/1/2019	$3,593,750.00	$267,369.44	$27,786.11	$239,583.33	$3,354,166.67
34	5/1/2019	$3,354,166.67	$264,680.47	$25,097.13	$239,583.33	$3,114,583.33
35	6/1/2019	$3,114,583.33	$263,664.63	$24,081.3	$239,583.33	$2,875,000.00
36	7/1/2019	$2,875,000.00	$261,095.16	$21,511.83	$239,583.33	$2,635,416.67
37	8/1/2019	$2,635,416.67	$259,959.81	$20,376.48	$239,583.33	$2,395,833.33
38	9/1/2019	$2,395,833.33	$258,107.41	$18,524.07	$239,583.33	$2,156,250.00
39	10/1/2019	$2,156,250.00	$255,717.2	$16,133.87	$239,583.33	$1,916,666.67
40	11/1/2019	$1,916,666.67	$254,402.59	$14,819.26	$239,583.33	$1,677,083.33
41	12/1/2019	$1,677,083.33	$252,131.9	$12,548.57	$239,583.33	$1,437,500.00
42	1/1/2020	$1,437,500.00	$250,697.78	$11,114.44	$239,583.33	$1,197,916.67
43	2/1/2020	$1,197,916.67	$248,845.37	$9,262.04	$239,583.33	$958,333.33
44	3/1/2020	$958,333.33	$246,514.92	$6,931.59	$239,583.33	$718,750.00
45	4/1/2020	$718,750.00	$245,140.56	$5,557.22	$239,583.33	$479,166.67
46	5/1/2020	$479,166.67	$243,168.64	$3,585.3	$239,583.33	$239,583.33
47	6/1/2020	$239,583.33	$241,435.74	$1,852.41	$239,583.33	$—
Final	6/1/2020	Final Payment	$281,250.00	$281,250.00	$—

		Totals	$6,683,449.67	$1,683,449.67	$5,000,000.00

Note: Interest rate floats monthly (greater of 1 Month Libor + 8.51% or 8.95%).

8/6/2018

Oxford Finance LLC

Amortization Table

Regulus AA01c

OF ID: 216052



Start Date:	6/22/2016		Disclaimer:
Interest Rate:	8.97885%		THIS IS A STANDARD AMORTIZATION
Term:	47	23 IO + 24 PI	SCHEDULE. IT IS NOT INTENDED TO BE
Payment:	Varies		USED FOR PAYOFF PURPOSES.
Final Payment:	$275,000.00	5.5%
Amendment Fee:	$31,250.00
Amount:	5,000,000.00		THIS AMORTIZATION SCHEDULE REPRESENTS A
Interim Interest Days:	9		FLOATING INTEREST RATE LOAN. INTEREST RATE
Interim Interest:	$11,223.56		CHARGED MAY DIFFER FROM RATE PER THIS
			SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT



PMT No.	Payment Date	Beginning Balance	Monthly Payment	Interest	Principal	Ending Balance

	7/1/2016		Interim Interest Due			$5,000,000.00
1	8/1/2016	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
2	9/1/2016	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
3	10/1/2016	$5,000,000.00	$37,411.88	$37,411.88	$—	$5,000,000.00
4	11/1/2016	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
5	12/1/2016	$5,000,000.00	$37,411.88	$37,411.88	$—	$5,000,000.00
6	1/1/2017	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
7	2/1/2017	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
8	3/1/2017	$5,000,000.00	$34,917.75	$34,917.75	$—	$5,000,000.00
9	4/1/2017	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
10	5/1/2017	$5,000,000.00	$37,411.88	$37,411.88	$—	$5,000,000.00
11	6/1/2017	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
12	7/1/2017	$5,000,000.00	$37,411.88	$37,411.88	$—	$5,000,000.00
13	8/1/2017	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
14	9/1/2017	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
15	10/1/2017	$5,000,000.00	$37,411.88	$37,411.88	$—	$5,000,000.00
16	11/1/2017	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
17	12/1/2017	$5,000,000.00	$37,411.88	$37,411.88	$—	$5,000,000.00
18	1/1/2018	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
19	2/1/2018	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
20	3/1/2018	$5,000,000.00	$34,917.75	$34,917.75	$—	$5,000,000.00
21	4/1/2018	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
22	5/1/2018	$5,000,000.00	$37,411.88	$37,411.88	$—	$5,000,000.00
23	6/1/2018	$5,000,000.00	$38,658.94	$38,658.94	$—	$5,000,000.00
24	7/1/2018	$5,000,000.00	$245,745.21	$37,411.88	$208,333.33	$4,791,666.67
25	8/1/2018	$4,791,666.67	$37,048.15	$37,048.15	$—	$4,791,666.67
26	9/1/2018	$4,791,666.67	$37,048.15	$37,048.15	$—	$4,791,666.67
27	10/1/2018	$4,791,666.67	$35,853.05	$35,853.05	$—	$4,791,666.67
28	11/1/2018	$4,791,666.67	$276,631.48	$37,048.15	$239,583.33	$4,552,083.33
29	12/1/2018	$4,552,083.33	$273,643.73	$34,060.39	$239,583.33	$4,312,500.00
30	1/1/2019	$4,312,500.00	$272,926.67	$33,343.33	$239,583.33	$4,072,916.67
31	2/1/2019	$4,072,916.67	$271,074.26	$31,490.93	$239,583.33	$3,833,333.33
32	3/1/2019	$3,833,333.33	$266,353.61	$26,770.28	$239,583.33	$3,593,750.00
33	4/1/2019	$3,593,750.00	$267,369.44	$27,786.11	$239,583.33	$3,354,166.67
34	5/1/2019	$3,354,166.67	$264,680.47	$25,097.13	$239,583.33	$3,114,583.33
35	6/1/2019	$3,114,583.33	$263,664.63	$24,081.3	$239,583.33	$2,875,000.00
36	7/1/2019	$2,875,000.00	$261,095.16	$21,511.83	$239,583.33	$2,635,416.67
37	8/1/2019	$2,635,416.67	$259,959.81	$20,376.48	$239,583.33	$2,395,833.33
38	9/1/2019	$2,395,833.33	$258,107.41	$18,524.07	$239,583.33	$2,156,250.00
39	10/1/2019	$2,156,250.00	$255,717.2	$16,133.87	$239,583.33	$1,916,666.67
40	11/1/2019	$1,916,666.67	$254,402.59	$14,819.26	$239,583.33	$1,677,083.33
41	12/1/2019	$1,677,083.33	$252,131.9	$12,548.57	$239,583.33	$1,437,500.00
42	1/1/2020	$1,437,500.00	$250,697.78	$11,114.44	$239,583.33	$1,197,916.67
43	2/1/2020	$1,197,916.67	$248,845.37	$9,262.04	$239,583.33	$958,333.33
44	3/1/2020	$958,333.33	$246,514.92	$6,931.59	$239,583.33	$718,750.00
45	4/1/2020	$718,750.00	$245,140.56	$5,557.22	$239,583.33	$479,166.67
46	5/1/2020	$479,166.67	$243,168.64	$3,585.3	$239,583.33	$239,583.33
47	6/1/2020	$239,583.33	$241,435.74	$1,852.41	$239,583.33	$—
Final	6/1/2020	Final Payment	$281,250.00	$281,250.00	$—

		Totals	$6,683,449.67	$1,683,449.67	$5,000,000.00

Note: Interest rate floats monthly (greater of 1 Month Libor + 8.51% or 8.95%).

8/6/2018

Oxford Finance LLC

Amortization Table

Regulus AA01d

OF ID: 216053



Start Date:	6/22/2016		Disclaimer:
Interest Rate:	8.97885%		THIS IS A STANDARD AMORTIZATION
Term:	47	23 IO + 24 PI	SCHEDULE. IT IS NOT INTENDED TO BE
Payment:	Varies		USED FOR PAYOFF PURPOSES.
Final Payment:	$165,000.00	5.5%
Amendment Fee:	$18,750.00
Amount:	3,000,000.00		THIS AMORTIZATION SCHEDULE REPRESENTS A
Interim Interest Days:	9		FLOATING INTEREST RATE LOAN. INTEREST RATE
Interim Interest:	$6,734.14		CHARGED MAY DIFFER FROM RATE PER THIS
			SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT



PMT No.	Payment Date	Beginning Balance	Monthly Payment	Interest	Principal	Ending Balance

	7/1/2016		Interim Interest Due			$3,000,000.00
1	8/1/2016	$3,000,000.00	$23,195.36	$23,195.36	$—	$3,000,000.00
2	9/1/2016	$3,000,000.00	$23,195.36	$23,195.36	$—	$3,000,000.00
3	10/1/2016	$3,000,000.00	$22,447.13	$22,447.13	$—	$3,000,000.00
4	11/1/2016	$3,000,000.00	$23,195.36	$23,195.36	$—	$3,000,000.00
5	12/1/2016	$3,000,000.00	$22,447.13	$22,447.13	$—	$3,000,000.00
6	1/1/2017	$3,000,000.00	$23,195.36	$23,195.36	$—	$3,000,000.00
7	2/1/2017	$3,000,000.00	$23,195.36	$23,195.36	$—	$3,000,000.00
8	3/1/2017	$3,000,000.00	$20,950.65	$20,950.65	$—	$3,000,000.00
9	4/1/2017	$3,000,000.00	$23,195.36	$23,195.36	$—	$3,000,000.00
10	5/1/2017	$3,000,000.00	$22,447.13	$22,447.13	$—	$3,000,000.00
11	6/1/2017	$3,000,000.00	$23,195.36	$23,195.36	$—	$3,000,000.00
12	7/1/2017	$3,000,000.00	$22,447.13	$22,447.13	$—	$3,000,000.00
13	8/1/2017	$3,000,000.00	$23,195.36	$23,195.36	$—	$3,000,000.00
14	9/1/2017	$3,000,000.00	$23,195.36	$23,195.36	$—	$3,000,000.00
15	10/1/2017	$3,000,000.00	$22,447.13	$22,447.13	$—	$3,000,000.00
16	11/1/2017	$3,000,000.00	$23,195.36	$23,195.36	$—	$3,000,000.00
17	12/1/2017	$3,000,000.00	$22,447.13	$22,447.13	$—	$3,000,000.00
18	1/1/2018	$3,000,000.00	$23,195.36	$23,195.36	$—	$3,000,000.00
19	2/1/2018	$3,000,000.00	$23,195.36	$23,195.36	$—	$3,000,000.00
20	3/1/2018	$3,000,000.00	$20,950.65	$20,950.65	$—	$3,000,000.00
21	4/1/2018	$3,000,000.00	$23,195.36	$23,195.36	$—	$3,000,000.00
22	5/1/2018	$3,000,000.00	$22,447.13	$22,447.13	$—	$3,000,000.00
23	6/1/2018	$3,000,000.00	$23,195.36	$23,195.36	$—	$3,000,000.00
24	7/1/2018	$3,000,000.00	$147,447.13	$22,447.13	$125,000	$2,875,000
25	8/1/2018	$2,875,000	$22,228.89	$22,228.89	$—	$2,875,000
26	9/1/2018	$2,875,000	$22,228.89	$22,228.89	$—	$2,875,000
27	10/1/2018	$2,875,000	$21,511.83	$21,511.83	$—	$2,875,000
28	11/1/2018	$2,875,000	$165,978.89	$22,228.89	$143,750	$2,731,250
29	12/1/2018	$2,731,250	$164,186.24	$20,436.24	$143,750	$2,587,500.00
30	1/1/2019	$2,587,500.00	$163,756	$20,006	$143,750	$2,443,750
31	2/1/2019	$2,443,750	$162,644.56	$18,894.56	$143,750	$2,300,000
32	3/1/2019	$2,300,000	$159,812.17	$16,062.17	$143,750	$2,156,250.00
33	4/1/2019	$2,156,250.00	$160,421.67	$16,671.67	$143,750	$2,012,500
34	5/1/2019	$2,012,500	$158,808.28	$15,058.28	$143,750	$1,868,750
35	6/1/2019	$1,868,750	$158,198.78	$14,448.78	$143,750	$1,725,000.00
36	7/1/2019	$1,725,000.00	$156,657.1	$12,907.1	$143,750	$1,581,250
37	8/1/2019	$1,581,250	$155,975.89	$12,225.89	$143,750	$1,437,500
38	9/1/2019	$1,437,500	$154,864.44	$11,114.44	$143,750	$1,293,750.00
39	10/1/2019	$1,293,750.00	$153,430.32	$9,680.32	$143,750	$1,150,000
40	11/1/2019	$1,150,000	$152,641.56	$8,891.56	$143,750	$1,006,250
41	12/1/2019	$1,006,250	$151,279.14	$7,529.14	$143,750	$862,500.00
42	1/1/2020	$862,500.00	$150,418.67	$6,668.67	$143,750	$718,750
43	2/1/2020	$718,750	$149,307.22	$5,557.22	$143,750	$575,000
44	3/1/2020	$575,000	$147,908.95	$4,158.95	$143,750	$431,250.00
45	4/1/2020	$431,250.00	$147,084.33	$3,334.33	$143,750	$287,500
46	5/1/2020	$287,500	$145,901.18	$2,151.18	$143,750	$143,750
47	6/1/2020	$143,750	$144,861.44	$1,111.44	$143,750	$—
Final	6/1/2020	Final Payment	$168,750.00	$168,750.00	$—

		Totals	$4,010,069.8	$1,010,069.8	$3,000,000.00

Note: Interest rate floats monthly (greater of 1 Month Libor + 8.51% or 8.95%).

8/6/2018

EX-31.1 4 ex-311x20180930.htm EXHIBIT 31.1 Exhibit

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Joseph P. Hagan, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Regulus Therapeutics Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and 15(d)-15(f)) for the registrant and have:

a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.




11/8/2018		/s/ Joseph P. Hagan
		Joseph P. Hagan
		President and Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 5 ex-312x20180930.htm EXHIBIT 31.2 Exhibit

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Daniel R. Chevallard, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Regulus Therapeutics Inc.;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and 15(d)-15(f)) for the registrant and have:

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.




11/8/2018		/s/ Daniel R. Chevallard
		Daniel R. Chevallard
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-32.1 6 ex-321x20180930.htm EXHIBIT 32.1 Exhibit

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Regulus Therapeutics Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joseph P. Hagan, President and Chief Executive Officer, and I, Daniel R. Chevallard, Principal Financial and Accounting Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.




11/8/2018		/s/ Joseph P. Hagan
		Joseph P. Hagan
		President and Chief Executive Officer
		(Principal Executive Officer)

11/8/2018		/s/ Daniel R. Chevallard
		Daniel R. Chevallard
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.

EX-101.INS 7 rgls-20180930.xml XBRL INSTANCE DOCUMENT 0001505512 2018-01-01 2018-09-30 0001505512 2018-11-02 0001505512 2018-09-30 0001505512 2017-12-31 0001505512 2017-07-01 2017-09-30 0001505512 2017-01-01 2017-09-30 0001505512 rgls:StrategicAlliancesandCollaborationsMember 2017-01-01 2017-09-30 0001505512 2018-07-01 2018-09-30 0001505512 rgls:StrategicAlliancesandCollaborationsMember 2018-01-01 2018-09-30 0001505512 rgls:StrategicAlliancesandCollaborationsMember 2018-07-01 2018-09-30 0001505512 rgls:StrategicAlliancesandCollaborationsMember 2017-07-01 2017-09-30 0001505512 2016-12-31 0001505512 2017-09-30 0001505512 us-gaap:AccountingStandardsUpdate201409Member us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 0001505512 2018-07-01 2018-07-31 0001505512 2017-05-31 0001505512 2017-05-01 2017-05-31 0001505512 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 0001505512 2018-01-01 0001505512 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-12-31 0001505512 us-gaap:SubsequentEventMember 2018-10-02 2018-10-02 0001505512 us-gaap:USTreasurySecuritiesMember 2018-09-30 0001505512 us-gaap:CertificatesOfDepositMember 2018-09-30 0001505512 us-gaap:USTreasurySecuritiesMember 2017-12-31 0001505512 us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2017-12-31 0001505512 us-gaap:DomesticCorporateDebtSecuritiesMember 2017-12-31 0001505512 us-gaap:CertificatesOfDepositMember 2017-12-31 0001505512 us-gaap:CertificatesOfDepositMember 2017-01-01 2017-12-31 0001505512 us-gaap:DomesticCorporateDebtSecuritiesMember 2017-01-01 2017-12-31 0001505512 us-gaap:USTreasurySecuritiesMember 2017-01-01 2017-12-31 0001505512 us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2017-01-01 2017-12-31 0001505512 us-gaap:CertificatesOfDepositMember 2018-01-01 2018-09-30 0001505512 us-gaap:USTreasurySecuritiesMember 2018-01-01 2018-09-30 0001505512 us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2017-12-31 0001505512 us-gaap:FairValueInputsLevel3Member us-gaap:CertificatesOfDepositMember 2017-12-31 0001505512 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member 2017-12-31 0001505512 us-gaap:FairValueInputsLevel1Member us-gaap:CertificatesOfDepositMember 2017-12-31 0001505512 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2017-12-31 0001505512 us-gaap:FairValueInputsLevel3Member 2017-12-31 0001505512 us-gaap:FairValueInputsLevel1Member us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2017-12-31 0001505512 us-gaap:FairValueInputsLevel1Member us-gaap:DomesticCorporateDebtSecuritiesMember 2017-12-31 0001505512 us-gaap:FairValueInputsLevel3Member us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2017-12-31 0001505512 us-gaap:FairValueInputsLevel1Member 2017-12-31 0001505512 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2017-12-31 0001505512 us-gaap:FairValueInputsLevel2Member us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2017-12-31 0001505512 us-gaap:FairValueInputsLevel3Member us-gaap:DomesticCorporateDebtSecuritiesMember 2017-12-31 0001505512 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2017-12-31 0001505512 us-gaap:FairValueInputsLevel2Member us-gaap:DomesticCorporateDebtSecuritiesMember 2017-12-31 0001505512 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2017-12-31 0001505512 us-gaap:CashEquivalentsMember 2017-12-31 0001505512 us-gaap:FairValueInputsLevel2Member 2017-12-31 0001505512 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2017-12-31 0001505512 us-gaap:FairValueInputsLevel1Member us-gaap:CertificatesOfDepositMember 2018-09-30 0001505512 us-gaap:FairValueInputsLevel2Member 2018-09-30 0001505512 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2018-09-30 0001505512 us-gaap:FairValueInputsLevel3Member us-gaap:CertificatesOfDepositMember 2018-09-30 0001505512 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2018-09-30 0001505512 us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2018-09-30 0001505512 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2018-09-30 0001505512 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2018-09-30 0001505512 us-gaap:FairValueInputsLevel3Member 2018-09-30 0001505512 us-gaap:FairValueInputsLevel1Member 2018-09-30 0001505512 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2018-09-30 0001505512 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member 2018-09-30 0001505512 us-gaap:CashEquivalentsMember 2018-09-30 0001505512 rgls:DebtFinancingAgreementMember 2016-06-17 0001505512 rgls:DebtFinancingAgreementMember 2018-09-30 0001505512 rgls:DebtFinancingAgreementTrancheAMember 2016-06-22 2016-06-22 0001505512 rgls:DebtFinancingAgreementTrancheBMember 2016-06-17 0001505512 rgls:DebtFinancingAgreementMember 2018-03-01 2018-03-31 0001505512 rgls:DebtFinancingAgreementMember 2016-06-17 2016-06-17 0001505512 rgls:DebtFinancingAgreementTrancheAMember 2016-06-17 0001505512 rgls:DebtFinancingAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-06-17 2016-06-17 0001505512 rgls:DebtFinancingAgreementTrancheAMember 2018-09-30 0001505512 us-gaap:EmployeeStockMember 2018-09-30 0001505512 rgls:TwentyFifteenInducementPlanMember 2018-09-30 0001505512 rgls:TwentyTwelvePlanMember 2018-09-30 0001505512 us-gaap:RestrictedStockUnitsRSUMember 2018-09-30 0001505512 us-gaap:EmployeeStockOptionMember 2018-09-30 0001505512 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0001505512 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-09-30 0001505512 us-gaap:EmployeeStockOptionMember 2017-12-31 0001505512 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001505512 us-gaap:GeneralAndAdministrativeExpenseMember 2017-07-01 2017-09-30 0001505512 rgls:ResearchandDevelopmentSeveranceRelatedMember 2017-07-01 2017-09-30 0001505512 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-09-30 0001505512 rgls:GeneralandAdministrativeSeveranceRelatedMember 2017-07-01 2017-09-30 0001505512 rgls:ResearchandDevelopmentSeveranceRelatedMember 2018-07-01 2018-09-30 0001505512 rgls:GeneralandAdministrativeSeveranceRelatedMember 2017-01-01 2017-09-30 0001505512 rgls:GeneralandAdministrativeSeveranceRelatedMember 2018-01-01 2018-09-30 0001505512 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0001505512 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-09-30 0001505512 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-09-30 0001505512 us-gaap:ResearchAndDevelopmentExpenseMember 2017-07-01 2017-09-30 0001505512 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0001505512 us-gaap:GeneralAndAdministrativeExpenseMember 2018-07-01 2018-09-30 0001505512 rgls:ResearchandDevelopmentSeveranceRelatedMember 2017-01-01 2017-09-30 0001505512 rgls:GeneralandAdministrativeSeveranceRelatedMember 2018-07-01 2018-09-30 0001505512 rgls:ResearchandDevelopmentSeveranceRelatedMember 2018-01-01 2018-09-30 0001505512 us-gaap:EmployeeStockMember 2018-07-01 2018-09-30 0001505512 us-gaap:EmployeeStockMember 2017-07-01 2017-09-30 0001505512 us-gaap:EmployeeStockMember 2017-01-01 2017-09-30 0001505512 us-gaap:PerformanceSharesMember 2018-07-01 2018-09-30 0001505512 us-gaap:PerformanceSharesMember 2017-07-01 2017-09-30 0001505512 us-gaap:PerformanceSharesMember 2018-01-01 2018-09-30 0001505512 us-gaap:EmployeeStockOptionMember 2017-07-01 2017-09-30 0001505512 us-gaap:PerformanceSharesMember 2017-01-01 2017-09-30 0001505512 us-gaap:EmployeeStockMember 2018-01-01 2018-09-30 0001505512 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0001505512 us-gaap:EmployeeStockOptionMember 2018-07-01 2018-09-30 0001505512 rgls:SanofiMember 2012-07-01 2012-07-31 0001505512 rgls:SanofiMember rgls:DevelopmentCommercializationAndLicenseAgreementMember 2013-07-01 2013-07-31 0001505512 rgls:SanofiMember rgls:RegulatoryAndCommercializationMilestonesMember 2018-09-30 0001505512 rgls:SanofiMember srt:MaximumMember us-gaap:NonUsMember 2018-01-01 2018-09-30 0001505512 rgls:SanofiMember srt:MinimumMember country:US 2018-01-01 2018-09-30 0001505512 rgls:SanofiMember us-gaap:PrivatePlacementMember 2014-02-28 0001505512 rgls:SanofiMember 2014-02-28 0001505512 rgls:SanofiMember rgls:ProofofConceptTrialMember 2018-09-30 0001505512 rgls:StrategicAlliancesandCollaborationsMember 2018-01-01 2018-09-30 0001505512 rgls:SanofiMember srt:MinimumMember us-gaap:NonUsMember 2018-01-01 2018-09-30 0001505512 rgls:SanofiMember srt:MaximumMember country:US 2018-01-01 2018-09-30 0001505512 rgls:SanofiMember rgls:CommonStockPurchaseAgreementMember 2018-09-30 0001505512 rgls:SanofiMember rgls:DevelopmentCommercializationAndLicenseAgreementMember 2018-01-01 2018-09-30 0001505512 rgls:SanofiMember rgls:CommonStockPurchaseAgreementMember 2018-01-01 2018-09-30 0001505512 rgls:SanofiMember rgls:DevelopmentCommercializationAndLicenseAgreementMember 2013-06-01 2014-01-31 0001505512 rgls:SanofiMember us-gaap:PrivatePlacementMember 2014-02-01 2014-02-28 0001505512 rgls:SanofiMember rgls:ClinicalMember 2018-09-30 0001505512 rgls:SanofiMember rgls:DevelopmentCommercializationAndLicenseAgreementMember 2014-02-01 2014-02-28 0001505512 rgls:StrategicAlliancesandCollaborationsMember 2017-07-01 2017-09-30 0001505512 rgls:StrategicAlliancesandCollaborationsMember 2018-07-01 2018-09-30 0001505512 rgls:StrategicAlliancesandCollaborationsMember 2017-01-01 2017-09-30 0001505512 rgls:SanofiMember 2018-07-01 2018-09-30 0001505512 rgls:SanofiMember 2017-01-01 2017-09-30 0001505512 rgls:SanofiMember 2017-07-01 2017-09-30 0001505512 rgls:SanofiMember 2018-01-01 2018-09-30 0001505512 rgls:FourthAmendmentMember us-gaap:SubsequentEventMember 2018-11-05 0001505512 rgls:TermLoanMember us-gaap:SubsequentEventMember 2018-11-05 0001505512 rgls:TermLoanMember us-gaap:SubsequentEventMember rgls:DevelopmentMilestonesMember 2018-11-05 0001505512 us-gaap:SubsequentEventMember 2018-10-15 iso4217:USD xbrli:shares rgls:loan xbrli:pure rgls:target xbrli:shares rgls:employee iso4217:USD false --12-31 Q3 2018 2018-09-30 10-Q 0001505512 8750343 false Accelerated Filer 25 65 REGULUS THERAPEUTICS INC. false RGLS P15M 20500000 4 P12M 5000000 0.055 1250000 1250000 1250000 P1Y 7.67 P1Y P1Y P1Y P1Y P1Y P1Y 10000000.0 2 0.055 P24M 0.02 0.01 0.25 15000000 0 354000 0.30 0.60 8072000 7139000 15000000.0 101800000.0 300000000.0 10000000.0 6800000 40000000 0.20 0.20 0.10 0.10 30000000

373000

13000

5743000

1235000

-271000

-92000

2995000

1856000

-134000

-63000

381199000

385793000

1284000

631000

653000

6531000

2679000

-1399000

2840000

2411000

1390000

-15000

31000

883000

491000

4374000

-15000

31000

2613000

1745000

106597

210816

575256

77809000

34768000

66736000

25441000

57402000

10847000

46555000

8216000

32867000

1494000

3978000

8216000

32867000

1494000

3978000

20064000

13631000

6433000

2440000

3993000

2440000

3993000

1000

77000

55000

4000

18000

7000

46632000

8216000

32922000

1498000

3996000

6439000

2440000

3999000

46555000

8216000

32867000

1494000

3978000

6433000

2440000

3993000

14941000

20222000

13519000

14084000

5281000

565000

1419000

0.001

200000000

8662435

8750343

1303780

8662435

8750343

9000

10000000

-15844000

-57438000

-10257000

-40076000

1921000

100000

400000

77000

-1844000

72000

1921000

24000

1250000

-1800000

19859000

19069000

0.0044

0.0898

0.0851

1942000

1672000

-2.11

-10.52

-1.18

-4.62

1985000

1292000

2736000

13752000

2993000

10115000

-15835000

-57596000

-10273000

-40146000

-7000

-139000

1000

-1124000

-360000

-579000

-4509000

-652000

-1138000

-54000

-418000

-1035000

-631000

-693000

-2405000

-1050000

360000

-589000

775000

676000

160000

559000

201000

483000

580000

1730000

620000

1848000

1444000

1573000

42593000

33190000

77809000

34768000

32600000

25654000

30000000.0

20000000.0

10000000.0

19100000

19167000

5750000

11500000

1917000

43415000

-258000

9538000

40079000

-47672000

-39256000

-15828000

-57457000

-10273000

-40146000

306000

15433000

56479000

9872000

38835000

-15415000

-56425000

-9854000

-38781000

1506000

717000

590000

327000

-16000

19000

16000

70000

2018000

2130000

373000

206000

182000

16000

217000

22000

48539000

4783000

4194000

2500000

43411000

219000

20000000

58310000

40101000

4000

2000

9708000

8324000

100000

833000

12697000

42727000

6879000

28720000

-345858000

-384161000

-344014000

1844000

18000

100000

18000

54000

100000

54000

18000

100000

18000

54000

100000

54000

6531000

4374000

8000

7.57

102000

3.88

35000

72000

10.68

57000

6.25

0.895

0.000

1.045

0.894

0.899

1.107

0.920

0.000

0.999

0.878

0.874

0.917

0.019

0.000

0.010

0.020

0.021

0.008

0.029

0.000

0.020

0.027

0.018

66000

3000

61000

155000

4.56

355000

58.59

603000

887000

1134000

53.24

4.56

11.70

P6Y1M6D

P0Y

P6M

P6Y1M6D

P5Y7M6D

P6M

P6Y0M29D

P0Y

P6M

P6Y0M29D

P5Y7M25D

P6M

46555000

6433000

1000

35216000

1578000

0.083

0.0833

7506529

5463096

8703626

8688831

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, from which the balance sheet information herein was derived.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investments</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We invest our excess cash primarily in debt instruments of financial institutions, corporations, U.S. government-sponsored agencies and the U.S. Treasury. We generally hold our investments to maturity and do not sell our investments before we have recovered our amortized cost basis.</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables summarize our short-term investments (in thousands):</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturity</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in years)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">cost</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">fair value</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of September 30, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1 or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,440</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,440</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1 or less</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,999</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,993</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,439</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,433</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturity</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in years)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">cost</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">fair value</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1 or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,922</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(55</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,867</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1 or less</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,216</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,216</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1 or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,996</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,978</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt securities of U.S. government-sponsored agencies</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1 or less</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,498</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,494</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,632</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(77</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,555</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation and Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, from which the balance sheet information herein was derived.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, we implemented a corporate restructuring to streamline our operations, reduce our operating expenses, extend our cash runway and focus our resources on our most promising programs. In connection with the restructuring, we reduced our total workforce by approximately </font><font style="font-family:inherit;font-size:10pt;">30%</font><font style="font-family:inherit;font-size:10pt;">, to approximately </font><font style="font-family:inherit;font-size:10pt;">65</font><font style="font-family:inherit;font-size:10pt;"> employees. We completed the workforce reduction in June 2017. In July 2018, we implemented a second corporate restructuring to further reduce operating expenses and focus our resources, which involved an additional reduction in our workforce of approximately </font><font style="font-family:inherit;font-size:10pt;">60%</font><font style="font-family:inherit;font-size:10pt;">. The workforce reduction was substantially completed in July 2018. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">25</font><font style="font-family:inherit;font-size:10pt;"> employees.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 2, 2018 we filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation with the Secretary of State of the state of Delaware to effect a 1-for-12 reverse stock split of our issued and outstanding common stock. The reverse stock split became effective at 5:00 p.m. Eastern Time on October 3, 2018 and our common stock began trading on a split-adjusted basis on The Nasdaq Global Market on October 4, 2018. The accompanying condensed financial statements and notes thereto give retrospective effect to the reverse stock split for all periods presented. All issued and outstanding common stock, options exercisable for common stock, restricted stock units, and per share amounts contained in our condensed financial statements have been retrospectively adjusted.</font></div><div style="line-height:120%;padding-top:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying financial statements have been prepared on a basis which assumes we are a going concern, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from any uncertainty related to our ability to continue as a going concern. Through the date of the issuance of these financial statements, we have principally been financed through proceeds received from the sale of our common stock and other equity securities, debt financings, up-front payments and milestones received from collaboration agreements. As of September 30, 2018, we had approximately </font><font style="font-family:inherit;font-size:10pt;">$20.5 million</font><font style="font-family:inherit;font-size:10pt;"> of cash, cash equivalents and short-term investments. Based on our operating plans, we believe our cash, cash equivalents and short-term investments may not be sufficient to fund our operations for the period one year following the issuance of these financial statements. As a result, there is substantial doubt about our ability to continue as a going concern. All amounts due under the Term Loan (see note 5) have been classified as a current liability as of September 30, 2018 and December 31, 2017 due to the considerations discussed above and the assessment that the material adverse change clause under the Term Loan is not within our control. We have not been notified of an event of default by the Lender as of the date of the filing of this Form 10-Q.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to seek additional capital through equity and/or debt financings, collaborative or other funding arrangements with partners or through other sources of financing. Should we seek additional financing from outside sources, we may not be able to raise such financing on terms acceptable to us, or at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to scale back or discontinue the advancement of product candidates, reduce headcount, file for bankruptcy, reorganize, merge with another entity, or cease operations.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we become unable to continue as a going concern, we may have to liquidate our assets, and might realize significantly less than the values at which they are carried on our financial statements, and stockholders may lose all or part of their investment in our common stock.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions. </font></div><div style="line-height:120%;padding-top:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our revenues generally consist of upfront payments for licenses or options to obtain licenses in the future, milestone payments and payments for other research services under strategic alliance and collaboration agreements.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2018, we adopted Accounting Standards Update (“ASU”) 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;"> (Topic 606) (“Topic 606”)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">using the modified retrospective method which consisted of applying and recognizing the cumulative effect of Topic 606 at the date of initial application. Topic 606 supersedes the revenue recognition requirements in Accounting Standards Codification (“ASC”) Topic 605, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;"> (“Topic 605”). All periods prior to the adoption date of Topic 606 have not been restated to reflect the impact of the adoption of Topic 606, but are accounted for and presented under Topic 605. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following paragraphs in this section describe our revenue recognition accounting polices under Topic 606 upon adoption on January 1, 2018. Refer to Note 1 to the financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017 for revenue recognition accounting policies under Topic 605. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligation(s). At contract inception, we assess the goods or services promised within each contract, assess whether each promised good or service is distinct and identify those that are</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">performance obligations. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We enter into collaborative arrangements with partners that typically include payment to us of one of more of the following: (i) license fees; (ii) payments related to the achievement of developmental, regulatory, or commercial milestones; and (iii) royalties on net sales of licensed products. Where a portion of non-refundable up-front fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as contract liabilities and recognized as revenue when (or as) the underlying performance obligation is satisfied. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the accounting for these arrangements, we must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation(s). The stand-alone selling price may include items such as forecasted revenues, development timelines, discount rates, and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time, or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">License Fees</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other performance obligations, we use judgment to assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Milestone Payments</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of each arrangement that includes milestone payments (variable consideration), we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price. If it is probable that a milestone event would occur at the inception of an arrangement, the associated milestone value is included in the transaction price. Milestone payments that are contingent upon the achievement of events that are uncertain or not controllable, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received, and therefore not included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, we evaluate the probability of achievement of such milestones and any related constraint(s), and if necessary, may adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Royalties</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of our collaborative arrangements.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for stock-based compensation expense related to stock options granted to employees and members of our board of directors by estimating the fair value of each stock option on the date of grant using the Black-Scholes option pricing model. We recognize stock-based compensation expense using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award was in substance multiple awards, resulting in accelerated expense recognition over the vesting period. For performance-based awards granted to employees (i) the fair value of the award is determined on the grant date, (ii) we assess the probability of the individual milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for restricted stock units by determining the fair value of each restricted stock unit based on the closing market price of our common stock on the date of grant. We recognize stock-based compensation expense using the accelerated multiple-option approach over the requisite service periods of the awards.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Clinical Trial and Preclinical Study Accruals</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We make estimates of our accrued expenses for clinical trial and preclinical study activities as of each balance sheet date in our financial statements based on the facts and circumstances known to us at that time. These accruals are based upon estimates of costs incurred and fees that may be associated with services provided by clinical trial investigational sites, clinical research organizations (“CROs”) and for other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If possible, we obtain information regarding unbilled services directly from these service providers. However, we may be required to estimate these services based on other information available to us. If we underestimate or overestimate the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, our estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in our accruals.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Prepaid Materials</font></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We capitalize the purchase of certain raw materials and related supplies for use in the manufacturing of drug product in our clinical development programs, as we have determined that these materials have alternative future use. We can use these raw materials and related supplies in multiple clinical drug products, and therefore have future use independent of the development status of any particular drug program until it is utilized in the manufacturing process. We expense the cost of materials when used. We periodically review these capitalized materials for continued alternative future use and write down the asset to its net realizable value in the period in which it is identified. </font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As disclosed above, effective January 1, 2018, we adopted Topic 606. Since ASU 2014-09 was issued, several additional ASUs have been issued and incorporated within Topic 606 to clarify various elements of the guidance. As part of our adoption efforts, we have completed the assessment of our collaboration and license agreements under Topic 606. We adopted Topic 606 in the first quarter of 2018 using the modified retrospective method which consists of applying and recognizing the cumulative effect of Topic 606 at the date of initial application and providing certain additional disclosures as defined per Topic 606. On January 1, 2018, we recorded a cumulative adjustment to decrease deferred revenue and accumulated deficit by approximately </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;"> to reflect the impact of the adoption of Topic 606. The cumulative adjustment relates primarily to our agreement with Sanofi which is described further in Note 7. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Below is a summary of the affected line items of the condensed balance sheets upon adoption of Topic 606 (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments due to Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at January 1, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheet</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue (contract liabilities), non-current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,921</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,844</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(345,858</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,844</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(344,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There is no difference between what our revenue would have been in the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, reported under Topic 606 or Topic 605.</font></div><div style="line-height:120%;padding-top:20px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU No. 2016-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:inherit;font-size:10pt;">, which eliminates the requirement for public companies to disclose the method(s) and significant assumptions used to estimate the fair value for financial instruments measured at amortized cost on the balance sheet. Additionally, the standard requires public companies to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes. Furthermore, the standard requires presentation of financial assets and liabilities by measurement category and form of financial asset on the balance sheet or accompanying notes to the financial statements. The standard is effective for annual reporting periods beginning after December 15, 2017, including interim periods within those annual reporting periods. The adoption of this guidance had no impact on our financial statements. </font></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases,</font><font style="font-family:inherit;font-size:10pt;"> which increases transparency and comparability among organizations by requiring recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements. Since ASU 2016-02 was issued, several additional ASUs have been issued to clarify various elements of the guidance. The standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual reporting periods. Early application is permitted. We are in the process of determining the impact the adoption will have on our financial statements and expect significant changes to the recognition of right-of-use assets and liabilities associated with our operating leases. </font></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:inherit;font-size:10pt;">, which addresses the presentation and classification of certain cash receipts and cash payments in the statement of cash flows under Accounting Standards Codification 230. The standard is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those annual reporting periods. The adoption of this guidance had no impact on our financial statements.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows: Restricted Cash</font><font style="font-family:inherit;font-size:10pt;">, which requires restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those annual reporting periods. The adoption of this guidance will have no impact on our financial statements.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation: Scope of Modification Accounting</font><font style="font-family:inherit;font-size:10pt;">, which provides clarity and guidance around which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those annual reporting periods. The adoption of this guidance had no impact on our financial statements and will continue to have no impact on our financial statements unless we have modification accounting in accordance with Topic 718. </font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2017, The Tax Cuts and Jobs Act (the "Act") was signed into law and amended the Internal Revenue Code, or IRC, to reduce tax rates and modify policies, credits, and deductions for individuals and businesses. Due to uncertainties which currently exist in the interpretation of the provisions of the Act regarding IRC Section 162(m), as of September 30, 2018, we have not completed our evaluation of the potential impacts of IRC Section 162(m) as amended by the Act on our financial statements. In March 2018, the FASB issued ASU No. 2018-05, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income taxes (Topic 740):</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118</font><font style="font-family:inherit;font-size:10pt;">, which provides guidance regarding the recording of tax impacts where uncertainty exists, in the period of adoption of the Act. To the extent that a company’s accounting for certain income tax effects of the Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the condensed financial statements. If a company cannot determine a provisional estimate to be included in the condensed financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Act. We have provisionally determined that there is no deferred tax benefit or expense with respect to the re-measurement of certain deferred tax assets and liabilities due to the full valuation allowance against net deferred tax assets. Additional analysis of the law and the impact to the company will be performed and any impact will be recorded in the respective quarter.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU No. 2018-07, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">, which aligns the measurement and classification guidance for share-based payment to non-employees with the guidance for share-based payments to employees. Under the new guidance, the measurement period for equity-classified non-employee awards will be fixed at the grant date. This update is effective for annual periods beginning after December 15, 2018, and interim periods within those periods and early adoption is permitted. The adoption of this guidance will have no impact on our financial statements.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issues ASU No. 2018-13, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:inherit;font-size:10pt;">, which updates and modifies the disclosure requirements on fair value measurements in Topic 820, primarily in relation to Level 3 fair value measurements. This update is effective for annual periods beginning after December 15, 2019, and interim periods within those periods. Early adoption is permitted. The adoption of this guidance will have no impact on our financial statements.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our revenues generally consist of upfront payments for licenses or options to obtain licenses in the future, milestone payments and payments for other research services under strategic alliance and collaboration agreements.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2018, we adopted Accounting Standards Update (“ASU”) 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;"> (Topic 606) (“Topic 606”)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">using the modified retrospective method which consisted of applying and recognizing the cumulative effect of Topic 606 at the date of initial application. Topic 606 supersedes the revenue recognition requirements in Accounting Standards Codification (“ASC”) Topic 605, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;"> (“Topic 605”). All periods prior to the adoption date of Topic 606 have not been restated to reflect the impact of the adoption of Topic 606, but are accounted for and presented under Topic 605. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following paragraphs in this section describe our revenue recognition accounting polices under Topic 606 upon adoption on January 1, 2018. Refer to Note 1 to the financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017 for revenue recognition accounting policies under Topic 605. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligation(s). At contract inception, we assess the goods or services promised within each contract, assess whether each promised good or service is distinct and identify those that are</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">performance obligations. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We enter into collaborative arrangements with partners that typically include payment to us of one of more of the following: (i) license fees; (ii) payments related to the achievement of developmental, regulatory, or commercial milestones; and (iii) royalties on net sales of licensed products. Where a portion of non-refundable up-front fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as contract liabilities and recognized as revenue when (or as) the underlying performance obligation is satisfied. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the accounting for these arrangements, we must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation(s). The stand-alone selling price may include items such as forecasted revenues, development timelines, discount rates, and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time, or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">License Fees</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other performance obligations, we use judgment to assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Milestone Payments</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of each arrangement that includes milestone payments (variable consideration), we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price. If it is probable that a milestone event would occur at the inception of an arrangement, the associated milestone value is included in the transaction price. Milestone payments that are contingent upon the achievement of events that are uncertain or not controllable, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received, and therefore not included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, we evaluate the probability of achievement of such milestones and any related constraint(s), and if necessary, may adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Royalties</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of our collaborative arrangements.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables summarize our short-term investments (in thousands):</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturity</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in years)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">cost</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">fair value</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of September 30, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1 or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,440</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,440</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1 or less</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,999</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,993</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,439</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,433</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturity</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in years)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">cost</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">fair value</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1 or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,922</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(55</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,867</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1 or less</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,216</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,216</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1 or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,996</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,978</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt securities of U.S. government-sponsored agencies</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1 or less</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,498</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,494</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,632</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(77</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,555</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-indent:32px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the allocation of our stock-based compensation expense for all stock awards during the periods presented (in thousands):</font><font style="font-family:inherit;font-size:12pt;"> </font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">491</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">653</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,745</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,411</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development-restructuring related adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,399</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,613</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,840</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative-restructuring related adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,679</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,390</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,284</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,374</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,531</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"></font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents our fair value hierarchy for assets measured at fair value on a recurring basis as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair value as of September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,631</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,631</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,993</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,993</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,064</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,631</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,433</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair value as of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,847</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,847</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,867</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,867</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,216</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,216</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,978</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,978</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt securities of U.S. government-sponsored agencies</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,494</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,494</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,402</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,847</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,555</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of September 30, 2018, future principal payments for the Term Loan due under the Loan Agreement are as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,917</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,167</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Below is a summary of the affected line items of the condensed balance sheets upon adoption of Topic 606 (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments due to Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at January 1, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheet</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue (contract liabilities), non-current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,921</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,844</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(345,858</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,844</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(344,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our stock option and RSU activity (together Stock Awards) under all equity incentive plans for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> (shares in thousands):</font><font style="font-family:inherit;font-size:12pt;"> </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">RSUs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted average grant date fair value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock Awards outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">887</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">603</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.88</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised (options) or Vested (RSUs)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canceled/forfeited/expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(355</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58.59</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock Awards outstanding at September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,134</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the weighted average assumptions used to estimate the fair value of stock options and performance stock awards granted to employees under our 2012 Equity Incentive Plan and 2015 Inducement Plan and the shares purchasable under our Employee Stock Purchase Plan during the periods presented:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Performance stock options</font></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employee stock purchase plan shares</font></div></td><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stockholders’ Equity</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares Reserved for Future Issuance</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following shares of common stock were reserved for future issuance as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock options outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSUs outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock available for future grant under 2012 Equity Incentive Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock available for future grant under 2015 Inducement Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total common shares reserved for future issuance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,419</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our stock option and RSU activity (together Stock Awards) under all equity incentive plans for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> (shares in thousands):</font><font style="font-family:inherit;font-size:12pt;"> </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">RSUs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted average grant date fair value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock Awards outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">887</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">603</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.88</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised (options) or Vested (RSUs)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canceled/forfeited/expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(355</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58.59</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock Awards outstanding at September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,134</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the weighted average assumptions used to estimate the fair value of stock options and performance stock awards granted to employees under our 2012 Equity Incentive Plan and 2015 Inducement Plan and the shares purchasable under our Employee Stock Purchase Plan during the periods presented:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Performance stock options</font></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employee stock purchase plan shares</font></div></td><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:24px;text-indent:32px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the allocation of our stock-based compensation expense for all stock awards during the periods presented (in thousands):</font><font style="font-family:inherit;font-size:12pt;"> </font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">491</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">653</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,745</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,411</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development-restructuring related adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,399</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,613</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,840</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative-restructuring related adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,679</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,390</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,284</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,374</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,531</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

EX-101.SCH 8 rgls-20180930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2101100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Effect of New Accounting Principle) (Details) link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Fair Value Measurements (Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis) (Detail) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Investments (Summary of Short-Term Investments) (Detail) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Net Loss Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 2419401 - Disclosure - Related Party Transactions (Detail) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - Stockholders' Equity (Assumptions Used to Estimate Fair Value of Stock Options and Performance Stock and Employee Stock Purchase Plan) (Detail) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Stockholders' Equity (Common Stock Reserved for Future Issuance) (Detail) link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - Stockholders' Equity (Stock-Based Compensation Expense Allocation) (Detail) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Stockholders' Equity (Stock Option and RSU Activity) (Detail) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Strategic Alliances and Collaborations link:presentationLink link:calculationLink link:definitionLink 2417401 - Disclosure - Strategic Alliances and Collaborations (Detail) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2420401 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Term Loan link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Term Loan (Details) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Term Loan (Future Principal Payments) (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Term Loan (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 rgls-20180930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 rgls-20180930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 rgls-20180930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Income Statement [Abstract] Statement [Table] Statement [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Revenue under strategic alliances and collaborations Strategic Alliances and Collaborations [Member] Strategic Alliances and Collaborations [Member] Statement [Line Items] Statement [Line Items] Revenues: Revenues [Abstract] Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Operating expenses: Operating Expenses [Abstract] Research and development Research and Development Expense General and administrative General and Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income (Loss) Other income (expense): Nonoperating Income (Expense) [Abstract] Interest and other income Interest and Other Income Interest and other expense Interest Expense Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income tax benefit Income Tax Expense (Benefit) Net loss Net Income (Loss) Attributable to Parent Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax [Abstract] Unrealized gain (loss) on short-term investments, net Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Net loss per share, basic and diluted (in dollars per share) Earnings Per Share, Basic and Diluted Weighted average shares used to compute basic and diluted net loss per share (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Fair Value Disclosures [Abstract] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Asset Class [Axis] Asset Class [Axis] Asset Class [Domain] Asset Class [Domain] Cash equivalents Cash Equivalents [Member] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Corporate debt securities Debt Security, Corporate, US [Member] Certificates of deposit Certificates of Deposit [Member] U.S. Treasury securities US Treasury Securities [Member] Debt securities of U.S. government-sponsored agencies Mortgage-backed Securities, Issued by US Government Sponsored Enterprises [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Assets measured at fair value on a recurring basis Assets, Fair Value Disclosure Accounting Policies [Abstract] Revenue, Initial Application Period Cumulative Effect Transition [Table] Revenue, Initial Application Period Cumulative Effect Transition [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2014-09 Accounting Standards Update 2014-09 [Member] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Calculated under Revenue Guidance in Effect before Topic 606 Calculated under Revenue Guidance in Effect before Topic 606 [Member] Difference between Revenue Guidance in Effect before and after Topic 606 Difference between Revenue Guidance in Effect before and after Topic 606 [Member] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Deferred revenue (contract liabilities), non-current Contract with Customer, Liability Accumulated deficit Retained Earnings (Accumulated Deficit) Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Type of Arrangement and Non-arrangement Transactions [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Development Milestones Development Milestones [Member] Development Milestones [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Term Loan Term Loan [Member] Term Loan [Member] Fourth Amendment Fourth Amendment [Member] Fourth Amendment [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Conversion ratio for reverse stock split Stockholders' Equity Note, Stock Split, Conversion Ratio Exercise price (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Prepayment requirement of loan from license fees Prepayment Requirement of Loan From License Fees Prepayment Requirement of Loan From License Fees Potential revenue through milestone payments Revenue Recognition, Milestone Method, Potential Milestone Receivable Revenue Recognition, Milestone Method, Potential Milestone Receivable Payment fee Payment Fee Payment Fee Minimum cash, debt covenant Minimum Cash, Debt Covenant Minimum Cash, Debt Covenant Proceeds debt covenant, conditional minimum amount Proceeds Debt Covenant, Conditional Minimum Amount Proceeds Debt Covenant, Conditional Minimum Amount Conditional amount, capital event, debt covenant Conditional Amount, Capital Event, Debt Covenant Conditional Amount, Capital Event, Debt Covenant Reduction of workforce Reduction of Workforce Reduction of Workforce Number of employees Entity Number of Employees New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] AOCI Including Portion Attributable to Noncontrolling Interest AOCI Including Portion Attributable to Noncontrolling Interest [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Cash and cash equivalents and marketable securities Cash and Cash Equivalents and Marketable Securities Cash and Cash Equivalents and Marketable Securities Cumulative effect of new accounting principle in period of adoption Cumulative Effect of New Accounting Principle in Period of Adoption Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Stock-Based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Clinical Trial and Preclinical Study Accruals Accrued Expense [Policy Text Block] Accrued Expense [Policy Text Block] Prepaid Materials Prepaid Expenses [Policy Text Block] Prepaid Expenses [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Fair Value Measurement Fair Value Measurement, Policy [Policy Text Block] Earnings Per Share [Abstract] Net Loss Per Share Earnings Per Share [Text Block] Debt Securities, Available-for-sale [Abstract] Summary of Short-Term Investments Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Debt Disclosure [Abstract] Term Loan Long-term Debt [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Research and development Research and Development Expense [Member] Research and development-restructuring related adjustments Research and Development - Severance Related [Member] Research and Development - Severance Related [Member] General and administrative General and Administrative Expense [Member] General and administrative-restructuring related adjustments General and Administrative - Severance Related [Member] General and Administrative - Severance Related [Member] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Stock-based compensation expenses Allocated Share-based Compensation Expense Common Stock Reserved for Future Issuance Schedule Of Shares Reserved For Future Issuance [Table Text Block] Schedule Of Shares Reserved For Future Issuance Stock Option Activity Share-based Compensation, Stock Options, Activity [Table Text Block] Assumptions Used to Estimate Fair Value of Stock Options and Performance Stock and Employee Stock Purchase Plan Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Stock-Based Compensation Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Potentially dilutive securities not included in calculation of diluted net loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Stock options Employee Stock Option [Member] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of options, beginning outstanding number (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Number of options, Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Number of options, Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Number of options, Canceled/forfeited/expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Number of options, ending outstanding number (in shares) Weighted average exercise price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted average exercise price, beginning balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted average exercise price, Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted average exercise price, Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted average exercise price, Canceled/forfeited/expired (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Weighted average exercise price, ending balance (in dollars per share) Number of RSUs Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Shares outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Shares granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Shares vested in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Shares canceled in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Shares outstanding (in shares) Weighted average grant date fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Beginning balance (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Exercised (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Canceled/forfeited/expired (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Ending balance (usd per share) Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Statement of Cash Flows [Abstract] Operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Net loss Adjustments to reconcile net loss to net cash used in operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization expense Depreciation, Depletion and Amortization Stock-based compensation Share-based Compensation Amortization of premium on investments, net Accretion (Amortization) of Discounts and Premiums, Investments Other Other Operating Activities, Cash Flow Statement Change in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Contracts and other receivables Increase (Decrease) in Accounts and Other Receivables Prepaid materials Increase (Decrease) in Prepaid Expense Prepaid expenses and other assets Increase (Decrease) in Other Operating Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued liabilities Increase (Decrease) in Accrued Liabilities Accrued compensation Increase (Decrease) in Employee Related Liabilities Contract liabilities Increase (Decrease) in Contract with Customer, Liability Deferred rent and other liabilities Increase (Decrease) in Deferred Liabilities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Purchases of short-term investments Payments to Acquire Short-term Investments Sales and maturities of short-term investments Proceeds from Sale, Maturity and Collection of Short-term Investments Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Acquisition of intangibles Payments to Acquire Intangible Assets Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Proceeds from issuance of common stock, net Proceeds from Issuance of Common Stock Proceeds from exercise of common stock options Proceeds from Stock Options Exercised Principal payments on other long-term obligations Repayments of Other Long-term Debt Proceeds from capital lease financing Proceeds From Capital Lease Financing Proceeds From Capital Lease Financing Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Net increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at beginning of period Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Supplemental disclosure of cash flow information Supplemental Cash Flow Information [Abstract] Interest paid Interest Paid, Including Capitalized Interest, Operating and Investing Activities Income taxes paid Income Taxes Paid Supplemental disclosure of non-cash investing and financing activities Noncash Investing and Financing Items [Abstract] Non-cash acquisition of property and equipment Noncash or Part Noncash Acquisition, Fixed Assets Acquired Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Fair Value Measurements Fair Value Disclosures [Text Block] Schedule of New Accounting Pronouncements and Changes in Accounting Principles Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Basis of Presentation and Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Statement of Financial Position [Abstract] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (shares) Common Stock, Shares Authorized Common stock, shares issued (shares) Common Stock, Shares, Issued Common stock, shares outstanding (shares) Common Stock, Shares, Outstanding EX-101.PRE 12 rgls-20180930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 ex42image1.jpg begin 644 ex42image1.jpg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
8&'EFW; M;(45Y@2N%,7QYU7P]\)KG1/BUX5\*:$VL>(8I+ZZURYTZYNQ:1-:@^:\5OF2 M/S L44ER%/EIC?N4 4#/"OCYX=^(GP]N_$WA/2S\7;W2)9UN=(U,ZCKEX8[D MZ/$2BM;'SY2]R7*HTT<"2!RQR%6J7PHU?QW\'_B?K/B35-(^*OF^)9HKK5$@ MTW4KA;RXG\*6*0-Y:J4W"]AN(R0!Y3A%?:-E>U^)_P#@I:^DPVUM9^'WO-3O M?%&I>'(':TNDTR4Q2R0VLBWA3R7#2"(R;&8JI+/&WAO6 M]-T*XU7P1HVI:G)=V;21VU\8+:QN8<1LS-'E;PJREF.8PP.&P #YP_X0WXL+ MX ;Q!K&J_%*S:?7]&L=6\^;6YQ;Z:OANS=VCM;65)<'4F?S98.8?%2>&_"#?;_[*OA?R6 FOSBZ@M9A=H&D$JS&*0RKG+_A'X:U32+/1++6O$?BRY\.J+R.6:V@2&:[3>55U8DBV'\0P M6/IBLOXA?M$W>A?!+0_B+#HNGQ>+I]7;PA=-#:76J11%;Z2VG\N*#$TZ>;;L MR #=AL\9;(!D?L:ZKKNL_%[3IM1L-4TN\/PXTY-9MM1N9KFZ21=0OULVDDF1 M)F+1BX;,J+)AEW@-D5Y+%?>-_ OA_P -?#;2_"]_/XKTWXB76HZM9WW@JYO[ M'6+2XULW:ZK%JF5MH&BMI&DR69_-4)M! SZA^S1^U7?_ !<^.)2WTC3]).LV MEC/JLD7AW4KF2XE\B0&-[OB*U\LQE1%. ZG<" Q-=E\4_P!K/4?!/Q0U*SA_ MX1ZST#P_JVG:%>'4A.+B_N[Q4DQ$\8*1*D&M'L-/M1J&LZ:KM-KNHP7<\D:F2:1DL MA;.YQ+.L6TJP9E>O?/B?_P %"+WX>_"ZWUG^RM%;4-2\*Z1K-E!"2\O MIVC,32,<+&B([YZX1JK^#_\ @HX/%OQH&G0#3IO"\DS2"4:?=1F/3TT>+47O MOMI/V9]K2I&T(PX#AL]J!GA_PW\)_%OQ-X-\17EW??%R.7PG#?7'AN-9-7LE MO'76 ]N3%.YFG7[-\HCG9R8V(8<#&#%X,^)O@;Q%JFE:51IFLWHN-4FUZ::)\1RQQ/&UJ]LZF^&_#6HW?A MW2UAU"QUI]:DM;\7$6B7-LUH+,,ZG#)*;VW1B.5>5>P8CL_&W[6/Q \%V_BB M\F3PO+9:9+H,5FMMHU[=7"_VI=1Q M'%*SS&-&;Y8U!=L8P." > ZA'\;'\5 M>*&N=7^)'G_VS=?\)+96.G:LJIHW]NPX-G.93#YO]G"3RAI\?F,A;=B0#/T9 M^P!X?M?#OAV[3[/\0+7[7KWB.[TL:[#J">?8R:B'26?SQS(RF,Q&?]Z4,A'_ M "TK(NOVU/%UAJ_B"$PV M6O2OA+\=_$&L1>*--\26VCMK?A[1K/78YM-61+6XM[J.9HU9'9F617MY0PW$ M;=A!^8@ CX@^-O[.7CV\M_C/X?T[PKXGN-%^*.IZUKEXL6G2M&9--GNY(<87 ME[IIM.$8'^L6U?;G%=5K,/QP/CCQ_P#9=5\>1ZX&UD/86VFZD;?^R?-C%H;: M9IOL:S_9@IB-M'YQD\T-SO8>N> /^"A?BK6? _\ ;%SX7CU;RKNUT^6WM-.N M]-NC-?VL4EBWD76'6%KAFMS+RC%E<$*DF/3/VC_VMXOV:+[X=V&M2Z$-0\3W MD<>IB2X\@1VX:&":6W5CEBL]U =I)/E^8>2M SXJ^)$?B[P_X:^('M1NT\0_:KNYCT;0H[=?+0+K>'='\36NLW#7O?[-? M[9UW\;_B8OA74-'M]*U2!-;GN$5V;?;VE[;06D\1/WDE2:0,>TL$BC(7)P?! MW[:GB37+^]GGL[+[''XM7PW';_V!J%LJ(=8^P>:+V0_9YVV MMBZ,<'[IH \ M:^'7A?QS\0/&GA31[2]^-]OX/O;K14\42ZG>:K:7*WXL]6:_59G*RQPEQ9AS M$P@W&/874 I<9$:QY*,3BN/UO_ (*/ZI#XVLTL=.TRXT)[^.%YX[*\ MN$FMGO+>#SC=1CRK9528R;YP%;;CCDT!J<5I?QE\;-^T2GCE--\4W'PZ3Q5; M"ZU'3O >HZ1?7]JVFZK$EO<6Q!N+R*"=[%1*8@N]L@#;D<3=>,/C#=:G\-6& MF_%>RUZQL/#%OJ/FKJ\_VR*:PB^W2/''MM(]DLDBRM/YLWFH3A JL/IOQE^U MUK]MX'^&5_I]K;6EQXYTZ6_N"F@7^N?9RB1-L6&T/F $R'YV^4;0.K"NU^/O MQHUOX?:AHVEZ-_8D%Y>Z=>ZO>7VIPSRP6UM:+%O"PQ$2.[//& ?E&XX8@*0 M#X[O=&^)/@+Q!\*=.L#\8;C4;6Q\*7VIW=[?ZYJ(OI+B\W:J'0'[/'L1G\W[ M0S[5V(D48 :K$OP>\6GAW7M;BN[[5;J:WOH-%+0Z"NJF<,P M4D9; )493!P#7E%Q_P %5=2OO WA74;6ST&'4-1LM6DU&VAM;K5H$O+6>S2" MU$UL2L(F2\B/G2912R@CF@-3R?2A\=O^$\?+,TUI_PG4/]CZX5LW^V M2&1K607'F,!P"NFJJ&W*MD *#]$2:!K6O?\ !-@6OBNP\<^-+H7:SD0VTUEK MT5K'JPDM[J**5IIWEMH5CF1)-TLP@4.N]RM-^('_ 4BF\/^+_B%HFBZ1I&M MZOX3ETR/3M.BO@USJ)DNK6WOD8 _(T3W2(F>&?/8&M6^_;0U_53IOB/13X>F M\$7%IJNI2![*=[Z:WL%25MA\U55Y(W 9/E8'(/0 'SAXNMO%MW:P^,H=,^) M'B]M&UC6QI.MZ;X:N_#FM:XTGA[9#)#?"GQ/ M^(.G:OICWGQ;MM"@NM7OM/EM;O7;-I/^)%"UNBS7+_:707H?;N*AY%.$ ;:? M;?B7^W1XO^$5]H6F^(;;PY9S^(([345O]/TN^U:*PM9;34)Y(WMX6\Z1HVLD M'FKM5ED9BB^6<]U\0_VL]<\#_L?Z!\17T&SCU?5K>":33Y96,49D1FX88;!P M",\X//- 'S/XJ7Q#\,O'FC:!XKUCXWOX8U*>.X!T^]U:XO[RZ;07>50T),_E MBZ56*1X1)2!A5)%?;W[.2^)4_9_\$CQF9#XN&A60UHR8W&\\A/.SCC._=G'% M?-NM?MPZEXP6+5H/">E6VM>#1;C4I;BTNM3;PY(K:S\2Q^&9DO;WQ#91OIUM-;F,Z5;2?"^J^3!;3K,?A_X?\ !.K7GA72M7A^(EA;Z_I=EILD MAN;.P,UN)XI"21+<+#=1.A4*K.)$P,!F]8\)_M0_\)M^SS;^-M,AL+W^UM?G MT;33#+OM[A!J\EA#/NSRIC02G!YY [4!8]AHKY"\'?\ !3]=$\*:[JWC'1I& M@TZTLKZ!+&S?2Y'6X-YO5?M\D:3+&MIGSHG*2&0*@W8!Z#5?^"GGAJ#4--\G MP_XAAL;[6%TRWFNHH5_MD.M_'']D E/S-=V:P_O_ "A^\#'"_, +,^G:*\]^ M O[1ND_M MXC73;'4-/D\,ZD^F7,5ZT/F,RDC?LCD=D!VG"RA'Q@[0""?0J! M'R[^VI_R>_\ LF?]C7K7_IAO:^HJ^7?VU/\ D]_]DS_L:]:_],-[7U%0 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?+W[+^R3_P!CUJG_ *CFJU]0T#Z'GG[0?Q!\,>#=-TB# MQ'8:GJIGO4OK.UL('FF\RSQ=>:%4@D1^4&VC); 4*Q.#P,WASX"_&SP\_AK^ MU--*?VQJ<:6T&OW&GWR7\=\M[>F)TE2972ZB24E"-FT8PIP>A_;"^!;?'3PA MI]C_ &[X;T>..=D/]N:4+^ O(NQ98<2PR0W2$YBE20;26RK9&/*/%_\ P3\B MU:#6M+O?B)I\>B>+;N2*Y:?3Q_:C-]HENHTAN3.%$GGS3>8?*;S(]J[4(+L M=SJWBGX*Q_ J\\*77B#^V/!]C;QW8NI_$=SJ$[AII)%EBOWG:[?PH+)]"X$XDD>ZN,S M+)OE\YPS,#BN:UK]@N]\2Z[?>)+OQWX;3Q%JFES:/>?9O#XCTIH5EDE(2U^T M':5E,1=BY=A&ZLV''EQ7'[%5A:Z1?VT?COP@GBO5=1NM6O)KC2$DMBEW!,MP MB6WV@,$ N)6BW2-L!&[S!NW '7K\+_@#K_@ :5=Q:%:Z7%KB!8[S5'M[A=1@ M>:S20.THD\US#, P;=+\[$L2QKK=&T/X1>)_B;8MIM[X8NO$^GB#[-;6>IJ9 MH_L*W,,>(4?!\H7EPI^7^,!ONKCP?Q9_P3-TJWL[O2XOB)#:0:QKEYJDEM>_ M: TLMYN%RF8KN)W_ '!ME1&+1J4F+=WFGR.\;I-9SI+%+:7)"[0Q+HP89C; M'/FWA?\ X)P&R\8_VIJWQ!6\NY=6LKE1:VDD)N+>TDNI7M&$EQ*H65Y8&D6% M8XP;;B,;S@ VM.^%7P:D\-RZC_PF=A9^(-.\/QV\^H3:_P"6-/26V^R0WLUG MYWV87/DR"(3O'O(PH;;A:]&\2_#;X7?M)Z18^'6OK/5AX9@AEBBT779;2YM; M>6(!%9[65)/(ECQE&/ER+C(8 5\_^(?V&Y? /@C2M>\&:_I?BK6?"1ZIJWBS2VB3P[9Z M3=:?;Q-'%%=1V]NLDKN\K)D"#Y?*BAW*^9/,*HR@'4W/A[X$:CHT.B/J'@U[ M(:S?016G]L)M&HW>]+F%5\S_ %K>>P\L=J6N75MX@OKF[F+QL)X;NZ6"=W4K%&C+M50.0^''[#FC^& M]1U34=6^)V@ZW=:Q:-I\$OV?"QN#;[9$#W,BJP$*Y2(1Q@O\B(,+7??##]F. M#1?AMX_\*?\ "::!J)U[0T\/PS66GK%+IUM#!+;QR7(\YC--M?YW_=ABO"KG M +?B#]F7X,WTXM[^]U73)O'%[_;MI9#QKJ=@TEPN^9Y;.)+I?(/[YV<6X0$ M.=P(K4OM#^"WQ8^&OAWP%;Z]H1:3/-9R6ZSW[O].U8>3;R,T8MI9I&$ M;37,TNR0S8R7.T*!R, '1V?PN^"WPF_:*MK*"?7/#_BG1M 779 GB74[;36 MLH9&B\ZZC^T"VF?<[EFG5G;)9B<9K<\>>&_@G\1/'EKXJUG6M GU+3]/@U=B MOB)H;2YM(Y-T%U(]4U#4+WP;J=[XR\.W5A=J=:5H]1TMD03L(A+L*;+9 M-TJKD"$?,-M:_C_X=?"7Q?\ "/4-5U;4;"V\):RFG23ZQ;>(9K")A:2J;-X[ MN&9&C*2!<,CJ2< DUY!'_P $]]/\2P>(]0O/'7AZ]U+5KF6\U22VTH+9PRO; M:K!(@C^T%HXO^)D3M+EOW3?-F33+A@"O?\ P"^ .DWE_->>*KX/8:>D>J)= M?$K5'22VDW1QF[1[TK*&\PHK3!B054' 4#=^'\GPT^!?P;T,^&-.\0ZI8_$> MW2XL;AWWP"N_#OPT^'-GX: M\8:)IGB7X7Z/%90:E?Z=]JL[BU:U6WE:2W2>)E5Q$KJ1*-K(.6&00"E\)/"/ MP+\#>$[71]&U2QB74+O2[M;?6/$-S!+RUOSX]T.0Z(ME:6;?V+Y:K!:2:=)#]H(N/WDQAL%# MN-@)EW!5"A2 >I7-A\+O@7X]EU1=+%CKOA32[>Q-VBR221VFL:FP2/<2=X>[ M@+&U+X(_L]ZQ!KTS>(KQM)U*XN-2U&>W^(FIQZ;IUS'>6]S(Z!+ MP1VDHN)HGS$$(WD_P!G M7TEY;);7'G*D3/+*R/N27TZ%]#$5Y?7 MJ^,[FWU"&-X8+4?:+I;D3F*5(+=761RDS(A<.W-1>(O@9\$UTF_\83Z-?6]E MX+NY1>P6>HWL%HNUXI3YUI%*(9X<"*55D1D"8( R:XJZ_P"";%C!X"2QT[QI MI:3P64IBNI]/<*0\FDNDQ:"YAE&S^RP T$0R"!I=HP!OQQB@#S"T\*_L]7\:Z1ILW MQ$,VFZ[=Z7;6]CXOUZ">VN8[BWLY8866[5HX&DN+<+&I$1!5@O&1WNK>.?AC M^T[X9L;36]-\6Z99L!SY;#?B3!SN'-8_P MX_8V\/>&]=T_64\=V&IW\J:%;O.L<86]O-/GBGN9E D/[RZ%O!N49V>4#\U; M>O?L1^%O$#6&F>);W0];Q-XEN;.UU'3HY?WNJWIN]\:.Q^: $ID.O!]IJ&BS03_$31IH=*LDNKN/3)K:VL8T8 M8QY>[;\M9-C\7?@C\4K;Q1\0(?"6O:GIESH-P-=U,VDHM19RV5M-+&\#2#YV MM[>U!VQ[OD49ZUO_ +0/[(.D_'JQ\&^'&\;KH^J>#]+?34^RJOVR02?9"[J- M^8]T5NZ=#Q.3GY>>/T'_ ()V?V9JWBG3-/\ $_P\N(M8LI+.YDN/"1GUW3$E ML_LP$5R+Q1''@;@IB.%=7ET'PU%?: MQ^%3-KT*#2(=._=WGVL#RC]G$FPPG(9UW<[@!H:/ M@OQ3\$_A5K@_L_PUXL7Q#I&HRW,MI.MYJ%]I8M[+#;=\LG^BQ6VI_)!"6C7[ M2WEQ[@V.DUCQ+\&+SX7^&O ]Q93R>&M0GFATNP!G"Q-#J,-@R[@VY56XO(U5 M<[0IX 50!R/B/]@72O$6GZOX;\&>+/"6FZ//J=QJ*Z<^A17EQH4D\4,Z-=:A:^3-!;3I-;RHS*T0DC90P++@2+C;6KX ^*_P %OBWJ]O9: M/ 3=SW>@VL=L(9K?RVAM_P"UM,(0$!8T52P(&TLC(V=I%=5^S#^S#X6_9A^" M]KH6D'3Y;NUTR+3M4UI8]DE^T"%"[Y=BH!+G9NPI9L=37!?#_P#X)\V'PV\: M?#[75\5'^TO!=Q&\S+:")=8MH])2Q$+J7.-KQB=7Y*[G3HQ8@$G[0NH_ S3] M,\3>'?%BZE;Q>!?,\5ZD=-N[ZWGMS?S.TY6:WD65M[3$R0JQ79,@*[645UNJ M2?">[\/>,/%DUM --\'0V,&JW,1D6&.'3574;3RU0[62,7 <;!\V[:=P %XN]6F42S6FHV;-$(K40&;RHVC2ULU,JC+?9 MSD?-@:/AG]A.U\+?!_Q3X&@\1WQ\/^)_$L>K/'L9);73E^SK_9B2(X8((K=8 MED!#*A P2-Q .2\/^(_@-X)U[3[_ $[1==E@U2UTCQ)!>;KRYLM(BO)YDL8X MT>0BTB:9)!Y$2+$I^\HXI- ^-'PIU3X-Z-X.\):%XGT.SO[FV\1Z/IUMIA61 M%N)[C58KJ-7;;Y3O;W#; W !0*ORBNB^&/\ P3K\.>!?'6J:OJ5V/$D?V-++ M0HK^&263142]O[M29'E;SF5K["LP#*(5.<\U6T[_ ()B> 8/A%X,$W-E87- MOX=M$@U.Y^R$3:U(MA):++N+LT14RM(@#,$)('4F@-#@QX0_9MU+PZ3%H7C/ M4M%N&@N%U4ZAK$J6\LEC+51G;>3$@GL^&SINE7WB^PU/PE#?6.LWU@-#%O<75_:000Q-'*DNR* FVAE:(1$[PV'"- ML'*:A_P37>T@TA].UOPGJEUIE_?W#+XK\+MK-HT$Z6T-O$D2W4.QK>WM(8P^ MX[OG.T%N #I?@!9?#/0OC1%['QAHVKWMS?1F6^GNYK/57M7,4T*22O(H6 M%WD*0@HH+RNBG7^HZGI>FV.BO9/# M/>R,\AFE:XE$H022*@5(\!N=Q KV:@1\N_MJ?\GO_LF?]C7K7_IAO:^HJ^7? MVU/^3W_V3/\ L:]:_P#3#>U]14 %%%% !1110 444V2584+,P51R23@"@!U% M,BN8YXU='1U?[K*V0WTI] !111F@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /E[]N'_D\7]DG M_L>M4_\ 4M4_\ 46VC7$U\TQD9)KB%A#/&44R1OYJ>2IVDX M%?;M% 7/@"Z_8Y^,VC7=WINF:?:3:3XWU'Q%)J37E$(M!;4M4VRRH@D#-#+ M8GSECC8,LBOG!DX[*[_8T\7:U\&M3T:^\/Z'-XHLO VL>$[+5ECBB%ZPE6*P M<-N>1=]JB EB2OS GIG[-HH"Y\/_ !?_ &8?B+^T;X_U7Q+;^&Y_"J7UGK7D M6NLKIUW*6DLM!MXX9%S.D9F-C=[9$W; J,W78>__ &,OA%K_ ,.?B5XEFU;P MEXLT;^U+J]N+:YO4T::UCBE='C4SPNUZTN!@AR4R&_V37U#10%SX=N/V>_B! M;&PALOAU! _A9+2YU&]1+..Z\37=OKMC>R2P7 N&_P!A'XEV?P_M_!S6FGQV_B[1-$T_5-0GAM1;Z1#9 M^=/(O$NF6EW%K7B*U M_P"$SM))XW@N%M='6VCU&)"Y 1Y1/&T6-[+-$2 (SG[>HH"Y\8/^RUK?@CQI M\.KNW\"ZM+I^DZ3J4%]'H5IHDGE7$M_;RQ^:MZP&&BC/SP_.-H&1P*ZC]F;X M)^(_!W@/Q_H^H^%_$6GZGJD&IK!/=PZ.EI=&6XG:,0RVS?:6W*ZG_2.GL:^I MZ* N?G,/V'OB7IVF>%&OO#&KWR>#H[/P_;1V%UIUS.=(M+J">WV1W;^07423 MH1)G(@'JN?3[GX,^+$\42W6E_"[5QJRZCI.JZ9KE]_9%O+8Q6D$:SV[?9YAL MDE\N2/;$GE$3\L!NQ]E44!<^-O@5\'/BS^SAXRTLZ]H$OCRS$TNJS7?A[[-: M^7=WUM&EVK175TN<3VYF9U;YFO#M7@@2>)_@Y\0/B5\+/#6@+X+UG2)O"J7\ M5V;^[LO)UB&1]QAC,<[MLFC5HB9%7 F&1@''V+10%SX;^)/[*7CGQIXNU/QA MX-\%2>"9K'3M7GT?1Y;NVB^U7$MOIENT$R12-%']JBAND4JS*ACBD;#?+7K/ MQ?\ V2+_ ./7BKPC;ZH\.G:'8>%GT_49A:0W%U',9;5@D$C$F"3]TV)54D8X M(.#7T710%SX8T+]BSQIX.O-/O;S09?$EHNGVSSZ;#]@M\K%J\%U"O$GPT\,^&M5UG2=0NDU&PUR2ZLX[=8H]!%AY#IO1EE,\2@*L M0B"2K\P"D#[7HH%<^$_&O[''B[P]9ZY!_P (OJGB>YFOC!3-YS&W^U2R,'521:G:6+KG[)HH'<^ /$W[$OQ;L?!&JV6F MZ?8S:IX7T2Y\+:0UO<+;66O:5=3L[P+&\KM#Y2RQE/,.=UBHW;7)KZI^!/P* MLO M_P#$6.Y\-Z396/B77#/'&EM#LO;7[';1_,JC[N]91M8>IQ@Y/JU% 7/B M_5OV3-:\/?#)-&MOAS;ZE?ZUX(CT&PGM39QKX7U0/*S74A9U*@EK=S+!ODS: M+QD)7>_M+?!WQ!XE_::\*>(-$\+7FJFW.E137LK64VF1PP:@TTOFI(R74$T2 M,SQ26[LKLP61&"@'Z3HH"Y\O_#SP'XE\+?M8^/O&-YX%\9/;^(+V'4=/:&+0 MG@V#1[* QO*\OVM)1-#+'A7\K(!SM)8[?[/_ (#U/X>>/7%]\,IEU2SN-5%W MXM6[M5;5$N]166,HHDWR*8R))/-"&+R=L8DR*^A:*!'Q[^T7^Q]XR^(OQ:\6 MZ_86T<]AJFM0^7;;;1)IH3HZVJW*3LIE18[@_/$'3?&KXSG;)/X:\-_$*T^- M_ACQ[Z:UX##:W"M=A.P BOKNB@= MSYP_8<^%.N?#'5?$EOKOAKQ'I4]W?:E<+>74&CBSF274)I8Q%+;,;MBT?F$3(9),'#M= A/E8#W#XQ? 'Q1X]M[>_U>]=_X1S7-%FFT M25M-00W,.(8HDN))D25B #*0PW*I8;0%KZ%HH"YYC^R7X8U#P%\'[+0[[2M6 MTP6,EPUN-0BL(IO)>YF,2NMEB$2"/86VJ =XY+;\>G444""BBB@ HHHH *** M* /EW]M3_D]_]DS_ +&O6O\ TPWM?45?+O[:G_)[_P"R9_V->M?^F&]KZBH M**** "BBB@ KYY_X*4:-IGB7X):)INJ>)]%\-17OB2S6)-=@FDT36I5$C+87 MYC(V6\NTY9R%WK&"&)"-]#50\3>%M-\:Z'<:9K&GV6J:==KLGM;N%9H9E]&5 M@01]10!^<'A7XX1_!>[M-(\-^"/#-OJ7AWXA,TVF>']4.M>'?.;POJ-RHTIS M'&UM(Q@42Q! 5:5SSYN3H>(/V]OBAH&FVB:1\3O!GBR_\0>#](\0J(-(B*Z% M=WVMZ;9-$ZI)EH5BN90JN1)E6+,3C'WI8?!+PGHGA6'1M,\/:1H^GVKR2VD6 MGVJ6WV*5T:-I8=@'ER;78;UP?F//->9? 7]@#PM\%/%FI:Y>ZEJ?C34[^UCL M$EUJVL_W$"3"<9$$$8EE,J1NTTH>1FB0[N*!W/#OB!^UW\1OAI<>(? MWXKE MU?Q/8>-UT33K[3-#L8M0U&S.BQ:BZ@75Q#91-&\AS)(_,:8",YS7E/@[]N/X MC:YH=[\4)_%]O'>VGPPFNTTTV\/V*:6WUZ6UEN@BNR[O*C5W*,5&>NT+7Z-> M*O@]X3\&=!U:*YN4O)DO+"*999T0(LK!E.7"@*&/( Z4X?"/PJ G M_%-Z%^ZBN($_T&/Y8YSNG0J16,6I"RBN=%U"]N,#<%:0/;QE&^:X)MTDD5[<1[)'*@*% M=OM#PS\%_"'@N&WCTCPOX?TM+259X%M-/BA$,BJZJZA5&&"R. 1SAV'RB:35K6-(X=2;8,SHJ,RA7^\ I(YX)K;KR?Q-^S?X@O-78^'OBMXQ M\%Z+'''#9Z+I&FZ/]BT^-$50D7FV;N%XS@L<9XP, 9__ S)XZQ_R7[XE_\ M@LT+_P"0*!'M%%>+_P##,GCK_HOWQ+_\%FA?_(%'_#,GCK_HOWQ+_P#!;H7_ M ,@4 >T45XN/V8_'0)_XO_\ $O\ \%FA?_(%'_#,GCK'_)?OB7_X+-"_^0* M/:**\7_X9D\=?]%^^)?_ (+-"_\ D"C_ (9D\=?]%^^)?_@LT+_Y7T >T45X MO_PS)XZ_Z+]\2_\ P6:%_P#*^C_AF3QU_P!%^^)?_@LT+_Y7T >T45XO_P , MR>.L?\E^^)?_ (+-"_\ D"@_LQ^.C_S7_P")?_@LT+_Y H ]HHKQ?_AF3QUG M_DOWQ+_\%FA?_*^C_AF3QU_T7[XE_P#@LT+_ .0* /:**\7_ .&9/'6/^2_? M$O\ \%FA?_(%'_#,GCK_ *+]\2__ 6:%_\ (% 'M%%>+_\ #,GCK_HOWQ+_ M /!9H7_ROH_X9D\=?]%^^)?_ (+-"_\ E?0![117B_\ PS)XZ_Z+]\2__!9H M7_ROI!^S'XZ"_P#)?_B7TZ_V9H7_ ,@4 >TT5XO_ ,,R>.O^B_?$O_P6:%_\ M@4?\,R>.L_\ )?OB7_X+-"_^5] 'M%%>+_\ #,GCK_HOWQ+_ /!9H7_R!1_P MS)XZQ_R7[XE_^"S0O_D"@#VBBO%_^&9/'7_1?OB7_P""S0O_ ) H_P"&9/'7 M_1?OB7_X+-"_^5] 'M%%>+_\,Q^.L_\ )?\ XE_^"S0O_E?1_P ,R>.O^B_? M$O\ \%FA?_*^@#VBBO%_^&9/'6/^2_?$O_P6:%_\@4?\,R>.O^B_?$O_ ,%F MA?\ R!0![117B_\ PS)XZS_R7[XE_P#@LT+_ .5]'_#,GCK_ *+]\2__ 6: M%_\ (% 'M%%>+']F/QT5_P"2_?$OI_T#-"_^0*7_ (9D\=?]%^^)?_@LT+_Y M H ]HHKQ?_AF3QU_T7[XE_\ @LT+_P"5]'_#,GCK_HOWQ+_\%FA?_(% 'M%% M>+_\,R>.O^B_?$O_ ,%FA?\ ROH_X9D\=8_Y+]\2_P#P6:%_\@4 >T45XO\ M\,R>.O\ HOWQ+_\ !9H7_P @4?\ #,GCK/\ R7[XE_\ @LT+_P"5] 'M%%>+ MC]F/QT"?^+__ !+Z_P#0,T+_ .0*!^S)XZ'_ #7[XE_^"S0O_D"@#VBBO%_^ M&9/'7_1?OB7_ ."S0O\ Y H_X9D\=?\ 1?OB7_X+-"_^5] 'M%%>+_\ #,GC MK_HOWQ+_ /!9H7_R!1_PS)XZ_P"B_?$O_P %FA?_ "OH ]HHKQ?_ (9D\=8_ MY+]\2_\ P6:%_P#(%!_9C\=$C_B__P 3/_!9H7_ROH ]HHKQ?_AF3QU_T7[X ME_\ @LT+_P"0*]&^&'@W4_ GAC[#JWBG6/&%WYK2?VAJ<-K%/M.,)BWBBCP, M''RYY.2: / /VX?^3Q?V2?\ L>M4_P#4_^R9_V->M?^F&]KZBKY=_;4_Y/?\ V3/^QKUK M_P!,-[7U%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?+W[ M+^R3_V/6J?^HYJM?4-?+W[+^R3_V/6J?^HYJM?4- ^@4444" M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y= M_;4_Y/?_ &3/^QKUK_TPWM?45?+O[:G_ ">_^R9_V->M?^F&]KZBH **** " MBBB@ HHKD?C3\,&%#%AEE?$;;T"L2R@^C"[B;/[R/CK\PXH DHJ/[7%Y6_S(]G][<,?G6,GQ M*T23X@MX5&H0G7DT\:JUH,[A;&3RA)G&,%P1USP: -VBF27"1 [G1<=_;A_Y/%_9)_P"QZU3_ -1S5:^H:!] HHHH$%%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R[^VI_P GO_LF?]C7 MK7_IAO:^HJ^7?VU/^3W_ -DS_L:]:_\ 3#>U]14 %%%% !1110 5XM^W1X!N M_B)\*-,M8?!$_CVTM=:MKN^L+#4VTS5K:% _^DZ?<+-#Y=S&Y0C]ZF4,@SDC M/M-% 'Y\W?P$^-7BC2+.9'\8:9X=T7Q=+J6B7GB^_LWUW1K,^'=1MGGNIH7) MEB6ZGA$?F/).!DL<#CQ[2?@H/C=XDL_"7@?P!_9-U)\.-".N-8ZO921:ZX\0 M:;-/>>;;SLK&2&WN7$TC+-,%/!*@5^LS*'4@@$$8((ZUC>#_ (;^'OAZ;O\ ML'0M'T3[?)YUS]@LH[?[0_\ >?8!N/)Y/K0.Y\3?$_\ 9$\3>$->\0Z#X>^& M6FWOPZU/QZFK6UE%:VUY;V%L=#B@,T&G27$5LQ:\$@/G*RHQ,OE$X<>;^#_V M#/B;I'PAN8KKP!/)XLG^'=YH=I=/<6'GVTT.MR74%JTJ. GFVK1JFS]VNW:= M@ %?IW10%SX/\5_LP^,/VHOVAO[:\4_#C4K3P-J'C71+^YTW6[FT?S["UT34 M;>5IH8YG4H;F:%3&22P;E<;L5/@1^Q]X\\$_M66FL:QH?B W%EXOUK4;G6K9 M=-BL[W2)A="UMWGR;N:+RI((UM754B:)2"%C0M]]T4!K>#_#&IWTPW2W-UI<$TTN!@9=E)/ Y/:OE/X)_ MM6?!+XX_ '1/&=A\(_#=G>:AXJT[PI?Z)W$<<,Y/E8>)HI8YE( M #*V,@@X /L$^/\ 0A_S&=*YX'^EIS^M'_"?Z%G']LZ5GKC[6G^-> ^.?BK^ MS'X'T[Q8[V7PQU"_\%V5Y?:CIUGIUG)=!;7B=$7: SHQ56 /RLP#8S3=!\>_ M *[T*\UO5O#?POT/088M-DMKN>VLVDN&O8!-%&8A'N5R.%7DN 2!B@#W\?$# M06) UK2B1P1]KCX_6C_A8&@[<_VUI6/7[7'_ (UXG=^,?V8M/71&E/PA1?$T M27&FM]CLR+N-I?)5P0O"F7]V"V!O&WKQ7;:'\'?A)XJEU>#2?!W@'4+G0[DV M-]%%I%L3;7'EI+Y3_)\K;)(V^C@T =N?'^A ?\AG2O\ P+3_ !H_X3_0L_\ M(9TK_P "T_QKX[TWXL1_\+-\:^'-4_9<\ Z>/A[I,&MZU^%TWBFUL_A1;VVF:9;ZIK"/:V9&CI,O MR^:VP#&X,@8<%E('/% 'T%_PG^A9_P"0SI7_ (%I_C0/'^A'_F,Z5_X%I_C7 MGOPS\ ?!/XR^'FU;PMX;^'>N:?',]M)-::3:N(I4^]&XV95AGE2 1FN)\1>- MOV>K;0O%KZ'I'PFUS5_"%C=7UW8>19VX5;=BDNZ4QE51)!L=\$(W!YXH ]W_ M .%@:#MS_;6E8ZY^UQ_XT'X@:"I&=:TH9.!_IT.F_8+3S_.1/,>(#9RZI\S*.5!&0,U3\+^//V7?&^C:OJ.ER_!^^L? M#]FNHZA<1VEGY=I;L2JS,VW&PD,NX<9!'7B@#W'_ (3_ $+./[9TK/I]K3_& M@?$#0B3_ ,3K2N.O^EIQ^M?.?B#XV_LS:1J'@Z&TT7X?ZQ_PF7B1O"MO)9:/ M:N+*\6V>Y*S@J&3Y%08QG,T?&#D=KJMM^SWH7ANRUB\T[X76NEZE83:K;7(==LM MFCT.U.V>YD"*S97A5&6., MG"\"@#V+_A/]"S_R&=*_\"T_QH_X3_0L_P#(9TK_ ,"T_P :\F\'C]GCX@_$ M*[\*:)8?"W4_$=AYPGT^WT^T>=#"P28 ;.3&Q"N!G:2 <5Y[^T[\;?@3^S%X ME\0:'J'P[\)7NNZ#X1N/&#VPTFTA2:VAD"&/>4.&/S-DC "F@#Z;'C_0C_S& M=*_\"T_QI!\0=!9<_P!M:5@\@_:X^?UKPSP_XK_9]\>7.E?$OHWPH\06EYJ MC:9>3PP6:?8F%G+=@[3'ER8XPP Q\C%P2JFNA^$FE? #X[1W?_"&Z1\,O$(T M]8VN%LM,M9#"D@)C* /;A\0-")/\ Q.M*XZ_Z6G'ZTG_"P-!VY_MK2L>OVN/_ !KQ&WUK MX"ZI=Z3:=Y)'E[1N'S#%2S^ M*G[*E]HMS?Q7/P>:SM+B"TG?[':#RIITE>"-@4R'D2"5D7&6"$C/% 'O1\?Z M$!_R&=*_\"T_QH_X3_0L_P#(9TK_ ,"T_P :\*U[XE?LL^&?"VD:U?S?""UT MG7H9KC3KI[.T$=W'"X29U.SI&QPY_AYSC%7-+\5?LS:WX;U[6+0?".XTOPPT M2ZI=)9V9BLC*=L6YMO\ RT;A,9W'@9- 'M/_ L#0BV/[:TK(Y(^UI_C0/'^ MA'_F,Z5_X%I_C7AVI^._V7]$\+:?KET?A'!IFKO/%9W#6-I_I+VYVSHHV;BT M9/S+C*\Y P:?\--?^ GQ=^-&K^"/#WA3P+J=_I.AV'B W-OI%I);75M>;S$T M;!3N^548GIB5,$Y. #V[_A8&A%<_VUI6/7[7'_C0?'^A _\ (9TKGI_I:<_K M7B'CSQS^R_\ "[QC=^'?$3_"#1=:L'6.ZL[NTLXI+9FB$J*X*_*6C(90<;AT MS6SX*MOV?/B1:V4VA:9\,-4CU"VN[RV-OIMJQDBM9%BN7 V9_=2.JOG[I8 T M >K?$_H6("R#JP&0#4W[-*?!3]JCX5_\ "7^& MO O@_P#LO[?>Z>WG:):AD>VG>%B<*1A@@<<_==<\T >PGXA:"$+?VUI.T=3] MKCP/UI3\0-" _P"0UI7_ (%I_C7AVF^._P!EW6M UG4;=_@_-IV@I&^H3BSL M_+@220Q1MDK\RO("BET_0M'U*9_A%'9:_=26.G2-96G^E MW$;JDD*#9GS%9U#+C*YY H ]Q_X3_0L_\AG2O_ M/\:/^$_T+/\ R&=*_P# MM/\ &OG^W^,W[)UYHAU.&_\ @W-8K.;7SX[2T=3((_,91A.=J?,V.%'7%=#= M7W[.-EXTTSP_);?"@:SK*V[V5L+&S9KD7 S;[2%Q^] .P9^?^'- 'KX\?Z$? M^8SI7_@6G^-'_"P-"*Y_MK2L>OVN/_&O&/"?B/\ 9I\;ZY>Z;I*?"2^O=.AG MN+F*.RL_W, '8>CX.,T >['Q_H0/_ "&=*YZ?Z6G/ZT?\)_H6%>(/B)^S#X>^'EEXHF'PD_L?4S#X._$3]F?PI\4-2\!^!?#6C>)]'LM6(O-,M2MD+I8RD;2>6 ?FD5TLX=E\MJ;I;:1BAV.81OY'"9;&!7DVL_M:?LY MZ!XD72[OP/X&M3:>(K#P[JUS-I]FMM827>F2Z@DJOY9\U/W8B'"EG;@<#(!] M='Q_H0_YC.E?^!:?XT?\)_H6?^0SI7_@6G^-><^%O!/P1\=?#3_A,-%\-_#S M5O#/D2W(U"UTFUDA*1;O,.0G52C CJ"I!Y%>$?#K]LS]E_QS-H-Q?>&_A]X8 MT?Q)X7MO$UE>:O86<+%99Y86@9-A"M&8QO;<5&X#/<@'U[_PG^A9_P"0SI7_ M (%I_C0/'^A'_F,Z5_X%I_C7D][%^SUIWQ0A\%SZ?\+8O%=PZ1QZ8VGVGVAG M=#(B8V<.R LJGD@9 Q5CXM:+\!/@-;6,OC'1OAKX<34Y'CL_MNEVL9NG4;F5 M!LRQ YP.: /4/^%@:$5S_;6E8]?M)>(O& MW[,'A'3M(NM1?X06EIKMC'J5A,]I9^7<6DAVI61LXD*\A/O$= : /=?^$_T+/\ MR&=*_P# M/\ &K^G:I;:O;^=:7$-S%G;OB<.N?3(KP+5/&W[,.B>'=$U>[;X M10:;XDADGTVY:SL_+NXHW$_;A_Y M/%_9)_['K5/_ %'-5KZAH'T"BBB@04444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 ?+O[:G_)[_ .R9_P!C7K7_ *8;VOJ*OEW] MM3_D]_\ 9,_[&O6O_3#>U]14 %%%% !1110 4444 %%%% !1110 4444 ,N( M_-@=1U92*^(&_P""67B2P\"_ E]*UW1M+\3^ ;K1H/& C>0V7B+3[&[%TBJ= MF[SH7#&)BHXED4D!LC[BHH ^);K_ ()Y?$'Q)X&TOX?7UWX.LO"7@M==DT?6 M[:>>75=9?4+>[@B2YA,2I"$6\9I&664RM&I 3) N0_L,_$O3_&6E>/(O^$(G M\4>'[[1M4MM%EU&X_L^\DMM%GTRXB>X^S[XQFX:2.00N3LP47<2/LZB@=SX. M^)'_ 37^(7CKQ5J^K77_"&7TOQ!T>'2]?L[7Q!J^A:=HFRYNY3Y5O9E1J*& M.[*E96MR\D;/N7SF5/M'P#9:QID6H6NIVFE6UK:W"PZ8]G<22R7-LL,8\R<. MB[)?,\P;0SC:J'=DD#H*0G:,T"/"]:_9DUW4OBW\<=>2[TL6GQ+\(Z=H&F(9 M'\R">WBU!':8;,!";N/!4L?E;(&!GR+XO_\ !-'Q'\0O".@6%EJ>B:>WA[P1 MHNBI'#=7-LMU?Z;J=K?*ADB59(X'^SLGFH?,3?N"$C!]'N/^"G'@#1M0UV'6 M]+\8>'$T?1+OQ%!)J5A%'_:UE;/''+)#&LK2QD--%A;E(20X.,!B/4_@)\=+ M3X_^#I-7M-%\0:#Y,WD/:ZM#$LA^57#I)#)+!*A5AAXI'7.5)#*P /4X?]B; M]G75_@3HOBR\U^TT[3]8\7ZHE_/;6NOZAKWE".".!/,O+TAYG*Q@Y6*)5&U< M-MWMX#K/_!.CXI:QI_Q+T6SU#PMX?T#Q1H.MZ;;VEMK5[=6&I7-](7BG%I/$ MW]F;22TBV\LJR,Q.P5]%_&S]N7P/^SYJ'B"V\3MJMI)X=?2Q/LME?SX]0E:* M*:+YLM&ACE,A.-BQ.<$#G"\4?\%#?"]AXY;PQI&A>,=;U9YM1A2>QTZ*:TA2 MPG2VN[IV:9/W$,S[&Z,3&X4'C(&I\WVG@+Q=K'Q_\-?#72M'2?1/#7Q'U_Q- M+J5YH][!?0Q7::G(6FE:+[-Y7FW:K')'/(TR,F8XRCBN_P#$'_!/GX@Z=\(O M FE^&=5\+:?K7A+X7VO@NXD$CHES=17-A*_EN8'V1NEK,JS%"\;2*XC)'%0? M\%6]=AGM$MOAQK>OV\\_A"WCU*UBM[:.]768DD>58GNBT9PV(XV8X/WGQS7J M<7_!3OX;2:MJ\6W7ET[3H-2FL]5\B%K37&T]9&NHK7$IDWJ(I2OFI&L@1BC. MHS0/4\C^'_\ P3W^)OA/QI#XGEF\+RWB?$"P\7C3[OQ)J&I,ENNB2Z5S MP&220>9YJ'8JMC9B, &L_6?^"=7Q;\:> =)\(:K6$T4]Q&8 L&(K,JR*TOS-D,0<#ZA_9_\ VM]"_:&\1:GI5CHWBC0; M_3]/L]8BAUNR2V;4-/NS*+>[B"NY\MS#*-LFR12OS(N1GJO%?Q?TGP=\2O#/ MA6[%W_:?BN&\GLC'&#$%M5C:7><@CB1<8!SSTH%<^6OVBO\ @G)XB^)'QR\3 MZII7]E:AX<^($.F0ZFM]XGU;3!HXM!Y;[+.S98KU&C *J\D)1]QW,&P/=/VN M/@KKWQ>^''AZV\,'2GUGPSXETG7H(=3N)(+>Z6TN4D>-I421D+(&P=CF33W,/VFY)F#81K24LL M:R/M&0K -MZ./]OCP7-\0AHZ67B5](;5O^$>7Q,+)/[&?5",BR$GF>;O)PH? MRO*WD)YF[Y: U//?@+^QCX[\ ^,?AEI&LR^$X_!OP=OK^_TK5+&XFDU?Q";B MWN;:..YB:)4@VI=.TC+++YKQH<)D@7/VX/V-_&'[0WC36[GPZ_ADZ=XH^']_ MX.O?[3NI89+2629)X945(9!(A92C@E2H.1N^[79_LV?M\^$_VG=?T>PTK1?% M^B'Q+H3>(]#GUFPC@BUFR1XDFDA*2N1Y;SQ B0)G>"F]?FK7_:<_:2OO@#XH M^&>GV7AF_P#$(\>^)TT"9[9HP;!#;S3&7#NN3^ZZ?W0YY(56 U/./B=^Q!XA M\9_M17'C*RN?#,.BSW-I+]FNHY)21%H^IV#;X0JJX+WL)V^8,HK\@@ V_P!@ MC]E_Q[^SSKGB!_$USIMEH%QI]CI^EZ'9:]=ZY#9O!YOF313W<2300NKHJVNZ M58Q'P_.*P?@#_P %4= \2?"JRUCXB:5K'A*231]0UC^U&T_;I.I)92E+E+7$ MLD[.F4^5T7>3^[+BO9?V=_VL/#W[1]WK-CI]EJ^B:WX?$,E]I6JK +J&&8,8 M9LP2RQE'V.!AR048,%(Q0&I\^_%S]A?XJ_$G]HVXUUM6T";P_!XVTSQ382R: MY>6ZI:VYMP]HVFQ0B!I<1R,+F661FPB[8P=R8>A?\$[?B=8Z5XHTIQX*A\.3 M:B7J>(-=U2/2_[0=;6R, :""-+B.0.?.&6$#;ZQUZ.[\/^,]*\1:%<6%JOAVYMK634]2DOFE6T6!8;B2(F0P M3<22(4$3&0(HS0/4\+\>_L"_$2[^##7/BW7#>_V-I7B1DL[.XFUZ_LDNWTN6 MUMEE:&"340'L)C(9 DC+,(QOQN)\!_A)XV_:J_:\-7G M[NRO;:"\6PL-=AE$)NH(I9I%DU&V;>8D0?,@9C%EO=/%G_!27P;X+TS3OM_A M[QQ#K5U!=7=[H4EA#%J.CVUM*(IYYUDF6-D#D;?(>5I1DQB0 X]T\(>+-.\= M>$M-US2+F.\TG5[6.]L[B/[L\,BAT<>Q4@_C0*Y\GQ?\$\_$W]M>*KB2Z\,M M'K/A[QUI-FIDD/DR:YJ$%S;$CR^%5(F$F,D$C:''-5/C'_P3=\1^/+=IM.O] M(M9=,TOPDMA:0ZA=:>EY=:/->/+%)/ HD@C=;E1'+'N9&7<4.W:W:^-?^"FO MAK3/ NOZKHWAKQ=>K'I.IW_AF]GLXHM/\626,,DDR6SF7<-JQN_[U8]Z1NT> M\"O5_P!E;QIXE^(W[/7A37_%\44'B+6+!+R\BBLA9I$7RRJ(A//@!2!GS6SU M^7.T :GAO[./[!^O?#KXL>&?%^M6_AZVEMKK7+[4;*+6=0UJ2*6]AM((=MU> M9>=Q';'>^V$?, $/).S^Q!^R+XO_ &7_ !)I8U67PY>Z6OP_T;PY=RVES+Y\ M-]827'^K1H@'@=+@_.65@8P-A#9'&>$/^"HOB'Q#XOT.WE^&/B:2'4]<\5:- M_9EA;PW.I7ATFY2*-X6-PL*#;YGF^:RC>FU"V5W]_KW_ 5(^%^BZ9HVH1-K MNH:3J.B6GB.^OK>VB$7A_3[D$Q37:R2)(,A7)2))74(2R@8) U*/C[]B36_% MOCKQIJR2^'ROB3XF>&_&4!E9]ZV6FV^G1RQO^[/[TM:2E%!*_,N67)QR-Y^Q M!\3_ )\3[[Q5X3F\$7USJEYXJMI+74;VXMX[:SUBXM9X[A62!RTL1MOFAPJ MMYG$HQS]@:CK5KI.C3:A<3QQ65O"UQ),S81(U&XL3Z8YKP6U_P""D7@T>!I_ M$.H>'O'>BZ;/%:3Z&^H:6D7_ E$=V^RV-F1*5!D./DG,+JK!G5%RP U/(/A ME_P3U^)OPS\5_#0V%[X8TZ/P]IOAZTUS5M-UN]B-ZNGVL,%Q;RZ<\+VUYY@C M98[DM;RQ+(.#Y8W>Y?LZ_LWZ]X$_9>\3?#GQ)/IL'V^_UV*ROM*N9)&>RO[F M>>.5P\:>7,OVEE**74>6"'.[ PH/^"FO@[5[C1M.TCPQX[USQ-K$M_;MH-C9 M6TMYITME]D:X2X;[0(% CO;>0.LK(RO\K$E5/DOB_P#X*J>*5_9ML_%ND^$) MX?$NL^'[/4;;1)K&.?[))47B+)%\P(B 5F)7+H"=H&IT+_L<_%G7 M_A[X7TV_M_A=97/PM.D'P^MLT\@\2/82ALWL:EI6G32SPZ;)>65A9P1V\CQ(9L)9EI) M&2(DR<*16OX*_P""@$6F>%+>TU?2/$GC7QE]KU.*YTWPUH*07%M;Z?+'%1%^69GD9P(T;! Z/6O\ @H'X2T+XDZ/X>N-"\:10:]>0Z99:O-I\ M=O937LT(EBM@DLJ7)9@RKO$)B#G:S@AL :GAES_P3.\9>%OAG\'/[)DT35/$ M/P\\+7GAC4=/C\3ZEX>L[K[5)!*US'=VD9F;:\ !B>/$@D))4H,W=,_X)X?$ M#X>^.O W_"(WGAC0M.T*VT&WO]5L-6U"!I(=/6-9;:739OM$-Z'1&2*:2:.6 M%7'S.8P6ZOX=?\%6=!U+X+^%=?\ $GA3Q-8^(/$=G=ZI)HMBEM-+9:?;SF)[ MQF:=5,>2H"JQF<[MD3;3CZ?\'>+]-^('A+3-=T>[CO\ 2=9M8KVRN8_N7$,B MAT<>Q4@_C0&I^?\ \)/V%?B'^TQ^SUIOAOQ-!H?@70-'3Q;#IUW")VU:]EU, MWUJIN+9XXUBC1+AI#B63SL(?DS7I&J?L/?$CXP?&CP_X\\6Q> =!O="OO#MO M_96D7D]W;3V>F75Q,^:[7&U(=FU G^M;=Q[5^T5^UGHW[-'B<2>() MIUT6T\,ZAX@O(K73FN+EDMI[2(LCB0=/M/\ J_+8OD$,NW:^[\"/VD-,^/%Y MXBL8=%\1^&M9\+74=MJ&EZY;1PW40EB66&4>7)(ACD1@00V1@A@I!% :GS[< M?L._$/P#\5-2\:>&/^$(UF_U&_\ $MO_ &9JUW/;VL5CJTUK,LXD2"0^=&UL M-T6S;('_ -8NWGUCX:?LK7&F?\$^="^#?B.:QFO;3P5!X9O;BT+-;^KZI/8OJUQ;:5#%(^GV"ML: MZE\R2,;-P8!$WROL;8C;3BM%^WQ\/+C29KR*]O)437+/0X52-"UXUU:1WT-S M%\^&MS:2&8OD82*7C*XH#4^:O 7_ 2@\?:9+O^*/#VIWVM^$M4EUD(\P M2Z\6W2W\"7H)3/V=;34)8^%OV"?&6B?%_0[VYE\)W7AW3_$^B M>*9Y#\ ^)=(U&:QD;6?$VLZQ ;4LR1P7EY+/&IRJX8+(-P'&.-"^!/B#PSK3^#/[3F^$$GPRTVXMKJ:9'E4W2QW$A:!3&CK+$S*H-HWABQDU"\%K%YLYB09;8F1N;T&:\U MMOV]M!FT36FD\'_$&V\0:)-:1R>')=-A_M*:.Z$AMYU(F-NL+B*4[Y9D">6P M?8V%(&IXS:?\$V?%-A\W/BG5XI;&:U%LQ@33862 MVN#YELOES/(NP,-T4GE@-]#_ !B^!=]\1OV@?A7XKA?3O[/\"RZI+=QSEO-< MW-F8(S$-I!(8\Y(XZ9Z5P.F_\%./"'BJU\/1^'/"GC[Q+K'B--19-+T^QMGG ML&T^Z2UNQ<.UPL*B.611N61E8(O$NB:KIM[XA\ M*:'J]IX:L]/6>_NKW4KBYAAB@E^T&.193 "@=8]B?/(X!*Q@:GD7Q,_X)>_% M_P 3?!^7P19:UX6?2KWP7)X>79KU[ID6FW1GO)/-DC@M]U]$RSQ*(Y9$2/:Y M$;[B#[+H/["GB&TUVSO;N;PV[1_%B/Q[-AY&+6BZ6+/8"8^9A( 0#\NT9W9X MKTSPI^VAX<\2SSVMQHWBS0M4L]$O=_;A_Y/%_9)_['K5/_4_^R9_V->M?^F&]KZBH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ IES#]IMWCRR[U*Y4\C/I3ZKZM//:Z5&STZ+3-/M66)8L06L>4CW!-SG)+L22>@'BNA?\%=],\3:U:Z=9>#[A[W5 M=$TZYTU'U$*+K5[F\M+6;2B?+)1[YOHI;\7MEX@2RC9<6RIM _=HI8824EBS1AG"M3Z@_:>_8 M \*_M4_%31?%&NW^I6[:5HNI:)-9VY40:A'=V\L >7/):%9YBGH9#2_";]@[ M1?A-8^'H[;7-4O9M$\)7WA>:XN$0R:B]Y<1W-S>R$?\ +9YD9R!QF1JY!_V^ MO%FD_$,_#V_^'^D)\1KG6[+1]/M8?$3R:7.EQI\]^9Y+HVRR)LBM9P5$+$L% M X;(V/AE^WXWC?Q3J6@W_A5=+UG0-*UR[U:)-2$\-O1VSPQOY:[XY!(L MBR$*0" 4!R "U,I_^"9=M8:19VFE>.M7T]-/LO#44!-A!-MNM#V+;W)SUWHF MUX^G.016=H'_ 24\*>&KC5[:SU>&VT2\MM7@LH(?#]DE]:?VBLBOOO-GG3+ M$)I!&"0<$!R^!CI/V,_VG/%_[1?Q?\7S:G8Z=I_A3_A'O#NL:3;1WAFGM&OK M'[2Z-^Y3=RV"=Q^X,#DXY;Q]_P %(KS3OB?>^$8=#TD07U]J^A6>J:;K#W\] MC=V=I[^!/V>[+P'\5F\5PW]S-280VKLJ';-*Q42$; JH<\>J^%?^"A7BKQSXI\) M^'M.^&?DZWK=UJ\=^VIZE<:;96MMIPL7>Z@>:T62=)([Y=N8H\2(R,0 7 %F MJ2749S\T$GE7 M2+YBKC$[X!905].C_P"">MG;^(HK:+Q?J\?@.'Q.OC!/#0M8=JZBI#K_ *1C MS/($X$_EXSO'WMORUXO\5?\ @J?XJUSX6^.+7PSH/A[3_$%OX*N_%.B:K8ZU M)J-FBV]S;6\J-,;,6\DJ"Z1@('GCR"K,HVLWHWA+]M'Q1\ M:WOB"ZMEM]3UX6^EV$%KI6G7-PT9>1JB&)V9G=BRKA5!ZGHGP4_8M MTGX)W_PPGM-8O[P_"_PA<^$+02QHOVV&=[1C+)CHX^QI@#CYV]JZGX]? @?& MR7P??\%2M>U# MPIXBUK1/AG;W5AX'\)_\)3XE%YXA%O+9^5=7EM0_+&Q+;1CG(!:GFOB__ ()@>$O'OP:\+^"-5UG59]*\,:/JNCQNL<8DG6^" MYE.05#QLJLO!!(Y!'%=O^RM^R+9_LS7>O7JW^GZAJ&OBWCE:PT&TT>WBCA5@ M@$4"C([](S=!FBEEFBA@MQ!:SAYW-O-@2F).%^?D[0-=CMOVDOV1+#]I#7H-0N=? MUG0KBV\-:QX:CDTXJDB1ZC]E+S*QY#I]E7'8[FS7E/A'_@E+I/@_5-2UBR\5 M?V;K\[:/<:=-I.@6FGV>CW.FO=F*2.V0;6$BWDZ2"0L6#G#+\NVY#=-\7:?X-EU2?6&BU);B^L[6XCE%F8,!4:\B1U:4,"&(!QBO M/-$_X*AZU\)?V;_ FJ:SIFE>+;\^#]*U[7)FUADU2?[2[))(EI;V\NQ5V[O, MG,$3%MJMPQ4#4]"^)'_!,.V^*6L6>OZSXUGUGQ@+.\T^^U36-"L]3BFM[B42 MJL%O,I2V,!!$10D ,V\29KZ3\#^#[7P%X(TK0;/<;/2+**QA+*JDI&@09"@* M.!V 'H*^;H?V_O%^M^+;C3=*^'.E2QW_ (VN? F@377B-H3J-Y;0S7,\\RK; M-Y$"V\$A!!=VD79LP0]<_>?\%3=8CN;71(_AU'_PF(GUM+ZP_M*ZN;2VCTVZ MCM25FMK*9V::20;-T2* #N93A2!J=5:_\$U;1M#M/#][XXUJ]$>'+'5K/PS MI)LX4_L8ZA;3VK.TH&Z?R8+F9(PV,!SNWD CZ*\%^&8_!?@_2]'BD>:+2K2* MT21QAG$:!03[G%?*>O\ _!3;Q.Z7E[H7PIEN-+TK_A&H[U-7UAM,U&.?7)4@ M@A%NUNV&BED42[W3"\KN/RA-;_X*@ZKH7B9/"$O@*U_X3R+5-5L;NTBU*[NM M.AAL%M6:99X+*29O,^VVX53;J 2^6&T;@-3TOX2?L06GPH^*T7B5/$NH:A#9 M:MK^JV-C+;1J+4ZQ.EQ<1EUY<+*K%21G#8.<"O,YO^"/GA2"TTF&SUU%$&@6 M/AW4IKWP_8ZA/>0VFX1RPO,C?9IBC%&90PP%(4,H:I-5_P""FWB$>']7UVQ^ M%LT>B>%/#.D^)_$"ZMJSZ?J-C%>F4/!';&W;?+"(9"0[1AL#!&:]4_8^^*_B M_P"*6J_%-?%*:Z1I/V6X,A6UB6/:C#RDQC.>!D#4]8U[PO M9>)/"MWHUW")-/OK5[.:+H&B92A7\C7S;KW_ 32'CKX76/A3Q1\1->\1:;X M:@T^W\,Q76GVQ@TO[$^Z*6> J8KN5E C=I% * A0I9B>S^.?[57B#P+\5-5\ M)>#_ ;9^*=1\-^&5\5ZNU[K/]FHEM)+/%#% 1#+YDSFVGX;8B[5R_S<0?LM M?MA:G^U9X_\ $/\ 8WA6UL_ >B16/E:U<:H?MM[+=Z98ZC$JV@APJB*] 9C+ MD,HPIR=H&I!\"/V!](^"7CK2?$D>K)<:EI\.KQ2Q6>D6VFV.VMM834X5 M.."P*+$3W7GK3/&O_!1QO!G[1=GX-/AW2+_2[OQ*?#!O++6GNKRTG^R/<*\\ M45NT$(+1LHCDN5FQAO+[5C>'/^"E/BR[^'^G^)-4^%UI9V6N^"+KQ[ID-KXB M-USZS]HODL(+H26VIW$=S+$$?@-%)$C1R=CG*([B]TZWN=5GEMA$HMY;]P9GMR(R0@VD,Y)9AQ7LGP:_:8L?C/;^ M-]4L;,KX8$WOV*VU59?,75REK'//)&H7[B-)Y>-M(\#6>@VOB;4/#5YH,]OXACN);N&\UNP@-G=(\*^0\UO.+:W_ ,% ->\,:3?66I^$_"VG>+=,\52^&9[*;Q/(UK.5L8[U)+9D MM&NKEV2:-?*CMBP.XG"KD\EIW_!5O6_%/PUU#Q;HGPS@N-%\-^"[7QIKYN]> M:UGMH9)KJ.:"",VQ,LB"TE8;_*#< [#Q0&I[A^TO^Q]I?[3%\\]_JU]II?P] M>^'2((U8>7=3VLS2<_Q*;50!TPQ]JZ[P;\&[7P;\7O&7B^*[GFNO&:V2SP,H M"6_V6(Q+M/4[@*:W^W_K6F^*;>[A\"VD_@*X\=/X#_MAME:DJWD MJ11 QE(KII+6**.62.57412S*=KC=P"P&IK_ +5'[ .B_M+_ !+M/%W]H6FE M:W'HS:!<27>AVFK)+:^:TJ,B7"D131M)*5<>XA!7 V3$8X7',?%?\ X*6:=\'/ MC-_PA>K^'62_A\51:/=.M\-MKI4MO:2+JS93_5>?>P0%.S;SN^4BO-M+_P"" MC'C\^+?&?C:U$6VH_#[3O!'A_Q4UA=:U]FGTZUN[K4E\V%1;MYLTMO%#*T; MLBKL"AB3F@-3KO!G_!(_PWX1$W.B+XA7[ NFV^D6#VGA^QL[F*WAO+>Z#7$ MT:![B4_9HH]Y*C;DE2Q+5UOB3]FJ]^)7_!1#0O'UUHM]I6@>!M$:'[7)=0O! MXDOB'2T9859G46D=UJ()D"9:Z7:&"Y'.^.O^"D-YH/QK3PA8>'-!OX=0UFY\ M.6EW;Z[)<36MY'83W49NEBMG@MU9H&7RVG\X AO*ZJ.%\%?\%2?%GAOX2>#8 M-1\$R>,?%P\!:?XPU\V$EV[72W)F6*.V6WLI%:XD%M*VR3R8PVU0Y&6 /4^D M/V[/A?K?QJ_8[^(WA/PW";C7O$&AW%E81B5(BTKKA<,Y"CGN3BO,O&/_ 37 MD^*$,^I>*/'EYKGB>[O=-N)I[S1[9].N+>QBN$AM)[(826/==32MEAF78PVA M%46/%G_!2O3O!4FI6VH^&+N#5-&U2\%[8-VTMM3;5-I3.TQ;(PA _? M.$W<9KE+7_@J;K__ @M]J,_PJOQJ#0:3/I<*W-Y%:7+WVI6U@+>:YGLHDCG M1KJ-]J"564/AOE)H%J>A_LQ_\$]-%_9G\26>I6GB#4-4>SM];@$H)&UCD?2WA"[U6^\+:?-KEG9:?K$L"->VU MG=-=6\$I'S+'*R1LZ@YPQ12?[HZ5I4!=GS9XP_8#UCQ@Z7\GQ8\41>(;_3=2 MT?6M2-E!*;ZSO95E:&&-P5MA$4"Q[,X!.=S'=61K_P#P2UT;4]/M(H?%%PWV M6^L;TV^HZ7!J%AWTI1+;/\ (YV6ZRJQ^Y(QQD<5]544!<^:O@K_ ,$_ MI_V7O!NN#P1XPO9?$MSX=ET33;W4+2!4MI#J6HZ@DS*B;.)=0=2H3;MC7"]J M^D;-)([2)96$DJH [ 8W-CDXJ2B@1\O?MP_\GB_LD_\ 8]:I_P"HYJM?4-?+ MW[U] M15\N_MJ?\GO_ +)G_8UZU_Z8;VOJ*@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@#Q[1?V"?A/X?\ $^F:S:>$K:+4='\37GB^TE^T2GR= M3NHS'//@M@AEQA"-BE5(4%01%XG_ & _A=XN6%;S0KSRXK?4K5HXM5NX5GAU M"Y^U74<@20>8K3XD ;.Q@-NW KV:B@#S'Q_^Q_X#^).OZCJ^HZ9=QZUJ5Q9W MC:E9ZC<6MW;SVD;Q02PR1NK0LLR>;>)=3)*)+A9I '<2LVYN37ME% ' _#']FCPA\' M?$O]J^';&[T^Y.C66@,@OYW@>TLTV6X:)G*%T3Y?,(WD<%B*Y%?^"?/PP'B6 M+4VTO5Y'M=3O=8M+9]"874D,'F^6GF?:)BP"XS(<8XKVRB@#QBY_ M8!^%\]H\*Z+J%O$VGZ9IR"#5[N+R%TX!;*6,K("D\2@*)UQ)C@L02*U_"'[' M7@'P7<6EQ;Z7=75[:Q:C";N^U"XNY[H:AY NS,\CL93(+: 9?.U8P%P.*]0H MH \)TW_@F]\)]/T^XMGTC6;Z*?P]<>$P+W7[ZX\C2YVB9[6+?*?+0&&+;MP5 MV<$$FM6^_85^'EY &2TURTU);\ZHNK6NNWD.IK<&TBLW<72RB7YX(8D<;L/L M#,"W->PT4!=GE&E?L2?#/1/!.M>';3PXMOH_B'PXOA/4($NYA]HTY?/(B+;\ MAB;FQD)+$@8ZCXN? WP[\;M L+#7;>Z/]DW:7^GW5G>2V=YI]PBLJRP MSQ,LD;;6925(RK,IR&(/7T4 >=?"S]E3P/\ !G6+#4= TF6VU'3[2[LTNI;R M:XFF6[N%NKEI6=B99))E#M(^6SWP35?XS_LB>"/CSXB_M77[+4EU"2P.DW4V MGZKVH618O]FN/(=/.BW,Q"OD#>^,;FSZ;10!YU+^RGX$EL-0M?[%VV^IZ M_:^)KA$N95#:A;1P10RC#?*%2V@&P80[.0(TETV[S7AN8)%GM96W<21D@#F:O=6-Z)KB*.*<+-%(KB M.1(8@T8.PF-3MW &O6J* /+8?V,/AQ;>#=;T"/P_Y>D^(M%M/#U_ MW,!-96 MJNL$6=^5VB1_F!#-NY)XJ;3_ -E_1O#/Q07Q/H5[K&D27>MRZ]JUG%J-RUKJ MEP]H]L=T)D\I1\RN0$P7C1L;AFO3** /-?C5^R7X*^/NM+J.OVFIK?&P?2IY M].U6YT][ZR=MS6LY@=/-A)).Q\@;FQC<<]%\-_@UX;^$4^LOX=TR/3/[?N8; MN\2)V\MI(K6"TCVJ3A L%M"@50!\F<9))ZBB@#QJY_8(^&EYXW_MZ73-5:Y7 M76\30VW]LW8LK;4G#"2ZCM_,\I9'WON(7G>_]YLZ6I_LR:/X1\%Z9%X+TO2[ M;6?"OAJY\+^'O[4EGGL[:RN&MS)#*H?=(I^RP*YO0?^"?WP MO\/"%8M'U*>&R>U;3X;K6+NXBTI+:\AO88K5'D(@B%Q;PN8XP%;RD4@JH4>T MT4 >4>-/V+/ /CCQ;)K\]CJMCKDNI2ZH^H:;K%U8W)FEMH;67#Q2*0CPP0J4 M&%/EJV-W-5?"G[!?PM\$_#O7/"FF>'&M]"\1Z'_PCE_;?;[AO-L-]PXA#%RR M@-=3X*D$;\9PJ@>PT4 ?*NO_ /!/6]\5_M06/BR[O-$MO#NG>+1XO6"SEODE MNIUA*(CVIE-HLFX@O<*F^11M*@EG/K7P>_8\\"_ KQ)%J?AVRU.&6RM9+#3X M+G5;FZM=(MI&5WAM899&2!"57B,#A5'W5 'J%% 7/)_B[^P_\,/CMXLU[7/% M/AB'4]5\3>'U\+ZCQM#,;>%0K#8$\^7E,$[N3P,>BT4 >,V_[ OP MSM_&4&MC2]5,]GK4OB*UMCK-V;&TU"59%EN([?S/*5W$LN["X/F/Q\QS3N/^ M"=7PMFT+3]-73==M[/3],.B;(/$%]$;O3O,>5;*=EE!FMU:1PL ;SXKWOC:;PW93>)-0\/?\ "*7%S(699=,W;C;F,G9@D\G; MDC@G KFO#G[ WPT\-Z'/"=MX7EU%[:2^D.J7;7LWVF\EN DC!01&'8B-,*, M(F%!R0,DYTZ** "BBB@ HHHH ^7OVX?^3Q?V2?\ L>M4_P#4_^R9_V->M?^F&]KZBKY=_ M;4_Y/?\ V3/^QKUK_P!,-[7U%0 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 ?+W[+^R3_V/6J?^HYJM?4-?+W[+^R3_V/6J? M^HYJM?4- ^@4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@#Y=_;4_Y/?_ &3/^QKUK_TPWM?45?+O[:G_ ">_^R9_V->M M?^F&]KZBH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /E[]N M'_D\7]DG_L>M4_\ 4M4_\ 4M?\ IAO:^HJ^7?VU/^3W_P!DS_L:]:_],-[7U%0 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 ?)__!0GQ7IG@C]JC]E' M5-9U&QTG3;7QUJ9FN[R=8((<^'=44;G8A1EB ,GJ0*]N_P"&M?A7_P!%*\!? M^#^T_P#CE;/Q4^!_@WXYZ5;6/C3PKX>\5V5G-]HMX-6T^*\C@DP5WJLBD!L$ MC([$UPW_ [U^ __ $1OX9?^$U:?_&Z!G0?\-:_"O_HI7@+_ ,']I_\ '*/^ M&M?A7_T4KP%_X/[3_P".5S__ [U^ __ $1OX9?^$U:?_&Z/^'>OP'_Z(W\, MO_":M/\ XW0(Z#_AK7X5_P#12O 7_@_M/_CE'_#6OPK_ .BE> O_ ?VG_QR MN?\ ^'>OP'_Z(W\,O_":M/\ XW1_P[U^ _\ T1OX9?\ A-6G_P ;H Z#_AK7 MX5_]%*\!?^#^T_\ CE'_ UK\*_^BE> O_!_:?\ QRN?_P"'>OP'_P"B-_#+ M_P )JT_^-T?\.]?@/_T1OX9?^$U:?_&Z .@_X:U^%?\ T4KP%_X/[3_XY1_P MUK\*_P#HI7@+_P ']I_\ O_ ?V MG_QRN?\ ^'>OP'_Z(W\,O_":M/\ XW1_P[U^ _\ T1OX9?\ A-6G_P ;H Z# M_AK7X5_]%*\!?^#^T_\ CE'_ UK\*_^BE> O_!_:?\ QRN?_P"'>OP'_P"B M-_#+_P )JT_^-T?\.]?@/_T1OX9?^$U:?_&Z .@_X:U^%?\ T4KP%_X/[3_X MY1_PUK\*_P#HI7@+_P ']I_\ O_ M ?VG_QRN?\ ^'>OP'_Z(W\,O_":M/\ XW1_P[U^ _\ T1OX9?\ A-6G_P ; MH Z#_AK7X5_]%*\!?^#^T_\ CE'_ UK\*_^BE> O_!_:?\ QRN?_P"'>OP' M_P"B-_#+_P )JT_^-T?\.]?@/_T1OX9?^$U:?_&Z .@_X:U^%?\ T4KP%_X/ M[3_XY1_PUK\*_P#HI7@+_P ']I_\ O_ ?VG_QRN?\ ^'>OP'_Z(W\,O_":M/\ XW1_P[U^ _\ T1OX9?\ A-6G M_P ;H Z#_AK7X5_]%*\!?^#^T_\ CE'_ UK\*_^BE> O_!_:?\ QRN?_P"' M>OP'_P"B-_#+_P )JT_^-T?\.]?@/_T1OX9?^$U:?_&Z .@_X:U^%?\ T4KP M%_X/[3_XY1_PUK\*_P#HI7@+_P ']I_\7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]M/\ A$/] MFC_A$/\ 9KT+[#'_ ':/L,?]V@#SW_A$/]FC_A$/]FO0OL,?]VC[#'_=H \] M_P"$0_V:/^$0_P!FO0OL,?\ =H^PQ_W: //?^$0_V:/^$0_V:]"^PQ_W:/L, M?]V@#SW_ (1#_9H_X1#_ &:]"^PQ_P!VC[#'_=H \]_X1#_9H_X1#_9KT+[# M'_=H^PQ_W: //?\ A$/]FC_A$/\ 9KT+[#'_ ':/L,?]V@#SW_A$/]FC_A$/ M]FO0OL,?]VC[#'_=H \]_P"$0_V:/^$0_P!FO0OL,?\ =H^PQ_W: //?^$0_ MV:/^$0_V:]"^PQ_W:/L,?]V@#SW_ (1#_9H_X1#_ &:]"^PQ_P!VC[#'_=H M\]_X1#_9H_X1#_9KT+[#'_=H^PQ_W: //?\ A$/]FC_A$/\ 9KT+[#'_ ':/ ML,?]V@#SW_A$/]FC_A$/]FO0OL,?]VC[#'_=H \]_P"$0_V:/^$0_P!FO0OL M,?\ =H^PQ_W: //?^$0_V:/^$0_V:]"^PQ_W:/L,?]V@#SW_ (1#_9H_X1#_ M &:]"^PQ_P!VC[#'_=H \]_X1#_9H_X1#_9KT+[#'_=H^PQ_W: //?\ A$/] MFL#XJZ;>^%_AEXAU+3;1+S4-/TZXN;:W:,R+/(D;,J%1RP) &!RX$;&,!3P?FQQWKHPJ3KP3MNM]M^ MOD_X1#_9KM/"UM-/X9TY[^/;?/:Q-< C!$A0;N.W.:O?88_[M95=)M>9M M0;=*+?9;[GGO_"(?[-'_ B'^S7H7V&/^[1]AC_NU!J>>_\ "(?[-'_"(?[- M>A?88_[M'V&/^[0!Y[_PB'^S1_PB'^S7>7KV>FH&N)88%)P#(X4'\Z;:76GW MZL8)[>8)]XI(&V_7!HLRN25N:VAPO_"(?[-'_"(?[-=OIFH:9K9D^QW5K=^2 MQ23R95?8PZ@X/!IT5UI\]FUPD]NT",RM() 44J2&!/3(((/I@T[,;IS3LT<- M_P (A_LT?\(A_LUW%GJ&FZCI_P!KM[JUGM<;O.CE#1X]=P.*2VU+3+R81Q7= MI+(W14F4D_AFBS#V<]='H<1_PB'^S1_PB'^S7;QZEIDTWEK=VC/G&T3*3^6: M2XU32[68QRW=G&ZG!5IE!'X9HLP]E.]K,XG_ (1#_9H_X1#_ &:[DWFG*(LW M%M_I&3%^]'[S R<<\X )I;2ZT^_<+!/;S,8EG 20-F-L[7X_A.#@]#@TK,/9 MSM>QPO\ PB'^S1_PB'^S7;VNHZ9?7TMK#=6DMS#CS(DF5G3/3(!R*2_U32]+ MNX8+F[L[>>X.V*.694:0^B@G)IV8>RG?EL[G$_\ "(?[-'_"(?[-=^([8SB/ M='YA7<%WN/2HKFXL;)L3301'0#EB%4?4D@#U)I"49-V2.%_X1#_9H M_P"$0_V:[>_U#3-*FBCNKJUMY)VV1K+*J&0^@!/)JQY5N90F4WL-P7=R1ZT6 M8^N+:S@'62>41J/Q)Q3GGL8TA8S0 M!;AQ'$3(,2L02 OJ< ]/2BS'R2:NEH<)_P (A_LT?\(A_LUV_P#:6F>>8_M= MIY@."OG+D'Z9J34)K'2;1I[J:"W@09:260(H'N3Q3LP]G.Z5MSA/^$0_V:/^ M$0_V:[NSELM1LUN+>6">W<;EECD#(1Z@CBH+#6=)U6*9[:]LKA+=BLK13JPB M(ZAL'BBS#V<]='H<7_PB'^S1_P (A_LUVL6KZ3/*$2\LG=C@*LZDD_G2IJ>E MRS>6MW:%\XVB9<_EFBS'[*?9G$_\(A_LT?\ "(?[-=_%';3LX1HW,9PP5L[3 M[U$MQ8/P/;OZ4B>63Z'"_\(A_LT?\ "(?[-=^L=L\[ M1!HS(HRR!OF ]Q5>_P!0TW2IHH[JZM+:2=MD:RRJAD/H 3R:+,%"3=DM3B/^ M$0_V:/\ A$/]FN\O'L].M6GN)(8(5&YI)'"J!ZY/%1)J6F26"72W5H;:3&R4 M3+L;/3!SBBS!0DU=(XC_ (1#_9H_X1#_ &:[BTO]-U"39!D" R_;K'RQ$TY?SUVB-3AGSG[H/!/2G9E>RG>UF<7_PB'^S1_P (A_LU MVT^JZ5;2E)+RSC=>"K3*"/PS1)JFEPJA:[LU$@W*3,HW#ID\LX;J?/EPO,JR2 M8ZX4G)HU&H2EI%'$_P#"(?[-'_"(?[-=O901^&:DM)K M'4#^XF@FXS^[D#[S9[>/8 M0K;Y -I/0&A+BPEMFF6>W:)1EG$@*K]32LQ2[(KJTE<]%296)_#--_M?2OLTS>W\T2PF+(&\.-N3TYI\D-O"RABBESA06QN/M2)Y6M.S*]E/LSB?^$0_V:/\ A$/]FNXM;[3; MZ3;#8!N*;OF ]<4US:112.TD2I#Q(Q<83Z^E K,X+_A$/]FC_ (1# M_9KN-)OM.UZT$]CDD$HD4_B#BEM+W3K^1$@N+:9I%9D5)0Q8*=K$8/ M(!X/H:=F4Z>_\ "(?[ M-'_"(?[->A?88_[M'V&/^[0!Y[_PB'^S1_PB'^S7H7V&/^[1]AC_ +M 'GO_ M B'^S1_PB'^S7H7V&/^[1]AC_NT >>_\(A_LT?\(A_LUZ%]AC_NT?88_P"[ M0!Y[_P (A_LT?\(A_LUZ%]AC_NT?88_[M 'GO_"(?[-'_"(?[->A?88_[M'V M&/\ NT >>_\ "(?[-'_"(?[->A?88_[M'V&/^[0!Y[_PB'^S1_PB'^S7H7V& M/^[1]AC_ +M 'GO_ B'^S1_PB'^S7H7V&/^[1]AC_NT >>_\(A_LT?\(A_L MUZ%]AC_NT?88_P"[0!Y[_P (A_LT?\(A_LUZ%]AC_NT?88_[M 'GO_"(?[-' M_"(?[->A?88_[M'V&/\ NT >>_\ "(?[-'_"(?[->A?88_[M'V&/^[0!Y[_P MB'^S1_PB'^S7H7V&/^[1]AC_ +M 'GO_ B'^S1_PB'^S7H7V&/^[1]AC_NT M >>_\(A_LT?\(A_LUZ%]AC_NT?88_P"[0!Y[_P (A_LT?\(A_LUZ%]AC_NT? M88_[M 'GO_"(?[-'_"(?[->A?88_[M'V&/\ NT >>_\ "(?[-'_"(?[->A?8 M8_[M'V&/^[0!Y[_PB'^S1_PB'^S7H7V&/^[1]AC_ +M 'GO_ B'^S1_PB'^ MS7H7V&/^[1]AC_NT >>_\(A_LT?\(A_LUZ%]AC_NT?88_P"[0!Y[_P (A_LT M?\(A_LUZ%]AC_NT?88_[M 'GO_"(?[-'_"(?[->A?88_[M'V&/\ NT >>_\ M"(?[-'_"(?[->A?88_[M'V&/^[0!Y[_PB'^S1_PB'^S7H7V&/^[1]AC_ +M M'GO_ B'^S1_PB'^S7H7V&/^[1]AC_NT >>_\(A_LT?\(A_LUZ%]AC_NT?88 M_P"[0!Y[_P (A_LT?\(A_LUZ%]AC_NT?88_[M 'GO_"(?[-'_"(?[->A?88_ M[M'V&/\ NT >>_\ "(?[-'_"(?[->A?88_[M'V&/^[0!Y[_PB'^S1_PB'^S7 MH7V&/^[1]AC_ +M 'GO_ B'^S1_PB'^S7H7V&/^[1]AC_NT >>_\(A_LT?\ M(A_LUZ%]AC_NT?88_P"[0!Y[_P (A_LT?\(A_LUZ%]AC_NT?88_[M 'GO_"( M?[-'_"(?[->A?88_[M'V&/\ NT >>_\ "(?[-'_"(?[->A?88_[M'V&/^[0! MY[_PB'^S0?!^1]RO0OL,?]VC[#'_ ': ///^$,']P45Z']AC_NT4 34444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 5S_P 5[+5M2^%_B*WT%S%KDVFW":>Z MN$*W!C81D,>!\V.3Q705SOQ1Z==:AIEQ;0W4DAC6V=XV5 M7+#D $@Y'3%=&$:5>#=MUOJM^JZHX\P3>%JI)M\LMG9[/9]'V?0T_"T-U;^& M-.COFW7J6L2W#$YS($&XY[\YJ_6?X3L9-+\+:;;2S+<2V]K%$\JMN$K*@!8' MOG&:T*RJ_&_4WP]U2BGV6^X4F>:6J[:7;/J:7IMX#>1Q- LYC'FK&Q!*!NNT ME5)'3*CTJ#4L4444 >4?M@Z[X(\-?"Y+OQGX6TKQI(;E;?1-%N[&*\EU&_D! M6*&%)%8!VY&['"[B> :^;/$7[,47[.OPK\-6VH0:9I%Q\7_'.FP>.SHD2V-C M96;;S'I\/EA?+@W".$M]Y_-Z9-:&8*LA5[:6,_,% Y)XR.YS5TS]E3P78^&-9T6YM=;US2=?B6&]M- M=\0ZAK,3JIW+M%W/)Y9!P=R;3D*<\#'IX?&0I4U%-[Z_I;7IOMOZ'Z/D'%>$ MRS TL/&I5NY]444](IGCOQM\$>"_@=\8?A5>_#;3 MM!T#Q1+XLMM U"PT6*.W^VZ?/!*TZ7$,> PC15F5F&5V @X//G/PRTZW^(/C M#X9>#/$:+<>"M7\5^.;^ZL9O^/;5+VVU64V\,HZ.H62:3RSPQ3D';7T)H'[ M/PZ\*_$G3_&.G0>(H?%>FRHT.JSZ_>WMR85!'V9FN)),PE25*^AX(.#3_AY^ MR/ITGP7E\*>-K:TU7;XEU/7[2:RN9H9;)[B_N+F"2*9-DL4R), 60@@[@"1R M=UC*2@K-M]WOM+5:]+Z:GM4^+O2NZTO\ 8Z^'^F^$/$VC2:1=ZC#XRMQ:ZW=:AJEU=W^I1!2H1[J2 M0S;0"0 K@+GC%6O _P"RYX6^'GB2UU73KGQJ]U9AA&E]XRUB_MOF0H=T$]R\ M3\,<;E.#@C! (QEC(>R=.[;[OT2Z27;K<\FOQ;@Y99/ ^UJSG>7O23]Z].$4 MGRUHV2<6ES*K[MO.)^?^B>%TF_8NTV&\^$O@G3K?Q1?WVF1?$F\NHEET:>2^ MG2*ZF\J W"%7PJMO"Y"[G537TA^U1^S=X''Q3^!)O_"OA?5]0UCQ6+36+^?2 M;=YM:"Z7=$F=BN9 616PV1E0>PKZ#L/V?_"&F_!VX\ 1Z+"WA"ZAGMY=.EED ME1TG=WD!9F+\L['.[(SQC J:?X(>&KNT\)0S6$LZ^!IEN-$::\GD>TD6%X Q M"/"EVFF:5IW@ M^5K>RN-0,4$4*/'A!YFV7$F %+%0&;(&U\0?$6J_"_X/_$6Y\-:K>RWVB_"3 M1+>VU%;"2PGAC2\U.(RB%_GC9(P2,\_+FOK7Q7^SUX5\:Z_J.IZC823W>JRZ M;+B:]X;L=$:TD& M]G:&>]>0.A&THRW*#J"OV@O /C#Q)X_T#2/$7 MBO5/$6JV>K2:G$L\^E+!=2116L3-\T*QQ+&5V%3D[NIS7J7@O]B[X>> _$>E MZE8Z3?R-H,AETBUO-8O+RQT=R"-UM;2RM%"0"0"BC:#@8%2^./V.? /C_P 4 M:CJ]WIVI6=WK>!JRZ9K-YIT&L #:/M44$J)-QP2ZDD<'(XK'ZW"SCSR]>OIO M\]]^AX_^M&&]G.C];KN4K/VMESJTF^1+VE^65^9OG^-*T=V_FGPO_:MK^QOH MWQDL+Z6]\1?""\UA;&]N)#N\0^'[>]FC:UE?G>'@B1DD()WQJV?F8GM=:^%E MQX4_9YM/%FNS1WWC3X@>,O#.KZS=(24B#:O9>1:19Y$,,95%]2&8\L:^C];^ M$WAWQ!\+;CP5<:5;CPM=:>=*?3H"T$0M2GEF)=A4J-O VD$=JP_C5\(IO'GP MUTG0=':VM%TO6='OD$[MM$%E?V]PR X)+&.$A<]21DCK3^O*4UT]Z_\ V[>] MOONS=<;4L1BH*WLXNNY-Z:4>=3C3NNBFY3:M:]GT27CG[/OP<\'?'[4/BOK7 MC[1=*\3:Z/%VIZ+(^J0K.^F64#!+>&'=_J5\LK)E-I)?<23@U1^$W]@VW[8' MPL@\-:_=^)- M/AUK%K9ZC=7 GEN$CU"S3YI J[MI4KG&3MY)/)]A^('[('@ M3XD^*K_6K_3]2M=0UB)8-4;3-8O--35XU7:J7*6\J+, IV_."=O'3BG^+OV0 M_ 7C*[T*>72]1TR;PSI[:5ICZ+K=]H[6EH2A,(-I-%E,QIP<_=%'URFV^9NS M5K:66EM-?\M"7Q7E]24W5JUN6<''DY8N-.])P]U.:NDVK?![JU3=K>;?M6?" M^X^(W[0GA^]TJT\"^.=0T#0IY)O!?B>4QQ20RS "]@;9(BRY1HLO&1@]5KBO MAO=:3%X4\&:9I6@:QX1DT;XM_9K_ $&^NHKB+1KAK&>5H+9XOD^S;9%9 .F\ M].@]Z\1_L?>!_%&EZ-#(M0:ZN)9[B^;R)XY)'E6X%53Q=/V:IW>GR[^=NO:_F:X+BG+U@:> LY_&6HW$8ETH/J,Z"YF$ M<#W*QPDCYHVR "O'5U#XZL/!/PVT^\TF&]Q+::S M>-(\-Q>F-B4D<+'$%+YV^;GJ&?@SX9$^#M4\/V.DP+HVM7%W=7UI,S M3QW,ET[27&X2%N'9V)7H,X XKFM7_8^^'^L^"_#FAMH]U!;^#XS#H=U;ZI= MPZAI2$8VPW:R"=5Q@;=^, #& !5SS*$[K5;Z^O75Z/II96?D=F-\0L)BW4BU M.G>4[2C>32DDE)*53W9*SC*,'&,HS>SBN;YL,?AS5/#GQB\"6FF:Y\#;K6;+ M2[F2RU&[M3HT,EQ_#KPUX7\0:2OAR'48/%B+'K4^J7$NH7>JA?N^=/.SROMZKEOE/*XI_PU_9. M\%_"OQ7#KFGVVL7FJV<#VME<:MK5YJC:="V-T<'VF601*0H!V8) )(%3+'T MVI*-]?SLEO?RZWT\S+$\;9?*E7ITG47,G;>_,Z4(]'53]K[MN7EE= MGC?[./[-_P /;/\ ;.^,XB\"^#XAX=O=#ETH)H]N/[-^35#1_@;X5T'X6W?@JWTB+_A%[Z.YBN+"21Y4E6X9WF!9F+?,TCGKQGC M&!1#,^65Y7?P=7]E6?7OMT[BP?B/&C6]K64ZE_JV\I)KV-)PFTXS6KD^:*ES M1EO./0^!-9M+G5?B)#8>!]:DO@3#L$ '+I MM<.O\:LG=11QX1H\$<*V2&4C(Q[9+&* M249/I*[MOHTONV1YM/BJEB(T\-7DU%1K*,0$++! M$?E<_P#'[)UYKUO]FWX1>$OVAY/BAKOQ#T32?$WB,^+=3T:?^U(%F?2[.W<1 MVT$(;_4KY.R3*8+&3<23C'OGB?X)>%O&/PH_X0?4-'@F\*_9HK-;!6>-(XHB MIC"LI#*5**05((*@@US/CS]COP'\1/$-WJE]8:K;WFJ01VVIMIVMWM@NKQ(N MQ%NE@E03X7Y+VNM=$]%T_I(]#%\:99B825)5,/.W(IP MM)JG"7-".]-[-IZZ*%/5ZV\4\,^%_"/Q/^/'PR\&3ZI-XW^&ND^#;O4M$_M: M<7,6KWL-VEONER%6=@.!R3V/C/]F;P3XY$Z'HMUHB6EGX M8V_V,VFSRZ?/I&U=@^SS0,DD7R\$*P!'!S5[X3? WPS\$[&^B\/V,L,NJS?: M;^\NKJ6\O-0EQ@/-/,S22$#@;F.!P,5C5Q:E'W)23[=-[W_I;GD9CQ32K8=_ M5JU:$DK*.BBW[1SYY23^)K5V@GS[/ET/D3X"Z7X:_9Y_X)YZO\1M&TS0O#7B M73;G6T_MFU\/1W5W)&FIW2I;DH ^PA$3);:@52>%KS7P/?/RU?XAV]RUQ/=2N8WNI+9;=78X8JH2.,84!79#,J;G)RO[TKW=M%=6[O MOU/J\'XAX&>*Q$JRFY5Z_.I2Y/=A[2#BFW&4ERQ]I=1E97TWNO*?VMOV>O 6 MK?&OX,7EUX)\)W-WXA\821ZI/+I$#R:DO]E7S[9F*9D&Y$;#9Y53V%$?'NG:/\ #RU>VT2<6EG;V(.H7C9@22)HPS$D8&WKR:^M M_$GPVT?QEJ7A^]U2S^U7GA>\_M#39/-=/LTYADA+X4@-^[ED&&!'S9QD AT7 MPWT6'XD3>+EL\>(;C3H])DN_-?YK9)'E6/9G9P\CG.,\]<5R4\P<8I.[LFNO M?U['S6 XYGAZ-*G4'(]7TVXT^>#7UI:_LK> [+XH'QE%H7EZ^VHMJYE6\N/)^V-;FV:X\C?Y/F&$E2VS)Z M]>:O?$O]GOPA\7]46]\0Z0+ZZ73+O1O-6YF@9[.Z"B>%O+==RML4\Y*D97!Y MKH_M"CS:IV;OTW5K>MK6O>^K9[37.JV>H);>*?#AB'ER0 MPM,A3_1FC;8$DC(P/E))S];>.O@1X2^):^&?[;T:"_;P=?PZGHSL[J]A<0_< M=64@G&!E22K8&0<5RWC+]BGX>>.?$VJ:I=Z9JEN^O2>;J]K8:U>V5EK#8 )N M;>&58I20,$LIW#ALBB&8T[INZ?7SU79IK:^^_D&$\0, I1JRC.G-W=3E6DI. M<7>/+4IRCS=JN MHZ7 ]_JUI+ Y N7V ON0)N4\<=.*Z3]KCX>$(M*' MANWNK=O[3NA>1R?:I([;,$>U,H""6;>V> *^X_&7PRT/X@7NA7&KV7VN;PSJ M"ZIIK>:Z?9KE4>,/A6 ;Y9'&&R.>F0*=\2OAOHWQ>\"ZEX:\0VAO]%U>+R+N MW$TD)E3(.-\;*Z\@&]K'FY97J/7;V MJG:$5-4](I)7C>.T6DDUXO\ L_\ P /#TOB;7O@K#%\/=!^)31^ -5E&EZM-!%%'C4 M8!YJF:-UW#.T< _.>>M?97@K]EWPQ\/?$,&J:;=>-7NK566-+_QEJ^H6_P R ME3N@GN7B;@\;E.#@C! -9W[-_P"S9:_"3P=X3?5X;2Y\6^&M)GT<7UM/*8A! M+.)G15.T'+)&;Z]R\/QGA*"KXJ#'[>X\%Z>[&+PM<6 MNI6JW!E!1$6637M1"&?.:^H?VJKM+CXP_ >WC=6F?Q;-.$4\E$TN\W M-CT&X?F*[_4_V=/!>LZ_XJU*ZT&VGN?&]E'I^NAWSL9]5UJ\U,Z; V T5N+B5Q"I"@ M'8!D \"E4QU*;YG>ZO^,4M[]+;[OU,L=QGEV*E[>2FI1]HXQLFOWE"G2Y7) MSO:#A\34I3CK*TKGQ)\,_$M_^S3^R-XHEU*[N[KP%\5K#Q%##+*VY= UH/>1 MI'G^&"Y2,8ZXF!Z;ZI?&[XRW\/V6QA\7WUJ?#WP\MM.L[>/PK/.(I]56W@$( MF7@DB'*R?[150S9%??%[^S3X'U/X*7?PZN=!@N/!M^LJSZ=+-*ZOYLK3.=Y; M>#YC%@0V5.,$8%1']F#P61C^RFV^;IIR3FNE9K M1YW4E%WN^VVEN^MKIGOTO$S*'BYXVOAY.(M#UW3].\6:-!X)\+JD>JZ.$BF\N7551S;3 ^60! MP",BO-_AO\$/!GA[]@SXT:]8>$O#5EKEFWC6T@U"#3(8[J&%;B^B6-9 NX(( MP$"@X"@#I7U9X;^&M[H_[0'BSQ7)+;-8:[HVEZ=!&K'S4DM9;YY"PQ@ BY3& M">C9 XS:L_@9X6L/ASK?A.+2POA_Q&U\^HVOVB4_:#>/(]S\^[>N]I7/RD8W M?+C KD>.Y6[-V?*_N6I\S/C3V562C4GRREAIM1>EH0M437NJ[;MLD[=-#XCM M/ QOM6^#.@2?"WP7\);S4KK3M1L/&=K=1F>_:W"32VB&"%3YT\88;9G"LI;& M]ABM3]K/XH/XJ^/OB?QQI=CXIU*\^!\EG!X>_LW1KRZLKRX5O/U6.2XBC:*, MM TSQO*\YFFN)&EF=FD9F8L M[L>3WP, 5I_:5.ZFXN^NG35ZZN[U6EMM^YZ*\1,%SQQ9\O+.: M-/ !_P ]=@62,_WXP.C&LK17TG]J3X5>.&\/^(O#_D>)OBPE_I%O MK!D&G>)-EC:S_8I@OS[71&8K@\QX*GD5];_"K]G3P=\$ID?PSI!TUH].BTE" M;N:;;:Q22RQQ#S'; 5YI,=\,!G &5_PQW\-E\#ZSX;3PM:0Z-KVKMK]U;Q3 M2Q[;]MI-Q$RL&@<;5QY17;VQDT+,*2T2>EDGI>R[_IZOR"GQUEE-J%.,U[-4 MXTY\L.;D@TVIQYK-J2YHV=_>DG)>ZX_-Z>/++]G#6?B!+=^%O^%->*X?"ZZI M)'H2QZOX?U6VMYPANHH(DC99=TJQL75,*X)R%)%#_@G5J5Q<_';3;*?Q1J&I M'PUX/MM,:VE\+W-FJW%P6N[F-I7X5E80MN;!DW# KZ7TS]C+P%IV@>(+&2QU M34W\467]FZE>ZIK%WJ%]<6N2?($\\CR+'R?D5@.O\ M3K/X MXRR> Q.&H4YNI5BES/EM=*,5;G]K42Y?:*WM';2W+?W=VBBBO&/R8**** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YK MXRZ):>)OA'XGTZ_OX]*LK_2KFWN+V092TC>)E:0\CA02>HZ=:Z6N:^,MII>H M?"/Q/!KES+9:+-I5S'?W$0R\$!B82.HP,(-I/3DC':M&LJO\27J;X;2E%+LMO0, MTF:SO%?BC3O!6@W&J:M=V]AI]FADGN9Y D<*^K$\ 5S-O^T3X(N;5;A/%6@M M;O-]F$HO4VF7:&V9S][!!Q[BIC3J25XQ;1HZD(NTFDSN**XFX_:*\#VNHR6D MGBS04N802\;7L890%W=,_P!WFF#]I/P(V,>*]#;+F/B[0_,"01P>N0?R-7[" MK_*_N9/MJ?\ ,OO.XSFEKC9_CSX-MH[J1O$VBA;(D3YNT_=$*&(89X(4@_C6 M%!^V1\+KF65$\>>%6>#=YB_;X\IM5F;//958_131'#UI*Z@_N8W6IK>2^\]/ MHKSJ/]K/X<2OA?&?ATG<$XO4^\0"!U]"*=!^U?\ #FYA>1/&?AUECW;R+U/D MVD@YYXP0?RJOJM;^1_>AT5YR?VMOAMY;-_PFWAS:KO&6^W1X#( M"6&<]0 ?R-,;]KCX:&(L?&WAS:H!)-['P#NQW_V6_P"^3Z4?5:_\C^YC^L4O MYE]YZ3G%&,49M+\7^'[U$P&:*]0@9.!SG'7BK,W[1'@BV MM()V\4:*(+H,T,HNE*2!20V#G'!!!]Q4^PJWY7%_O7+#\Q4J?M >"FCL77Q3H1CU+;]E(O8_P#2-V N MSGG.X8QZBCV%7^5_<+VU/^9?>=KFBJC:S;0Q@M,@!S@YZTP:]9@Y-S%_WU66 MIH7J*I?\)#9?\_,7_?5'_"0V7_/S%_WU3LP+M%4O^$ALO^?F+_OJC_A(;+_G MYB_[ZHLP+M%4O^$ALO\ GYB_[ZH_X2&R_P"?F+_OJBS NT52_P"$ALO^?F+_ M +ZH_P"$ALO^?F+_ +ZHLP+M%4O^$ALO^?F+_OJC_A(;+_GYB_[ZHLP+M%4O M^$ALO^?F+_OJC_A(;+_GYB_[ZHLP+M%4O^$ALO\ GYB_[ZH_X2&R_P"?F+_O MJBS NT52_P"$ALO^?F+_ +ZH_P"$ALO^?F+_ +ZHLP+M%4O^$ALO^?F+_OJC M_A(;+_GYB_[ZHLP+M%4O^$ALO^?F+_OJC_A(;+_GYB_[ZHLP+M%4O^$ALO\ MGYB_[ZH_X2&R_P"?F+_OJBS NT52_P"$ALO^?F+_ +ZH_P"$ALO^?F+_ +ZH MLP+M%4O^$ALO^?F+_OJC_A(;+_GYB_[ZHLP+M%4O^$ALO^?F+_OJC_A(;+_G MYB_[ZHLP+M%4O^$ALO\ GYB_[ZH_X2&R_P"?F+_OJBS NT52_P"$ALO^?F+_ M +ZH_P"$ALO^?F+_ +ZHLP+M%4O^$ALO^?F+_OJC_A(;+_GYB_[ZHLP+M%4O M^$ALO^?F+_OJC_A(;+_GYB_[ZHLP+M%4O^$ALO\ GYB_[ZH_X2&R_P"?F+_O MJBS NT52_P"$ALO^?F+_ +ZH_P"$ALO^?F+_ +ZHLP+M%4O^$ALO^?F+_OJC M_A(;+_GYB_[ZHLP+M%4O^$ALO^?F+_OJC_A(;+_GYB_[ZHLP+M%4O^$ALO\ MGYB_[ZH_X2&R_P"?F+_OJBS NT52_P"$ALO^?F+_ +ZH_P"$ALO^?F+_ +ZH MLP+M%4O^$ALO^?F+_OJC_A(;+_GYB_[ZHLP+M%4O^$ALO^?F+_OJC_A(;+_G MYB_[ZHLP+M%4O^$ALO\ GYB_[ZH_X2&R_P"?F+_OJBS NT52_P"$ALO^?F+_ M +ZH_P"$ALO^?F+_ +ZHLP+M%4O^$ALO^?F+_OJC_A(;+_GYB_[ZHLP+M%4O M^$ALO^?F+_OJC_A(;+_GYB_[ZHLP+M%4O^$ALO\ GYB_[ZH_X2&R_P"?F+_O MJBS NT52_P"$ALO^?F+_ +ZH_P"$ALO^?F+_ +ZHLP+M%4O^$ALO^?F+_OJC M_A(;+_GYB_[ZHLP+M%4O^$ALO^?F+_OJC_A(;+_GYB_[ZHLP+M%4O^$ALO\ MGYB_[ZH_X2&R_P"?F+_OJBS NT52_P"$ALO^?F+_ +ZH_P"$ALO^?F+_ +ZH MLP+M%4O^$ALO^?F+_OJC_A(;+_GYB_[ZHLP+M%4O^$ALO^?F+_OJC_A(;+_G MYB_[ZHLP+M%4O^$ALO\ GYB_[ZH_X2&R_P"?F+_OJBS NT52_P"$ALO^?F+_ M +ZH_P"$ALO^?F+_ +ZHLP+M%4O^$ALO^?F+_OJC_A(;+_GYB_[ZHLP+M%4O M^$ALO^?F+_OJC_A(;+_GYB_[ZHLP+M%4O^$ALO\ GYB_[ZH_X2&R_P"?F+_O MJBS NT52_P"$ALO^?F+_ +ZH_P"$ALO^?F+_ +ZHLP+M%4O^$ALO^?F+_OJC M_A(;+_GYB_[ZHLP+M%4O^$ALO^?F+_OJC_A(;+_GYB_[ZHLP+M%4O^$ALO\ MGYB_[ZH_X2&R_P"?F+_OJBS NT52_P"$ALO^?F+_ +ZH_P"$ALO^?F+_ +ZH MLP+M%4O^$ALO^?F+_OJC_A(;+_GYB_[ZHLP+M%4O^$ALO^?F+_OJC_A(;+_G MYB_[ZHLP+M%4O^$ALO\ GYB_[ZH_X2&R_P"?F+_OJBS NT52_P"$ALO^?F+_ M +ZH_P"$ALO^?F+_ +ZHLP+M%4O^$ALO^?F+_OJC_A(;+_GYB_[ZHLP+M%46 MU^R8?\?,7_?59_B+XC:'X0TJ2^U/5;*PLH=F^>XE5$3>P1YI6=[) M!I:[-ZC-<5>?M$>!]/N+:*?Q9H$4EXN^!6O8P91E1E>>>77_ +Z'K5>7]I;P M"I/_ !5V@G85#;;Q#CA[KS6OL*O\K^XCVM/^9?>=YFESBN0A^.'A"9E5 M/$FC%VB694-V@8HS;5;&G9HKS:3]KSX9V[JC>-_#2EMVW-]'SMW$]^VQ_^ M^3Z583]J;X=S73P#QGX>\Z(@/']M3'PRKO*F^CX&&)[^B/_WR?2GI M^T;X$DTM[W_A+O#_ -CCD,3S&^CV*X.-N<]$-,O+>&Y\2Z-!->+"\$0^#M]<5UBGYUQTK-QE'XE8M2 MB]F24444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7,_&>YTJS^$/BB M778)[K1(]*N6OX8#B66 1-YBJQZCX1TN MXA@6UAGLXI(X%/$*E 0H^@X_"M*LJO\ $E?N;X:SHQ:[+;T/!?\ @I[*T'[! M'Q2=0[$:%, $;:3T[Y%?C/X"L[";_@G!"KJ]S*/'TV1<1*1DZ:H8+O5P2 2P MX4_)UZ5^S/\ P4YOVTK]@[XG7"-*CQ:)*5:(L'!R,8*D&OR!\.^.]4U[_@F[ M'>:U=QWDQ^(9N_DFB1B5LHW$>T'/SKO4X )+Y.1DG](X-O\ 4'I_R]C^1\'Q M7_OJ?_3N7YG!Z3:)XI:/3G06D5T#'+YEU#"I:0O$[*F_''FS@8CY\M.>U>D^ M)=&\+?!"[OM4\=>6^LRV<&KZ?H#0EFN/,FN54R7#*8HA_I"-MSR$/ XKC? ' MB?3_ (!^,C=Z_/!J.IZ/92W\&C7-W(GVF59)/+\Z3*[,+Y_DO^!WT/E<)S\MJ<>:?;MZ_P#![&M\./V:?'WQD\0?VAJ+:SX? MT_0Y+^\M]5\3W DL[ZYD16@,!X+2290@IE'$?7 Q7+>(?%EK\.?#]W;_ ! L MV\1S7!-KH,MC";"Y<.0LZS1RH-J-B2/+'>02%&QMRW_VA/B7H'BK4[RS\+2W M-_9V^EV$VHW=R\WDWST?2HM"7X MC^$M+LGM[[2[.T6_DO"MS/*$MKE4,T+; LBJ6)4-PI!VU%.-9P]K624?Y?A: M7KW?9V-*DJ*G[.BVY=_B7W=EW1+>1:'KDE]!I'B87^J0RPVEW9ZO%]@G$\I< MF-0YV%P\DP;:2 9$(^5"QJ>))KSX>ZNME=:7)J.I_:83#/!GP;^(FCZ-+:V/B;1M?(U+4-5TO6-8A2/[1$52 M.*.22+#R*7VJ'\LX;)+%>.]\,?LX^'/!-KJD=[:R><]FAU===O7TNYLUCB8" M\MXXMXGN&"7OS EB7R%P21$\;2I.TE+T:U[;I[&E+!U:JO#E]4_GUZGF5KX- M&G:?#>ZC>Z)9Z'J$,C6TUWJ$3M*B)YDD21PL[;@&9"H+.QFD.23BJ-A\2? V MF^(;%7EU?Q*NNVS7%IJDL1L(EO@P;]Z@#2E4D5'!4?*SR 95VQVVJ?LU> ?A MOI']IZ]-K>G:3#+9ZS92RR0:?TZYUW2+Z M&[M-*LK9K>XDEC>3#FI'K6C6.AIX?^)UOXC\.:C=6 M=[J=A<:XIO[BQ1[R=?($ 3S1&ZX;=C&YF8 CFO.-)^(MW9^*]2\3?;&U1TAG MFO((+F0W%=6MENDM7TAH]LD\LE_,/W\()V[P HW>F"564X32Q,DH/9I6Y7VOM]^_ M<*4HSBWAXMR6Z;O=7WMO]QA?%KX9ZC\-_&]V[FW@@N+=+FQN(KL(L]N[S;9$ MW.C8VO"<;AMV].U4?V=H+.]_:5\#-!8[E_MVR-F)8X3LS,K"+.Q\;=R]6Z02 M75S-MBO-5@N;:5KA&@F29XH@Z^8S;L?OS\ISO?U)K1<[PL MU4[/7OI?^NQEHL3!P[IV[:V/W"G0QZ);\[B)[@ [<8'GO@?E^=5SN*]3^=0^ M*_%6G>$_"\-S?W<=K +B==TF%RWGL, =SG@ M,'!:24*/U-([TAN'@L(Q:P_0'YI/_'_RJUI_PG\.Z/$,Z;;W M#*H!ENR;B5OJ\A9C^)J^2FMW?T0N:;V5A;SXP^';+G^(+@>ATRXA/Y2*M6-0^(GACPSJ L&U#3HKP)N6RA(>8K MZB-)94!MO"N/5;O4(HF'_? M'F#]:1==\62;2= TV,$\C^TR2/Q$=-0CV7WAS-[-_<3'XBS(1OT'7D)[" /^ MH:H[CXN6>G0[KO3_ !#;_33)YC^4:M4UUJWB9' BT73I1CDF^*_IY9JK+XC\ M61RX_P"$9LW0'K_:@R1]#'_6CDCV7WH?-+O^#)+3XU^'98MTVH&QSP!?PR69 MS])0IK6L/'6C:LX2VU6QFD89"I<*Q/Y&LE_&&J1';/X3U1N/F:&:WD7\/WH8 M_P#?-9$_B+PMJTLHU'PQ?PMT=KK0Y#N_X%L.?SH]C%[)_)ID^UEW7W-'?QRA MNCY_&G-ST;]:\RT^R\ ZQK2VNE:RNG:DBY6UL]2>V>,>I@W8_-*W1X0UFT7. ME^*I7./E2_MH[F/\=GEL?^^A42HI=;>J+563TM]S.PW_ %_.E!W>OYUQ[ZQX MNTDCSM)TS5$[M:79BGI\7K+3W==6L=6T4H 7:ZM3Y2?61-T M>/?=BI]C+IJ7[5+XM#K<>Y_.C'N?SJAH7BG3?$^G1W>G7UI>VLOW)8)5D1OH M0<5>,H%9V:W-$T]A<>Y_.C'N?SHW_6@MBD/0,>Y_.C'N?SHZFE(Q2T 3'N?S MHQ[G\Z"<"DWTP%Q[G\Z,>Y_.E'-%(!,>Y_.C'N?SH)Q1NI@&/<_G1CW/YT;A M1FD 8]S^=&/<_G1FC=3 ,>Y_.C'N?SI:3=0 8]S^=&/<_G1FEI )CW/YT8]S M^=+13 3'N?SHQ[G\Z6B@!,>Y_.C'N?SI:* $Q[G\Z,>Y_.EHH 3'N?SHQ[G\ MZ6B@!,>Y_.C'N?SI:* $Q[G\Z,>Y_.EHH 3'N?SHQ[G\Z6B@!,>Y_.C'N?SI M:* $Q[G\Z,>Y_.EHH 3'N?SHQ[G\Z6B@!,>Y_.C'N?SI:* $Q[G\Z,>Y_.EH MH 3'N?SHQ[G\Z6B@!,>Y_.C'N?SI:* $Q[G\Z,>Y_.EHH 3'N?SHQ[G\Z6B@ M!,>Y_.C'N?SI:* $Q[G\Z,>Y_.EHH 3'N?SHQ[G\Z6C- "8]S^=&/<_G1NH# M9H ,>Y_.C'N?SI>E%(!,>Y_.C'N?SHW>QHW>QI@&/<_G1CW/YT9S1G% !CW/ MYT8]S^=&ZC=0 8]S^=&/<_G1G-!.V@ Q[G\Z,>Y_.E!S10 F/<_G1CW/YTM) MGF@ Q[G\Z,>Y_.FM.J DG&/6L+7/BAH/A[4Q97.I6XOV7HC7+$? MA5*$G\*)0?\ ;_>8 M]PA%*]KXPU=1OO=%T>,_>"0O=28]F)101ZE6'M5^Q:^*R,_;)_"=:7P>_P"= M0WFH0V,)DEN(XE7DEWP!^-<=J7@B"&Q>36_%FJR0("9/X^'$L*R6?V77\#:)XEDU-C[&3Y\_B:M48O:[]$9NM*]G9?,Z^Y^*7AZR4&7 M7-+7/ 'VQ,M].:SY/C;H@N1%'_;%R6^ZT&E74L9_X&L97]:K:3XUM(=T>C>$ M];^0XPNG"T4_0R%%/YU=D\5^()XMUOX6F0_W;N^AC_\ 0#(*OV45NOQ2%[1O M9_E7&=WV1ES^#8-*?B'<$_+X?UQAC.=BK^A:H$U_Q7(G/ MAW3T8'HVI;AC$JGFU?Q(MH&72--,N?F4WS +^.SG\J7LX]E]Y7/+N_N$/Q! MNA_S+VN8S@_*G_Q=*WQ',1^?1=? '4BU)Q^1JN_B;Q;&^!X:TV3U9=4P/R,= M2MXWUBT ^T^%M3QCEK>>WE4?G(K'\%HY%_*OO#F??\"(?&W1DNO)F36K9N[3 M:5=)&OUD*;!^=:%A\3] U1P(-8TZ4D[0%ND))].M9\7Q?T<0LUY#JFEI&/G: M^L)844>I8K@#W)Q5VRG\-_$?3X[JW;2-8@;(CF0QS+^##-)PBM7%H%.3VDF; MR3+(/EDW?1J("A[#!0?6L^2#^&7WZ%*K M:ZU!=:#=NRQJ+M0()6/ "3 E&SV&=WL#7E__ 4UO7M_V(_';1I!LNK"TMI9 M7D1-D7TY1QE'F7VH_FCFS&<7A*EG]E_D?D;X;E MC8Q6UK;FTOI 8(9&FAMX4C!4@$[XQG/V?JC?ZE\#BO6-!^$GAGP5X9T_6/&] M^=+T"ZFG.E!8&O)-2\O=PNT%(U,0 \SY1DKR:\T$VT6D^*?#Q\1:G&( ,CS$.5"9#GW*Y^28;W8MI*_VI=:MUT;3?$&E^#M86TNC=WEW'-H>E6<-Q<*T3<*@C165CM. M]6W$C)%0>,8Y_@KXNU63QU=6'B;PSI3,%:TM&BNTG$C/#]G\Q<3Q_==BQ\MB MJ[VW ;M7XJMH_P &++3?AUIVIWFO>,=,M]0\,:G=Q%[&&S6^60H4M5&RZXD8 M%P>H7@G;GS+X9>*_%:A8)IZ:G;[&2.-XC;NI:%RY=3M M*!BW48!KGHPJ5(N:LJ?1/1M=[ZM:(VKRITY*&KJ=6M5LM+;;WN;NC:QX1U>S MM!:ZU_9>H7=HVH?V5K*%(;:)1B-C=#]W(7A 4EB-WG39^8JM4O%<%W\.?#D5 MSJMI!?S75O#*H%];-'%9ED*3RA6+D.S@J&0[7?:GI^BII5]J02T6U # 2-)"SQ!C$DF"K9=4^@I3QM*E\2EWL MTOP:>WF:T\'5J_ UVNG^:?7R/,[#PI>>(-$DUJ5;'3-.-RMKJ2W^KVR7%GHM8W\&FVAMH+/A^5 M:3!D1U>X0 #F-ESAE4MZ/J'[,W@VY^WS2MJLFBZJ+J"YO;J[2RT^6]55E;%U M*&>M>--%DU:\0>)-)*I+:^1LN;;R9Y;B4QVL0585"QC+%5)#]1SCU;PSX=M MOVHOA-$O@N75_P#A-/"IO?$5[HR3G4)YVN_*2(PWO)(IUXSI: MUFO9O1M+X?._F^K049TZMU13]HM4F_B\K?HF9?C+X-QQ>$[?Q+I=U%=>&[HW M%QIEXKFR\]6F>-HVCEVE'5;AR5^7E>O%>)?MLNZ 22/=PI M&=C+YJM'\JC(8]ZX=;2>YT6'5H+]K[1C/''#?>;R,'-=6% M$?A/XEU6&TAOY=-TNYNDM9DW1W!2)F",.X.,$>]='6!\5=4U71/AEXAO-"A: MYUJTTVXFL(5B,IEG6-C&H0O!-7U6^BWZOIZG'F#:PM5IM>[+ M5*[V>RZOLNI>\):@VJ^%-,NGB2![FTBE:)!A8RR E0/09Q6C5#PO&Z_8+^)Z3AFB;0Y0P4 GJI'4@=?>OQ^T>7 M3K#_ ()SQ6^GZU?WUDWCV6(&9)H$D7^STRI2.3!7'7>ZIZYXS^E<%J^";_Z> MQ]-CX'BS_?$O^G;_ #.9O_"=KK/Q7T*^\2ZAA_\27P%Y>D:EH%IIEQ=7 N#?+80E \3 M3(RQI)%+&I;]SW!Y%<_\#/%,NI7ESX0M;&ROXKR&2?1[*],4-G!J@3?#,I4B M-7+*JEB[LP^5OE#$4?A&D7Q@\'^)?"FI3)K_ (HT6U?Q'9/812SRZK+;QLLM ML\GW?]4S;F49D$:_,V%K[>K2<:G/55U"VG2S>_RZGRU&I>')1=G.[^:6U_,W M?@?\);+QD-<\1>++>[N/#OA9_)E!O$==1O7B,?EM(1'-&CILFV-MHDFDPI;Z99:8?*B-RD^^/.1O8\(&?<^ 6W+NZ2^&8-:\> M?LQ^%[SP9'=6^FZ3&8]>T5( GV*\AV1F=X_EDF20R^82B.5WMN.5 J'X+^%- M0UKQ:^G&W-K./(&JB4>4MNF-J[T;9MH?IP8BNJDJM2I;W;Z= MK:;>9Z%"C[-4H4[KF5V^]]=_(]*N/V)-4_;#^&DWC8W^FZ#\0X;>W\/7EE.Z MK%?*)$DENVV(&2>8^:,8P3N'?CS[PO\ L"?$KXBMK:2:'J^GMI<\BWUO/=(C MSPS.UTL$0,GROM*CV%RP)R#6AJW[<7B7QIIVL^&/@Q_9_A>RT#1TDU'Q#?/O!O[+O[1_P ;;?6]7U7Q7XF@O+"%I+,W'B,S MM?W 4L(%*3$195"=S84$ ?3DPRQE"$I8BM"E'3E4M7%/I_5['7B%@Z\XK#T9 MU):\SCM)]_ZM<]0^"/\ P39\1?M"F6?Q==?\(IX:NH;BS:2ZYV,VCZ/X> T[2[>VG39*XE/F7#.5"-+/ MY:,20Q^5AM^937%?"WXO_M&_ "SU2;5M>?5=/TFP:>?0]=NAJWV^'E)%C93( M8SM!YW =!@YQ7H'B/XOZ)^TQ\/CXM\'V/]EQ6T)MM1TM67S-/D$:JPM*-2GLG'9-]_-K2^P1GA70Y**E3J[OFWE;_+MH[EFO!%8>88WC$<)B59)+A)""&."0.,9KUKX-? M#GQIKGC?3_[&@NK!(HA,+Y$^R1V-JR(F'FD=58)O2-0'+XMP=H)K U2R\/W_ M ,=/B3\1OL][)X<\ >1G0KQBYT M)>]&RLM=&]$OFWIVU/,K4I24*RTE=W?=;M_+KW'_ !__ +!\71>&I/[*UG0/ M$UU)8^&KJQL+F 6MR\< :)(4=2^(I)%CD)=@,+@D],WX8S:IX?\ VCOAUX>N M+JV^VZ=K4<%U=0QDVEQ=C4)&GMI0V5$@R"K X#< X((Q?A+XZU#0?A]XA\8% MM&OO+F@L_#\EG,_G:#64]>CV4Z="I3Z13\];?ISP07%S;S7*Q2O&"T(,S9"GMZ9%5-9U2U\-V M#W5Y<0VMO$,EY&"@"J_C/QK#X.T&RMK:!M0U.[N[H6ME#@/.WGN2?0*,Y9CP M/K@5EZ!\.IM4U"/5/$LJ:GJ*-YD$&#]DL3V\M#U8 D;R-QR<8!Q7X;&-ES2> MFI^QW>T5J5&\9:WXR*#P]IPMK1S_ ,A+40R(5Q]Z.(?._P#P(H.X)[RQ_" : MLQ?7=4U+6&/_ "Q,OD6R_2./&?\ @9:NS9X[6(EB%4#))XXKBW^(5_XTNI[3 MPK;QRQ1L4DU6Y5A:(PX(C YF(_V2%X(+9&*TC.3_ (:LOZZD.,;WF[O^NAM6 MOA_2/!ED?)MK&P@0;B518P/7)K(G^+FF3,PTF"_UV5#M*Z? 9%!]W)$8_%J? MI_PCLYY8KK7IY_$EZC;\WH#01MV*0C]VF.QP2/6NEU/5;/P[IQGNY[>SMT'S M/*X15_$\5+E&^MY,I*5M+11RUYXB\77R*=.\/6<&2"1J&H>60/I&DG/MQ]:^ M$?AE!^T+_P %$]?^*WC#PY\;IOAA8>!_%%_X5\/:'IVD036DLMFJ@S73RAG9 M9&89&/E&2!VK[Q7XFWGB%T'A_1+V^A]DO_ !3X>L-&BOXY9IAMN)+6:5@]NTJY M#%1U.>P 52]E=)?F.DU?=LY/XB>./CK\8?VRO G[.LGQ2C\&7]MX$_X2WQ=K M_AW3XC+J$@F^SB&V,RG8I8;BVT'YCQQSYA\<_P!ISXX_LK:-^TO\,[SXH7GB M34/AKX7T_P 4>&?$TUA;IJ*P7$T,;0S!5"%U+G#%22,D]0!]*?%C_@D5%=_\ M(-K7PW^*7BWX?>/OA]HJ^'M/U]UCU#[9IPY-O(/BA\6[:&UU?Q?J"+'Y44+H8XH[-957RU" ;2YZ \8 M K/WF]'K_P #^OS--$M=O^"?''Q]_P""G/Q]\._L8^&-"L?'PM?B/X;US6K? MQ/J<%C%]JDM].,2JS9!0)+]MM\$1KRO7KGUB7_@H-\7_ (2?\%+X8_$_B1+G MX5V]GHFDZEIS&..WM[K4=(>YAGWF/<"9+>0G+8!;'2N_^)7_ 1G^&'BSQO\ M5M8A^*\&E7GQ*T"UT:-'C67^RI(Y+:2>?FX!F\XVJ_*=NW<>6P*TOCE_P2(\ M#?M"Z3\1[9_C)Y,GCJ#P^EO(T,=T=+ETJ%H?,.9P9?,5W &4V!L9:J]E4O>W MX=O\Q>UAW_'O8^7/@1_P5/\ BY9_!']I+QGXP$GBJ:QLM)U'PM9WUE;FRT%= M4F;[.6 5691'-"0#NSL .,DUZM\:M)^(7_!/KPSX!^(]W\;/$'C.XOM=T_3O M%_AN_L$TVVFANCL>2S$21O'Y;'*@Y#<$C *GWC0/^"1OA>33?BKHP\>V6N>& MOB;X>T;P]+IGV%$ETV/3+5(()$ECDY<&-''[L8*C.[G.-IO_ 2Z^*NM:[X+ MM?BS\7-5^,7P\^'E[!J6C^&[>TMM/GN+B#_4-=S-@W(0<8=\MSSROQS^('Q*_8/^'GBKQ+IK^*-7UK M08KF2_AN(S+=NP/S2QE8U4YZA21BO)/%?_!*WX>^+/A5\9O"GB_4M4L)OBMX MIN?%>GZ@^C26\?A>X=5$0#)(8I1&0>69-P=@ NI:1XC\-QVGA35;)IV46]G M.[32?B;::QJ1>> MRL+@Z:+51+'#&3#N9<-MW.2< 'FK]W_P2D\^S]I*!^3^ZY!P.V/:OB%^S7X!\9_M5_#;XH:%\0[+PF M_P /;+4+*/1((D+SM=1AWF@=:FG?1?@SP_ M2?'/QH_:L_:M\=_#A_B5XN\!^%O@C8Z=H]Y?>&;.VO+_ %S49(-[7EPSPY"M MM.4CC"_3K7!K_P %0?BO!\&[CX31^++*\^*0^+5O\,X?&W]FQH#8S%F6_-N? MW?G[49=N,#(/49KUWXX?L@_$ZX_:%UOXJ_ _QIX@\)>(O%EM%8^)6M/#\,MO MK*PIMBG-M?LD:RH !N1N0.!\S9HZ#_P2Z\.>-_V/9O$?_ F, MOC'4W9?$7]MDJ3=1@HJ[<@#8C.N#]_=AJW4":[9PIK.FZI'&[K+"\4:HT.!]U\X. !QS M\C_L0_\ !2KXA?M^>)/@S\*+?X@W_@J:TTQ]6\6>*+BVB2_\77$+$O86.Z,Q M?*K*7;:&^5B!A?G^E?#'_!+#XDQ:_K7BCQE\>M9\?^*-0\-W'A6V,VG+IUE: MV4P.?W<;MNDW9)<\\D5PFO?\$S_!ND_LN?"WX=:MXVN_ _C[X5WBW.B>+9K5 M9[8N)&>56@\XQ"&8'!1I%+$+G/*G*-"4M8Z^74T==1TEH^_0_0.^\8Z3H:*E MSJ5G"V, 2SJ&;\SDUEI\:?#\T[1V]W]LE3JEM$\S_@JJ2:PO OBWP5X>TBUM M="L;6]D:)6:;1-$=;2X?'S,K(IC )R0-Y//4]:Z&Z^(&J"1!9>$=:ND)P7\R MW@"?422*?R!KH]FEHXOYZ&*J]4U\M1LWQ.+P[K/0/$5[_LK8M"?_ "+LHM?' M>J7J?+X2UN(^D[P)_*0U874?%UR?W>EZ);HPX,M^[NOU418_)J9':^,Y)#ON M/#L0[;(Y6(_-A4^ZNWWE7;ZO[A5\3:^S ?\ ",RH#GDWL7R_7O3H-<\1228? M0K>-?[QOP?\ V6HY-!\6.26\1Z5$?X5_LHMC\?-IPT'Q"V"WBFV!Q@^7IRJ" M?H7)IIP\OQ'[WG^!+8]&MY6SRHO,8'_?-5_\ A)M?C4;O#99N^R]0 M@?GBI%T#Q!O'_%41L,]#IZ<_^/4'P_XK+EE\2Z=MSP#I/;Z^;0^1=OQ$G)]_ MP(I/&6KVT>Z3PMJ38_A@FAD)_P#'A3+7XDR%2UWX=\26*C^_9^E[KVM]_\ MF%Y+O]Q WQD\/03I%<7SV'XCW<<6[4O"^N60YR-D5SQZ_NG?\ Q]JS;G5?A[X\GCDU"VTI;V+/DG4; M/[)=1>Z>:JN/J/SINFNS^6H>T?='=1INY'/]*?Y9]*Y7_A6=M&%DTC7-;L>/ MD,=ZUPF/]V7>I_*G&V\9:-]RXT?6H><"1&M)2.W(W+G\!^%9\B;TE]^A:J-; MK[M3J/+/I1Y9]*Y6+XO0Z8T::]IVHZ \AQNN8]\ ^LR%HU'^\PZ@=>*ZC3=7 MM=8MQ-:W$-Q$W1XY RGZ$<5$HRCNBXU(RV'>6?2CRSZ5. "]/V"HN65?+/I1 MY9]*M;!1L%%P*OEGTH\L^E6M@HV"BX%7RSZ4>6?2K6P4;!1<"KY9]*/+/I5K M8*-@HN!5\L^E'EGTJUL%&P47 J^6?2CRSZ5:V"C8*+@5?+/I1Y9]*M;!1L%% MP*OEGTH\L^E6M@HV"BX%7RSZ4>6?2K6P4;!1<"KY9]*/+/I5K8*-@HN!5\L^ ME'EGTJUL%&P47 J^6?2CRSZ5:V"C8*+@5?+/I1Y9]*M;!1L%%P*OEGTH\L^E M6M@HV"BX%7RSZ4>6?2K6P4;!1<"KY9]*/+/I4[<4TRICD\47T B\L^E'EGTK M*\2?$+1?"7RWM]$DY^Y;H3)/(?18UR['V -9,?C77M?FV:7H$L,)7H1E<;=7OFGC?ZI*Q M0GWQ348WWOZ$NJ#9P: MG?*?NO;:?-(C?\""[?UJKI'Q#\-6.+/0M-GN4A0",:=IC_9]O^Q(%$1'L&JV MOC37[V8I:^%+R)>J37EU#%&WX(SN/^^*T]FET^]V(]K?9_VZ[B4_EFG23>-;I?W521I5LQ R!]KQG_P =J*/0/%#*XE\2V7.-ICTL*5_.0YH/A_Q .OBF M,-_UX1__ !54N3R_$&Y+O^ S_A(_$2J2_AP-Z*E\A)_,"@^*M;C^_P"%[O;Z MI=Q,?RS2R:'XG8H(O$UC@#YM^EAR?RD _2E72?%MO%QK>DW#?[>GM&/TD-+W M+]/Q#WO/\"I)\2;Z&;:_A+Q)M'5U2%E'_D7/Z5^>WP5^(WQG_P""AG@SQS\4 MO#WQI\2_#1K77[W3O"&@VWAZ.?1K>"V*JOVZ0Q.SM(<[L-\G) (PH_12"3QC M$?G3P[./[JO-%^N&_E7P_P#$#_@EA\2M)O\ QGHG@3XD:]X-^%?Q&U&74O$' MA/18+.[W25?E*@$#_:'%1**;6FGDRXS:6_X%7XJ?M(_$']I M7]M/PQ\"M+^*,7PVL-!\$)XC\7>(-!@B,VK7K.L1@MFN5/E1AOF!QNPQ!Z"O M*OC?^VO\8/V>_A9^TU\+9/B3/XE\2?#2#0=5\+>-/LMNEZ;2^N[1'AF5%\IG M42D;MN3ECZ8^COC_ /L''Q%XI\%>-OA_XB\9?"3Q_P"!- C\,Q:P=)CUV+4= M-3&(+N$EA,P(R'R3DDX)"D>,+W2?B3X3EOD^(\\4$+3'[+J5OIL>\%"J^9)/N^4#I M7N?CK_@H+X]^ ?\ P6)\66'B;Q1<#X(:6EGI%Q92QQ"#3+NYT47L4F[;ORSP M3]6Q\Q]JL^)O^")NG?&GQQ\9-<\-^*;W1K/XM7-AB7[7%WI*HFGRZ= M;-;AB$E1'WH[C[J[0W\7),.A):-Z]OO_ *^9:KIZI:?\-_7R/E?X!?\ !7GX MT^'OV;?CGKFO>(I=;\87VH:!;^#H[JTB-OH:ZL)) YVH 0D3I@2$Y9%!SR*^ M@/BGJ_[0W_!/[Q9\*O%.J_%;6?&_A[QUXIL?">N:;XAM;3*O#7Q3MM#MK4:$J6*>'6TJU2" M":*>+],^&]RFI:%I,N@ MIHUO'=IQ%<3W>T"XD4=,_-GG/+ ZK#5(Z6_&]OD8O$4Y==/3]3YR\-_\%&?B M!X9^)/[0_A_XF^)-2N] EO?$^D> =;>5;>'3]4TU&<6C(BA&+))"R>9GYEP, M[CC[P_8:^,>J^*OV!?A[K.F:-63Y$(,GWM MF>_%>.^)/^"5OPL\?_ #XL^ +CQ*_B_6OB+XMO?%NF:U8:3]IN_#5Q-L*1^8 M)&#[=IW;Y(_,#MP.H^DO@/\ L^^(_ G[(?ASX42FV@TK2/#D?AR>^N_EN[F) M8/):010NRQL1DC$K$9ZU48U(NU3;S=@*OAWX\U#6H[/5O#WC?0$70] M ?B9X9_X*#>!OAA<_M+_ !$M/#7C31=2UVYN8X=/ADL7@;Y(8\0\I@X^;)XK MIO\ AU?>V%YX,\-?$+]H[7O&?PQ^'FIQ:KHWA1=(ACU)Y+&ZT_2_BKK'Q2G^%]SXP6VA6-1;[&DN1!AD$Q61%Z%?O$#.,?2'Q&_ MX)Q?$F'X_>+?B)\*_B^OP8N_B$L;>)["'3HM:M+R9$V+<1K.J"*7&26'4D\U MCS?\$D/ %E^S'I?@)/BOJUMKV@>(&\86?B=9+8WR:Z3DWTF[+-G@%-X!"CG( MW4/GEI^K=QIQ2_X;0SO&'PU_::_9!^"'Q?UZ_P#C#9>*O#FG>"KW4-.?4X%N M=9TO4(HI'#Q2)##&4.,_O%;!"X! .?%OV$_V]_BC_P %%?BK\-?A_;?$>Y\% MV'AWPQ;Z[KFIOIB1:CXXND"QW$%OO!3R4EW"1T"DE7V@ 9'M>A_\$[[?Q'I? MQ!OOB;^TAJ/COQKXS\+W'A*VU$F*QL='M)5;_ESCFVRMO8L*ACL/[/3C]:D/AGQ3;C,>O64K8P/.T_(/ MX+(M)9?#W2M5L$:WUG6G 7&^#5IB&_'>:E;X>:C8X_L_Q1J\2J.(K@172$_[ M1==Y_P"^Q6WM%>UU\XF/+Y/Y,K3#QWIRCRT\-:J2?FSYMCM'_D;/Z4^3QUK. MG!1J'AG4 I.&DLWCN57WQE6Q]%)]J=+<>,= 0L]OI>O1H,E82;2=_P#=#%D) M]BRCWJ?1_BOI]]J2V-^L^C:C@?Z->Q^47SV1_N2?\ 8^]%FU?E3] YDG;F:] M0T?XBZ%XGN6M(KZ);H<-;3 PS+[%&PWZ4:M\)]#UN7SY-/B6XZB> F"7/8[T M(/ZUK>)/"6E^,;#[-J-A:7\)(<+-$&VL.C GD$=B.:Y^;P9K?@P^9H&HM?6J MC)T_49&D!'_3.8Y=3[-N'TZU,9+:$K,II_;5T0R>#O$GA.-FT;5O[3A4[A9Z MMR3_ +*S(-P^K*Y]GZM;7&B:E*2(X;K&VXQWB<95_IG/J!6A MX/\ B%:^*YI;>2*;3]3MP//L;E=LT/OW#+_M*2I(.#Q5_P 0>&K'Q;I4]CJ- MI!>6DXVO%*@97_ T.>MJJ^81C;6F_D+>:-;ZO9-#<0QW,$HPR2*'1P?4&OG' M_@IWH]OX'_8&\^1R/,?^"GFM1Q_L3^-+ZWO#"C66GM' MI+&47>ZYH_FCBS%IX2K?1J+_(_)OQ-# M?Z[\.+3Q1-->6=AH-G;07L%JP6]LKIY[IK-IGE!R&C;[D>YN%#F<&!HE6*:.:0(=K_ZI>AZ>2_"/ MXBVW@GQ5%826T<_A_694CUJRS&EMJ40++ME^=R2-Y(>:4!"-_%EQ+HJ+8AKN;0V-RK01Q%/DV[@FT')CR?NG<*_8L31;E:HKQ MA>5K[KKIY:_)GY5AJUHWI.TI>[?L^FOGI\S.^ 'PID^,_C:'3KEK_3/#]IIK MZM>.+E+DV-HA=XXPLJJ^Y;A&CX;_ ):]>":]+3XDOX3N+?0_#6EZ5X9\-"_\ M]#;_ +RXN29',;3R.2[XWME ZG*_*2.K_P!F#1-5UCX4>+/#6@VM]H?C72-3 MFCU+1V14FOK5EV1%9)=@=HW60E-Y+%BRJ,\9W@+0]''T[Q->VFB^(/ N+_2[V=E)OSB>."WG^16Q;JL> M)!DXY[@UYW:?\$]OB3-XO;P9%97L&HZ1 DMM>QW.RP=8DC1I068;DG9YDS@' M$*<#G/2:Q^UW<_#;Q38_#/X<66ECQS;":"_U^YMEN;?1T\MF:%(T7#.J@H2$ M4 X&TXP/+/"?P3_:._:B^)WV?6?'/B"+1\2SRZH=<+VT<8#;6CMXI V&*@ ! M1U&:\_#+&4^>K4J0I4VKI2_-+MY?@>CB%@JBC3ITYU*E[2<>OD_-=_Q/0/A; M_P $]?&7C;QR=(O+*;1M)\/:C;Q3W6K3>9:2".26.>(88@O+'<1RA?NMYKC( MY%;WQ/\ .H_LWZ5-\./#CB7P?X.AS?:QYB+= MI%>7?"?2_P!J'X&?$BWT\>+M2TZWBO#:JFKZJNJ6&+0K/P_X^\,+)/J%I$,"Z9Y%C\ZW!&Y02WS[-CH&=]_4 M,8JGB_:JK*<*M-6^'97ZM!AY85472A"=.J[_ !;M+[*9SFF7VG?M%?V1H_C2 MRTY)WMI-,M=?0+]O@EE8!6?!1)@4S]Y2O)P3AL>.Z7J'B3X+_%N-?[+FNO$G MAK5S%;V$]T9(A< A_)@5$V1PA%QN'+$] 17I/A'PWXE\2>+(_\ A'=,NS)> M7$RK)%;AIC,>S2L0D>4".SLR@&>5AR,59^./P_L/BQ^T/X<\,:L^HZB^CZ)) M?>,/$%O:%VM-J?:#'N5") D8VDAG!\S"G KTJ-2G2JNE+6#BVUVM^CVL>55 MI3J4U4C\::2?>_ZK#59CY4M])(PN"B@ M)MWQE+DJ$^7#))M48P0,5VX;#SA)TULO>>M[-K;]?FCDQ.(A-*IU>B=K72Z_ MI\CZI_:IU/3X?V[_ -GZPU#1;:ZU&Z\/>%?+OX[HHD7[Z3>!&/E/;&&&!]:_ M:> YB'TK\6?VM+6QUO\ ;N^ 9O\ 6+M+R/0O"TMM8&-I$N-T[AB)&90 ,%HXK&8N M-%55>*E3KZ][-4G&5KK6+:\SZ/HHI#TKA/C1:*^=_%7[=$OP8^(&H^'?'.@6 MRR67V>1+O1-2CN?/BN'E6+%M+YKR>"Y+OPY#I\ MVILB2VT6IR26T+@D$J[*K.AVY_A.#C(K>>'J0MS;/8]G&Y!C<(Z3Q$4HU;IMT5X1^S_P#MV:1\;/%6E^'Y]$OM+US5+9KE$@N8=0MT M"ABWF/$Q>$?*<&:.,,< 9) KL/VA_BWKOP5TBSURRTK2-6T1)HK?4(Y]0-G= M(TLT<4;1$HT; %_F#LF!SFG+"U8U%2DK-FM?AK,:&.CEU>'+5ELFXV>Z5I7Y M=6FEKOH>CT5YW^SY^TGHW[1>G:E+I5IJ-I)I$PM[I9Q'+#O.?]7<0L\$O0YV M.2O&X#(SQWQA_:\O_P!GCQ_)8>*="TRXT:ZMY[ZQO=/UB&*X$$4D,966&Y\I M?,S,N!'(Y;!PO&*(X6JYNDE[W85'AK,:N,EE\:?[Z/V6TGM?2[L]-='JM4>Z MT5POB+XY6MC^SQJ?Q"T[3[^[M;+1I]8ALKF&2RN)UCC9]A5UW(6VX!*GJ",C M&>&\4?M'_$#P3X$M?$VI>!_"AT>XELU8VGBN6:?;-PSZTH M8:I+9=;;I:_,G"<.X_$OEIQ2?-R6E*,7S:>ZE)IMZH]SHKSO]HGXX2? _P , MZ=>PPZ-&? -Y\,[FZUCQ1'X9\?7%@8/#KR:U>6HF,<@D8>3 _S [BI(+:>Q31_$6MB?3M+MO$,NN'1XX[>*)HI)Y/F#LZM(5/02"N_Z MDOJOUF[[;?D[_IT/MGPC#_5S^WU5DO>Y>65.R;NOAESOF5G)W4;>Y).SY>;Z MDHHHK@/B0HHHH YSX@?&'PG\)UM#XI\3:!X<%_O%M_:>H16GVC9MW[-[#=C< MN<=-P]:YK_AL7X2_]%.\ ?\ A06O_P 775>-_A;X9^)8MAXC\/:'KWV+=]G_ M +1L8KKR-V-VW>IVYVKG'7:/2OF_]H?]GSX>:?\ M8_ 73[?P5X0@M[_ %/5 MC=6\6DVR),-)\ M?>'K?5M#U.PUG2KO<8+RRN$G@FVL5;:ZDJ<,K X/!!':N2E_99^&0B;_ (MW MX'Z'_F!6O_Q%>?\ _!,&VCLOV*_#<,,<<4,6IZXD:1IM1%&LWP [ #H*4Z= M%T74IWT:6MNJ?^1EC5U,?E[J*4*E.#4^6S4XU977+U7L_Q/?Z***XSY M,**** "BBB@ K ^*EOK%W\,O$,7AYBFO2:=<+IS!E4K<&-O+Y;Y1\V.O'K6_ M7/?%G0;WQ3\+O$6FZ9=+8ZCJ&FW%O:W+2&,02O&RHY8SL]NCZ/L^YI>%X[N+PUIRWYS?+:QBY)(.9-HW< MCCKGI5^J'A6QFTSPQIUM<2>=<6]K%%+(&+>8ZH 6R>3DBK]95?C?J;4+JE%/ MLM]_F>%?\%,+1[[]A+XG11RQP.^B3!9)&"JG3DD\ ?6OQXL?!UQX5_X)Q6EI M=KI/Y2[V5U%<$ 6"AI-X,H&,$DJA8#G ^\/V#_X*=>=_PP7\4/(C,DO] MA384'Z>Q^OX5^.7P^L1I?_!.6R\M;Y9T^(K*0RQ^8\K6"+B,8+NV3P%*GW4< MU^E\%W^HMW_Y>Q_(^!XL_P!\7_7N7YGFFC275AXLLS:K/>:O!<(+,)&[F7=@ MHJ_,Q=7Q@$/M;.W:QXKU;X8ZC#X _;>BBT.]VVVI6MP;&RLS%:6UJ;VU9H[? M=D[\/M!8*Z\DX%<=\-_&-KX4N]3N)/.L-2CMIX],N8VVBVF11(P)& .4*L5' MRDJ 6?+#>^!'@?4/"?QDB\.:PD^E>)+G2XX;36OGZ+[SY/ Q:G3Y/YD_3R^8WQC=7?[,/QNT'Q_X96* MTLM30:E8R0F]NS:QR'RI;0R.1$VP[D)W=50@#BNQ_:H^(>C> OV39-7\(R6T MO_"T;X64# M;;1="LGFMIK-@J6VH2>5 Q=3&<^7(4<9.U^#Q7FPC&I5PCJ*[EHWIT3:3[NZ M_,]65X4\6H.RCJM^K2;7;=CO@Y\*+OXCZWX2L?"VGZ'IWAQT36(-,\XB3=)A ME,QF4HQ;%[&>&&[N0--@"PS M!0K! 552\8^8YX4\'KG_ +:O[!7CW]KCX^^+];\-^$M!\&VOAO2$F"V\Q9_$ M\K&1U5_+ 3S&4'/)QE,DDY'S&8I8O%JCBZGL8)-WNM^;KKKV_$^FRY_4\(ZV M$I^VFW:UG_+NM-/0Z7]I[X2Z;XR\'>&_%/PKOM*&BE(+@SW%Y')ED$IU:-2C53E!*=G?HM4V[ZGFY]"%*M3JTG:;<&U; MJ^B5M#4_:C\:C1]-?X3Z'=#4X$U 7VO10"6ZM);[@(D36_*I%RI58MNX < MUJ?%W1S\"?V2=0\*Q_:H9KB[L%U*>WU%F%U=[6NRODW&TJ(H?(B*DX+,WR9Z MS_\ !2+7](\7_M+>*],M?#$?A2Z3[.ES&]KEM2E"[BTYA.Y%8896#,. 67)& M-'X_F#3OV?9=)U'2;6#^P["+1$T87 6RN+RX6.Z@U5)2(!YHB+80(V=FWG)K MOIS2HX5QC\34GM=O37S_ "/.JQ?ML2G+X4XK?;73R/'O&=F-.^&?@^W#)J%K M?6K:C M%I8]J0Q&4%7VN2R;\C;MD4MQ^[85/HHN/AWX+U*VUV34#IOB:RM;[2+*X=4W M%V(5Y(QM6+9Y6P$ ;O. ;*\U;_9RD^T_'WP*#"Q1_$-NWSJ 9'65/, #_P#+ M9@&2>F*G:7S-%@PNW_2+D8/_7=Q7$?%&XFUZ[T_ MPS9R/'+JY=[R5,@PVB;?,P1T+%E0?[Y/:OP6G'FE;U/VEOE@F9I>?XWZDX5W MA\(6\AC8KN5]8=3R >"( 0>G^L]=OWN^MK./3H8X8(TABC 5410% ' %)IF MFPZ3I\5M;Q+#! @CCC08"*!@ #L, 5F>/_%P\'>'7N4A:ZNI&6"UMD^]<3,< M(@^I/)[#)/2J(+G^V=3'S)YBXM[4]<11]!C^\QPB.+Y5"[1P .*'R0WU?Y N:6VB.2B^$O]K!'US6-6U9 MU(;RQ.;6 '_KG$5ROLY;ISFI-2\/>#_ =D;NZM-%TZ&#'[Z9(T"$GU/J:K^) MO'5_J>NRZ'X2C-OIP/(R!@O(1R$&..21QGY$^#7[<7F?$*"YU^ M3P;XG1=4UJTUC[+<32ZOX6M;#[8?MEPA#11Q'[,JG CP9TP6Z&G)Q5ZC^2$H M)OW%?S9]?0_$ZTGF\G2M%UC4549#067DQ'Z/)L3]:;JFM:_J,/[OPA!(O9+R M]B7_ -!#BOFN\_X*5:IIW[/EAKVKZ;X?$>*3XF@T34;*_DENH-.AN+5[N"0 MB(AW8Q>6I X$GF#^&KGP@_;?\>?'OX/>)=5T33_#,&IVZ'P^;F/_ $WX>Z7)GEEM MIH')/_ @E9E[:Z=H,^[^S?'7AV64XS;2-FMZ)?WME:OX3M];WSB#+7M[.MK867EJA\MI9S(&8R$KY9RHJ?X:_%;3?B-K M/PXT[Q1XKU:35-;TC5I-<1]0AF33M3T^XM8)+=8A%Y;*9)I@&*9*QKZUUQE! M.TI?==_\ YI1FU[J^^R/9U_:%M[+5X;#1?%UGXLNYR^S39;,BZ8J=I_>)M50 M",'M*KWG@B/PH[D-_:EG*UY)&Q.3N6U9'^NYMOKGI7DWCS]K MR#PEX6^(4:&RUA_!NN1:7I^GW7AV29;N%H;)R[F-5"L#YH)F$&YO*R0&4@' )/%;KD M3M%6]?Z7Y,YWSVO)W]/Z?YH^J=*^'M[XHMXY;/X@W/BZWM2([FPNY_LH\PI_O$+ M7S#\5OVA-9TW]L?2/"WB%]'UC0KRW5X[BY6XT*\OB[*'AMG5E7SD#9$,C.TC M 8$>0Q[#]E_]KN^N/$EOI=A;^'[Z'7]%'B+2=)ABE>_BMC(%,%Q($'[Y4D@; M<596\Q@6&W>[;N^6[;\M/Q_S0:VYK)>NOX?Y,][T;Q'XHO+:UNO RWVKZ1*5 M*KKS+%$T?3,T"SN/%M@NO6,'C5?!VM7FCW8LK2R_P!, MBMVE\G!GYZS\%]*$Z/'JD M7CB_^Q6X,ABUC4WDT^56))!VNF!UQR548^4XQ46E_&+PIX3M]UYX0EB11@7N MEZ<;RQ9&(&?.5!L7D$E\#OD]:HZ3I'PYN[@WWP_,LNK6HSC2[8W05C\VV1)/ ME4GGJ4/7FN@F^*'CS1[)$U/PGI]A9,2'U1IFD2"/'#R6R*S+[KYA Z[JUDI/ MXKOU?*_NZF2:7PV7HN9!%X=U'5W34O!VD/H N5#"0ZA$MM,.H8P)YD9![E=K M'UZ58OO%/Q'\.M$-971;>SP!+>:98RWV3W)C,B.@^@D [FL:]\#VJQ?VS;?$ M.V\//=HSAM(BBAMISQ\QBD,BG'/0!N>M9=IXRT_28)O[>T?Q/XJM$!==5L6N M;BRE&1\Q#E4C/7(4E1ZXJ>3FU24OEK][_KR+Y^7XG;SZ?Y(,J/;01QD<$;MN001C!.:J0WG@[7+7GQ;J^MH/XK7497_6WQ6&_@/2 M_%4*:QX8\*6>C:B\8\C4H[J"!SWQ)M60/SV96IB_$GQW\/8HX?$;>#;>'O?V M(DNBG7_60YB;I_$A.?[HI>R_D>O;1?DF-U+:S6GS?YLZ/!]J,QVOB6_X( M_>-?W/![?.33)KSPA:GR9/!FN7"$[OFT*>4$_4J:GTGXF_VSIR7$?CSPI+'. M@=)+:UP#GG.&F;UJ]!XEN))@H\Z!H]Y"!\K6>HMYC_5)(U4? M]]FLN;HG_P"3?YHTLNWX?Y&3X;L_#7B2+_BG?&UY,D)^86NKK=[3[E]Y_6M< M^%?$=K$S:?XK\UCT74+!)D ]O+,;?CFLO5_$/A^ZY\2^%I]/6(\37UBLL0]_ M,3R\8>''5HKG3_$%IG#QS1FUN0OJ'7*,?8JO^\*ETWX MF:5JMZFFZG#-I%_-E5M-0C"&;_<.2KC_ '2?PJ$ENE?T+N]K_>,'PIT.[_TC M29KC2I6Y#Z=X_UVGOY:O_OQ\QO] M2N?0UJW-AHWQ T(>9%9ZK87"AE.!(C#U!_KVKG9O#&N_#W$FASR:MIB'+:9= MRYFC7OY4QR>.ROD'IN45,;7M!\K[,))V]Y77=#O^$H\0> \?VQ9?VS8 X^W: M=&?-0=C)!R?J4+?[H'3J/#WBNR\5:7'>:?=6]Y;R9VO$^X9!P1]0>".U4?!W MC>R\9P2&!I(YH#Y=Q:3KLGMWZ[73L?T/8D50U[X8)+J;ZIHEP='U=N6DB0&& M[]IH^ _UX8<8/:E+E;Y9Z,M-I7AJCK5D)IRMFN2\+?$)[C4AI.M6_P#9>M*" M?*)+0W0 Y:%\#I-<.=7U?XL-C3'GT?P^1S?;<75\/6% M6^XA'\;#)[ <-5QIN6NR,Y3L[&QXF^)UEH>I?V? DNJ:LP#"QM!OE0-G#/V1 M>#\SD#BLU/#/B'QI(6U?4!HUI(/^/+3FS*P[[YR,CKT0+C^\:Z#PSX/TWP;8 M&&PMX[=22\C9R\K'^)V/+'W)-86J_$>YUK4IM*\-6PU&\B8QSWCG%G9,,9#, M.6<9^XOIR5K>'_3I?-F4[;U'\C1L?#GA[X9Z;-]2Z1\*H#>)>ZY/+K^I M(=ZO<*!#"W_3.+[J_7EO\3^/].\*.EKB2[U&92T%A:IYD\V/1GO/\ Z:^ZOQ,V/P-KGB#+ZWXBFCC;C[+ID8MX]OH7.Z0GW!7IT%0W&B M^"?ANUN]W'ID%Q(^V&6Z?S[J:3'\+.3([8^IIZ:'XE\9DOJ%Y_PCUD[?+:V+ M![EU_P!N4C"D]PBY'9S5ZU\+^'?AU:2WSQ6MKMYFN[AMTK^NZ1R2>?>GS=&_ MDA6N[I?-E;_A8MYJB/\ V+X=U2[P<"6[C%E$?QD^B2'QGJQ'[_0=& M&7+>N1Z=8PI]_F%0M\1M1\3KL\-:++=(0"E[>L;6T8=RIP7;CT3!]>]2# MP-K>L-G5O$DX3JT.FPBU1AZ%FWO^(933LH[I+\6*[D]+L5_!-ZRG[;XOU8]_ MW:P0A?Q"=/J:YF]3P'=:B;>X\57M]>Q?>BAUV82CZI"X_E6CK&D>!?"=TL>H M);ZA?2$(D5RSWL\S#D?*V]B?PS5_3O%5S?*5TOP=>PQIPCW(BM8R.Q )W ?\ M!!]JTBY;ZV^2)=MNOS9CI:^# H"V.L7Y7LT-W.__ (]G-,O)_!D,NY_!.JS. M>?,70)7/'J=E=#%-XWOU;S(O#&C8/RL)9K[(]QB''YFHKV[UG38OYG_".>(+%I.-W]FW5OV_V0 M,5$=*\%H^XW/BFW?H/\ 3=2 7'MNP/RJ_)XNE@VNWCG0'3."!;KS^/F5SWBC MXWR>'KE+>#Q9X7U2^E7=%8P:>S32X(SEOM 51R.6P.:VC3G+1-_C_D92G&.K MM^'^9J6VO>%GU%+2W^(UQ!)/%U]X8O6LM+\8?VQJ MV%<6#:='>R(K?=9EB:/8I_O.P'!YK'DTCQU\18E;6K7PPND2(/,M-+U0K-/_ M ++R&(\=$RXZ;B,YJ:A_P (9\./L6CGP!=P7DP/D6VD)'+*^!G)\IPQZ=2/ MJ:I4U>S=WVT9/M':]K+OJC>F@^*GB.SC-P-!L+8[B\-G<,MW+SQ\[*Z)QU W M>S55D\3>'/A.8K?5_"U^-0O?E#QJ-5N;PD\_=+3,!GDE0H]N*PK*:7Q)JK0R M>*M7\ VD@RMC-.\E[.OJWVE2L(![(#GKN'2M:&9_A N-#OM'\4:G>)O2W-N[ M7U]Z$S*SD#J6VNKKQCJMWJ,@"VZ:FZ:D9F7M' M"5SGUV8)[FGZUK?BWQDGD^(_#ESX?T>1!YG]GQQ:E,Z[>0QQ\GIA8W/?/.*Q M-(B^%^GZB++P:EW-XB7]TZZ9=-'=1$$Y\YG.T $GY7SR?N\4_>2TO;RM)?-D M-Q;N[7^:^Y'36OBSXGWNE_\ $OT/1'B(79>7A>SDD!/)%KER,#H'E4^H%8NL M>-O"VB7PB\?W&OW&I>2TPL]0MS);.HY8K%;[HW ]]V..E6->\/>/-.T#[7K/ MC#2K6QB8E[-CY,DT?0*]XBC#'J2D(]!_>J#1?B3<>&])!TOP+-I4$S'[1K5V MC2VI7&3)D SR#DX+J@.#\P!I1@FO=2^3M^+_ $0W-I^]=>JO^"_5ES3?#^G_ M !.TZ&\\*Z)IFB64PW0ZFMU]FD('1A';L"5Z?*[+GG(K(\0Z%<6LRV__ GV MK>,;JQ;9=:4+=G5F)X#?9=C)U'^M+C'4'K5'^S_!7Q+N+F^CO;KQA>;2LTND MS?V;8VVX9^=T9OU=W^1$JD4KVOZ/]-%^9V"^/=?^'FEM+)X#T[PM M8A?WM$TNA'CH7BBPY&.>N,=2*?I/Q:T;QO&[1^.-5UZ5 CS6V@V. @;.. K MN <'JV>.M<5HWQ+CDU4R7^BV]DMO'YC:ILN?$F"HR3> M$OB1I4-WJGBN^2+.(YTTV.R"^P:2(LOX$5,Z,5K..O=:_P"?YBA5E+2#OZZ? MY?D=1IWA>PEP4\$ZUJ7.Y)]5N4D.?;S96=?^^15ZTT[4M.N0]KX#T&,'JXOH MU<#WQ&?YUB6WPDU"]L$G\)?$C7?)CCV+%K'\%-5/^%A>%=>G@MM4CBLKBZ;RXK?5K0VS2G^Z! M(!N/L.:J^'?C;$T,)UF*&TBG(5+^UG%Q82,3@#S, H?9U'U-=KJ.EV?B"P,5 MU;V]Y;RCE)$#JX/L:Y)>X_>C;T.E>\KQ:^:,*_\ A#X=U092PBLY/X9;%FM9 M!Z8:,J?UJM)X9\1>&91)I.K_ -IV\8(-EJ2Y9O0+,HRO_ E;/'2J]]X%U/P- M)]K\,3/+;KS)H]S(3#(,\^4YRT; =!RAP!A<[JZ#P7XSM/&^EFXMMZ/$YAG@ ME&V6VD'#(Z]F'X@\$9%#E)1NGS+S*48MV:L_(J>&/B5%K.H'3KZVFTG5HQN: MTN!RX&,M&P^61>1R#QD9 /%;&M>'[+Q+8M;WUO#=V\G)CE0.I_.JGC'P58^- MM-^S7D1RIWQ3(=LMNXZ.C#E6'J/I6-X%\1ZAI>LOX=UZ02:C ADM;O;M74H! M@;\=!(I(#J/4$<-@19/WJ>C[%7L^6>J[E2;3=4^$R^;9-=ZSH*_ZRT(;+Q3HUM?Z?<1W=E=QB2*6)MRNI]#5PINSGI7!Z MC%_PJ/Q@E["C#0-%<_*P /S,K8Y8T:5-_B_/_@CUI^A MO>-_ EMXL@AD$DMGJ%FWF6MY <2P-[=F4]"IX(JOX&\;SZMZM@\=5((/2NFX;GK7)?%'PY.]O#KNEQ[]8T0F:)5P&NHO\ MEI 2>S@#'HRJ>U*$DUR2^0I1:?/$ZV>(.NTCY>_?-?,G_!37P[9>'?V&_'6G M64,*0/;V4Z6[E"H+:E"=B;SMY;[JG(R0 I^[7T?X?UR'Q'HEK?6LGFVUY$DT M3C^)6 (-?/\ _P %3X4D_8Q\=$HN8[+3Y'=C&JA%U&)CDN&&!C)RIXZ9/%=. M676,I1?\T?S1RYE:6#J/^Z_R/QVE>&UEC\R9FMRGFV[!2VW80&^8 #\H'/?_$"]?P'\1_AGKTT[:=J5PUM:S9W<]E:SPSRJ8\R,6 \IBK<%G'W%8L67);:ORF]I MVCW^B_%+PQXC\5P?\)#INMZC<7\4D\R>3Y/F-;K.9'*LT@D"2K%O X VU^YX MB=Y6>R3^=ULOS/Q[#0M&\=VU\M5J_P CLOVQ?!$MCXR_X6%IT$:W5MK$MG?R M)<7E]-'>P,)8[K,2B-?-C>-PIV#)8=Z[J7X]6=_\%?%OQEL[B&;Q58Z?]ANT MNGC-S:ZO*(XH)XXSO9("/,=<..8N1T-I6\4?EWX\TCDJ%;>BLFX%=HR,$@U\ZE">&PW/J^=1](M[/[O4^B7/'$X MCET7(Y>K2W7GKZ>9P/[.7P[O?B7\(;/_ (1NUTRRN-3G1-7N)VD>ZU!UN(X= MV778PW3+)LW@,>""!BOT+_9U\(?#GP#X@\,>'M:U"R'CC4=*GW6T5[!Z'AE=*ECO!IX6TES:W;#4= M.W-("K/O^4RYW=4...!ZW^VW^R]XJ_;@\5_#K2/#7A3PKX;BEMY+R7Q9:W7F MDQQPH/)'E@'RLNBKELEE. H&:\K/I?6,9]6Q$O94[R]ZZTWWUU7DM3U\CBL/ MA/K5"/M:GN^[9];;::/7 M)PJ2)&<8C#K,NY=KX"7]?9G[/&@:[^SE^PUKF@^(? ?A?1]2TZ>]LFO/M( M676I$6X'F[2I?S0P7'W@4?(QR*^/_P!O7QSH^I_#?PQ8Z=X5CBGU>]U*]AU2 MZDS/'NO'.V(*%^1PZY#YX (YY/7PUS>W>&_B4N9J]T[JW5WV\CDXCY71CB/@ MJ70GMK^YM6L;8XM8HO+N MH_>RN&W#80L*_,0>>H_X*#7UAX=\-_"[PM?^%FT?7;3PQ:176NBV66XNT"6_ M[M%4[S&K;U8DHPYVY -5/A-;VW@S]F6STO5=/@M].\B3Q)=BUD/V;Q/91;[> M2QN&D2$PA))$(S(_WV).%7&U*RRZFXK64M=O>2>C]--OO,*W^_U$Y:1CIO9- MK;UUW^X\/\+6?V3]GN:_AF;4)[_53!=2"S7[186ENJQ")VC/*/)+'@C*E@%^ MUL':-(MJ[-Z >8<,OEE4&2S!8@/[ZD5UWP?DN_AUIMMK]TM M]I_A;4H;O2+JVC92C21*)O+BVD":,X7#L2V(V(;=(1R">><'TQQ7[8P?=7Z5^1\6W6&P5_P"1 M_F?I7#.N(Q?^)?D2T445\4?6A1110 4444 >"_M >//&&@?%>&UT7XD?"'PS MIQAA+:=XA@+Z@[$G
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
2\C'NSL68GN6-9RQ$I4WSN\KI_G?]#@Q&?UL3@JOUJI*5652,XWO[ME/ MF:?2[<=%_+Y(Y/X'_L9?"[]F_6K[4O!/@O1M!U#4"?.NH4+S;3U175FUZ/3;A].55#%K@1L8P >#\V.#Q6_6!\5M-U76/ACX MAM-"F-OK5SIMQ%82B3RS'.T;"-@W\.&QSVK?"V]O"]K76^V_7R[G)C^;ZK4Y M;WY7\/Q;?9\^WF:'A>2[E\,ZN9+V*UB2X_.>:OUG5^-V[]-C:A?V4;WV6^_S\SQW_@H% L_[ M%?Q.5U5U/AV\&&VX/[L_WN*_%KPYH=WX>_8*>SG>VO\ R_B!&WF:9-%8E&Z%O6OTF_X(;3*OP!^( 4Q, MO_"J+HTZBW;_0^I\.N995F%-]/9?\ I3/NKS]QHWU2 M6\PU/^V>XK\O1Z]RUOHWU5^V>XH^V>XIAXH^V M>XH"Y:WTV6;RTS5?[9[BF3W(>/DT!J? /[%_A1O%?[;?Q[FL+G[!K&C>);BX MAGV;T?S1&@21?XDPCC&'2M3@&FZ] FZ:U9MRR+T\R)\ M#S(\]\ CC(!XKXU_8"\7V7AG]O3]HJ+4&>VCOO$ CAG=#Y)<,3M+]%/3&[&> M@YK[:\8>"-/\<6$<=R)$G@826US"VR:U?G#HPY!]>Q'!&"<^K4?NPC4VLCW. M+U;-ZLH;VI_^FX'GWCOP1?:M\>]/U70)H+'4M-TB:28.@\J]=Y(UB27OC:DH M##YESW'![7P=\08O%$DME/#)I^L6N/M-E,,2(.FY3T9">C#(/L<@<5H7B^[^ M'_QHNK#Q5/%)]NTRUBL]31"L<_ES3@^;QB)SYB#^Z3TP2%KT7Q-\.++Q[;1W M;2RV-Y8_/:WUN<36['T.,,#W4Y4]Q17:M&-3:VC_ *Z'RE):N5/>^J_ \RM/ M#.H>%_VBO$FKZ) );.QTNRFGTS=M6]:>6Y\UHNR28@0XZ/QDCK7H47B/2?C1 MX;F!6.XLY@UO-;2*5: CAHW7@JP_,&N%\'?$F?2?VA?$6B>)_(M+Y].TXVUU M$K+:WBEKI1@GA'^0Y0G/H6[=AXK^';7>K?VUHTWLK/Y!2=T^3:[NCBOA;X@N/A3IT2XMRVR"_1G"#><'#C=\ MK#TP>.ESX ^*;7QC9ZUX=U5([/6].U&\6_T^?#*$>9W4J>DB-&ZMD=F (!R! MF?''2M2^%/P[N)-&C?4?"NG317IM!S/IR12([O%D_/&$5OD^\H^[GA1M=_6+ M+1W^3,M/8:ZK\4:OQ'TVP_:"^'UVNC32Z/K-G%+;QS/%_I-E*R8:*5,C*GC* MDX.%(/"M7G>L3/\ &[X4Z;KEG;/I_C7P[:6]W=:9,H8WT2X=[J:GX?MO&T%MXG\,:A;PZD81Y0]."P/#?" M:R7QW>:IHGV2X\,>,_"&H3/:>:1F:"<^<& !_>VS%VC/O&3\K*,50GR0NOLO M[O7NB:\>>7*_M+[_ /@C?V4/'&BZ-86/@W3IYVTZ>%[OPX)^&^S C?:'))\R M!F (/\#)R><>]8321SB2?N.JI_\ 7KY#\7?"C5=0EU6PT*W.A?$3P3>)JUC; MQ.RP7D(#[#;.?E.,R1'IF-D60<)CW3]GKXVP?&KP/'=RP/IVL6H$>H6,HVR0 M/DCIS@$@^X((.""*,=AKKV\'IU_1^C[]QX'%-/V%16[=O3U1W\D[3ON8EB>Y MII-2+&I7H:LI9)98DF&3_#'GD_6O+ND>I5$\Y= M)C(^:1D'+28^Y'W)4MA$XD6TLS+FWM[B0>8 M[2MG;(Z)Y0_NJ6.,\-7KN<:<%2CLM;]W_G^1Y"BZLW5EN]+=E_D)\;(]2^)_ MPC\1&&2YTK0&TV6.W(79=ZM(R,J!!UCA)*\_>?)& ,%NWU+X@V/P]LK;P_X= MTZ.?4U@5;?3[?"^2@&U6D;_EG'G@G'T!/%<)\8?$^H_%>STS1]"\W3],U/5+ M4?VO(H#SB.43-]GC8'?Q$Y M)RSN>PY/0 =!7G22Y$I>>GW;G?'XW*/EK_DH:T\\+ MB10PAM=T" I$I)QPH!?[S8YXXI?CSXQ;Q)X)\1^'_#<$>I:TMG('DW[8-,DV M;E>5P#M8?>50"Q('0'(3P9IFK_$_Q?XEN'DN/#6@?:H87C(VZC>;8$;U_
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�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Ȋ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�R$#L?NL%88 M/!'S4R;2]6^%67L5N=<\/#)>S+&2ZLAU/E,3F1!C[C?-_=/1:I?!"TT?Q]\+ MKG2ML.J:9:7US:0KC_5QK,S1)CJIC0HO8J4[8IW3I>]JEUZ_TATE/CKPT\.C^(M%427=VL>Y;NR5@9XY5X#_("R\@AE&",FNFT3XN?V MCJ4&GZY NF7TBC[-(A+6E\N,@Q2$#GG[C -[$=,'&0-XQSO[4O@W%IGQ!^"]A;3K;ZI8QJ]JI#;U=89&C1@ M?[V$4YSG-+XJ?-/5+1,:]VI:.C?0N?%NS?1H[7Q39[UN=";?.L>/])LR1YT; M>P7]X,<[HU]Z[*&Z%U!'(C;D90P(.=PKS_5TU/X7Z5-!=_;-?\,&-E+A3->V M,>"#N'+3(!QD#?CKNZUI? ;58M7^$^C-!-'<16T)M!)&^]6\IC'P>_W:SG#] MVI;V-(3_ 'CCL-^,%FVD6-OXHM8I'O?#CF=DB'[R>U.//A'U4!@/[R+TKK[. MZ34+2.2)E:.10RL.0P/(I+F!;RTEC8!E=2I![@URWP/DD3X<6EG(TCR:1+-I M9=^6D%O,\ <_[PC#?C4?%3OV_4O:=NXOQ>TJ6/1XMC;3VKIM)U&/6]+M[N!Q)#I:,GT+]0C6/^SY-*T_49'N$+!8EOXY' M^49/F!4...&Q7T[)\ZX]:^1O^"BGAHZ!^PW\2-.N)EC@C>T,"A-S2P/JT)[?4?$>@?VTM]+#IU MRC"[MY4$L"JEO(%<.1N16DG^7.>3@X%;<.OZW^SYKL'A;3;CPC=RZ9J4 TV2 MVTN2\>"ZNPLCWB&5<'$.$^1L8?/:L'P9XB:$O[&2/M'->CWGQ9\-ZSX;TFS\77.H7,5C<3I83VLWE7$(9)X]TZJ 2GEJ# MAE7M@CDU^PXM-347#FCU7GW_ #T/SG"^]#F4^6?1[::*S=_34K>*=!\/?'XZ M+XKT99-"UZ_-SJ,VB7B/(;J#3TW*+,(A@MU8HY99#E3C /?@_A)/XR\->(UN M_#A&FW,3&WOYUE00L>)F$DDI*2R*TCL$"DC8WW>E=/X.^-_B']G34],T?PWJ M0U?P]HL$,>HVEKIR-IYCGO"9VDFD,NU9(\*9 S#@\@"KUSX8N/C3XDE75K7Q M'X7\':C+/:6^JR3B4&1Y& M[4^4J&)PH7H"YP6?!4-E%U*,'3J).ET;UTOM; M1[6MN:S5*O-5:5U5ZI::V6O,KK>]WH5KO5O!OAO5M7U3QEXM\3_$KQ+H\NG7 M\CVMJK:8(PH500TBED5Y$7Y=F&9 <_,*N>"/VD=%BU4:1',UA+IADATVZU2V MCGT[1(4W*S?98<8#QSB-7R^2!GU%S0_AAX&\*:/;7+&37[VSTX6.^Y8P66HP ML08<6RG+;(F$@W.3^ZE)^9 :H:YX;T'XKZ-J&F:C'I^@W,<=L]FUN4AB\B/: MH@F1$W;1A5!R#YL6U5^4UA_L]1>^I-=]%;TBD=:6*IM/>I8!MRC!#-D_>K74Z!X: MU"?28=*T[6O#ED\!NC>B.\O+Z>)6=IF"J&R-S<$D?O$(;:[ P>,_@3X!\9F. M"+7]1\-(^J'4+^9+C[:7EVR>7Y,APT8C5)V!.[]W'EADIB>?#P?+:44_22?J MK;BY<3-.2<923\XOM9-/8\TBT[Q!XI^)>F1ZM"]UK&L 1W-U)*IEF6ZDEM2R MON:.XC^>(C:,87&%XKT#0/$VG_LW_#Q)/"UXOB#Q;KJ75G)J5K9RRV%A/8A< M!+6=5-M9^!3'5;OP]J&?RY M(0&N#*ZL#\F\[?DWIBN>/CVX^)/BZT\0?$'6KQKKPA?_ -J?8;FQ^Q7B!XH' M\J$HZJ&E<%L;6.,D+P:Z*GM:[M)+V2[/?LK*_7I]YA1C3PZ]R3]J^K7P[7=W M;I>SMZ%"SG7XK6::I<7GAI=&\*:RB,OF7(+.6:6=MK/D(+D_,%&>%P*\T\7R//JK1W M3*8K@O(_D3RW"QG!9^(IW7]WME;[JX^S*/2NG">\G>-ET7;_ (/7YG)BX^SY M;2O+J^_S[=/D?57[3OQ9\4^"?VV?@%XJ:9X>U30O"ZWVF0W)6)Y!/(/ MFC4 XQ@'@9XXX&/V3@Y5?I7XO?M8:_9Q?M]_ B._\/64]]>Z%X8E%\WV@26K M?:)-P\L.JD\#&02,7/B)O"-O:Z?-+)K2QK(=+4(29PK J2O7!!SCI7YGC]L;QO\ M6OB!_9?P]_:7CTW0+*8I>>(_&9TC3(9@,?\ 'M:;/M$F#_#_&<0TJM>A5C3A3^)SC4Y5I?XH0DKOI&_,^B9^K%( M3@5A_"^1YOAMH#2:Y%XG=M.MRVL1*BIJI\M?](4(2H$GWAM./FXXK=KSVK.Q M\-6I^SJ2IWO9M=>GK9_>DSXK\!7_ ,.M'^ _@K4]:U@> 9X=:N=&$:O!K*) MJULK/(S17S&,1KEU(DA=)(T/E[LL,U[5^P?JEIJ_P9OI8 )KT:[?)J5^FJ?V MG#JUV),27,5QL0.C84 !%";"@ "5\_\ B[Q;X@D_;#\:ZOX:^%VM9AT.Q5]. MN_"U@\>K/)+7*?D 4444 %%%% !1110 4444 %%% M% !7-?&7Q#%X2^$?B?5+BQ@U2#3=*N;J2SF'[NZ5(F8QMD'Y6Q@\'KTKI:Y_ MXKZ[?>&/AAXAU+2[1;_4K#3;BXM+9HFE%Q*D;,B%5Y;+ # Y.>*Z,&KUX*U] M5UMU[]/4X\Q=L)5:=O=EK:]M'K;KZ=2_X/OUU7PEI=TD"6R7-I%*L*?=B#(" M%'L,X_"M&J'A>]GU+PSIUQ E%_P#/V.GR/B.)I../C*/2F_S.,?7-2^)U^VKZ M?IVA,5A.88M+CCLD;9/'&/+021<_:8"V2N-S'MFM67P-J'B:[U34H)(;?0([ MA+V[U..9K18$DDO).9T883E0J%^_053^$=M<^)-?TE]41=/T94-U=W\Y0Q:< MB^<&:1G!/WHY#@'.%0SI626[[+^KG@T735+VE:[?1=WI_P #YES4 M?'NJWNI:QX=B\/V-])J4UPCWT6FQ:CLB6TCYB<;Y$G*$EI23GY200,#<\!>! M-.\?/.-$OM\*Z9K.H:'IMP9D>=M;A^V10I=O<09"P1G# F-P5XP#V\;EM-$ M^.4GA_2KS5W$7\\:>7O=[BQ1?M4L6%+J5F 88 #%37+2DJR2 M/\V]^^B>QTSC[&48U)*<_P"7:VNBNUH^_D>C^(/ &J>"I+WS[.\6'5)S-&+V M'S)%R00N\MN.-EJ'(8$F:3)X-8?PZ_9^77]"+?VIJ%O:ZA,VE:>\<_V87I=2 MQV(Y&^4[WVNI*N-CDY!0ML?#GQB\%Z7->0013Z%KE^T<(ANH-1L8+2V7"I$A M=OE*L5 4;O+#YQM&<#7M*\:?$3$NIZ4_ATV:+=6-G:W3:>EYYAW2VD22,#)< M&26!BRXSL)SDBB$:G*[58]-4[_*Q=2='F3E2EUT::W>]_P 3=\+^&;V*._TW M%M#>WQGLY/M%N?+5I \.[YOFPI=,R% QVS,.&KH=3^!NI:7X5N1/(;.TLECU M%3J$YM[[R8Y)B/F :3++<2(2@.)HT)7]X,\]X4\2_%S6]:$-MX;GM+J[NTM] M0DM(/L]S="YB4.Z/.V5DC+.H*,WTRQ[!$\GEON" 2LJJQ7HN<;J3C.52TJD4^RU;?HOZV",X*F^2G)I M=7HEY7?]:,M^'?&=OX1U!-;\-Z1XHU[2)3:6&[Q#:KJ5Q*/-<;K:9QLAPRX# M=N@&5W4ZQT#6_B-X5L[C3H+5[ZTTN\*Z9!>&7=:G[0%FDM8GV$[SL?"8)!8Y M)P.O^"/QVT&WU7Q-X?OM(T>ZL+NT>8+KMU,UJ9K55DB>Y=N_"O6T.E:>_AR >&;&UTIM*NV@TRYFNI%F^(M.U.6WN[? M3I!+)[9$W$F4,3MS\PR,5B_LUZY(W[2/@@.ES'!!K5M)(CR.\4NT0 M%4 7CF::(+\OW8@3WJ[.IAINLE=*6GG8CF5+$05*3Y6XZ_-G[J6K;="BX^]- M.<>G[YZ89<#CU[4EF3_PC\.1M;S[CC_MN_N?\^E, P:_#[:L_4X?"K'->!'S MXI\69!R-2C"^FW[+!C]2U=2LH4^U<7X5\RP^*WB:WDD!6XCM;R)!V5E>,G\X MC^E=9=SQVT+2.ZQHN26)X K:M%\VG9$4OAUZ,YSPI.J?$?Q."5\P?96(SR%, M9P?ID-^1JMKGCF^\3ZQ-I'A=8VFAD,=YJ4B[K?3^.5 _Y:2]/EZ#.6/0'A86 MN_B+\=+XV%Y]^RR2;A >JHWVH R=2$^7'WJ]/+SQ'J$NC>&%CDN+=S%>:G(NZVL3W4 M?\])1Q\@X7.6/0'B9M9O/B9\;TCL)KS3O#.HZ6T#WJC8^I&&4,P@.'A%$D&GV%DG8A4C4=3G^M%9K:6G]?D31UBU'1 M)O4XOX2>#+?P3\2/&(W2SW-X+6>6[N)#)+.2C EF/;(.%&%'8"M.Y\=ZCXZU M0V/AAQ;V<3-%>:RR;D7!*LD (Q(^<@M]U2,?,00.&-U<_%/XRB(B\L?"VMZ5 MN4E?+DU3[/*01ZI$PN>.C.(ST7[WJFJZKI7P[\/AYS%9V-LJI'&B_@J(H&2Q MZ!0*==6DF]9-+_(*+332T2?_ 3$^'^BZ-\-+#Q9=Q-':V<.H>=>7%Q+E\^1 M$S/(YY/U)JGWWF!YVC@\]\-+:[\7_& M?Q$WB&TEAL52SU:TTMWW1_O%DB#2X&&F46ZG;DJF]<$DYKO_ (D^+_['ECT_ M0+=-2U>]7Y(<_)9*=%>W]R^ M,+#+(F!DD)&-O"CMZDDFAJEO/\7?B9X6O=1@DMO#T$L]S8VD@*/>,B +-*/[ MOS';&1W!;G@:I+VLG%V2OKWTV(DW[**EOII\^IPO[0NO3>.?BS\/]O'_L6_$,1?\$Y_"#@W&A^%_#'AX)J M5_N,4M]+$61X(&P-H9EVEAR"2B\C(Z7]O7Q(OQ/\3_"C1K"W_P")1+XW31M2 MOHSA9&N+"]B:*/L1@E7((P6"C)SCR7X0_$B;1OV<_"NFQ6?F:)H^M:R]GI( MSXAN4U.Y2UA7K^Z$SQ8]?*<\A!F\+2B: M!\-=2^/VO>'_ $\?]F^$M'VZSK#1VWDJ\SG?&C=O,D)+*G6&-%)Y=G: M%#X6TR'3[>".V@M8UCCC1=JJH&!@>E(17)_== W=*Y\=B956HQ^%?GU9O@L*J2YW\3_I( MK:9K-OJUDL]M,EQ"Q(#HV02"0>?8@C\*N6VI>2"C#?&W!![?2HKC3FLP&SOB M/W77H:A)#5PV3.Y(NS668O,A.^/U'5?J*\L^/'[/VG_%;[/JUJL-KXFTE2+2 MY=E6UTUJ^Y&QZ^XK@/C9\89M+UFP\*>$;.UU M+X@ZZC/:VUPY%GIEN,AKZ[*_,L*G@*/FDI0(C3PD!MSH59)!/PJ#YWF^,=2T[5M1M?AYX2U:4ZS;3VRQ:UKEM:_(C>8[*;>/! :1A'<; M?-4[VR7IGQC_ &++[X-R_P#"R+&_E\2>/YMG_"0ZIJ2[5U0*RM'M0$I;PQD; M B#"HQ+;SN+=C8>+;3PK-X.\9:?*DW@N\D>QNHW)>;P^TRX>'@']T)HU#+G] MVRC'R_=]ATU6IJHOM=/-?K^9XRE*E/D?V>OD_P!/R,;XB_L4:=8?$+PAXIT[ MQ!XDUJ_O[R47;7^LSG3=11[=V&ZVMVCMQO=(_F6/L"0<"O6QDM[B-BDMI*.,J?O M*P/!!';!%<4[*$7+;OU^9VP;YI);]NFW0X;X0:)K/P_\)O=>&9%GT];V[671 M;EOW$JBXD :!C_JC@9V_\A#AU/3]V6(/((Y!(K(^"?B>_\&^&=+T_Q+'LCOF=K+50!Y%V6D8A'Q]R M7O\ W6['/RBQ\$H8'DLM7DOS)!?P??MUAB>4[AT="54%6XRP/! MP:M\KK^_WO=>7]>I*O['W/N9T&K?#.^\%7$E]X7:.#>=\VG2-_H5T>Y7'^J< M_P!Y1CU4U@R_$BS\<_$?PWH\L#_ (F7NE:H-%\01II^I]+>>,?Z+J0ZYCR3AP!RAY'8L.:R]4\)Z;\6?BIJ MUU>6\EO=:!;0V5AJ%J_ESVDKYEE*-[CR<@\$+R"#64?=;]KVW_ N6J7LN^QT M'B/P)%J5XNI:?=3Z3K<0Q'>6^,N.RRK]V1/]EA]"#S7&V'Q5CN_C[9Z3XJLH M+'4=&T]_+O8"1:WC7,BB(*QX5RMO-F-CG@8)KH]%\5W/AC4(]*\33PHTC>7: M:F$*6]V><*_:.7CI]TG[IYVB#X?^$XOB#H^NZC=VMOJ%CX@O)#"" XEM8QY4 M9^C;2X_W\\&E&T4_:?)E2]YI4]^J.UUOPYH_B_2IK*]2.XMY1AHYXPRFO)=. MT[6/ ?Q;O)+5O,*CO, BQ9'WPK+RU;=_/JOP.A>6 MZ^UZIX3B!9Y7R]UI* =6XS+$ .O+KQPPR19^!(74?!G]NC89O$TSZI(ZG)99 M/]4&/JL(C7VVX[4HITX2ENG_ %\ARM.:CLSLM%U>U\4:3%?V#_:K2X&4DCY4 M_P#U_6O,=1^'G_"2_&[5==T:1]'U?0K..Q2X6,&&Z>7]Y(DR?QC:L'.0R]CS M6[XYT6X^'\=_XGT.[33I8$:>^MI&;[+?*H).X#[KXSAU&>F0PXJ']G?QK+K' M@UY+PW5GXAO)GOM4L;K'VBSEE.X1MZA5VJK D$(,$T4XRA!U*;NMB9VG-4ZF M^YL^$?BC)J6H_P!E:K;R:1K<:DFW9LQW"C&7A?C>G(SQD9P0*K6&JWGB;XS7 MDY!^P>';-;6&;?DO3:OCR-.C:Z6=/DF MMB@+;XV'*L,<$5Q7P;\5:S\+M$M]/\7K%]IUR8W8U0(/+EFDQ^YFX 20#:H/ MW6"]CP5&%XN<5KM;_(J4FI*$MN_^9ZT=5FW<2O\ ]]5QPU2?Q1\96VS&6'PY M9;'4,3LN)R#@_P"T(E!^DOO71ZYXU_X1W0[F_N)5BM[2%I9'VCY5 R:P?A#! M?V7AMKZ\)CU/7)GU"Z X96DY5">Y2/8G_ *Q@N6+E\C2IK)1^9V,<=U.I)69 MO<@UQ.J6]SXG^,MC:#R18^'K1KRY#L-PN)%:3GLM2)JT M<,)C2+S$])&S^52)?K=#;$PM'Z$8&T_CUH&2PH\\7^DQ?+V=CM(_&FIIMM*Q MV3&0_P!Q>I^AJG<6%SYGSJ[Y[YW TB:8^X&0I$/5VZ?A2 EDOA8R%4BVX/\ M&,FF_P!JS,^1(V[TQ_2IEU*W@BV2EKL>A& /H>M/6]@>'%KLM9!W9^>(P_\ 37&W/X5&FGQ;-R,;G'54XQ52[@N!\TVXY_B)R#7"_&O]HOP- M^S9H":IXZ\5Z-X7M7;;#]LN )[ENRQ0C,LK?[**QX/%&P'?G57A!6-?)'H!\ MWY]:2#5I=NQCYBD_=8;J^:I?^"A'BOXGS_ KQUXSM&?;%KWB.2/PKI,J MXXE0W :\=.F,6W/;UJQ9Q?M8^-#(CZM\ O $,O"""PU/7KB,?[[R6JD_\!Q1 M?R&?2IL89%S)FT^O.?PZT][6*VBWQH;K_:ZJ/P%?*6H?LQ_M)22--WE2OFC01[X^F6R%=\YA)YV,,FFS,]@N M88>#TD^]_P#JJA]C2&Y_G4MNXU"0#[/N]3'Q_P#6J66_M@@615N9 >65=@ILMW#?1;1*UN/[ MI7"_I0 _[!:)+@SAO]DD\9J2TL; MF+)R85_O,=H% NI3P@C<_N&&?YU-:-]N^_;Q[<[C4VUTL1R%GC)20=<_?5JU/$FCRZSHUS92QR^3=1-" MX(."K @C\B:XS1;:;P1\5[W2WAD2SU^,ZC9[4)C$R[5G7/0$CRW [YD/8UVS M3SVZD?O%'I5SC:7,C&&L;,Y[X0>(KF_\#VL-S-(U_IA:PNQN.5EB.PYY[X## MU# ]Z^3T_9XT/]K#]O3X_P!IXQU'QI<0>'X]!ATR'3_%>IZ9#:+-8,TF([:> M-#N(!.X']:^G],U*Y\%_%NX@,NVQ\41FYA&#E;J(!9 >WSQ["/\ KD_M7D/Q MH_8\L%^+7BWXB0_%KXI^!+CQFMG%JUEX?O;.*"]-O%Y,(0-:R3;RN?N/DDG& M**D&YWCU'3E:'O:6/FP?MJ:S\)_^">/B_P #^)/&TUIKFF_$*\^$>C>)[V[( MG-FMP$-[)-G/F061E)?.=T YW'-0? _4-#_;N_9L\9^"7\5ZOK-G\";O4;?3 M]>L/$U[!?:I8LCRV,CF*1#(#$H1GEWY,+X )+5[5\+OV&?"?@OXT^!M0U#2I MM-T#2+>\E\.Z%=79N5.I3*&GN[MFW&6\DB5R3O91B0_,3NKW+6/V8]#U+XU: M[X[BO=6T_4_$WA?_ (135+:VDC6TN[97=XI60H3YT?F2JK!L;9&!!XQSE M?1LFG/VBML?GWX8^#VA_#O\ X)!>'/%NA6_C<^*/%T_A>U\0K:^)]0-UJGFW M]H72$27(2!YHY>"ABR)!R!T]DT/PIX;^%>C>/?\ A'_A'\ M)?%[ZG;",Q$$E/[4NA&L\9_LUZ7XR^'^E?!'P_K?B2P$VT M&DPQ>(H)HO/M+O26C:((QB,L[JSOK+6+K3I(;@SQ-&96,=FDA=0Q*DO@8'!'%.I3Y)*4NH0GS1Y8 M]#XP^&G[/MI\(O\ @EWX6_: TGQ9XMC^(GAFTTO5S#>^([V[L;MVF@CDM7LY MI7B(GBE(!"@@R(5VX K]0?%^KZ)IO@2YFU>Y$%G/;;9O,(0+O&-OUYQBOB_P MO^P-X9^ _CWP[X1U/Q?\2?B)H%C!:W_AKPMJFJ0?97O+-D1'FBMX(0Z0JMNR MF4LN48D$JN?K?PW\*;[4M236?$1^WZFAS;PHI%KIX/:-3C+>KMR>V!Q3E"S5 M2>B>Q*EIR1WV9S'PA\2ZY\7_ (=Z3N5_#ND6T M+E(SB^NYXLQ2@MUA02(PP M/G('5>171_$'PS;Z5\(=:L-*MHH_+L)3;0IA0TH4LN3ZE@,GJ:JZ-J=M\+_$ MOB6RU:]MK2U\U-3M 6W.Z3?*ZA1DLWG!^ /XU[FI$\+7/Q4/GZ\+BPT+GRM* M4[)+P=FN6!^[_P!,EX_O%L[1I)I5.;:.YG'^'R+61\@> O$NH7OP7T3QIX O@9 M;?%.RU37KCX@Q^.9;"&>ZUFYE75 -=DM! ULS^408$O#VI>'+RYM9=0BTZ&*=%#DJWF!0V6C9#UR=P]:X_XB? 70 M?'.C:KXHL?"6C>&X;61M5^U0:=%!JFK.DGG2,TBKOC63:W?>V_)*]#ZT<7%U M+*Z5_O7\OI_5C]2K\?827-.TY-SY[.VL+O\ V>6O$7\^ON;''?M:?M-:QXW M\5>$#\/5\4Z/>>$]9N[N^FO+:2WM-12UMI)9H H.)P41QMSU9>5.#7FOB#Q- M??$OXD?$O78O$^N26>O:1I=OI6IK'M.T/P_!H]BEEI'V:- T$CJ>T>ZO>\8V;V7,MF?,?QX_:F\6_%G2_ U MQH.LW>EVVBV]WHFM7%O*?)O=8?3KS 9E(!XI?#_Q8U+P'^S1 MX,\)17MY%XHCU*PU6]NH9RM[J.G%K26$/)G<58W21DL=I6WD'M7U'^TCH'A. MVT)/#^@^%]%U+7KS5[:_>4V,7DV$SR)&;J;H=S(#'D9=@V.%RPJ_%;X>^%OA M5\*M0AFL]-O?$WB.UAT:UD:UC62X8,%MHXU"D1Q0NRE% VI@'KR=Z>+IN,(* MG97T_P"#Y:G5_P 1#RBFH0C@_=I.QU6U6/:;>($8F4VZ!A,5^1MK# +;N(\?^!] M=\2>"]=\=2Z]>:OX@TN0Z]XKMH+LQV%O;RPH#I-NV"%E2W(_>@;EVG[OFM7J MOQX\+7=X-'\!V1L]9\1:RD::DTBJ]II5K@K#:K&5.$3&=XMNT9,8D!Y;-=#\3_! M_B_]E_0O#6M:%XAFUW6]6EC\.ZI;ZQ=226MS=7LY\F^"Y.SRKB4_NTP#$VS( MV)CWK7=%TS7--^QW=C:ZA;[XY2MU"LJ%XW5XV"L",JZJP/4%01R*AUG0[/Q$ MD:W]K;WJPSQW,8GC$@CE1@R.,]&5@"#U! (KR?K;DU*:OJ[^:Z?=K_21[N'X MNLJ2KTHRM*7.N56G!_#"W:#<^7:UX_R1M4^'WA9O O@G3M)DU&_U:6RBVR7E M[,TL]S(26=V)S]YB3CH,X& *V-XJ.K=M9K$HDN,JG91]YJX9/6[/CJ]6=:I M*K4=Y2;;]6>5?M0_LW#X\^ GGL62R\2:*?M6E7Q)0I*OS!"PY )';D'!'3GR M#P!X]G\1>._#UU>&;PYXEUN%M,2[EA DN+VV!+078& 7 22-AR&V1.F,KM^L M;N]:\ 082)?NH.E?-?[76A3^"+W^TX!]GTGQ"52>[C7Y]'U2/#6EX#@A0Q41 M.?1EZ]#ZV7UI5%]6E\OZ_&W^9XF/H*#^L1^?]?A&V@$ K@:'Q5\9?VA\,=;T?Q)8P?VU80?;XX< M9M]52!U??'GJ/E7&=:C,.G^-=!U"R,4_E B:"[8 M0"3'7R7\P;QU4QL,Y4&O0/'UUIOQ6^$6N:9?6KVNMZ9$QND#%9;2<*VUXV&# MM/)5OX@2#W%$H\LHI]-/2S_(:?-&?+UU]?\ @FF]W>_ J#RA)/JGA@C+SY,D M^DKUP3UDA'][[RCKE/;WUQH:/97]JX)3RY6(]G1O.Y M4\$#VS6E\,O&UW$MKH'B3RUU0VZO;72KLAU6/;]Y1_#(/XD_$<'CD$M+KX8_ MM :O-HUA+=:+;Z5;375A&@1IE9%[-V#K\PXSN'RGM);#0_B)X+CFD,6H M6MX%EMS&Y5HR,XD##E&';'(->8_!;QK=>%A>0^()7DM=6U>[^P:M)TN2LS1J MLN CLL8*M]U@>H)Q44]8R<%;:Z_K\C6=N>*F].C/0?!GQ%M_%IFM9T>QU>S M&;RPG8>9 3P&']Y"0<..#@]P0.%\ ^$;[P]8:CK?AAP)9-4NWN=-DDVVM^/. M;E>OER7@Y^8'@CLOB+X1M-=TO^T?M#Z;J&F(\MOJ$6!);#JV2>"AQ\RG@ MBN2_9V\82Q>$-,T778&T[7+F%KY5?_5WBRMYI:,^JF3#*>5([C#%P2]E*4.Z MNA3_ (D8S[;G=^#_ !_8>-[>81>9#V1@@]""""1S7G MOP[\'ZAX;TO4M9\-.HDFUC49+C396Q;7R_;)L,O_ #SDQC# 8(Z@\$==\2/! M\-S;2:U:3G3-7TZ!GCO%Z,J_,8Y%_C0XZ'IU!!YK"_9Q\:F\\ Z7I6J02:9K MRVJW4]O*,>>'^?S(S_$N6Y[@\$"E!6IN5/;2Z'+6JH3^3.S\'^/['QC:3& 2 M075LWE7=G,NR>U?&<,O;(P0>A!!!(K/^%TH%GJQ3[K:M=8_[^$']RN!IFM649\N\5-\9QT[=00:YG]F3QPVK>![>VU6!]-UZ[\W M5)K63HPN)7FW1D_>0&3'J,8(!J?9KV4IP\M"N>U6,)^>IZB&X;Z5R_PV(34_ M$H7A/[5F11+,#L)9O)W[_\ CV7!91GS%_O5N)\.O$GC"[;^SK*UGN][+WN;S3=1:VGOUN;?6OV>NJBJ*%!+;[OZ;/S/#NG*G*K7;W2]6O^ C)N/B%=^!-; MMK73[#2O%-N;*WM=/NV2+64E+W;%FG5V=W&_Y5 ;Y<$C&[ G\ >!].\8:[9^ M&?/\7:;XCEFDFEM]0NF@TV6#SRY-M!LQO81D*&*KG/=<'LO@!I,'PC\!>%=> M\4>%/#ZZDEKJ8MY-:,L>L2W-JYN+?[-;C]U,!(RG>2I;<>>F?--?\>Z/\8+J M:VU&\OM%.LWLOE7-HT]P)GE6.128VP:_+Y(2W64(419[&42K<1 MOY1 V,%:[DVG"CR[9V'45B>$/AW]N\0:IJW]H/IVF:;F>>YF=H8X99BT1BE< MMAP X49;2REFN?+> M66:!I-HX+\-SYGE,!R:R/$Z^/OB \^EWEC'X;M1.@DU0!]/A6:)41)YV9@A$ M@:8!5!PS'KBII1G[RA4C;:_5+S7]:FE:I!N+G2E?>UM&_)_UH;%M\.KKX8_$ M*XMP9Y]2LE$5E!/&9)+Q"RRJ6< G!%7=)\@8CC%7/ MBEH8\*MX1\:Z#X5*+@"0XX-;WA/QY=?$CX9?V)K$NCR>)-"TM9H M9/M?GW^K^:CRO;.TBLC.D2JP^;@1D%[BQL8;)7MI@UQ)G:_F*J@8Y 7IC'>OV>A M_P!6*_%S]L72;CQ-^W[\"=4A_LZUM(-$\+G:9HTG17N)2%$;$.1P>BGWK]I( MO]6*_-.*K?5L'9_8?RU/L^'=<5BW_>7Y#J***^,/J@HHHH **** "BB@G H M**\IO_VX_A%INO2:;+\0_"_VN'?Y@2]61(]AP^YURHVGKD\=Z]*T#Q!8^*M% MM=2TR\M=1T^^B6:VNK:5989XV&59'4D,".A!K2=&I!7G%KY'?B\JQN$C&>*H MR@I;.46D_2ZU+E%<5KG[1W@+PS;ZW-J'C#P[9P^&KB*TU66:^C6/3II/N1RL M3A'/]TG-;7@3XD^'OBCHQU'PUKNC^(+ /Y9N=-O([J)6P"5+(2 <$<=>:3IS M2YFG8BIEV+ITO;5*4E#NXM+5)K6UM4T_1IFW17)?%#XY^$_@M)I0\4ZW:Z(N MM3M;VDER&$3NJ%VW/C:@"@DLY ]ZZJVN8[RW26)TEBD4.CHVY7!Y!!'44G"2 M2DUHS*IA:].E&M.#4)7Y6T[.VCL]G9Z.P^BL36/B/H/A_P 7Z7X?O=7T^VUS M6Q(UA8/,HN+I4&YV1.I"@-9_#<>K:>VOVMLM[+IPG7[2D#': M)3'G=L)XSC&:.26]A_5:_+SO MB[]C'7/"WQ6^-WAFPU'XC^#?%;:BDSS>&O\ A3Z:49F%O(^S[64PGED;L_Q; M-O\ %7W5\= [?!SQ*(SXF#_V=-@^',?VL#L/_'KGCSO[N>^*^*OV?_$?B+0_ MVR?AI81:E^TQ'I>JS7\=_;_$5XHM.N56PG=!%M(\R4.H.S!X!;C8:]S+K/#5 M$M]7T[>:?X6/V3@&49<.X^G#W:B522E[E[1I-V]ZE-K;1PE3E=_$M&OOO3M. M@TBPAM;6"*VMK9!%##$@1(D P%51P !P *E/2EI",BO#/QIMMW9\2^+?$?B2 MP\.:?\/-;UK6=#\9R^*(-0UCQ/-XWM[.TGMEFS,846Y%PD5O-?U(K,9&@N0 4#2\QRN9&WJ7' MEC.![9^Q?X>L/"GPVUK3K#4K"]%IXCU".XM]/LY+2QTF?S?WEI;QR5P_R_?Q][CUXK?KG_BOI.J:]\,/$5CH<[6VLWFFW$%C, MLIB,4[1L(V#CE<,0%[6NM]M^OEW.3'\SPM11O?E?P_%M]GS[>9I M>&&O&\-:>=0_X_S;1FYR!_K=HW]./O9Z<5>JAX6M;FQ\,Z=#>N9+R&UB2=RV M[?($ 8Y[\YYJ_6=7XW;OTV-J%_91O?9;[_/S/"/^"F8N3^PC\3Q:1M+<-H4R MHBIO)SCM@]LU^/'PRTF/0_\ @GQING7VDWOGW7Q"F3RKB.*-,C3E,K&1T)C1 M5#%F )P"!@]/V#_X*?7QTW]@GXH3CS04T.7!C W#) R,U^.OA*XO_&G_ 3> MBCNKZ[U>>]\>RK+F>:669/[/0E&"(9&''*JW(!Y7M^D\')O+Y7V]K'\CX3BA MVS"+6_LW^91^)7P\OKWXB6FDZ6E_=Z;XETZ.'39H;I+?3A'=H!"Z"56!!D+J MY)W N<8RM>D^,=1T7]F/4].:0^#M1UZQT6TBC:\T3SLZ\-C)=/>1A5*>4\BK M(" 2">=IKB/"ME=>._ M]I=UJEMIFI^ )5\0Z9?O"K/IT%O&A-H4_>,D6P;E M,C#XL%VQ.&( M87"JJ2G4H1]^6L;]+?$DNZ?X:EG MP_\ #76_CE\2#:P75U=:C!/ OAV&UUSR?&=_?HD>I%H_L]K;Q!R74&+;R&:=_.(&-T9R*K_ TT M/3/A]\'_ +7I+Q:KJ'C\"_N?$$,3*L: MI@!O[4NOAW=Z9.I^T2)>V\ M=U&-+3*SVNGI+)]H^P7B3- LM MM]H+/"WE[&!X0BWD..,K]3^*_CUX-_8_^$":1XOU>&QENKD7\>B161N;VY&X M!OW>X?NSM4;F/7/S'M\HV'[>WP=\.ZSX@6Q^"4FJV&H0")?M=Y&AM80F&V*$ M;R]S.[$EB*5.^KC9OE\E9. MR\F/UWQWXG^)&L7^C^"-'O8M6U.RGB>*W\VXO=0>"]\PJ9Y"3L,3AAY3 ;93 MZ5Z5)^SA\/?AKKMS9:C87.N:KJ+.-;U.YU)IKR*6=\/ I0@*(]LJEB!O('. M15O]C/\ ;[^$&BRV6F:>MQX U21OW\^IPK-:WT_V1YER3D,0=ORIO"X$FYJY\1BL1#$ M?59PE1C^,OGV7J=6%PN&GAOK<:JK2ZIK2*].[[V/G[XH_LK'P]X,OO$.CZE- MKOA..6,7:?8O*NK2V6::=VE@&U,?(BAWR&R"%Y !\/OBY)8:!?>&M&;407WA'PH?LVKW' MFNMUH]A-NNY#((WXE;SGM\@9.P=VKU:&(5>$J.*=^573M;;\+[>MSQ\5A7AY MQK81)F6D.FKIC06!M/* FG;R M-AECP &49RPF/7BM+0K"T\!_&GX:_;40ZA/J&E-=NL$4TVGM.RR6J3HRY#F$ MHI>(J-RMD$X-87PS\1:/\5=0D\2H\=OI?PXE;5'T6>(I!?S.(XK9TW!VBB"Q MD%6^6,1K@Y=BE7X.Q:A>_M"^"/$.I2SW]Q?ZI:037S2&-98S/NBBW+YL$BJ" MH0 H0J #IQLHU/9.E5?P)WZ-NVB^ZQRU)4_:>VHK2;5NRUU?S=TKG[92^)7T MWQ%I.G2;$M-32[:W;H3-'.Q9?Q1LC_<;TK;)RN*Y;XJ:9<3?#ZUU.UM_-U/0 M+R>_MXP^3+ME??&">A>,NOL6'I6Q8^*;*]\-QZN+B+^SY(/M"SEL((\9W9], M5^-RC=Y^ETY6?++R.7^(5U;^#/B'H&OW,OV>TFCETJYD8XC3?B2-G/08: M,J">\F.IJO;VUQ\<)$FNDEM/"BG,5NZE)-6QC#R#J(3V3@OC)^4X.5XM\'WG M[1NG3-<22:?X?11+I<1!#7DRX:*ZE'!V*P!1,\X#'!P!VO@CQC'KG@B#4KG; M9M#$PO%D.U;>6/*R@D\85E;GT%=#]R":^):>G8RC[TW%_#^?6^>P ;RF/\ USJ.&"?XUNDEVLEMX2^]# PP^KCG MYI!U6'IA>K=\#Y31U'PNW[14$RZK$\7@_:1!9R(4?4SCB64=HQU1,/;?P#X)O+#6KMGNO#<@LF=AF:[4_ZA@HY M+2+@# Y8,!TI;0M'62_"X-WJ7EI%D?Q^\26_PYTS1?$DC[$T>_5)(D4-+%+GQ!J\'B+Q B&[10;*P+!XM,!SR#T:4@X+CZ#CKGZ M9\.Y/'\,^I^*;;_2;N![>VLO,+)I\+C! [>:P/S..G0' YH:%\6I['PI%H< M34O&%I*^F-;;ONO'M_?S$ [(S&T4A./^6B@9' M\5?&;^%OC%X;L])\F?5-8MY[!E;E;7=MD267'11Y4F.06/ [X[GP1X=M/AGI M]W>U=QX0A*O)E=IU24=8O^N:-PP_B M8%>@.5**E35OA6[[_P!=/0'M)GEM9#<2VVH7D:D_98Y+ M>1_+5N )66$XQDH.2!E:O>,O%-[X ^+4-AHL41U#Q1IRI9+M_=QR0N0\D@'\ M*QR ^K;0OIB/XMV=I\)?AQH=U8!KK6XM<@=//<(VHW4Y:%F9O4B1L^@'' K5 M2_>*7?;Y]68-?NW'MN_3H<#^U_X/3QA%X$\$^'4U"W'A_7K76+EM,D1)HH88 MIC]G5W=0'G7>I);(4L?3/S/^PG\;_#E[X[\"0ZYHVKVUC837$5E=1)&]GI\5 MWJ$K6UQ<;FRJ275T($9H1KJVK2WFH:S>N^ MV2*!+=VN9U'WMJ(0B@?=#)7A?_!&_P#9OLO%_P"QEX@U'Q5:0:AI_P 0]NF0 MQDE6_LVTB^S(N<[E83BY=6!!&]2#GFJE.-*ES1>K37XZOYVL*,)5:O++9._X M:+]3[UUHIX>MY)KJ2.&WA0R/,[!8T4#)8MTP!7@'C'P-_P -M:'JMW>27]IX M&ALY8O#J0SO;2ZA><[=5R,,HB95-L0>NZ7!S$5Z73OV9+[5GMM.\9>//$GC? MPC8.&MM#OXX(H[C P!=R1(K72KV1_E8\N)" 1Z[=Z5&VG2?8ON1Q'$6,% !T M ':O(OW/722.0_9I^)\_Q,_9_P#!/B64-YOB'0;*_F1^SRP([ _B37;FVBO1 MF#"/WC8]?I7D?[$=N]K^QU\+5E4+(?"FFNP#;@";6,]?QKKOBM\4]'^#O@JY MU[6YS#:6S)%&D:[YKN:1@D4$2#EY9'9451R68"G;2X&?\;/BI+\*]-LK6PTQ M]:\4Z[<&RT?2EE\K[3-M+,\CX/E01J"TDFT[1@!6=D1J?P*^"S?"W2[R_P!4 MOAKGC+Q#(MUKVKLFW[9*!A8XUR?+MX@=D<8/RJ,DLS,S4_@7X#U6\\37?C_Q MY;0OXNUF#[+:60<2)X9T_=N6SB?D>8Q"O/(O^LD"C)2*(+ZK]BCNC_H\@)_N M/P?_ *]._<&073KJ>ERV5Y%'=VDR-')%(,AE(P17R4GA&_\ @0GC;3(XI+C0 MM)U*VU80L"Q>W>598KD'))*2QR1R^J@-P!S]9SQM 2K@J1V(KP+]M:&7PI9: M7XG@YMQ;WFB:G&02LMK<0ELD=,I)$K#/HP'WJ]'+9RY_91VE^:/.S&*Y/:_R M_J;7Q!TN7X/-H\2L3X/U#5[-H&^4+I+F5?DR?^6+=L\J6P,*1MV_BGHTW@#3 M]5\5Z(ZQ"&UFGU2QW;8KY A.\=DF 7AOXAPV?E(Y/1=7>STKPKX)U QWVFWT MT%WI)E_>+=60C+O&V>"T>#6[N&VTB]#;B\) MD!E@?.(&^'_ ,:Y8-6G>]\,Z18"V@U GY], MDG<-Y4[$_,-L:8,?!\O@74+GQ3X?9)?D#:K8 A/MT2C[Z@\" M9%'']X J>Q6E\"[6W\6_#VXU]H4FC\932:A*2NX31/\ )$K#V@6-2.VT@USI MQY95-T_S?_ -W%N48/1K\4CK?'.AZ)KGA"];47AEL(8C<2&8[/+"#<'#9X(Q MD,""..:\T^"JZS\)?#5E'XG6ZGM?$,S7T.J2Y:2%YCO2WNO[K*I5%8_*=@!P M<9R?B(;GX;:SI'A&29I/">O7(?SI-S'2K>)E9XG;_GD[&.-6)^7S"#D8KVB] MM+?5M(DM9HTFM)H_+DC< HZD8(([BAWITU%N\9?U]Y2_>3YMI1.6^.LXO/ L MND"&&>Z\0NNF6T4R@@-)PS[3][RTW.1W"&LK0#XY M:;2@,*%E/):+I\_5<'<2.1A>$/$EQX?^*8-[)<7?@W0BVEZ5?70#BVNFVA][ M')*#/DK(>0VY#_>;V74-6LUT^:2\AMS:B-FE+<+M YSVQBE.]-*DU=/7^O,< M$JC=1:-:'&?$[Q(?%$NE>%;:Y60^("9;@!^EC'M,K#V;&H(KBQE8R7VC! %D]9(.@23H2OW6P> QW5Q7PO5/AW=ZCXQFM'_X1 M77F46T*R-(^C6:EO+=<](GW&1D _=[QC(''KNN>*M%T#PQ<:K+.ZV,$#3-*& M5@R8R-N.N>WKFE57):$5=?F^H0]^\I:,XS7_ !]I_P :;W1-'TX12VLKC4=3 MV?))!%$P*PR(?F1GEP"K '$<@[''0^-/!-OXEDAOK-(].UVQ!%I>QYRHZF-Q MD;XVXRI^HP0".+\/_#^]\,PS>,=.65?$.LR_:]6TM@HCN8< )"#VEC4<-_$2 MP/!&WM'^)^@_$)+KZW-R]O$I5HO)_?+*#M\DIG(DW?+M/.>*4X\K2H[?J$' MH_:[_H<7=>/3\3_&]AX+U/2X;"_TLIJ>L0.7,5S%&V83"V<,C2JK>P0JW)KU M'5;33];TV:SNM/MKBVG4H\$O%=AX-OR+SPF9XKJ M>]E_>'3XLGRK6X;.2CNN%<_PH5O)[USEYXWM_VZGY;#,5LK<(P])7&WIRJR>E=?&7=0H9B%& H.:YWX7V$^FZ?/J>H6T":Q MK4GVFZ&W=Y(QA(0QZJBX'UW'^*NJ_M:8KPVT>BC%8U-+0CT.B";O/N-CT^>4 MX"-^/%/.DM'_ *R6W0?[^3^E02732]68_5LT):S3'"J[?05E=FJ)2EI"<-)) M)_NC'\Z5+^*'_5P*3ZN2?_K4TZ6P^^8H_P#??!I5CM8!\\S,?1%_K2T&.&MW M2GA\ ?PC@?E3T,=^_P R&-^F8QD$_2HS?6\9^2#/_71LT2ZQ+*FU6$:^B#;1 M9@BP_AJ53G*%<9SGI^'6L3QMXQ\/?"_PS?:YXAU6TTS2-+B,]W>71H?@Q;I\,OAI,<-X\UW3FEU+6$_O M:98RX"IC.+BX&TY!6-@,UU/P,_9"^%/P:\5Z=XAL]'U3Q]XWU>ZGM+WQUJUR M-9U-98UD$C37$AQ"H,1AV0JJAL+L'./7K^,06MW?ZYJ=OX2TGPY?/=))'J$? MD7=E'#R]R[H%B3+.2H/'E(=^"5KAOBK^TUH7P&^%_AGQII.A_;/A_JVIHNI: MC:6TIDLH;K>(KN*W2,O/YMT\*G:N2+CS!N Y6@CT-/#^LW=C:7MU>V6G16-Y M--&AX$\3>&=2NK?Q8GBFRT75I- M4N9+35S?FPN%/G>5F)CA4R,0G@# VFO /%7CGQ!^UE\$?C=\-_%&BZK_ ,)! M'9OXC$V.MZ?#%)>V,A:?3]\4;,C&&\MVC9&^?8L)D :0BO0/V*O&^M^(O!K M:9J&E>.)[2XL4T\/Z=I\FT!K6WM@$N75U^3A^0"]1EOX7?'7X. M?M!:AJ.@Z/X]U2>P\+1:!XFL_$'B*\U)-,F%O&6N-+,QD\L M--&(VA41HT90C:8]KLTS]CSQYX<^.GASXL76K+K^NW/B::[UW1X%@$%CIT]K M+:1P0W!1)7CMT-O(4;AWCD955GQ2 ^@Y/"$[ZU/)I7B.1;A=+%M!IMR4F@B? M?M&?%;XE>)K2#0- N]6FA\->' M=9U"">UUOPK9VL?-]8RQG)+7,UU(L>8Q( A9\':.V^*'[<.L>%/VC5\!>%O^ M$8U,:1;0P:BNMWLEA_:VIS[9$TZTN=I@%VMM^_,39+B:$#:-S*]1'.Z-^SCX MV_9LT:R\2?LU>+)+_P (W5NMVOP_\8337.ES6[!75=/G?_2-/J?LV_MU^'?VD=2OO#=_I^H>#_B'H"_\ $X\)ZV@M]2L^2IEBQ\MQ;DCY M9XMR,"O0G%>AV^@2>,M-&N6^G'P_XFN=*:V@>] E%@S@.%FCCE\N38X&0C\X M8*^&S7FW[0O[+'AC]J>X6RNKK5_#OQ \$)#>Z'XQTVU-I/IUS(K\VTYR)8LJ M1+ Q9""H<'*FEHAGL\%I!>/MB=T8_P +KG]14Z^')ER6=0%Y.WYB?PKYS_9H M_:K\36/Q$E^#OQ?MM/T'XI:?"\^FWUH/+T_QU8H.;VS)Z2 ?ZZWR6C()&4/' MOBRLC9WMGUSS57N(MB_^Q']S$=X_CDZC\.U,.LW+L=[;P>H< BC^UY#& V)! MZ,,TANH)1\T&WWC;^E-+NA"K"R_0XJM0:T.9^*>@WNL>'DN=-)75](F6^LIVD[/;7D0D4,.4SU5@>C*<@@\@@@]*TAJTJKRV_V M;!KS;6/'EO\ KQ9=/>Q^9H7B-S):HD>YH[X_>A11C_6XW ?W]W/S 5K"+G' MD2N^ASS:@^=[&G\?]2?_ (03SH@&U>RGCNM*CC $D]RARD8P.C\JW;:S9XJI M\)VD^(5M:^+-=AMI-0E!$%DH/E:-@E6C'K+P5=_4$# ZZW@70Y[J_.N^(+=) M-4F!^SV\;DQZ=$?^6:GH6/\ $_?..@%?+UVM]X]_:7^+,%WXX\3^ = \/:U# MIFB_V/J*VL.FWK:9:79O+J(KMN%F:9\++F(?9R-N9":T4DH>RCOW_0SY6Y>T MEMV_4^K?B?I:^(_"DGV=+>&_L76\LY"#A)8R'4'G@'&UO]EC7'^&/B'+^TCH MMO<:5"^E>&'.+JX!*7%^ZMM>&/NL892K..6YVD#YJ\ \%RZC^WO\;/%^D77Q M'\1:7X&\!V&F06)\-7 TX>)IKFT$SZFY&2]LSLRI&2T3>2<[NJ: MA^T;!IFOZW)_D^7TN]5OX%FD,BCRM*4CDS\Y# Y'E_>)!& 2/@KP]^V= M\3=.\8>&]7T[Q'JFNZ-H^A:YJ'BZS:(79M]/_P"$AO;=+Y4!W-+;V\<+(@Y> M-' !X-/T875C^SIH_BK3/B)XYMQXR\?G3+*_TS77MXKV.7Q:UG(&$> [/9$L MKGD;3@X *?*XWDKM:K_ ((JB:E[CLGHS[D\2>!I_"/AS^WK.6XO_$NG3KJ, MUV5#7%Z%!$D*C'RJT;.JHORJ2"!D9KI/$/Q:M;#PQ97R22ZC)JR*;&UMVW2W MA89 4>F.2QX Y)%?%_Q*UO6?#/[77B_P):3_ !X\96.B>'=%;1[70O%L5JZW M%PU^TSW4DUQ$S!O+C'F .$5.<< ^9^,?'U]^S[\>_BG:Z_=?&&^/AC1--O-, MG\/ZW!#;>'XY8"TWGB6?YHTE=&>39*H7+.,=7=2AS36VWFO\D/EY9\L'O^?_ M 3[;\4^#+W1?%NB^/\ 7Y+>XN[&;[+-:HF^#3[28[,1_P"VKE&:4\[0X 4' MCT_Q1XHMO#&C?;+LOM)"1QQKODF<_=1%'+,?05\0?M$>.?B _AF*?Q-XB\1: M];Z1X-TZ'4Y/ASJUH)M+UJ2W=Y[BYT]VC^VP3!HW1NH;WQE/#+JNK>$M"TO6U4-'HUCJ%K<3/=6Z2@HDUTD,40=E.V2< 9V\M MRYX*<^GY>0E!0FX0Z_UJ?8?AWP-?WGQR2]\4VS6MOK]O]LT[3_,W6UG/!M4M M+V:X:-HRO8")]OW23Z+\0?$6B^$?#KKJ32W#WN;2"TMUS)=R,"!&@ZD^O8#) M. ,U^?G[8WQ5U3X+^'O&?@_PUXW^+6G^)K6&SU#PZ?$,/VJ5[A-2@M)Y[*\D M6-) MOUO+,0W%J3T6:WE65),\K, 2-I 4JG,E4EL@C3Y6Z<=V?=/[.VB7>K>';+5- M>VOJFD;].AL_O1Z9Y1:,XR3ND8 9D/4$;< \TOBIXJU0_M$>'+'09(VN+O3+ MNTU"612T=D6:*2%CZMMBN,)GG.3P*^0_C1X@\6? _P &>--+TH?&3P?K/BIM M$EMK[7_$UK>RVRS:I:VUS,H@NIO+8H456)!;>P'"$UZI>6]S^R#^U#X>\)OX MRUSQ)X3NM&F\7:G)K$ZW=WIDT%U!:M(;@J',%]0TN'P]?:C;1ZGXIU_5XDBCY$5JL2O/'&IZB))(HV=NIP3_= ^3/ MBO\ MKZ_JO[54GBZX@UNR\!:7XEL_!8M;G2[@V%A&72634VNO+\A)Q>>7:,I M<%?G4CCGR?XS_M1?$Y--GO-5\5:E]J\?^*;[3OASK:SXDT^#^WEM;FQ9?Z22*VT=D50.#7NMU>R7>-QZ= . /PK\]]&N_%/PC_ &1O MBC\2]+\?^+TUKX8>(-7M-+TJXO\ S])N[>QN3%#9-;."NV11Y8*8<%@0 /QK\^X? MC5XR\3_!ZP:TU7XEW&EZE\58?#UGI U:W@\6VEM'I\YN;*YG\U$1_M,9=5DE M+>7M)IZYK'BCP]HW@+P9#J7Q0\$0?$'Q;+IU_?>)-:MM1U2&WBL)KCR M;::.:=(C.T012&#KB0J Q5JY^9LWU/K96ATYODQ/*#]X_=7Z"H)YVGJ^ )];\,Z7XC^)H.E>,O!T*6_BN'-U%:7NN):3^3=EC)<6\ZQ2C$F M67YOF(<*M*W^(/BOPM\7[3Q!XE\3^-XM%U[QF^DZ=XAT?4K?5?"=Y93W;V]M M82VB.KV<^YHX?.$;%9ERTI!*T>H['VNF=I'H:-;7/B.>:&.: M>RNGF*P/#?B3QEHO[$_BGQQ,WQQT[6[?X9W>K6^JZ_P"*+6\T MY[HZ?YBR0PQ7*<:DHR4H[H4X*47%[,[CP;JW]L?!+4_#U MDD]EXE^%]R39EWRU];>8KF$L>-H93"<\JT*,>HSZ7\;;V+Q9\$-2\;: YM=7 MT_3Y]R/D>3G\_/B%??$+P/\8O'R>&Y_'OAA+3X<7_ M (IU"S\::I!=7.IOY'EM-9212S;BA$3$B0;6"AUY6NL^*^H^,OA7^Q1XG\+3H3C&49^GYV9^A&FZ=I7QH\ 6T.R>&6W(4 ?)=:;+]/US:?$%E-#9PRF+;#>PQQ*?-0X )!D.] 3L;V(KP/ MQ-K.O_L4?$WX=:EX9\1>)?&D?Q'TV^_M[2]=OS=^4UM8&Y2_CE*F5 C*L;_> M!64 +N"U[S\.O!4OQ ^".BW=Z\=CK]^O]LBYM7+BTNIF,I*,0"R9?;@@;EX( M[5Q0DG"3?PO3T>YVRBU.*7Q+7UZ$OQ8W!_NRR;"O_7.0=4-:VMZ9([E-)T^]F<>9:I*"+'Q/X=BL9E8)"%:WEB?;);NH^5T8=&'K_2N5M_[/^-7CV:;_ $74/#VB MVOV=6&)([B>=0SYZ@A82F/\ KJWH*MZ+JMS\,M MV+4X.6GSCA)!"LF5SR>5ZX'H/C'X?VOB[3H49I+6[LSYEG=P';+:N!PRGN/5 M3E6'!!'%69".59"JH#ZJU:7A+QC M?Z3X@.@:]G[2 6L+X#$>I1#GGL)5_B4=0-PX) F=].31K?\ K] A_?V>QS?C M'Q_J4?AZ;PGJA73_ !)JSKI]A,'NJ[F9#TQW!!KLO$WPXL/$6 MA6MN-UI/IX#6%U"<363@8#(3GMP01@C(((-R @UN>!O%U]#J)T+Q#M35H4+0W"+LBU.,<>8@ MR<,.-R=NV00:)_"G#1K5H<-9-3U3V,/7?BY>>%/#U_I>L+#;>)4MF_L]AQ;Z MHS?)&8L\;B[*&CR6&1U!4GN/!/AY?"OA+3=-3I96R0Y)R6*J 23ZD\UQ/Q'\ M-6GQ?^(%AH3';:F>#6UX2\=SP:^?#NMXB MU>-"]M*%VQZG$,9D3T9O\)(/0BB<4X>[ONRJ3M-N6VR.DU[5XM T>ZO9V M"06D+S2,3P%4$D_D*^5OV]S_ ,(O_P $[?$T^I0W)EO+>PNI[>*V6:5YY]5B M3'(.W.1TKZ ^*LK^([G2O#,:>8-6G$UZP?:8K2(AG..X=@D>/20G ML:\E_P""IC,G[%OC18I#$_V2P".DOER*3J4(&#M8CV(!..A>&?"VMZ7:375L;B22YBTVZ1(EN+=Q]IAFD*E M6;:UMA5"I^Y?"]*[RV\"Z'^S5\+_ H?%S:+?RS27-YK4$^DIJTEUIA8-#!Y MT* +B412,."I=>0.*X/X/>%V\06C_#O4_*M-)\3VAMK**:(^9I%T93(;J))" MTSLS861ML8VJO*[0*K:'/;_&VV\2>&X;9]=\:^';/S=-E8R&+6;J,1PW2IL* MJL;Q*R[2 79$;AB5K]6K0E+]U*7NQ=VUNXO9_*^I\'AYQBO;1C>4E:*?22W7 MG=)6V[$'B34?$/QZ^(5GB\C=,NC>6IED^;)8S 2-&C$@83C[ MV*OW'AN/49K1V9?A(**Q5>*E.7?5+U7#5K6T&HQW7B"SM M+W[5;Z1%!',/-\LDYCEV2 B0G;C'7%IZ'X>TV>+PCIMTHC@.KV\H8 MV-^L\4KB1K9_DWH9XI7,0 7S%!(%?6?A?QIX?_9B^&FJZQKOB#3_ _I.K6[ M6ENYA\V2[14E\M+=5=M[*6GS/XH_P""B7P?M?C.=?TKX57OB21C M<$B[:*VCN)Y JM.(-LA!\M%7!;&.P(KCP%?$XIS@L.ZL5M+OY-Z+\3NS'#8; M".G)8A4F]X[VOU2L[?<9<_Q4\3:QJNDQ6^E):>*)9(K-]1)^V36[7<,T4<4, M9/D(O[I$(0*5: @XW5V'A#]FW0/!WAS2=>^(>FWNI?$:ZLXA+I^I:BTIT81( MH&(PV]II(G\WG=L(SQVK?LT_M^?!KPOXREF?PKJ'@6\O+O"7P1=1BMX#,LWD M@KM9%W;SDJQ_>&O;_C_HND?$TS^,!>:3K>EZ]$)K>]MRHM[EECV@Q,2>%B3Y MB4D*@2$@ <3C:^(P]98>5%THOKU;[7[>1>!PF'Q-!U_;*M-?9Z)?S-=_,\)\ M>?LKVVKV=QK/P^OUO/*M+QVT25=ERCR(8L1R+AYT#2SN-S\*PZ\UQGP5^*EE M\.)Q9Z_]AO\ P!J!CT_4++59!>)#;QDB%HK&+[DKRI))E@257J M$]7LM4L_._=R>6(PA;SC&H)23:1D DQN!]T13, VT>:?M"? \ZE\2;-?!-E M:'4/$T@U^/PS(KH8N?*,@ 908DV[E1Q_STQ\JMGT,+B%53PN*=XVNF^EO/NM MTSR\;AO96Q6$7+).S71W[>3V:-;XJ?"I]1^$WASQQI/]EW]WIJW46OQZ?:Q: M.]]>W!$<&;?PO\$M-U75;>]NK^9YYDBE*37_ M -E@*K/,%9"DT0E:4X*ABK,=V.FM+IGAWXB?%&?X4Z)J)TW3K&7%Q>,LLHU* MWMMUS/$B/N+2M*I;< -^<=% ;"^*NL7?Q&\0RZS% B6.EW4ATZ"Q)$6C1%%# MQK-$&4(0NYUEB3EFSC=75AE47+2D]FWM9\K^%?/7[CAQ4X>]5IKIR[W7,K&5>5852*2,SR,&( ./ISBOVT@/[L? M2OQ._:N\6W6F?MY?L\VL6JW":7?:#X6:>QAN"4D99Y"K,JJ$(YXP,>PZ5^U] MM_JU^E?G_%M_J^#_ ,#_ #/JN&O]YQ?^)?D2T445\4?6A1110 4444 %0ZC9 M)J=A/;R;@D\;1L58J<$8.".14U% TVG='@/AG]C?6]*B\%:?>^,M/N]#^'#- M+H,,.@+;W3N+>2WB-U*)BLH5)#D1QQ;R/F/6O3_@7\)H_@G\-K3P^E]+J;PR MSW,]T\20^=--,\TA6-/EC7>[;47A1@5U]%;U<34J*TWIZ+S_ ,V>UF/$6/QU M/V6)FG&][*,8ZWD[^ZEUG)^=]>A\_P"M_L7ZO?\ AW6O"-KXRMK;P!XAU>;5 M[VR;10^J*9KDW,T,=YYP54,A;#-"SJ#@-P"/2/A'\$+3X1>)_&VH6=QYB>,M M735FMQ"(TM&6U@M]BX/(/D[L\7^2*Q?$N8XFC*A6J> M[+=*,5=MQ;;LE=MPC>3U=M]SQ+X[?L?W_P :_BQH/B5/B5XPT"#1)99$TZS@ MLI(8O,MF@;RC+ Q4L&);?Y@() "Y!&S^S=^RQ!^S4^JI8^,/&&O66JN)18:K M+:FTL7Y+-!'#!$(]W<#Y2><9YKU2BAXJJZ?LF]/1#J\39C4P*RZ4U[))1MRP M6B;DM5&[U;=V[ZL\N^*'P*U[7_B:WBWPIXIM?#NK76CC0[P7FDC48G@61Y$> M,>;&8Y5:1\$EE.1N0X%97P:_9(G^%_B[0]2U/QMKOBR+PII\^FZ+%?P0)):Q MS&/>9944/,V(U4%N .Q/->S44?6:BCR7T]%^>XH\29A'#?5%)F>'X-0M[C39[82QWZW<21G+ M9&W;LR.#U[8S7.:7^RGK4&M^&[;4/'=WK'A3PCJB:KIEG=Z>KZDC1JPBADO= M^7B3=_SS$C -(PSGVNBB.*JQCRIZ+^OU%0XDS&C0CAH5/#4\>>'WT^34-7TQ7=7\_3;Q[6<8._8 MF\/^*-0TJZU'Q-\0KV?1+M;ZQ>7Q'<,;:900'4YX."0?4$@\&O9**BG7J0^! MV.; YUCL''EPM5PWV\]']Z.1^/&@CQ+\&/$FGMJEGHJ7>GRQ/?WDLD<-JI7! M=WCDB=0!GYED4CKFOB7X8^&='_9Z^(.G>+9?^%<^.]5T)I#87%K\6+EKB#S( MVB=H[:^9H=QC=EYF&-W6ON'XT6TEY\)O$44/AJT\8ROI\RIH=T\:0ZLVPX@= MI 4"OT)8$-VN92>."ZKQTYQ7M90E*E-3E:/572O^*_.Q^O>%E&E6RW&0QF(5.C]J//&+ MG=6LDZM*3NM'S24+:7OH?JUX(\3#QIX-TK5Q;M:#5+2*[$#2QRF'>@;:7C9D M;&<91F4]02.:TR<"L3X96"Z5\.-!M4T5?#B6^GP1+I*NKC3 (U'V<,ORD)]W M(X.WBMRO"G;F=C\5Q2@J\U#:[MUTOWN_S?JSX^^)/Q,^'WCFVTKQ#<_!KQ%- M8:_?_8/#/B/1GM+34-1N2S>5Y3I/'/"LFQF5G91A?F"\9]5_8/T73]"^$>KQ M6=QXFFO'\17\NJ1^(%@&H6MXS@R1R& F)^JD,A(8,#[5JZG^Q%\,M;NI'O/# MC74!FDN8;.74;IK*RF=MS36]N9/*@D+$G?$JMDGGDUW?P\^&VA_"?PQ%HWA[ M3H-+TZ)WE$,63N=V+.[$DEF9B26)))/)KT,1BJ4J/LZ=_G_P[_0^ZSSB3+J^ M5_4,#[3XD[2U22O;>I/777E44WKHDHFY1117FGY\%%%% !1110 4444 %%%% M !1110 5SGQA\/R>+/A/XETN&\AT^74=+N;9+J9]D=L7B90['L!G)/M71US/ MQHT>S\0_"'Q18:C?KI5A>:5<7,$-G%'',!@2J$ #?B.?QK2K*KK4EZF^'5J45Y+SZ M=^IX5_P4OO\ ^R_V%/B;/Y$=UY>B2GR9%#*_3J#U%?CIX9UV34_^"<"7#6.F MC=\09Y#'911#[U@K!64LJG&0HW!P!QM(K]B_^"E]Y!8?L)_$V6Z,@MUT2;S/ M+8!L' X)XS7X^Z(-,NO^"=-L=%M-6L+.'Q_)-&+N[B:?>+%&5K=@J,'Z<1JS M$[OE89K](X-2^HNZ_P"7L?R/A.*=,:G_ -.W^9RWPP^(:>!/'6F7DMN'MK.3 M+*P$D4L;85T16"@94N.8HP03F10)O#\>D:C8 MSQ/(+"TN;8Q&2+8A(VH$#$=$!'![5P_@SP;:^(Y-0@7@(WRUN?!_QY=^+?C(OB/7#';CP7;WIFAN%>YU&YACN4&)K(E"(Q\\3$D ')P7(S7I'B?2S M^RWX&\3>.O$4FG7MUIEXMKHVGR^:R23O_P >Y\QHT#+A4DD"CH7]>/%/VF(Y M;'XOZ?X+DUNSU>/1=/CL;*[M+]XWM(Q(,1W069HOW88QOGR>@(X"YZ'_ (*! MZ,/#7[)_P*\-P^+[77-)OFFNQ=KY;VMBWE1(45H@2T<9>0Y8L_)!)XKR)X:- M>KATW;VWQ+75)-M^3=M?7R/9HXR5"CB':_L?AVT;:5O-*^G8XJ#PS?:SXL\4 MW/B&\/CCQOXE'V>\O;>9C:6\;3!P$)"$G,18DE8UC0\G< WV!\)/V!;9/#EY M=6?@_0(++Q-$HD"1OBXLY(9&\LD7 R-S)V7D*1T!7@OV=OA!8W/Q3\*:7'XD MT;7SI'ABSM\W40;3+D-#(1M ;YU)C3DC/S#J1@0_MC_MX^/?V2?CAXLT#3?$ M/AOQ3#XCTA$M&M2T;>')5+HK.BLRK(%(SC:#M4X'.?-QV)QN-KK!9>^65KZW M2LG;39*UKGIY;A\#@*3QV9+F5[*UF[M7UUN]['GWQ^_9RTSX$>(9M*O?",=I M87NFM'?_ -FOY9(TMAY3K(]O(&3.&\I60+N&Z(X)!KZ'^)G@*Z\G+\2\PP\J%:7OKF=]7[T=GY7Z M^6AR9CAHY?B88B@K0E;33X9;K1Z^7F>L?$[QV?V7/AY;37UCX=O/&VI7BW&G M)J5O-/L>HW%[ M9:R9KJVMGNT_<2^9M(9BDLG/RE0GSFKW_!131(/ 7[0_B75#XFC\4M^4;&3:0([E+ZE?ZGIMS<>(-/CUL:I%$MUI MD,]NL=I#IP)\_-QY88@F7(9L]N-\/RJC0J+>HTV]>EGRV[?Y'-B9R=>O2=K4 MHM):=FKW[OOYZLXE-:E\)?!BPL+R:ZN]2UNX_M:62\MPETD"DQ01ER0Q*XD8 M-OC4!R%8Y*F+X&7[P_M ^$"L!RVLVDA90!(@\]<@OF-^@!P#,K9!)SUR]-U6 MZ^(.@WTGB#[7Y/A6QM;33;V5/,+,I.%ED!97+F17"AB?W SA>#8_9UMVB^/_ M ()>24R,=>MF+,R.R/),@D<%N&G8X+9S(H^[&@R1[4Z25&KS;^]?[M/P/!59 MSK4N7X=+?K^-S]X8I@GAQ#(?^7BYR3Z>>_Z5X;X @'B_QS-X?N,+X'21[_14 MP/+U;#9>/':&%R&4?QAQQM3GTOQ?X8OO&FFV.E[C#H4ES=2:A()!YUV!NWC.234GCSP/_;GAV*/3REE?Z6XN-.E P(9%! &/[K E6']TFOQ" ME.,+KO\ AYGZU.,I1373\3HR$M8#DA5 Y[ "O"Y8D\2_%K[2\4T?P_UR[57) M;]UJ.H(JA)2,Y$#;0F,?/)&IP5;+='I?C27X_M)H\$@ M^6>[_#S]1R7ME>.R_$U'F2RMB[$)&@R23PH%>)^*#_PDWCBU\:20NO@N*6.W MN8B2HO@K'RKYU[QQL>!W4ES]U15SPWXEO?BSXDO/!.H2+Y'AIE75[E&"_P!L M#/R(@!/R'!\WT/R9Y->LW&CVEQH\EH\,;V/ZSHUU>>-;#XF7T$D M=A9_Z,NGM%AHK1CQ=2#KYJEL@'[B,^.2U0^ [R3Q9X['A?4I3+X7T25GT>5^ M1KAB;[C$\,+=N,?Q;%8YP:]GU>:VL-(N'O#$EE'$QE+G"*@&3G/&,9IZX>5M MV_R[>I*M7C=Z)?F9OC'QS;>$?#ZWW-U-.1%9V\1S)>2M]U$]2?7H ">@S7!: M3X8O?AEXYM?%6J2"XG\3%++6'!_=63$_Z/Y>>B*Q\L^I<,<+QRG] ML+="R-N[>$4N/^65GGYE;' EP4P#\PBVCJ)">_\ C%J5O:^"I]/EM4U&XUH- MI]K9L<"YD<8P?10,LQ[ $]JJWLY>RCK??T_X'YBO[2/M)=-O7^OP*GCS6)O& M>N?\(II4KQ%T$FJW49PUG;MD!5/_ #TDP0/[H#-Z9R?"6K:7\!9M8\-S'['I M6G1-JFF(26_T=F_>1(.IV2G 4=!)&!VJ3]GNW?P;IU[X9U6Y>[\1V+?:;NZD M^_J229"7'IR%*D#A2F, 8K&^*^DW?Q,\90WVEQB>#P!\M=-C\?:K$QURRN4O?*Z_ M8+'E7@3 R2(G=CUR^>NQ;);+2X)(]"'\,TZ$.UQN!Y!=% M1?8/_>KH?'/B^/QCX)TZQT:YS/XL406\JKDP1,NZ67'3*IG&>-VT'TKF-%OV M\ ?".?P-9MY6IZ9/%H-@,AI3!*,0SX]H@YSC&87]#5PC7 MWL^=_P#@IY\996_89\7>/;>"XGNO%MG-X6\/C8!/Y5S;S0@KW_>.S.!U(6,' MG@?6W[+?P3M_@+^S1X$\(Z>/,M?#FA6=B64?,SI"H=V]V;+$^I-?$O\ P4#C MNKG3_@[\+HX6EB\-^,XKZ]1&W[;*U8-;/(#G((FA!/\ >)%?HAILLEE!&(V* M%% XK/')6BX;:I>G3\#3!-W:>_Z]?QN*#FL_Q>YB\*ZDZDJRVLI!!QCY#WK: M>]BN_P#7+Y;_ -]!U^HK.\7:9_Q3&H$R+]G-M(&E3G8-IR<=>*X+]ST3SO\ M98\3:?X/_8H^'-WK5U;6^F:3X+TR6XOI'$20Q1V419V8\!0 22>U9'PQT&__ M &D/B%#\0M4MS!X2T9G'@S2YXBD\^Y2K:M.C8*O(A9(8R T<;NS?-+MC\D_9 M.2+]L3X"_"[298;J;X=>"O#^E'4G=B(/$VJ16L.+?D8FM;=QND(.UYU5T_.A,3"3GV M^7GVS783:9/$,[-R_P!Y3N'Z5C>-;.*\\(ZG#<(&@EM9$E5CU4J01^5:T&HU M8R7=&6(2E2E'R9\^?#>QU/XH?#GX<6MA=QS>)O!5L=11U&U92EHBQ1N/[LT% MU'DC.-Q[BN[U]++]H/7](M()KB#^R]/;5FPNR:PNG)B@;IPZE+@8_P!E@17% M_LR>([-O&7A"_@40V]]X+L-+8ECF.[CC,YB8= WDY.<=%'M7:? /7)]!^(&N M7C_9CH_CVXEU32F\MBX$>$96+'&UTVRJ!@Y:7(KUL1S0E*2W6WS>IY%"TXQB M]GO\DB?7/'-SXT\-Q^$[I!!XAO[K^S=12,C]W 6DN%&2?+>(?*>QD /(-:^ MH.?@+JK:I:N8?"U\P_M*$$^78.< 7"CH$/&\# 'W_P"]GG;^^&H>/;OXG0V1 M-KI6[1RD88-A(E&Y3W6+C[U=;\39;/XBO9>$K&=S;:W"+G4Y000 MECT901_SU_U8[[6_P"OW=#K3DTY=5M_7F+\.8H_'JZQXDU& MUMKR'Q"OV:T65./L*[A&"O0;RSN>,D.H/3 YKQ-XUN/@[/!X5C260:_)]E\/ M7CR!Q:R'&89=W)"+N=#SD)M)W;=W1>$&C^%.IOX9OKJ--)CA>ZT>ZFEP/(7E MX&+<[HA@@GJA'7:U5-%^&G_"Y4O?$&LV9:VU*#[-I4>X"2UMVGPXFU:*7P].ZS/>OOWPQ')2PD8KMRY4A26W,B ML" =I;?/Q)O_ +I&F/Y0VA3@9!WCI^=>)Z[X3O->^),WB_1K0W6@:%< WEG&RXUBX0%&N$' M]^ $JO9SNS]U#2S^*-1T;Q8OPPMKP[KJ+SX-3,X,MK9<[H3SN\_ (0GJOS^LYX)K6Z02)(L@P0>E>9>)? $OQU\5KJMK=VUC:^%)6_L>Z)W?:KP'$CL,8 M,( "#!^8ECP44U@^/=0F\(^/Y?#VD7,EIH.NRHVKS1Y_XDCRMCY#T0S],<;2 MQ?\ BR?9="T*'1M+M[.Q@6"UMXPD4<:X5% P ,4-.@E43WV]/Z_ %:L^1]-R MEX \3P^,-,D%S)%9ZII[^1?VAR6@DQVX&5;JK=P17+7N@:=\>?$\\=WNN?"F MBR/"JE/W>IW(!5FQGE(R2HS_ ,M%)'W5)POCQ8ZI>^*$7PG'??VM!!C6C:]? ML)ZH.H\\\F+(R/G['GT_P+I5K)X/T[^QHXUTLVZ&VVD!?+VC&/PI2M2C[6#U M?X?UT&KU'[*>RW\_ZZG/>"=;'@O7QX5U9KNX_=F32KZ1E_TV(=8F.2?-C&,D M@!E92,D/M[A;R"/[MLC>[,36'XZ^'"^,-$-N]Q';7<+B>UN%8,]O,OW7&/K@ MCN"1T-0_#3Q)'XGT61+Z1;?5M-E-K?VZ*3LE7NN>=C AE/=6%8RM*//UZ_YF ML;QER/;I_D=&=7D0?(L47^Z@J*?49[@89W/MVJ4FTB'_ "WD^I I#J,,/^KM MH\^K$M6.G0W175&/8D^U3)IL[C.PJOJ>*<=7G9>'$8]$4+4$DSRM\S$_4U6M MM0U)FTZ*,9DGC^BY8_X5'=75CIMK)-)NV1*7>21@B*HY)-1QVSRO\JD^R@U\ MS_M[7M]\<_&_A/\ 9UT>XEM)_B'')JGB^YBE\M].\-0.JW"[L[E>ZD9;=" > M#,>-M+0$C%^#4-Q_P4.^-EO\6=F7^(9WI M;*XX7,F 64U]$^#YKWQQ+'XBOI=;L[#5M/M_+\/:I;0(=-E5G'H=,ETWPQX:M;273)=/O&MX@\9=!;>4A4F.-$C M.'RC;P,'::\D_;)T/Q!K]SHGB707T&[\*Z/83W#S:AJ5XMMIUR9(7AU%K>T& MZ_\ +1'V1;XP"^=QW;D6B#J>I_&/X!>&?VB_"O\ 8/B[1QKNC[S(]E*[B"8E M&3]XBD!P Q(#9 8*PPR@CFOA;\&==UCX&^)?AE\2V35=#@$NAVFI37*O-KVE MO$/*ED"@&.X17,3-P6>'S5QO 67]DOXD>*?B+\.=1O=?O[S4[+^U)(M%U*ZT MK^RKC5+(1Q?OI+;:NP&?[0J$J-T21-SNW'P?]K__ (*(^(Y/C&WP._9[T2U\ M;_%^51_:E_<9;1?!,1QF:\<=9,9Q'GJ1G)Q&PU?5C5SZ1^.7[1GPL_98\-P^ M(/B!XDT7PU:V\7V>.[U"=4FN!P2D:\R2$[02J DXSBOF&?\ X+92?%N[N[;X M"_ OXK_%BWA?9#JD>GKHNCW)_P!FYGRP'^]&#[5H_LV_\$_&;4 M+WXZ_%.X"O<:QXE42V%@P8L$M+0_NHD4D8R"1C*[>-(;&(9DNO"?B"UUN4>N+=.3^#U]XIKOV6+RXDWCUE.?TI)M5 M2_0)*K1@=XSQ^5%I(+H^9OV9_P#@L-\#/VE]9AT!_$LO@_Q@[^4WAKQ99-I. MII)G&P;_ -T[$]%21C["O3M$_9LT/PK\4KGQ%H&IWVGZ=K=])J>MZ)=QI?Z= MJ-TP!6Z029>WF5D0@QL$.TY0L0PH?M-?L+?"S]LCPU_9GCOPGHGB((C+;W,T M7DWUENZF&X7$D9X'W6&<#.:^/]9T/XX?\$9I?[1COO$'QP_9NM647=K>'S_$ MW@FW "[XI.!<6Z=2,?*HZ( 7*L&C/8-4^.K:?\>_&>K:F9?$'Q7M[^;PIX%\ M$(Q1H+)F5A?A2!^YN-BS3W0RL<4"QC]XC*_NU[?Z?J,WAOPCXQO+ ^+KJVBU M=;:V\VUCNY[1X7DD@!;)1)BAV%F.U@&R">' M(M*U$VVG^$8HR<71>0!9[ETR)))D,8C=HE0(TAENS6P%C]H_X%0?M/\ @R#P M]JVKV'A?XDZ+=3Z]X2U/2KK?>Z*\$Y2WO$5@K,I1XEF3&P^:Z9(*M6I^QG^U M3J/QW\*ZQH?C+3]-TKXF^ ;W^R/%>EP$B-9@,QW<&?G-K<)^\B9ATW+R5-=C MX=^)-C\>_AW'KO@RZCLQ.158)(#M(97&X8SX M!^V'$_VG/!AN;O3M%QH?CN"&&16U+0)9=AN63:27L9SYP^4'R_/& M0#1IN+R/K0FTF7[LL3>QW"FBP4G]W/&WL3MJ.SMSJVFPW=G)!>VEQ<4UO* M)$D1AE6!!Y!!SFF&)XVPZL/K36^C%U)VT^9!S&WU'-0LI4]U-+%*T!RC,GNI MQ5@:M/MP6#C_ &U#?SJM1ZD45]/$,+*PJ1M7D;AUCE'^T@I!J4;_ 'K:+ZJ2 M*>&LY3TFC/7C#"L]N@V5-7\1V&BZ=-=7T<5O;V\9DED+E510,DFO.T\ VGQV MMY=6\007EG;LA&B6V<26 ZI.6TZ.YC/A[0Y5: M_P#,C.+VY #)#GH43[SCNQ0=F%=TNE%A\DD)P,##XS70I>R2Y=)?DO:.1%=C9@3J?N3*.NUQ[<$,.U>*?M#_ +*GPT_: MR^*4EMK5M81A(UL]3U".^EM'U@H=T=FRHRK.J$DMY@;9D*H^9L=_^T/H&L3: MMIJ>%./&+12;'C=<+9\"7><$ YQY>X8\P+_"'K\\?BE/\!H/VAOCJOQ\L[^5 M%TW2X_A_:RK-_:4EL+7%Q'I?('VW[<9=^T[O,().,FM)O$7PQ^,NI2:SJ7BSX9_#N#4KRVO MI7DN'L9]6N=+C@E4\JRP7,!P>05R>2:RA17JW>@Z983@DZ@MU]MA, W.IKU_X8_!F[_8N\ M0_L__$KQ]K>G:+X.N_B+K6I3V5DUP-$\#07NG310VN926B4S ;O,VA6;! P2 M:YFW[>VGZBLHQ]C?7]#[@\/_ +*?PZ^-WB#4/%OQ&^Q_\+%+#3-6DM]?N;!8 M5AR8X4$4J;HP'W*3EOWAS@\#L?B/\)OAS\/_ ;J^NV-YH%E?FVMP9Y[MKG[ M>MK$88H),LQD!C8QGJ6W\Y.*_-GX]_!3PS\=/^"?W[3'QBATVRU<+\0-:U#P MYJTT)/VJPEELHQ<6SD9QN1MK+P1O'>J7[67@SX=Z/^T'\$+>QM?@_P""?AW- MX/U.ZL1XQL9I=%O)S+;"28Q1S1'S';.P[NB,2.1@V6W^?0(QM'V+W_RZ MGW=\//V.?@G\8/"NB:]XBT[3K<6VGII6G:7'JDT/V"QB+*+.8B53/M)=2K[D M7)5 M>PB6<,DGF )S(0,L21RPYC6],\)>+O@5\$[B\\>Z'=Z/X;\"ZA:Z7%\3=+N/ M^$>UJ7SB;J".2*?=:W\#8B1,N^R-"I/RY.=<_M+>[V_0.1\G)?WN_P"I^I?P M5_8C^&&ER7^KWOA6TDU37HX)HH+[4I[^ZL;6*1984\Z21I/]8B,P#;,J ,@9 M.7X^^%7PYL?%'BFVUSPYI&JWOC323H6FRK,T7]I:=/.97LVD5AA(IBS9'*HR MA>FVOA[]F'Q)\4]4_:B\'W?A"7PSX$FE^!%M<1VOC=+J_%OIR:E.%C#++'(6 M& 49R28MN1G)KR36/ GC3]JG]C[X ?#'PUI&N>+-8LO"MWXKU&'1;B*WETNU M66>WLLM-+&I+W9\UAN)Q#'A2%-5"<+OF5UT_3_@DRA*RY79]?U/T@\<_\$__ M (5_#GX9R3ZM:M>WDGDS:O\ ;]=O9/MMLDR2R(@>8LNS:&0J0P,:\GG.[X8_ M9Y^&T*?^"@6N?L_76D^#_"OC7XA1_#_ ,1:=KFA>*K>3[+#JMG+:QW!V(Z[ M)@REDW';^\ /6O+?#>N>$[3PY^SOX>UC7_A\EAX>TSQ5]N_X6#I=P^EZ=<27 M-O(UBUN)UD66&0RQ(#(3\F[D.*(UY)&O!.J?L;:W MI6K6_@3Q!X1\3Z=)KDEKH-NPT.:$.RRV\4;.Y"QS1G(W'YF/4DU^[$9X@'B32HXK9R#DQ#9( !V!KN3Y%+EBK6? MXK7[MCD<>=QO)WNOP?\ 3/V*L/V._@E9^-[KQ=;>'M-O+YM4;6)I[C5)KBS2 M]9]YG\AI3 LF_P"8';P<$'[_68;:[U+PEQ\'^ M"[.YBT;7M-AO4G;5X1+([RRK\T3@!?+P0<[LCVK]H[XK>#/VN_BM\8/$GA7Q M;K&H>!;#X'6VB:IKWA>U>_;3[J;4_-\L("HD98COEC#!A'Y@.#FO%35CU[7/ MN?X@?LQ?"7XK)JNIZO8:?.NL:A;7][=6VJRVRR7EO&\44NZ*10LHCD9-PPS+ M@'(48D\,?LC?"W5/A_J?A:STJ/6]$U">.[N8+C5;C4&BF3_5RI))*[PNN,JR M,I!&1S7P;_P3R^'OPX^*^O\ QF\"W_ACX8>/O#L'ARPU?^WO!J74/AR\GC6< M0I-9RNT<5\@8NQC/0X89%?2'_!$;X2>'/A__ ,$\O NN:)HECIFM>+-+$VL7 M<$>V;4I(YYUC:5NK%0Q SZFJ3N&Q[;X*_9*^$_PT2;1[32[+[9>:A9ZQ<)+? MRW5_=DEO,$>[))SGFO@7]G&Z^"$7BNU7XJVOB*Z_:C?XHW* MSIIYN1XA$WV^3[*Z$,N--%H(MQ!\GRP>IXKSWXGO\.W^#?QEC\9"\D_;!/CJ M\/ASRUG_ .$@:X%XO]F-8 <_9!$J?<^0*&SVI774+'ZRS_#7P=<>'?V(O@MX.L'LK2PVV6I:9-I?V M6?Q)>36\]I-$T,D8CDG*[2A*@@<=B"*_+7XDZ?X[TS]K[XI^'Y'U -^T'XCA M^&>OR6[$Q6%PMGHMP\V.@_<3ZB!CU/I6I\#OV=]9_:9N_@MX6T3PKX \47(^ M!,I \8SW2VVGDZQ-&+F+R%+F==P Y7@M\PHYUV"Q^BG[?_PJ\-W&H^ M3U?3 MHM0^QI?Z.MNDA$AM+V!;:=<@@E=C*S#GB//4 CDM$_8N^%.C_$*;X;2Z/=26 M1L[FXE@N-;O9K4Z3)%Y9A9'F*H5:4*#@':H(/6OSP_;F\.?$O3%\/:+HG_"6 M>-;+]EK3=.\-1>(=/FCBM9-9*K<:CO#R>;)BUCCA"A7Q@[NO.I^T9\2?$GC7 MXE?'_P"/_@2ZN-9\-3>"-%T+Q'I<1WA[#5=%Q]J4@\/:W"H6&.ADZ8->C&NE M1BI1U5]?R^X\YT)>UDU+1VT_/[S]#/!/[/'PY^&T.I^#=-TQ?^$@UC&C7&IS M7DMY/-HSCSG)EDD9HHVA1D;:5!D"\#*FO:/AY:6?P2O+3P[!*J>$KJ'=HTK3 M&1;0HN6M]YS\FT%T))_C'0+7Y=_%SX*7.JWGP$UOP[J5YH&@_&CPYI?@/QNE M@N9M9L[338;JYG1L_)+Y<$ELQ R57\#]Y_&_Q#X,^,_[)VN>#?A[>:?<:-I^ MF7U@SV"_N]'CL$9&1!QM9718U(X!R1D*:<6G:#5D]_)_\#0&FES)W?3S_K4[ MRPTB7QA)+\0--FMUUR\EV:0CS 1WEBF=L!/3$GS29&2I93VYZS7OC!8Q_#0: MO#C[1=N+.WM)F"2&[9_+$# ]&#\'K@ GD5^0W[ 7CGQ5\,OB3^R;\._$7]HW MGA(O$_A'PMHQ\6R7?A^ZAAC35I5DM],O)//>/:HD&X@'3?L@?MQ> M"_VN?@1X;?4[_3(O$^L>%/[7U[0Y 0UDL1,?D+@\E1%GE6-:1DZO[][K\?ZZD2C[.U M%;/\#H_A%;-$OLW@F_E,L449.E7\K?/J*]660]YP4E!Z@1\NQ_NJ>N<';^(GARQ\1>%+E+^;['% OVA; MI7V/:.GS+*K=BI&?3 .>":X3X$:Y=?$G7;G5?$.V/5M.B6"QM2ACVVS]+L(> M09RI_P!T+MX(.2/O-XCMOZ_UN*5HKV'?;T_K8V?@E*W@VQ'A/5=J:W9!IVG' M"ZL&.6N5]RQ^B07%GB6PD@ \]+G.V+RC_>+D+Z' M=@\$U?\ B'X-_P"$IT^*6WE^QZK8OY]C=[<^1(/4=U(R&7N#]".)^&'BK_A? M?B :K>PK#;^%9VMX[59-PDO "K7 (/S1;21&>0P8MZ84???M^V__ /4I^ZO M8/Y?UY%W]GF^NM*L+O2_$*I#XR:0WNINIS'>;P )8C@9C 0#&5V8/8GJ_B' MX=LO$?A^7[7,]D;3_2(;R-@DEHZCB16/0C)Z\$9!R#47Q"\%-XELX;JQE%EK M6G$RV5UMR$;'*.!]Z-NC#TZ8(!'&V?C)OCQ?CP\+8VL.E2*/$D3G[LHY6UZ? M,K_?)S]S;V?A?'+VT=._E_P NJ8S]GKQ1=>*=0')+LIY5FVG(52>*_X*G&7_AC#QQQOB^RZ?\H5&XU*%7.Z0JI7!R&W+Q@@@].K!., M\92J1_FCIVU1RXSFAA*D7_*]?D?E)H>N_P!G3VS^7Y $H.1$ACB*L<;D553= MP#M5)P,=6(.>]U>2]E_:E$^);>357TS7-0LM8%G;;+.UMR\ZQW*DJ<.2X9F MV;B=WS#J:X#P7X:L_%'BZSL-2O;J**^FBC:0G]Z&'$6XL !(O1"X4E,Y#K\P MNVVM7/BCXB>%/#_B&7^P])T&^GL(H+BT!C2/>\Z1".0,Z3[BL2R%/XAR>*_: M:]).3:WY7?TM_F?EM"L^11ELY*WJG_D=YXA\:V_[,_Q:O)-!T+PHOA'QE,EY M-IVH7DVH6UJ8YOG@,2*R^>K+( 5W KRO2O<+3PII,'B"]\>2SPVOPZTRP7Q M%8RR0.;F2%$0M'S&J1MN"!4.3^[3D;<'PW]JWQ-<:-X5\,K=2?9(_%4TFN2Z M%+<-;ZSI-S/&!)&WEL/OE0ZA[?\ BQG)K>^(&G2?#7_@E3XI>Q\5PZHVN>(H M;>]TVUGCF73\RL2&(9W$CA4+ MC@8 KYRMA_:4:%1.TIM0;U=UM?U25CZ?# M8A4JM:G))QA%S2TT=KV\TV[VW//]5\9W/Q<^)=MXZ\1W*:J;FS*>'-"T^60P M:/:F-E5904!RJ9&V+TU&.SD@6X=-\T- MR,QR_.+@?-@E>AY'W@:\V_9-^%>G'X0^"+4>*+/4VO;C^T4CM ?LMN3J.G;D ME.5<.-S)M( RQ/3D^L_MD_M,>*/V%O$OP_U+2-:\':OIB6TUG)X9L8S;D+)$ MI$@"$YBW(K*2H(+L,D'C'-<17J55EN7.TM4MTFHWT^?F=&38;#TJ;S/,ES1T M;M9N\K:[^>R.!_:%_9>L/V:/$MAK-GX-T>WE;53?1&+?&QA3[Y8":1S&&D0D M@' ZICBO,/V<_&5K\!?$BZ$^L07?PQ\:WJ:8^FZA,S7NA7;JX2; 3R$XV.R M,=R.>,D5]-_!+5_$/[1G[$^I^)O$/BSPAK-W?R7=_%"4WSZ(76X.P2%]RR#* M ;0$4C!ZU\A_MT^!M.T7P#X9U&U\2V]PVDWVI6$.FW"_P"F/BZ<;D(W$HFQ MKV5U;LT]F8YQ0AA5',<%&T;*26BT>GS36Z/ MH'QOX?MOV7--\9:KK\>E:I:PC^RO#\-W!/-:W%TX93]HB\DDQJH+AD;DLWR\ MUYU\&]87XB7?BKXE:_IUC:9>:9HJ6&KS(]H([5B9H$8?)&B;% 7<5:7[ MJX(KH/\ @H!IW]N>%?AQXOO?%(U/4;SPY:2W.CQ7*07ME&PMSN38/,,;,79F M97(YQ@9Q0^'GD>,OV"3PX?L3?:8/#EM)ON)+N]$K3/M9XU4 M;EC&$8$ ;:6'7^Q*M+XIOE;UV71>MKON&)G_ +:Z$4N6"YDM-6^K]+Z+='G? MP=U*\\%?"WQ#J.H7-Y.]^HT2U@U&W69X.5EG=)2&4ABJJ0@;.[+%<;EY76M2 M:<02F(M*XVE9.9!T/!+?*#R,K<9SU7::M_#&_OO'FDZ?X;U W5YX9L8;O5I; MB&+B RJ(_-BV<10@]%*K_K#A=^TUCM8_:9)6%Q'/'P5^91#MC^:(,&8*(1C* M*Q5&/\4IXKZ>%)*I-RW?Y6LCY*I5?)!1V7?ON_SW/J7]J7Q,;/\ ;L_9\W:3 MI5VUWX?\,!)9D\RYP9F););D@\#)_'G-?M5#Q&*_%G]JR\T.S_;N^ 0D,-F23D="N/2OVF@X1?I7Y1Q;&V&P;7\K_ #/T+AO_ M 'G%_P")?D24445\6?6!1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% 'G_[5>@?$5^S9XXTW_A(H?"7V[1;J ZQ-+Y4>G;HV'FN^1M4=SG@ M9KY@_9,_9+\26WQ=^&'BJ/X>?#/P#HG@ZRG:?5_#6I?:I?%L<]F88_NQJ3$6 M=9MTK,V57!Y)/VKK-E::EI5Q!J$5O-92QE)XYU#1.AZA@>"/K5:RUK1]-LXK M>WN]-@@@01QQQRHJQJ!@ ' ':NVAC)TZ4J4%O?\5;^KW\C[+)N+,7E^5UL MNPT;^U1>) M_P!H[Q)%IFH1:7\+/'YU!8Y%M)IH+![./@O M\*D.DWUMXR6-KBS\7^%+C7$DDL+@N[;[6XW,L4OENF^!V5"""#&V2WL7[&NB MW^C_ 94W5U%/97M_<7>DP1ZL=5&GV3OF*W^TY/F%>>A95SM5B%!KTL31IP@ MU"VCWUO^?]=S]!XCRO X7"58X7V;Y*B2G%RYGI*_NN;LG927NN+5G&>Z?J]% M%%>:?GP4444 %%%% !1110 4444 %%%% !7,_&>'2KCX0^*$UV6>#1'TJY6_ MD@&94@\IO,*\'Y@N<<'FNFKFOC+>:7I_PC\3SZY;2WFC0Z5HKIP5_K%.U_B6V^_3S['%F5OJ=6]K-NJ1E!M!]P M,5HUE5_B2]3?#?PHVMLMMMNGD>%_\%+$$O["OQ.5F1%.AS@LY(5>G)P#_*OQ MOTBPMO#W_!.NUM#JD.J1CXB2();>-@\BC3T&Q5D,;_-P/W9!*GOR*_8W_@II MI9UK]A+XF6P\S=+HDH78"23E<# YYK\=[?P3JGA/_@G/:6NMZ6;&Z@\?3"1' MB:-2JZ>H^9E20,#C!WJ5SG..M?I/!;_V)J__ "]C^1\%Q7?ZZM/^7;_,\@T1 M9QXCB2T\RQU8W,?V8B0HT&W C;.%*JIQ@%% (SNS@UZS\,K.#Q5^VPDFB6NR MVM(+@6U[;PP7MO=/9VK*MPA !4%]A95*CC&ZN5^"WAN[T_4[CQ/;26<%KIUN MXT:74 CVMQJ)#)#$@0LCMN(XQ&0.67;FLWX.WT7PA\$>(/&,\:Z)XAU6T.@: M?'974L4NFRW"?/<2QE=H0QJX(5LQY7Y!D5]YC+5%.,-[YNH3?JF99;MTD0IMDY?;@_P M,<5UO[4W@?0/&W[+O]C^$)K'/PTO?M955A2\N;>0-#-RK275S,J/Y"R*?,A2,1[#AU)VM MD#(JK\(/&FHZ1XBN-3N)3?W-TD*ZA#))YJW!"9".S8#*8TA# L ZF8 EQ@^5 M*^*%S\+M9\ M*WGA^;0=4T 0QZ+;ZJ4\SS7C*JHE$C;58;48QJ58B1RI.VOMSP9X.^$&MMXJ MU67PY##>^*+""#6(#IIBB $#L\<0**3_ ,M890LR_?8"HE);^]RR> MJ>J\O^&/8R[.998_8X^DW%[>[S16EO==TM5ZGTE^TS\1]-^&GA'PQX0^&FE: MZO;B&2)F,HPK2$K%"OR#N69@$&?G+P3X*T_QM^V=HFK-J6E MSZ5X/LH]4UM[>4M#9&R.V*-G=OONXC&,_P![L,U8^$O@7X\_'ZTU6&3PWY-I MJEFT?_M4^#+35+%_B=X=2UM;6^OTM-;:"X$%C;7Y M8%#!N9XY?FJ9Y,8R=>E4MO;[ MUHT?N?K7C5/"TFDQ7,(33K^[N8%O$8%(K@W#A4?' W'@'^]P>2*I_$?Q3=0B MWT;1V7^VM7W>4^,BSA&/,G;_ '<@ =V91TS5_P ?R:59_"Z\?7$\W2P;PW"2 M#<9$\Y_E ZY/08YSC%><_!&.]\!Z^T/BWS#K&OA387LQ#DP)DQV3-T\R,$G_ M &\LPR<$:/C#QPVOZ=IVG>&KE)+[Q!%YT-T@WK9V_&Z MX/TSA1W8CT-=%XJ\06WA/0+G4;MF6WMHS(P499N.% [DG@#OD5Y;X,\+WWP: MOKOQ9>1,UEX@;[1JML,N=&!)*>4HS^[7),BC^(NXZFG3_>+VD]UMY_\ #?\ M "I^[?LX;=?+_ASL-9^%L>E^'],.@8MM6T$%K261B?/S]^.4]6$G\1.3G#=1 M6/=_$O\ X6H(?#NCFYL=1N 1K(;*S:/$IPZD]I'^ZA[@EQD*,]AXE\(OAK8ZEX5M],L_^)<^F[7T M^>%A)XAL/"_C&>YTZ:SNX[?4K2QL;F_D MU.Z\N6:*&&.W1Y'C*02RL=O"Q@'J<>KZQ\7K6X\ KJ&C_P"E:E>2"RL[20>6 M_P!J)QY<@/*[3DOZ*K'FO"?VLOV4_%/BS5_@Y+X'U.\T;Q'H.OWM[?\ B2WM MH)I;?S-*O59Y%E1T*RS-'&?D;;Y@P.*B,G&+]IOT]>K')7DG#;KZ'M&D>,/" MO[3'@&XN_#>LI+_95TT*W"1/#Q8)62*0*\WNI% M$C";C'F,6);!/)-?GYX3\&_&#XPZ/_Q)O#U]H]AX3@UK3S964T]G/.)+O2I9 MT2&:XE:TDFM1=PPH)<(=Y#(&&*7QB^"'C'X>Z[XK\2>"_!WB?0/AIK?BFS%U MHFI660G [N*P[6HTE=UD]#[E^%[_V M!\;=6OIP5\-ZQ;NC@F4[KE-NT;!),LA7DY\OKRJBMXM\8Z7K?[1W(2.XD7[3'&;0!FD=L<%B2U>K_\ !/GP MRWAWP_\ '*PO-%EDU_7/$U[K2,P$,'B*UGCVV\T+;F&US'(#_=+<]JV5>\G4 MMLK/^OZ[F3H)15.^[NCIOVA=9N?"?BOX@:O';6Z?:V\,Q3YQY=YIH[9;N,SJJ97/+9X]_^!?PP\0O8[-6\,^-_ M$/PAL/%E^+'2=.OI)90ITJS2"X"^:KF%;M+T%,X2:8/M 7KQFQ_9Q\7:U_P2B\%>"TTFZM_%7A^QT6_GT6[G7SKMK&]@NY+)Y,E M-\B0M'DG:2XR<9-'[2%WXC_:Y\":QH^D?"KQ'H=E_9]I#/JVJ(FGZLLK:A:R M/;6@1V?8D<1WD=5544DEAQ7Q!\5OV:OBQX5\7>*=(^&=KKNEZ5;>(]2N?# M$&B1E+N2J'4F.,\"4EL=ZP;/\ 9/\ $WQ \/?9I_#7B1]!B\2^ M$KQ=*O-.DT^"&2"^+7]PB2W]S*T@@8":3<$DVJ5+D%JG6^@C[>^*?[2/A/X, MZKHFGZ_7]LL9K*8;6*G=%,B2+R#]Y1D8(X(-?-/[;_A3Q/+^T]\ M*?$>D1?$>/1]$T+7;"\O?!UO:7%W;27#Z<8HV6Y5DV.()#D+G*#D5ROQX\(> M-_B7;> [WPSHWQ0N;/2+-SXS;5;B#3]2\2Z4+U"VG*D.(_M3;6D5D$?[I3'O M!GR#F?4:/MB*]>#[CLI]C6-\5/$$D?PQ\0,RHSIIT^QBOS!O+('(]Z^)M*^" M7Q8O/C9XAN;&37]-\57&J>(I;;56T^1;66PEMKH::DMV]\T30J7M D26H>.2 M') &YWYGXO?"_P 3>'_@?X?/A'P%\2- N8M1T>W\1RW=\T\M_=R6E];3O% 9 M6,SI+/$TDJG$N4(W^7D:T>5U(I]T8UKJ$FM['IL7CKPC\._V7[<1ZPUGXCUO M6[C4HQ%$9+D6*7GV:>X6(98K%:\?M)Z(;?X:Z7I/AEU_MJ-UDTT M1-LDABB0^./%_@W4M;E\"^);.6VTGQ5H.DWA MECDDTUV\0M3FZUM%*_W[+Y'F4* M$5!4D]7'\MW\S] $U#3/"'PDM+^UB\W1ULH?LB1#>9E< 1HH[LV5 '_GUB+PEI%W;R^'].N["2P@6=X6,EQ'#)<3R+M#+&# MO"L49QN+;SYU\6/#WC#0OV1H?@3#X,\2+XUTDW%C=:\L,4FCMILURS2:NTPD MW\<3A"GF^?%@*0-UVG^9]!_M*?M,>!?'OC23P.=9NX M[KP_?$S36ND7EZ)+^*(R_94,,;!U1#NN,'"(ZJY'F5[CX(^+NF^)/A;%XD>1 M;&V6$FZ5P5^R.G$B," ?E8$<@'IQ7P;=?L&:AX4\;^)=;TWP=?-<"[\97%GJ M+7!,CF?3K9;*;=O^\\WF[6]1^'O$['^G\V4TH2YXO67]+ MY(^\K[PEK7C*YC\<;9+;7].RVB64C,HBMB/FBDYQOF7.3CY,H,$H<]C=_'") M/ ]GJMJ]Q>2ZEB.RM$_UMQ,<_NL=B"#NS]T*Q/2O@S2?A%XGM/AW<6^IV'C/ M2?#E]>^%K?5M.2UN-,:ZD744-\49K^YFDF,!9)9(RJRAEP7()'UA\%/AQ:_" MKX@6WV^"XL[+6+79HNGF4S#16C4>9#O9B&>2,*S-U)B?EAS3BU4C>:VV_P O MU%)>SE[G7?\ S.EG^'FIPZ2VN?:8Y_&R3?;5N>-C, 1]E!QGR=I*?CN/S/Y5G9QA?,NI"#A1Z#N6. "37 >!O"L'PI^*?V_5I7EN_' (F>*/, M5E=("PA0G[L;(#V&YT).&?%.-IQYIK5;?Y>A,KPERPV>_P#F=(?AA_Q1,MHU MR)-;DE%^VJ&-1+]L'27'0 <#;TV_+TJA#\>+_5-$@TNTMX1XSE=[62R:/Y+- MDP'G?H?)&Y64_P 0= .M=+\0/&MGX4M$CLTGU#6+T[+*R4A3,W0LQ_A1+TKP?%\)O&L'B6]N[B[E\2NEEKLNU0B2$XMV7/*QH6:,#OY@)Y&:5. MTH\U17?3^NQ53W9)0VZG8Z%X+MM+\(76E7/^G#4PYU"6907O'?AV;CG.< =@ M !P!7&V7Q=U;PFS>"$G?4?%D VV#2D_OK0Y"74K# VK@JV.2R@8&\5VGCKQ] M8^$8(((+:XU#5K]O+L[.-E#RMW8G^%%!RS'H!QDX!XW5? R^ (8_&74IR]U*WWF/ITP!T4 <"N?T23_A6OQ .B%B-(U]GN=/! M(VPW'+S0+[, TH_X'[5WEKK%M?64<]O!$T3J&1PVX,",@BL/XE:7+XM\*306 MOE6U_ 5N;.95P8YXV#ID^A( ([J2.]90FW*T]F:N%HIPZ&RK$KQR?85QOCK2 MY_ ?B6V\50JZ6$@6SUE<83RB?W,_"UI?J7MW MN(@9(NC1..&0^X8$'Z58UVT'B#2KFRO,SVUW$T4B.>'4C!!J(MPG9_, M/R+PTR1U!S&H(ZLXIZZ?"I^>Y7W"@M7$?"35YIM"FT>ZE\W4/#TS6$Y/WG5> M8G/J6B,;$^I-=:MM+(0 K'Z TIP<9'X*_L2?$K7+-[K^TSHLNG:6T>%;[==D6EKCW\^:.M;X8?"; M3OAE\(?AEX!CT WNF>%-/LXQ>I,(TLY[*./RG==RLQ=P2 %(R#N[9.NQ5^YL MZ_I>M>"OA?P_%SXN^/O .OM/IG@5_&/AE;=2_]DZO%#JZRY.X+;3B.%D"[3G[ M0&SGY32_L]^+/$?C;P;J&N^*+*ZT=M2U2[FT[3KN!8;C3K!7\N!90"?G94\T M\G!EQG %&K \:_X*@_M>ZY\&?#WAGX7?"@KJ'QN^+ERVF>'8VC)BTB #_2-1 ME^5@$B4Y&X=(+E=]]K]^W M,D\KDDXW$[5S\H]3DGYT_P""8NE-^V#^U?\ &#]I[681-:7&I2>"/ 696=+7 M2+-MLT\8/'^D2_,3U#+(!PW/K/[6W_!7KX"?L4^-#X:\;^,POB6-4>;2].M) M+VXM58;E,NP;8R00=K,&PP(&#FA);L=NA].2W,D_WW9OQJ/'%>8_LM_MD_#; M]M#P#+XD^&WBBS\1Z;:R"&Z$:/%/9R8SMEB<*Z''3(P<'!->&ZU_P7L_90\/ M:Q=V%W\58XKNQF>WGC_L'4SL=&*L,BWP<$'I572"Q]@8HQ7AG[*'_!2?X+?M MO^)M4T?X8>,T\3:CHMJMY>0C3;RU\F(N$#9GB0'YB!@$FM/]K']OCX3?L.Q: M&_Q1\6Q>%QXD>9--W6-S=&Y,6SS.((W("^8G+8^\*=UN![#0\SR6[PMB2&12 MKH_S*ZGJ"/0U5TG6;77='MM0LYH[BRO(5N()D.5EC90RL#Z$$&O._P!G']LG MX;?M;/X@7X>>)X/$9\*W0LM4\NVGA^R3'=A3YB+G[C?=R.*5D%CX^\7Z0?\ M@BY^UM;>+=(BEC_9H^,&J"T\1:5$F+;P+J\O$5Y"H(6*VE8[7 50,8.V):^ MQ_VG?!_@#4_ !HOCO48-+AT72WG.H:6\\3R1E)W% M=@\Q4ABVIYCABL?S>C>+M#L]=U75_"OB.[^W:?XQTV:/:BVZ((KH&0# MY@WG)PQSR<9&<>+VWQ,\+_LYOXE\'_#_ ,(WNIWOASQ'INDV]OJ6KR)I\>IW M\$4BPPRR>?);Q16LL3D1Q; )-J+G?CU;PI\H M!+A( ',4MN7#!<^9\HD4D' (!!HUV$>8_P#!-+Q=JND_"#7/ACK]S)-XA^"V MN3>$FDDP)+K3T1)M-G..N^RF@&>[(^>PW\Z^9;"^7X3_\ M%9+R!((1IOQB\ K?3@<%M1TBY$6\?[UM?(#_ -<5KZ;$EHY_Y:Q_DP_I27F' M45;U"T9_!A339++]R>$CT8E32'1IL9$>\>JG-/03'-96 M\J_)=1Y]&!6N;^)FI7WAK0EBTY8I]7U206=A'D,#*V?F(R#M10SM_LH:VWMI M(^JL,=B*XG1-WC'XH7U^Y1K+PXIL;10.3<. TSD^R^6H]/G]:UI+5RZ(SJR= MN5=3I_"'@3_A"/#5K80QRN(E)>5U^>9V.6=B.K,V23[T_P 3>((/"GA^ZU"\ MD\BVLXFEE<\851DU=2\DC'RR/^!Z5R/C'5KGQGXXTWP]YI>RLP-3OP5#+(%? M$,>3TRXWG_KGCO2BG.5Y>K"7NQM'T%^%OA^X@BNM>U*/RM9ULB25".;6(9\J M 'T0$Y_VF<]Z\?\ BG^U-X(^"7QP6U67Q!)J=XTC7VD1>%=2G>Z$6Q7O+5D@ M*R&(2(KE"05D7)!"@_2<>LE$P8H&[9,8KYM_:C\,:OXH_;1^$,^F:;BRDT#Q M'I=[>Q$#[%Y[::P;&W>DW@TS[7YOD/+]K>'[.KM+F%<2=B ?GQ77^+OC!H'@'] MH(Z-INJVUQXHO-+&L:KX>B4O<3V0D\H7D:XP75A@J#N=5/!VBOD;Q/\ LC>/ M?A-\/[O5$_X2O7OAW_PL+5-2U[X;H]M%%<:6=9FEAFM'6,3 !/*N"C2D/M92 M '^7H?B?\+_BA;:W>_';2X-#;7?^$VBN=&T";2I'U6[TA=VF):?:1<; CVTL MUT(_).'?[V>CYWS)Q7NO\@Y5RN[U1]!_\-7^!OCA:ZIJ]EXDTZ[\!>!+_P G M7KQ(V*'44D5%MF&W)",59N"#NCP<9JIXZ_:U\"_#/XM7-DFK"Y@O]032-;M1 MIT\EC#?,%"@7'E&W%QRH:#>';(PI88;XS\0_L7_$OX#? OQ-XB\/:9?7C>-/ M$>J6OC+192B/=6AUJ6>SU:(#C='&V67C,N?%A]=\&>,M7U+PGX6^(N ME7USXMCU.YL";/5O _B*U:]20WQ>8F2WE:'#E8-CBXZ))]XG,TTHQNMOZ\Q* M":;;L]_Z\CW+6?VS?!?QH\1IX(\/ZKJEYI_VB:WUF\M- O7LH4A9U>#[0(/) M =XW0MOVX1P#G%9?@S]L3P)X>U&.]T6XUR7P+J=LVH&ZD\,:E;6.G (7^T)- M);K$8)%YX?K@KG><>:_LK?L]>*/V?/#7B/Q+XCU?Q9I^E^(-:\07-UX;A2S_ M +/L7N+JY\B;B(S&!D:-AB0;&P3E20N%\#-+U?PC^R:GAO78?CR]U!X"FTN> MPUJQTP:!;3KIY3:DD:"78&7;&2QSE^WO M[77@O]H;7=#\!:#K%S')XQMWFSJ&G7>F->6(C+R+;?:(D\YI$!'[LG";W_AK M6N_B9X7_ &<]:T#P/XRO;&QL=?ODL/" K-@,"@SNZ_+ M?[*?[,7C']FSXL?!/5_B%+XD\=>'KS2XH+7[9)%&_@+538F"/S?*1!-%Y#26 MP+;BC."!\Q-=[^W?\ /&?[2?C_QCJ,;Z-X?\.>"/#267AF?4=,EO;BYU6:5+ MM[NT9+B'RI(Y+:QC1F#C<)!MQG<.32]BE=?KW_0$DW[5NS_0[S]K;XS>$9/' M^G>";_4Y+;4=,@&NS"RTRYU2X@56*P^9#;Q2,(&(?>[[5PH7^/C=\,?MZ_#2 MZT[25.IW%SJ>I:=_: M=&TJ\U.[KQ5X0\;6?C7XHZ3I>I#5]"TNTU*[TNZ@A\J:W,%P^S9OSM.UD'F/DJ- MA;C/BMX-^+G@;QS\-]:N-/\ 'NAZSJO@Z70M2/@_2=+6XN%.I27!@E1%,$4J MV>9,Q#;O7&[G-5)MVH=%M_G\R8I*];J]_P#+Y'TY\#_CIX.N/VH;J&'58(KC MQCIJZGH^EW44MM7WC M7P[#KEC?Z-X!T)/"6LZW'%!'[ZR\3>$O'5E-J.GSE&DM+&.6_DEG+#AMLMP4?;GE!V( MK559N?M4M8K_ (!DZ4%'V3>DG_P3Z7_:O^*'@[PQ\)_!WCF?6)[#P]+>0S7, MJV4D9ETUE-Q-YD;JKH D8?:5W$H%Q\V*Y#0_C!\/M!_;OTJ2TUBR:'XF:7;S M:))(W[C52;>28")\;68J%;&)KNPM->TZ'[.-/L;ZUB&DW4*F1VC:"Z**H+-M^RC)(Z[PFXP=-:WC^;3 M,)I2DJLNDOR31^D7CS]K+P3X"::/4=4E6:#5_P#A'VM[#2[F\N#>_95O/($< M$;NQ^SNLA(! !Y/!J]$/BGX/^+7ABYO_"5_8W]E;7+VUVD,9BDM)UP7BFB8 M*\4@W E74-\P..:^0O!'@SXJ^"]3T_Q7X[\"ZS?ZOI/Q;FU#4(]%2*Y?4;1/ M#$>FKJ,*;U BFF0-M)RF\J?NYKWC]DKPOJU]\1_BQX]U?PUJ?A*R\=ZG9MI> MD7IB6\,5K91V[7,ZQNZ(\CJV%#$[$CS@G \='L;(U?A]^V5\*?%L^EV^CZN] MM#XBN/(TVXN=%O+"SU.9MQ"0SS0I%([;6P%8EL'&:U?AY^UAX'^)NL6UAX?G MU^^6[N)+2&[3PSJ2Z>TD;LC_ .E&W$& Z,"V_;D'FOD_X(?LC_$'X9_"?X%7 M>OS^,/%NA:)J-M)K7@JZ^R1_V!P-%'&\B6TI5GBEDDRIW@EHPK;G[% M/ACQ9\.;;1] UQ?CQ8W":IJ2/8O8:RZG$]RFI7>B116&FW%]J$MU;?\ 'Q%'#%&\TGEXRQ12 MH'.<5\HZ?H7Q:\+_ 2^&GPNT#PKXNT?Q)X)GL=,U$C1=+O?#>MQV]Q"7U%[ MJ=F=%*1O*H11,)'Y7(!K0UOX.:_X66XO]4\&?$%&'CWQ/J-GK_A"ZC&LZ&EU M/&T$JV[DI<6TZ!]ZLKX*1DQG.50'T/X@_;:^%_AWPWI.MS:S>76E:XRK9WMC MH=]?0O*TQMQ"SPPN$G\X>7Y3D2!_EVYXJ:\_;+^'>BZA%;R76OI=-8)J+0)X M7U-I;6V=Y4229%MRT(+0RX\P+D(3TYKR#0/AU\0_%_[&GAJRU_0[EO$$/Q!T M[4UCEL[6TOI=.BUZ*<75W%;GR5G,"F239U.20&)%7OCU^S'\0OB?^TOX^UOP MAXR\1> FG\&:79:9=6D-K)8ZI=QSZ@[0SB6)Y JB2/)B9"!*3DD##=["-S]I M[]J?P/X,T;X4Z])KFE7&@^+]=CDTV[B?S8]1W6LQB\HJ""7=HPIZ9('>N*B_ M:($_"#X2>)/AYK#,/&3R3RWUG::)>W5O9K?/+.DD[PQ,BJ$,C'.?AO\.-.\/CX5Z%X!\()8VMGJT;ZE-I>I3)+/)(LB7"%S$]E M;A)6SN\UVP>0>L^%/P+^*/[3GQ3^)/Q#M-;\2_#+QK+X2T6WM$5;4Z?JEXD5 MQ%<^9NBDD6)I(<+)"RL$<,,YQ7J\\X48IKS_ #L>5R0G6DT_+\KGV;\ /'7A MQ?V6M"U2*YL[W2;;3Q$US#()H[QQ\C.C?Q^:WS*?XMX/>LO]CCX:6/PDLO$. MC-8QZ?JTUZVHO#O\QA;7!9X@6/)PWF*3DY9&/? \T_84ETSQ->V?A:V\/ZKX M1T#PMHNG:K8:#>2!Q%*RR6KKY@=O/6*6TDPQX8R(X)XQ[!\<_&+> /&GAZ^T MTP?VMJ3G2'C<'8(YF58YI,?P1S;/3_6$ C-$DY2E36\M?3K;_,$U&,:CVCIZ M^?\ D97QSN([3XAVJZ9+-;V\L4=KXHGAVJEI9LQ\MR^05DSN (Z([L?NI7K4 M'A;3;7P]_9B6MNMAY'V;R@F$\O&W;CTQ67X=^&=CI'@^YTN?_3O[3#M?S2C+ M7;N,.S?7H!V '2N!\'>)M5\<+<>!K:XE0^'9OL6KZJ#AFA !B6,@_ZZ2,IN M/1,MWQ63_>0M!Z1Z_J:Q]R=Y_:Z?H9_@*5O'7C2?P9<2^;X?\,R>=#7['J%DPN+&YVY-M,OW3CN.H( M[@D5B^/O!W]@>&M/OM!MUBNO"O[VVMXDXF@ Q+ !Q]Y 0/1E4]JIS^-#\;@E MAXPG'F0-R/O ?*?X6"GL0UD^&O#KJ;YE_T^]^]'I<9'Y&4C M[J]NIXP##UFG2TC_ %>Y4?@:J:R_JUC+G\:?\+R$6E:'+*FENH.L7B,4: $< MVJDK#&AXT\*R>#I[7Q!H%NJOI4(M[JRB3 O;-?X%&*8;*T!'A[Q#)@M(^YH+\C)8GJ?.Y).?OJ3U>NJ\=^-E\,VB M6]K$M]J]]E+*S#8,S<9+'^%%SEF]!ZD DG::C2^'^KW%%7BW4?O?U:QF>)OB M6-3TRPMO#,D-YJ>OQ>99NW^KMX>-UPX_NKGIQN;"\9)&3=?#D?"6"'7M#2XN MKJT7&K1K\TNKQ$EGL7^ M)45[2//4TDOP*&L?$G2]-\$IKBW N+.YC1[4P_.UTSX\M4 ZLQ( ^M?.'_!2 MPWT?["'C:[UR2VBU&2SL79!'$8[0-JD11%9\99>!DM@L 0!TKOOAYH\FB_%* MUOMHZ\\Q_P5Y_8R\=* M/-G MNO\ +<_'/4+>&XN%C\BX6.:-H[1-S)+/YF"2H))R_&YAYN>!DC@=UXRAE\6^ M._AMI_DMJ&HXM8+_ %.%H;WS)+R;S!$\;!L2(A'.2V,8VC &3\+?A[!XR\66 MLK2QP^']/F#ZS=,%>SM(N6+2;57J%/RR1*6Q@$D\:W@=]GQ\UOXA^+=.L8_^ M$1NY=7E73YGM9=499@D;PJ%*%0[(.=F_U)S7[7B*D>9VWBGZW>B1^586$N5- M[2:^Y:M_UYG0?M@^/!?>.AX'T^XMKR_GU:2\O7WW=EEZG)*DITV!$WQ^7&^[#R,S_/ MA-I& 3S53PGXOUZ+QO;7M_?3W#V".\<1O6D>ZCXP"SY9> ^6R=GVR+. #CP9 MPJ1@J-+14];]Y*SVZ),]Z-6G*HZ]17=167]V#TWZLQ?VXBN"K!CL3YH50.00#UQUK[W^!<_PZ^)NL>&?%FOZ39? M\)A::9.C3PZ6L5I.C[0)2VTJTAAC3 #L%#$*<8)^5=<_92U#Q-XDL/B9\.WT MZ7Q=>+/-J?AF6?[,NHKY;!I4884,P)8KN9$/VDOC9^SE\1'DUWP M9??V?M>*32?['$2",A@@2=8F;Y21@AFR >*XLRP4,V3J82:C45[^]RRUW7I MY[,]'+,?4RIJGBX.5/2WN\T=-FM59^6Z9]:?'SQEX0_9Q^'&J6GPZT:QMVU# M4KN;49;VQ6(^8[Y2))'4+Y1>24]68*C*J\_+\=?&GP1-\:_%O@G0)Y]*M/%- M[>-'/IUN7#6MO/F:6XF#']WA$WD#^^>F*V?A/X[_ &@OC9\2?MD'@^YUN.:] M%P([C2H].MX)#D(QG")]U6QR3D$\'->B^'?@%'^R+X8^VR:K9:_X]\1I)!J- MW&V1I6UU?RXF/)' WD%G90RB,]ML%0CE7N2FI57Y\SNU;7LE^)AC*T\VG[2, M'&BO+E5EKHNK?X&;^U/\/-&^,UEK6L>&$MY=6\"6JQ7)L98HHSI'4K==MQ%,? M/RO[J5=A.')$RC J+P7XZ\4>#?%>_1+VZFCBFEE\H3%29#\H#PY", A0,K;A M^ZE&-Q-2?%GQ_;?#3X]Z%XBU"'4M%BU[1I+#Q3H%I>J//+1^09(U4@1AU*L1 MM7;Y9(R"">B-*HH+"/6WO1?73=->?0Y)UX2F\7'W;^[-=-=$T^ZZ^1YSH%]N M^ 3VL$4^FW-MJ7FWD?VA(Y]3MIU$J2")!E(XWB3 4$9&1M()KG4O8[6UEF5- MD&YO)N4"M!E\!T?!/B9XF\+*WAZV\.W=G<: M?J.K2RM*&'F)Y$(ED4%'^T"#D( P^8Y0;JY+5?"EUX:U1M.U2*=-44L6@N T M%Q??MS_ +/MT=3T^W2Q\.>%DBL!)(9)\SR99<+L 4=.02.QQ7[3PKA%^E?B MS^U+X"U/6/VZ_@#?6^D3MI>F^'O"YN;R.VD_=L9G &[D_P (SG&T=>M?M/#_ M *L5^0\6M/#X-)W]U_F?I7#::Q&*T^TOR'4445\4?6!1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% 'GG[6?PTU'XR?LR^//"ND,B:KK^AW= ME9EVVKYKQ,$!/8%L<]J_/E_A;X"U/X23^#+3]E?XE_\ "UAI9TQKL63_ -F0 MZ@8MGV@WGG^7Y8?Y\XQQ7Z%?M3Z;=:Q^SAXWM;+Q';^$;NXT:YCBUF>?R(M. M8QD"5I."BCNPY Y'2OA;]@[X3^'O"_[8N@W?AG7_ (8Z:F^2YG@T3QFVHWNL M*VE+')9"#)\R-+E9+CS)"6^7( YKZ'*JCAAYRO\ #K;5:I=6FM'\_D?N_AEC MIX;(<9B/:RC[%NK&,74C>48K2,M%RVDU9MN*W^]?V=/!%]\,_@!X(\. M:F4.HZ#H-EI]T4;XRIKLB,BEI"<"O G)RDY/J?B&+Q,\17GB*GQ M3;;]6[L^);JYU_X(?$:+X56WQ$L?"6B>$C#KEMJX\-2NMP+J2Y$%OJ=R)_*9 M&*2[V9(O,*J0ZL:^G?V<_A)_PJ#P'/;2:G;:O=ZSJ$^L75S:6HM;1I9VW-Y$ M09@D?3 W,226))8FOE#6_ '@=/!][\6U\+?$C4M-\:ZK8>';6S_X6#>PR75J M\\D,-R?WX9=\T^SR))&"*00(\N*^D/V*4\):?\'9M*\&:'KOAO2M!U6[TN73 M-6O6O)K.XB?;*BR&:8;-W3:^WK@#->QC]:5U??72._79WW/UCC;W\L]I2I(TR6-JK7#P1!=WFS; 1"A'1I"H8D 9->:?MH^(0TVA>&M<\3R^#/ M OB2.XMM;U1=,\Y9,^6B6S73AHK,2!W&]URV,*RMC/-? _X:>!OV5_CGI_@W MX9>(A]CUH?:-9\-+;OJIMP(/W=VUT"7M=VU<"9BC[OD4')KT(8:FZ/.[\UF_ M+3SMIZ:^J/N\'P]@:F5K%5.?VKA.223<'RMZRGR>[;^5*2>G-.G<]Z^)'Q;\ M/?"&SL+GQ)J46DV>I7:V,5U.K"WCE8$J)),;8U.W 9R%R0,Y(!D\8_%7PY\/ M[33YM8UG3[!-6N([6Q$DHW7LLC!42)1RY)(^Z#QSTYK@_P!L?XBW7@/X<65O M%<>'M,L_$-\-*OM6UVUDN=.TF"2-R9944;""0$'FLD>Z0;FZ*WD.A_LV^'/V M-_%OA'Q-H_C71]1U'5Y8M+CM/$$40F^UP)"?*A4PE=NY5&7I4 M<-"<%*3:;O9=_P -/Q^1EE/#N"Q.#IU\1.4:DW)0BDW[3EZ&?A'XGU&_T^/5K*PTJYN+BQD("7D:1,S1$ MD$88 @\'KTKI:Y[XM:]>>%_A;XCU+3[--0O[#3;BXMK5XVD6XD2-F5"J\L"0 M!@Q:EX2TNX M@@6UAGM(I(X5Z0J4!"CZ X_"M&J'A6^EU/POIMS/$()[BUBEDB"E1&S("5P> M1@G&*OUG5TF_4VP[O2B_)>7X=#P/_@J"YC_8&^*)!<'^PY@-BECG*]AS_P#K MK\8/#D6[L\MDXTY,/L49*9X8?,<'M,\0Z?=GPOX3UG[>MOI]FMU"RE8VOYG).6.\.5.2!P!PH%;WQT^ M&$MOI,CZ3XZAFTO2M%M;^Z6::5+IK.X*^9O%+P7]O;VE]K-C+:0ZO/&SI%+NVVFA4^"/Q9MO#5IXA\/\ BF[EL_#OB25; MCS&MMB65X(RY8K)NGE1(\(P09R_)Y&>R3X?ZWX&U;P]K]HUOJAUN!6L9M+D6 MXCGDDF*HK -O13D;EPH)9L_,3GC?CM\/_#_AS7+VZ\+^9'9SZ;9+J%G=B4FQ MEU%$GD>2]8!94P63@KQ@JG+EV:[ M7^ZWKL?1O_#8$_['7@*Y\&W>D:;K'C^XA@UZZN9HU\JUA:1$>W;R^7GA8R,< M#:IWDC@UY[X/_P""@7Q&\!C79'UR[U-]2E9KR\N=/CD-E'$YMA.AV ;C\G;! M%NY(W$D\KX0UOX0>#-(TI(O$&MZYXEE34+/4M3U31 \(N)&#QR1I)*/F++D& M0OD*<@%J[7PW\=/"_C^WU*:2YMKD_9<:RVNV37=S<1M&Q%O:F *L,X\R[.P# M=\APV,UY3P%"BI3>&PLRKUFHK$U/B_0;6*YNL3#%U;0K&EN(XR0%'FRF1MKDDJXP!D YWQN\ M+>()]B*2?[43!.K1E656CCVNKA3$N590)IG?*,0Z#Y!)O!;!S@+7D/@C1=6\479">()= BT M;39KV>:Y\ZRW6?FM,9@Q60%HKB1U 09)''.:9:^"9K[Q5J_AZ2 6$[1SQ:A= M"VD-Q"8D6[WRP?,TF!'*FY<[NH)XKU;QK\4K#X,_#>/0/ T%U;Z7JUE;>)-7 MU"2R74(M2CEVI-#]CE&8(-P+;">=O7I7J:TOW=+WJD]WI9+\=.RW/)O[?]Y7 M]VE#9:W;_#7N]#,^.T>D>!8_#+RZGJ>M>)[6XL_$,]WIEF);6R9X %>*0G!2 M:90[#;M_NC))-+X50ZEXE_:-^'NMS6.VYU'6X[RZL8I3]ECO/M\BSW,Y)"*> M!A. 6[8&"MYX!;XC>!_$/C'Q#=AH%E%!ISV37I@V2I.V G[M8P%.P= MT]Q3OV?]8NKWX^_#ZQO4B9;/5X8;:W*(8HA$\4FT!E^4L/.Y SO3KG-2HVPT MHIWE%2N_D]$*K)RQ$&_=4G&R^:5WZG[6ZWX2N?%%_H<=RZKI6F7EU>/&&S]I MG%P_E!@<_*GWNOW@O0#%;'B;PO9^*M)>RNX]T38((X>-AR&4CD,",@CD5F^- M?!MWK>E6.HZ9>_8=9L)KGR)#EH9E,S9BE3^)#CZJ>1[X\WQJM[/PWJ1OX?L. MNZ9$&ETYWRTCGY4\L_QH[D*K =3@X/%?B'ORMR/;_,_6U**^-;G(0^);S5_B M[:>%?$4T4NF:%,DD%Z5*IJ=T5#0Q2?P^:BY"/6N M1$_"ZT@^'ATK58TNY-1+W5^S$MYL\AWNP8\C#'"],!5QC KGO%'Q&O?V??# MU]+KS3ZGHL$9-CJ 7,BMT2"?MDMA5DX!R 0#RVM1*K)1I[K\2*=Z4>:IJG^! MSU_I4_A?XF,]C:SW?@3PW-]HNK.+#_9;QQG="@^8I&AW,@X#2 J,J17M6G:K M:ZYIT5U:31W-K,@=)$?D^%/'5IXMTN:: M#):,8[F"7Y9+61>J..WUZ$8()!! MK-^#-WIO_"O;"#392ZVR;)PX*S+/DF3S%/(#G=O?C/'!X0U:1 M[9K77]+00OILOWVN'VB)5/ =7=U"LO!)QU! TOA]XSMI4319[4:-JFGPJIT] MF&!&HP&B/1X^G(Z< @'BN:^,O@I?B!\1O#5I;3_8=2TOS-5-Y&,O&J?+&A'0 MH9&#%3P?+/0X(N_/4Y:NR_)?H1;DI\U+=_U]Y-:_!JY$:'INH:'.J^);&'9 MO8E3RN>XP3 MS-IX(/C#QMXB\3Z3>&RU6"Z%C9W*_-'*D$85HI%XW)YK2@CJ"N0123;;]IOT M?J4TDE[/;JA?B+)3ITNTL9HAV0GED'?YAU;.@ MOPY5/AWX=ET":W@U/0;5/L,P;,4R;5W1,1]Z-P!]#AAR!6=XX\?#Q9X8.@WT M']G:X^H6,%S92G(FA:ZB\QXVX\R,IO&1TY! (Q6G>Z???"B^DO+!9;_P[<-O MN;&-=TFG$YS+".I0\;H_JR]P:]YQ5_BO]Y#Y>9V^&WW'G?V0?%#]F>76-("6 MWB;28[N66W<G_"4 MZ;;2)L^Q[MD=W"H/I."Y'4&9O2M+P-H#:K\-]'\3^&GADO7M,7$.X>7JT&YL M(3T#C/RL>G(Z$UX[X@TF73/ G@[XC^'$-K)X5NS#K$$[^6]IY0-M+)*#]T,J M)YHXPHW_ ,)SW4XJLI46[7?W/HG\UH<R^]=;?)ZGV$'PP&*DK$\# M>,;3QYX6L=7LSFWO$W '[T;#[RD>H/!^E;'G"O"<7%\KW1[L9)KF6S'TA&:; MYPH\X4%#M@]!^5&T>@IOG"CSA0 V0[#@5\^?M.^*+[Q/\=/ ?A32+C;=6=S) MJ)PO1S@(BJ6 M)_(5\R?!'Q%K7B[Q]KWB)X?^*D\1HD>E),JL=(M9-LDDSD=O+-L O+ MR7[0[K Q/7/#R>N0IZFM#PCKC^/$U/P;:0B/3M+U6Y35[J,-'\C3-(EK&PXW M,K -C[J\<%AC,^%=S=Z3\,K#POX>D:;5[UI[N?4)?WGV*":XD<3N3PTC*V57 MN3G[HJY\-M5M/A'X>U_3;*WFU"]EUZ>*SM@^Z>ZD*1EF9CSC)RSGID]3P752 MO*V]]/\ ,FBOAYNVO^1J^-O%EO\ #'XK:98:-IADG\2Z6UI:VL6!&DMNP9"V M!\L8CEDW,>/D51RR@]=X4^&NFZ!H%\M[>->WVK@OJ5S-'S<,PP5XZ(H.U5[ M#J>:XC6?"3^$MW"7.K76JJE[=/PL$#12JL48_AC5BGUR2*L].K[V.F'Q--:]%ZF%\ M*(+KXR^&X]&?4(9?#OAR=]/O;M'._6GA8A5!7@1[0C-_>W;1P&SVGQPTRUT_ MX4WTAN;."2R"S63*WS+<(0T2HHY)+* !SG&*YN#Q99_"'XA:YITL*6^F75K M:W>GPP+F2XG/F0R11H.N%C@.!_?)K8\.^$+OQ+JZZ[XC4"=3FPTXL'BTT8ZD MCAI3DY;L#A>,DN=^=3VCNA0OR\?CP!>:[X:MK)[O4[?49)--LXSM-Q%.!/YA/\$2O(Z%SW3C)(!ZO MP3X'DTZ[DUC5[@7^O72!))1D16Z9)$<2D_*O/)ZL1D]@(E>$_:2V6R\AQM*' MLX[O=C/A7X1E\2:?:>+;Z/[3JNJVJNC&/"V4+@-Y* \CMNS@LPYZ "I\?4DE M\*-I=M;SS^(;Q@^DPQ?ZS[1&1(DA[+&K*"Q/&,CG.#@>&_'\G@S4-9\(Z;NU M37+:^DEM+?)5(+>;$RR2D9V1H79!W.P #T[3P1X+_P"$<>:^O;I]1UJ^ ^UW MCC&_'147)V1CLH^IR225+FA/VDOE_78J%IP]G'YF5\"_",VJ:!#XHO\ ?>ZY MK,*FXG:,H+4TCQX_A'Q1XB\+::G]HZVUZ;^TM%.V.V@G ;S9&_A3S!+[ ML00!FNP\$>"!X?>:_O;DZCK5\!]JNV7&[T1%YV1CG"_B23DEU5*,_:3^2%3: ME#DA\S(_9\\"WDWA[^V-;D%WXGG9[34+B248C:%V0QQ#.$C!4D =<[CEB37H M4^@?:(V622VV%2I!D'-<+X2B3P[\5/$=@LC[=22'5E0G(1BODOM'8$Q*WU=C MWKL2V-WH:PQ',Y\WOZ6[N_99+:10!]66<_A'7 M:><**JUYN^HZ.UNQR7@B>T\,_$WQ%HGD7GDW/EZQ;2$@1OYN4E1?=70,W_79 M?>NX^V6ZGY;4'_?8FN#\9AK#XE>$[P.52=[G3V7'4R1>:/\ TG_E77!O?]*5 M6-[2[H*6EX]F_16T-Q\1YY/L^L)-9Z;$JS&9QI\RRR2958]^QID\H%F*9 M59$ ;#,*\#_X*+SK%XF_9TD@W:?J2+_X^RCZD5[OIM_#_ ,+' MUB(7VL2S)86DC6DMNRV-NI>X >*38%:1RK!P'8J$BR%##.M%L M-;\13^'=2_:'\/>.U,QTV&QTG6;S3-0O%R(HXTFBFL?*=PH^78FULDKUKU7] MN_XFW/P>_8#^*'B:Y=+;4]-\'WK!X"0$NGMV1-IZ_P"M9<=Z\Z^('[2WQ3N? M@Y"&\2W>O\ B.XDTK5;^P.H6VFQ//-(KF \^7+#) 4=58H% )(_;K]E[4 M8;O]F#X=SV_,,GA?37C '53:1$5\$_"[X]?L_P#_ 6I\?\ C_P%\;OAIX>\ M)>._A_?/IUHEYJHCU2>*-Y%D\JX412?NY%;=$"0-P)!R:4EL-,ZK_@D=^Q/\ M//A5\>?B3\7_ (*_%71/$_PL\?6KP6_A?3K4C^Q9#*DL0D=I"ZM&OG*(WC5M MLOMS^>__ 3%\9?LD^%O&?QF7]I2V\/SZC-XE8Z(=2L+JY(B$D_F[3"I ^;9 MUKVG_@DIX0T3]F#_ (+@_$WX:_"+Q+<^*/A@?#UP;J87"W$2^6+=QEU^60PS MR-"''9V'K?LUZ?X>AO+&&"SUN?3K&YMF$ ML_\%+?^"E_Q!\'>'+V9]-^ GP\N]2D" M_/$;F!!/,BC^^[RPQ'OF+T6OTT_9M^'?[-7[#_@?QYJ_PE?PAIUI!IC:UKZ: M5K@OG:WM(Y'$C@RN550[\\#YN>U?C[^P#XT_;#\3>+_BC\:/@[\.-*\61?%C M5+B/6+^]CM6B,GF/+)#$LLR,$S, >"#M4?PTY;)"7<_6#_@AS^TL_P"TW_P3 M/\"WMW-%-J_A6W?PQJ&P_=:TPD.[_:-N8&/J6)[U\R_\&QW_ !_?M'_]C;#_ M .W%<#_P;B^-_$W[,W[4/QC_ &?/B!HUSX<\0W-O%XBBTV212EG,BJ)4&UF! MWPSV[ @GY8NIK<_X-QOB[X4^&>J?M#Q^(_$WA_0)+KQ7&T":EJ,-J9@#<9*B M1AD#(Z>M"=[!W/U[KX9_9]U!O@W_ ,%T/C?X/C@CBT_XH>"M)\9H$&T)-:-] MB8@>K[G9CW*5]B>"?BWX5^)9N!X<\2:#X@-GM-P--U"*[\C=G;N\MCMSM.,] M<'TKX\U^ZCOO^#A_0Q!\SV?P1D^TD?P@ZM+M!_,'\:T8D?4GBC]E_P &^,OB MG;>,+_3KF75[:1)BBWT\=I^)EEX0\0:+9 M3?&SP]\*)[R*1DMM22P+ZE\P&Y#=$?=Z?+_>KI?A\9+?X0ZC+J_CRP\:6\T4 M\O\ ;4]M:QVL03DXIB/)?VKHDTW]IK]EGQF9K29QXCO_ M _)/;?ZN9-1TB=_D.3\AEM8B.3T7ZU].5\I_M1PR7LRFYNB MR#+32$R.3C_:8UE?&H&[\&1V(8*-2OK2U;_:1[B,.I]BNX?C741KLCQZ=*OE M_=^K.?>IZ%^6^M_+)>V10!D[&(KC?@X++6++4O$9CND?Q!=O-&6<,#;I^[A* MYZ*40.!_MD]2:?\ %K6F\.?#+7;V,GS(+.0IM^]NVX&/?D5I^&-(C\/^&;"Q MCP$LH$MU ' "*%X_*A1_=W[NPW\?HKFV;:T=&_?NN/6.N*\':;;^+/B5K.MF M:VECTS_B464C(=R8P]QM/8&3:I]3"/05T>JZC'I&D7-S*P$5O&TCL>@502?Y M5S_P;L6L/AMI32 I/>Q?;9PP^823$R-G\6(_"B*:@Y+T!ZS2^9V,FC+,A'F6 MS>H+_P"->*:AH-WX%^+I-M#<7G@[P^IN[B-9@ZZ=25_A\_*]Q M7L+, IY_2N.^#"C4?#EYK#\]X]WEQ<=OW2)^.:THRE"+D]5L15@IR M2ZG;V=C_ &SIR2PF"XMIDW*ZR*RNI[@YY!KQ+Q[X4NOAU\1=.TR".>7P3;'^ MV]2LXXO,_L_:Q$6S'/D^;B0H!E?+)'RY ZN[T>\^$5\]YH\3W?AZ9FDO-,C7 M,ELQ)+2P#TR26C[YRN",%_P@U*W\;SZ_XBCN!=VVJ7GD6Q'($,(\O:/;>)20 M>A8U=)2IIU%K'_/]3.K:HU!Z2_R_0[RSTU->TA)H?)NK6ZC#(R.KI*I'4$'! M!!KQ7X@Z7<_#;QII7AB;SI_!U[+_ &IEQC+VQ)R9;]\*,=TENHW2:1ZF( 9:$=T MZJ,[> %%?P+9:7\5YO%6J3I:ZAIVJSKIT,@(>.XMH4['N/,>7'H_#*+Q?90R)?QV&IV+>98WL0WO;O^7*GHRG@CK7%_ M#;Q3'XW^,NI6>J2)::IX4LELYK9?G2224AVFCY^X46+![;]IY%7]/U^Z^$TR M6&MRS76A.RI8ZI(V3;=%$5PQ/4DX63H>C8."V+X3\"KX^\%'7HI?[.UNZO[G M4-/OXQED1I&$18?QQO$(]R'C!]0"%!-0?,]-D_4ACN+/6=&MH[36;:''G1A(!( M&4G[WE.%E3U4MCEC7H6E:7=K\5_&WB?P\ZW5S'?VHGM0X\K4[8V-L=H/0.,E MD;U.T\,<4I=4DU+XSZGXGT2.6\TZYT*U6_T_!$ETB37"3C8>DT6Y/E(RAWX"O[6BF]UHR2BF><*/.%4H7C;.Y 1WV+([9X\N-_45OAJ#K5%37S\EW.?$UU2IN;_X M=G&>&[.'XJ?$>TN;"ZE%SX^NI=:OYFC;S+324A\BW@5OX#(A+8ZCS9".<5Z' M?0CQA\9=3\):(S6NFV^F6<>JW$#;/)C#S!;:,@?>9>I!^1?0LIK \(^';CP_ M\4%\(>'/FNM+T9%U36$4>7:23LNX8YQ(([>,(G\*NI/ ^;J/[1M/A;\1)=$T M.S-[J<^D0?9K;?S*WG3EY9GP=HRI6FV[0UTT_S?Z'E48)*\M- M=?\ )?J6/B7XBM/A1X[\*)IMA'-J.KVT^B6%E"-A9E43IGLD:K#(2QX' ZD MZZ_")KOP5K2W]RD_B#7+=A<7VSB-L$QK&#]V.-CE5^I.223D^(O $?A6VT_Q M#JEVM]KR:I:S2WC':D(9Q"Z1@__&"5[32)KBP\/J= ML^J1MMDO0.J6YZA3T,OUV\_,.-WY8N#TZOT9V67,^9:]%\C/T'Q_J'QB\/V^ MG:)++9$0+'JVI)@BRDZ20Q$Y#3 AAG!"=\D@58D\-V?P?\;:'-I]J\>EZA'_ M &3=>6_J2>I) M.22>23FO+OBKXZ;PO\5M/ET!;>34-0\O1]3GE+"VLM[9MVD8=7#N0J#EO- ) M .:*7[R+H06F_P _,JHN22K2WV^1UGQIU6TO_#\N@+$U]JVK(5M;6&39(A'2 M8L.45&P=_8X Y(%9_P +":\TNYO-=D2Z\8VSM8ZM/MPJLA^[$/X86&'4=PP M)YS72>!_ -KX2$T[327^J7I#WE[/@RW#8X_W5'\*C@<^ISRGQ&\9V?P6^(UA MJLXD:W\4C^S6M[:+?+/>*I>$[1UW(KIGUV9XY"A[T71I[[A-Z#.%[DPZHJ^ _BK;W^Z./3O$JBUN26QLNHUS$P'3YTWJ3_L1BB#2 MC[.._?\ 1!*_,JCV_K4Z7QSX4C\8>%;BQ9S S /#,G#02J0R.ONK!2/I7RU_ MP46\73>/?^"??CGS; W=Y#;V5I>V]J[I()DU6..0Q,#R0063DYXR"#@^^ZAX MCO/BW=&QT*X>ST"-BMWJT?WKK'6*W/IG@R\@8(7GE?(_^"EOABU\-_L(^.+. MQCMX+"PT^QD:!@I0QIJ$3N &S^$! )&=Q!SFNG*_=Q-%2WYX_FCDS'WL-5< M=N67Y'Y*^(;[4-)^'">'7%[?V6NVUK5 D4A7E>7 M7JQY\Z$M%XD\2>'Y-9L)-5TK1I4$KI\TMME(WPN"!A66X 5CMR6XS6U'X@\ M3_LX^+8O"&FZ_IOG:5J*KIYL/#2S.S3H)9KJ*251C,>%)4GY21CG(_9*\)\\ M52=IJ[:Z/\'M9?(_+L-.FJ^,":7X^T>UN-#\4:I'>^(= M0TI@]X)X[$2 >5,J^7;#]V^4QQ\O/W17 _#'2/%-AJ,%[X52'2Q#=?8M2N8+ MQ;6U&V-)6DDN)6VNZL'?@,%VG(QQ4/EKIUX>Y+:2>W]>:-4W0:H2]^&\6KWU ML]/U1]5>!_C[M/_V>$$(K1RQ* MC.SAQ&O0D&O(_L^A!RJN@YM[MII6[)-;;>9[']I8B4(4EB%"*V2:;OYM/=_< M7/A+_P %!/%GACQW)J&IWRZ[I&MZE!+)9ZE$L%M")7=Y)@P4;##% D0;(C&R M0\\FM?XG^.KOXVV%S\2/#=G]G\(^+8&62R2U47>E,&A0))M[R2+)(#R&4.,? M-7$:W^T)X',%U8RW,\&CV2W+SV-[IR7=DEV5$;;(F:.>']])/_$V@ZB-(MK";P]JJ"RAU>]V$?9VFW&/Y0'R''W@ K98,".7T MO:+$0H^SEWLVFO.RT>VHGF5;V3P[K>TCVNE)/RONM]#>T;1+3]GO^Q]6\:7F MG0+]FEU&ST>TN(FN[MHR"$+*6BB3:QX8A?O #+-GR0+XG^,7Q2&=0^R^)_$6 MJLUO<7$+Q123,H7R]Z;H2CQ;&S@CY?0\QWVFZW;>.])?6[;=XCUN.-Y)IY,W M,XN)IK8A)0S+.A61. 20$Z>OJ7@OQ)8_LY_"^&;PZ'-K$%NT7 MV*2T\MU\NRF'[R0A@AE&._'6O9TH>]3M.K+1;6\_EWW;/'C_ +1[DUR4H:OO M_P %OIT12\?:#X?L?V<6EU;7;SQ3J6O6DECIBZ9 U[E;>\AD:=G;9B6*$S0@ ME1\H.<@ 5PGC+4+_ .(WA:UU22RU![BVGBL62,%+O5K6*U3[(LH3"JHS*SMV M4 9SMKJ/!=K)\?Y4O];OM.N-!\*ZU?MW#Q&*_%_\ :K\;76B?MR_ '3(X]+6WU/0_"S2P&V@> M2-5FDQAV3( )8#:1CTK]GH.$7Z5^6\6W^KX._P#(_P S]!X;M]8Q5OYE^1)1 M117Q1]8%%%% !1110 5!J3S1Z?.ULJ/<"-C$KG"LV. 3V&:GHH&G9W/B[2+[ MXF^,=7\&$^+/C-:Z],TK>,;1M"@L].T:,02.YMG-L8Y6698UC"O/O5CG!^8? M2W[-FM>)_$'P;TJZ\7PW,.MN9E8W-NEOLEKI&.K: MN_DSQK\1_B:Q%HVM+;Z+J=U916LE_:&U@D+D1*J- MB5Y4W!1]SVKU.BBIBE*'(H)?TMON_%BS#B2EB,++#0PM.'-K=15T_<^%I)J* M4;*-W\4FVVU;YI_;#\7?$FY^+?@O2?"'ACXDIIEM=W$MUJV@7.GK#=YLY"BL ML\P7:LNW(G558C"DDK7H'[-'Q)^(_C.+4K/X@^ [KPM+IY7['J+75HT>JH>Y MAAGF,+CN-[*>H8?='JU%*6)4J2I)/"^F?V-*GB'3=2BMC MI]I>JR>2UE.A,DI?,F[<2NT+]UA@^^44?6(\G+R*]K7%'/<.L+['ZK!SY.3F M?SU2T][6[D[NZC9I)Q?BG[3]K\1M5^*?P\L_ 6KW6B1.-2GU"=K+[3I\CQQ1 M-;Q70QD1NVY]I))7UCRQ<91UOC>/-9UC0O#SW&AZ/'KNH!U"VDEX+0, M">3O*MC'ICFO)O%'CSXW7OB;P_ST^VNB-6M)]?CD%Y;L,$HP@#)(A M *\[3D@CD%?*?K?_,\_+\RI85>_AX5'KK/GZJVRFEIT=KIZIW2. M6^-ET]G\'_$DZ7&@V30Z;/)Y^MQF73H<(26N%!!:(8RP!'&:^(/V3_%VF?&W M]K_P/?S^+_A;;WOAX7MWI]EX<\%7^CS:^KVDL+JMQ 8/#]J'%C,CM/<"1FF<6Y=0% Y(8 MCK7JYC^>JLM3].X!I0?#^8U8NTU&IT5[>R>W[N=[[2O*GRQ]Z M+;T7Z%4A.!2T5XA^-GYZ2:[:ZQ\2O#OBW0A\+]-\7ZGXG^S2^#7TNZOM5T=W ME9'NI8/MD<8FB'[V1Q!& -Y$A."WUG^QUXQA\=_#/4]1BTW2+)I-=OEFN])5 MUL=9D$GS7L6_YL2'KDM\RMAF&&-"^T_XN>!?$%SJ,4?P^\=VP!9K.&RDT74] MG8+,TDT;MCLRH&/\2U;_ &./$7BCQ3X#\0WGBK3MQBZJJ4;JVENOX6LGIYGZMQ1F<&?BGXL\-S:'% M'#?:98:?:>7"[/* Y:YMG8LVQNC$853C# F7X$?LOW'P2^('B+7W\=^*O$C^ M*-LM]::@EHELUPH11<*L,,>V38@4D'##J"0".2_:'N_$EO\ %V?$?2_ M<>G0-8S>#+59VENBTOGBZ\N-[D841;-@"8W9.<59_9FO/$LWQ2NUM+WXB:EX M!;2V8S>,;5()UOO,C\L6^Y$N"GE^9O\ -!&=FT_>KTG&:HMQ:M;LONO;?R/T M6IA\5'*92H581I2@KKEB[K1\KJJ"O/F5^7=6M=M7)/VS]>V7.@:+KOB35/!_ M@#64GBUS5+/3Q(KG,:QVTMT219QR!WS)LYQ@21G&><^"G@GP%^SW\=-.\*?" MOQ!/]AU%/.UGPW:PMJMI:J828[MKK):U=MJ##.PDW<1Y)<='^V;K36]YX>T[ M7=?\1>%OAYJ0FCUW4=)L\@MF,10W%T,O:0.#)ND51T ,D?\ %SOP5T/X?_!_ MXY:9X:^$6N7;:9=IYNM:#I1^S\5KP]^GU M[_\ ;%^(E_X ^'=BMK?:1HEEK-\-.U+6=4T^6^M='MWC?,SQH-OW@J RLL8+ MC<>Q\=\._L]>#OV._%OA/Q#X5\;:;<:KXBDATXVFL0I>C6XY)_L>>+/"NN^ O&MF-:\52063VEY"NK?\)'! M)-N>2W2!0]OC>QW0;;=^B5^;U=M+?/Y;E<,2Y,G5+GE'VK MFN2,.:-:R>E27(^3EZ6Y^DN6G_$?V%1117CGY,%%%% !7/\ Q8N]7L/A?XBF MT!&DUV+3;A].14#EK@1L8P%/!^;'!XKH*Y_XKV>KZC\,/$4'A]VCUV;3;B/3 MG5PA6X,;",ACP#NQR>E=&$M[>%[6NM]M^OEW.3,+_5:G+>_*_A^+;[/GV\S1 M\*RW4_AC3GO@5OGM8FN 0!B0H-W X'.:OU0\+17=OX9TY+\EKY+6);@DY)D" M#=SWYS5^LJOQNW?IL;4+^RC>^RWW^?F>)_\ !1C3$U?]B#XG0.P4'P_'O%&F:K_P3YF^P:4^D6T'CMVCA^T^=ACI8,K[FDBP3AP ?[_? MK7[5_M_V4>H_L9?$J&5MD;^'KO;H9(;&8"(_V>C@@%7/RR%,G&,C@]Z_2>"K/!277VD?38^"XLTQL7T]F_P S MA=,NHO#PAOLM>&OCI=W>F> M*WD75OL-OI=EK0FV+$4FG*K);,R))_J H8-_$)]1UJZT/P]8K'J3W*J MBS7H>:[!:*,PNSY,B E$ 4,,D9S7VN.DE%5&[2Z6>OH?.X)-R<+7CUNE;UWT M,SP#^TUXV^'6K'1M3CU'Q3IFI27=I;:7X@M$A@TVXBC"V_E<.1*F BC8H?O MFN5UGP5'\5?#4ZE<3"-_WQF=F"E%9G;^\ #M7:ISL^ M%O'7C?XN>/\ 4H?#0T[5+B2XU/5M>CL$,+2!8E1MYN3M$3!8U.TAER37/VVA M:!!I&O3^)+:/P+=Q1R1/(S27D6M/-$8V:.1"R%A%+*%"($R<[LJ11"FH2'=*DO[G3?#I347DCN9KK6G^V3 M+-$7S(BX$:N728L!D9B0#A_EI^*;6]\M<1R7L<&FQ1J;D<"Y41 MYWR,DLGRNVX[LDJS!*VM2\)ZO8Z?^;I,ZWJVIE1B"Q0G&588# MR:1+>DW\MFT,CF*-V0F1PX#;7SO,:DMC)4[#E=Z M4D_>@[O[V85DU[LE9?<7-.\0VFH6D.G76D:+?:-IL,D=H9M/2U,*RJL;S1M" M0=Q :3< "ODN,;AQ!I/PR\&ZOK-D6FUOPVNC6C0VVFW3BZC:^9@&\V5,2JC. M43:JG+[\85&ROA#PI=>(7DLK6PO;U8S)IYO+X,TB'7O[-UW7M#M=0ELEU"WL["7[?'.!#&0@.7G4@R+F.=6.&3 MF9R46U"37IK^!<(MZSBOG_G_ %Z&[X)_:3\8_"KP=JD"Z#I\>O7EW%:VFI6\ M@N[BTE+2+*UE&ZE55D&TIN (?Y 3B&UTW2_%NDCQ'\0K_7_ !#JEC:WFDVJ M7I&G7-Z([J9O-6??O,:)A=NPC(*@BL;P9%XV\-_#6]UWPEX=;P[H^CW-M>72 MSWL5Q]GB,T@3ST)-PHW!"!C+*;.&YTNVU"?2[ M2VC:UAEM&O+C.]YT(\S>S%1YB$AE7!/-<=:,*;/F/'-:OP;\477BGX\?#S3K MS4;Z_P!,T75[&*SC6V8@0+-#Y8#) !C"6V23UD'O73)2/Y=I>1Y%KJ/7&"?N2$8RA[GY2PZ-\=VJ>,_'FB:$^R2U@5]4O8V&0ZI\L M2D>\AW?]LS75:WX?L_$NG2VE]!%=9+_>@)/*_P#3,XP!\I_A,,WB>P^*GQ \.P6, MWVFRTM)-6N, CRY0##$CJ>5;+2G!&08_:NR\/^)['Q5IB7EAMAH^JR'$09LV]Z?6%^Y_V3\P],&?#-C\0KGQ4^I6B2(^KF M%&)(=/)CC565ARI!!((/!S50;BG[7MHQ5$I->S[['3^,/!-CXSLT\\/% M9;W4)V36[C^)&[']".#Q7FG@/XAW.A?%/Q+_ ,).N;;3'@T>#6ECVPRXC6<^ M:/\ EF'?@IK?BW6M4L8O#T5W?7-W=2$-'L^T.H4@[3ES:QV"5I5(VTD=SXK\-Z;XST*2&]C2> CS%D!PT3#HZL.58=B.17FO MP9UK4?A1X'M#JZ-=Z)J$LU[_ &G&N9+9YI7E;[0H_AW-_K%SU^8#J>7^%/Q% MUKQ)H/B>71/#&N^&+?3(4F_X1S7'B61K>9':*:'8S&W9E4YAAC>2*_32K;[19W2&*=#Y29)0\E23PPRK=B:J.E%V]Z-P>M57 M]V27ZD7QP\.V'Q T[PS)'-ACJ]N]M?6KCS(>I#(_X#CH1P,')VUS7Q7\ 7'@>71[_ ,,N+>%=8MWE MTN1L6DS,Y4%>"8F+,.5X.'=%3Q1XF\:C0F@D:]E%U=:5.GE?:K>:/;-; MSJ02LPE68J^.CH,E:W?!6BZM\)?&?B>PT& ZAH45U'=C3'?$T*S1@L8)&/(\ MQ9#L<]S@@ "JGCJ6R\2>+] \8>';_P#LK4[>8:3J3M&4D1)3B)+F(X) FV ; MN@D8J1D&NI2?,W??K^.IR\JY4K;=/PT.%_9=\57WP)++5;]5T#6$@;3]2 M7:9+#6K1N,DGAPC'=M)$B*SD>I@^#7[0.H?!OQW_ ,*_\=--':2J9=#U2Y;> M#%N $+2])54$!9/O;0-^"&-5B\-+$+V]/>VJ]/S)PE=8=^PGMT?];'TJ1@T4 MV.3S%!&"",@@]:=7B'L!7!?M"_'[3OV??"$%Y<6EWK&LZO1:=92W$\B0PP(9))';"HH&223T %?'NE?&:[ M\::Y>?%06K7GB#Q9#)HWPZTG&7L])$F!>,K!?WMY(GF@GI%Y(. DAK2C1E5F MJ<-W_5S.K5C2@YSV7]6.._:9\%:O\5+#Q##XS\8ZQ>^+-*L9+TZ?H%Y+#I&@ M71B9K:S@C 073;AYDLEP&.Q0-J++LKU7X4^-)O!'[,-EKVFPKJ'CKQSI">(M M0DDW&'3VN(_-&]OX8XS)LCC'+=N-Q'&:CX.N/A1X U735N+'5_&MG8S^)_&& MH&5I8=)B57F52.2SR21>FYQ%SA0N.S^%]M_PB_P/^%_PW\/BVN?%=QI6GW^L MF=G<0QP01,[RMU_UAB41G!*D@ #I[+A3IM4J6JW?G;J_+_@'DJ4ZB=6IH^GE M?HO/_@GJOA/3]/\ @)X TO0-*M)-2\07,2JD&_=-=2!0K22O_"BX^\>@4*H) MPM0?!'PY#X0M/%NOZW\U.\/[^X9=]S>N!D1HB_P *]E4849)[M6!\&? E_P"-/"&G:MXH M54CN)'U*WTH',4+RR&7?*?XW!8X_A7L"1FN2[<)3;T;W[^2.I>[.,$M4MNQ2 M^*LM_P#%C2+">>)['PNFL:>L<$R;9M5!O(5W.#RD>#PO5L\X'!]#\5>-[;P/ M;6]E9VKWNI3@1VFGVV [XXR<\*@[L>@'&3@'B?CA\06\0ZAH_ACPZB7.H2ZQ M:I/=,NZTT]HV,XWD$;G_ '/W%.>F< C/<^$O!5IX&MKB[N)WO-0N!YEYJ%RV M7DQ[]%0#.%& !45+*G'G6G1&M.[G+E?JSC-/\*W-G\:O#^J:](EWK%YI]ZBA M&)M[!=T!V1*?U/3]X05YXSV]+TO2M( M^&GAV0)Y%C9P9EFEDDQN;JSR.QY)ZEF.2:*VG*YZNVB%3^TH:*^YR'@7PE%X M,^,^H1O+)?:AJFCPW5Y>S??F=)74 ?W5 /"C@8](CO-1^,/QPD%G]OT;0#HB!KHCRKG4$^T- MQ'GYHD.#\Q 8@Y7;PU>IVUKI?@#PZ$C%MIVG62DDDB..-1W)_F32JZ23EK*R M"C:2:CI&YR?PX\&6W@/XF:Y;1F::34;&UNYKN=]\MW,'G1V8_3RP , #@ 5 M?\0^-[KQ#JTFB^&/+ENHODO+]QNMM//'''WY<'(0<#^(CH>1AO=2^,GQ:NEL MGN]&\/Q:5!YMQM,5UJ*O-+M\HYS&AV-EL;B""I7J?4M#\-VGAO3(K2QACM[> M'.U$''O^)/)/>E6M&2E-WE9:%4;R3C#2-WJ<7X,^'EE\/OB[)+;F2>]U_22U M_=3'=-R-:-HIJ.UV1B#XS:%I.XN9D^H,#_X5TX-GZ'<*3OBUNS5,'_GI*(C^DAKKQTKD_B<%O\ 4_"] M@>?M6K++CT$44DNYKF_P!KGX0_\+]_9>\?^#%2-Y_$>@W=E;>9]U)VB;R6]MLFQ@>Q KE_V8_C MP_QG_9+^&OC[^U=(T^.:Q@_X2*;4HR/)DC1H+N ,741R+=IM+-D?(PP<@A=2 MNAC>(K/X)77Q]@G/A+2;[QQ-XE?0FN&L B1ZO'IIU.,S$\;VMU4I-M8YV@'B MM?QP'_;:_P"">^NQ+I9TV]^(?@NZMSIL[AFL+J:U=# S8'S1RDJ3@APZ/X%T[4;BQ\/S0S"2+5[9&&^\CZ M_NWG,VTDG>JB3.'%'6P>9YU_P1W^-)^.'_!.?X:7EQ&8-4\/Z=_PC6HP-]^& M>P8VIW#LS+&CX_VZ\M_;C_X( ?"+]M/XOWGCO^T_$?@CQ+JS>9J*13MD( R4(!Y)!))JI^SKJ"?\$\O^"H/C7X4:CFS^'_ .T#'] M5C\'+J>J:[KRK'J.MZK*LEW/&I)6)0JJB1@DG"C).-Q; Q\S^)?^#73X*>)_ M$VI:I+XX^*,4^IW4MW*L5Y9!5:1RQ _T;.,FOTNK@?VGY-8B^!'B)O#^DZ]K MNLK K6FG:-J*Z=>7KAU/E+?X6_ MGPGX_P!(T7QQ\2C%\1=!/AW499KRT,D-LT\4S^61;@!F\K8=P(VNPQG!'U=^ MQY^REX;_ &)OV>M!^&_A-[V?1M $NR>]9&N;EY)&D=Y&554L6<] . !VKY(T M?X:?M+V4UU'=7?C_ %*T%CIL"/C]H/QN\,S>/+CQ#+H:>%]NLOJ=^DT?VG[-8+% J)*R-*LJ73O M,$5F,DH)91&6E:;(;O;<[7Q1_P $Q?!GB#]O_3?VB[?6_$^D^,[&U6TFM+2: M$6&H((7@/FHT96056=BQ _T;.,FOTOHJN5"YF?+_\ P3E_X)3>!_\ @FA/XMD\':]XLUL^ M,%M5N_[:G@E\G[/YVSR_+B3&?.;.<]!TKSG]B,V?[0/_ 5G_:6^*%LTMSIW M@VWT[X=Z5O=O^"AW[7EG^Q3^RQXA\8.INM=D0:9X M>T^-0\NI:G/\EO$B=6PQWL!SL1L GBLC_@EW^RG>?LA_L>Z#H6N2&Y\8ZY+- MXB\3W+XWSZE=MYDNXY.XH-D>[//E ]Z5M;(.EV2_MB_#/XN_%/Q'I5AX/F\) MMX&\G.L64^H/INK7\F6'EI=?9;E8X=I7.R-9\5R_&F^UW4[;PUKFBSSS7$C/+-)IIWQL4M[)8?)C=;@+$-CAPVX,_U!XT MT!?%5GI>G7FC:7K>G37L4U]'?,,6PA!GBG1"C"21;F.# )7;G>&R@5GY@>#? MM,W#^(/VX_V:/"4<:F/3[C7/%=W%&,1PK::>+2(X]/,O^/\ =-?3%?,_PNB_ MX7%_P4Z^(_B;YSI_PJ\-6/@JS(.Z.2\O#_:-Z<]F6+[ N/ZB5A^1KJ M%0+Q7*_&V0VOPVU&\5&D?3@E\JJ,DF&19!C_ +YKJ89/-A5@>,<$=Z3_ (/^Y$J_D!6)\8();C MX6^(1 GFSC3YVB0?QN(R5'Y@5KZ!>+J.B6V-I\-=#1EV,+&'<,=&V#/ZYK3\46 MYN_#6H1!=QDMY% ]+T M?Z&[.,QL3V4UY%\+?!U_X>^'>E>)/#83[3J\"ZEJ.FR'$-_)/^]D96_@ERYP MW0X (Z$>O3"M*T/5H?[-U>W1X$1^ M([X1R,A>$_Q?=R5^\,C(Y!K:'\-RI]U=?>9SUJ*-3L[,[/PEXXL?&NE2-$7B MN+?Y+NTG&V>U?'*NO8C/49!Z@D!_ 5EK>A1&YAU(R7VH:1G D M>1V=W@)X5\G[I(5O]DY)[KQQ\/$\2/\ VAIMPVE:W"FR*]B&=Z]=DJ])$.>0 M>F<@@X- 9!:)NA.0QP2"? _P"*5KXS\'Z7:7$!T_4?L$,OV:8@ M^=&47$D;=)$((Y7IG!P>*(Z4KPUC?5=@?\;WM)6T9C?M*^'M-^(?P^T2[MKA M1.FN:7+8W]OM=H6:\A 93R"#GD'@CK73^&?'$PU,:'XBACM-6*?NI%'^C:BO MK'GHV.J'D9XW#FN+^.?P]N?!OAW^U-!)_LZVU"TU&]TC.(I#%FQR1R M,[6] 237CW//O!EC=_!GXF>-WL[7SO"\M[;326<*DRV"FUB4RQC^*/\8^%;6/4K?68Y[748(9>+U&190\0^Z9L0GKC<%VDC@B;3 M?$=]\)OB^]EXDN3=Z?J^G1QVVJE,?ZF1@!<8&U6_???X4\<"G?&'X=ZAX;T: M76_"V9K2TN(M5FTI#A7>)_,9X".59UR&3[K@XP"Q)WO^\3EU7R>EM3GM^[:7 M1_-:GG/Q0T+3=(\9V6M:+_R ?$DG]IV]^A;;H.K6_P!UC'V25&D61>VQL]37 MO'P:^+5C\7O!R:A;YM[JW=K6_M'8&2QN$XDB;'H>A'# @@D$5YSXXT)?BKX% M3Q=\/9[:[G.R^.G2@+%=2K\P+*<&.;&4/0,K,&_A*^=>'M4;X+>-E^(_A%X[ MSX?Z\B6VO:>#MET:X0A-KJ2-I0CR^1E2 #\OS+TRH+$4N5NTUM?OV?FUMWMW M.>-9X>KS+6+W]._HGOV/K>BJ/AOQ)9>+M#M;_3IUN;.[C$D4B]&! (J\1BO MU3L]SW4TU=!11UKFOBE\4M'^$'A&XUC6;A88+=694R-\I )VK^ R2> 22 " M:J$'.2C'5L4I**:]NC^ZL[.''G7LY^Y$@)QECZX M )/ KYQ^!7A7Q#XG^+NN:K'+'"GYJ]V M%'ZM!T[J\M&^W]?GZ'ASK?6:BG9VCJE^1+\']0^PKKMCX2A2\O=2U20R7TQ+ MQ6D28B\V:3_EI*Y1W"CDAUW%1S6QX1CTOX6_$?Q/<:A=2RSO:V*RWTWSS7LK M-.=H4+:U;N\\O1I"1DJ, MN+=W -U" ;@C MMS_JU)']XGI7I7B7QEI_@/3((@C37$B[;6PM4W3W! X5%X'IR<*.Y K@?C+X MXO/B+X4-AX:A$EI)>VD3ZO,/]'#?:8L>2O'G'/<'9UY.,5W?@_X?V/@N.2Z= MGO-3N% NM0NFWSSXZ GHJC)PJ@*,G %8S_AQY^[T1O3_ (C4.RU.$\,^"KOQ M1\;+Z]\3K$OVG3K>XM],C9>3 MB-I#Y<,"*7EN'QPJ(.6;V'I[5Y=XO^(EUXD_:'\/67A,17;?V1J23WDP;[%& MRRV6""/]:5W,,(>"P!(KT7PI\/(/#]X=0O9I=6UB4%7O+C&Y0>=B ?+&G3A0 M.G.3S2KZVE/ML%'K&/?<\\^$GA2_^(=EJ5AKZR6>CZ)JDL,&C@X\Y&VSQ^>P M.&"K*%V#*_)R6KU'Q18:>/"-[;WAMX-/:W:.8N0L:(5PV\)_% MOQ%I-K#+J>JWD%M>0V-J 7P4=-SG[L8_=]7(SP!D\5LV7P_O/$]]'?\ BB=+ MEHVWV^FPD_9+4]06!YE?I\S<#'RJO.2O=S4I:+=(5!I1Y8ZO8Y7X7^*M>^,W M@33H[2232+&"(6E]J6W,UY+'\DH@S]U=RL/,89X^5>=P['Q!\,;,_#._T33( MHK1G@8P.5R1/]Y)2>I;> V3SGO6?X&U^R\)W_C""[N(K6TTS4_-:21@D:":* M.7J<#JY_&A]4USXIN1IXGT'0WX-Y)'B\NU_Z9(1^[7_:8;N> .#14;Y[QTBM M0IVY;2UD]"+2_C&^N>'=.AT:T&J>(+NW5I8 VV&QM?\ B66'S(+QEPMM(C"2-(D_A0.JY .6QR34GP&\-V?@ M:RU_1K2%(DTW5YOF'+.)52X#,QY8_ON222<5L^*_B3#H^HC2]/@?5M9E'RVD M)_U0_ORMTC7W/7H 3Q2DW&I:B4HJ5/FJC]+^(VG2> +77[J>.SM9X$F/F-RA M8#Y/=L\8')/2N*^(?@W6/C_X3O([E)-%TE5\RQMW4>?=2KRDDP_A3(4A M_"H_V9J7B7 M2>BZ?JKRQC&/DG"S\>P:1Q^&.U>1_P#!5JUAO/V(_&B2R.G[K3G41QF1W9=3 M@*JH )RQ &<'&:WP*MCZ5OYH_FC#'R;P,[_RO\C\B]"CC5/.M9Y;C4X&WI;3 M0JZ3*2N#P9@3D0]2O,KX/6O4]"^)OAOQUX5L]*\6VMS>:3I]Q,+#R;DVC:8D MI<9)!"RH(RC%"Z^%?PTUOQI<&9=5%C!I\S+_EL?E6!YHRY:6J:5TUTNO,SO"OQF\2_LSZ[!IVE:EK.M M^$-(CM;:73KO38H]*U*TN)IV>1SN=1&ZA?G7IZIJ$&GZ9I+XST5?#=%2H M[>S@VZ:>S^'TYM=/N,_1_#'A*SBM&@L&UF\M;,V3ZCJ\C"UO(WXCQ;1\*5C= M&PS''E2Y^=5)K>)YIOB1HJ0W)M=/OK:"& @:?!&D]D"BK"[J-^(RJ $@9==J MJ=N1KZ%X &NZ);7]E):^(M/GAF^R/93K)>;%\R.5S;@B1 =]PP!7@RPJ,X8U MF-XA72M6FU;4[F33]1O EMB-'66[D3/*[QM54#G#YV,A .&&ZNNG*[YD[R\^ M_HZ6[U.2ZTB$/>7*AI-S!2&9DR^ M_4N,,RR'%74/AYX%\8ZC:6%\=:\*Q7&I->7\MK+]M@G.U@/+$@5HU0+<,&R? MW: G)95INC^9XIN)AI"76HP:X0PN[:VF=7\I-JJZ$<%"5.!EB Y/5!6EJ?@3 M3=,U+3U\4:WH7AVPO[R2WB5[H7$T)\DP2+*D>YD9890NYL?/"N,J^:ESC%OE M;4O+?[NH0C)KWHWCY_YF_P"!_C)K/P/UO49Y/#VB:WHL%E,VG7$ERQMF -K M)Y$JL5G$N&WL 2(M0^*_B4:[\3=8\2:OI?AYTU=8;^R2V#S/#$W MV6*7>OE-)C(V @JNXKP*K> /"OB35?$'B&'P1X;O+2^^QWWFZC]JACGU%XXB MSSI;SNS+&X+*=F0H;U!-:/PH^)-W\1;G4_"[^(--TZ^\4/ 8WL89HS)J(M8X MEBD:5)$6-E)#$A1N (8#.>*K"*4JE.*YK*[O[R7>VMM/0ZZ,Y-QIU&^6[LOL MM]KZ75QGCCXHVR>$8?#5A;M#H5IY\.GV;M]J-OB=I&D>5U)D8QP2@D C)Z5Y MUJD'V&_5#>33O^\6ZR$"1MAV=%!EA;((FP"@)VQCN*[?QSX;US1M4NX[F4B6 M#S?,\T(8[Z)FGMQ(C JCC_2N&5\$<@<5S>J>,Y]1T+^QH;NZ_LF\E>[>RB@: M402'>?X(23M+J/O'_4-S7=AHI0_=;>IR8MN4_P!YT\OPW/HS]N/4;;PW^VQ\ M"+J>R>[UZX\,>&)+2Z%PODV[)2&#>NX8[$U^U<)RB_2OQ:_;XT6PU/ M]J#X"H_B)=+%IX3\.R66G/#(96;[2Z@AL # Y.XJ?E[]OVF@_P!2OTK\KXJ= M\)@_\,OS/T'AQ-8K%_XH_D/HHHKXL^L"BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** .._:!D,?P1\4L(]1F(TR<[-/U%=.NF^0\1W#LJPOZ M.6 '7-?'G[.7P*\;:K^U5\.?%#^#/BAI_A[0GO+JYOO%?CRWUNU19K&>*-[> M))G;S"TBC>/EV.W'0C[E\3^&-.\:^'KS2=7LK;4M,U&%K>ZM;B,217$;##(R MG@@CJ#4NB:+:>&]&M=/L+:&SL;&%+>WMX4"1P1H JHJC@* !T KNP^-=&E M*$5K*_?9JW?]#[+(N+IY5EM?!T*:E*LI1;?/I&<'!VY9I-ZOXHM?D6J0]*6D M;&TYZ=ZX3XT_.#QIX=CL-+TQX].\.ZAJL.NW(N_%%E?ZC-J/Q$CA8M/:F*TM MGN'B8.GF-^]@C,849' ^O/V%4S\"%G34[*^MKO4KN:WM+2YGN(M$C,A L0TZ MI*#$005=$*DE0J@ 5\^:5\/O%/B+5]%\1_"5_B3#X2T,7=MH,OV?1'B^QS.I ME2V%Q(LK0,T493SQN 1<$#BOH_\ 8Z.DGX77IT__ (2#^TCK%V==_MM8EO\ M^T=P\[S!#^Y'&S;Y7R;=N*]_,9IT+)]>^V^ZZ?TMC]PX^Q<*N3^SC-2DIJZ4 MFY0;<])P:_=NUMG92O!)1L>L45S6L_&;PAX=U*:SO_%/AVRO+<[98)]2ACDC M/7!5F!!^M4/@C\?_ Q^T'X=N=1\-WZ7/V"Y>RO;9G0SV4R$@I(%9ASC(()5 M@002#7B>RGR\]M#\=>68Q4'BG2E[-6O*SMKMKY]#YX_;2O-/\,_'%[W6_#6D M_%FUNM*MUMO"L_VNZN=&*23;KE+6&VN$*S%@/,=4(,6T,1TN?L,W=AX@^+^H MWVC^'M)^&-E#H[12>#[8W5O/=NTT9%]);36]NJA-K1AT1MWF$%OE KO]:^&N MI_$+XN:_KGAW5/&?PTUE+>WLKV[GLK&ZL-;CC>?RBB2>8WM8+.W=TDD6..!%&6:.,EF+'Y! MC'.?4GB*:H>S;UMW?Y?#\[WZ[GZ3BL\P5/)/J,I_O/9J/Q5'K9:>S4?86_O* M7-]M^_='*?ME:@T5YX?M->U;Q=H7PZO%G77KS0;<\-F/RDN;B,F>WMR/,W/& MH''SNB_>YOX)6_PZ\"_&S3-%^#6KW\ND7"E];TO0HUO_ Y;+Y)V2O,3LMIV M.PXB?=)G+QG.]>C_ &RV\R\T"'Q%=^,[+X:RI<#Q#)H$?R9'E^6+N2,_:8[; M'F;C",?WR%Z\U\$O^%;Z)\;]+L_@K>:E)H\@)U^U\.I'<>&8U\C]VTKL=D5P M3L_X]R7;_EHI^\%3_P!VZ[/;X?\ M[S[?+866K_C'N7W_@J.T4O8:-V=9\K_ M 'J^SO\ \NK2B>A?M@^/M9\!> -.?3-3?P_8W^H+:ZMK2:,^JG2+0QN6F\M> M%^8*ID=61 V67'(\6\&?!?X8?LH^+/#&K_#'QFBZ_P",'@BEM O]O-XIM6F+ M/,(XSOA W,WG1%(4Q\RD#%>T_M@^,=;\'_#ZP;3-1O\ 0M.O+]8-9UFRT?\ MM2?2+/RW9IEBSA?F5%,A20(&)*'&1XUX0^&WPJ_9V\6^%M2^%?C&<^)/%CPF M>UM2?$#>*;9I,(\T*G*F[5GR2MR[Q_B67O"ZDD,:V\CQLJN6'*@$@Y'(Q715S7QET2U\2_ M"/Q/IU[J$>DV=]I5S;W%[(,K:1M$RM(1D<*"3U'3K73@W;$0=[:KI?KVZ^G4 MX\Q7-A*L;7]V6E[7T?7IZ]-S5\*6,NF>%M-MIY5GFM[6**256W"1E0 L#WR1 MG-:%9WA"RCTWPEI=O#.MU#!:11QS+TF4( &'U S^-:-95=9OU-L.K4HKR7G^ M/4\<_P""@EN]W^Q9\38XV2-W\.7BAG<(O^J/4G 'XFOQ6T;PA)X!_8(>RURR MMX9K7Q^EPWER1S&2'^SU,N?F=03"Y8>N,@=*_:?_ (*$3FW_ &*?B:RQ^:?^ M$=O!M)QD>60:_$/P#J*Z3_P3OFE)D2W7Q]YNH2W*L%A T]1M50V)F) 558;< MD9X!-?I?!'-]2G;;VL?R/@N+>7ZY&_\ S[D1_"1+'3]=CU/Q;YMIX:TQ9+^[ M-IA)Y/*EE&R%,#>Q:)CVX@K[2M4FJT707--K1=(_/\[=CYJC"#HRC6?+33U[OY M?Y]Q_P :?C=KGP@!\/>'/%6UKBQTF_EM-'CBC\@)#';W*I?1'%U(9#AU(()' M0E<5Y+JFOZ!XDM]'T7Q[IDFF-:6K3W6MPL;6XTN074I:1K3 24D@J?+(+#!^ M\*7X.?!V7XRZ[J437*:+8V-M/-K4ZPR(]JLR[98DMY%,3MYNUU573ALY7MZE MX<\2>%_!5IIVF^%=$CD>.V$E_P#VU$+NZU)UD*NFUE95#QA@%5MH+\$GYJQC M&CADZ4%S5%JVM-?-_I]YIS5L2U4F^6&R3U7W?K]QQ_A3]FBU\0Z?#XN\,_$S M3M4@UA[C7+V.RLKBWN;5;8ED\V- 2B[R3RFT,H ^]71^&_@1J7BZ2]U'Q!XB MOO$5]J+I-;W.G1?VE!IM\D6UFG<,HAMMLTQ5"%_U'7Y0#IZS^ROXA^(/AD?$ MGX4:1?:;H?V1;"?1K&5C-8:E-+%)=21J6"M;*A7:=PQY:Y7"YKE5\6_$#XG/ MJT]GK%W)'=)+8ZA)%9/_ */:F:9DG?8@$@\EK@8/!_=8R,%>?ZU5KINC57G= M+FCY.QU?5:5"2C7HR\K-N,O-78D/[.WB;7M,AT^\^(-MGC):2ZGN[9+ M65S:W/GN@VI$9HI!AF^XAX^:N1\:>!?A]\#9KW3/[;B^)'B/PA=W-M'9VF[3 M;&)6V?OQ,23(R%6RJ=R.2%KT+PE\+OBG^V@LGA[P_)>3Z?9VDNGIT4.5=)2N_ MN6VFFIP?@3]IGQ;\,_$DVH0:E<:%X=NS=W4CQ6V+3!@\D,L#'==N)YU(:1B6 MV!CCLO[4W@2\O[70]?\ MVD:]I]UI%IHT5[%$"QOI&\Z5&LH,^1,$=B5?J2. M1GA/$WP,T/QSH7B3Q%X*BO-+>P3[7?>';N9GBGM(WDF9H)0AEY/E?NPH &/F M(PU8_P #_C\?AKX>U70M0U?6M-T;Q1:SA&TB!8#)<9S)?F6Y8$LC*T8Z9"-P M,G/2J<6_;X2-I+24;:M6[]_P9RNEKLB2-<,0\HE"E?NDC?S7/\ [.)^S?M)>!]U MI$)%UZ!TC:./)??"L>.,A=\LC=>D29Y6M?\ :8\,6'CBRTSQ-8>)K6[CUO3M M.TR]L]6%V+RWE6W$Z!P@9"\RJF.VX-]W)J#X.Z_?VOQP^&&G7%G+%J45];/< M6CW16X6!KV14"2+\S>4B@%'W?)CT-*GR_59N'VE+3MI_F35NL5"-3>+CKWU5 MOP/W2:1!X?B*D[1/',;3_H$7(Z?<%?B/_+N7K_F?KL?CC?M_ MD=,>E(_AENU275-#NFT?5G&7=%W07)'3SH\@-]1AO0 MUQ?[/GQ&.E:%=VOB:/\ L[4+S7-1,=PYS:W6Z\F"!).@.T* K8;CH>M>P$XS M]*X#X.Z5%K?@;5+#4K>.6-=9U**2&5 P,?VR8ID>Z%3]#6L*EZ3537;]3*4; M5%R:;_H=?K_A_3_%.ER6M];0WEM(/FCD4,#7F7PPM=?\":+>36&==T V M4K?Z7 %N95)20G]X,!?E?!Z_/S@=*WA#6? K9\/7(N]/7_F%WLAVHN>1%+@L MGLK!E[#:.F3\#_B59ZG=:YI%TKZ7JL&K7)%A=868JQ$F5P2K [\Y4G@C.*TA M%JD[:K0B^U<$%26Y!Z M5YU^R/:Z_P#LD_!W4/#WBB&?6[;PU+)J>J:NIVW;ZZNGB8X:,337 RK; MOW;#:<17SW_P2;^'VB^*/A]X[^+]Q:Q#Q!\=/$5UXAN8[B037-KIS M2.+&UDR.BPMNQC_EKCH!3/B3\4/$'[/'QR\+?"KX88O_ !1XJ\0R7H(PR,/P(JLOQ.BMB]GXHL)-#=OW9FF(DLKG(YV2C@#VD"'V-< MS\./ FEW,%QI%O<2Z?KGAMA##>6TVV>:U;/V>1^HD4J"OS C=&W<5K;]WKHU MU1"^.ZU3Z,K>(I=?^"?Q,TK59Y;KQ%H&IQ_V3,%0?;8W&9(6 M ?,>O0>)?!_A7]H/1+OR+DQ7GE-:O<6S>3>6H(SL=3SW!VNN,X..AJ'QS:ZX M/"UUI6NVCZK93 "+4]+CQ<6K AEE> G.48 YC+$D<*.E4_A[J'AWX[:.+OSU MMO%&BO\ 9;NXLY##&_&=UJWAF^\/?$/1H-0ATZ0V5W>VT1DBDP,K+)%@O&&3:P==R@EN1BN3U? MP>NEQ6WAR]BM_%W@6Y"2^&KF)P;W3=J']W%/DAV4\%_'S2KJ3 MPUK+:;=>84O(8"8BDH;GSK=L8D5EX; =2#ANN>B$^7]Y'X7VZ/OW7](PG!S] MR7Q+OI=?DSR_X7?M"^(/V?\ 79-%\0^9XD\)V\C1VUY:1-]KLH_O!9;?[RLJ MD;HQV4NORD*/I_P5XXTGXB>'K;5M%U&TU/3KU-\,]O('1Q]:\%^(-E!8:;!I M'Q8LGW.QALO%^C(Z(@!S%YVW+PR?7=&3WR<5Y)XV^*,/[+-P][X5UM=?E,J+ MJ.KZ>@:%MS #[;:+A99\9^:#$IQ\R@?Q+_-'<_\%2OC.(_"FA_"?2U?4=6^(4C2:O8Q2&(#0H"IO#+,I!@BDW1P ME^NV63;R,C%^"?A*\L+2]\>ZM=;+GR?(CU(18CLHSM006,3#&]@%16Z(,#DY M \ _96^,'@WXS^-_&OQ=^*&H:F+37KJ.TT>R=?%*TO+GX,:?X1T"!+"; MXKZ_;Z9J6I;@[W<#'SKQ(2V&D5+&&XS,W7DJ"6&/5?A?J=I8ZYJ+?"0>Q^#7A6 MRGT'3]5DM'@NM6FG9/MI@W8:(;8H8@X 8*9P"-_'TGJOQ!\._!7PZ='\-6$$ MAL1Y/D0#;;VK8P/,< \DX&U0SG/"GDCB6RV2_/R,KXJ MZ/:^#?#2G6M6CGU[Q"ZV,NH3X1;2!N9Q"N?W:B,-M')+%^'\-?AA>:SK;^-?'LT%WJV"=-MG MB$<.AP'&549/SMC"S'" '[Q/RTK.35.&K6[Z+T!-1O4GHGLNI'KFN:1X+^)&F:79P1K:>';- MY4L;1-T]QI)ZFM^/P5J'Q$G%SXH$<>GA@\.BQOOC]0 M9VZ2'H=H^48_BZU#\,/AC8?"'P_<:GK%ZM]KU[BXUC6+K:K7$F!GGHD:@ *H MP %%<]\0/BYKWC6==#\%0_8[K4,I#J=W#G;'T:=(NI1?[TFT,1@!LYJ$G.7+ M3Z?:9=U"-ZG7HBU'X]L[3XIZSDZ;I=L@:0,A+3R#LJ%GB4LV / M)]ZZ'2_ M[XGO(M3\52)-)&PDM]-A8FTM#U!.<>:X_O,,>@'>;X=_#30O@KX M69+?9'@&>]O;A\R7#G+/)([I6_A[P*GDSZ@1NU: MX0[;6#.'GCC."P'12V S$8##)"2]I*U+;NQ\WLXWJZOLB]H7Q%AL_%GB'4/* M:_GO+E=/TFTLQOFGAA&UG(/"#SVF&XD+A5YK>TOP#=^*;Z/4O%,B3NCB2VTR M)LVEICH6X_>R Y^8C XVJ,$FY\,/A+I'PET"&QTR!MR(%EN)F,D]P1QN=SDD M_P"-1?$KQ).HAT'2'_XG6L QHPY^QQ#[\[#_ &00 #]YB!ZXSE-3G:G]YI&+ MA3O4^X9\-MNM^(_$6M(6:WN;E;*WW#JD V,1[>89<>H />NPR%!SVJCX6\-6 M_A'P]9Z9:#9;V4*PQ@L22%&,DGDD]SWK"^)_BR?3;>'2-+8-KNLDPVG&1;+Q MOG8?W4&3_M':N>:P?[RI9'1%^SA=E7X;V\>M^-_$_B#8WF7$L>E1OGAX;7?T M_P"VTL_/M[5VC'@UG^#_ W;^#O#EGIMJNV&TB6-<\DXZD^YY/XUF?$OQ?)X M>TR.VL LNLZH_P!EL(B,CS"#EV_V$&6;Z8ZD"B7[RI:(HODAJ4O!%R?$OQ$\ M0:MY16WLRFDVLI.?/$?SRL/;S'*?6(GO78E@ :S/!OA6/P=X:M=/B._[.GSR M$?-,Y.7<^[,2Q]R:I_$3QC_PAV@M+'']HO;AA;V5N#@SSMD*OL.Y/8 GM1+W MZEHCA[D;OU,G0(E\2_&+4]29"RZ#9KI=O(#P'E(FG&/HMM],'UKM,UA_#OP? M_P (9X7@MG99+EV:>ZE5<":>0EY'Q[L2:L>-?%MOX(\-W.H7 9_)7$<2$C4=V9BJCW-$_>GRQ]!0]V/-(P%D_X2CXU@B)OL_AFP*^?N^62>X()0#U1( M@3_UV6NU')]JYWX:^&[CP]X>W7Q1]3U"1KR]9/NF5^2![*,*/916IXC\0VGA M71+G4+R00V]I&9'8]@*535\L>F@X62YI=3G/$,0\2_%S1;7Y_*T""34GP?E, MD@:"-3^!E/U4>E=AFN5^$^A7-MIUYJVH1F/4M?G^V3(3S"N L49_W8PH('&[ M<>]=7LHJO51705/;F[B9S12[*-E9F@E?+/[+UI;_ "_:H^*/P3U!%.A>))6 M^('A&*Y&])K>[D(U*V4XVXAO!+?38 M?$/AFW^(_@K4+6_2^MK8W,&D:@$#_-;F3S%26WE="I<,8KAL-R#4'[./[)5I M\ Y6O[CQ+XC\2ZS*LRE[N[:+3[033&>5+6R0B"%#(3C"EPH"[R *O_#'X\:% M\8/@]HOQ2\.:E96OA"_L9=3U& ()!XP0"//O^">?[?U_P#%S4[WX1_%VUC\(_'KP6OV?5--F(CB M\01J.+^R/21'4;B%Z"?MO?\$]/"'[:^BV%U>7%]X5\=>'6$WA[ MQ=H[^3J>C2@[AM<8WQYZH3CDD%6PP3[H:[,K?'[XD^._#/BO64\+7.MW6IP7 MUG%I^D#25DL)[-XD:ZG:?R20\:F9U_>@,\2)M.[:V+\!/CIXZAO_ :_C2?4 MI;74K"[;5-EC+<"*X$=F85'P8_:;MD M;P1\1?"FMS. WV1;Q8;Q!_M02;91^*TNHSRF_P#CI\;+RX:&V\/ZY9#Q5J'_ M !+9[C3(670[&]6:"VE8)N):VE6TEE2;:^+F8$%8QB3P=^T)\9KG5-%N=6\* M:V8M-G!\1V5KIT:0HCO'8YBEDP\JI-!>WF(@SF)K<'"NN?JV.:.9 RR1LO8A M@16/XT^)'AOX<:--J'B'7]$T.PMQNEN=0O8[:*,>K,Y %.PKGR9;_%WX]Z9H M&C#5X[ZSN]1DTN:23:LD9@EM;]YV:2/36-LPECME:)H92IV /A]U?27B+XV: M%\%/@ /&GCK7+72-)TG3([K4K^[?:H;8,XS'&69F.%41JS$@! 2%KYP^+?\ MP6D^'2:Z_A7X.:/KWQY\>2QL8--\+6S/90L, -<79&Q(\GEU#@=\9%8'PY_X M)X?$;]LOXCZ9\0_VK=4T^[L])G%YH'PRT>0MH>DM@;6NV_Y>9@\"^(O^"HW[3NE?M"^/M)NM'^$G@MG;X6^&-0B EOI&X.LW,9! M&2 IB&3@A2IP@>3[TUO0K/Q+IDEE?VT-W:2E2\4J!D;:0PR#Z$ _A5BSL(]/ MM8X((XX88E")&B[511P !V%2;*I*Q+8AKS'XQ_%'3/@1X"\;?$SQ7I>G:?%X M.L+A;2\%RKS7]H$CD6,$J-CRW'[M8\ME@ASEL#L/$NISZCJ46D::-&OY!+'_ M &Q;7-V4EMK*590)%158LS,FU0VU2 YW97!^:/'NC67[6W[3WA[X4:!8Q1?" M;X(7%MJGB@6R>78WFIPJ#IVD1[<*5M\+<2H/E&V!".2*3!'HG_!//X,:G\'_ M -FNQN/$>3XS\'1XL\'ZEIN2OVVV>$,#@J2I (/8@\@^U0?#?Q*WBSP5I][+\ MMP\02X3'^KE7*R+^#!A^%;Q3*FN&TGS/A[\3KJQDVC2O$[F[M&R MP#*%=<=2),]L[0]^#CVU,Y^[+F^1UNN:5'K6BW=G*,Q743Q.,]F%\&]6F MO_ =K!=Y^W:9NT^YSU:6$F-FQV#;=P]F%=0.?3_&N%OROPW^)YO-I32_%;K' M.P!*P7BKM1V.< 2(JIZ;E7NU$%S0XB%Q R-R&!!'KFN2^"UR; M7PA_9$O$_A^=]-*D\B./'E'\8FC/XUV QL&*X7Q:S_#SQ]!XAX_LK542PU3C M_4.#^XG)[*-S(W^\AZ*:5/WDX!-\K4SN6&Y37&_!A_[)T[4-!==G]@7LEM$I M/6!OWD)_[X<+[E#7:(^4_E7"?$&V'@3Q9!XOC0_9_)6RU?8.1;AB4E/M$S,3 M_LN_7 ITES)T^X5'9J?8[HG.:XOX4C^P;_7M!961M/U"6[BW?\M(KEFF##V# MM(OU0CM78P3K:T8Y9E M_P!J,_/T)(##JU*EJG#N$W9J?8[/&ZO//#'AFRU7_A(_"^J1?:%L[\WL&N^TC4X-7T^&YMI4G@G021NARK*1D$'T-JFZUO0P<)?)'ONK1?291S(!S\ZC(&-PZM69\/;/1?'-AKGA^Y-K?VEM M>M>VACDR?(G8RQRHPZ8)M'@O+2:*ZM;N,21RH?#S7/^$T\$Q)%J<0V:GIV&^SZI;YW-A%Z2J3N5E&3\PP:-I;Q7Y&_-J>L_#-O+U$3ZYH&"%O43==V2^DJ ?O%Z_.OS# RK< MM63\--"T7Q]X-FT5Y8[C_A'KMH[*YMFVO;PL?,MVB< O$0\9^"?+M M+G.-9L#$7AU. ;B&VKRLB,2VY1N(W#!X%:0W]G+W9=^ER9O3VD=8]NII>*+S M4-"\+ZEHWBAWNM&OK62V36H5PUNK*5!G4#Y"HP?,'RY&2$[KX-T6+XD^"]/U MNPNEL/$MK#]EFO;8;@TL>4=77.)(]RD@'L000:T_ ?QBTWQS!#;W2_8KRX7, M43D-%=K_ 'X7'#K[<,.ZBN.\9>#]5^ WBIO$/A+R8_#VH.7U;270^1'+P/M* MEIIQBW^[?NRW79_\.*4DOWB]Z/XHD^)GC1M,_LF;Q);"PU# M1[K+!3NM-6MG4QS!6.,_(3)Y9^;,0QN S71_V/JGPYMQ+] ^+^DSZ1J5FBO<0_O].OD4F1#_ !(>5=#P M0RD]NAXKAM+U+Q#^S?K@T:93K7@^9\:1R%N+-,<6H( MX(:(EH^S(-AZ-BL#5K"WLOB1?VS0C0[OQ4GEWNG7?[RRO)F&UT?C#PRCA9!A MED.#]_8>Z\8>!].^+$7_ E'@V^M]-\9:6C);7AB(()',%Q&<$HW *L,C@C! M K$/C30OCMX,Y&">:Z83^TK]GW7 M^:,*D+I1=O+L_P#)GE7PN\?:O^R)\09M"DMM4N?"3DRS:9(#/>:6G_/:$]9H MUQAL&?%=C*?MRNN-H9$!D$RD#)0,KAAD8W >23_M>ZI\+O%, MFCZ%;WT%AJDB,HL/(;^T-\F/.0,WDV,S*I9ED;:V/A@VX3E>-]NJ9];?'']I[0_@UFP^;5O$4D?G0Z;;$&14_YZ2GI% M%G^)OPR:\*\,S:I\1=9O_%OCR.#6A:J#9Z'MQ9Z<00VZXD(P#G85B"ES@%@Q M(VP>%-*\ QV7]N^(=;ED,D@=_#&G++<7\UWG_E[!NVH.@&WD^MZ-\ M-_$'Q(U&RO=0^S>#?">G*DNG:-"BM>*V"3).W,:.,X"KOVD9#9Y&<8T\+#E2 MUZM_DO\ @?>;3E4Q,^9O3HE^;_KY%;PKHMM#KEKXG\>F+5/%+I)_8NB6UN6; M3+4E<".$$_.<*7D;H=HRN,&]:Z'J?[0OCYIM:0Z3X=\+2LMO;6\Y\V>[965] M\J\82-RI"'AG<;CBHM<\;Z9I(N?#7PYM#KGB*>1(=0O+=A,-.0AOWT\[G#., M':N68ELXP#72^$/A)=CPW;66M7JVFG01X_LS3Y7$3&T MLE58(9GPL:._W4+,R\?>.[A3FE^'GP4N8?"VG6WBF^74OLJAC8PJ8[/S"0Q9 MEZR,7+'+<9/"BL"]\9Z/J_Q!BT30[!M2T_PI+YCV6GQJR2WG\"L3A$$0)&O$/C./=K5Z-'L"2#8:;,?,D4]-\^ WU" 8_O&LI^Y&VS>MWOY M&L/?G=ZVT26WF<_\8?B)!#XP\,>&M%MAK%[]O%S>V-K@O;0PQM(C,?NQCSQ MOS8X8XST/0CP'J7CG][XIN5^R,05TBU&_ M#?B?4M:S::7I5D#I&G!/^7M@VZ=T49+$R#;P"3Y1/>N@?Q)XC\:ADTNR.@Z> MVY?MVH(&N''9HX0>,^LA!'=*F:<4HPTMU?\ 7_!+@TVY2UOT1E^)]5TCPC\7 MM+N+B6&SAT?2)8(843YI3(_B.X$8D\,Z,3S(XS?W M*$?PCI!SW.YL=E/(PO@I\/K5O&/B+Q/))-J5S+.-.@O;M_,EDC@R'93C" RM M(-JX7"#BNKUKXK65I>26>F0SZWJ>B;V.>\"^!K#PA\;-=-C (H/['LEE=F+R32^;=,SNQR6;##DG-;6 MI?$[^T=1>P\/6W]M7T;;))5?9:6ISR'EP1N']U)]3 M\1730V37PL5TZRE(MYA"@#%I,!Y!O9U*_*N4.017I]O;Z?X1TG"?9=/LK:/@ M8$<<2C] *FORJ=GJ[(JC=QNM%=GGG@#X;_:/BMKE[XAGCUC4XTMKB/\ =;+: MV H'4DG@ :GX[\>^+I_#-I%'?A MC!8:BFI:E<3:SJZ\BYN/NP_]OS.# M\-WFN?$'XM>(X[+[5X>T66VLIG>6';>76?.4E%/$>=J_,WS87[HX->G^%/!M MAX+T_P"SV$'E!CND=F+23-W9V/+,?4G-8?A57E^,?BAQ_J8[.QA!ST8>>Q'U MPZG\179;<5&)J-OE6BLOR+H05N9[W?YG&^'[K[-\)<(9!+96446$W;)6OXEC<@\? M*Y4_@:]:O"B_'&S_ .>G]BS_ /?/GQ?UKR#_ (*J/<6W[%'CB2TABEG^R6 S M)*\*HO\ :4.YG=,,$499L'HI]:[\!?ZY0:[Q_,X<=_NE9>4OR/R5^'VG3^)? M%6G6=NMIIT=\R W4I$$=L-D18[E '$DBC&#PBBMKXV_%?3/B)+:V>EW5]/X5 MT.YC?3+/4]%=3#:2J(99FEC9F+F3OP-S<=<5SGBZ\FU_P]X6UBUALH].LK-; MF&\O7D2'[2ES.C(BP L&EV(06!;"1@MTKV^X\::+^R!X7\+:8_BK7]0O="GU M2XNX=&)(U@\ M5;N3"R1%BBRQ'('S#W)KTOPC#X/^!NL1:?HFF76MZVUZ1)K&IHA61%D9Q'! M ZH&W1X(.6P,A1P<.2G0OSQYJKU=M+:]^B7WLWYZF(MR2Y:2T5];Z=N_X(Y7 MPI^S/X>^*=E>:GX%^)>F7\\?V3P[:6\^G3VVJX9%+RPA#ER=CJ2 W[MY,]*Z M32_@5>^/_$,\.O\ B34?$6@V$1L#I^E,UW?FU5RD!2 [7C=6MF\QF'/ON-=4 MG[.5Q^TC NN^ _#\>B^*/"MP=3\0VUEN@CU.. 31VKP(I"B9RF7CPGWNHY%< M3;^)?BC:WNGZ)#?Z@GB?PI"MNMH;8F^)6W074)D0%OD6=0.6.X2Y()%RV!Y1*C %=.GP[M_V5;-/!MWH%CJG MQ!M+-8/$6N21&XM[.)%C,*0;P2(S!(49P@.[8*?UN<)JE*=Y/I&R=N[=KKY: M]A?5(3INK&G:*^U*[2\DKV?ST[GE/@OX]>)O#VHZ-JGAZ.;P[8+':6LPLW98 MU47C9CFN6^>1?+CD'EJ0H! /(KK/C;/H=:TKQ-#I5_J.M:AYU MNFFRVD+>1';"2UBS++'YB%5DP1@D5+>?#CPY^T/JMM/X?AD\*^-)[*Y&Q"'T MZ^N'!C&1L_1KA4LVEGVX4A67L!' MS)D,%Z#->>W]I/:W^+^TMTEPOF[(D^91+*)@I(.[*0S$8/\ RT&.M>N?$[1K M#XF? K3=:T_QC<7%YX-MKZ5D\023-+=VT]W%:M+OMRR%8I9W&>7B:; MP;\+-.LF@MT>74Y%TQFG>.*]6*WC8-&_^NC\XR$IRJA@00,MC3!S3YJD=&W9 MKS[_ #T9CC(R2C3E9I+27=.VGE9W1].?M]^%];\0_M2_ 34H--@6'3?"OAZ> M:Z:Y5!#_ *3)\F"^!R1T SZG''[3P_ZE?I7X?_\ !02]6']KC]GB\47J7D/A M'PZ\MM(6.U1<2MR^[+$-P?E!XSD]OV_@/[M?I7Y?Q5S?5,%?^67_ *4??\.V M^MXJW>/Y$E%%%?%'U@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 45D>//%R> ?!FIZU+9:EJ4>EVSW+6NGVYN+JX"C.R*,&,SS9_[!2>'J?%!N+]4[,^3?%NM_ M"+1H]9DT?1_BQ8WC-//_ &=I-OXHTFPNK@Y)!2V41*';JP0]R?LA:OX> MUOX$Z3<>&_#&J^#K-]S3Z5J5G-;75M3? GXR_%# MX?\ PNTW5OB/:ZYK^AZ]%+NO[#1F;6/#GBXM4VF[V>_-=?DO\_D?HW%6'JT\#4I2G*<85$N=UY5(R:YDU&/)%736M M[32LTG!W/([+]H'2C\8O'!\=^ _#2>#M(\2/H,?BB.S64V4JP02*;\,#LC?S M<"8':" &"Y#'T;]FCXAZ=XC\=>.="T[2_"L46@3V[QZGX="_9+Z&<2-'&Y4< M7$:K\XR1B1",;L#@]3^-^L_"GXB_$6SN_"OB37-5U'4T30O#NG>'633M4MV2 M(&Z>_6$QF5AOWF:5=OEA0O&3VG[(^L:EJ6H>+4@T.^T7P.MS#+H,>H:&NC74 M;N'-S#Y 5"8D/E[)&4,VY@2^W<77@O9.7+;1==.G]=M[;&N>82"RRI7]ERKD MIC%ZN6K3M[DO><=:;OY_\ MEVFE>%_BF=:\;P>&_%OAF\L((=- MT/5/%::0UC/&TIFEC@E989_,#1@L2'7RP "#Q;_8DM--UWXB7^M^#XO#WAOP ME%IK6EQH.E>*5UD37;21NEP\<;-#;E45U^4[G\P[ONBD^.UUXC\.?M/ZKJ'P MRM7\0^+IM$LXM:L+G1X;NULX!).;6[M?*9R9(->_ M:6GU+XB6LFB>-QX=E@T_3X=&AL[6:Q^T0F:3SHKJZ\UED\H!6D4H')"?/FM6 M_P#9K7Z=W_Z3M\_F>C4G_P 8[[/G5_9)VYY\VR_YA_@2MK[7JOWGQ,WOVS(/ M.O- _P"$A'C5OAJ$N/\ A(5\/M\A/[OR_MBQ#[4UMCS-WDG'_/0%>G,_!&3X M<0_&_2X_@F-4_L3!_M__ (1L1_\ "*[?(_=F4M^[^T9V?\>W[SKYG KI_P!L MO3?MEWH$GB"Q\8ZG\-X5G.OVV@3<%B8Q&;J"/_2)[;'F;DB)']]&7[O-_!*] M^'6J_&[3)_@M8:H-&"%==N_#ZI;>%Y$\H[!(K 1RW(/EC-NN]<8D8 ;3G3_W M;KL]OA_[>\^WR.'+7_QCWV_@J?#;V&[_ (VO\7^7;_EU9,]L^,G@[Q'X\\.0 M:9X>\2GPI]HG O[Z&U2>[%MM;A_!7Q#:Z MU\/-3U+PSJ[RJ=9DGE;4(O$:;]S_ &I96),IRY$J%&!;G['P$"_(5V;]WG_NMN=W:O'O"FH?&V?Q3X:' MQF?4M.\+F:#[,W@U-TDMUYI\M=6,69$4C9N^S_N,YWL%XK/#QJ.E[LDEV[__ M "7Z'FY#ALPEEE\/B8TJ;YN:#23JV_EC9^WMLE+2$MK/4^NJ***\P_.PHHHH M *YKXS6>EZC$O$\&N7,MEHTVE7*7]Q$,O! 8F$CJ,'D+DC@].AKI:YGXS3: M5;?"+Q1)KT4\^B)I5RVH10'$LD B;S%7D?,5SCD<]ZZ<%?ZQ3M?XEMOOT\^Q MQ9G;ZG5O;X9?%\.SWMT[^1J^#X;:W$:7'92--9I:1+!(WWGC"#:3TY(QVK1 MK-\'O:R>$M+:Q5TLC9Q&W5_O+'L&T'WQBM*LJO\ $EZF^&_@QM;9;;;=/(\< M_P""@EZFF_L6?$V=RX\OPY>$%2P(/EG!^7GK7XHZ+XGO_''_ 3^EO\ 6[N+ M5)QX\!1YFA?RE&G(H_UI"(?EZL#G\3G]L?V_0K?L8?$S$J^=IQ M$W7!!_6OQ1T2_L/$_P"P7@3Q^L<2)),P#'3D4,"1U^1\'Q??ZU'_ _P S.^'_ (HL?%GAJVT+5+>_O[OPN]WX MFT6:R>07K7 /FRPA@$$B2!.D:?)RP;^%LOPW;WOQ;^#6NO="/0]:\-6XU&^M MY[:T03:+K'7K64I-&02 M*A&0KX.]P&/[!M!JVA^-5&J:E<+N$MQ>0KLGC/EX,;([!5!4*?D(#$EJH? M"_3YM=\5V/V9BM_.\4J86.1U.60$*59&)=<@JI),L2(R*I KZ1XSUG]D#XL_ MV1.+K6/AIKD@NY-)O=/MK33;^UN$7RIY(RQ^<81\$*U_9E^ M">O^,+*<2ZQXKN8-/T+4[:&)+*X#@M]JM45 $\N%8P,$L'1?FXKR9\W\..OM M?A?>[V?;E6_DCUH)->UD[*EI)=K+==[O\6>@:]^W?#^SS8:EX<\ V&H_$#Q7 M;6<=_J\8N6&GZ(\>T-@1.WF?,_*JQZX)( \+\*_\%!OVD/B!=^*M8\)KINC M6T,']H:K#9:':(C!4"#B=&=V$<8P@).$/'!J+X,?#$^'K^RTSPSIFN:NGB-? M/NM8$/SZI:LP<(H7UE]#, MLTFN6JZ<8=(Z)7[.^NF^Y\+?LW?\%2?'F@>$+RW\1>!8;KPYH]L[W.HZ-;OI M\^G+("GFE0PC=AN)Q@'TQC-=#\:+C0O%_A6U\0^&]4_M[P]>1^>+^X*?:)Y M &\Q@?,CVR2A<*8BIF+8<9QT?[7WP:U;X?QZ3=6*W7CFTUJT59KBVA?[%>QS MOY:PH':0,"Q4'YU*B;<-PR!X/^SQJ&B_#K]H1OAS'+JB^&OB)9N\%I=JC/I- MW(C-:O$XS]\90D8R&7GBNJC2PE>+Q^"ARO=I;-+>_9KIT.3$UL70FL!C)3ZFE\%_%FI^$O&FGKI.GS?:)"$MU5-XFCDC&V0H/E#'S8W;> NZ=P M %'&3<_#G3X_VE?%MC;7NDQ^&O %O'?:K:R-:^4L19)7MHY9"-S+>S,IS)\R M_+NP!GMOC1\5;[]F+PJOAOPU.FG>--8"3R7L$-K#K>A6.U&%I,Q",_FY#YPI M4(:A)J&C_ &?R]TKRQQ^;$6#$Q1F4 M[22ID7@5Z%*K.,\">+3XC MAU?Q+XDTG4O^*1N8=4T4WJ>7!?77<(N[.,%E^N<'+U#2$\%_!3PWHPCE MTZ;Q$S:Y?VZWOVFW*R?);K O.W*!B5)=CD;E.%Q9_9ATV(_'KP5$#&-NOVOE M6@W*7*2J6PF" P&,_(F,')%>M*E#V-2IY-+T2_5ZGC^TFJU.F^Z;]6T_P6A^ M\\0)\.1ALG-Q='DYX^T/BN.^ ]L-)^&>GZ7OWMHA?378]286,>3]0H/XUV4# MB;08SD'-SN] M_2OP6/O1E%=[G[/LXR9W3'BN+^$UZ;6^\0Z*\+Q-H^J2E&(P)XY\7"LOL/,9 M/K&U=CVS7%>,[C_A!_B#IVNDD6&IJNF7QS\L)+$P2'_@;%#_ -=!ZG2DX3LQ58J458^=/VU_!GB.V@^&/A/2[Y]:T7Q3X]TY+K3K\!W:WM M$FU)H!*1RC?8L$2!OO8+!(=$LM6U71=. MNM,LY+M?,2W@N3&9P$/RY;RD&[&0,C."' M4TI;K;%HITRWQ'?VD@MFM8D7NRX&P 9PV5XY%?'_ .REX)\8>)/BIXB_:9N; M2Y\3_P#"332:'I,<@\J\3PQ;.4BDBBVA&:XDC-W\N PD4*/FK,_:ZOO%D_P& M^(T'@[6]1O\ X-Z/H&H2W.I!FO\ ^TI4@!M/O]-FGN8]#M-+\/V>G3Q7(UZ:.U41Q1.N K%4W,7"HB[F M)VJ6K;6,O=]Z)GHU9^[(]9^'?[1?@KXT:_>:#I>I)?9)'^\:[$*1 1!))$2[92N6)HB^76D[>3)DG+W:JOY MH])^*G[?^L?!7XOVMS\2_&WA+X>>!M.VM+IEKITE]KFK,B;IO-5F+V\ ;^** M&0,N")AFJND_'/QQ^VW'9>*/AU\'K_PQ/%)(+/Q-XA\0QZ9;7%ID&,R0V^^Z M82(=P1D3:W&\W7BKQG=:KX0TEX=UCH&E:M; M2W]ZA)00W-P(VFG=V9$%M#&4W#:7EW8&L*,^=RC>/XK[R)U8\BC*TOS.G\+^ M//CCXALI-+\2_&'PE93:8X74#X3TFW-Q$=S84WMP;BW71^)[5DGD:_P!>DM9+G)PBA; PHXR0-T9! P&.T8KY M)@^+WQ%^&?Q6U7QO=:UI_@'PWSG(:^\<>/+:2+1H9%QNGA@ \R[X)VR. MRJ1UEZY[,-3PZ7/*[?:/7[_\CDKU*[]R"27>73[O\R#5_B3\8/%WP^_L;1M. MU&/P"@_?WVNZH6>\B9F+)]MG;SGB92"-AE?;P)N-H^??BM\5?#'P9^'>L7WA MV6;3O%EGI$[HY)NH;"\<&.&*.&TWFVE:1D56N2B_O!\NF0*[Y9I*G3=.A%06 MNG5^J_S^XX8Y9&=15*\G/;7HO3_@?>>)_L_> ]0LM#\)^&K7X?:E)>7%M#H6 MA>+;B6*PMI-0AM&D**J32F<[89?F=<90C!/$GP0T_POX'F\8X MO_%4\U_K6G7-A(EO::;!B5W5%:2'R]Z1IM1 TC$AF(&/B3>V3Z?H&D2W\T&]24$EX=H>WLH5RBRW&'&W"@;W /S]XR^'/ACP MW^W/\-M1D\1O\0KF.^EL_&GB"6=);"^U65([JSTGS6;"6T2[O;MYW,S"2>$MEM\A4[0OW>6QG._P#L_P#_ 4+\">( M_'^N^'M)\(>,O$GB;P?=?9;HBWB>ST^9B05B$.5^5@P8A6DR&R6P:A_:_P#V MA8_AIX0\8PC3MGCF'1+F73M#\ 3_ &^]LY$MY"MQJ1B*/';(Q'+*JCU8D"O/ MOV9?B'\%/V%_V6]+\.VWQ L?$_C?4[*/5M3TR'2%U>6\NI;=&=TAB42"(JHP M2^#G<DVJ7*K+>WX:ILOV-6SJ/N@@UL:)\5?#GA6[:'PK9:UXW\17)\BXOX[2 M1XU*_P ,L^P11*,Y\M,=>%KXJ_:B\:?&34?A;X_A[H_AZT\>:=? MV\1\BW6T^(EOJ-Q,S,69GDD=.I8G+$#L.!@1*5&ZVW@CQ;\0[];S68X;4QL"ANB'AMN/O0VRL5+9Y#S,Q!'"X-6KKQ_X9^#4E MQ96=Q%JFO38:\FFN5#;N@:>4_*F.R 9 ^ZF*\#_X:O\ AQXCOA)XC^(-K8V" M-F+3[/Q_IQ:7'/[V47B[E(Q\J@#KDFNS\-?M2_!CX>V,+>&9OAEIBW#"2-Y_ M$>GVWFLQ SN1I,L22,\DFL9NG\+=UV5DOON:P4_B2U[O5_=8[FQTW7_BO=QW M,T1N8_E9);R%H--MB#R8K=L23/Z-+\HP"N.A](\$>!++P'92LLKW-[=$27E[ M.P\ZY8=V/ '.% "J.@ KQO4?VX_!T]JA_X6C\*O#HD.0\VK+=;0#R,;HAWZ MY_ U?T3XW?![Q[-B\^+WA'Q3(I^:V_X2*T\DD=1Y,; $>S _G7+4J M"O D7A 7%S+*;W6+\JU[?2J!).1T7_91;4]2E2]UN]4"XN<$*BC.V.,'.V,9X&>223R31:VWA_X0:(Q+V6 MEVI;<\DTH#3.>I9F.68GN22369<^-]:\9$Q>'-/>U@8D-J.I0M&B_P"Y"<._ MU.T>YI6;5J>B[AS*]Y[]C:\:^/;7P;91[A)#?!D]OJ\VNZR8YM9NT\I0G*6,/!\J///8%C_$P!Z!0+'A7X=VGABZEO MG>:_U6Y7$]_QE MD^[&/KSZ U*5_J&YXJ\4V?A#1I;Z^F$,$(R< LSGLJJ.68G@* 22 M0 *YKP;X=O\ Q-KW_"3:[$T$^TQZ=I[$'^SXC]YFQUF?C=R0 H _B+3>'_A[ MJ1ZQXBN$O]4C),$2C_1;#/_/->I;'!<\GG&T':-CQ7XUT_P %:>)K^?:7 M.R*-5+RSOV1$&2S'T I?#[E/5BO=\T]$7]3U2#2-.FNKF:."V@0O+)(P58U' M4DG@5Q?AFUF^)_B.W\07D4T.D67SZ1;R@JTS'C[2ZD#!()"J>@.XX)X6U\,Z ME\2K];SQ!%]CTF-A)::1D'S"#D27!'#'H0@^52.2QQM[2YNX=)LVDFD2*"%= M[,S *@'4D]A1_#7+'=_@4KSU>Q*7"(2>,#\JX*&4_&3Q0LJY_P"$7T:XR"RD M#4[E#P1ZQ1D''&&8 @X7EKW5Y\:+D16GF6?A$K^\N.4FU7/\*=TAQC+=7S@8 M')[S3=/BTNS2W@CCBAB4(B(N%0#@ "C^%K]I_A_P17=1V7PK\20)@?2I***P M-PHHHH *#S110!\C_$FQN/\ @G#\:=8^(FFV\]S\$O'U]]K\:V$*;_\ A$=1 M?"G68D4$FWEPHN$'W2?-' <5]'Z%K!CEM+_3KJ_\4Z3XKO1<074$MN]II-L; M38V^YSG9]WH[^P@U6QFMKF&.XM[A#'+%(H9)%(P5(/!!%?) ME]X-\7?\$U=5N-0\'Z9J7C?X#7=P\]]X7LHC/JO@AG8%IM/0 M(]-G6WTK1K>%5N)RR.@5RR"%TQ(C1.%^:7YMI7GN-*\9V.I:G#IKS0VFMO8I MJ$FE2SQF\MX6.W_P!H75YM1\3?"WPU)J=R=TU[81OIMS*W]YI+9HV9O+ECIFL?%+0K=CS:V/BVY$7_CY=OUKH?!'_!!W]FKPE<1SWW@R_\ M%5U'SYNO:Y>WN?K&TOE_^.5]BT4N5#YF.6XU*S:6"[@_=R3>2%D4DF-F0.3A9 =IR$44@L7 MOVG/VA?$'@RXT3X4?#Z2QU[XY^,+*..2^6SQ;:!:J-LVL7B+D1Q*=WE1L?GD M94&1FO4OV9_V=]&_9@^$MEX6T>2[O61Y+O4=2O9/-O=8O96WSW=Q)U>61R6) M^@& *QOV5/V3M)_9DT'4YS?7?B7QIXIG%_XG\37_-[KEUC&YNR1(/ECB7Y8 MU &-]RRP3Q_ZRVE4Y21 M3V92 ?Y\5MTUNHIQDXNZ$U=69RW@#QC-J[S:3JB_9]DT?JC8 MZ?PG@\UL^)_#UIXNT.YT^]B$MO<)M89P1Z,#V(."#U! -9GCSP!'XJ:WO+>7 M[%J^G$O9WB#+1$CE6'\2-QN7H<#N 16$_$-KR_&CZU"NFZ\B%C#G,5VH./, MA;^)>F1U7(!'<[6YO?I_<9IN/N3(/ 7B.\T?4!XM]^'\ZV'B9O[XQA6/W MQ@$E^O=31)=Q-$ZJZ.,$-T856U?1;3Q-I4EK=Q0W=G=)AXW&Y7!_SFN12+6O MA0Y"+<^(= 'W0#NOK$>@S_KD]!]\?[79:5-OB"[AO$!;3W'P4OC;S[YO"$S M_N)^K:,3_P LV'>')X;^#H?EQM[R&>._ME>-DDBE7((.0P/\Q6?H'BG3/&NG M-+97$5W%DQNH/,;=U93RI]01GVKGIOA_J/@F=Y_"DT4-NS&232KDG[-)GKY1 M',1SSP"O^SDYIOWG:6DOP!>ZKQU1!<:7?_"2]FN]+@FU#PY.YEGL(E+36!/+ M/ O\2=28P,@YVYSMKK?#GB:Q\7Z6EYIUS%>6\O :-LX/]T^C#N#R/2L/3?BS M8I#;'*Q[1R_Q-94'B3Q-X7VIJVEQZM"JX>[TM@K$^I@<@@?[K.?:J6M^)/!7C6>"/5 M7ALK[/[@WJM8W*-_TS9@K9'^R:;BY?%KYH2DH_#]S(?'/P8^U7,UQI2VTD-P M_G7&F3DI!+)_SUB=?F@FZ_,G!SD@GFL33/BYJ7PVN%L]6BO9K4(/W.H!8[N( M$]$ESY5P% Z!O,P 3N[]7%X8UNP5#H/BI9X5;+1:C$+M2OHKJR.#[L6^E/U2 M]\521>3/X>T75(7X?;?L@(_W6B.3^-:QE=)X[_0=6 MUK1HCAEB_P!,N(EXY1UPTJCGAT#^Y[Q>(_@WI>H3RW5OX(UW0M6N,"2^\/WM MO:3MCG#.)4+CV8$>U9$-UXF\'V;#6]"\ZG==G:_WW.67-'5JS[J]OR&WFH^!_%\#-H6M#2I(QYCZ7?V4T/V. M5ANWB,A)K=^>B%1R<@DYK.UW]H+6? .CSZ?K^AR^.]#D01K-80R27# D#]X6 MB2(CGKN!&.K&M2X^')^) CU&*W.6B9+?58_%2T\U MM\T<38?%_5?'&KFX^'NEZ[;7K!5AEN[B.X>RSG"2"$R2A>ORW*D#G&VH/CA? M?%'QC,(/&<_AGP38^0L4.LZ>/-NI-VT%)8/WC>66)XZ# .1U'JR:%X6^(US) MX$H%9?WLY&.&CSNP^MX3\.7-DU M[9_$@VFHWQ9FMM.E\FTN95R&!M(R),Y^\-WF<8+<4D_B.RLM#DL;KX;SP0I( M3%J<<9MK,D<^:TA'GQ'/.=A'^U6[S:O)]_E;\]&_-*YBLJHJ.GWWO^6J^;L? M,*?!CQC\(?$NFZCX,\+:SH?B!X5>"XUR\@5MV\AHHI,B.4,"?W4JJVT[@ PR M/0]-_:/U+5]8@T;XU7-QX$EU&3[/#)= 16TKDD;8H_N 8QEW,Z@M]\=*]PN/ M!'CC7-$;.OZ=K_ABZC&+"'8;ID..!=N"L@ZX!13T^>N1N_#GP_TF[%C%=QMK M&%5M"\10M>W$JKG @/S2( 1D-&61#/%GQQ CU34=1TG0YHP)Q"C6+3*>HCCSYH)'!,K8 Z1AL,/&]>^'NJZ3K$- M]X=L]>^'SS*\ESX ^6N.>%BO?I2U??5_Y'5#%2^"K'1=M$>[ M6'B/PI\(].M?#^CQQ>9:KY46GZ='YLJ8[N%^Z/5G('J:Y+4O&OC'XV:@^D: M(?#^D%FAU#4XW6XN+=>ZQL,Q";GTD"_Q8/RU@Z/XK\":8]OIT_\ PD=Z9TWK MIUO")X)%YPS1VF8RIYZY6NGF^,6L2VHL_#_A/4M'M-BI!-=:=)(4)ST@3&!Q M_$ZGGD"N'V$H/F4;R[R_,[?;QFK.5EV1V'@;X1^'?A?ID7V6V4&T@$/VJ[D, MLJHHZ;W)P.,X&![5R_Q$^/0U>YE\,^"(VUSQ-=QG9)%\MK8QY"M,\Q!3YUAT^Q)86UE;J4A229^%'8<=6/8!CVK!\7_ !BUB2=;33[5-.GN5!@CF7[5 MJ$@[D6R'"#I\TC@#(R.Q=\/O@*9M<_X2/Q?+)K>M'FTBNI!/%I:GG"# 3>_7>F]EU!6^&BM>[Z$OP^U^^B\&V.G>&;%[Y8XR)-5OU:WMI92 M27D53\\NYB3P I_O=ZO:UX/L]$TRYU[Q9>R:Q+8K]H"R@+:P8Z".$?+UZ%MS M9/WNU=TTL=K'\Q"(@SDG K@X+EOC'XDAFMR1X6TJ?S%\*5 Q., :HO\ ILBYS96A MXD8XZ,X!1/\ :)/.TUC9U*ES9M4X6)_@PS:II.I:TP_Y#U_)=QGUB 6*(_0Q MQJ?QSWKLF. :KZ3IT>DV$-M BQPV\:QQHO15 P /P%9'Q'\6_P#"(>&;BXC3 MSKR3$%G#_P ]YW.V-/Q8C/H,GM2?OU+(PD=U^JFNP'S 5B_#GPN?!WA&RT]I/.EB0M/+C'G2L=TCX_P!IBQ_& MM/4[^'2;&>>XD6*&%"[NQP%4#))-*H^:=D*FN6.IRE@JZK\:]2F4Y&D:9%:$ M@]'E0?\%60EU^Q7XZ@E@BN(S9Z>Q23:ZY_M*'&4+J..N2<< M<@]#[!\&K66YT"YUJYA:"Y\17+:@4/H)O+*I8Z?.^>=JKJ43;C\C<#;G..QZ=:]/ 6^OT8]I17XH\_'JV!JR[J3 M_ _*CX6>)M*O;2_\&^(76?P[XQFM(+J:)@TU@$=8I;=H@L*E=Y)1?,+X"XR M /'TL= MM_Q4-Y9:G/>:CV%NT=[<$Q6<4DB,+DY0[6W97_EK;D! MP0#+.75BJD;7QQG\2_LT_&.^\<>"[W4;#3/$%VXU"UM=+AL[>>2&9OM%K(9# MN:( @@E,%9 23UKT%-<\/6?AW5_BU%IFG7/A>PTB6]L['3K>*/3K2Z"H@TV4 M*I#2^9-RQ<[E+$*.WAU:S2]O%753;O?1;:?W;$?/M 1N6.Q(+B![9Q#I$*RK%%ND999;L-C!#')QD_6N-^#NDW M_B2/_A.X+;6/%/BOQ#<$S:CY2A+!Y&$,D:YW$ R2HA?:0JG 6OT2_97_ &?- M5L]*TB:]\1?8'U32W_XD]Q%-#>LD;>6)06EY0DHY)C!_>"+3Q9@^)_B?HO[3GP^NO M%OA/5-4U WOF/KMG>^7)+I[%T*P.'+ #\2>%M'GU MS2-6F\4R_P!J3R :9%)_Q+IH=I".SR2J)"LDHP4"DH@)7 S\:0>)K#]F+XI^ M'_%,=GJ>AP>))ELM=I5O)E56R5?'I6F%A@\?'ZU@Z:A/ M:RZVU::]-K&.+J8W+W]4Q=1SAW?2^B:?KN;?AC6!H/B:*6QMCJ.R5[F.0/(8 M7E1B!MQF1R#&Y7DGF ,Q(!JQ\?\ X?/XX_:($V%E=66A>,O&EJVLWD<@B:" MW+KQ+)N5A&SP1L0,@KA254DUZ/\ %K4K/]C^TUC5+1=/?6-4FD@\/0WD-O\ M;;=V8H-2M)'4$1J@C"@[MW&"N,UQ/PATG4;7X8>.?B-XJNY]1\0^(]#U"&UN M=4TA)?-A2 0RRO/&6VOO,48W$9R^0Q QZ$,4Y?[53V^%=Y-_HNOH>?/#0Z;'_ *+;V,-F@5;6-+==D2JDQY(! M/,4Q))/7.:L_"JR'@;X$:WK%LD-A=^*IDT6-[._)L[JTAV33.T;#>K^:L8R6 MC]!@<-SMKI4*7$D*2K;))M4B13&TI?H&PH#!B3M)C;/8FO>H4H*;:^SHONU? MS_0\&O5FTD]Y:_CHOZ[GUI^WSXQO]!_:L_9_AM9X$L=0\)^'H)XF8>;S213;$7 M+Y&Q653QQVZ]^!7[40G]VGTK\CXJ26$P=E]F7_I1^D\.7^M8KUC^1+1117Q9 M]8%%%% !69XR\8:;\/\ PKJ&MZS=QV&E:5 US=W,@)6"-1EF. 3@"M.FRQ+/ M&4=5=&&"K#((IJU]2Z;@IIU%>/6VCMUL[.WW/T/---_;$^''B7X<^(?$^@^* M](\1V/AC3YM2OX=,NDFN8XHHVD;]WD,"0IQNP">]=CX#\?V'Q"^'.C^*+/S8 MM,UK3X=3@,X"ND,L8D7> 2 0K#/)^M<#\>/V(?AK^T3I-S#KOANTM[^>![== M5TT?8M0@5U*G;-'AB,'[K;E/=2.*[SP'\/+#X??#31_"MKYMQIFBZ;#IG>]^O;UZ_9 M*DC91691L!8*2H->P?#[X@:5\4/"=MK6BW#7%A=%U4O$\,D;HQ1T>-P&1U=6 M5E8 @J017G'AS]BSP[X=U33)/[:\77MAX>W'0=-NM5>2TT%C$T2O /O%DC=E M0R,^P'Y<8%>A_#7X<:7\*/!]MHFD1SI9V[22%IYWGFFDDS7O;W^TER;65^?IRG#:[ M^V)X6T+P=XG\1?9/$-WH/A2_&FW5_;Z>7AGF$IAE\G)!=8I 5=L @X)P:ZO MX4_&K0/C/:ZG)H<]XTFBW0L=0M[RQFL[BSG,:2>6\3S79X]N\!Y/G9%<(Q))4Y.?0? M!?POTGP#X@\2ZGITA/>E4^KXN66FK^-MQ=K\J76V%\:?VA-.^".K^&K*[ MTG7=7G\3W4MK FEVZW$D(BB::21DW!F541CA S''"D\5TW@3XAZ)\3= 34] MU.UU2Q=F3S('SL=3AD<=5=3D%6 ((P0*\^^+7[$_@#XV?$C3O%6O:?>SZII[ MLY,5_-%'<9A,0#JK# "G(V[3D#)/2M[X0_LS>"/@-JFI7OA30TTFZU@(+V1; MB64W.W.TMO9N1D\]:4OJ_LERWYO33\S/$QR'^S:?L95/K*7O>['D;YG=7Y[V M4;6:6MM5K[NCK/Q@TS2/BGI_@];?4KS5[VU-_,;>WW0:=;_.%EGD) 17>-D4 M#+$@\8!(BTWXX^']5^(-EXYU;3SJ>F72Q[[+5(5QO\ (F4E79 R$CT< M$9&<9?Q9_9OTOXK>)(M9_M?Q)X=U86G]GSW>BWYM9+RUW%O(DX(*[F8@@!UW M':PR:C^%/[*'@OX,:S:WNAV6H1OIMM)9Z=#4I^UY;U^6R2?NWO:5AWQS_ &H? M#'[.VM^';3Q+_:,,7B-KC9=P6QF@LD@5&DEG(.Y(P'&6 ( R3@ FM;Q%\;M$ M\+^*/#FG7/VTP>*R(].U.&#S;"25AE(FE4D*S@$KD;6QC.2 ;'B[X2:5XV\? M>'/$5]Y[7OAA+N.TC##RG%RBI)O4@[N$&.1WZUR'AS]CGPGX5\5:=>VSO\ C;]"L/\ MV%+#4_;]4EG2W3<[*B^K' K \3?%CP]X M.US1=.U/5(+2Y\0W!M-/W@^7/,%+>7O VJY .T,06P<9Q5CQ[\.]#^*/AU]) M\1:58ZUIDKJ[VMY")8F93E25/&0:X,_L,_!TR(Q^&O@PM$P="=*A.UAT(^7K M6=-4O^7C?R2_S.#+H96U?'SJ)ZZ0C%]-'=S77=VGQ"M?B!;&/2]C6DFU8-X 60SE!MA)'ED]A7UM^U[JT?AW]EOQY>27 MVNZ7#::'=2-=:(0NH0*L9.Z$G@/Z'MUR*^)?AO\ _X9?%OXF?#O3-4MOC'X M;\2MK5W87%M=>,9[OR[A---W&7E6 MJVZ=F?J7A["C_86+E75D_:>]&FIR5J3=W><7:.DH$#M*NY8[NX\83Z7>:6+B6V$5Q-LB+PN6B=4(W(PW MJQYVM[3^RA=_$>;PC=1_$+5/!FNM&ZG3=1T*\>X>YB.[/G_NHX]X^7#1J W/ MRKCGYO\ VF-=M_ FK?%?P[8:SIMYX;\8WI'BF^_X0V_U2Z\/O/!%&Z&ZA_T< M[4V.@E(,6YW?LC>%/"5A\2OB!K7A*Z2"#4TTRUN]&?2I-,N].F@BE!D MFAD5&S,) P;8 VTX)[5B(_[*KK9::/RZ]-WZV]#HX@PZ7#5-3@E&,(\C]E/O M!OWI.T')U)O2\9**_FBRS\?/"/@-/B!+KGCC6+7P+_H<%M9:Y:^+IM$O-1PT MI>"18VC#)'E2F6(1XQOYXQ9SZM-XCDUR>. M,'=Y0EDED,:YP2HQD@9' KSC]HV]/P__ &B[O6?#=UI>M^*M3T:UAN]&O?"E M[KKV=O').8Y$DM3FV61F<$2<.4!&-IS9_99O!XU_:!O=_,[6\[>EOUO8\RM@:[R+V MJKU%#V:=O?Y>GN\CC\-_M\_)U26D3?\ VR]!_M*]\/77B'1_%'B'X=60F;7; M#1KO:-^8S%+A_;.\,KJ%SH&J>(- USQ7\/- M)2>37=,TZ_V(IS&T=Q/:\&[BC"OF/?QG/ER'&WF_@CXU\!?&CXWZ;XA^$&AZ MBVD6Z^3KGB#37.F:/<*L)$=M);L!]JE7*8(C!C \PT+1J=/0_VOX-%G^'^G_VA9^, M+S5UOU.@KX7,BZFE[L?:R."(U 3?N,Q\K;D-G(!\?\+Z5\:9_%/AC_A<[ZE/ MX566'[/'X/?+K'?#B^ M*3;S@WU@ETMO=/;[3N:W+?(T@.T['900&^8' /FW@O\ ;Q\/?&KQ':Z+\.=* MU;Q=JR2HNLQM$UA%X'E4]E[L;KOV_\ D?U9 MYV08C,(Y8UAL-&K"/-S5&TW2OVE=>QONG+XY;-O0]UHHHKS#\Z"BBB@ KF?C M/K-GX=^$/BB_U&P35;"RTJYGN;)VVK=QK$S-&3@X# $=#UZ5TUO0XL MRERX2K)NWNRUM>VCUMU].NQH^#[R+4/"6ESV\ M8)K.*2*$'(A4H"%_ 'KL2-&H9U'EGD D GZD5^+?@L:*/V"[E--OM4O-/@ M\=L&%];1JBH+ ?>3>Z,NI) K\8O!G@^]TK]@F2R_M*PU46?C\2(;&87,,1&G*P#J5<<-D?,I7(S[U M^E<$V^HSN_\ EY'\CX/BZ_UN.GV)?FZ;8N6BMKV8&- M8A>E_+1"(7W*$9@<A)%H\&KSVEC?6&FVMN@):XEA^[(0CYW/D-)VQBO6/CMX2TO M]K/]EG5/!GAJV>WU#P!>^=X=TRU:&:'R848/&MPDC[VFB(9=S9W-&.X%>7]; MC1J82,V_OR/6CAIUJ>*<$O?\ AOU::;2\M/R-7]D34_"?A_XH M^%5T74=9N-+F\.6)M+2W5Q>;5BF<%QPNYBD6=HP-Q&<#GSK]MZ_\>0?M _$- MO@K=?$B[T1=#63Q>UT6\M80TH_+C_;9=BOK4(>TTLT[= M[W??R/9P"HYAAOJTY^RL[IKTM9=EO\CR"76O"6D?L?\ A6VT2]\=K!NTU//U MUKC=%(TUHH1M_P!T "+ C(38[8.=U?%?Q%P]3&56]5+2_62T3_KGA*5G9Q5[6VW:(O^"@7AGP3;?M">*_\ A#+W4-2G:2.ZNY[IOMP@G)+2 M1VPG(5F#CY@7W+DA5QFM3X\1V=S\ )6GN=0LHDT_[3J5\L0CU1]= CBBMWC_ M ';&V-J5YV'"@GL,[?[67PJOOVF- /Q'\/:7_:'B6VO_ .S-6L-,MK>YU&]7 M*K#?-$'D%NFT%" JGYMQQ@UA>+'N/&O[(>O>,M0MW:;1)=.L=7^T:O;Q1I>1 M,MNCHEJ5*9M955U_O0D&,G)/5A:JE0PUY:P:B[[IZ+[NQQ8F#C7Q&BM--JWP MM:O3S[GF'AF1=:^&VJ6>NO8&STBVMI=%NXX9?,\M@0L=O*RJS@H+DLK+E/O( M235_]FF*SN?CCX)A\R>-8]9L58R1H-D'G*8PK+R(SQA5PK'[TC' -O6H_P#A M:GP=\'ZY'=V]T-,+>'[I=.MQ#]CEA8RJ88HTPY*.IWHC='XCY+N^ GA>:W_: M&\#_ &5XU>SUV!FDM ),M)*OFF7:9!'G"@H3&NXG"9Z>Q*<94*M]'[VG9K_/ M<\=0E&M2ZKW=>^WY;'[BI)YV@PG_ *>;D<>UP]*NV""4W#E5DSR MN[/#="QQQD5MK,KQ9!R#Z5^&*\7S+N?L5E*/*S#\">,X?&FD>(_AM$$L_.\2Z0K?+#+(!?6RD\*KG D5?]KY_5F-'NU/*0)R@^Z)-: M\,W_ ((U6?5O#T"SV]P_G7^F A?M#<9DB)X63 Y!PK=R#S6UX4^(&F^,D9;2 M?%S!@3VTP,<\!]&0\CZ]#ZU6\/\ Q2T77+O[(+H6FH@X:RNU-O<#_@#8)'N, M@]C4WB?X=:5XNE2:YMPMS$,1W,+&*>/_ '9%PP'MG%5)WTJJS[DQTUILS?C1 M\#O#?Q[\&W&A^);"*]LKF-HSN'S*&&#@^_?L>]?.]Y^P3J^GK9:=XI\>_%OX MB>#-*0QP:.GB46BS1D\1W(C6.6Z51Q^]N&R.JU]"0>$?%7AN+98>((M43=E1 MJUN&D13_ AX]F0!P"RD^I-3W/BCQ1IL?[WPQ'>G./\ 0M10Y]R)0F/S--1Z M737GH#?6S3,6XUKP)?> )O!]W:P:7H5S8/ICZ9<63V<*VS(8VB"E54)M.../ M2O*/@W^Q'\&OA9XME\1:;XCU+5_$$<*6EGJ6H^(?M5QI5NJ!1!"V?E0@ MD$ MN0"Q; KVYO&FJW$7^D>#=3.?O(9K=A_Z,JC>:E=7!&WX>W$R=RTMF I^A>JY M$G?;YHGG;5M_DSQ+Q3^Q1\+;OXQ3>.K;Q9#8>+GGCNFN?M<4JK<)&(UN!;\0 MB?RP%\SR]Q48R:Z?7-8\1?VA"T'BJW\8VUJX*Q)H>R\MR!@NDB1NI)Z>.&U-Y%'S?;5D^RS_3 MSBD# _[(*T^7X,7FK7/GV-AHW@82+\SZ=)(+D\##-Y9CCW #'(<<#DCBMIS3 MC:_+_7;-? O]B_Q#\-/@_H]A?6'@O4]5M4.IWVJ>)["*YOKG M59#OGNMZ@A"SO*0S,Y4$#&*] L/&^EVU]OU/PYX@\9:C;;6^U6VW4-/@;('R M[=J1@9_A3.!DY(I^J^&X= U)(I?%3_$'4?,#"SU* WKH/>.VV1(..&>/KU)- M=.OC_P N5E2](&3]V%"C#C!R?IBGTV3_P#)?^"Q?:W:^5_^ M C%M_#FE_%*_:[N]7T?PX^YI'AT:?[/?E1WDG(5QTP=JC_>-"_AY]H\5MXMA_LZ\N;M1Y-@CY/VIKW 9WBX9%4NQ?9G RP[O49OAAJX,W MC?68=3ODW2K;Z_']D=1T_=VK*F0,X!"DGCYC5VT\-7>MZ>J^ HM:\/6IC'D7 MUU=.ENH[;;:7>6_X$B_44-W7*[I>:T_S8ETDK-^3U/EWPK^PG^T';^.;_4/' MWQ+AN-&U0J=:N?"5JMMX@U^)3E;>2\F=?LT2#)&W76N^) M=.\06T05I+:^B:UMD4#YAMB8*V3S^\#>WI26/QRU (;+1/ \FM10KM$^EW$1 ML%[8$L@0-CG/EAL8QUK&G3C;W-?1V7XFTYRWEI\KO\#A?@[^R9H/AWPO=6'A M36-'\)Z7>.'N-)\.I#Y1/?S9PJS2DCKDKGISWV]&\+Z;^SG'-8^"_#?@B_U1 M@/\ B7Z1I0T^>4^LCQ[D'U<*/>I-?T?3?'-_;R>-K&^L44L5M+/194C'/!>Y M1688]G0'G(-=#X:\+_#BRA>+0M:M]/4N7=;+67B.\\DL!(.% MQQ_%5#1?V>/ACI:+*.MXEA!YTO37IMEX,OIIO.L/'> ML2P+]R%DM)HA]6\KS#_WW6C_ &7XHAZ:SI4F.F_3V&?J1)_2L'7O[J:2[>\C M54;/F:;??1GFEE\)OAW9,$@T[Q?:[CDA(M30#ZX&,5?;P3X'\M4,_C-E4_*& MN=3PISD8YXYKLYH?'&\^5=>%RIZ;[2?/_HRI(X?&*6PW/X;DFS\VV&5% ]OF M-1SK:_X_\ UY'V_#_@G(2>%_ L\1AO-*\0:LN/\ E]L;Z\4_BZD5Q7QT^ WA MOXJ> +O0M"\ -I<^I*('U=?#=A<36\7.[8MRP ?T9D<*>=IKV&ZM_&IN/W-Q MX8$>!P]M,6'XB0"I+>R\8.I\[4= B/\ TRLY2/UDI.47HW?YO]$'+);?DC#\ M$:1K_@7P'HGA_0=#@CL]#LH-/ADU?5&:9XHHUC5G948N^%&23R<\ULGPMXCU M5Q]N\1QVD)&&BTZU6(C_ (&Y<_D!GT%-O_!_B'68P)/%UU8$'DZ?90*3['SE ME_3FJ.H>#O#]CD:UK]YV2XWD>ZHP]ZS=(\6> _#5QLT6U@O997RQTJP>[R_\ TT>-6 /NQ'>MB3QG MK>HS>7I_ABY6-A\LU].EO&/7*C<__CN/>FXZWDF_5V%&5M$TO17*X\$:WXPB MSXAUCT^/=N:/281&TB_W3)(68#W4*?0BI+?PEX6^'>;^X-I M!.1AKV^N/,E(ZD>9(Q./;-2VGHW?R12NG>*^;*[^,]=\;NT6A:>VG6>XJ=1U M*,KN&/O10<,W/'SE/7D8SI>%OAQ::#=F_N))M3U9QM>]NB&?']U!T1?]E0!^ M.:ICXL_VVI7P]I&H:QSM$[1FUM3[B20#!]?\7.IUS5OLMIDEK' M2RT*2 ] \I/F$#_9* ]P:-4K?"OQ#1Z_$_P+GB7XH6>BWIL+*.?5]6X_T.T4 M,R9[N>%0>[$>V3Q6?;?#Z^\9S1W7BV2&XC1A)'I=N2;2$CH7)P9F'^T H/(7 M(S74>'?"5CX4LA;6%G!;0J2<1K@DGDDGJ2>Y/)[UH[#GIQ67M%%6IKY_UL:\ MK>LPAA54&/2G@8I116)J%%%% !1110 4444 %(PW#!Y![&EHH ^=_BK^P=]G M\?WGCSX0>)[GX5>.[X[]0-K;BYT3Q 1R/MUB2J.W;SHRDH!/S'I7-W_[:FM_ M"K2[O1_VAOAQJW@ZWGMWLKGQCX9,NJ>'9HG&TN9H@+NRR6('F)A3@^9T-?5E M-FA2XB*2*KHPP589!'TI6'?N>=_"CXC^'_BUIB:U\/\ Q[I'BG0(]-^PVUO; M7D5] +A3E99)@3-OQA65F]\!LD]5IFHZ]'=Z1;WVG6,BRV#2:C=V]R0EO=+Y M>(XXV7+(V9"&+ KL (.[CRKXG?\ !.'X-?%7Q,VNW7@NTT?Q"QW'5_#]S/HE M^S?WFFM'B=C[L37,Q_L%>-/">\>%/VC_ (S:7#G,4.J3:?KBQ>@W7=M)(P_W MG)]Z6H]#W73_ !KJ%U%H1F\+ZW:/J\DD=RCR6S?V0%1V#3E92"K%0H\KS#EU MR ,D2P^*-3NK573P]>PM_:3V;QW-Q"K"!79?M2[&<%& #*I(?##*JH ]TO!X@NH-0$MWI6C)#J4+V=PF;DS62^4TBRJVP)( MY$R?*6"J4;).0/#/B-^W/\(/!WBW6M$TG4=6^+?BW5+J.>3PMX9#^();>2%8 MT&$W&WM$4HK-O>,;\M]XTEO_ ,$MO GB95;XA>(OB1\5Y0^\+XI\474MJI]! M:0M%;8]C$:]T^&_PC\+?!WP_%I7A/PYHGAO38!MCMM,L8[6)1_NH *>H:'SQ M-\,?CC^V;D>.M1;X)_#V?[WAKP[>BX\1:K$3REYJ &RV4@ %+4%B'8>;TKZ M^#WP5\*_ 'P+9^&O!^AV&@Z-8KMCM[6,+N..7<]7=NK.Q+,(=%4 +=PK_ *=;C_II&.) !_$G MS'^X>_1Z)KVE>.=(+VD\%];291\8;'8JPZ@^H(K8:/)/?ZU^<'[6GCOQSX=^ M//QI\1Z%K'Q0T5/A_J>GPVNHZ1;Z:WAG2K8Z98W,SZBC*;R55,TKMY:N0K#; MCFM74@U[VC\C-0DM(ZKS/NB;P!J'@L-)X6NTB@7D:7=[FM2;W2893'LQ5O51D5XIX'_ &T?$4WQ7'@C M_A'(_$>KV^N7.F70MKD07$%C%:1W2:F05V21R1SVHVKLQ)/M&=O/M\7Q2\/Z MW(;&_<6%P_!M-2B-N9/7;O #CW4D5IK+=7*1V#8X=?9@1[53\_Q=X4&'6T\36:J3OC/V:\!]-O,;_7*>F.] M*_PEL;1-V@WEYX?D9MP^PRCR3_VQ<-%@^R9Y."*E#>,-&D+,NCZU;J.%3=:3 M'\]ZD_\ ?(]Z:>EKW\F+K>UO0KS?$GP_J]K]EUV";2VF4K);:K;;%QW!;F-O MJ&(I+/X;::D?VCPWJM[I*RKE5M+D26I'8B)MR#_@(&?6I+GXE"VLLZUX>UNQ M!X919_;5'_?G?_*LE$^'6O7+M#=:397CMYDBPW)L;C=ZR*K(V?\ >%6DUJKK M\4#<7V?X,V&A\9Z+ !#-HFN#@'[0CV3@=R67S%)]MH^M,U3Q1J4=HRWW@V]O MD;Y62TFAEW?A(R#%1+X!DO85DT3QCKEC&#EO)GBO5?VS.DI ^A%:$>C^)K?" MIKMC< =Y[#YC]2KJ/TJ?=\OQ0];=?P9S#V/A)D4W'@[4]-?J$32G8J?K!N'Z MU'-8^%YOF^U>.+1>@1)M4@'_ 'R,5TLUMXW60^5=^&"O;?:3Y_22GQQ>,UME M+R>')9<\[89D7'_?1-7[17W_ !?^1'LV^GX+_,Y,Z)X8",R:A\09, 9"7FJL M?R!IT6F^'RQVQ?$#4.!F*:74"A'IB8A:Z>Z@\:>?F&X\,K#WWVLQ;/L1(/Y4 MZUM?&#I^_O\ P['SUBLI3_.2J]IY_B_\A>R\OP_X)YM??"G1M;O&N-(^'VNZ M+J&YF%T_V5(IV/4RIYKAQP/OH3]*N6GB/QQ\-X(K=_!'AY+$R;7OK.=OW:8^ M^]O'$QSGLA;\.W?7/ASQ)J49CD\31VF[A9+&QC5U]_WAD7]*RY?"]I8#R]:\ M,O0SW\5F?R@6('\15^WYERSLU_V\V9?5U%WAH_DC!F\"R?%!X=8MO%EA MI]S&P'VO1K00S8'\#N[MG'=6&/\ 9K UJ\A\&7[GQ)K=SXYM8QM9;>_*W"9; MH]I&1$V/[PPW8 GK;\3^ ?A1JWGNERMYJ+,&DFT^>74+G&4C MGI5_0_&NO^#XHX].\*7?B330@5)H;)-,NE4#JR2%%)/' ">PK9-M>[?YJWW, MSY4G[VGH[_@9FGWO@GQ5JC_$?X?U.WUB'A[JPMQIDT38S^]$VUG7ZHZFMA[ M_P"*NDVC"YM-%O+ 'Y9K<>;J.WWB8QPY]PW_ &J\OB'_A=3"V&C:1HFJP_, MD>I7$D>HVYZ$A(PC 'GYDD(//)%6Y_A;\0=.AB^S^-I;ZV20M)9- D+NA_Y9 MK<%7< =B?F]6I-I:2M?^]K^*$HO>*=O[NGX,P]/^%?ACQ*]&\-VDFDS^'=,\76)9#YGA^R\V9V[/)'C8" M,?>$A^@Z5)K6G?#;SHH?'6F-I]](,QRZ_F=TOQ0=,C;_ M (0/4=0\06A"F*WDLVN;+:?^>5U\NX?]M'QQP*MMO1W:\]%]Z(22UT3\M7]S M,WPMKNO>(;V.#PA>1Z;:X+3:9XFG-Q/$/18<^8HR<8\S XQZ5GO$;BS#?\ M"3KK^EO,F9I?#<@&F!@0?GA0!V!Z?.C#&/UHT#X57'B*%I=,^)%[JEO@_\2_[0'LD/3&487 'L MTI'M5*?+K=+\?Q7ZA*'-HES?A^#,%-'\+^$+:/\ LZX\'7VYL.UD[:3J?J2/ M)W,SDGT3KUJY_P +%\1FW*Z3I?CW3%P5BN-61)K3CC^%);C!]75G6^IZ3;7R1V/B[6O#,J-C M[#J:_).0/N@72DD#_IDP^M1[6+UM?UU_+_(KV4EI>WI_P?\ ,Y[[/J?BO31% MK?Q?\DJY,T=IIZ:?&P_NDL=^!ZAAGN.U=!X?\!>$K*Q:-?%RO;RG,BV5]#:> M81W+0A9"?J]=)'#XCO%5X9O"VLVF,C,+Q&3Z,&=?T-17QU&#;]H\"6-ZXZ?9 M;J&0+^,@C_E6$JS>B=E_VZOT1O"DEJU?[W^K)M"\2^!?!$,JV%_H<&3F40S( M\KD=VP2Q-33?%J.^,::+I6K:RTIX>. PP1C'5I)=H(_W-Q]JAMO$%Y;D$>!K MR)^^V2UX_$/4TGCO7D=1#X+U)E(^\;JV0 ^G^LS^E<[@GJ]7YR1T*9X8[/(8Z59,?(;!R!+(<-*.F5PJGN#790P1Z;:A$"1Q1+A5 P% M [5S,]YXQU0KY-AHNF+D9:>X>Y8KZ;5" '_@1J!OA7+XAN&D\0:Q?ZG$^/\ M0XV^S6B8ZC:F&8'OYC,/3%1+72$;ONPUSXES:Q=MIOA>%-3O0Q M26Z)_P!#L?4N_P#$P[(N22,$J.:U_ W@B+PA9RLTKWFHWK^=>7D@ DN9,8R? M0 =FX_C1:4H\M-:?UU"\8RYIO4Z7Q%XDL_".DS7U]<);6T"[G=ST]@ M.I)[ 5R_AK1;GQOXCB\1ZO 8(K4'^R;*11OM0PPTS^DK*2,#[JG'4M5C1/AQ M<:AJT>K>)+I-3OHB&M[>--MG9$=T0DY;_;E<'XSN3\4O$!\-VV'TFS=9-:FS\K@69CU+$\DGK3BO9^\]_R"7O^ZMB_$GEQ@*, <8]*^>/^"H<> M[]CKQN5,P8VNG %68 XU*+@$!N3T^X<\9XKW/Q;XSLO!FD&[NY" 2$BB49DN M)#]V-%ZEB<<"OG7_ (*'_P!J^(?V(/'#:C;/:7UQI]BQMK?"YR2<9XKKRR#^MTI/;FC^:.3,Y?[+4CUY7^1^6'@2P\.:WXPT^TUJ5XM M*\S;(TBK%;I'_P MD'EDE8\XW!20K8*E6PIOW.HR?$CXW>&1XFNI=%TS^U[F MWLX]/MGMY(H!Y@**NU8Q;M<#8SF3?AV.!VIQ>'99H_-2"VGE\R)'2-%9)/+& MV/SPN3"H'0%85R"?O#([S7+ZR/QO^'GPY:6ROWT7[#IDT#SO:7,,]Q#O%?C;XB1_# M[1M'UC5IM.U%[S68K5+#5?(O[R11*[JB&1854H@+;1B(G'5J]RT3X;:#)\,O M%?P"CN;."REL%MY]2L5AG@OM6=%87#$2N\&QT(,>%^ZQQUKP)8J-'#X=/5J2 MG9?RI[O[U9'T:PSK8BO;2\7&[_FMLONU9YW^PW/X3T?X1^%KC1-2OD1Y0EY' M<(5N9)6U/3 Y0)E0@D)4#DE"2>:[7]O74?$S_%WX=O\ !6;XEO\ $>:VG#P3 M.YM([8VR&0YF_="4JL;.$.#P3\U?,_PNM[[PI>1> [22ZTGQ5X'D>6[T74H+ M9WNKI3OEEM"PW/AT1]H92T:?*3W_ $%_94_:;G;P=H\>L>%M6U#4=.L)9K:_ MD$]W)%#(PS$DGDDL 4 Y_P!5EM?(3_1S";UPZRE_ MFR $"E2RM^5^AS9Y9TX9?1]YV44[6N M[_G;=GH?[='A[P:?"/PU9;S4+WQO>>&M.BU*TO;EY+"SVQ6NQF1_W:R,K<)N M5&(^;/=OPGLH+[]GRS@OWN8KN5!:ZM>7,45I=Z=H1,C"2Q4; S&Y52P5W^;R ML;MQQZ5^U7X6MOVR;;Q+!HMO;2Z[X"B6XT;;;6\EYJ=D 6:R@MA(=Q"K&XD9 M#]X8SG%>*?#NKV-[9:[X)T6_5K*]O+*P(L)HC*5DC0I(CI< M1HZEF7B0G><4Z%?FR^$9.SC)-IO5)[6\OR(Q%+EQTY15U*+2:V;6]_/?U/'/ M@9K,=U:OH^I26=WX7U6VN6,UY;22?9[J-HI9))'95\FXVK&"%+1MNVD@,36/ MI;V=NTD,4EXQ5I#!YX !E*[)6!P6$N>K!6DZ +&N#77^ =4B^+G[/VN6$,UC M/-X6U#^V/LMNNX1V]R@@9I9B,S2!R% D+,=P&'X YV]\&,D1B@TFI:.^WZ^K3/EZD&J<.756O?\U\K'T7 M_P % X=!F_:M^ $%[K&KQB'P?H3P1VUHDT;-]H<(03,IRPSG@XVKRGA+4=>_:G^ \SZGI7V33/"?A^66UN+V"&25Q(AS@E/F Z5\:_!W]A3XF_ +QU:^)?"G MPF_9[TO7+)76WO/[=U>62$,I1MN^(X)5F&1SAB.]?>]%=F'QU2C!TX[/??\ M1GUV0\:8_*<)5P-!*5.K\46YV>EFFHSBFFNZ9G>$9-4E\*Z:VN1V46M-:QF_ M2S=GMTGVCS!&6 8INS@D XQFM C(I:*XWJ[GRV_8ITF"/3= M,;Q/XKE\':/J4>JV7AEY8/L$$L4OG1+O$0N#$D@#+&92HVJ,8 %>A?##X4Z; M\)K/5X-,:Y9-:U:YUFX\YPV)[A][A< 87/0?K7345M/$5)JTF>IC,]Q^*INE M7J-Q>K6B3>]W9*\GUD]7U;/'O&G['6F^,+GQ+ GBGQ9I7A_QE.UQK>B6<\ M M+]G55E^9XFFB$BJ XBD0-D^ISV7P_P#@QIGP\\8>(M>@GO[S5/$SPBYFNI0W MDPPAQ#;QJ L4?F/@8SER22:Z^BB6(J2CRMZ?U_DON"OGN/K4?J]2HW"UFM% M=>[O97?P1U=W[L>R/._&W[/4?B+Q_-XHT;Q-XC$:Y>6L=G>3Z6\#QWL<9^&"AL-C.*E^'GP$C\&^.I?$VI^)/$7BS7FLVT^*ZU22%5M8&=7 M=(XH(XXEW,B%CMR=B\\5W]%+V\^7EO\ UZ[B>=8QT?8.>EN6]ES:EI>EEG.CO<,-.O7)4J]Q"/EFV%?E#Y M4$DXS@AT'[/OAC3/B1:^*],LWT76(4$-P^G2&VBU*((42.YC7"3!!C9N!*8& MT@9![:BA5JB7*GH9PS?&PI*A&K)02:M=VM+XE;;7KWT[(Y+XP_!W3_C;X?M] M)U>]UB#2TN!-=6MC>/:KJ2;64P3%,,T1W9* C=@ Y&0%6#&WW1XW0MSNC;*G)XSS7HE%$:U2*M%Z#H9QCJ- M.-*C5E&,;V2=EKH].MUH[[K38****R/-"BBB@ KG_BQJVJ:#\+_$5[HD#7.L MVFFW$UC"L7FF6=8V,:A!][+ <=ZZ"L#XJQZS-\,O$*>'2PU]M.N!II4J"+GR MV\O!;Y1\V.O'K71A+>WAS6M=;[;]?+N?;S-#PM=7- M]X8TZ:]0QWDUK$\Z%=NV0H"PQVYSQ5^J'A=;M/#6G#4,F_%K&+G)'^MVC?TX MZYZ5?K*K;G=N_0VH7]E&]]EOO\_,\8_X*&0)<_L4?$U)&9(SX>O,E3@_ZLU^ M+/PPL+CPK^PPR:AIG]FWD?C[RP+B#,KYTT,CX>2,DX<$%2#\P(S7[4_\%!GF MC_8I^)YMVV3CPY>%&!Q@^6>_%?B[$KJX^('[!S_ &S5#J4,WCLP:A::G<>5 M]J1M/5"L,A)"R E2I.A!"UG>%M#N?@ M%\-=)O$CS:$QBB59-+TT*S7=TLR$DRG*J68<,2"7/RC0^*'Q&L M_!'Q"\)Z-%:VFJ>'O 26=Y*DFH?8)II+2-'EG>/=@S3;A&APWR[>>?EZ3XX? M 7PO\5!I]]X)M?$-U'-X1M?$$5G!HC7GVJT61%6S2X=POG&:21W)C)/#8)7G MZ259*2=:\8U-;^2V5]UW9XD*3E%JC9RAI;S>[MU[(Z_X-:%I?@C]F71U\&W= MS_PC^C2,GB&Z\XVEP]ZP/\ 5/[2L3>Z9KJS)KNE MI=FZDB>.+SYID*[8(WA_=1(3@KANG2O>?#'@SPK\6M,L]6\%ZQ]NMYW6*ZM6 M#"XTZ1BFW=@_(B1,"/O1YCD.,XSYN.H2HSG[2_++7FWO?N_U['J8+$QK0@X6 MYH]-MNWE^I;^.'_!/O1?VFM)U'QOX7U3_A!/&/B%OL&IA+(S:?J>9%<(P #+ M*7C5RRJ.@)6OGGPU_P $U_VB_"^H>)=+\.7FA:DLMNECJ;1ZRA\M'02#_6@- M&QC;J #M=AG!->P_&G]LG7/@[HH^&OP]U32[I?L[ZG=ZU:-]H;^TH981/8P* ML>P*%7'3_EHO(R,^/ZO8_$/X6_VS%'I>O>8MC=7=_!-J$B-)9"YFVPRJI;RU M\GSB&+9^6''8->5U,QIT7&^-O'%K:^'M:@=5L-$D?4+G4X AE:))BNR,L$[9/R_3' ML_Q;T#PUX/\ \/@KP_I_P#8.DZ,QMK6)6$8?XN)HIQ/'879F!NH)RH4;$,GRE]PVQY' M3GEQ\L;/$*KBYITW\/+HK^BZVZLZL"L''#NGA8-5/M7U=O)^O0Y_X=C5[C7K M"V\/-J$=U:',Z6]SY;K&BL$64$A'V!$1MQ*AHI1@#(KR KX.T7]HGQ5H.EZ. M+[PK\3IX;*_O8XUET_2%R$^TVZ;0A5=023+-P%CP,;@:Z_QE^TCX6\"^#=;\ M.^#M6&HZWJ#)I=]XDC1X8;"*5IH@T+(?-&UXXP7V[2N.M>+?#?X)#XCZ!>ZU M'O#4:WVO^"4M-6U M34;G4FL)_.N((H%G\IG'[U D._+G>6.?9;>SL?%?[17PX\5:))I>DW^LW&E0 M7\I60>48)EBFCLT4,SBXF5I#*VW(< G+L*Z8UG*E*K-64TW\TK=.ZU.:=)0J M1I0=_9M>MF[[^3T_X8_82\LX=7\,QPW,:313374]5?#WQ(TGQ/=?9[>\5+I?O6LRF&=,>J-AOZ5^1 M4XS2;2NM3]/O%V3T9:\+_$;2?%P9+6YVW<(!FM9E,5Q#G^]&V&'UQ@]JD\5^ M!-,\96\2WUL)'@;?#.A*36[?WD=<,I]P:J>)_ NE>,0AO;9'DBSY4Z$QS0$] MTD&&4_0UEGPQXE\/J?[,US^T(47Y+;4TW$>WG)AOQ8,?K0HPO>#L_,J3G:TU M=>0Y-,\6>"Y'^R7-KXBL !MAO6^SW<7K^]4%7&,8!4'CECGBPOQ/^!55C^(&NZ0D8U/PO?2/G#R:;/'<1IZGYS&Q'T7/ MM4A^,'A^-0MS/<698X"W5G-"?R916OLY/XHW]#'GC'X96]2])<^%OB7IP4RZ M3K-M)]W#),C'VZBJ\?P@L;%5&FW^KZ3&GW8K6\;RE'H$;*@>P K-O;WP#XDO M?,EE\-37;#;N:2(38^N=U.7X<^&+V$I:7,]KNY/V#5)H#]>$_!FDDBX\7:O Q[2^+ M+I3^1FH2O_\ LAM_^T=%#HGC;XBT+R#PJQ:,ZR+^)G(/Y4W4-%FA!^W^ M-+N(X)<+]FA"_0[-P_.N:E_X5_%&B3ZD=0SP&GOIKO/XEFJ=;SPA:X?3_"EW MJ=S!S&8M(;_\&&U9[CQ)JGB,19W+!>S M72C')#K#\O\ WT*\4^ /QP\>?$G1="\=>#/A3X:;P#XEE$MK;,18ZE!9.3Y= MZ\[ML8E=KM$D1P&($CD 'Z%/B?7-4LR-/\*_9BZ[0NI7,<*_1O+$GZ9KP_P= M^P]XYT7PUI/A7_A:%QHOP]T.]2\L/#^FV"F>VCCD\R*S-\65Y+9&QA#&&90% M9F7(.<^9:7_']$:4TGK^G^8_4/\ @H;HDNE3:E?ZG+X3T2&PN-5@NWT"[G_M MBS@D2*66SD9%5]C21G[C;E<,JLIS5=_VV_A#/XLDTCQ)>^.[F[AFLX;Z#6-* MN8X-/>Z"?9UFB"A1N+IQM.PL"VT$&N8\9?\ !-[1KGPY8Z-XR^*^I7^BZ!I< MVC>&+":&*#^SH)'B)WA6'VAUCA2-3M7YZT^+3()IV@A:YEE4OA MF0G*[2$9695# GD+W_@G;XJ\>:(OAF_\6P:5X%T:'5(O#FFQVBSW6G"_@F@? MS9?E$@BBN)DC&.C_ #%B 1;_ &A?^"5T'[1/BR]U+6O'%].+ZQM+51>:;%=R M:/++-CAUS4-N.]K_>RDE+O;[BU\.OVX_A>^E:CYGA379= M?36M6TLZ99:7+JVHW4-A<-"]TY4$A,"/.\C#2!!N.,R_'+XEWL/[-)^)/PW\ M,6L5CJIL+JUOK5KB2:2TN9HD:\D@M!O*11R&5ERYPA&WKB3Q+_P3)T_5KU;J MUUO1C+9:GJ]WIL6I^&;?4;:SMM2G%S/ 8G8!F2<;XY 5*CY2&4D'UCQ!^S<; MK]GG1O NB^)]8\-W'AV.S.GZOI\<,,J2VS*REX4186CY\^?";XF6\WA&[UWQ;X]T_QZ;75+;2M#O_#TR:Q!K%W-&S^0+#YW MMYX]K;PS#Y%+;D 8+Z%;_MPVWA_P_ILD;R>*+NZ@O+F73]-\.WL%]IL-G-Y- MPUQ;CS6C\N3Y,'EC]P-69K__ 3:7X@1ZKJOBKQ5::YXOU'4].U-;MO#UNFF M*UE'<1Q))99(E#)=SARTF\[EVLNQ<:N@_L$WG@&UTZZ\)^-(_#'B%-.O=)U" M^L?#]K%!OINM'P]'_ &79R7']H7XWL\$&](Q(R)&TCE3M1 68C!QG6/\ MP4?\%^-/'JZ8/!_BN[T2/0+G6+B[&AS7,]M-;W9M9;5K=$9_,21'5AUW #'. M:U/%O_!/32/$GP]32'U=+J^LO&%UXQLKG5M-BU& 3W"R1R13P2'$R&.9QG*M MG:P((K'U+_@FTLGA:'3].\:S:.TNA7>BW[66C6UM%=]K>@^1=7^!'K?[;?P)FNDM]0\/:X-<_M;^QO[*;PI<-?I<_9OM M0&P(>/(^?<#C .<8-=9X+_:!^#/C^?P[;Z9XBFMI?$ME<7]M;_VG/9FW2"2. M.59D\Q?*0Z,=TE]QZ9!H_ARYB'V3 MQ1=HA^4>7K329]LEC4LO@VTGEX\8ZU%M4+M745X_,9K>N?".DWC9ETVPD/7+ MP*?Z51?X4^%Y'+-X=T0L>2391Y/_ ([6OM5W?X&?LGV7XE"'P;:1;E/B_6)= M_'S:B./R JO>Z5X5MH0;[Q-<;<8W2:Y)%[]5=:UXOA7X8@D#IX>T574Y#"SC M!'Z5H6GA72[ ?N-.L8><_)"J_P A1[5=W^ >R?9'$9^&>H(4DU/3=:_V)=1: M_;_ODLQJYI^M>#-'ME33M%=_+/RI;:+*@ I.JGO M=_,:I-;67R.;C\?7%U$O]G>%];G!'RM*L5JH/N)'#_DIIJZAXSU2 A+#1=)) M.%:6Z>ZV>AVJJ _3;[_ *UGSKI%%^SONW\M#F8_ 6L:Q;)_:WB: M\:3^-=/B6TB/T^](/^^S5W1_A-H6C7GVM;))[S&#=7#&>91YE%@N M7:*I>91YE%@N7:*I>91YE%@N7:*I>91YE%@N7:*I>91YE%@N7:*I>91YE%@N M7:*I>91YE%@N7:*I>91YE%@N7:*I>91YE%@N7:*I>91YE%@N7:*I>91YE%@N M7:*I>91YE%@N7:*I>91YE%@N7:*I>91YE%@N7:*I>91YE%@N7:\A\UW6-/UNYG\4RQ3:S9KX@U"+3-4:.&.!?/LEF%O(/*BC4AHR&"\YKU' MS*/,HY0N><^ _P!G,:#^TCXI^)&IR:3-J.J:;;Z#IB65HT/V.PA=Y,2EG;?* MSL,LH4;8HQCC)F\0? '4_$?&(=>1'#KM@H'_ 5A_I7T(R(_55/X M5%+IUM,FUX(67T*"K]HN[^\GD?9?<>/V'P&+!?(^-?Q DVCMJ%BW'_@/5L? M.YQG_A<_Q!^GVZQ_^1Z]$NOA_H-\K";1M+E#_>#VR'=]>*K?\*F\*_\ 0N:' M_P" 4?\ \30Y1?5@H2[(\;\2:#H?AKQWI/AG4_CQX^AUK5;6XO+. W=F=\<. M"^7%MM!P20K$%@CE0=C8X/Q_XU^'7@W1M&U+4?CS\5I8M>TPZS8QV %W/-:@ MP OY4-HSC'VF([2 <$G&%;'=^/O^"?NC>,OB/?\ BVVU*/2-<.HZ=<:?]FL$ M^S6MI:Y#6SQ9_>>:LUXK/E2!2/*?!'BSX1_%C0KF_ MM?B]\1-0@LM..KR?VKHD8E^RC/[Y4N+ .R\'! Y[5HCQ_P##C1-9BL+7XD?$ M>0>?%:?:H/"L!LH+B7;Y5N]S_9WDI,^] (V<,2Z#&64'N-;_ & -%\5Z3:6^ MK7=IJ#6'@&'P7;N]B1Y,D88?:P!)WW#]W[?>I[?L8ZI'X:O/"L/BBR7P?JFO MVOB*[B;2R;_SH9H+AHDF\W8(WF@4Y,9959E!^ZRGM)=W]X_9KI9?(X70_P!I MC0M:NK6"P\>?&M#?6ZW5D][XX66W+RDVN\PLKQH2CYC M)&8EJQ>_L7^*?$W@O7M/USQ7XN7NHOH%PDES);7D,\4+ 7G$"Q M1")40KC[V2Q;?GS?W?S_ ,RN5=SS;Q)XSCUS4+>W\7_%KXGVMC=6C7QMG^&\ MJS:;")#&9[B273R((MRGYY8T&%)S@9'1?&_X?P?!K2]#MW^/'Q9:34H);RVM MH+'^V6NK6+899RMI:-(D2>;'F0_(-ZC!R!7:7'[(7BF&;4#IGBCPUI4>K^'9 M/#ES&F@3RK%$\LLGFQ;[PD/^];[Q<9 .,<5L?&S]DN;XC>&O#&DZ9J6E6UGX M:TM]+@_M#3I)[B$E(D2X@N89X)X)56(@[),.&Y P"+5>HMM"?84WN>.6/B'P MUX$N;F&Z\6?$"6Y2]DLF.@:)::Q),Z113._EQ:>9RHCGB9I/+*#S%&_<0*V? M!.J?#C7-0UF;PU\=/&=OK:^8>QCT5QOQ ^(FJ_""Z\8_;_ (P>.O%$7@HVS:M!IV@1 M/=Z='-&TJ,XAL)1(NQ69G4*JXPVW-5$\:^"?'WAF[U_6_'GQ:T$:3I0URXEU M3PY;V5U:6A,RK-_QXAUS]GE(Z$A01PPSL1?\$X=5T2/4+C2_B1K)U/7],U?3 M-:?4K?[;;WJ7Y+95#(KJ8G"[-TCD*"N?F)J?XI_L_>/]4LM6M-^F_P!F>)/" MMOX1U7[':_;9VMHC./.A#RPB.0K<2C:WF ':03M(:X7>JM\G9_Y&;LM_QU, M_%C01!?P:!\?OBG9#31? 7NH>'!=Z;=M9)+)=)?:)%HKSA@2#%%?:;&) <<[7('&3R*XCQ M'^PM\/M'A[Q)KSZZ=0N-1TR:-7CU'[1M*))(JQRP&95$L; 2(LB$ M8<;?9/V=?V;]8^"OAJ6TTWQC92P3"(QBVL7:-PJX)8S7$SMGC&'&.>N>*Y6G M[WXK]4+1KW?P_P C$/P+L1>2R77BSXIZ#=D#S)HM-L(V^GFV]J0?P8UM:-\, M+:Z?[-8?'GQU]HB',;WVGR2Q_P"\DEL3_P!]"O1I+OQKIMRB_9-"U>W'^LD2 M62UE ] A$@)^KBJFM>)A>J+?6?!.I7,)Y=UBM[J)/J-^X_@AJ^6_G\_\S._1 M_E_D*;FR'9(_ M$,]J#_P$2#^5'L^__I(7[?F<_;_LZ_%8WQ-Q\<]=-N?NI#H5BK_]]%&'_CM: MZ_LU>);A<7?QE^(]QGJJ)ID('T*68/YFM&V\ >%[Y/,B\3:]*IZ&/Q1=D?I+ M5Z#X3Z)$ZG^U_$C[3NP_B&\8'Z@RX(J.5>G_ &Z6F_Z9@^%_V6+;PKXHM]7U M/QKXJ\1?9F+>3K36<\39!&,^0'4=_E8<@5W&I?$[PWH%Q]F?5++[2BY%M WF MS8]HTRQ'X5BW7A#P/I^7N_[*?^\UW=;]WUW$YJ;3_'O@KPQ9K%8WFBP0 X5+ M3:RC\$S1R7_F8^:W9$__ L35M>PNB^'[QU+8-QJ!^QQ*/4*09&_[X ]Z;%\ M,)_$LL&K4Z[>*Q5Y4;;9V^#A MM\V""1_=7(=4O-; _Y=W(BM?QB3 ;_@9;VKI8UL]"L J> M1:V\*@ !$C4=/0"L[0B_P"9_@:OF:[(Q_"OP[:VU0:MK-V=5UO84$I7;#:@ M]5A3)V#IDY+'')[5XY_P5)GAMOV-_'/F+ 52STZ0^=&A0XU*(@?.RJ>>VX=1 MCG%>JW?Q'K2Y\0W&2OF6^%M8N."\Q^7&<#";FYZ8S7D?_ 49&M7? M[#WBX7=UHNGZF8-.W-'\T< M..E'ZI4C#L_R/SA^!\&DZOXM^WZT\UMIGAF#^V-3OLN!:VQD RB,S_,[J%5H M)LY_@.TBM#P7:ZA8^,/$OQ6UC;XQ2Q2/6?"UI<6\<\NHW=S(H@65U.Y7B#E@ M@&-L3%<* QH>-8[;P5\%_#/A'0;>T*^(&FEN[6?4/LXF6[F_<6ZS*X$T,#02 ML"23^]7CYVKT7Q=X%\%?M0_#KP9J/A@ZAI6HZ_J5YI!2&SDU.*UO8[<1M-(Z MR1KS!&BQ\,%WG'3C]2KUE%^TG=0F^6^]DOQ7-K\O,_.J-!M>RBTY0]Y+S?X/ MET^9-^R'I.D6G@'Q?=^%FO$\2:ED=]@=ODA(R5#[+A=Y)KP[X8>,]2 M^ GQ+TS4(M,GT_4]+BCL3H^H3[)KNUDQ%%#+:P*/+,C22W#(YP>,$C)KZ'\, M3>"_VA;^:7P;JATVZA=S<:+, +V/-PT7F0%&(V9C;E&W#>]SL_B!^S'X5_:^T"761U;4H()9 MK;9J/ER-;\PN6@G4 *=Y7'(YX]O=?'?[2T_[(_AZP\/>&=2TF^\3^+IX]%U- M7E\TZ#;NEPUJYC5.9F\S+;MV-HSGK7A]M??%C4-0T#Q):0ZK<>(?$Q2YM[K[ M28IF\RU9;N98\DN'BM0ZDJN#*XP2HKGRR6/I0ERSC[)Z)35_SLTOF;YG_9]2 M<6X2]JM9.#M_FKV'? S_ ()<_%K4O' U7Q!XYT?PNFEZF(9Y[>X?5;B"Z5UX M,2CRPV77DMW^M?1UW\$?!W[*GPVOO!'A6SU&PM/*62_U&=UBN[J3;L'VB1MJ MCARR NBJS1G:>A^=/AW\0/'_ ,#[G3/&MM!?Z/9W$MO]LE:9KRU"QO=7-Q!) M]Y@TDJ\?)D)''\WS U[CI_BV/]LCPC;>-7OK*U\5WEK%/KFBVDS/)8NZ1Q1, MBJ!)Y+0JTI ;L.O%3FLL;5J*>(J)TMO=5E?S2_5V*RSZG3@XT(-5O[SN[>6W MSLKG->#8WTB>*STPSVFJ2L_DF*5XC-Y@/RQ,@5AN+2!,E&RG7Q7\0+:TN)!;P(#:Z<\:K(X M\\2>,[*>\LH=2:31S:6UM=K/)%(K.Q(,J3>7\_RAA[M7*^.]4B^+_P 'O#_B M&:XTB+Q-HTMW9QW5U<>=:+YRQ2)2]=U^31Z!_P4,T6;4_VN?V?6>W9[5/"OAXW= MW!'_ FXD7!<'RP"3QQWZXZ?MG!]Q?H*_%+_ (*&>)+_ $C]J?\ 9\T^#7-1 M::]\)^'TF02&**5?M#Y*_:^+_5)]*_/N*VW@L%?^67_I1] MGPY_O>*_Q1_(DHHHKXL^K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N? M^*^AWWB?X8>(M-TNZ%AJ5_IMQ;VMRTAC%O*\;*KEARN"0'XO M%GPD\3Z7/?PZ7!J.E7-M)>S']W:*\3*9&R1PH.3R.G6NC".U>#O;5=+]>W7T M./,5S82K&U_=EI>U]'I?IZ]#6\+64^F^&-.M[F7S[FWM8HY9 Q;S'" ,V3R< MD'FK]9WA"P72O">EVJ3IQQG\:T:SJ_&_4VP^E**\EY_ MB>/?M_W;6/[&'Q,E2-)F3P]=G8_W6_=G.>1Q7XX_#OQ9_P )'^PIT5-,864<2-8QJ[RB K]V)&Y(ZG)R1FOV-_X* 7*6W[%_Q++M(BGP]> M*3&N7YB(X&1SS7XU?#VSTF^_8@NQH'A;Q// /&S3007#),XVZ9^]8#[.XPY1 ME"[1@R8+''/Z+P+A>W=[XATR70 MXIO$?DZAXA'V1X?,\BP1(4.9(,L#A?E;>.P%/T6?7/ SPVFI6>MW4P'G06>MU#QQ87UI>>&]:\.W&J:;!;PZ/_:;0I'J M&GQK+<8\JX8 _P"MMH3L*JW&0.>/KJ]2T_A4H/=7_%7_ "/F^FR@=25AD"LV( M5#':K!P.,;6AWWC7X=>.]T1K 324'CR#0O%SRV37.F6GA>98XM VH;B1!MQ(C^6)) I! M#.KDMEALRA4G0C[.<[QZ6^)>6MUION;3A&M-3A"TNM_A]=+/7;8P_#O[0.B? M"SPJ?#?A'X616$MAJ-[H>HSW%YYM,6\@W9.?-'/S CTZ7Q M5+HMI=0^'M'L]&>T9+34;K3[*0/=B!2BAI/FD<_=VDELB\1L%DW5SFBZ]X)\ M?VLL^!_B%J5K?ZA?RP7DVFWLMS=ZC:1V;8FM3 MN\V,1;3$#Y4?+%M U+PMK-WKLUA=7>I:);2.ES DSNOVRZA ,9!V@ MG&#SN8$9-;P5JEGX*^'>F7%]X1N=7UF/1[VUL[?4Y%O[-8%EN9S<)"P#.6E# M!, $C!SCYCK)RJ5/;59*:7PQ7YN[_0RBH0I^RI)P;^*6_P E9?J+XD^&+_#W MX3W>KZ_<:O>:YK%XVG6%OKNH6]PKZ5&5N(;MT9P6;YOE!/3''%,_9TU34-;_ M &D_ \4DPG^W:K:6\307;LL;(D$B*RQ.489ANHCG/4^E:/Q/^(E]XCUZ[U,6 MFKC=,UND[6[E%E229MB;2BXS#""!(W!Q@9YJ?L]:#JR?M%>#I+O0O$3O>:Q9 M-87SVLT4<4?G*(Y2TUN[$';"QVRX^=^>:OG?U:HZUKM/Y:;?(SY8_6(1I7LF MOGKN?M'=*/[$MP.1Y]P/_([5S_B+P;I?BF,)?V-M,;D/\ LGJ#[CFM M^02/HL&\9;[1<_=4@8\]\?I55HSOZ'\J_&(RY7H^Y^MJ-XJZ.-'POO-'N4DT M?Q%JEE&F?]%N"+R"3Z^9F0?\!=:E@O?&6G;O-M=$U-5/R^5+);/CZ$."?Q K MKMA]#^5,VL.Q_*MO;-_%9D*BH_#68;C=[_ ".? MUIMW\8M)LAMNK'7D;IL&BW,N/Q2-A^M=> P_AS^%(T&X?=_2EST^L?N8^2?1 M_@<1)X^\'7"L\XB@R?F^U63PG\G4']*ISZ_\-Y@_F)H)+C#[K5/F^IVUZ#]E M_P!@?]\TAM?^F?\ X[6BK0\_O,_93\ON/.6O_AWI\($&BV4@/SC[+HCS9^@2 M,YJYIWC/PS.N+'P_J,K#C;_84L'_ *'&HKO([; ^YC\*7[-MZ#]*3KPVU^\% M1GOI]QQTGC6XBA_T'PCJ\W^R1#;_ /H;BIDUGQ3J$?\ H^AZ98HPR&N[XLZG MW1%P?^^ZZORFQT-!B)[-FH]K'M^9?LGW_(Y4:/XMU2WVW.L:;IY88+65D6=? M=3(S+^:FF1?".*[M]NJZQKNKN?O/+>-!N_X!#L3_ ,=KKE1MW1J=L/H?RI^V MDOAT]!^QB]]3#T/X%(KQ6:(B254 M)(5@>A]:_/+_ (B!/BMC_D6?!/\ WXN/_CM?97_!;*VDG_8%\0*D?\^MS_ M -^F_P *-0_XAMPG_P! D/Q_S/N?_B($^*W_ $+/@G_OQ?\ /K<_]^F_PHU#_B&W"?\ MT"0_'_,^Y_\ B($^*W_0L^"?^_%Q_P#':/\ B($^*W_0L^"?^_%Q_P#':^&/ M[&O/^?6Y_P"_3?X4?V->?\^MS_WZ;_"C4/\ B&W"?_0)#\?\S[G_ .(@3XK? M]"SX)_[\7'_QVC_B($^*W_0L^"?^_%Q_\=KX8_L:\_Y];G_OTW^%']C7G_/K M<_\ ?IO\*-0_XAMPG_T"0_'_ #/N?_B($^*W_0L^"?\ OQ"?^_%Q_\ ':Z#X=?\%L_CK\6=7GL?#_@CP9?S MVD#75PVR6**WB7 +R2/.$1BA9K@"9AZ1[C7S] M?_MG>&Y= \:Z7IW@G4="A\61Z/YEQ8Z;:?OI[(77FS-;LIB0R_:%X7[NP\\U MPW_"W/"GBSX:>$/#7B#1?&4=OX$O[N6RDT\QH^I6D\YF\J3H(I0Q_P!8N[C^ M&J7F?*4N#<#.[GEM..L>DGIR7;MSZ^_[MKW2U>Q]3?\ #Y#]H5;_ $6U?X=> M&8KGQ'=RV&FPR6LZ275Q$ZI)&%,P(9690!/V\1X?\,Z/I]YX+E-YIVG MZO FKV\"?VAI]S>W[*/W]SZ6$?\%-OVI/'EF)]*^%OA:YB-G'J&2&C/V=UW++AK@':1SFL76?^ M"O7[1>@6]U-=_#OPE#!9::NKS3&.4Q):M(8EEWB?:07!4 '.1C%?,UQ^UX)K MZ67_ (1W6?WOPY_X0CD\F7R]OV@\?=]NMZ3OS._/K:RZ=3[,^& MW_!7+]H_XP1V!\-?#;POJ_\ :;W$=KY$$W[]H%1Y@,S#[JR(3_O#%1:!_P % M??VB_$]UIL5E\./"TK:NUVMKNAF0/]E+"X+%IP$$>UMQ; S-\ /VPKGX% M?"[3]&M]$U@ZEIRZUY5W"=@1[ZWMXD8#&.?$7@?5(/#W MB?PGJ6A6E]_:MWH[Q?Z7>78S-,L;H5,;ON9XVZ[R,T:]3FQ?!>"AB)4Z&64G M#WK2N^G-:Z4KV?N[>?R^B/#O_!4+]IWQ;XLN=#TSX;>#+[4[:U2]:."0NK0- MNQ(CBYV.OR-RI.-IS3X_^"G/[4=QIANX?A;X6N(M\T:"%7DDF,+%9?+1;@L^ MTJ0=H/2OE.\_:OTBS^.6@>+;#P;/%+IN@7NEZE<6UE'8RZS.!/[1L9[J9I([BUD M93M*!BI4\'/:EK=U'I>TNY] 6?_!9']H3 M4-52/>OF3PO\ M6:7H]QX4\0W M.A^)9O%'@_PG=^&+>)53[)>-*MRD=P[?>7:MQ\R ')7[PK%\=?&WPS\6)]$U MO7?#_B^/7=$\-0Z!]CL9U@L[F2&-HXK@2 ;XUPMS=<%Y=*2C_9 ML(KJ[-ZW>B7.M&DM;Z7^[[(N/^"E_P"U-::=I5V_PN$?9]==8]/=2S_ &MC MGA0+C)Z'/ICFJ/A[_@JC^TYXL\)#7-.^%WAJYTV2.2:%A#*);E(R0[11&<22 M*"IY12.#SQ7R'\*OVG?^%?W_ ,'YY_#^JW'_ K1]0:Y"]FD^CE96]IUM%\W2^Q]#M_P5C_:72R\.W)^%_AS MR/%MI-?:/)]FFVWT,,9DD93YW\*#<0<'':HM3_X*Z_M%Z+X%3Q)=?#WP?!I+ MVJWRLV_SC;L<+-Y/VCS?+/9MN/>O'_!/_!2=M+M(K/7/!^IZI867AA=.L(HV M$?\ 9VI&">WDN8LCB-XYR&3K\B\\5P__ T_IMY\$;CPSJ^D:]XHQH?]EZ?; MZO96\W]E7.,+<0W:JLRQI_#%MXSC=BJ2,:/!V']HTK7 MOH?1OPN_X+(_M!_&GT MK4]16P\'ZE_9%[)I-B]G:;W2K2VGMY8+AL#=)*LY.0, @>E+7J=68\$X" MG6G'"9;3G%/2]U=7CK?FW:LQ?\%H/C]+\2++P>/ /A,>)M2, M; MP3^9+YR"2/'[['S*RGKWKHI/^"H_[3\?B33M*_X5?X6>[U;SOL?EJ[Q3&%#) M*/,%QL!1%+$$@@"ODK7OVH+&Y_;JTGXKZ;X5U:UT71;BQ>#2IF#S&.VMXX0I M?&TD[/3O78>%OV][32-6\(W?_"$W>CC08M6CO[/2+>&*SOYKVVEMUNQ&R_ZY M5D4,&)4A,<5*N3B>"L%&G3G1RNFVX7DKO2=I>[\7=)?/<]O\2?\ !8/]H;PK M97]Q=^ /!ODZ6UNMV\.^<0&X9EA!,<[#YV1@/<>XK8N_^"HW[3FG6%S0Q$2PA3*@#7()*AESC/45\F_ O\ :8T?X1_%_6M4U'PUK_B7 MPSXAM(/M]C)##9R275O/'/;R*(U\L*CQKQ@9RWK3/%G[4B_$[X.KX>U_3==C MOY-8U75KFXMK*"9;AKUHGVAI07C"F/JAYR/0505."L"JT8PRZGR>[>5I;-:V M7->\6G?R:\SZLUG_ (*M?M+Z#X._M^X^&7A?^ROL,.IF:**25DM9E5HIF19R MZHRNI#%%X+1[_X<^#H&O;B"U2'+-/')/@0K)$+@O&7R M,;U'6OG'Q)^W!'XC^&^KZ"G@^[TB\OO">D^&X=9L(D2_86EM!#+',^W+P2F' M. 0RC;UQBI]3_;,TK4-*L#J6@>(/%>IZ=J&F7NGWFK65LM]I*VL\[Z;7/=/BC_P62^/WP7EB MC\2^!_ ^F2S2/$L>]I7#IC<&"7#$$9[XKD?^(@3XK?\ 0L^"?^_%Q_\ ':^8 M_P!I_P"(UM\"YL+>%85DD+JH,(&\C<1N89/'->:? MV->?\^MS_P!^F_PH=[GUN4^'G#E7"0J8O!PC4:U6JL^VY]S_ /$0)\5O^A9\ M$_\ ?BX_^.T?\1 GQ6_Z%GP3_P!^+C_X[7PQ_8UY_P ^MS_WZ;_"C^QKS_GU MN?\ OTW^%3J>C_Q#;A/_ *!(?C_F?<__ !$"?%;_ *%GP3_WXN/_ ([1_P 1 M GQ6_P"A9\$_]^+C_P".U\,?V->?\^MS_P!^F_PH_L:\_P"?6Y_[]-_A1J'_ M !#;A/\ Z!(?C_F?<_\ Q$"?%;_H6?!/_?BX_P#CM'_$0)\5O^A9\$_]^+C_ M ..U\,?V->?\^MS_ -^F_P */[&O/^?6Y_[]-_A1J'_$-N$_^@2'X_YGW/\ M\1 GQ6_Z%GP3_P!^+C_X[1_Q$"?%;_H6?!/_ 'XN/_CM?#']C7G_ #ZW/_?I MO\*/[&O/^?6Y_P"_3?X4:A_Q#;A/_H$A^/\ F?<__$0)\5O^A9\$_P#?BX_^ M.T?\1 GQ6_Z%GP3_ -^+C_X[7PQ_8UY_SZW/_?IO\*/[&O/^?6Y_[]-_A1J' M_$-N$_\ H$A^/^9]S_\ $0)\5O\ H6?!/_?BX_\ CM'_ !$"?%;_ *%GP3_W MXN/_ ([7PQ_8UY_SZW/_ 'Z;_"C^QKS_ )];G_OTW^%&H?\ $-N$_P#H$A^/ M^9]S_P#$0)\5O^A9\$_]^+C_ ..T?\1 GQ6_Z%GP3_WXN/\ X[7PQ_8UY_SZ MW/\ WZ;_ H_L:\_Y];G_OTW^%&H?\0VX3_Z!(?C_F?<_P#Q$"?%;_H6?!/_ M 'XN/_CM'_$0)\5O^A9\$_\ ?BX_^.U\,?V->?\ /K<_]^F_PH_L:\_Y];G_ M +]-_A1J'_$-N$_^@2'X_P"9]SC_ (. OBK(P!\->"N3CB"X_P#CM?K?X3U- M]<\+Z=>R!5EO+6.=PO0%E!./SK^:I-(NUE3_ $6Y^\/^63?X5_2;\.5/_"O] M#X/_ "#X.W_3-:J+?4_!_&WAK*,JAA'E=*,')SO;K;EMU]39'2BEV'T/Y4;# MZ'\JL_!!*1EW4[8?0_E1L/H?RH"PS90%XI^P^A_*C8?0_E1H%F5[K3X;V(I+ M#%*IZJZ @USUW\'M FG,L%B-/E9M[/8R/:EV]6\LKD_6NIV'T/Y4;#Z'\JN- M24=F0Z:>Z./'P^U;3+GS-/\ %6K)$O2UNDCN83]69?-/_?RE"^,K.;F3P_?Q M8Z-'+;N_X[G _(UU^T^A_*F%&/\ "?RJ_;-[I/Y$>Q2^%M''W7C'7]/D5;CP MC+=$GYFLKZ&1%'_;38Q_ 4V7Q793$FZ\,ZJN!EBUDLH'_?).?RKLO+(_A/Y4 MN"?X?TI^UBNGXB]E)[O\#SFX\6^"+NX"S:'=[LD$R^&KG:I]V,./QS48O_AM M#<"=[#1+>9N0TNG"*0_@4!KTDV_/W?TIIM<_P?\ CM4JT?/[R?92\ON.#M/% M7P^LV_$:4UV^XY6W^)]O>*#9:3KEP!W&GO%^D@4_I2) MXR\0ZA(ZP>%980.5DO;Z.-''_ -[?FM=9Y./X/TI?+_V6_*HYX=B^2?2&Z"66G6]R5@=D,^R]B81Y4JP#8VG!Z.:]S93MZ'\ MJ\)_X*7Z>]U^Q]XN5M/O;]7BTY(8[91O,QU*#8U]; MI-_S+\T\B+AMEJI=))) M!(K;X9@#V)]\5T7C_P $ZU\*-:@TW0]=\6P>%-;FMH-*OI/$$-M;W%EM6[O' M4@\2J>"%&X!2.Y%8&C+K7@F%+E['7]-$BR7%C#/:3K&R@C'7[/&=I^R?=4@_ M/ZUZ+:_%^X\-V%MIMSX0?6+2"22233]2M0_V.-XKEU,,D@4Q-Y;*H;:1@XSW MK]AQ,Y*:=))KJK[^?JC\MPT8N'[QM/2SM^'H;WA7P=>_MN?#SP]XFF\)W7]M M3QZGJL^L:/&JZ?=2VD>VU%^K S3."FU2IPV[H3NKQ.W^$M]X&D@?Q%JH\-Q: M/+*\-M)U/P!9:\L6B M6ME'_P S!\)?%OP/\$O[87P)X"_MF_MK>P\06>M:Y?RR M:A.IC6.1XE7!4YD=\;<[%E;(PM26O[1>M^"I]3NM2\*ZMX2T#5 MQ<:II8FM M+UK=F62'[/=7!D=FD:X;?&3PO0+@UZ7X=UO2O!^G66G>'_#8TO4X898M,G>U M>?484DWRS(TK?,0L<-U&=FWYXH\#:Q0XT6LZ/X[OM6T;QA8W&M)=F*:*=$42 MVUS%N#&%I5PRD!QY84A(2K,S$JHP52A-MSIMKJW*\OEK9=SI5.K!1Y:J3Z65 MDO+N[G+C]I+QGH6HWOBBZ^'L=T+3=8'4X[>YB%S*ZBW01S1$+<-(D+,7='&\ MC&-P%97B;Q-\+_B#XDO]0F\/I\/-;T466B6>I:/=2OI4/R MJL=#Q+(/!2W6F64\UU+]DB-G)<2-$T[R3J@"LWE1^9C;D/<1C*@ M'<>VITY)^S:_PO\ !INS$J%-7\6S:AHZ0$L 8>&D.TA00J]#7%_VGE6^XR$)&N- MN4MFC&Z1/]:#@]*XK4O#NM75T+JZT;Q'KEIMDCDFCM)]CE!+YB!I(;A Q\JX M VMR;A??/3AZC=Y5++LNR[&&(I1]V-&[[Z;^9[K_ ,%%?$5WX/\ VMO@982Z M3H-W/)X7T*W=IE!NU?[4Y)7YM\8!7@\ Y.2<3^MXO\ Q1_(DHHHKXT^J"BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "N9^,^G:=J_PA\46NL7C:=I-SI5S%>W2KN:VA,3!W PUN66^VSWMK;OY&IX/M[>T\):7%:2FXM([.)()2,&5 @"M M^(P:TJS?!QM6\(Z4;$.++['#]G#_ 'A'L&W/OC%:595OXDO5F^&_@QMV6VVW M0KZC:Q7D!CF1'C<8*N,J?J*\N^.7PCU3QB=&LO#]VVAP1//)6 M2L;+OYYVME>.0:]890XYII@5CTK--K8ZJ53V81:LZ4/\ P$^9]-U[XD>$ MO$R:9%M/U2RO=5N);9[^XOECL8K9U"K); ,YBD0$D$1#D'. MU+]G3/W:.=A',(QDIQI1NO+<^3[_ .%?Q,?PO'+IUE/;^(;R>WN+X2ZP_P!A M00(&>.$'=A99508\M"_'&IZ[' M?V>G:W;&X2X'D/+''%;HTTQ0-ME*F388AC8PP!AQ@BN3T;X8?$^TM=$TW7K/ M7+ZTM+>U,L]I<*)97*R;UEVW$1+(3M+;B""IPQSC[*$"@=*#;H?X13]I((9H MXQY%3C]Q\K+\.O&ME:7GV6T\0JW]HK)'^_$;3\/PQ%Q\L0.W[OR\\PG'.UJ_ MP:\4W/B[Q=J]TNHS6$E_;0V5E:7+)-)9_9K82F ^:L:'S1,.55^&PP!%?1YM MT8]!0(%':CVDKF,LZ3VFO6:>W MM##P[_O6B+A^"=I<]2YYSK^$?"GQ-F\7:3J>LPZFDLU\L[V%K60_8D_NI_WS1]B3^ZG_?-2[!1L%*P7(OL2?W4_P"^ M:/L2?W4_[YJ78*-@HL%R+[$G]U/^^:/L2?W4_P"^:EV"C8*+!!M$8X72M-P/^G9/ M\*V]@]*3RQ3+C5G'2+:,?_A ]&_Z!6F_^ R?X4?\('HW_0*TW_P&3_"MC91L MI:E>WJ?S,Q_^$#T;_H%:;_X#)_A1_P ('HW_ $"M-_\ 9/\*V-E&RC4/;U/ MYF8__"!Z-_T"M-_\!D_PH_X0/1O^@5IO_@,G^%;&RC91J'MZG\S,?_A ]&_Z M!6F_^ R?X4?\('HW_0*TW_P&3_"MC91LHU#V]3^9F/\ \('HW_0*TW_P&3_" MC_A ]&_Z!6F_^ R?X5L;*-E&H>WJ?S,Q_P#A ]&_Z!6F_P#@,G^%'_"!Z-_T M"M-_\!D_PK8V4;*-0]O4_F9C_P#"!Z-_T"M-_P# 9/\ "C_A ]&_Z!6F_P#@ M,G^%;&RC91J'MZG\S,?_ (0/1O\ H%:;_P" R?X4?\('HW_0*TW_ ,!D_P * MV-E&RC4/;U/YF8__ @>C?\ 0*TW_P !D_PH_P"$#T;_ *!6F_\ @,G^%;&R MC91J'MZG\S,?_A ]&_Z!6F_^ R?X4?\ "!Z-_P! K3?_ &3_"MC91LHU#V] M3^9F/_P@>C?] K3?_ 9/\*/^$#T;_H%:;_X#)_A6QLHV4:A[>I_,S'_X0/1O M^@5IO_@,G^%'_"!Z-_T"M-_\!D_PK8V4;*-0]O4_F9C_ /"!Z-_T"M-_\!D_ MPH_X0/1O^@5IO_@,G^%;&RC91J'MZG\S,?\ X0/1O^@5IO\ X#)_A1_P@>C? M] K3?_ 9/\*V-E&RC4/;U/YF8_\ P@>C?] K3?\ P&3_ H_X0/1O^@5IO\ MX#)_A6QLHV4:A[>I_,S'_P"$#T;_ *!6F_\ @,G^%'_"!Z-_T"M-_P# 9/\ M"MC91LHU#V]3^9F/_P ('HW_ $"M-_\ 9/\*/\ A ]&_P"@5IO_ (#)_A6Q MLHV4:A[>I_,S'_X0/1O^@5IO_@,G^%'_ @>C?\ 0*TW_P !D_PK8V4;*-0] MO4_F9C_\('HW_0*TW_P&3_"C_A ]&_Z!6F_^ R?X5L;*-E&H>WJ?S,Q_^$#T M;_H%:;_X#)_A1_P@>C?] K3?_ 9/\*V-E&RC4/;U/YF8_P#P@>C?] K3?_ 9 M/\*/^$#T;_H%:;_X#)_A6QLHV4:A[>I_,S'_ .$#T;_H%:;_ . R?X4?\('H MW_0*TW_P&3_"MC91LHU#V]3^9F/_ ,('HW_0*TW_ ,!D_P */^$#T;_H%:;_ M . R?X5L;*-E&H>WJ?S,Q_\ A ]&_P"@5IO_ (#)_A1_P@>C?] K3?\ P&3_ M K8V4;*-0]O4_F9C_\ "!Z-_P! K3?_ &3_"C_ (0/1O\ H%:;_P" R?X5 ML;*-E&H>WJ?S,Q_^$#T;_H%:;_X#)_A1_P ('HW_ $"M-_\ 9/\*V-E&RC4 M/;U/YF8__"!Z-_T"M-_\!D_PH_X0/1O^@5IO_@,G^%;&RC91J'MZG\S,?_A M]&_Z!6F_^ R?X4?\('HW_0*TW_P&3_"MC91LHU#V]3^9F/\ \('HW_0*TW_P M&3_"C_A ]&_Z!6F_^ R?X5L;*-E&H>WJ?S,Q_P#A ]&_Z!6F_P#@,G^%'_"! MZ-_T"M-_\!D_PK8V4;*-0]O4_F9C_P#"!Z-_T"M-_P# 9/\ "C_A ]&_Z!6F M_P#@,G^%;&RC91J'MZG\S,9_ 6C$?\@K3>#G_CV3_"M%=/B$8PBX7H O2K&R MEVBF1*I*7Q.Y"+),?=7_ +YI?L2?W4_[YJ78*-@I$D7V)/[J?]\T?8D_NI_W MS4NP4;!18+D7V)/[J?\ ?-'V)/[J?]\U+L%&P46"Y%]B3^ZG_?-'V)/[J?\ M?-2[!1L%%@N1?8D_NI_WS1]B3^ZG_?-2[!1L%%@N1?8D_NI_WS1]B3^ZG_?- M2[!1L%%@N1?8D_NI_P!\T?8D_NI_WS4NP4;!18+D7V)/[J?]\T?8D_NI_P!\ MU+L%&P46"Y%]B3^ZG_?-'V)/[J?]\U+L%&P46"Y%]B3^ZG_?-'V)/[J?]\U+ ML%&P46"Y";*,#[J_]\TR6RCNHMC*K+U*E M800#,DY52=B#NQQ@>Y% $4OAZTGD&ZVMF*\ F('%#^&;&8L7L[5M^,DQ#G]* M_//PK_P45^*/QL_X*T?"CP1>?#_QU\*/ MUH^K7#6>OHD4OB&5(T^=D0LH6( MXVX8G+FOMO\ :O\ C4W[.?[-OC?QTEH]_+X5T6YU&*V4$^?)'&Q1<#G!;&?: MGS2[ARKL=C!X?L[?:([6WC"YP%C Q4?_ AFF>;O^P66\YR1 H)K\NOBNO[3 M7P#_ &%;']J.7X[:[J_B>VLK3Q+JO@VYL;:/09+.9XR]HB",.NV.3AL[CM[' MFOM_]I']I[Q+X2_X)_ZG\3_ OAV\U_Q3=^&X-3T;2H+5[F62XN(T,8,:99@I MDW$#LIHYY=Q.$>Q[4OAZP$Y;[':^:V06$2Y.>O;O3?\ A$M/!_X\;+///D+Q M^E?FQ\<=+_:%_P"">GP\\"?&G5OCAXB\>F]UO2K3QCX5U:SMTL)8[Z6.%UM$ M6,/&\;R+M .< ^XK],H9]\(<$_,NZA2EW&XQ[%.#PM8P,NRQLT*'Y2L*C&3S MCBGCPGIX+8L;4;N#^Y7D=/2OSSUS]N;Q[\7/^"O7PMTCPWJT]G\%IKW6?#J) M$?D\1W]E"C74Q..8HI)4B4Y^]')7TC_P5>^,WBCX#_L0^)-:\$:HVC^+[J^T MO2=)NUB65HIKO4;:VR$8%6.V5N".U'-+N')%=#WNW\*:=:2[X[*TC?\ O+ H M(_'%%SX7TZX7][9VLF#G+0K7S/\ []D+XY>!?B5H^L^)?VE_$/C'1+*;?=Z M-<>'["".]4J?W;21QAUP2#D'M5[_ (*F_M(>+O@#\$?#ND?#N:TM?B!\3O$U MEX.T.ZN4$D>G2W.[==%3PWEHA/((R1D'I1S2WN'+':Q]%+X>L0'Q9VWSC#9B M7YOKQ3X]$M(QM6WA49+<1@OB$6T=QH4HC+PW=L4"':9 $*?-\I/&<$>O_MC? /XK_&R70O^%9_%^[^% M8T\3"^\G2(+_ .WEMNPGS0=NW#=.NZB\A'/"%C_:_CB.;0;.U MALUF#+:6>^- QFEP[D _*J G[PS^C07 HNV@LD+1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 5S/QGU2PT/X0^*+W5;+^TM,M-*N9KNTSC[5$L3%X M\]MP!'XUTU$/A)XGU66RAU*/3=*N;I[28?N[D)$S&-N#\K8P>.AK MIP:;Q%-)7U76W7OT]3BS*2C@ZLF[>[+5JZ6CU:Z^G4T_!]U!>^$=+FM8?L]M M+9Q/#%G/E(4!5?P&!6E6=X0U :MX3TNZ6%+9;FTBE$*?=B#(#M'L,XK1K*MI M4DO-F^'=Z46M=%Y= HHHK,V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X@_:N&/^"UG M[,W_ &+7B+_T&*OM35%MWT^478B-MY9,HEQLV]\YXQBOGWXV?LE^(/B/_P % M"OA#\6+2]TV+0?A_I.JV%];RLWVF9[I4"&, ;<#:?3M/O;EV2*V>5=A9BH+#Y2>0*13/C[XT:_K'_!:+Q'O&8@Z#?-TZ8!QAONK7O$7AGX$^ M;>35]3TOP]X?TV.*S2:]G2W@B& D:;F(&> .]?!_P OV=/VZ?V;O@YX=\$ M>%[[]G*ST/PS8QV-JGD7VYE08W-A!EFZD]R2:^HOVJ_V5-0_;3_8AU#X<>,+ M^ST[Q)KNDP"YU"PB+P6>I1A7\Z)6P2@F4D \[: /D+_@L'\&OB)$/$FD?'[ M6/&?^"L M_P"VP/V7/V+8]8TF[DT_4?B!<6^@Z;J8MY)5TA+I?WEXRH"V88=[J .6517E M/Q#_ &._VKOVS? N@?"KXO:O\+M&^&MC=V)X;65)4C"2*%B M#O&A;!XYQFOT%MM&MDL(K8P1&&W0(B%!A !@8';B@+GXWZU^W[^SOX$_;!_9 M&TWP/XGGE\&_#*TU>SO[AM+NDD6:YAMT1W5HPSM)(K,Q /).<5^C?_!1+]D: M']MWX0:#X-N/&UQX&MH?$ECJTUS;(#I6\JD3W)NHXEC\L!=IQL.*O_ /!1 M[]C?4_VP/@YH]MX7UR/PWXX\%:[:^)_#6H3*7MX[VW)PDRCDQ.K,K8]0<'&* M!W/D7]I?]GVV_P""37[2OP%\:?"S7?%B:3X^\96W@[Q7HNI:O-?VVJPW7RK/ MMD)/FHP9@0>I7T(/7?\ !<_POKWC7XO?LGZ7HNKWWA_^T_B&;!]3M,>;8O-& MD:RIN! D"&4H>QKI-&_8[^/G[6_[1/PW\3_M"S?#_2?"OPEOQK6EZ'X5DN)C MJ^J*NV.YFDE VHA^94&W_\%&?V0-1_:]^!^GV/AK68O#GCCP?K=KXG M\+ZI+'YD5IJ-L6,?F#KY;;BK8!X/0]* OJ?(_P ?_@G)_P $H?VG_@5XJ^'O MB_QQ>:!\1_&$7A+Q7HVM:Q+J,.J"Y1MESB0DK*K+G<*_0[XW_%&R^"?P:\4^ M,=2.+#POI-SJMQSC*0Q-(1^.W%?'GA[]D/X]_M6_M(?#CQ=^T#/X TCPW$+ MQ]6TK1?"S3W!UC4MIC2YG>4#8B@[@@SS7M__ 4\_9Q\8?M.)G4,,C(R!GFBBNS+X1 MGBJ4)*Z=G%6=/ 5ZE-V:A)I^:BS4\':K)KOA'2[V4(LMY9PSN$&%#, M@8X]N:TJ**PKI*K)+NSIPDG*A"4MVE^04445D= 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 F444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D! end XML 15 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1

Document and Entity Information - shares
9 Months Ended

Sep. 30, 2018

Nov. 02, 2018

Document And Entity Information [Abstract]

Document Type 10-Q

Amendment Flag false

Document Period End Date Sep. 30, 2018

Document Fiscal Year Focus 2018

Document Fiscal Period Focus Q3

Trading Symbol RGLS

Entity Registrant Name REGULUS THERAPEUTICS INC.

Entity Central Index Key 0001505512

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 8,750,343

Entity Small Business false

Entity Emerging Growth Company false

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Document And Entity Information [Abstract]
+ References
No definition available.
+ Details

Name: rgls_DocumentAndEntityInformationAbstract

Namespace Prefix: rgls_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 16 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1

Condensed Balance Sheets - USD ($)
$ in Thousands

Sep. 30, 2018

Dec. 31, 2017

Current assets:

Cash and cash equivalents $ 14,084 $ 13,519

Short-term investments 6,433 46,555

Contract and other receivables 13 373

Prepaid materials, net 4,194 4,783

Prepaid expenses and other current assets 717 1,506

Total current assets 25,441 66,736

Property and equipment, net 8,324 9,708

Intangibles, net 676 775

Other assets 327 590

Total assets 34,768 77,809

Current liabilities:

Accounts payable 1,235 5,743

Accrued liabilities 1,856 2,995

Accrued compensation 1,292 1,985

Current portion of term loan, less debt issuance costs 19,069 19,859

Current portion of contract liabilities 72 0

Other current liabilities 2,130 2,018

Total current liabilities 25,654 32,600

Contract liabilities, less current portion 24 1,921

Deferred rent, less current portion 7,139 8,072

Other long-term liabilities 373 0

Total liabilities 33,190 42,593

Commitments and Contingencies

Stockholders’ equity:

Common stock, $0.001 par value; 200,000,000 shares authorized, 8,750,343 and 8,662,435 shares issued and outstanding at September 30, 2018 (unaudited) and December 31, 2017, respectively 9 9

Additional paid-in capital 385,793 381,199

Accumulated other comprehensive loss (63) (134)

Accumulated deficit (384,161) (345,858)

Total stockholders’ equity 1,578 35,216

Total liabilities and stockholders’ equity $ 34,768 $ 77,809

X

- Definition
Rent, Less Current Portion, Liability
+ References
No definition available.
+ Details

Name: rgls_RentLessCurrentPortionLiability

Namespace Prefix: rgls_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsAndOtherReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044
+ Details

Name: us-gaap_ContractWithCustomerLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of noncurrent assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316
+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(4))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1)(g))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 17 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1

Condensed Balance Sheets (Parenthetical) - $ / shares

Sep. 30, 2018

Dec. 31, 2017

Statement of Financial Position [Abstract]

Common stock, par value (in dollars per share) $ 0.001 $ 0.001

Common stock, shares authorized (shares) 200,000,000 200,000,000

Common stock, shares issued (shares) 8,750,343 8,662,435

Common stock, shares outstanding (shares) 8,750,343 8,662,435

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 18 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1

Condensed Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Revenues:

Total revenues $ 18 $ 18 $ 54 $ 54

Operating expenses:

Research and development 6,879 12,697 28,720 42,727

General and administrative 2,993 2,736 10,115 13,752

Total operating expenses 9,872 15,433 38,835 56,479

Loss from operations (9,854) (15,415) (38,781) (56,425)

Other income (expense):

Interest and other income 201 160 483 559

Interest and other expense (620) (580) (1,848) (1,730)

Loss before income taxes (10,273) (15,835) (40,146) (57,596)

Income tax benefit 0 7 0 139

Net loss (10,273) (15,828) (40,146) (57,457)

Other comprehensive loss:

Unrealized gain (loss) on short-term investments, net 16 (16) 70 19

Comprehensive loss $ (10,257) $ (15,844) $ (40,076) $ (57,438)

Net loss per share, basic and diluted (in dollars per share) $ (1.18) $ (2.11) $ (4.62) $ (10.52)

Weighted average shares used to compute basic and diluted net loss per share (in shares) 8,703,626 7,506,529 8,688,831 5,463,096

Revenue under strategic alliances and collaborations

Revenues:

Total revenues $ 18 $ 18 $ 54 $ 54

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).
+ References
No definition available.
+ Details

Name: us-gaap_InterestAndOtherIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=rgls_StrategicAlliancesandCollaborationsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 19 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1

Condensed Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Operating activities

Net loss $ (40,146) $ (57,457)

Adjustments to reconcile net loss to net cash used in operating activities

Depreciation and amortization expense 1,672 1,942

Stock-based compensation 4,374 6,531

Amortization of premium on investments, net 92 271

Other 182 206

Change in operating assets and liabilities:

Contracts and other receivables 360 1,124

Prepaid materials 589 (360)

Prepaid expenses and other assets 1,050 2,405

Accounts payable (4,509) (579)

Accrued liabilities (1,138) (652)

Accrued compensation (693) (631)

Contract liabilities (54) (54)

Deferred rent and other liabilities (1,035) (418)

Net cash used in operating activities (39,256) (47,672)

Investing activities

Purchases of short-term investments 0 (48,539)

Sales and maturities of short-term investments 40,101 58,310

Purchases of property and equipment (22) (217)

Acquisition of intangibles 0 (16)

Net cash provided by investing activities 40,079 9,538

Financing activities

Proceeds from issuance of common stock, net 219 43,411

Proceeds from exercise of common stock options 2 4

Principal payments on other long-term obligations (833) 0

Proceeds from capital lease financing 354 0

Net cash used in financing activities (258) 43,415

Net increase in cash and cash equivalents 565 5,281

Cash and cash equivalents at beginning of period 13,519 14,941

Cash and cash equivalents at end of period 14,084 20,222

Supplemental disclosure of cash flow information

Interest paid (1,573) (1,444)

Income taxes paid (1) (1)

Supplemental disclosure of non-cash investing and financing activities

Non-cash acquisition of property and equipment $ 306 $ 0

X

- Definition
Proceeds From Capital Lease Financing
+ References
No definition available.
+ Details

Name: rgls_ProceedsFromCapitalLeaseFinancing

Namespace Prefix: rgls_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585
+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInDeferredLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in operating assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586
+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).
+ References
No definition available.
+ Details

Name: us-gaap_OtherOperatingActivitiesCashFlowStatement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfOtherLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 20 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1

Basis of Presentation and Summary of Significant Accounting Policies
9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented.
Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2017, from which the balance sheet information herein was derived.

In May 2017, we implemented a corporate restructuring to streamline our operations, reduce our operating expenses, extend our cash runway and focus our resources on our most promising programs. In connection with the restructuring, we reduced our total workforce by approximately 30%, to approximately 65 employees. We completed the workforce reduction in June 2017. In July 2018, we implemented a second corporate restructuring to further reduce operating expenses and focus our resources, which involved an additional reduction in our workforce of approximately 60%. The workforce reduction was substantially completed in July 2018. As of September 30, 2018, we had 25 employees.

On October 2, 2018 we filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation with the Secretary of State of the state of Delaware to effect a 1-for-12 reverse stock split of our issued and outstanding common stock. The reverse stock split became effective at 5:00 p.m. Eastern Time on October 3, 2018 and our common stock began trading on a split-adjusted basis on The Nasdaq Global Market on October 4, 2018. The accompanying condensed financial statements and notes thereto give retrospective effect to the reverse stock split for all periods presented. All issued and outstanding common stock, options exercisable for common stock, restricted stock units, and per share amounts contained in our condensed financial statements have been retrospectively adjusted.
Liquidity

The accompanying financial statements have been prepared on a basis which assumes we are a going concern, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from any uncertainty related to our ability to continue as a going concern. Through the date of the issuance of these financial statements, we have principally been financed through proceeds received from the sale of our common stock and other equity securities, debt financings, up-front payments and milestones received from collaboration agreements. As of September 30, 2018, we had approximately $20.5 million of cash, cash equivalents and short-term investments. Based on our operating plans, we believe our cash, cash equivalents and short-term investments may not be sufficient to fund our operations for the period one year following the issuance of these financial statements. As a result, there is substantial doubt about our ability to continue as a going concern. All amounts due under the Term Loan (see note 5) have been classified as a current liability as of September 30, 2018 and December 31, 2017 due to the considerations discussed above and the assessment that the material adverse change clause under the Term Loan is not within our control. We have not been notified of an event of default by the Lender as of the date of the filing of this Form 10-Q.

We intend to seek additional capital through equity and/or debt financings, collaborative or other funding arrangements with partners or through other sources of financing. Should we seek additional financing from outside sources, we may not be able to raise such financing on terms acceptable to us, or at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to scale back or discontinue the advancement of product candidates, reduce headcount, file for bankruptcy, reorganize, merge with another entity, or cease operations.

If we become unable to continue as a going concern, we may have to liquidate our assets, and might realize significantly less than the values at which they are carried on our financial statements, and stockholders may lose all or part of their investment in our common stock.

Use of Estimates
Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.
Revenue Recognition
Our revenues generally consist of upfront payments for licenses or options to obtain licenses in the future, milestone payments and payments for other research services under strategic alliance and collaboration agreements.
Effective January 1, 2018, we adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606) (“Topic 606”) using the modified retrospective method which consisted of applying and recognizing the cumulative effect of Topic 606 at the date of initial application. Topic 606 supersedes the revenue recognition requirements in Accounting Standards Codification (“ASC”) Topic 605, Revenue Recognition (“Topic 605”). All periods prior to the adoption date of Topic 606 have not been restated to reflect the impact of the adoption of Topic 606, but are accounted for and presented under Topic 605.
The following paragraphs in this section describe our revenue recognition accounting polices under Topic 606 upon adoption on January 1, 2018. Refer to Note 1 to the financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017 for revenue recognition accounting policies under Topic 605.
We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligation(s). At contract inception, we assess the goods or services promised within each contract, assess whether each promised good or service is distinct and identify those that are performance obligations. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.
Collaborative Arrangements
We enter into collaborative arrangements with partners that typically include payment to us of one of more of the following: (i) license fees; (ii) payments related to the achievement of developmental, regulatory, or commercial milestones; and (iii) royalties on net sales of licensed products. Where a portion of non-refundable up-front fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as contract liabilities and recognized as revenue when (or as) the underlying performance obligation is satisfied.
As part of the accounting for these arrangements, we must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation(s). The stand-alone selling price may include items such as forecasted revenues, development timelines, discount rates, and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time, or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.
License Fees
If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other performance obligations, we use judgment to assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.

Milestone Payments
At the inception of each arrangement that includes milestone payments (variable consideration), we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price. If it is probable that a milestone event would occur at the inception of an arrangement, the associated milestone value is included in the transaction price. Milestone payments that are contingent upon the achievement of events that are uncertain or not controllable, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received, and therefore not included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, we evaluate the probability of achievement of such milestones and any related constraint(s), and if necessary, may adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.
Royalties
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of our collaborative arrangements.
Stock-Based Compensation
We account for stock-based compensation expense related to stock options granted to employees and members of our board of directors by estimating the fair value of each stock option on the date of grant using the Black-Scholes option pricing model. We recognize stock-based compensation expense using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award was in substance multiple awards, resulting in accelerated expense recognition over the vesting period. For performance-based awards granted to employees (i) the fair value of the award is determined on the grant date, (ii) we assess the probability of the individual milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.

We account for restricted stock units by determining the fair value of each restricted stock unit based on the closing market price of our common stock on the date of grant. We recognize stock-based compensation expense using the accelerated multiple-option approach over the requisite service periods of the awards.
Clinical Trial and Preclinical Study Accruals
We make estimates of our accrued expenses for clinical trial and preclinical study activities as of each balance sheet date in our financial statements based on the facts and circumstances known to us at that time. These accruals are based upon estimates of costs incurred and fees that may be associated with services provided by clinical trial investigational sites, clinical research organizations (“CROs”) and for other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If possible, we obtain information regarding unbilled services directly from these service providers. However, we may be required to estimate these services based on other information available to us. If we underestimate or overestimate the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, our estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in our accruals.
Prepaid Materials
We capitalize the purchase of certain raw materials and related supplies for use in the manufacturing of drug product in our clinical development programs, as we have determined that these materials have alternative future use. We can use these raw materials and related supplies in multiple clinical drug products, and therefore have future use independent of the development status of any particular drug program until it is utilized in the manufacturing process. We expense the cost of materials when used. We periodically review these capitalized materials for continued alternative future use and write down the asset to its net realizable value in the period in which it is identified.
Recent Accounting Pronouncements
As disclosed above, effective January 1, 2018, we adopted Topic 606. Since ASU 2014-09 was issued, several additional ASUs have been issued and incorporated within Topic 606 to clarify various elements of the guidance. As part of our adoption efforts, we have completed the assessment of our collaboration and license agreements under Topic 606. We adopted Topic 606 in the first quarter of 2018 using the modified retrospective method which consists of applying and recognizing the cumulative effect of Topic 606 at the date of initial application and providing certain additional disclosures as defined per Topic 606. On January 1, 2018, we recorded a cumulative adjustment to decrease deferred revenue and accumulated deficit by approximately $1.8 million to reflect the impact of the adoption of Topic 606. The cumulative adjustment relates primarily to our agreement with Sanofi which is described further in Note 7.
Below is a summary of the affected line items of the condensed balance sheets upon adoption of Topic 606 (in thousands):

Balance at December 31, 2017

Adjustments due to Topic 606

Balance at January 1, 2018
Balance Sheet

Deferred revenue (contract liabilities), non-current

1,921

(1,844
)

77

Accumulated deficit

(345,858
)

1,844

(344,014
)

There is no difference between what our revenue would have been in the three and nine months ended September 30, 2018, reported under Topic 606 or Topic 605.
In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities, which eliminates the requirement for public companies to disclose the method(s) and significant assumptions used to estimate the fair value for financial instruments measured at amortized cost on the balance sheet. Additionally, the standard requires public companies to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes. Furthermore, the standard requires presentation of financial assets and liabilities by measurement category and form of financial asset on the balance sheet or accompanying notes to the financial statements. The standard is effective for annual reporting periods beginning after December 15, 2017, including interim periods within those annual reporting periods. The adoption of this guidance had no impact on our financial statements.
In February 2016, the FASB issued ASU No. 2016-02, Leases, which increases transparency and comparability among organizations by requiring recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements. Since ASU 2016-02 was issued, several additional ASUs have been issued to clarify various elements of the guidance. The standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual reporting periods. Early application is permitted. We are in the process of determining the impact the adoption will have on our financial statements and expect significant changes to the recognition of right-of-use assets and liabilities associated with our operating leases.
In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments, which addresses the presentation and classification of certain cash receipts and cash payments in the statement of cash flows under Accounting Standards Codification 230. The standard is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those annual reporting periods. The adoption of this guidance had no impact on our financial statements.
In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows: Restricted Cash, which requires restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those annual reporting periods. The adoption of this guidance will have no impact on our financial statements.
In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation: Scope of Modification Accounting, which provides clarity and guidance around which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those annual reporting periods. The adoption of this guidance had no impact on our financial statements and will continue to have no impact on our financial statements unless we have modification accounting in accordance with Topic 718.

In December 2017, The Tax Cuts and Jobs Act (the "Act") was signed into law and amended the Internal Revenue Code, or IRC, to reduce tax rates and modify policies, credits, and deductions for individuals and businesses. Due to uncertainties which currently exist in the interpretation of the provisions of the Act regarding IRC Section 162(m), as of September 30, 2018, we have not completed our evaluation of the potential impacts of IRC Section 162(m) as amended by the Act on our financial statements. In March 2018, the FASB issued ASU No. 2018-05, Income taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118, which provides guidance regarding the recording of tax impacts where uncertainty exists, in the period of adoption of the Act. To the extent that a company’s accounting for certain income tax effects of the Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the condensed financial statements. If a company cannot determine a provisional estimate to be included in the condensed financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Act. We have provisionally determined that there is no deferred tax benefit or expense with respect to the re-measurement of certain deferred tax assets and liabilities due to the full valuation allowance against net deferred tax assets. Additional analysis of the law and the impact to the company will be performed and any impact will be recorded in the respective quarter.

In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting, which aligns the measurement and classification guidance for share-based payment to non-employees with the guidance for share-based payments to employees. Under the new guidance, the measurement period for equity-classified non-employee awards will be fixed at the grant date. This update is effective for annual periods beginning after December 15, 2018, and interim periods within those periods and early adoption is permitted. The adoption of this guidance will have no impact on our financial statements.

In August 2018, the FASB issues ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement, which updates and modifies the disclosure requirements on fair value measurements in Topic 820, primarily in relation to Level 3 fair value measurements. This update is effective for annual periods beginning after December 15, 2019, and interim periods within those periods. Early adoption is permitted. The adoption of this guidance will have no impact on our financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 21 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1

Net Loss Per Share
9 Months Ended

Sep. 30, 2018

Earnings Per Share [Abstract]

Net Loss Per Share
Net Loss Per Share
Basic net loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of options outstanding under our stock option plans. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted net loss per share.
Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive consisted of zero and 575,256 shares attributable to common stock options and restricted stock units ("RSUs") for the three and nine months ended September 30, 2018, respectively, compared to 106,597 and 210,816 shares attributable to common stock options for the three and nine months ended September 30, 2017, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI http://asc.fasb.org/topic&trid=2144383
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1

Investments
9 Months Ended

Sep. 30, 2018

Debt Securities, Available-for-sale [Abstract]

Investments
Investments
We invest our excess cash primarily in debt instruments of financial institutions, corporations, U.S. government-sponsored agencies and the U.S. Treasury. We generally hold our investments to maturity and do not sell our investments before we have recovered our amortized cost basis.
The following tables summarize our short-term investments (in thousands):

Maturity
(in years)

Amortized
cost

Unrealized

Estimated
fair value
Gains

Losses

As of September 30, 2018

Certificates of deposit
1 or less

$
2,440

$
—

$
—

$
2,440

U.S. Treasury securities
1 or less

3,999

1

(7
)

3,993

Total

$
6,439

$
1

$
(7
)

$
6,433

Maturity
(in years)

Amortized
cost

Unrealized

Estimated
fair value
Gains

Losses

As of December 31, 2017

Corporate debt securities
1 or less

$
32,922

$
—

$
(55
)

$
32,867

Certificates of deposit
1 or less

8,216

—

—

8,216

U.S. Treasury securities
1 or less

3,996

—

(18
)

3,978

Debt securities of U.S. government-sponsored agencies
1 or less

1,498

—

(4
)

1,494

Total

$
46,632

$
—

$
(77
)

$
46,555

X

- References
No definition available.
+ Details

Name: us-gaap_AvailableForSaleSecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for investments in certain debt and equity securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-URI http://asc.fasb.org/subtopic&trid=2209399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-URI http://asc.fasb.org/subtopic&trid=2324412

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-URI http://asc.fasb.org/topic&trid=2196928

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 320
-URI http://asc.fasb.org/subtopic&trid=2176304
+ Details

Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1

Fair Value Measurements
9 Months Ended

Sep. 30, 2018

Fair Value Disclosures [Abstract]

Fair Value Measurements
Fair Value Measurements
We have certain financial assets recorded at fair value which have been classified as Level 1, 2, or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.
Accounting standards define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The accounting standards provide an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors that market participants would use in valuing the asset or liability. The accounting standards prioritize the inputs used in measuring the fair value into the following hierarchy:

•
Level 1 includes financial instruments for which quoted market prices for identical instruments are available in active markets.
•
Level 2 includes financial instruments for which there are inputs other than quoted prices included within Level 1 that are observable for the instrument such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets with insufficient volume or infrequent transactions (less active markets) or model-driven valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
•
Level 3 includes financial instruments for which fair value is derived from valuation techniques in which one or more significant inputs are unobservable, including management’s own assumptions.

Financial Assets Measured at Fair Value
The following table presents our fair value hierarchy for assets measured at fair value on a recurring basis as of September 30, 2018 and December 31, 2017 (in thousands):

Fair value as of September 30, 2018

Total

Level 1

Level 2

Level 3
Assets:

Cash equivalents
$
13,631

$
13,631

$
—

$
—

Certificates of deposit
2,440

—

2,440

—

U.S. treasury securities
3,993

—

3,993

—

$
20,064

$
13,631

$
6,433

$
—

Fair value as of December 31, 2017

Total

Level 1

Level 2

Level 3
Assets:

Cash equivalents
$
10,847

$
10,847

$
—

$
—

Corporate debt securities
32,867

—

32,867

—

Certificates of deposit
8,216

—

8,216

—

U.S. treasury securities
3,978

—

3,978

—

Debt securities of U.S. government-sponsored agencies
1,494

—

1,494

—

$
57,402

$
10,847

$
46,555

$
—

We obtain pricing information from quoted market prices or quotes from brokers/dealers. We generally determine the fair value of our investment securities using standard observable inputs, including reported trades, broker/dealer quotes, bids and/or offers. Refer to Note 3 for information regarding our investments.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-URI http://asc.fasb.org/topic&trid=2155941
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1

Term Loan
9 Months Ended

Sep. 30, 2018

Debt Disclosure [Abstract]

Term Loan
Term Loan
On June 17, 2016, we entered into a loan and security agreement (“Loan Agreement”) with Oxford Finance, LLC, (“Oxford” or sometimes referred to as the “Lender”), pursuant to which Oxford agreed to lend us up to $30.0 million, issuable in two separate term loans of $20.0 million (the “Term A Loan”) and $10.0 million (the “Term B Loan”). On June 22, 2016, we received $20.0 million in proceeds from the Term A Loan, net of debt issuance costs. The ability to borrow on the Term B Loan expired on March 31, 2017, and no amounts were borrowed under the Term B Loan. We refer to all amounts outstanding under the Loan Agreement as the Term Loan.
The outstanding Term Loan will mature on June 1, 2020 (the “Maturity Date”) and bears interest at a floating per annum rate equal to (i) 8.51% plus (ii) the greater of (a) the 30 day U.S. Dollar LIBOR rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue and (b) 0.44%. Under the original Loan Agreement, we were required to make interest-only payments through June 1, 2018, followed by 24 equal monthly payments of principal and unpaid accrued interest.

In March 2018, we and Oxford entered into an amendment to our Loan Agreement, providing for the modification of the loan amortization period from a 24-month period commencing on July 1, 2018 to a 15-month period commencing on April 1, 2019, subject to our receipt, following the date of the amendment, of unrestricted net cash proceeds of not less than $30.0 million on or prior to June 30, 2018. The ability to modify the loan amortization period under this amendment to the Loan Agreement expired on June 30, 2018, as we did not receive unrestricted net cash proceeds of not less than $30.0 million on or prior to June 30, 2018.

In August 2018, we and Oxford entered into an additional amendment to our Loan Agreement, providing for a modification of the loan amortization period. Under the terms of the amendment, principal amortization and repayment was deferred between August 2018 through October 2018, and during this period, we were required to make payments of interest-only. Amortization payments will recommence in November 2018. In addition, the amendment contained a minimum cash reserve covenant, whereby we will be required to maintain aggregate cash reserves of not less than 110% of the principal balance of the Term Loan that would be outstanding on such date that our then-held cash reserves would first be completely exhausted based on certain assumptions specified in the amendment. There were no changes to the maturity date of the Term Loan, which is June 2020. Pursuant to the amendment, we granted the Lender a security interest in our intellectual property as additional collateral for the repayment of the Term Loan.

We have the option to prepay all, but not less than all, of the borrowed amount, provided that we will be obligated to pay a prepayment fee equal to (i) 2% of the outstanding principal balance of the Term Loan if prepayment is made prior to the second anniversary of the funding date of the Term Loan, or (ii) 1% of the Term Loan prepaid thereafter and prior to the Maturity Date. We will be required to make a final payment of 5.5% of the principal balance outstanding, payable on the earlier of (i) the Maturity Date, (ii) acceleration of the Term Loan, or (iii) the prepayment of the Term Loan.

We may use the proceeds from the Term Loan solely for working capital and to fund our general business requirements. Our obligations under the Loan Agreement are secured by a first priority security interest in substantially all of our current and future assets, other than our intellectual property and certain assets under capital lease obligations. We have also agreed not to encumber our intellectual property assets, except as permitted by the Loan Agreement. The Loan Agreement includes customary events of default, including instances of a material adverse change in our operations, that may require prepayment of the outstanding Term Loan. All amounts due under the Term Loan have been classified as a current liability as of September 30, 2018 due to the considerations discussed in Note 1 and the assessment that the material adverse change clause under the Term Loan is not within our control. We have not been notified of an event of default by the Lender as of the date of the filing of this Form 10-Q.
As of September 30, 2018, we had a net liability of $19.1 million outstanding under the Term Loan. In connection with the Term Loan, the debt issuance costs have been recorded as a debt discount in our consolidated balance sheets, which are being accreted to interest expense over the life of the Term Loan using an effective interest rate of 8.98%. The exit fee is being accrued over the life of the Term Loan through interest expense.
As of September 30, 2018, we were in compliance with all covenants under the Loan Agreement.
As of September 30, 2018, future principal payments for the Term Loan due under the Loan Agreement are as follows (in thousands):
2018
$
1,917

2019
11,500

2020
5,750

$
19,167

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-term debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_LongTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1

Stockholders' Equity
9 Months Ended

Sep. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stockholders' Equity
Stockholders’ Equity
Shares Reserved for Future Issuance
The following shares of common stock were reserved for future issuance as of September 30, 2018 (in thousands):

Common stock options outstanding
1,134

RSUs outstanding
66

Common stock available for future grant under 2012 Equity Incentive Plan
61

Common stock available for future grant under 2015 Inducement Plan
3

Employee Stock Purchase Plan
155

Total common shares reserved for future issuance
1,419

The following table summarizes our stock option and RSU activity (together Stock Awards) under all equity incentive plans for the nine months ended September 30, 2018 (shares in thousands):

Number of
options

Weighted
average
exercise
price

Number of
RSUs

Weighted average grant date fair value
Stock Awards outstanding at December 31, 2017
887

$
53.24

35

$
10.68

Granted
603

$
11.70

102

$
3.88

Exercised (options) or Vested (RSUs)
(1
)

$
4.56

(57
)

$
6.25

Canceled/forfeited/expired
(355
)

$
58.59

(8
)

$
7.57

Stock Awards outstanding at September 30, 2018
1,134

72

Stock-Based Compensation
The following table summarizes the weighted average assumptions used to estimate the fair value of stock options and performance stock awards granted to employees under our 2012 Equity Incentive Plan and 2015 Inducement Plan and the shares purchasable under our Employee Stock Purchase Plan during the periods presented:

Three months ended
September 30,

Nine months ended
September 30,

2018

2017

2018

2017
Stock options

Risk-free interest rate
2.9
%

1.9
%

2.7
%

2.0
%
Volatility
92.0
%

89.5
%

87.8
%

89.4
%
Dividend yield
—

—

—

—

Expected term (years)
6.1

6.1

6.1

6.1

Performance stock options

Risk-free interest rate
—

—

2.7
%

2.1
%
Volatility
—

—

87.4
%

89.9
%
Dividend yield
—

—

—

—

Expected term (years)
0.0

0.0

5.7

5.6

Employee stock purchase plan shares

Risk-free interest rate
2.0
%

1.0
%

1.8
%

0.8
%
Volatility
99.9
%

104.5
%

91.7
%

110.7
%
Dividend yield
—

—

—

—

Expected term (years)
0.5

0.5

0.5

0.5

The following table summarizes the allocation of our stock-based compensation expense for all stock awards during the periods presented (in thousands):

Three months ended
September 30,

Nine months ended
September 30,

2018

2017

2018

2017
Research and development
$
491

$
653

$
1,745

$
2,411

Research and development-restructuring related adjustments
31

—

31

(1,399
)
General and administrative
883

631

2,613

2,840

General and administrative-restructuring related adjustments
(15
)

—

(15
)

2,679

Total
$
1,390

$
1,284

$
4,374

$
6,531

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1

Strategic Alliances and Collaborations
9 Months Ended

Sep. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Strategic Alliances and Collaborations
Strategic Alliances and Collaborations
Revenue recognized from our strategic alliances and collaborations was less than $0.1 million for each of the three and nine months ended September 30, 2018 and 2017.

Sanofi
In July 2012, we amended and restated our collaboration and license agreement with Sanofi to expand the potential therapeutic applications of the microRNA alliance targets to be developed under such agreement. We determined that the elements within the strategic alliance agreement with Sanofi should be treated as a single unit of accounting because the delivered elements did not have stand-alone value to Sanofi. The following elements were delivered as part of the strategic alliance with Sanofi: (1) a license for up to four microRNA targets; and (2) a research license under our technology alliance.
In June 2013, the original research term expired, upon which we and Sanofi entered into an option agreement pursuant to which Sanofi was granted an exclusive right to negotiate the co-development and commercialization of certain of our unencumbered microRNA programs and we were granted the exclusive right to negotiate with Sanofi for co-development and commercialization of certain miR-21 anti-miRs in oncology and Alport syndrome. In July 2013, we received an upfront payment of $2.5 million, of which $1.25 million is creditable against future amounts payable by Sanofi to us under any future co-development and commercialization agreement we enter pursuant to the option agreement. Revenue associated with the creditable portion of this option payment was deferred as of December 31, 2017 and recorded as an adjustment to accumulated deficit upon our adoption of ASC 606 on January 1, 2018. The non-creditable portion of this payment, $1.25 million, was recognized as revenue over the option period from the effective date of the option agreement in June 2013 through the expiration of the option period in January 2014.
In February 2014, we and Sanofi entered into a second amended and restated collaboration and license agreement (the “2014 Sanofi Amendment”) to renew our strategic alliance to discover, develop and commercialize microRNA therapeutics to focus on specific orphan disease and oncology targets. Under the terms of our renewed alliance, Sanofi has opt-in rights to our clinical fibrosis program targeting miR-21 for the treatment of Alport syndrome, our preclinical program targeting miR-21 for oncology indications, and our preclinical program targeting miR-221/222 for hepatocellular carcinoma (“HCC”). We are responsible for developing each of these programs to proof-of-concept, at which time Sanofi has an exclusive option on each program. If Sanofi chooses to exercise its option on any of these programs, Sanofi will reimburse us for a significant portion of our preclinical and clinical development costs and will also pay us an option exercise fee for any such program, provided that $1.25 million of the $2.5 million upfront option fee paid to us by Sanofi in connection with the June 2013 option agreement will be creditable against such option exercise fee. We are eligible to receive royalties on microRNA therapeutic products commercialized by Sanofi and will have the right to co-promote these products.
In connection with the 2014 Sanofi Amendment, we entered into a Common Stock Purchase Agreement (the “Purchase Agreement”), pursuant to which we sold 1,303,780 shares of our common stock to Aventisub LLC (“Aventis”), an entity affiliated with Sanofi, in a private placement at a price per share of $7.67 for an aggregate purchase price of $10.0 million. Under the terms of the Purchase Agreement, Aventis was not permitted to sell, transfer, make any short sale of, or grant any option for the sale of any common stock for the 12-month period following its effective date. The Purchase Agreement and the 2014 Sanofi Amendment were negotiated concurrently and were therefore evaluated as a single agreement. Based upon restricted stock studies of similar duration and a Black-Scholes valuation to measure the discount for lack of marketability, approximately $0.4 million of the proceeds from the Purchase Agreement was attributed to the 2014 Sanofi Amendment, and represents consideration for the value of the program targeting miR-221/222 for HCC. We are recognizing the $0.4 million allocated consideration into revenue ratably over the estimated period of performance of the miR-221/222 program. As of September 30, 2018, contract liabilities associated with the Purchase Agreement and the 2014 Sanofi Amendment was $0.1 million, which we are expecting to recognize over the remaining estimated period of performance of approximately one year.
We are eligible to receive milestone payments of up to $101.8 million for proof-of-concept option exercise fees (net of $1.25 million creditable, as noted above), $15.0 million for clinical milestones and up to $300.0 million for regulatory and commercial milestones. In addition, we are entitled to receive royalties based on a percentage of net sales of any products from the miR-21 and miR-221/222 programs which, in the case of sales in the United States, will be in the middle of the 10 to 20% range, and, in the case of sales outside of the United States, will range from the low end to the middle of the 10 to 20% range, depending upon the volume of sales. If we exercise our option to co-promote a product, we will continue to be eligible to receive royalties on net sales of each product in the United States at the same rate, unless we elect to share a portion of Sanofi’s profits from sales of such product in the United States in lieu of royalties.

X

- Definition
The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-URI http://asc.fasb.org/topic&trid=5833765
+ Details

Name: us-gaap_CollaborativeArrangementDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1

Related Party Transactions
9 Months Ended

Sep. 30, 2018

Related Party Transactions [Abstract]

Related Party Transactions
Related Party Transactions
We have entered into certain agreements with related parties in the ordinary course of business to license intellectual property and to procure research and development support services.
In September 2014, we entered into an agreement with Sanofi-Aventis Deutschland GmbH (“Sanofi Deutschland”), a contract manufacturing subsidiary of Sanofi, for the manufacture of certain drug substance requirements and other services to support our preclinical and clinical activities associated with the RG-012 program. Pursuant to this agreement, we engaged Sanofi Deutschland to manufacture RG-012 drug product and perform stability studies on our behalf. Expenses incurred under the agreement for services performed or out-of-pocket expenses were less than $0.1 million for each of the three and nine months ended September 30, 2018 and 2017.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1

Subsequent Events
9 Months Ended

Sep. 30, 2018

Subsequent Events [Abstract]

Subsequent Events
Subsequent Events

Reverse Stock Split

On October 2, 2018, we filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation with the Secretary of State of the state of Delaware to effect a 1-for-12 reverse stock split of our issued and outstanding common stock. The primary purpose of the reverse stock split was to raise the per share trading price of our common stock to seek to maintain the listing of our common stock on The Nasdaq Global Market. At the effective time of the reverse stock split at 5:00 p.m. on October 3, 2018, each 12 shares of our issued and outstanding common stock were automatically combined and converted into one issued and outstanding share of common stock. All of our stock options and RSUs outstanding immediately prior to the reverse stock split were proportionately adjusted. All issued and outstanding common stock, options exercisable for common stock, restricted stock units, and per share amounts contained in our condensed financial statements have been retrospectively adjusted.

Tender Offer
On October 15, 2018, we filed a tender offer statement on Schedule TO with the Securities and Exchange Commission related to an offer by us to certain eligible optionholders, subject to specified conditions, to exchange some or all of their outstanding options to purchase shares of our common stock for new RSUs (the "Exchange Offer"). The Exchange Offer will expire at 5:00 p.m., U.S. Pacific Time, on November 11, 2018, unless extended.
An option holder will be eligible to exchange their options (an “Eligible Holder”) if:
•
on the date the Exchange Offer commences, either an optionholder is employed by us (each, an “Employee”) or is a non-employee member (each, a “Non-Employee Director”) of our board of directors and has not been notified by us that such optionholder’s employment or service relationship with us is being terminated; and
•
such optionholder continues to be an Employee or serve as a Non-Employee Director and has not submitted a notice of resignation or received a notice of termination, as of the first business day following the Expiration Time (as defined in the Exchange Offer).
An option will be eligible for exchange (an “Eligible Option”) if it:
•
is held by an Eligible Holder;
•
has an exercise price equal to or greater than $4.56 (and an exercise price greater than the closing price of our common stock on the last business day before the Expiration Time); and
•
was granted under our 2009 Equity Incentive Plan, 2012 Equity Incentive Plan or 2015 Inducement Plan.

The exchange ratio for each Eligible Option will be determined using the Black-Scholes option pricing model and will be based on, among other things, the fair market value of a share of our common stock, the volatility of our common stock, U.S. treasury rates, the exercise prices of the Eligible Options, the remaining terms of the Eligible Options and the term of the new RSUs. For purposes of determining the fair value of Eligible Options, the fair market value of a share of our common stock will be determined based on the trailing 20-day volume weighted average price (the “20-Day VWAP”). The 20-Day VWAP represents the simple arithmetic average of the daily VWAPs over the 20 consecutive trading days beginning on October 15, 2018 and ending on the last business day prior to the Expiration Time. For purposes of determining the fair value of the new RSUs, the fair market value of a share of our common stock will be determined based on the closing trading price of a share of our common stock on Nasdaq on the last business day prior to the Expiration Time. In no event will an Eligible Optionholder be eligible to receive more new RSUs than the number of shares underlying the number of Eligible Options.
The foregoing is only a summary of the Exchange Offer, does not purport to be complete and is qualified in its entirety by reference to the full text of the Schedule TO, which was filed with the Securities and Exchange Commission on October 15, 2018.

First Amendment to Second Amended and Restated Collaboration and License Agreement
On November 5, 2018, we entered into an amendment to the 2014 Sanofi Amendment with Sanofi to modify the parties’ rights and obligations with respect to our miR-21 programs, including our RG-012 program (the “2018 Sanofi Amendment”).
Under the terms of the 2018 Sanofi Amendment, we have granted Sanofi a worldwide, royalty-free, fee-bearing, exclusive license, with the right to grant sublicenses, under our know-how and patents to develop and commercialize miR-21 compounds and products for all indications, including Alport Syndrome. Sanofi will control and will assume all responsibilities and obligations for developing and commercializing each of our miR-21 programs, including our obligations regarding the administration and expense of clinical trials and all other costs, including in-license royalties and other in-license payments, related to our miR-21 programs. Under the terms of the 2018 Sanofi Amendment, we have assigned to Sanofi certain agreements and all materials directed to miR-21 or to any miR-21 compound or product and are required to provide reasonable technical assistance to Sanofi for a period of 24 months after the date of the 2018 Sanofi Amendment.
Under the terms of the 2018 Sanofi Amendment, we are eligible to receive approximately $6.8 million in upfront payments and a payment for miR-21 program-related materials (collectively, the “Upfront Amendment Payments”). We are also eligible to receive up to $40.0 million in development milestone payments. In addition, Sanofi has agreed to reimburse us for certain out-of-pocket transition activities and assume our upstream license royalty obligations. We and Sanofi also agreed to a general release of claims against each other for any claims that arose at any time prior to the date of the 2018 Sanofi Amendment, or that thereafter could arise based on anything that occurred prior to the date of the 2018 Sanofi Amendment.

Fourth Amendment to Loan and Security Agreement
On November 5, 2018 and in connection with the 2018 Sanofi Amendment we entered into a fourth amendment to the Term Loan with the Lender (the "Fourth Amendment").
Under the terms of the Fourth Amendment, the Lender has consented to the 2018 Sanofi Amendment and our license, assignment and transfer to Sanofi of certain of our intellectual property, as required to be delivered to Sanofi under the 2018 Sanofi Amendment (the “Assigned Assets”), which previously served as collateral under the loan and security agreement, and has released its liens in the Assigned Assets, provided that the Lender will continue to have liens on all proceeds received by us pursuant to the Sanofi License. Under the terms of the Fourth Amendment, we now have the option to prepay part of the Term Loan at any time and in any amount after 10 days’ prior written notice. We are also required to prepay part of the Term Loan with 25% of certain payments we receive under the 2018 Sanofi Amendment, which payments consist of the Upfront Amendment Payments and the first development milestone payment in the amount of $10.0 million. We will be required to pay the applicable 5.5% final payment fee related to each such 2018 Sanofi Amendment prepayment. Under the Fourth Amendment, we are required to maintain cash in a collateral account controlled by the Lender of (i) $10.0 million, if we have not received net proceeds of at least $15.0 million from (a) the issuance and sale of our unsecured subordinated convertible debt and/or equity securities or (b) upfront or milestone payments in connection with a joint venture, collaboration or other partnering transaction, other than pursuant to the Sanofi License (the receipt of such net proceeds, a “Capital Event”), or (ii) $5.0 million if a Capital Event has occurred.
The maturity date of the Term Loan remains unchanged and the Term Loan is required to be paid in full on June 1, 2020.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1

Basis of Presentation and Summary of Significant Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented.
Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2017, from which the balance sheet information herein was derived.

Use of Estimates
Use of Estimates
Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.

Revenue Recognition
Revenue Recognition
Our revenues generally consist of upfront payments for licenses or options to obtain licenses in the future, milestone payments and payments for other research services under strategic alliance and collaboration agreements.
Effective January 1, 2018, we adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606) (“Topic 606”) using the modified retrospective method which consisted of applying and recognizing the cumulative effect of Topic 606 at the date of initial application. Topic 606 supersedes the revenue recognition requirements in Accounting Standards Codification (“ASC”) Topic 605, Revenue Recognition (“Topic 605”). All periods prior to the adoption date of Topic 606 have not been restated to reflect the impact of the adoption of Topic 606, but are accounted for and presented under Topic 605.
The following paragraphs in this section describe our revenue recognition accounting polices under Topic 606 upon adoption on January 1, 2018. Refer to Note 1 to the financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017 for revenue recognition accounting policies under Topic 605.
We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligation(s). At contract inception, we assess the goods or services promised within each contract, assess whether each promised good or service is distinct and identify those that are performance obligations. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.
Collaborative Arrangements
We enter into collaborative arrangements with partners that typically include payment to us of one of more of the following: (i) license fees; (ii) payments related to the achievement of developmental, regulatory, or commercial milestones; and (iii) royalties on net sales of licensed products. Where a portion of non-refundable up-front fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as contract liabilities and recognized as revenue when (or as) the underlying performance obligation is satisfied.
As part of the accounting for these arrangements, we must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation(s). The stand-alone selling price may include items such as forecasted revenues, development timelines, discount rates, and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time, or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.
License Fees
If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other performance obligations, we use judgment to assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.

Milestone Payments
At the inception of each arrangement that includes milestone payments (variable consideration), we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price. If it is probable that a milestone event would occur at the inception of an arrangement, the associated milestone value is included in the transaction price. Milestone payments that are contingent upon the achievement of events that are uncertain or not controllable, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received, and therefore not included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, we evaluate the probability of achievement of such milestones and any related constraint(s), and if necessary, may adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.
Royalties
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of our collaborative arrangements.

Stock-Based Compensation
Stock-Based Compensation
We account for stock-based compensation expense related to stock options granted to employees and members of our board of directors by estimating the fair value of each stock option on the date of grant using the Black-Scholes option pricing model. We recognize stock-based compensation expense using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award was in substance multiple awards, resulting in accelerated expense recognition over the vesting period. For performance-based awards granted to employees (i) the fair value of the award is determined on the grant date, (ii) we assess the probability of the individual milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.

We account for restricted stock units by determining the fair value of each restricted stock unit based on the closing market price of our common stock on the date of grant. We recognize stock-based compensation expense using the accelerated multiple-option approach over the requisite service periods of the awards.

Clinical Trial and Preclinical Study Accruals
Clinical Trial and Preclinical Study Accruals
We make estimates of our accrued expenses for clinical trial and preclinical study activities as of each balance sheet date in our financial statements based on the facts and circumstances known to us at that time. These accruals are based upon estimates of costs incurred and fees that may be associated with services provided by clinical trial investigational sites, clinical research organizations (“CROs”) and for other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If possible, we obtain information regarding unbilled services directly from these service providers. However, we may be required to estimate these services based on other information available to us. If we underestimate or overestimate the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, our estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in our accruals.

Prepaid Materials
Prepaid Materials
We capitalize the purchase of certain raw materials and related supplies for use in the manufacturing of drug product in our clinical development programs, as we have determined that these materials have alternative future use. We can use these raw materials and related supplies in multiple clinical drug products, and therefore have future use independent of the development status of any particular drug program until it is utilized in the manufacturing process. We expense the cost of materials when used. We periodically review these capitalized materials for continued alternative future use and write down the asset to its net realizable value in the period in which it is identified.

Recent Accounting Pronouncements
Recent Accounting Pronouncements
As disclosed above, effective January 1, 2018, we adopted Topic 606. Since ASU 2014-09 was issued, several additional ASUs have been issued and incorporated within Topic 606 to clarify various elements of the guidance. As part of our adoption efforts, we have completed the assessment of our collaboration and license agreements under Topic 606. We adopted Topic 606 in the first quarter of 2018 using the modified retrospective method which consists of applying and recognizing the cumulative effect of Topic 606 at the date of initial application and providing certain additional disclosures as defined per Topic 606. On January 1, 2018, we recorded a cumulative adjustment to decrease deferred revenue and accumulated deficit by approximately $1.8 million to reflect the impact of the adoption of Topic 606. The cumulative adjustment relates primarily to our agreement with Sanofi which is described further in Note 7.
Below is a summary of the affected line items of the condensed balance sheets upon adoption of Topic 606 (in thousands):

Balance at December 31, 2017

Adjustments due to Topic 606

Balance at January 1, 2018
Balance Sheet

Deferred revenue (contract liabilities), non-current

1,921

(1,844
)

77

Accumulated deficit

(345,858
)

1,844

(344,014
)

There is no difference between what our revenue would have been in the three and nine months ended September 30, 2018, reported under Topic 606 or Topic 605.
In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities, which eliminates the requirement for public companies to disclose the method(s) and significant assumptions used to estimate the fair value for financial instruments measured at amortized cost on the balance sheet. Additionally, the standard requires public companies to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes. Furthermore, the standard requires presentation of financial assets and liabilities by measurement category and form of financial asset on the balance sheet or accompanying notes to the financial statements. The standard is effective for annual reporting periods beginning after December 15, 2017, including interim periods within those annual reporting periods. The adoption of this guidance had no impact on our financial statements.
In February 2016, the FASB issued ASU No. 2016-02, Leases, which increases transparency and comparability among organizations by requiring recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements. Since ASU 2016-02 was issued, several additional ASUs have been issued to clarify various elements of the guidance. The standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual reporting periods. Early application is permitted. We are in the process of determining the impact the adoption will have on our financial statements and expect significant changes to the recognition of right-of-use assets and liabilities associated with our operating leases.
In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments, which addresses the presentation and classification of certain cash receipts and cash payments in the statement of cash flows under Accounting Standards Codification 230. The standard is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those annual reporting periods. The adoption of this guidance had no impact on our financial statements.
In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows: Restricted Cash, which requires restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those annual reporting periods. The adoption of this guidance will have no impact on our financial statements.
In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation: Scope of Modification Accounting, which provides clarity and guidance around which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those annual reporting periods. The adoption of this guidance had no impact on our financial statements and will continue to have no impact on our financial statements unless we have modification accounting in accordance with Topic 718.

In December 2017, The Tax Cuts and Jobs Act (the "Act") was signed into law and amended the Internal Revenue Code, or IRC, to reduce tax rates and modify policies, credits, and deductions for individuals and businesses. Due to uncertainties which currently exist in the interpretation of the provisions of the Act regarding IRC Section 162(m), as of September 30, 2018, we have not completed our evaluation of the potential impacts of IRC Section 162(m) as amended by the Act on our financial statements. In March 2018, the FASB issued ASU No. 2018-05, Income taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118, which provides guidance regarding the recording of tax impacts where uncertainty exists, in the period of adoption of the Act. To the extent that a company’s accounting for certain income tax effects of the Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the condensed financial statements. If a company cannot determine a provisional estimate to be included in the condensed financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Act. We have provisionally determined that there is no deferred tax benefit or expense with respect to the re-measurement of certain deferred tax assets and liabilities due to the full valuation allowance against net deferred tax assets. Additional analysis of the law and the impact to the company will be performed and any impact will be recorded in the respective quarter.

In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting, which aligns the measurement and classification guidance for share-based payment to non-employees with the guidance for share-based payments to employees. Under the new guidance, the measurement period for equity-classified non-employee awards will be fixed at the grant date. This update is effective for annual periods beginning after December 15, 2018, and interim periods within those periods and early adoption is permitted. The adoption of this guidance will have no impact on our financial statements.

In August 2018, the FASB issues ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement, which updates and modifies the disclosure requirements on fair value measurements in Topic 820, primarily in relation to Level 3 fair value measurements. This update is effective for annual periods beginning after December 15, 2019, and interim periods within those periods. Early adoption is permitted. The adoption of this guidance will have no impact on our financial statements.

Fair Value Measurement
Fair Value Measurements
We have certain financial assets recorded at fair value which have been classified as Level 1, 2, or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.
Accounting standards define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The accounting standards provide an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors that market participants would use in valuing the asset or liability. The accounting standards prioritize the inputs used in measuring the fair value into the following hierarchy:

•
Level 1 includes financial instruments for which quoted market prices for identical instruments are available in active markets.
•
Level 2 includes financial instruments for which there are inputs other than quoted prices included within Level 1 that are observable for the instrument such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets with insufficient volume or infrequent transactions (less active markets) or model-driven valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
•
Level 3 includes financial instruments for which fair value is derived from valuation techniques in which one or more significant inputs are unobservable, including management’s own assumptions.

X

- Definition
Accrued Expense [Policy Text Block]
+ References
No definition available.
+ Details

Name: rgls_AccruedExpensePolicyTextBlock

Namespace Prefix: rgls_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Prepaid Expenses [Policy Text Block]
+ References
No definition available.
+ Details

Name: rgls_PrepaidExpensesPolicyTextBlock

Namespace Prefix: rgls_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue from contract with customer.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388
+ Details

Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(f)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901
+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1

Basis of Presentation and Summary of Significant Accounting Policies (Tables)
9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Schedule of New Accounting Pronouncements and Changes in Accounting Principles
Below is a summary of the affected line items of the condensed balance sheets upon adoption of Topic 606 (in thousands):

Balance at December 31, 2017

Adjustments due to Topic 606

Balance at January 1, 2018
Balance Sheet

Deferred revenue (contract liabilities), non-current

1,921

(1,844
)

77

Accumulated deficit

(345,858
)

1,844

(344,014
)

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109236672&loc=d3e765-108305

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=109236672&loc=d3e725-108305

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794
+ Details

Name: us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1

Investments (Tables)
9 Months Ended

Sep. 30, 2018

Debt Securities, Available-for-sale [Abstract]

Summary of Short-Term Investments
The following tables summarize our short-term investments (in thousands):

Maturity
(in years)

Amortized
cost

Unrealized

Estimated
fair value
Gains

Losses

As of September 30, 2018

Certificates of deposit
1 or less

$
2,440

$
—

$
—

$
2,440

U.S. Treasury securities
1 or less

3,999

1

(7
)

3,993

Total

$
6,439

$
1

$
(7
)

$
6,433

Maturity
(in years)

Amortized
cost

Unrealized

Estimated
fair value
Gains

Losses

As of December 31, 2017

Corporate debt securities
1 or less

$
32,922

$
—

$
(55
)

$
32,867

Certificates of deposit
1 or less

8,216

—

—

8,216

U.S. Treasury securities
1 or less

3,996

—

(18
)

3,978

Debt securities of U.S. government-sponsored agencies
1 or less

1,498

—

(4
)

1,494

Total

$
46,632

$
—

$
(77
)

$
46,555

X

- References
No definition available.
+ Details

Name: us-gaap_AvailableForSaleSecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1

Fair Value Measurements (Tables)
9 Months Ended

Sep. 30, 2018

Fair Value Disclosures [Abstract]

Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis
The following table presents our fair value hierarchy for assets measured at fair value on a recurring basis as of September 30, 2018 and December 31, 2017 (in thousands):

Fair value as of September 30, 2018

Total

Level 1

Level 2

Level 3
Assets:

Cash equivalents
$
13,631

$
13,631

$
—

$
—

Certificates of deposit
2,440

—

2,440

—

U.S. treasury securities
3,993

—

3,993

—

$
20,064

$
13,631

$
6,433

$
—

Fair value as of December 31, 2017

Total

Level 1

Level 2

Level 3
Assets:

Cash equivalents
$
10,847

$
10,847

$
—

$
—

Corporate debt securities
32,867

—

32,867

—

Certificates of deposit
8,216

—

8,216

—

U.S. treasury securities
3,978

—

3,978

—

Debt securities of U.S. government-sponsored agencies
1,494

—

1,494

—

$
57,402

$
10,847

$
46,555

$
—

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258
+ Details

Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1

Term Loan (Tables)
9 Months Ended

Sep. 30, 2018

Debt Disclosure [Abstract]

Term Loan
As of September 30, 2018, future principal payments for the Term Loan due under the Loan Agreement are as follows (in thousands):
2018
$
1,917

2019
11,500

2020
5,750

$
19,167

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1

Stockholders' Equity (Tables)
9 Months Ended

Sep. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Common Stock Reserved for Future Issuance
The following shares of common stock were reserved for future issuance as of September 30, 2018 (in thousands):

Common stock options outstanding
1,134

RSUs outstanding
66

Common stock available for future grant under 2012 Equity Incentive Plan
61

Common stock available for future grant under 2015 Inducement Plan
3

Employee Stock Purchase Plan
155

Total common shares reserved for future issuance
1,419

Stock Option Activity
The following table summarizes our stock option and RSU activity (together Stock Awards) under all equity incentive plans for the nine months ended September 30, 2018 (shares in thousands):

Number of
options

Weighted
average
exercise
price

Number of
RSUs

Weighted average grant date fair value
Stock Awards outstanding at December 31, 2017
887

$
53.24

35

$
10.68

Granted
603

$
11.70

102

$
3.88

Exercised (options) or Vested (RSUs)
(1
)

$
4.56

(57
)

$
6.25

Canceled/forfeited/expired
(355
)

$
58.59

(8
)

$
7.57

Stock Awards outstanding at September 30, 2018
1,134

72

Assumptions Used to Estimate Fair Value of Stock Options and Performance Stock and Employee Stock Purchase Plan
The following table summarizes the weighted average assumptions used to estimate the fair value of stock options and performance stock awards granted to employees under our 2012 Equity Incentive Plan and 2015 Inducement Plan and the shares purchasable under our Employee Stock Purchase Plan during the periods presented:

Three months ended
September 30,

Nine months ended
September 30,

2018

2017

2018

2017
Stock options

Risk-free interest rate
2.9
%

1.9
%

2.7
%

2.0
%
Volatility
92.0
%

89.5
%

87.8
%

89.4
%
Dividend yield
—

—

—

—

Expected term (years)
6.1

6.1

6.1

6.1

Performance stock options

Risk-free interest rate
—

—

2.7
%

2.1
%
Volatility
—

—

87.4
%

89.9
%
Dividend yield
—

—

—

—

Expected term (years)
0.0

0.0

5.7

5.6

Employee stock purchase plan shares

Risk-free interest rate
2.0
%

1.0
%

1.8
%

0.8
%
Volatility
99.9
%

104.5
%

91.7
%

110.7
%
Dividend yield
—

—

—

—

Expected term (years)
0.5

0.5

0.5

0.5

Stock-Based Compensation
The following table summarizes the allocation of our stock-based compensation expense for all stock awards during the periods presented (in thousands):

Three months ended
September 30,

Nine months ended
September 30,

2018

2017

2018

2017
Research and development
$
491

$
653

$
1,745

$
2,411

Research and development-restructuring related adjustments
31

—

31

(1,399
)
General and administrative
883

631

2,613

2,840

General and administrative-restructuring related adjustments
(15
)

—

(15
)

2,679

Total
$
1,390

$
1,284

$
4,374

$
6,531

X

- Definition
Schedule Of Shares Reserved For Future Issuance
+ References
No definition available.
+ Details

Name: rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock

Namespace Prefix: rgls_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1

Basis of Presentation and Summary of Significant Accounting Policies (Narrative) (Details)
$ in Millions
1 Months Ended

Jul. 31, 2018

May 31, 2017

employee

Sep. 30, 2018

USD ($)

employee

Jan. 01, 2018

USD ($)

Accounting Policies [Abstract]

Reduction of workforce 60.00% 30.00%

Number of employees | employee 65 25

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Cash and cash equivalents and marketable securities $ 20.5

AOCI Including Portion Attributable to Noncontrolling Interest | Accounting Standards Update 2014-09

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Cumulative effect of new accounting principle in period of adoption $ (1.8)

X

- Definition
Number of persons employed by the Entity
+ References
No definition available.
+ Details

Name: dei_EntityNumberOfEmployees

Namespace Prefix: dei_

Data Type: xbrli:decimalItemType

Balance Type: na

Period Type: instant

X

- Definition
Cash and Cash Equivalents and Marketable Securities
+ References
No definition available.
+ Details

Name: rgls_CashandCashEquivalentsandMarketableSecurities

Namespace Prefix: rgls_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Reduction of Workforce
+ References
No definition available.
+ Details

Name: rgls_ReductionofWorkforce

Namespace Prefix: rgls_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.
+ References
No definition available.
+ Details

Name: us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 36 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1

Basis of Presentation and Summary of Significant Accounting Policies (Effect of New Accounting Principle) (Details) - USD ($)
$ in Thousands

Sep. 30, 2018

Jan. 01, 2018

Dec. 31, 2017

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Deferred revenue (contract liabilities), non-current $ 77

Accumulated deficit $ (384,161) (344,014) $ (345,858)

Calculated under Revenue Guidance in Effect before Topic 606

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Deferred revenue (contract liabilities), non-current 1,921

Accumulated deficit $ (345,858)

Accounting Standards Update 2014-09 | Difference between Revenue Guidance in Effect before and after Topic 606

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Deferred revenue (contract liabilities), non-current (1,844)

Accumulated deficit $ 1,844

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 37 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1

Net Loss Per Share (Detail) - shares
3 Months Ended 9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Earnings Per Share [Abstract]

Potentially dilutive securities not included in calculation of diluted net loss per share (in shares) 0 106,597 575,256 210,816

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1

Investments (Summary of Short-Term Investments) (Detail) - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended

Sep. 30, 2018

Dec. 31, 2017

Debt Securities, Available-for-sale [Line Items]

Amortized cost $ 6,439 $ 46,632

Unrealized Gains 1 0

Unrealized Losses (7) (77)

Estimated fair value $ 6,433 $ 46,555

Corporate debt securities

Debt Securities, Available-for-sale [Line Items]

Maturity (or less) (in years) 1 year

Amortized cost $ 32,922

Unrealized Gains 0

Unrealized Losses (55)

Estimated fair value $ 32,867

Certificates of deposit

Debt Securities, Available-for-sale [Line Items]

Maturity (or less) (in years) 1 year 1 year

Amortized cost $ 2,440 $ 8,216

Unrealized Gains 0 0

Unrealized Losses 0 0

Estimated fair value $ 2,440 $ 8,216

U.S. Treasury securities

Debt Securities, Available-for-sale [Line Items]

Maturity (or less) (in years) 1 year 1 year

Amortized cost $ 3,999 $ 3,996

Unrealized Gains 1 0

Unrealized Losses (7) (18)

Estimated fair value $ 3,993 $ 3,978

Debt securities of U.S. government-sponsored agencies

Debt Securities, Available-for-sale [Line Items]

Maturity (or less) (in years) 1 year

Amortized cost $ 1,498

Unrealized Gains 0

Unrealized Losses (4)

Estimated fair value $ 1,494

X

- Definition
Maturity Period Of Short Term Investments
+ References
No definition available.
+ Details

Name: rgls_MaturityPeriodOfShortTermInvestments

Namespace Prefix: rgls_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (aa)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 39 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1

Fair Value Measurements (Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis) (Detail) - USD ($)
$ in Thousands

Sep. 30, 2018

Dec. 31, 2017

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis $ 20,064 $ 57,402

Level 1

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 13,631 10,847

Level 2

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 6,433 46,555

Level 3

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 0 0

Corporate debt securities

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 32,867

Corporate debt securities | Level 1

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 0

Corporate debt securities | Level 2

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 32,867

Corporate debt securities | Level 3

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 0

Certificates of deposit

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 2,440 8,216

Certificates of deposit | Level 1

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 0 0

Certificates of deposit | Level 2

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 2,440 8,216

Certificates of deposit | Level 3

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 0 0

U.S. Treasury securities

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 3,993 3,978

U.S. Treasury securities | Level 1

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 0 0

U.S. Treasury securities | Level 2

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 3,993 3,978

U.S. Treasury securities | Level 3

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 0 0

Debt securities of U.S. government-sponsored agencies

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 1,494

Debt securities of U.S. government-sponsored agencies | Level 1

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 0

Debt securities of U.S. government-sponsored agencies | Level 2

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 1,494

Debt securities of U.S. government-sponsored agencies | Level 3

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 0

Cash equivalents

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 13,631 10,847

Cash equivalents | Level 1

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 13,631 10,847

Cash equivalents | Level 2

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 0 0

Cash equivalents | Level 3

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis $ 0 $ 0

X

- Definition
Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258
+ Details

Name: us-gaap_AssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1

Term Loan (Details)
1 Months Ended

Jun. 22, 2016

USD ($)

Jun. 17, 2016

USD ($)

loan

Mar. 31, 2018

Sep. 30, 2018

USD ($)

Debt Financing Agreement

Debt Instrument [Line Items]

Maximum borrowing capacity $ 30,000,000.0

Number of term loans | loan 2

Stated interest rate, percentage 8.51%

Period for principal and interest payments 24 months

Amended period for principal and interest payments 15 months

Unrestricted cash raised target $ 30,000,000

Prepayment fee, option one 2.00%

Prepayment fee, option two 1.00%

Debt extinguishment fee 5.50%

Term loan, less debt issuance costs $ 19,100,000

Debt instrument effective rate 8.98%

Debt Financing Agreement | London Interbank Offered Rate (LIBOR)

Debt Instrument [Line Items]

Basis spread on variable rate, percentage 0.44%

Debt Financing Agreement Tranche A

Debt Instrument [Line Items]

Maximum borrowing capacity $ 20,000,000.0

Proceeds from borrowing under term loan $ 20,000,000

Term loan, less debt issuance costs $ 19,167,000

Debt Financing Agreement Tranche B

Debt Instrument [Line Items]

Maximum borrowing capacity $ 10,000,000.0

X

- Definition
Amended Period for Principal and Interest Payments
+ References
No definition available.
+ Details

Name: rgls_AmendedPeriodforPrincipalandInterestPayments

Namespace Prefix: rgls_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Debt Extinguishment Fee
+ References
No definition available.
+ Details

Name: rgls_DebtExtinguishmentFee

Namespace Prefix: rgls_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of Term Loans
+ References
No definition available.
+ Details

Name: rgls_NumberofTermLoans

Namespace Prefix: rgls_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Period for Principal and Interest Payments
+ References
No definition available.
+ Details

Name: rgls_PeriodforPrincipalandInterestPayments

Namespace Prefix: rgls_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Prepayment Fee, Percentage, Period One
+ References
No definition available.
+ Details

Name: rgls_PrepaymentFeePercentagePeriodOne

Namespace Prefix: rgls_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Prepayment Fee, Percentage, Period Two
+ References
No definition available.
+ Details

Name: rgls_PrepaymentFeePercentagePeriodTwo

Namespace Prefix: rgls_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Unrestricted Cash Raised Target
+ References
No definition available.
+ Details

Name: rgls_UnrestrictedCashRaisedTarget

Namespace Prefix: rgls_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Percentage points added to the reference rate to compute the variable rate on the debt instrument.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of cash inflow from issuance of long-term debt classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=rgls_DebtFinancingAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=rgls_DebtFinancingAgreementTrancheAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=rgls_DebtFinancingAgreementTrancheBMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 41 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1

Term Loan (Future Principal Payments) (Details) - Debt Financing Agreement Tranche A
$ in Thousands

Sep. 30, 2018

USD ($)

Debt Instrument [Line Items]

Future Repayments of Principal, 2018 $ 1,917

Future Repayments of Principal, 2019 11,500

Future Repayments of Principal, 2020 5,750

Long-term Debt $ 19,167

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04.(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04.(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04.(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=rgls_DebtFinancingAgreementTrancheAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1

Stockholders' Equity (Common Stock Reserved for Future Issuance) (Detail)
shares in Thousands

Sep. 30, 2018

shares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Common stock options outstanding 1,134

Total common shares reserved for future issuance 1,419

Common stock available for future grant under 2012 Equity Incentive Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

RSUs outstanding 66

Common stock available for future grant 61

Common stock available for future grant under 2015 Inducement Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Common stock available for future grant 3

Employee Stock Purchase Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Common stock available for future grant 155

X

- Definition
Aggregate number of common shares reserved for future issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of equity instruments other than options outstanding, including both vested and non-vested instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=rgls_TwentyTwelvePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=rgls_TwentyFifteenInducementPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1

Stockholders' Equity (Stock Option and RSU Activity) (Detail)
shares in Thousands
9 Months Ended

Sep. 30, 2018

$ / shares

shares

Number of options

Number of options, ending outstanding number (in shares) 1,134

Stock options

Number of options

Number of options, beginning outstanding number (in shares) 887

Number of options, Granted (in shares) 603

Number of options, Exercised (in shares) (1)

Number of options, Canceled/forfeited/expired (in shares) (355)

Number of options, ending outstanding number (in shares) 1,134

Weighted average exercise price

Weighted average exercise price, beginning balance (in dollars per share) | $ / shares $ 53.24

Weighted average exercise price, Granted (in dollars per share) | $ / shares 11.70

Weighted average exercise price, Exercised (in dollars per share) | $ / shares 4.56

Weighted average exercise price, Canceled/forfeited/expired (in dollars per share) | $ / shares $ 58.59

Restricted Stock Units (RSUs)

Number of RSUs

Shares outstanding (in shares) 35

Shares granted (in shares) 102

Shares vested in period (in shares) (57)

Shares canceled in period (in shares) (8)

Shares outstanding (in shares) 72

Weighted average grant date fair value

Beginning balance (usd per share) | $ / shares $ 10.68

Granted (usd per share) | $ / shares 3.88

Exercised (usd per share) | $ / shares 6.25

Canceled/forfeited/expired (usd per share) | $ / shares $ 7.57

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(3)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)-(4)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price of options that were either forfeited or expired.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)-(4)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Net number of share options (or share units) granted during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 44 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1

Stockholders' Equity (Assumptions Used to Estimate Fair Value of Stock Options and Performance Stock and Employee Stock Purchase Plan) (Detail)
3 Months Ended 9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Employee Stock Purchase Plan

Weighted average assumptions

Risk-free interest rate 2.00% 1.00% 1.80% 0.80%

Volatility 99.90% 104.50% 91.70% 110.70%

Dividend yield 0.00% 0.00% 0.00% 0.00%

Expected term (years) 6 months 6 months 6 months 6 months

Stock options

Weighted average assumptions

Risk-free interest rate 2.90% 1.90% 2.70% 2.00%

Volatility 92.00% 89.50% 87.80% 89.40%

Dividend yield 0.00% 0.00% 0.00% 0.00%

Expected term (years) 6 years 29 days 6 years 1 month 6 days 6 years 29 days 6 years 1 month 6 days

Performance stock options

Weighted average assumptions

Risk-free interest rate 0.00% 0.00% 2.70% 2.10%

Volatility 0.00% 0.00% 87.40% 89.90%

Dividend yield 0.00% 0.00% 0.00% 0.00%

Expected term (years) 0 years 0 years 5 years 7 months 25 days 5 years 7 months 6 days

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1

Stockholders' Equity (Stock-Based Compensation Expense Allocation) (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Stock-based compensation expenses $ 1,390 $ 1,284 $ 4,374 $ 6,531

Research and development

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Stock-based compensation expenses 491 653 1,745 2,411

Research and development-restructuring related adjustments

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Stock-based compensation expenses 31 0 31 (1,399)

General and administrative

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Stock-based compensation expenses 883 631 2,613 2,840

General and administrative-restructuring related adjustments

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Stock-based compensation expenses $ (15) $ 0 $ (15) $ 2,679

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=rgls_ResearchandDevelopmentSeveranceRelatedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=rgls_GeneralandAdministrativeSeveranceRelatedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 46 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1

Strategic Alliances and Collaborations (Detail)
1 Months Ended 3 Months Ended 8 Months Ended 9 Months Ended

Feb. 28, 2014

USD ($)

$ / shares

shares

Jul. 31, 2013

USD ($)

Jul. 31, 2012

target

Sep. 30, 2018

USD ($)

shares

Sep. 30, 2017

USD ($)

Jan. 31, 2014

USD ($)

Sep. 30, 2018

USD ($)

shares

Sep. 30, 2017

USD ($)

Jan. 01, 2018

USD ($)

Dec. 31, 2017

USD ($)

shares

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Revenues (less than) $ 18,000 $ 18,000 $ 54,000 $ 54,000

Common stock, shares issued (shares) | shares 8,750,343 8,750,343 8,662,435

Common stock value $ 9,000 $ 9,000 $ 9,000

Deferred revenue $ 77,000

Revenue under strategic alliances and collaborations

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Revenues (less than) 100,000 $ 100,000 $ 100,000 $ 100,000

Sanofi

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Number of collaborative areas granted | target 4

Deferred revenue $ 400,000

Sanofi | Private Placement

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Common stock, shares issued (shares) | shares 1,303,780

Price per share (in dollars per share) | $ / shares $ 7.67

Common stock value $ 10,000,000

Restriction period in which Alliances could not sell, transfer, make any short sale of, or grant any option for the sale of any common stock 12 months

Sanofi | Minimum | United States

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Royalties based on percentage of net sales 10.00%

Sanofi | Minimum | Outside of the United States

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Royalties based on percentage of net sales 10.00%

Sanofi | Maximum | United States

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Royalties based on percentage of net sales 20.00%

Sanofi | Maximum | Outside of the United States

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Royalties based on percentage of net sales 20.00%

Sanofi | Development Commercialization And License Agreement

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Initial upfront option payment $ 2,500,000

Deferred revenue creditable against future milestones $ 1,250,000 $ 1,250,000 $ 1,250,000

Upfront payment non-creditable portion recognized $ 1,250,000

Sanofi | Common Stock Purchase Agreement

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Deferred revenue 100,000 $ 100,000

Deferred revenue recognition period 1 year

Sanofi | Proof-of-Concept Trial

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Potential revenue through milestone payments 101,800,000.0 $ 101,800,000.0

Sanofi | Regulatory and Commercialization Milestones

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Potential revenue through milestone payments 300,000,000.0 300,000,000.0

Sanofi | Clinical

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Potential revenue through milestone payments $ 15,000,000.0 $ 15,000,000.0

X

- Definition
Collaborative Areas Granted
+ References
No definition available.
+ Details

Name: rgls_CollaborativeAreasGranted

Namespace Prefix: rgls_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Common Stock Transaction Restriction Period
+ References
No definition available.
+ Details

Name: rgls_CommonStockTransactionRestrictionPeriod

Namespace Prefix: rgls_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Deferred Revenue Creditable Against Future Milestones
+ References
No definition available.
+ Details

Name: rgls_DeferredRevenueCreditableAgainstFutureMilestones

Namespace Prefix: rgls_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Deferred Revenue Recognition Period
+ References
No definition available.
+ Details

Name: rgls_DeferredRevenueRecognitionPeriod

Namespace Prefix: rgls_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Issuance of common stock price per share.
+ References
No definition available.
+ Details

Name: rgls_IssuanceOfCommonStockPricePerShare

Namespace Prefix: rgls_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Revenue Recognition, Milestone Method, Potential Milestone Receivable
+ References
No definition available.
+ Details

Name: rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable

Namespace Prefix: rgls_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Royalty Percentage Based On Net Sales
+ References
No definition available.
+ Details

Name: rgls_RoyaltyPercentageBasedOnNetSales

Namespace Prefix: rgls_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Cash received from collaborators during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585
+ Details

Name: us-gaap_ProceedsFromCollaborators

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: rgls_StrategicAlliancesAxis=rgls_StrategicAlliancesandCollaborationsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: rgls_StrategicAlliancesAxis=rgls_SanofiMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=country_US

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=us-gaap_NonUsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rgls_DevelopmentCommercializationAndLicenseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=rgls_CommonStockPurchaseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=rgls_ProofofConceptTrialMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=rgls_RegulatoryAndCommercializationMilestonesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=rgls_ClinicalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 47 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1

Related Party Transactions (Detail) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Sanofi

Related Party Transaction [Line Items]

Expenses incurred for services performed or out-of-pocket expenses under the Sanofi agreement (less than) $ 0.1 $ 0.1 $ 0.1 $ 0.1

X

- Definition
Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
+ Details

Name: us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rgls_SanofiMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 48 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1

Subsequent Events (Details) - Subsequent Event

Oct. 02, 2018

Nov. 05, 2018

USD ($)

Oct. 15, 2018

$ / shares

Subsequent Event [Line Items]

Conversion ratio for reverse stock split 0.0833

Exercise price (usd per share) | $ / shares $ 4.56

Term Loan

Subsequent Event [Line Items]

Potential revenue through milestone payments $ 6,800,000

Fourth Amendment

Subsequent Event [Line Items]

Prepayment requirement of loan from license fees 25.00%

Potential revenue through milestone payments $ 10,000,000.0

Payment fee 5.50%

Minimum cash, debt covenant $ 10,000,000.0

Proceeds debt covenant, conditional minimum amount 15,000,000

Conditional amount, capital event, debt covenant 5,000,000

Development Milestones | Term Loan

Subsequent Event [Line Items]

Potential revenue through milestone payments $ 40,000,000

X

- Definition
Conditional Amount, Capital Event, Debt Covenant
+ References
No definition available.
+ Details

Name: rgls_ConditionalAmountCapitalEventDebtCovenant

Namespace Prefix: rgls_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Minimum Cash, Debt Covenant
+ References
No definition available.
+ Details

Name: rgls_MinimumCashDebtCovenant

Namespace Prefix: rgls_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Payment Fee
+ References
No definition available.
+ Details

Name: rgls_PaymentFee

Namespace Prefix: rgls_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Prepayment Requirement of Loan From License Fees
+ References
No definition available.
+ Details

Name: rgls_PrepaymentRequirementofLoanFromLicenseFees

Namespace Prefix: rgls_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Proceeds Debt Covenant, Conditional Minimum Amount
+ References
No definition available.
+ Details

Name: rgls_ProceedsDebtCovenantConditionalMinimumAmount

Namespace Prefix: rgls_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Revenue Recognition, Milestone Method, Potential Milestone Receivable
+ References
No definition available.
+ Details

Name: rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable

Namespace Prefix: rgls_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770
+ Details

Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1

Namespace Prefix: us-gaap_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition
Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=rgls_TermLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=rgls_FourthAmendmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=rgls_DevelopmentMilestonesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 51 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 139 180 1 false 44 0 false 7 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.regulusrx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Balance Sheets Sheet http://www.regulusrx.com/role/CondensedBalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://www.regulusrx.com/role/CondensedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Condensed Statements of Operations and Comprehensive Loss Sheet http://www.regulusrx.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss Condensed Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 1003000 - Statement - Condensed Statements of Cash Flows Sheet http://www.regulusrx.com/role/CondensedStatementsOfCashFlows Condensed Statements of Cash Flows Statements 5 false false R6.htm 2101100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.regulusrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 6 false false R7.htm 2102100 - Disclosure - Net Loss Per Share Sheet http://www.regulusrx.com/role/NetLossPerShare Net Loss Per Share Notes 7 false false R8.htm 2103100 - Disclosure - Investments Sheet http://www.regulusrx.com/role/Investments Investments Notes 8 false false R9.htm 2108100 - Disclosure - Fair Value Measurements Sheet http://www.regulusrx.com/role/FairValueMeasurements Fair Value Measurements Notes 9 false false R10.htm 2111100 - Disclosure - Term Loan Sheet http://www.regulusrx.com/role/TermLoan Term Loan Notes 10 false false R11.htm 2112100 - Disclosure - Stockholders' Equity Sheet http://www.regulusrx.com/role/StockholdersEquity Stockholders' Equity Notes 11 false false R12.htm 2117100 - Disclosure - Strategic Alliances and Collaborations Sheet http://www.regulusrx.com/role/StrategicAlliancesAndCollaborations Strategic Alliances and Collaborations Notes 12 false false R13.htm 2119100 - Disclosure - Related Party Transactions Sheet http://www.regulusrx.com/role/RelatedPartyTransactions Related Party Transactions Notes 13 false false R14.htm 2120100 - Disclosure - Subsequent Events Sheet http://www.regulusrx.com/role/SubsequentEvents Subsequent Events Notes 14 false false R15.htm 2201201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.regulusrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.regulusrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies 15 false false R16.htm 2301302 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) Sheet http://www.regulusrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables Basis of Presentation and Summary of Significant Accounting Policies (Tables) Tables http://www.regulusrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies 16 false false R17.htm 2303301 - Disclosure - Investments (Tables) Sheet http://www.regulusrx.com/role/InvestmentsTables Investments (Tables) Tables http://www.regulusrx.com/role/Investments 17 false false R18.htm 2308301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.regulusrx.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.regulusrx.com/role/FairValueMeasurements 18 false false R19.htm 2311301 - Disclosure - Term Loan (Tables) Sheet http://www.regulusrx.com/role/TermLoanTables Term Loan (Tables) Tables http://www.regulusrx.com/role/TermLoan 19 false false R20.htm 2312301 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.regulusrx.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.regulusrx.com/role/StockholdersEquity 20 false false R21.htm 2401403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative) (Details) Sheet http://www.regulusrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails Basis of Presentation and Summary of Significant Accounting Policies (Narrative) (Details) Details http://www.regulusrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables 21 false false R22.htm 2401404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Effect of New Accounting Principle) (Details) Sheet http://www.regulusrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesEffectOfNewAccountingPrincipleDetails Basis of Presentation and Summary of Significant Accounting Policies (Effect of New Accounting Principle) (Details) Details http://www.regulusrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables 22 false false R23.htm 2402401 - Disclosure - Net Loss Per Share (Detail) Sheet http://www.regulusrx.com/role/NetLossPerShareDetail Net Loss Per Share (Detail) Details http://www.regulusrx.com/role/NetLossPerShare 23 false false R24.htm 2403402 - Disclosure - Investments (Summary of Short-Term Investments) (Detail) Sheet http://www.regulusrx.com/role/InvestmentsSummaryOfShortTermInvestmentsDetail Investments (Summary of Short-Term Investments) (Detail) Details http://www.regulusrx.com/role/InvestmentsTables 24 false false R25.htm 2408402 - Disclosure - Fair Value Measurements (Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis) (Detail) Sheet http://www.regulusrx.com/role/FairValueMeasurementsFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail Fair Value Measurements (Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis) (Detail) Details http://www.regulusrx.com/role/FairValueMeasurementsTables 25 false false R26.htm 2411402 - Disclosure - Term Loan (Details) Sheet http://www.regulusrx.com/role/TermLoanDetails Term Loan (Details) Details http://www.regulusrx.com/role/TermLoanTables 26 false false R27.htm 2411403 - Disclosure - Term Loan (Future Principal Payments) (Details) Sheet http://www.regulusrx.com/role/TermLoanFuturePrincipalPaymentsDetails Term Loan (Future Principal Payments) (Details) Details http://www.regulusrx.com/role/TermLoanTables 27 false false R28.htm 2412402 - Disclosure - Stockholders' Equity (Common Stock Reserved for Future Issuance) (Detail) Sheet http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedForFutureIssuanceDetail Stockholders' Equity (Common Stock Reserved for Future Issuance) (Detail) Details http://www.regulusrx.com/role/StockholdersEquityTables 28 false false R29.htm 2412403 - Disclosure - Stockholders' Equity (Stock Option and RSU Activity) (Detail) Sheet http://www.regulusrx.com/role/StockholdersEquityStockOptionAndRsuActivityDetail Stockholders' Equity (Stock Option and RSU Activity) (Detail) Details http://www.regulusrx.com/role/StockholdersEquityTables 29 false false R30.htm 2412404 - Disclosure - Stockholders' Equity (Assumptions Used to Estimate Fair Value of Stock Options and Performance Stock and Employee Stock Purchase Plan) (Detail) Sheet http://www.regulusrx.com/role/StockholdersEquityAssumptionsUsedToEstimateFairValueOfStockOptionsAndPerformanceStockAndEmployeeStockPurchasePlanDetail Stockholders' Equity (Assumptions Used to Estimate Fair Value of Stock Options and Performance Stock and Employee Stock Purchase Plan) (Detail) Details http://www.regulusrx.com/role/StockholdersEquityTables 30 false false R31.htm 2412405 - Disclosure - Stockholders' Equity (Stock-Based Compensation Expense Allocation) (Detail) Sheet http://www.regulusrx.com/role/StockholdersEquityStockBasedCompensationExpenseAllocationDetail Stockholders' Equity (Stock-Based Compensation Expense Allocation) (Detail) Details http://www.regulusrx.com/role/StockholdersEquityTables 31 false false R32.htm 2417401 - Disclosure - Strategic Alliances and Collaborations (Detail) Sheet http://www.regulusrx.com/role/StrategicAlliancesAndCollaborationsDetail Strategic Alliances and Collaborations (Detail) Details http://www.regulusrx.com/role/StrategicAlliancesAndCollaborations 32 false false R33.htm 2419401 - Disclosure - Related Party Transactions (Detail) Sheet http://www.regulusrx.com/role/RelatedPartyTransactionsDetail Related Party Transactions (Detail) Details http://www.regulusrx.com/role/RelatedPartyTransactions 33 false false R34.htm 2420401 - Disclosure - Subsequent Events (Details) Sheet http://www.regulusrx.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.regulusrx.com/role/SubsequentEvents 34 false false All Reports Book All Reports rgls-20180930.xml rgls-20180930.xsd rgls-20180930_cal.xml rgls-20180930_def.xml rgls-20180930_lab.xml rgls-20180930_pre.xml http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/country/2017-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 55 0001628280-18-014023-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-18-014023-xbrl.zip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
QQC_6^B>]J;)I^_W#FO)!:4R69)@CTN9.X*)>/ M" "_/1<^?)3!^CI9P4I7?LK+K]-QOL7IMNW13!#/#=,&EEKX 7Y!U&RZ[P*U MN$<"'.17:RK%HE4\&BJEAT@VS:";!BZV[NKL?#X+B'#AE-5:$D<=ET&KJD\, M$3),+]CQ(OI>UJV!\SH$/R@?UT#DW9*;XOL,;:/G&=JV.J<.JR CCE@/"R', M?4)&HH33[!Z?:-%PW!,M2:;H :;^8E_7D9X+\V6QCMO=&>GZ]-&,F*@]\YQ% M81GE!$5WKP'AJ'O=K:_G&FA1C3L2C9[E&P&*ET*SP[?-[G#*RKY(:6Q'W_93 MX)#:,L24\@1SPI6W/@9)"*IPH4S&X;&DN6A?YDB'0>GGN^IT4VF=$ MNQB=;'$X9%'(8+&C 3%K'<4B&N*4K]3NH(UO;C[0\Y'[L:CT+NFW\S%H,(^= MZ;MD_?!T9AA"1E+I)%C2UH/A8^YG-8-T\[WLSJ3=Q=+?&)"^!/UK,2^>-K:Z MRF"_WK>W; :3EG"8<>FL,H9%YG#E+0U8\.:Q3^P,2- V//UE0+D+#H;%Z?WR M*B_OVKZ#!R\7R*@CF%$F-#!=$R\=MQ5NT2Z3F'/O0XKWPX+XB+#9[.\9%!EN[GB0 M9R#@8Z#HS>I,JM&3**Z')D/[WU\ /^\"*N'S,A\ML?OU*S[;0ZMGTW_-Y_\9S%+NS<_ ^*IM^_G M#\'EIIPNX"N_2O<7WW6_ J,!%X]]919"Q-@CBK&RCF.O.$7W".,XP#VX/FE5 MD]$]2Z&W P??][0&57>4RKS2G C,L0B!4>BUMO?]M-0VGP_U&3R^OH'GF*YB&E_FOJX17NIH=>O!^M5RD$WC0J_HD:59A9BCU MDB/,C=,\.,0(#14Z'N;RYMPYA^BB7D#K_A21+\:K!$BZZ'J^G"YOW\[7%V _ M/J[6Q:&0^RNX?P&-8%7>'0OI_87W'_[G%*18CJ]N8U&F6)]U]&&5%1.4ADVA MB5D^W!T^_YATBG(CY!>OT^WQY,I]NQX?+_JY+%8WT, XG<-GT]'L?@"XT=V= MY^]JG',YMFI8586RF'%0\@C,HDQQ1E10AAFE'*D7?]HU:K.>Q- +SZC/$]Z'Q.NU+?3JFCX.I+I[MO[]WB M4RTWS]>8W^;%ET5>?DW8O)W?K);P=0'#= M()8+HP+ '#3CECCL7#C3ZUM:H-0VD@Y< G\-@L-%P#&E&'.LK#1>J>YC6I<;_+"\]GZ^PX6"97*)B*1%BL'$"- MG>#1$SO 9$*G%_-W5[L<#VQOTUZE6K^=+T!'75OC>Y3!ETMD1KB ,)>",<\% M1A;^C<8&#O\%$IL?U>XX!6*WJF K8/5%AO5%#1=Y^7#Z,06!7+S0B47*X+5X M^:N]ZUZ;K\F\X3 ^G5)<2ZY#I(2$C;KA:;#T7!6^8XGS/&G>@#'_B][;H18J M4D$,$^F8.;)11X0LD2;E^25*]!H.6U^5&S)Y#T.T+VY"X_+%[,*\G*Y3G6V3.#X_*983/=G5M]1*@L2F<"ILS(JGJY)%\%''V5$6*C FD<\ M=A:N/0@2M0=I7]3Y[=/G'NP9!G-80[8LWOQ3E\G)TF=O1^(]\\M#HMXO%*I_8V]\^_5Q\SE$36,^ M=G;.;!!\/ GZO;N![>WW^_/OTC'\^GME.RK(?/!,$Z(-E8(S'L!R"H)A2Y"G MWO+F>OWA<^& O"5=8-<[-3?%:A33[HRE5NC3 !8I38:ZR VIG@(UIRM M^Z-E)FPCVBDP?MV$9 (F[^BXEEYS&B(,_$@]EK#6(*OUB?A6?^_I]'0[#,'> MV;3>.UFL0<%[-;4=I3*.J'0P7B1&DDM"#-:8$6QA9 5'PX 2 W8LQVUL.1JS M4W*#-.(&J>X6\X :#\PY3SC\;$4Z+8JT0P8+Z0;H8S@=-YIA=DINT$;2PRI,&:8-NP_Z^W7ZZ2.&2 M - .9FPMDQ'E.(&941-!N!/82L>D]6!\"$[)$>ZE[M>3OH->VP*Q^R,"+PZ= M[F_H>#O_FF]N,NOI-0]WDUP5Y?)S7EX_^O+$X?V?QE?Y9#5+5W9]A78D]&-1 M?AH]OB_I79T[*PZI)[.>@F$5F!##E'0(;_IN4=*.O EX@84)Y <;'A^JP*O&9)U&%9_Q:QLWU@(.FBD>>".@U[B MC#2Z&N8.(X*&>:%':_SH,GBE&;1_D;4YHL/T5YXS1U]S@)6+*.42$91)&2VS MFA%3]=WJT*?>=HHMY=JB;Q1@=1BXYQM@)8+6T$]*N1%>2>FL4Y6:;*-NOC=\ M'@%634G4'J3G&F!EN9<(66^M$E@;3C%R52^CTZ\]P*HI<5I#]*\ JZQ!\/ GZ^[F[Y2JY7T;+U+[;ZL[JE_R7+U"M M=MD,D/,1N: (#40P%4(453\8H6)X.E6W7K&ND.MMU^<9)L^-=BNO=:0U;J3_S5/H@L;0Q@#)J8E1"5]A%R9L; MB=U=]J!)CL*YI9;"B&D2E@\' FN4%4&2XQ,HYYYFI=+=MUC,TVL=C; M)]_LB3)I5%^&G:,V4NL]=BGGL'$PR:!@/4M/<8]-RW$E[@B[ZAVW0P2?U MNKTG'J5^)1G'GG"$#0_16 M^;B9>S?XOW\X8U)8A061V@5M+6$L'9FWU"%JC#?\3,^Y=2'7'=3I!LQSX5 T M)A -/5?(\70H55O.B?5*"6NLZC,:KGZHQVD8.LL)MC: \4,0]2@*YZSN4X3U#,ACP"W:@>$4X_,15:M+J]/=@H\9 M_/MT>?6XR.'Z1-V:,RT=-H)':I3BT2DK%)%8*(ZET&SHM&E5P>T7RNX]$)^6 MQ?B/JV(&XEBDI)L//.K"9/[^;6:Q6%W?GSXC:_^_W#JAQ?C1;YA]EHWM@6WS;C;JZ: M27LYUTGDHSM&@\@OU]:&O7UXY,/H=AU:^.>HG#S.LEIU^)=\>55,4K=W&>>] MO#>C01&B(]'.."Y!=4DY39P0@N&@G:P5-'5:#+=9])V_,_.84 $H1191\BIJ M)0CU6C'+,->RSY-S+UK] V-0,4RY#-JML.YS"IG9XSEX\ESF%8W.(L2LT)R! MJ9*RRB/D U)&:-2G45?+.3 @2CS?83@"U[[TQ[W +;8A]] [6%UAU?QU=)WO MM1"[>%W&D*28.X615$QJ"J:7$!AIZ1W&.N(S]5,TI,]SY^H9(/X7V>M#+P*V M/-@46XU!_X]6,"^IY-J1X&SH]<1];8?*@*E\&)Y],?6);7)GQ>P-(-Y:)B,J MQ( LC%@1N [6&DL<-Y1)I3 -0XSF/*FHG]\:VA*P?9'GL:V;,-H?>[ZE1.:B MD8Y;1+&%.1SF<@$CU::P:LRH/R(VJ;O0S2$1IQU8>UL=5U\6T\ET5-ZF<)B- M!V6/Z;"U3(:C)488JF DP"0O=0A>**[2?,\5;7[C=$=7DPS7C&@+X]YX]-#* M-(;>7SSR;>[7F?86SC!2WH2@HW$<,V-Q"'RC?!(,R)ZINM^"F)\3IW.46$UP$F?&9=D 0T4X(%6#>H5LA2[TKV20AT&%(G49\/4YRKI(^6,UB9 M8]26<)_6M M^;)8E@#G,0;_\6_/O&-(4TR(0P+&+C8"IFEB@PD^4!T'M*TZS!V$X?SNS%'C/<Q*.-JN2KSE'LG[9V<.A-W4^Z\JY.>^^C*,V("0T(:XP3F@<5T*R&7!#', MHL+U=EJZ/E_9?%NN_IG+(]^1^>2ZHE*I=,T4 B/$<(ZU9L$*QRQIOF/5=O[O M'BFS]:1FOV /.LRRW7U3(9./U@6" N/4"(#$.(:QMMA+ROJ\?+SAVJ%%[ MG_0P3%_+)A;V/&*;;LO#A 9!#0LNBN"T)XAB3U[=/FEM,3?8)VT7R]=",2T) M-:#H&B,(>&JL@-5-&*?@?XN86OJSVT:?U=F938JZ@C@S$$\I':"LH$DSP$*J,;X&4-IS2W3PS_X"G]:S&_ MZ^J=,_%1.O!>6'[ Z\&"B$0P&[7P!&85K1!77E,:*5Y?&#/ %?<,B=^=1(8_ M%M:]VKA?GMS?]C.4[21L;<\KP9YB:9+Q@2C%O;&:R73(0<"< U^PU[1[>DK. MMRJ%OGC^:./'C6ZFR]'LKOU;=X%V$/C@NK(HI4,JH. 5X4H'I038ZMD?2U*OH4#]ZU->1'' MQ>4\I<&^NZ0B71Y0ZYK@EM^4&<4H"18KQA2/G"KF!9C1+EV0HC@^X47"#QL5 M[?2Y_@9EB^_+L"-4H^@\4IYC#X-:,-!?K/">"JKZ/)^P<[/R9+S:NG-Y.BD, M>A?S[1QFR_S^WOMWF^[OVEV6UI\=[]IIWE,B\,$AH&>[IU,D@B' TF<&DB-2[B./I,-/3GH S!\'47^[310[ONC+S MB<^_YK/B)C5]H\/OW1*I43J3GDJ-G*?(!DYB3+?[!2%IVB<&+20,SUO=DAR_ M2V#:-E:--T6KIHR>-.43_%@FTW.3-W7W_N@A=614!*^5Q(91#,.**AH%00)T M4(2)/N)ZALX;C(F(L!DR#@VQ&H^P'O=.I@W.L6LKYEC8^'EDY<-P VE=TP=]2K( M&/+)7QHI(9H+Y WG(>6(0EIQ3(^XH[(S;6,HWIU. #Z96_IN!Q.FSH^+E1G# M<($O_CH#LW-KPRD? XT*,6H-ULX3Y;6')03L(,]-+3NN:W?S.9R!4802Z6(4 M"#EJ"(T$QMX:1Q,C0WV>/NCZ#$QMRG1V!N8PL ?M/6Z6:EPQ+*2C3!$F292@ MMGE1 2"M.X-[R'JCP,[4XH?A.)A(EG/(MJP\0]A9%X,@@5--/*N01=S0[)F# M=UC.Y88LZ27MP@/TK5]QHP=P#& HQ.%,V.4BM%;!P97\-QZ9[3' MPCJ>\ACTFO?RE/F>ZXJZ=J+PPX#M<0-E64Y3NHAUBW\#L2T^?OJMSM;)]G(9 M,29@T&F\9M WF8+-[A5K[D)S&^+,DH8W)%&;X YFO:Q_4.%C,9O%HDQ?]G,P MY=$+L\B\"M($8VATTI&(HZ[058+6BEH;V/S7H2$\!!F<(<-/<.H*,QHL!O.2 M665%< 8[O,$TW8G]FI)BMD2NSD]B'2:2?OBC31G!) ME0\N&*N,YCBH"DWAS!#/,[\N@A\EC][8G12J=$@AG_A5"8LG0K&D4PV=TSYHBX[W,P M\@<_K+J4Y6!&UK'6X8FTP*/:E2F)P*(E@06& A:1@)PJ65GBFR]GY^!T./FX M&Y!H!S\,O\]-MKS*R\]7HTWNLL6OQ?QKO@ T.MX,;]203#A".8H146R<%T1R M5:D;%/Z@5[3 G=!)T8=L7M%(Z6Y3_= V9!RX(2/65C(N>&3,6E3) #OVFIP4 M'9.T_['42(3G/XRZW[8_L F91T)JS--E;M$)C*7!I)( ,G& I^[_Z0?141(\ M_S'T7VL1G70,/6U"QL%:58&#QF^%,S!M&5KM\5'BZ6L*-W@M8^@H"9[_&-J8 MB2<>1M^U(F/<:,IT(#AB@30/5E5^($J5;Z[2#<^W\%I&TK%"//_!="^H9[Z5 M]3KM1\O\_O[0P;@9#FEI)D7D+M*H.3'1.Y&NW]G(DR%G7Y/#[RS\$!T*[Y]I M, Y\!&;$:Q$]%I0(JVT0,BAZ+[FHFX=:G[-[HQON#W ,'RC^\Q^X._?A!S)Z M#VQCIE.21BT5&.1(41P0M]4BPAPZ(DG=.3M7SGP(=\N!\Q_'3RWK88[C ]N8 M(:<%V%F&*D<)Z'\1L^IL S.<-#=+S]G!<^;CN%L.G/\X?A1),,Q!?$@#,XHP MHAB'E'U=!B:MTY7T.&6R^8'SX=FP_S0CN$,"G"(EY3I1V>)I.^XS3VX:<^P[ M2\#D.),CPZ8G3DZ3T.GK=DZ3X1_1VD[MV0Z?V$N>SDA MYXZG,Z:)@9748"2%EH2[(%G5P729=H\$:YB6LW]9%VW#VCC9_?=OWYI_<.?S M&6,^&L-3N*VP6GM#9:S:*P4::.[+5B2P6YI'X3-\N9Y&GEL20PY'G)V)'+14S.@C8NA:WZEI23*[Y=P.3,T%/YH7 M%],]LGWT3(:#D99@ICF7G'A).2=5NSPRS9-VM>ZE[T)\S9'HR\>5TCZ^OWBD M/NS)??[B\UF *2LJR@CBW! 2K9&NZIL#V'J4\KDI6VT"VQ=IOL=G]#(D>Y.P M'EA3AB5#'G$4./=@/G&?XD(1@[3#5N99D_#Q]?B_8_<6I0:F2YT&EEK0- M5UQ?%_.U-_?#*EW@H$/ MJA83JING,^@L5J076;<%6&,1?TP;&0GKV_5NQ?5U.C ]FDW_=VW;_#*=Y8ME M,<_W&).'U9)Y3$&-)YA@':@@DGDEJKX9?\0=VYT%'/1"ADY1;+X$P"/3\;Z1 M__2I="&1]=9C[DGD@@G+;64,7E1E->Q*->[UPM[6^/RKE;J3SLYCD?/@HMI@QXSK&6%'26RSU-I MYVKPGD(09T#BU+.]=RVU4G]&?" <*1CU!F$7I NJF@!$$$8.VYCNF3_ML?=H M"?S%XD,P'*3Y_L] WI8TP$)5ST#''#&7!1+A_-?O#;\YD//LH^)HBV*)%/OL]0\-YP M0K@P2EI/K;@W@0 09T]D@ECAA1#!<*&,](ZSLPP%:B&V#^7W%$8G(\,!Z4^]"NZ_D3V"\!WO;K>*;0GSV1M-/W3N4V^K9?;H^?R11T7J?+P90U01 2O'+W M;==J0/=JMB*W(_K>VRFGU9?%=#(=E;>?1NO;X-/6SQXGVM8RF7,A0)<(H5[2 M=+=G.KZRZ:/2L?FXY*]>)VH;W-X(]-#*='/L^XM'4.R_-7QOX0S9X S77!$" M1DA$5FKU,-T)/4PMJT5I/N='5Y#]LQ!F4"K=H'ER&GY\**=?1\O\PVPTWNW2 MV5T@BXHAZ:E@CF!BN!*H.E6L0(-B0[P(N461%1U@U*4N^6D)S4LM^SDO+LO1 MS57:JMSAA]GZ?.:9$49C;+S0SDK$>*Q"ZI5%NOD%9.+5ZR!M MLI6>[.ESUN MX=:58^?SF9$A&!(#*/0R(AA42%;C21'LV3"UBY;D5'2'T.N0_J!4A2$)_1AA M+_+QWRZ+KV_&Q6J^+&^3O&7U2Q*W?"3NSD.W#EYF7*, ?;;V60!@6 M/--5>VE4 TKHUA+NQ9$0]*7,P7+UV_Z8[4=/98QJPT, #G,?+>*8V"JV28,2 M/# 747NB/!Z+_@(#ON;S51X!B&H?\??I\LJM%LOB.B_#M_%LE2[T,8M%#G\G MGT??=H8!'%Q;9B,1F%-EL,2<2<9!K:EP800WYTAGJOT@$@ET#_41L?Y/ ,A' M=\G@7KR]?G>!C#CFP"Z.F("Q1!@-EM.JQ<:Q 5Y ?%)RM(IF?SZ"8ISGD\4= ME:NV%^4NK_76,IE"WGM.C<>:VD@5HK[RS!NA4//II+.0\$%,)VT!>D1LT$5> MEOED,Z\Y^'&Z3(:ON000%\NX2AFL'F+7MX<%'59/)@0'79L+Z:/RV I%7657 M&QU"\Z"SSB+,3S_%= QR7S//2POGN^GHRW0V7=YN^O8Q'Q>7\^G_OKAZ-:LH M+A:K/>1ZL42F M&+.,.&ID##Y*XV2X[Q\2L7E:I,-]H^?%HC;@;+S.I;>E;!3),_QP/#-=*_HA M+]<-VK:R[2^9:1$QL@HCFL(16,#8R'O*,]WI5$J4E'(^PJ._?^ZA#'T&[ IZF'[?>3G5( M\0P1C!RC&B-A::#61%[Y!RP7MOGTH5\E*SK$=A :<%.%-R-.8(.,0X@2QA0W M[C[,P3J82YN[]-"K)%(7J+9EB&\4ZOV3S+YRF4#8NO\E7UX5DP_%$GJ>TDY4G\.S^?3KEGS$QU>:$:N5 M,^F2'XF=]!%+?3\>2+!''.5ZQ<[A/B%O3K;B=C1;W@+#Q]"6T>5=TOOW\U_S M90JKVNK[VUH/K"BLSL#5E\6 M^?^LH+'A:T+JZ?M;3M;_[%UWF?FWO;*?(P"/VO.N1IK];44RCIC#H&XX!>S@ M* BK@#Q>"(N=X:B6D=A++_%XXE' D&J-NDL@/*0\JEX$2:C6'.8SS$)V3"@"Q$5OJ!$,]TN.PR-.C MI%LKD^EAT/1ERIXNZV0@U@KBM'11(FNX!(PW>*C@T4#/#K.]51($%OUFCC:6R.1&Z3KS> MIL)Q-"ZGD78ZX;7WN..V(AE6U$3KJ"+2#3QYVS$BVRG]HQ%Z MC5P8Y+H_! JTM+I_SLOK=\5HOGM!?_I41IR7W@9IL8^$12*X(E7;P$3O]0:C M>FOX\3 7;<'16%2Q6)7+*P,=F.S/%O?BPYFRC L4&14F",8C\51O6FJ-X\W# M(#K;06A7<&V@TF=RD\=ZQO[\P%M*9# G,<'348B I<0.RU YSJQ&I/FA@JXS M_K:I:;4#S@F%OS^]Q+8R&1=11HVY$P&L4LR$(:+J(\7GD(;D*,GM9\)1.+U. M3@Q2\1H.%09!@;U>N!>?SXP5TG/#" >\HL#&8'R/%I,#/('8@IQV2[X1,KU) M_;L[X7\MEOE=1/?-;)H2XGZ%KU(87DI5BW<1XL"J,HT-4Q1C9B*16&$L6*7; M.F9P<]VA+ZZTL'_8+6:]L2B%=J]#&5QQ?0,3[EU:XP=7IKU]>.3#Z'9MVOXY M*B?O;];>S? MY4->)"7L]WQZ>;7,)P;Z/;K,-]_DZR#R7>3KIP695\X;F!60 M\Y"<9%L\'2 ]'9*=IV2=(G>LVGC3L: U6W3@OW3V1>:N&E([!$ M:\L"P"%XU2;ECS@,TMDAU9:'?5,H&HMGDQK:C197R( M:"J,BC+X".N1T4"HJK5,'W$(L+-SH>T*KAU[$;W4R7H]FZOW4&=^T*LFA%),P%1I@B4GGI0V5=A6!X<^]%9T;9L]?6^[\>G5.TX=E_YTW^I=C;#T+25 5U(F,(HBP3@B9DBHKA?R,)8? MSN[T'Y7^M,7[@M)?>#K#GGLGB>%84PV&HZ-^$5W1SN](SXH=Y*U8;(ZH8%-4/H-7)AD!N40Z! 2RI]>G^<@B(Y M3EDUZ]Y1N;U,QBQCFAAEM79<8(:HY/?M)K+7'>FHN]XY,;;:KG1X)R"C'O5<6^?SB+P049K;&< M>9BRI-415[U2F@[\J$9S(>V0]E'(O!:Y#U+Y/J6X3R/F=\5\4LS?SI=Y^64T M_^/]Q46>\_[HT/K%4^PX:(8#4/A&O#(ZQC5;X3SZT+JD\RU%OF MCQ%@T3U$O=%C.D]I/M?9JN-HO$ZKMKG7U19E6?P):HL;W< W.Y/?'5(-(($= MID%ZS"1 SK'39(.$"-SWF4>BD4YXO'.W0[@:FP*_KA(&Q46U/;(U3NJ[![.( MC9;&!FT-(,4A\5MMMNZN2C'*-&?>>(1LC,5$(?8^"M;+Y)E]GH7+=;O>U"-9I M*&-'B^GBTTV9CR;OYX]5K5TG#^I6D2E,F3.".0E_A'81U*D*@8B/\"YT%H?7 M+5U:@ZIYA-"4L)1]$(ZS!A' MU35=7N)XQ,909P%]K0J_0ZP:<^"W>;G)Z)Y/4F#IQ]%T?:=>>9EO#>';529# MH 9A+K@F7B'NB?-<5.V.^HBT3YU%[;4JXQ:Q:>$034 MRS1W2#BBD&641$*$0_><=/:(/;_.KE%H=_)N%Y]NY/OYSZ*1?*%NA;P.+T')EQIIO>C Z1H!"WC=Z;"95M\'J./!!+P;KEDD@GN-3$2!J(9E8$EJ"O MI5 .]<@#-5I$FNXA5Y9SKHUV8,@%3# H#<#J'O?'&AUYJ"V;&D<>#L/B51]Y M,-%*SP*G#'NN/%%,B +E'".V6!JG?(9RI&'VF+=?^3A,%C.,QJ$4/8VR.NENQ'9V\BDH/CZ0\#Z13V^R\C4-E!!/GB8^5+6KR_ MN%?A/^8)(9#+^XLX78Q'L_^;C_;$[1U5=<8CITY():E1'%-FB8;U&HQE)JVW MQ_B!^C8%F^JC/4,X0-*]G:=^O.P8/J:Z3)-HA<+8(QLY@&,-88@')2.S3I+F MCH;>?5 ]D*LI;,,E%+Q]EU';&1&.#!Y7!,:$VIMBN8)(D "+2!@ 5 M &UL[+UMC]LXMB[Z_?P*W3D?3@^03(ND M^**-O?"3GKZ (.+@F.K$I]Q6;7]DD[FUU]2EFQ7I>P2)5)2>BZF MI[M253&?]2SR68OD(OGO__O+W2KY7&RVRW+]'W\"?TG_E!3K>;E8KC_^QY]^ M??>2OY.O7OWI?__G__CW_^?ER_\C?GF=J'*^ORO6NT1NBMFN6"2_+W>?DM\6 MQ?8?R>VFO$M^*S?_6'Z>O7QY^$M)]<5JN?['O[E_?9AMB^3+=OEOV_FGXF[V MNIS/=E7;GW:[^W_[\__CJK?!GF>_UC]]/BKV^53OV@_ M%OSX?WYZ_:ZR\^5RO=W-UO/B3__Y/Y+D0,>F7!6_%+>)^^^OO[RZB"[_T?W& MC^OBH^/[;;%9EHMWN]EF]WKVH5A9&-6G?=H4MT]_Q&JS>? )CJ'<,02(8^A_ M/O/!NZ_WQ7_\:;N\NU]9>G[L@;\#X-VW8&.AJTCXN0O(:ZP^_L# >-_;H5N$ M1?SM1P;&?.AH>KV(T7\??VQ@[&$A1^T9Y6ZV"MPSOOG(BYA7[K=>VZ_J7W2? M?D5^J\9K43W[X.++KE@OBD4EF@\^.EDN_N-/]JN;_?;EQ]GL_N:5C5IWA56O M7>&B$_^PW6UF\]T-8DP2@B600J:4(B.H9 @RPW)!&,EOJH^[*=8O?WW7-%Y] M*\S'_\G'_F^9W13;6B\@'J?QX0)4=(R=\;4/_OO_]X,N,!<^7\ MJ:Y00;F=;3]4>&J++2[ ?BQ6NVWSG9?N.R]34 ?6__D,-8_)+.?!R#QPLW*I M0[FIN]V#WL$W\Z3<+(J-36F:OS3;S)]Q0OT;/\Y+&Z?O=R\?^,.E-H&M*,-V ML0,KUHBG&/EFO!S;>3_[L"IN.%%$9XP3D&)C4$H11DTC5"I\LSM&A6?'BN=' M^PR1W878=&6[F[:9<[.>[-YMWQ>;SC-VKAJT1]^&:CW>"O&EJ\7=4-;5=[-ENL;G4),)!-Y3J%$$E.= MLZ:M+(704S8ZM#"&=AR@^:M'%P);2TAD[@+HR'.TA5:2;QFY+B<]&)R,IO2Q MX5MAZC\LY7ZV6;O5T:[N-+%?V%\I-M6Z\_:FX^U!L M;J"$0N6(V62(4 ,9D7EVE#8CTC9R$[C)R/KS2_&Y6.^+9+^V?2?9-K"368.[ M&F+S!\C;Z5)HZJ\+U8BL^TZ5&HKY XH?PDS^?@#:,@:$YGI1[\Y4?VN*G#\ M.#CWCP*)XZ$*$VF.TBI(^#'S1-2(1.VX82264674[MAQ0>SU*V1Q^.J\2M:& MJKA+94="VBR7^;,WL26S#@9<6C;KRD5;!:DSLNUQY1YRDZM,X&7 M@;I/)X4PUA!9KJN6?EON/LG]=E?>%1O]9;[:N](KOMT6]I_%^]F7FS1C3$& M(69***,IA&F#!&74=!"1H.U'UIFJYB#9U/[I)#9AZ?;2H]&8[B19A_J]!N^A ML*]!_"(Y8DX:T(E%/8JT^=#ZO/I%<=*D!#*.A4]K:$0VV\KLF_O"S1C7'_67 M^V*]/9/UE$&*8*J IB)5*!"OG3H. M0YV?!IY8:T"-EL!=I.>*EO6G=!J*%<".,G1G\TWRMH7]W4]\O5!6$E?EO9M\ MUHW?9$KD1&N.,\$Q=UNPJ%F\TB35TB^=Z]-2] GB 5RU3KLXP?--X7J1V399 M&XI'W[3LC,(S9(U"#9U[76'I:I85@MUIJ%,@6[[)G,(QU%:E_EJLK2RN;)-\ M<;=<+ZL-Q.7GHFF5DTPPB*C04E)$J&$F;UJ%D'$?G>K;5F2EJN%5HVSV *"? M5O6FM)U:#F+/V=V-G4$BG69" M2 2(X5 RU52>Z)RK]&9W/+CB/S5Y]M.]U.G""9IG%\#*;^9T/:=TSY/6<2H7 ME*^^4[B1YVT^\[76O$U#4WK@?VY^YLF$MVX<#MJ\+K?;&YZE*:>(2LJA$DH; MP8^Y%4]SU4DY/#X_LG8X#(=%W5H_6M> ]2+-4SDB\=55.^J#=3\X0'\>24!. ME+21D X$3DQ$NEAP248ZL]%62'XNU^7#QFKE.BXLV32'2)!A*@7C/#.9!,W1 M' T(9CZ3I_ZMQ5YNWGTJ-LFR'C5U>O)GSR7G )RV4YUAZ?33H'-L1QFJX?UY MM-7H9QF[(E'AV)Z&8 6TIXS5+_W$[-7:#OEBN[.3N&H@']J^01*"#&4DMY*9 M0T4E%DW]@Q$T\SH/W+&)R++5H*I6*\HS#?,3KJ[\M5.K :CSDZ@'K!V4_]5U MUB+=.? 4+U>$J">1TU"?OD9\<^% $Y\=>:XJDT !()@+?,\:X5BJ*8Z[*_/C=82HA8P),/'E%UA2\XQ?*+)(Z8HIB7=PN=S>I2;.8RQI9*YM]4AUSXTA61SRN2#2)6F@QPG[37[Y,C)ZH63+*R.#RW&_S(:;FU$(T7SVT$2\G# M!)#O=IOEA_W.W1N7[,KD[6QSK1(WSC;".3O7M@PZL3@-Q>B(_?%60 \&6A=# MN"4I6=[=;XI/5HN6GXM3D[;]-[=6I@X7*MOO;XK9ME#%X;^G>TD)E0 +I1F2 MAFDL4P:/P#CUJA = ,X@NZ#SC. 7UJ69TS+)9[5')4W'J!_*(EV MDFM5LKRM\JO1SOGTIOA:=;Y6Y9;/EFN;4_4O:/ZX\'^(TQ-UH; %2* &!"8J 8 M1ND1+C!>I])' QDY))SP)Q\M\N2'596,E>MD^ZG<[%[:C[Q+ENO/Q7;GSGML M7R3KPG-6/)Y_^P612;DV>&@YF? BX9]GRY7+NU_>EIN7[V:KXD5RUC%J\Y._ M5AVDSM8/=B<'PY.#Y2^2V:WM,,,?N8_EP@ZA:[!>,^V -AP-+ M0'IL4;$<0P(P(%IGR+:?BV.+ @FO]9 ^[41>'9'?S$?\XDLO"MN%B*'8\U/Y MEE.'%Y-86KE"X165#4'\-(0RB"5E^&[I)U=ZMEE;:=Q:;7SWR?8B,=LNY^Y( M\'*UWQ6+&P,QEA!EDID,89R3-&U:M1*)6UUQ'*JMR)ESLZB;W+NKC1W %\D' M!_%PF< !9/*#39D6[H+0S=DO7MX;B4-Z.Y$;DF\_H6N0N30S>7>@6ARIKO$- M*V?/D'5%TD+1/ U9"V9-&:N[M\W]Q6"-[L M=^YU3)= MP1Y=<;O1>T6((_MK&OH80&%(KKMX9>K;1 ,:,ZYN[M+XDQ9ZQC-MU@)16NY S8:)M(UUBZ,D*#D#N-<1C&E#)"Y^LXIL17,5NY)Q#>?2J*W5\W MY?[>#NS#JW\RU9G$&G$.4V') C(GS=C2W.]-@E8-*B$!S5+#!#$N+>24"2-3 MF.<#7I,:95$"3!FFWISW#\.VI94-1W573^K <5]^N,-=& MYT(0/S&]"V+2)=T+QU<'_7-W!._D:K;=5@\7TEQ*#C,HL,Z 27-!,*P'H6M81.;\ MA,N#M-CJ])"3=I+4D=[BS?H7MVVYJ6=3 MVU_7Y8=ML?GLM._5^GZ_LS^V%"U7R^K0R3G8^BU$+NW ,H9I2>RH(YQIB[D> M<4!*W4FP0H/$ "$ ,&""RX\3T_O1:+@4+L;U2^MZE-GVD_[O_?+S;.7*_>K7 M##.:2FTXQ8)GT!T NDQ.8.""I]0\70+*4@S"J@K)Z4XA40 )FWD!))@H^PL M-K+..U!)<4+E68'2C;26M2?1^?*L.G%4G0'R?M T4#W)4[1,TQ*VG M#8^K1P(PTCJ)7:[M-'TY6[U:;W>;ZG'=*F6&$J,\U1G-#629@MJ89A5>*>SW MTL2E-CB1.@68DBQ3F(!4V'\;+C2V_]'0@,C25CS.A8*PTE9SWF]FZ^VM';!\O7AG4ZOEW-W" MQS3RPF,'+$83^\V.Z6HXL/N=!JDSHB1()KP3-O)7,:AR0C+ MLT9)L-1>TM^N1:%$1K@U#$.!#99,:@*H$(81JV<@]IG ([AD8=$EVR,\/SD/ MQ&X[G1Z>6#\!=G":,W=?7R1'F"^27]^--(-N1=D5@0U+^324,[!-9;HVB)@ &:G(51!+'F\(!B,G;:B].N[]YMJ0^3K-RHH-36$T P: M(@30DG-TS L,]WO;\4HSJX=N,B2].M?WOTE M:=BLW;STG?WY7I;;HJ%=E>SWF^6 MVR,X2'.%@*10,J,H8 "KXXC32$,?X0H$B:4J%\!(M_*%4ZB9LKDEM_F)$JE[ M-R&RR*F'LTB7/%2Z]_&(_>6V 9]8:]=S;P43+?<%1^>9,^=G1[\QJXVO$8 MN]+S$)1/0SM#&W6Y*#T<9][:5QY)J=% M,NZUG>+7&HC7SW8G9A8];'DDC3U9J>/$,%F R'%N4ES MG8O4RAX5><9%/: ,TMQK.?-:.T!9<<4ZDU)!;+\6Q#UIE>8RY8!0&7MO^#", M8'\A:LU;=R&*05DH(8(3$B+828A\V9VN$'E;TD*(NK'31XA0LS9O(WN&<4H9 M8P;%@[#"/47 MHM:\=1>B&)2%$B(T(2%"G83(E]WI"I&W)2V$J!L[_LOY3]PO;[:J9 MHYS=5R][OEZNB^K]SAML[$PQ9P!;"I&=CFAV+ 4SAJ7=TJ:N8)0=^@)D6!H& M<4XRFT!"YF2!,R:AB#W).Q^D3]_:]"(Y'5 XVI$TAB1_=Z8DE2V=-PMB^=%W M&V$"+NPNL?&\%WDKHAOKK38I(CMT8JH>W=R+&QN#\-PV/APNS9--<;U'=^>Q9SM.#WG9Z/ RS?D)[P&3%]*F[ M6X<5SHOT7%'$_I1.0^H"V%&&[FR>XC2?EWOW[/S'M^5JZ8KICI?"9C UU @( M&-4XPP;F#!NB9:[<>R&\[0F%*RTX]!D4F1V1*2:0"BH$$B)/E<:*Q[SS^ 0J M:5"-=N'Q98*NC:#^K$YD" 4PY/$8"L5-VT'TBYUDKMV,<[FS"0:_OU^Y@Q$V MMS@\"R;W=_N5_?/G0M_>%O-===IUZ7Y^N'W4W9ZBC18@!S(3/.4$DGJ@Y0+F M7F]/]H3"C=ZMSU3XDS,#ZG<#DY,) MR<&&Y&1$MWN38[NOG4Y.R'-^6AK=:5%4MQ_=5Y1Y(#].0[V',K8<9:QXIE*+ M_[NO7[XUY>;GXO>S.+0IU_;+^:%TI"JODX"X*[- !CE14 $LP%$U""# :^[G MU3)".M4"2< R@!7,A,TDD6)&4J#<:;W8\\$3V.2VW"06;G*>CCT W*GJ-[ C M6J:YH_G ,_,-27^^JB=8N2)1O4B=TVQPQ!1+@R&6)ISC,C1#-8*&%>9[#: MM:@4D51ID&M#;&Y*&=$99BFU^:H!/(M]!.LL%3BB3 XP$X?S99I[)F-A>/9= M:QR*XL[+CI?8':D4I15SK=8C0S _#6D+;-/%5X M.DQC8SFIG91.P#]^VAK)-5'4MANY5^0WLK>FH<>QC2P''0&Q%;L^CB9S0DB& M) $VBEA(6@#6R$&60:\:D^X@K/ H]\*5<&7$-HJE0J"<"RYQEN54356U.\VZ MX[DJEG)'\-) VCW*)+\KP4'UV]-GWZN"^YK96\,[\=K^Q:35W+5;+'Y=6ZKK M;:R_[I<+5Z_X:GT (XK;Y6^?T7J MZZZ'2(?P9;OH,3$W^L6.83PXK<+BURV.D@[HU&G$C"$-#E5DW)7KUJM(Y;HZ MS?+;[\J[8O%[./BQ7R]W7&RXUR0%$U8T&&<,YK/8Y9F&#NCM5NJDSRQ_F M->!D5:-<%ML_OTC6Y?JE.V1:K'W?\.E'=LNEGL%8]ES-:4@G(4/NT=S>S2KG0L\UZN?ZXY?/Y05*+A1W6 MR_ER=^-6:H3F/.>,4D@!52QMAA=%F?33LA8-ZE1F F@!"#684FRGZQD!G E, M!$"IURFJ3H)VABE9'$#Y)J#]66V;8 Y*IV\">0"7-.B2'\ZIK0'^>>C4\#G& MKJ9^P>B>AI*%-.B;U"TP5VTU[=W^P[;X[[W-,O3GZF!$<_"80NE*00Q,;2-( M&$!):C)%;&,,YK#M(='.GQ]OI)T@)0=,HQVDOT3.E4'5F\]I#*7^9I2!^UFO M87,XI6FX<3<1"B4045*Z)3?1-*4YHCYK6IT:B+Q*]7C@=#N\WHVZ3FH3GK5^ M2C/.P?&G2&FO,'X<3E)=/$VXKBQ=^/ \.KC9V$Y4G5.LZZ,U@DCDF-G_8VVD MI,RV9:5,($DRK]ORN[4065>.1^%.L Y/693KE[.S[U4+5E;3#Q?O=2A0[\AO M.^V)3ZV?^,1@->81Q(?$71&H?D1/0Z%ZVO#T*<1>C+0^AGAJ95]JWE:&0A H>\:_&FY M*K:[+T@+S-^BG._=WZQVGZ?!XP-(T?E\%":.*>3@SRL#=R+.&NOBP>[7>[C;[8\8M3*8S2HB 2BEF4IUI5:\* M<(&HU^4;'3X^NB1_V"4G2)UFX%U(:Y>11N;+5X:]J(I3#OP-(=>*>[NS-XW4 ML(\!CPMO^W+134%^GMT5]5D^P! W0B(&J<#0""VA;IIS3\)TUQ&/1H95DQ>) M@]9Q$MR=R"[:$HG#7@K3EKX!E.9$3VN]Z<#H%%6GBQE7M:,AF?M6YJZ<]>.]%\TMY+VMF/G E(:$\#RF = MI5\UG/W+AVDS5!G!D "L :5 JJSIK4\A5[7+W9M8^B:N*KLHLO26&<2V\UA MA^#/3W [43=(A5S-C4>1G"^;TYB^]K;BF5*Y;JST4)UZLHR)H28'6!*=8P8R MPB%IVD. Y#UUIV4KXRA/IP6T'E1V5I\(+ ;1GU&6T"[RXZ=!GIQ.5H5\[7A> MASHQTU&)FJN;!*$*\PQBJWN& ,X!.*I>1KTN,NW6PL *U$MSVI+626\B\-53 M:\:Y(NA)6MI+C">-DY077QNN2TLG1CK*RNOC+0TXS220:2H9RPU.-1&LR:C0R=WG2_XJ8[CYW$)@Z%??6F#7M#:,[K%I?&]"9TDLK3P8SKXM.5 ME];ZLROG__A4KBQ-6_W?^^7NZ\_EKJB^^^Y^M=S)PB4/[(JE^E%2 7R1G#JHP#ZR"GH1>4\=8OIF( M:D8S[[&:QN6QMW1?K;;7QJ*.WWV6;Q MIGIS;JN_%)OY".;*F-V"2>XW# 3@1LQ M;CCX+S\X_,FYC0\.S'[XFIS_7FUH4EGZ(JEM?9&<6?LB:>Q-:H.38S>J3!XX M[@SCQVOA:F(]:2)1;FJL/ Z.4\/7OL+G[::X/P#ZQ4Z6EIL*;GGKRHJ,]<-K MV^QZ6YBBV-YD3 *A! ?*()P!H#+07 ZC($+MRWX"MADYIIV0VMG)$:J[*&#E M:MU<3TU6![C);>%UY"XD\=>CU)B<^T69,[I_>4AW55KH@"8UTL2,1[='!=)( MM'?EQ7%RH?CR#^ M5.P^E8NW=EZY=G% M$3LL-=B.%R/O/FW*_<=/R5T#-JE=[*.1D5W3(DI-QRM^@:MY^>0,^(O3$>CD M@/U% FX['NL6\N)YK%PA[<7@I-@[CF F$RX$,+0?O]#ZS MN(/8VYA]HVA.%)509CP7F4XE([CY=*9$UGZ6UOXS8X>[.BFU,RR?C-^#DS83 MJ#AT>$Z0:B9,-"9\YC9Q&.DX=VG!3,MIR=&LB],.?\,GH)-=4)?]W.VA8#\M MU\N[_9V<;3^Y8[VRM H[6^]N4I@CPIFA6AG%),^M8#9-97G>7LZZ-A!9VVI8 MR=SB>I$LW$'U>0W-8X1W9J^%\ U!G)\*-IS)BK/J<+\9+8MJ7H@DH:V\3RH!=QFOMOYP7Q6)[WHXLUXLJHW6Y:X6$WY5[VSZ& M*!.IH "1E$,H,3XM!4EM6AT3"=]J]/7_ ]:'POS"?G7$F]S5(VE6(?9:D@Y) M?ZL]@)&8]]T%J$E_H$I53=*1]$:^^+BD>^T$C$1^U[V 8$YHNQO0GI_+^P$1 M.)Y @(EC5QF[=WJ$HK.V#HW(V?UR-UM5I;L/XJ 1Q,!,Z@QF#%*FJ-)-79G6 M'+FT^+_;59>3E M[6_EYA^WI>V'-PAP027E-(< 8,52E"%)[&Q+F%1QT.K)F.Z?'CEX'#&Y,H[? M&U1>6XU=*&NUUQN9+=\MW#.B?AN,**^MULB$==U!]2*N[9;HM[9>WNGLP:/7.W?^8^].\[ZYU7?WJ_*KJQ8"DF9082Z-ACFCF71? MDQS*G*=:@%9+1'T^/[*4'@"Y7EXTD-K)0R_.KBOI4'3Y:>D!47(B3#]+V!/U M_-NFH'];S/_RL?S\HS7V4,MOOWA$]1(4L*!H0J1 MC#"()".2,$&11KD27B\'Q$426Y&*WY,3MN0A?-OWDH,!R7+]\-=J&[H]21K9 M=]?U;GIN\U/&V!Z+UW2N=I)C"46B.5 9H1R9HVF0TZ?KK,3NRUTZ&XA/73WY&N@WS25JNZ$X_&J>A M-SUM*$-V+,\7HFI T-GB^&QW9:>WT;T+^\A/*?JX:Z?;/?FQ?T=^!W#@-H1[*V,=O M4@_)<>Q%S]?'FPNI4 # % II3&9R3G*%:EQ$L=3KJO;X:*:^^/FZZQ6I S@R M[BIH'!\.O!+:QGV36@Y]W>(RU^$\.HWX,*"]@99&NS+=K@QVMK4M+]Q_W*3D M\VSE\-CO_#3;_*.H0M>[8K[?+'?+8GN#D4JI,=(HGD&5$F4(.0)(/=YA"]ML M[')8BS*QV*HC(?L4:8;UP'4='YE\/\$^\EY]H1_Q?@*; MO)L [SX%LJ/QW[%(-J ?6M;)^C!TL58V"LT3*-^*9%@9O8OZS5[D_FZ_LCWU MM(_*DJ*"[PJBUS8)GI_3V_IC>VK3WOC+ _=:L-L%OFA+38^WF M)Q-QEF><._E)'_WTS6SES$]OCW[BS_DIRGRD.\M7)B(#N&X:,Y A#"T''Q9^ MVBYFV^76MG*"4*Z6\Z^'?[\OONR$9>P?-X!Q +4&!C%"LXRF-KYP+9!,#0$I M]7JQHF63VCTZAC'GFC"<@U4]=CXR>(+K;U1R\Y._U?QW.I (Z\,I.._:NJ&9@^J>AD*&-*J-V63_E M^W5;O+G5V]WR;K9SU!.)OO?EON/LG]=E?>%9O'LH6 (H*G4J16 MOX3$JH2@@9K\;K$F#=CQ]O%*TO8VDV-W]K.OCU NB%:6!W7'&M T@S;1$.;.M^@BB$O$>W2 M/C3:9" WV B$"9!,8P(ALY/NU.E+]-==W2MK+\4WCR^%>%.K)_'M-'5LSOV$ M]=);5\T35M4^RQ%S4H&>3,+8@>HKJAO3<=.0WJ@6MGHF*B2;K8H,[$Q[LR\6 M^HN#4#Q6_9SIC$)*8&JDEADP!H!FR-M97ZM%OA;-:$%,:K(4Y!G$6F'."-(F MQ[G.%;'-Q]Z,L;^VG,]6R?N-N]3?C>BWFV+>?/?=;K_XFE06S%8^V]@]N6U1 M+C -*:F!>2AB<1X_M_^'X[+;=WX?7=MO[5QFXM)T?AK8);-\',J0, MWJ5\'_%;-@UN'[>H;&.IU$KF0*=2H10;U0P7R'P?[KO<#I2:9P:*/#<*8T#R MG&BFM+6)804DB*SI-;KDIYG]RTL_W>[+8 OA'I \/^5N>&N0]93NOE3ZOJXW M#*4]7M3K2JW'*WH7.;@DWX&8FX!^A[+DFQ?R0K$3X'C(TSMBBDNT[)/2U]Z0!! ML ,=':EOMRXR*NM^0>+J<8WI[)?Y,GIE[2.:S6RY M^=MLM2]^*F;;_>'1TZ?;-P 2!AD6G(J<8)8CV_QA<+-< B]=;=]JABGA.L<9 ME01CK'-.-#],0R,CV%7&[L&>U]W,-FLKR]NWQ:9:G>8?MM6^X T&FG&%,LP!3FVS MAMM4!Z0Y52J5G+3=^;GX^2J7*<0Y-U;I,2:950' 664 6 3JXA7\#607-UV M4H%*_M[ &OKJE@OL7!EJO0F=QLCJ;\;C.US"\-)UW)S&:9KSE$N8J93DF9T7 M9MB(9N!P1(#755$76X$I4@I+X$Z@8F5XGF.MH2:2:&,GH?$O'MTEK\OMV1CR MO">J.WW=="<.<_V%9[2P?Y$@#^WQ)W6:XM/!CF?4IRLSK6^1^CQ;KMRQ/U-N MWLW.3_\==8^RG$(#-$ V@'.NL629S1\R++*4BNRY!WL\6F*&90Q0B!&5UE(J MF(0(IU1#EFIK?+P153T&[>_N9INOK@S_ MW:=RLWOYOMC<):_6GXOMKL.*;GS?M)//2;G%3UP;Z-5AK6]U]80_>6A ?4?Y MB"5P/3F_5@\WE#NGH=K#F?NX4FY8GMLJOLLWU'([7Y5NK>887K(4$B,-X:Z$ M0UB90$(>YBP:,E^N/+H"[1D^#4B*<&2J9X@@1FJF,8=., MD]10KS+^IUO0--<@RSA2P+AW:CC'*8-0I%B3-#5>8Z5#$E/E+*_+F6=E?D>V MVJE*?*+\1,7A>;ES1%7R,MX*R)/$7!&5?D1.0U-ZVE"&[%J>H?N'M7;#XOY\73AW/XJG*>.Z9S M6Q]D_J?%6EW+4QEP>"D)(:P038V=;M!4$,5S.^.HY85@['7#61R$0$*46_55 M*5,8*,HYR5+,+%:%"&*Q,Z/SQ83&K*2V*[E\X.YDG/N+)_.:.[J_6\O"N. M[VF]KI%4[V@!Q)6=8:;2( -5YE8":"U9/$T)](E=5]NA*<9882K2'$.,A,BU MX:DP7$JJ)8L<@0[0DB.VI '7Z=V]7H2VBP%#<>FGY)UIC*+"5SBZHJ4AF)V& M(@:QI S?[X*H4_T.ER(\);DBKBV@*202Z68X20.\"JJ>:C@O6#\BE6;&F#Q%N6)DM_N_>JX@M@ANN M2^*X'@@DC"^3(];CGM:S(AF;=X_++$;CO]O5%F']T.ZN"Q^*G@A#\6B>P#T8 M<>PJ8W=0O[S[K\7:-K:R$9$O[I;KI=LJK-[1>! 4+7< $-WP[''#%T17YQDP M#&DI&7?'6X@ NDI'6&JD0*)U-N[;+LSMT$]S 3*(&0$Y)-I.03(,.!0YCEU< M<%G^@F;DH9W1(BQE?/^&X823.0<69G>\JDQ#:JLT:<.,B,3TAJV626 M*L4@-@C"')-4<8QUBH!(#% -XL.@U\BTDKXJYH;V#FIR&IH8UZ?*-)#,Y:K3>=:IJKIK=NR7_S MN5B8+7=[MTTXM%Q>R: R67&.%/NH@PB"$;U6=4RQX1/-% MBW6G*;C!,SEN3IB\N3U(Z/;D!_.M'WPN*1G0-1Z+4E-P4;?5*4]7]5R5ZLC3 MI>6IV+1/8)TJNHGE@-VXZ^G0IT-O)?"'!]NV?+Y;?E[NOCX"EJ>8,TI3Q7+) M-<\0TZP9X]SDK1[;"0@'V@23$*$$!)48((A44N2"G] YZ[5,$ MAF9U+Z>80)X2A&E&&4BEH9DKG4VUK8E'4>AH4G+>=Z88DKH[Q3,\#>#]Z8:J(8QO$;8&\\%H]]F<[I]C M*1",$YLT0^;NX3?-"R ZMQ:,>Z?-V7.2B"*CH=:N##6E.30*X307E"D&\]B! M[; K(K[)JD>^BZ:]$WV#T93]USTN1;J39@J!*K##6L6LL3K)U,+7:#S$OJJF MHV=:;\*O=\O%GYW^'"]L8 MM&(CC2%I*A&'R$"9VBD=I90;DZ5>UWP,ARKVM.C"FL^ELM7MU;K5OA=\1G=Q MF.VC<;P;9C$ODF-'V5=J[8<>VTOA?3V-B#."W9Z;3;&8;SVWJ1JP?Z6Z4(]E M@%"),@8S"MT9AU21I@TJ)/&:HWA]7?MZ* MDS-&8/1:^CBF Z>AX.-2\#BI'-\?WH>O3[O3S65EG#-FC!(R3ZE66"C)=N>S'C4A6\Y <+T'=SK">C[41I.#+]A.DJC^/= M?GR9JRLB%8;C:0A5(%N^O>LX&$/!9MZ7&<&:@R?>P?O3/,T9\EOL^,/)Q7IZ'S M0QKL.]L.S77TB%%7B;_9[[:[V7JQ7'_\I5RM3+EQ/[PQF6*:8#;=.XTLQ_+;Y$#QG N&SB(O#B= SHS+OF[,R^I M[?M>@LM5)\4(.&%ZQ7<>A *1$"HPA?3)",'J(+\W($-: (A,)I@@6G(@08T3 M2(S)S7U5(OYN-]OL!H]6+3'ZJ-YC<[J'JQ?)A^+C&"IF_=7^XF[[ M:GTXJW230Q@)VM 3JA=)!=!*UVC!R-=YPT2B MB'X;+PP=C')GO YFV5A4[%QOL"GI;;%T]VY=GF)/,BX]=%/$H-2Q/_PQ(E)7 MXP.'HUX^:!V+W$:4NWVN6*CJ^9A#:Q6P[?G=#_I+L9DO+=(;I#67(,,&9@)J MDVK%=0,D)1F]61 "MU"D_J-,YUCYQY8BN1V2)X(J6T6,D'XP> M(1I[SH+$P '!F_EKHA_/C1,1]H@&/A;OV%P.-5DXRW7X>J&_W"\WU2>< @O6 MAAJ..$VER!1$=I9#&MR:05\]'QWO&/(OW;UMJV+QX^T!OOVJ<-#'G&D$\/PP MDX^!7#YZM#FS\W"YW\G2T>)/;-=%G*.$ZS83B6[3X2/P3":TI\;;')(@IX0) M8C#(@+:!7I&FX@) :52].:37 T5+?X3^6T.-,7WB8W'8">JX*S1)Z1MWCZ"M MF_\8TM;#_NA[!'Z>&$&Z?BN6'S_9C)2[QS$_%LV$Y>UF.2_X=TM!WO8-X??$M\ M#,=/9,_\V)EJVX\+54EE??)W_L&]>3O??;_U82V].TQ0#=W5_G!1-SA!\<)R M'%].+&[? )9J9')&!&::T!3J%#?H4\+4J%5JO9 /4KOV3+0^KV3[X!X:GQ]N M_US8_C/;G-T).EXE6[_>,:E@'K1+?!\1_ \9ML>/U:U[TK]4@&[/RCA1V=-K M\>^<>K( XZH%,A@YE@]W3%]MY@H?E8N-7* M"*K=+@:+T>%UBQ$#] M1.WE'RU6>_DU9KB.T\'^(!$[$CFA@W9,'TZF&/6J38RFU'"H,YVE&A #K3V- M30*JL)/L42T9.ZH_4\XZ]C)XY&XTD:K7P7K0Q"MBO[>L(*;?QRRG#=(?OY.< M81I<#5V&&]##4]LOQQ1QHG)M=,JPQ:YS)&KTR'!A1BS<[85[@'+>9[.%NKBW MXT;Y)$7Z^]GQ;-M!_AC"&YR5D78\_;P674P/;X^\6F]WFWTU%WVS^U1LWG^: MK6N[?B[7GXNMM>;\1B\B(<*I,2D"7"H"*6;-VC"R_TL'F8_%@1YY G8Z(>$N M^AYH\A3)R9%G2^/[=_#I4?T2T)G-265TLK-6GR9/1\.;.[:.SU5NO\]+)#NY M.D8(CMOGOO-(')F<4 %Y"!].*"[7AY&P@HP:D N:88)-E@F1-OB!S(8L"PZ. M?9#"X%H_SP\J#G^ /[S;)Q.D(_CZNXG/?[@P'._<:[0.]2\3?'UY&3[N=O+< M^"'WT;5L*B4T!U@I#(PD % .8 ,_Y89-8Q+L"3KR]+<.LA\W8]W%&=S)8\?7 MB/Z=:GA]7.C[1XFN\>_XC-6;_NBQM2LM@X767GX;/[+^K4H+3G<"I<@PC0TQ M@DAN,P&.FCN!$%3H>"_=^RD$6$_LK03XX1UU[SO'V4.ZY93R,"V>8L#U]?W8 M 3>&OR<>F/'G"[TC)8P.WEM_$#KFFJ.X\69)CG M*,LU! :0-,=:L*9L&"&FU*1BKC_\0@H0;A[M_JCQ^$>S P6BOMZ;_QH_'AA7$I,(>0&ICD'F@JMCK=B9 (@ M/%C):G#D Q2M=MS'_Y"0GFHU+;:AE4V>3= MS):;O\U6^^*\Q(<2@Z5!)L?65"5)ADBS*IJE4@QSBG DVX8^5UCM\"4+"S>Y MM7B3SP[P5&8^D;K/V+.C\7O.5&=09P4YWYPHK-A)'#V)XR>I"/K^[MF-TSO& MS2NB].-_F>PC#GO#YR@1>\'WE,G<0)43HP!!D(A<:$(U0T?33"XF6>';WZQ! MBG_%MY?^[K>+X:\Y&+2_?#_Y2M!.\H=)4O[U,I.)IR.MN^G_GX/X4S;!Q,/3 MW^-G&U>O?WS"OERA5.24 9BG# &=8M&\<)3)E$ZRQ+F_59'72HXW&T\SPPC> M1\9.,\;L'E/--5KO(1C;>1JKE#>W[\-.1A\=SS M]J4R)PSD'#&)H$B5 5GSOGK&,5332$-"6Q4Y#3F[OWF:B4CP7C)V(C)F!YEJ M(O*XM/Q?+1'Q[!,3J%$/UV__Z(E(--Y&JG(/[?GQ$Y&S>S&?-PZE($4 :,H- MHCJC0N:-<1AEU$PC"PEJ4N04Y-IET]/,2<)VF+$3DM'ZRE2SD3-"_M42$9^^ M,&:1?MC.^D=/0>*0-G1I?PR?CY]\>.PS<6,TS)GDC!F-!+=Y57,Y'592ZPD> M".AOU !G!?2C^ZM;)AW?F;3_GS3\5BORK> MW!Y;XMMML=MRJQ_+V8?E:KE;%MN?BMG61I[%F_4OQ7R_V5BEL,8NM^]G'U;% M^^++3EAG_^-&9YD$&68&2BPY4 )C34":4Z4)P8AX30N#(I-I9F?A3"/* *9" ML5QE3!$AM"#,B-@+S&?5U/^UM![>S#]]3>Q,+SF85#W[DX&A_5VRSG=9!WM.36K[7 74)]\]N)9%W_KU.3OE5&)LRJIS!JZ M\CZD2ZX%TE%@MV) M#-L@ICP>A>'X:3NH?BYVKJFWF_+S9&<;$E.QHPF MNV%\<$6@!W;R-*1\:*/+40>6=WAXM9Z7=\7KIDT; M(-? :[O7[Y,CB[73AI7%,?AP/E%P?51VH&HR@ZL+]F_'2&<&VG9UOOB_^^VN M6IY[7]KIC;5ON2H>M/R^;#E2CZ.2TLP@0)E4F-,4YQE#M(&JB 0^(V84@)$' MWIE-R:Y,-HU5R;H>D>Z[[NNYB]S[0[!.RMZYU3C.;I=I3=[/?GG7(QLTPI@AEF0J;V*YFBIFF1Y5['"8(T&#GNG&.L MEN1G9^"2XHO;W?.\FRD,S^U"Q. 4^TG^.;P7R1%@1?0YQ&$ENPUI5R0X*.?3 MD-2P)I41^VB( J4;;!A6%.20XAPCA%'*\[HQJ C#_:N5GVTBLJR]VY7S?]3E MGO,S7"%JA9^GKT_M;E#FPM323J'6R;OZJ#6/TU"@OD:TJM#QY*3U@L%\OCF( MVIFBO;E5R^V\W*^KK=.WF^)NN;_;OJK*>ZIT\48::C@G7%(N48Z,)$(V8 @V MO'E5H.6B0!P0K4;;P[9O<'T"Z*HCE"><+-_?WG-E'\DK+N?N( M[N@V.V\ )S^<0_ZS\\D1=96X-;A?)&?(!YYT=V+WVK0ZKKNFH;&QC7P\-1Z" MT[8:715:/K654F^O'W?<;QC+H%$8028P@! IF/.F?4&UUPPX7*NQ-ZD=4#]] M#"=,0QLCV%7&[KY^"OAJ M;>789L2J./SW; E2SNZ7N]GJN/XH%13$&)EI99@AFF=Y>DR3[?]])#!@LY$U M4'YRY?N/MI5.M;JK4_7CO_DI94CFVTGE2*3[:64#,OFA@?EG1_Y)/&NHHVWM MM&?QBF!&<,4T%#.&867T;MQ7,VU2VR2OE:#_4LR+Y6=7];R]86EJ-, Z$P) M)G/!C&HP@#3#?A/ZL&U'G\>[FB3GB8-8EE4>M#D![*N8O7CO*IK1"0^IFPW8 MBO]#'OI+"_X'4LXK5'J)9PB73%4_@]CVK(2&8["[BMIY__ULN="'[=4;R@F@ MRF2$496S+(72-.*-= YD7^'T;"ZZ5M9XDCO[5S?+V:JW.OKRV5408Q 94@,; M8O4S^_8#B=Y#NKQTKB/34Y6VKN8\JV:]>.HQ=7XXF:]FB3>9(8A0R;6A.5*$ MF2QM#N8@#F"79Z(#M=Q!T3J\\-R,OKIJYCP3/,RC>T^;.['>>F@T^7' M*X[7F1YJHOP$=WZ3Y#[D3U4%^QGU_.2X/V?])\9O9U]=+GD#M%U1*1_:[&KUYNYU_T!3ZC9;FLR^\YP8_ 8=E;[]AEF!Y['UG Z MS5U]R9ZJG'6VI_4M>*!V6YJ[:-Q##032PP9K48*Q;#8U M?UON/LG]=E?>%9L&Q]<;HT N,ZB T5 #KIF1S?%S) 40_?2R7]NQ:V5J<"'3 MQ)YD=U7-X7@.(IQ'YG^W>),&\(NC?GX=6SVO\NDEH&$\,U4-#63=LS(:DL7N M2JJ*VV*S>:CBB#! &62(YP82:)!&C8IG(D->+ZB&:3&R:C:0DHV[P>^T.Q)0 M1#OQW%4Z8U,<1#"/I$\HPWR"."]E[$/\5/6PETW/JF!_QL)?I'@#-",J YAK M Y!(B4EQLZR9F5S2FUVYFZW:"6# 9KU4\(BP]3C].?PM/B$Y;R>&(]'MIX@= M;CJ9^&@ :VJ8S94SWE;U/.BV*Q-=;F=[-5 M\=-LM]\L=U_Y>B'+U:J8'Z[4J!#M'B%BF:(\!08R03()#82D6=W VN1>JZLQ M<43.@QW<0R7ZW0'T,J!BQG1/2QV=B&<\U;5&G;C!G#C<+Y(&>>6K$W;GJTD( M;W>BK\GQ .Z;B$@/8>ECZ1Z,W<[YK(5H<^G=U[=V?.PL+O="Y'UU"PC &<^) M4D@@+('A@A[?<< ,LJQG4MN]X6$SV_L:9R4+10.R9V;;@_6.Z6UDNH/EN W. M%TF%]$5%NWZ6]F%RW8LD^B2\_3TQ$4&-8-ASJ6\H[CK+Y:OUSO;@Y8=5_2KA MC6V'PI28+(>,,"2$@DW9+(:8ZIXJZ=U>='&L@&V736JT/ +L.]OWI[:C%,;A M-)@"GN"-BJF6:YGZWG[[2FDH#19AE(@!-540R.:[2F<,^IUI>5 D"(OC![A MAA;5X*[I);AC>B6H&)_\]=T5"'CZP%_*8SEYTC(?S>AV(2 NYUUVR%YMMWL+ MJ7AS*\N[NW)=/8)SDY.<(:HH9! 8RC3/09/($Z'\7M[LWUID47^XL;*L(;J% M@GD%,MDZE!U>TPC L_^&5GR*^VQ;O3IC]X OJ0".MR_U)%\M=Y_Z<3T-H0QH MSY6=I!!,=2H <.V\N:]457\I-O.EU>&;5$!D4(I2;G(KI+FAF6[:)51X/5?1 MO[5!Y:VH83V6MZ0\P.ZQF=^-Z@Y;]M%9[K4Q7[%9PTN.^$;<>'^*KK;;Z[VH MGI[ ];3GVE9Y *;:"MPOQ7V]%/OFMKJ_[G6Y_NB*JU3Q87>3*@J @AR9W$A MH("*N#858I(9!OUV=_JU%7_;>[.T^?3];)4T,-TC:/4)48OT4 !3?E@M/\XZ MZ%M/IMMIVP 4=]*U$RX7+ YW9KX^M7*5Z[,Z?'^?&-849PDHN4$813C% .F]I0DNIV+XH%:FK0_&Q> MO]^RJDYEWS8@V\E6*&ZOZ]8(M'9,R!RXXXLX%;S3BN"PC"[*^=X-L,.3JA-B M]@&P@1A^%!V>AMI:!T1]\ZFNK&4)#-G]:N MF$8F',.PSILXGMRU54O7NJN[M_]Q5:.?9RN7H[\M-LMR\?BZEANL00XE$ A2 MRA4A69:)!@+ F?#1RZ -#Z"8R^8:(RN8E7JZ"NSJB^($WT\UPW+?3C='H]U/ M.67#V2#\7'Y7KM\B!WL*AJ(H20>CN@CX+&9#V8=,Y<.GI F50PIZ"8CYCS MELJNS$]9(SO;U$H<^S$65A4A%8IA2"%WKZBG0*9I4YU*7:Y;JZ)>M]Q,"M.J MOR8V ,,H8N'N('U6"[_C0=K6 =_3(&UM4Z=!ZL=8VT'Z;G]_ORJJU=F5 V!6 MY>^OUK?EYJY:K3U6"0HH;0U6+&[*W%K:=#!YQ^Z4LP8AOE[2,P;E?VO* [DH<'<;D#.1HY=,M MR;LBBJ'IGX8L!K>JC-MI?2]+MZ)1;'=O9\O%#6(YS*F6&@% #!14Y,TMFU0; MFG5Z0];C\SM4N71X*;:!E+CW8GVO//=AJYUHA6>HXP7F-2L.QPNW\+3:+]P4 MJM[56OZS<,M1AU]Z<79]K\ONQC^K=\[B%8GJ1/8T=*@;]&_N)N]LO\?S"^5= M\7[VI=A6K5"9I<:X)QXDSX1[%OMXT3EE0I!N#U-[-3&4KCA4R<[!ZJ0MGKRU ME9<(7'5](L'Q4T&I5&;PAQ#.B;@J$MTHFXI.=$3_[3,&/5AH7<=@C;))S^E( M[WIQW!9\M2ON3D>X##69!@(3;BC4*);I.+)/M0T5SO&.OK9E\%J!0W O3$,/ M(]CUN+PA$G.>&OIF\W:VV=5_.+NIR2R_%(O#Q3+U?3,+<*-(IAC2C! )F*(D M1\<'%1A2*.N@ID';CZRK/S?B.7MXHU6("_^BN,-+24?S1#=-+3>)PYLT?SY# M_"*I,->783779 V<.79@]7F=C>*C22EN' N?UMZ(;+;>9' 'USZ5*TONUNUP M[+[^7.X*=18*'>Q+-?V>[$SV3.@_RLY0/7<3 A'<,OMA%&X]=Q0>(+6 MQ,%,3CB3OSND205UZ$V%MA1>VU8([H9IR&0$NQYO+41BKOU2X/%*:_<(X@=W M:^M/L\T_BMWLPZHX('I7S.N+\=WNL,V]9LOU^\W,+3T?=/LIN*[ +4L9H5SE MB@#(E$HMSDP* ].,>=T[$ TDRFF*4@2D2 %&$+(\-]P(Y XR4YH/\P97AX<% MQO-:VQ7-[\!AODNC1Y,.K\9^.+S0>S*KD?:38DGVRD+*[WGOU/=^+)Z,!@5EYHB M"JC0VDZ:M=#U8-12,^:U*AP8FN ZA5@@G*D4IYPQ U*!(:$22DU0].6+VAJW M2&SM24Y@DX<6'0XE'&QRN=R#7VS,\ESX&-C)+5='INM?SR64H*ZUTE[EZ^,M MN03UR[5UF7$ZP#1"R%C&/U[A&=,';8/4F\W'V7KYSZJ<59;K;;E:+@ZUK>O% M6SLPFUM3WMS6VZ:SU3O[G0/XIW)^R=),YM+&48W37$(,,E3GC*F=#VB?,!4< M',AIQGC.M4$$2T)%1IFB6"O%-31Y[)O5Q6R[K.X9.P=?*=>[_=W=;/.U>M-P M^7&]O%W.9^O= Q6SQL^]ZT6&=V^[ #5IS_J%J'-3JFO73\94KGW@:^O?HT') MR:)I+ F%=LJ5^#2:_Z<1H<8SOYS(./3=OZW;/,/QMCQL(Q\+>)1464HQE0AC MHVDNB-8,06:8 :(MO>,!VDKYJ9B#>^AEC0(QSNBU(*VJQN) 5F?QB /:](W MVX?!^6I]K/ITN?G;V>;-IH*RJ%97WA:;=Y]FF^)&8F-(#BB"$/,4.MDZL)=OB8E'=SOI M&YII/^4[?TKAA:M*<\5I!XCU*JX%F50H!SZP_CQM5Y0O).G3$+Z@%CT^JAZ< MK0ZR5S6SY?O=IW+CSM[=*"@S(Q'#&!--LPQJ>!1:8B?J'>7.NYU!9:X2LVTR M.\)+?CA\J[O ^1/K+6Q1.>TC: =@R0G9:"+VF*)VXM69V,F)5G=++HM53W8Z MBY1[D\:V)B13.890(,* :X6CO&[--NOWRF'7-L80IV4%+90PM26SHRA%X+&_ M(+U(#K!&5J,#"!\E\F1SHBKD:\5S"M2)E<[J\V:_V^YF:U29 MX0QF1''1-"FTR7M)D$]#8^A0><(72HR\N.VH2+%H#2%+9]A&UJ8S)#X"U87< MB:I4)U.>DZKN_ RR^7E<9:, I4#;_Z="D\S^D['#D27*$,=RD"VQUF FO@\V MUNIU$/)C[7=Y.W<:*C&PS2%WMCHR[E\9*-WB\(?27=?TN>";C:L$:>I"W(G) M"S]^;[_:NCLDK&%52=,-QU3DR,XG-518 !IJAJ@ $J__YZR[\LMS=9#KF2A(.4DIQ"&RMI MUK0D4]+^;<..GQ\[HC2HDB,LF[Q:8"W#02_JKNOY4*QY"O*8A'F\3#@ <=V> M(^Q 8+LW")^V^(D8$8*?";PVV->",EQOZ26SJKR;+=DK9?H1J OH.P^1V-7X3U\ M;GOI]61IDN+K:\-U^>W$2#L!GJW+V^5/Q=V'8G,#-*<"@BS'F&*H*,(8UI^? MJ923]J+K\ZFQA;;"XJ,-7I2TD=%8;'A*9P4C^?L!B)=:>C'BHY"QF.FHBM>[ M2DO].[/IHN9UL7L*.M<)=]G7XQYZ=EY):;W\:;8M^,=-42T;BK3416^PK82_M/#2VIL'FH40_R6FC[ M,+SY27J-*7G 6!U$^J+!E[2Y/T,3D.0 1I1!>XV' M /]2?-RO''5?W24@-@84&U>%4M>L_+1<%=M=N2ZV-0(%$#$0 @ARC0BDF6*D M0<"5:+_.&[C=R%)]0GNXXN?I9AX_'1< M=GFNV[1<5GE@U\4EE&[63T INR(O^_O>KQS[EV);V-_]9,56%9^+55D]+'56 M1V?G U4Y^/OR;;%QKS^;$AE1+(KD]J,Q/XK.1CR(G&&>%8WA2FV M#4+_$V-Y'/=.HZ1V8)O+,0?48,KCD-7%#E!IB%-FI9"G0&HJ-6M4D6C"J<_9 MCV$015\S"*=!7A53 _LU>D2)Y-+Q(HIGX=;H,>7D@#@QI8.#O_N8TL7F<#&E M,^.MYNUG:+Y9-[!@7R_GQ?K;W46-D=(42813S25A&NLFN!%D_]=Z>A^G^G5@7;A=P-MN=C>_N(!;3=!2=\4TAA 3SJA02)#C M(K@-I1"WB6%^GQA[$N. >!V1\R3D>@B)QX5G]M^&AC9INS7H+&6W?WJ$<2EIBH_:(''6JM;8]S.'&<%> M*PC>M+0SYVL;C.B?UJNEW?[N_KS M,0,: 4:$,3)+&<^PXO7G4YRV']-^GQIY5-=@V@]G3TZ>']#QZ/ ;TC4.[\J3 M[H/Z@>47AG4W=L8?V!UQEWW[AW=DOSZXMJW?*4J$EQSEF$ *I32IHSDZY#/&Z.SQ <\/J4*<*A!"D MMI2D8?GLI4VC;/\_3] UF0K'[D3T*J!!CX4K-%=M%>SM9OEYMBO>KF;S\^T. MP[*4*D0R"0'DF)$TTW5C=FZ6&1_5ZMA$9*6J425'6'XBU96W=L(T &5^8O0- M6V$F5]Z"]#0Q5T2H)Y/3$)Z^1I1!>U?[59?CK>1_+ #67(KN2A)<7'QRW5B1&G6G-HM)24FM1F1REM$B,&@I.*2GO2F;@)ZTM^&,F1G:JERRSLE M?+BX+@>1:/ ;^[_^_.J]5LF[]_R]?M=ES&^+^5\^EI]_K*UQPYXV?W"CGIZ- M^I/%3PSQ#G2,.YZ[ "X[N]YOF>+GH6<@A1 MJ]W;+I\;>>RZ-^.6BVK);_>I2#H,Y4YDM5N0B,63W^!VS]W\^FZDI8\[K;V?DWF]7!>O[+RE.AFK,I-1A1F12NK,IAD-1(.$ MEY(,"BRR% 5\=>X"#>OH=BHX61_[R>C [HWTDFTX5UR1\U$\/HUX M,([IW[RL.QK_[2]"^%RL]X6Q!#9'9W];[C[)_797WA4;_66^VKN'@/EV6]A_ M%N]G7VZ$@01@Q#B@ &5!613W=GZ\G/BDU-V12%B.F :0A#5PF].I\=FL^4# P]TI9AM_VH5 MQ<[';J#,9&ZX 3 5&F9("XR:QKC,6FU<]6PB3TK&Y#&?OF5X^VO0_+F]5C $/QU?2/ G\>VSP)65W<7W,^^=JE>ZDQENYGR,"SZR7*#*7'#(GF M:N@BI@OD7*UCZDOH-)+) '9\4\T4AIF6EQ3=%IM-L:CS5&F_7.[<\]3\XVRY MWN[,?K??%*=KCF\(P3P'F%!EF *","2;5ZMYKG6K"^[BM!Q9KAJ\R>8 .)D? M$2>S ^3DML*B'KC<0A?1'VSN(_&BZE/U&HWL"27$\V\HA.JSO[MFW:RJOE[,/R]5R][7& M]DLQ+S^NE_^T>;R4AB'-M434W?-GC$F/ 53BU.OH9."F8Q?2U$EVG5TG:[K3M^FJFI340" *"'!S MWSW7$'*VMYJ73L>48]E*K)XMF.RN6F7K!D[VRWR9S9JEV6I]^.GI79\T]#J$ M]P,SZR>*';CL_4WV^/74EFV+,&LA#DRK1]0^,+UAYG8#I*5YW=)\]WA0 M_[5G;/XZ&:>B\8@TCB#^CMF:.LU@\XVQ]^;^/EW<5Q.=*TS*0A"&"DBXUAAT M!^%X40KE%T5[?CSY2;&C&?*]0>0;"/N2Y1KJ)N3)-Y@]:/55UJ*YRIK1.7S( M^IB3LT%I('UC"3M#X3\++'OQX'C68&_CZ-C2QVJ]L6+5_-+JU;R>30""0.:X MA( *K+'@AG3'' 2APCU^C&4PL;0< 6J\KD64V3#RQ[?Y];>,+Q;S1MS7UD7? M+V9V>;[)UM5B<95MFA;=-(O%V^D?539=/EAW;5?KV7I;3N/*CK[M(8;V]W:; M:,UK&\VA^]T?:G_KV/E[;=M'ZDZ'>/42/1DN?L='1[/CWMVBO 3'7@E+3XY1$^&0HX2[/*31].8 BB(4D8C MHC57 !^JX H&F5,-ICB6ACXJL#H@W(5^X1O3 ;SZ'P1(2VG/C?\C3-X(P*EY;SFS"]V7(2>4_U@_3Q>;!&KAN MQMK72DS7U>S]\O=JT]3\6T^T$)IRB A$$BNED:;=65E1Y@H[JWQO2ZG7\RV^ MN5VS?VF 95MMWV%M%MW+:KM*]SF%U)]>![$?E%D_L=]!RP[8LA9<]GZ967C9 MI\'Y])#[07D-D_M^_+H)_FLTG!+\:/2-0/#CM:5.,<#\5LJJ^K)YN[2K\G; M?6Y.#$V@(DHRQ DL<M9"2"(3K=MHM1,^HEY)!*3)!Y>8.I,NJ$/K^-(,O1J M01UOE'DE%+YLS'PY75XW%V2?O%^9BSPO$;>R5DI"80XPZ^SE"#&G,O3]K21/ M)-BIL@<7^.9Q'Q*=,@<#\>>;-7B9NK!GBOMPZ)4O&(C+T%R!YW!T31"<;O7I MY$ $ID80)\9I1QU[#/56Z68_QWI_OG]M&&"%#,TISJ56F($"=W:YH3ZWQB)8 MNY!J9SN8&>^M/;[T!NMX0F8CZ?F>U'C*[LMN;X5/R')=0B^F^CL'T3U]RR$W1$"-*3$ %#G-=[60%<$(^^P+1K!V:><@ M8LF7,[U]G4,*9B,[!Q'=.3BS&\LYI& YD7-P8#N"ZO#^>6/H[ M/%D#*.A-4W^ZW-+&29GRDW(ODI)DAI^2<28M',S;.'+"X?#K2.,G7"UV[V@8 M+34S@@N2*QN\,E$:V!DJ2NR46.CQ^6$5(^CUT1#2_%4C 5^]=.,BKXL^)\11 M.SS9&Y]Z^#;@C'X$<>&J(._JY:Q>OEW:N?AENOSC_$C*G$L)M:9+JX#K'P" ( M#<@YTIIUUB" */PXC[N-(3)O!UP]GO(()M%-S8;@+R"_YDO= ,=VWCF\>-&7 MS7$H4N]6G#W"$\J*<]AEO__^9ELDSDROVRM(OTW_G-_>WXIZM:I_S)=?Y?3. M_L[FP0H?E!!KIF#.;!!(H"S1#@+51 &OZ"NFX<3ZM,.5?>F 9=<[9)Z15U2R M'0.P2_'L&8F9PR)F2 M.28D[ZQC2(O)=[L0KT/>T^ACU6<>' -TG@:/GX-.G%]NWMV>'VX 23$N9$J1P(8Q WE)9[ $*P'I?X>IE-''%N\63S'<1L M9?_UZNCN=I]D8#^Z0_*#@S'=*V5XE74XVSV/JVS7"1]>9WV /.(Y#IU3BU$Z M8AP"F:)A9Q.0$;D+DTDQ7<_7G^Y6U73V?GF\'0TG!<2YY#27S/Z7EM(0TVW$ M4 /]CJ1%,YI8(EMDV;J%UA2V^-Z=KHBIE7TX#U'*@>CNJ9-;ZC_MJ7]TL.62 M(GF:/F>)C- #8Q3(&,TZ*X_1>'/*/FZ+!]W4JP^K^?)Z?C>U W;6*?2'[0,R MZTE>%H@!"3A#JJ0YUQJ"G6'&&13.&?=3XX6+T>F1#AZG1ZNZ&_+U:YT?#63T_6WC]/YNII]GJZ^5IL)*)B&A)(2J0(0 MA:0BM+-G2N2^7.EE);&K.<:675MPV:I%EVU:>!X2UX]+!S\R&(U^?N,1@PVN M; LL^SPL@QY.83 FPYQ **-NBG^N\:<4/@IA(U#T..VH8P\EGTS3JMK%O*:J M#AG_K0=YOZPF)9& 2E0 D6-D$*(2[+V$%!YUHWI;2IU?VN/+;JKJJGO'J5[Z M/'_9GTZ75-*03/J>Q=B3:!H2#^BNNACT_<"$^B2/AB0V,&_4CV#'G-$K/)Q, M%\7B;P32'J\M=8H1%DOB/_^H)P9QP$O% )$ED-(N"FBY7P@4;I=MXUBZC,1O M?M2Q%,F)SKX2'YO)Z!+_>6!"8TE\;&*32?PY@B-(O/U\D,3[\#=VB?=JB[/$ M^S/D7.1/_[F9+[_>S]??=K8G2$H-J(&H+$E!F#2P[)8+!2?$_1V8L,\G%O/V MV$;U"%6CZI[5Y0)8@EKY(XWA<)8FH< M1_K"H#\O[1+:_O[7._3-376]F7\_BOLF2C"C%2^U04!KR0PQ>PQ6JKQ*6<6U M/$2 -C^4+*DZB.T1YEA7/((H=Q.=R[$=$-V=N>BQ1SO"NQXO,'E&W-+TR#C4 M+U';G"]]]&?01S\_5=?WJWGS=B?_/ITOFM/4IEXU3^AM'[.B6"M=HD*I7!D. M"B;MR,*H,$P+H-VJ+<2T-X16'C!>97N4;V[JU9OF#=/PE^YZ<^TNET/2'""2 M/1E.IHVOT/:*(L8B?3PZ&*U%+ZA?7+9<-:][B/']S5.K!SSO]C7 A,*%A#JG ME$@.J:*%9CL,"@CJ=>$MKN4QZ."[T*J!D3O!318OQW\"@72A/HE*>K%X1B_3 M],8XE#-1V^HAQK/'9L=OTTUCYF&W:7[SZ5N]VC1+_K?+[S:6W1YN19(K Z0N M$-:(YH76AG9VS.U%SD[4(M]6LCC .SJW'?LK@'(=MK_3GVFW#Q86.4_LO4:D< MP79,W/;4J0:=7X3]U!L]B?5O+9#Y?U4S6:^WE[DG0L)"B>8E5EDH##&0!=_! MT"4VT3M!H]?%!V?:+= ^J(<1X^E[<_V?2#/ M]4&2<-J7RS,1=;)N&4=0G:YY]4##.ZJ,7EL??[]HR@/]NJK7Z^:ZPG31X/IU M.E^*RH[NZO/TSXG"3&D&F3":JH(;4]"RPV88\4K?#H,H<8A^@)4UN#RWU ?J ME"@Z?('^2"'.AV9D;3NR)SUXE7UIVY+9QHQ*N]WX#Q?TR/W[4ZA\[#;[27\2 MQE/[@W?VWP[8B,8"YY!@R%!I/9/6*23HD@LYA:8E/Y]3>,1_ J<0UK\_MU,(;',DI]"'\5"G M<,#U&.6D4(HP; K#H2+"E 8@W9EG4'EM9$8SFCC4U^O-_+;5B)OI?)5]GR[N M/4^[Q:,W3+P'83:Z/E]6<$]QYJ&IO6D?IVSV;]8KRAB)-[>;5KM-#KZ5F MOGEXN[3C[[;=\^!?UIO5]'HSR36A4&*1YU !:U>"?"NZ]K\88^UTA2B&H83S M<03 QZE-LJA8\%]2K?U_MH[D(OIUTG9W'9"E#*F52$)(+DTN^^74@JG M4DW^7TT\J?=@L@:-^ZSVI.;U:9V.%;]Y[4A(C(G]J,DG9G88+9>?VH&XZ[X# MPM]?;\_2Z.5,33?51!.N@4 J%UP96-H(3J#.#D/,Z6!C^->'\N"[PV 65J:< M+POV(,W=JZ?C*]"]NU(5T],_(N$5EQ]&V.4%HB?^%X* /DSX"(:9KZ^GB_]; M35?&_F0]P:2YQ$,1D. 6O" A_=CP%Y&M9&UM$2'S$@(M$9-% M3ACA@.YL<9$;IP(H_2P,+"0[S]I+2KP(]!635-SUDQ,GVN(+RA$93I(20M[8 M1"6H#2=E)9P1%V'YO)K.YLNOGQYNO]2+B0"44L&!U#;\4=!&0:3LOJ\9$^ MN;?[&!^KK_-F^V*Y^7UZ6TT YAP3+E0I><$18(;PS@RCW'G=$?3QU(<\MKMP M!U!9@\I]RH<1]OK,3\Z5GP!XTA1#"%YBX(0>]"+K\K+0#WX=:=#XBH2T\<9J MNGB[G%5__I_J8<* TD7!.#5$"P&)*4#1V3&E GXJX?OU861BARIK8646EZ]0 M>)/FJA0I^0J2"G>JXHG%$Q+.JD4H86.1BV#\S_2B'Q,N@B'O5ZM'28\N=YKC MYC^*(HQ$4TB"E;G>F1),:.?50["!Q+*QP_4H0>>_%Q).W^OJ,0AS?@(21%H, M$3G%Q0D=Z4W=Y:6D?Q/JB$/)-P(Q\T6UDM;"UWKU,+$+(*K*'&J(2J0@0(S( MSHK&R#FM&?+M8:*/%E/6@?(-/3S9<@T\TA$5%'8X) M7NB?11M]6/!8G-2WM_7RTZ:^_N/3MZD=-N_O-^O-=-DD3R:20"0-TP8(D0, M" ![/2J4<*KD',G40,N6%F+68KS*MBBS(YC>JYA>[#HO:88B-FQ]$\IIQ.7. M&8+.KWUB,#L688K3F.>KHG@9;/?M;^_)Y4Y.=*2)*7I0B)U@4 M@I9E7E((2J8D*'/@%-&D1ZD@PE27TN0&-->-RX(BK"RI(H>D9"BQX+7 LR\- M\NRX==E1\[(O#]GQG]LU,6O;>)4UKLN\7UVD8 ;/QP!#DN?G MP8]YVZ6*_[D%-?#S*R>H>4$W8Y$YCEI&O5M1QQUB?HJC;^\6]4-5M=GHG27! M<(EY29D5,Z5ESH JNKE2:BU]U.:E[Q-!QY1=1F!>H.2,N/0A$ED:4#%)!]VYFA/?T>[6:?JVRZ0&QYYO#8^ALK'!].;&@LKF.U39ROF6XHCZ] (N,GEWCL1!7F5-2[.FJ5G7UNRCYZW, MD;G'E_IN*.?8:]S\"[K&?GRD=(P1>NHB;E'_>5==V^7/W^N%_$!S06\8VI47\(<#].)H/&+7UNS0V)_=);[0 M0VSRG&IA& YA7B]D(7*-?5U[0,2;KQ?&YQ?T@^1=QBL==-[1+ M#!HV_\(.,8R/(=QACY[R:BFJ_5? M KS@A?K0P_V-O_O&Y_>:-E[ W27IJM?\W&7'QX@,FSC:%O7%W:NWKY MM?E^\_KS;]/-[O7GC]7=%MOZ_Y+"A!):4,(*X)XW8A4%H?[..X>H,AAF!)6<$P+PC$N4"E*IO7Y7(FE""I MW9.YMYBK[ XJV^R/>2KK%$1/V^5OGOL;/\S30W[3Q0@/^*CO OSK= M4_M&-#\_*HHZK'OIR_H9)S)8AX[#50S7W/I"$R>9[+]=-C@^_Z@G)::F+)1 M6*)"(Z (SLMT0PAKW.080"0$;2 [:/>Q-(A.,H!T04SN9 ,I:[LZ"#O93)Y M]^B&Z)*>I@>2RW@V7VXK65ODHQ7N/;=QQ-J_JWXZ@0YH8K@HA_*93HCM.*TF M-JA#P" @(0>0$ ET)T&$"F]ZAX$0I EXB65BAD,">>&"ZV8RA6!E$MA4K\. M\KH8(Y!:C-VZ(I4<1^^% 06YP3YV26XP1A5EKP[[6679KY&]A3F TQ!IGD!. M.)(<:\T)+(75_ )VLUP5))]LZLUTX2^X$P,0HKQ]4JXDL"@*(@MH_\TP RC M?H7O]A@"9_'EIJ3C1'.F:WS3QQWZF4GAV7[7H?ZQ6DPW34)RM7GXO)HNU]/K M[>6$[CH"9I1A:!>A4 / 27F/KS)R)1O0XYE&\YM2)!J3G1O+UMVIV MOZC>WYP"(!X>_4Y;6@U0UN1NL1%80P.LH[,+D=TD!"+WVR,.0@"EQ,)@H124 MA)2M=RU;.D!N%$^=@.E -T'EZ?EZU>PC/OYMKS*;B3O)<1/XXOWCN;^;JFO2 M[-N&L'MN2S9I;XU#@Q.W\>E&Z@",]HV.'B/@?\[7DX*52.=*4:.@*#!F3.#= M[.K36!A&&Y(QP@ M.& 1^"JNG2F6%YWI\:E6O^:X14>A//54M.; [G)=K8TE MX#A6^\=\\^WXKTPX@*4 DI6F*5H@2LY,ETX76B$>0?"I',C"?+VPD;;<8U0/-YJ^6$;\#A!. K)=N7;7]&C]^2H!3]^:]W\ M02*6G;=[[K^LJ_^\MX*DOS?'&#Y7?VZ$I>N/"> V_")6';#&4EICF-D0O,P) M%[DDR*\JS$DK"@IMM#4%2T"DADU=>\Z1II"6):&I0]X#L&R+S',?)IP]Q[V6 M08CSW$]YREGVSP96UN(:>K?D%#_G=D1Z<=F]<%$H8[22TDX351)("HZ0H5J6"MDY5;B_%G'B^XP+:+! ) M9?H_[YLR0F_MH%ANYM]]'KWI1?1YA1J*8S]MV@+*MHA:HEY_^"8>8QY/$ S M7-C# 2$,NA7X?[G)+PAU#()&4$R_;POJ>,/%6Y;-_&935%ZC4'%)3 M\$)!W(514 JI!ZFJ=Q(=8U 5IC2Y)8$R$I!<4YS9F4",R/AD"YG]YINDUSN M4/XD-=-.T7MN67ZQKAS)K.ZWM[B> M0><(FQQ!2+G6JJ"%%DKLU J)@@Y3'-L',%0&T5R8DBI$."@+0 I58FPP1%9O M4Q>:^?CI;VZ"->(N=/'DSA\5(,H)_<"2:A))9?3-=?Z5UEB^K]3?N[:][E0$R]^K5)?4R,8GE> M2*@H@CEF)0.2=5IJXWNG9%!RD)3E3=2A-"H*HK@H(;>.:FVC;YF7\T7#X]>PX&)D//-]/2?Q>I*'QL_NZ6#1$ M\V]1^\75IVUE]5.CJG)Z-]],%UO['ZOFB%XUL^:WE7C>KM?W4]LE$V47FZ8H MB49 2*:XP@#OI8UQKUO*_M8-8Q(4&M@U!R)%J8N"PKP HC18(RE3+\P^-Q4X MLNN=+]JJSVH']M@7S7=X_=Q1@LYP\S.7[0<_![(+!%JP5]D.;N<)/A[WQ:Z$ MU-O7^B*)2_"F](S6I^N><8AXPO;50PWTT (1AS)([V^.*\&T%YZ/C$!C%1A M!&>2$&@(SKFEFA.+BIK<[]U57^,,VRB6&$9SZVH*!K@B0"IL"E1R+FCJLA - MJNQ=[;H1G(YCQZ#]DO1Z!N-'51T.8)M_>UPW:E?%(;O<$45/3L\%SJFZ9QQ: MFJYY)RLX).'1/8!=V'^M5]/F5-]1F*WFZ^M%O;92?D @B@(5D EC(V>-'J$\E%2XX#S@F>]/4@\&Y#& M[XIQR&>2ECT+0E.QYRJ:?+VN-HSFA,(&'CD)%0\'6401,B!K*Y MG+O<[&W9WBNA4(A(80,U!C$D>ULEIU[/MH992+VAM(6335MP_SM$([PY\Y&* ME'2%*,95UC%V6>EXPLNK"A+*XYB$)+@-+^I)/T:<%V;3]3>^G#7_U^S8?Y\N MFKUZOI'3U>IAOOS:OH8V83DEB(-2@I+#DN6:0=39ULRO-$PAQS+7*;GD;]"1AS/[E2KS9-6N;M\GNUWK2G9B8* M2TT@YD+!YODXA86B.U,(:\PGWZO5E]K]W$F "9^Y=HS&X[2!1;7-8\X/N'P/ MB820YY@K3LV:9S[X0-=;![H2G:5X3LG9O&YC9ZH#3F;@P=VZE$I7Y<:A:Y#8]7-3^]Z@C; M ;J0-KW(RADMZL?B.+2G9QOJF./*3UM:,7N4IIFHG N,=4$4+0 0N4**=8:: MF\H^PA+P^8%495_M\1 U73_*T/H)30B/;BJ3F$(_B=E&04\2M,/JRW,^SHA+ M#_+&H2Q]&E!'&T@]-G@FB"$I%12EUCPO* <0=-E>)"24/B\=^GW92TG\GSK< MG1 7LYD3EJ-+^Z;2]Z_UO7LQWRQF AH5&X*;HTK MBJ@J"FUVIG$.J=<[15$,)I:L \:0W$L<2MWT:G V_73K &^_=K((LU_V&+,. MY.EG!9((F MO9X0L*NWC$+2X3:H3#M/@1,_O]7*W:IG O+#JJ7)KLL2Y5)S* M+M[## BO4W=A%A)+V#9AT3.CXT.8=U(G$5=]\CH'2!=+[1P@N&5W E@??IDOVON4=JW5WE7_5B\L M(>MMY:O#=0#):0$89QH6A/!2Y)SM941SK^N,T8PFCA^.<+;9AO41TO_QWPH$ MV;^WR9PS#TLE)MU-2R["MY_:/*5Z5WWP4J?_71D[(U7121^'F,5O5IUXL 8+ MXM.K"]A0 W"!4UJ+ T+/^TI]*/06M)3L M!4O8Y:\OG6;(3;)":1V=2 4WY+0L]>/&]\#SA^E#<]*PVZ0C7$BJC%W,*9R7 MA.I"%SMC>:&Q"#GA[&DBL0#M3][>;6&%'6+VI,<]56D?6#M&%SR0_ MYN7<0JX?D>.0F;Z-.'',N! M*T\49ES%1]_>+>J'JMH]E_R"74T9QD"K7&()$2>,XRZFRH4P7A>Y^EL;2(RN MCXKX^JE1!$+=5&E8+OW4JU%/5U> M98MJO);[W0[>WL?\PWW^3]>E/?5JM.G1XZTUQI!3G40 &2XR+'M!2=:42$9Z'0 M" :'EY3K[A9[\'(L#M-NXC(XR7ZJLR\)\,/BRSJ 5_MHZ.%"DN1"VQFMBLKZ M.$0L;I.>%?Z,SI?7<<,7HC!"B:("&X&@D9(RTE0"VUKC4!K@?> PP,8@1PZ[ M>V'!GVAM>;O\@NT$,Z^=0^S!Y3BDJ'\,<=KLD[F?3 SX_""G%'O+3 AOH3OT42GKOS-_Z>UXKVUX M9^[&(29]&O#JMKLG%U&6:D?'J06Q.H5*IDL*.4>0(F/VUD$>;[7F83/U@NV% MU=DN]W/]>"T7<\\\7/?BL'I>[ 8GU$_A/K84-MCV)R1WZ(Y4;D@V9_5U^ZYW MN^,$!1"7OLJH?MREU@L'5+U%WY%"0 MDH8Q50)3E(;E7%+9'?P0B$/_0G!A9@9)URWV[P]&2]CY,!F6LTM$8N^TW47O M#[_(CT?R+H#4<<2A,1KR2@HOF)N +-ZD-+ D%.:@N?18*H,!Z_*$@A"I ]-W MKWYWD+Q=C'S=ZPQY)^JBDA.A.U%:\BP7%HL=YZ>,3M\^ MI@4ND"Z1$"0W6.N"@O(0 FFOLPP]S"16I4\G*QYXW@GNPZ2;) U$HI\B'8/Z MGUU1 [[9K.9?[C?M*_>;.OLPO>A5X:#J!A'8'H=0Q6C(TU>18G'C$S[5R];L M[F$W"46.F$*,2TT+IJS9?91&A?)[;BEM2VB;3V6J^R_@[\" +.[ MZ2K[WN#[]\Q^_@IL_Y>MO]GI9>.!^\VW>C7_KVIVE157C( KG.,V2BBN*$57 M.2;='VW.LE>S[=L ]YOUQOZBJ=(XW62?[("J;K]4JPR#JZR93]DO]\OI_6R^ MJ69_:?^&JJYW?P*V?X)=9?:;=]5U\_[VPCG[&B\*.>ZY5T*/H$X>QS0.A_]" MD-&#!^?KMS,[9N;U:854 MP/@]E-[?7.)(XX P:Y[H>#-?9M=;D)[W#+K-T[O!= M93OU;"$.?&OW5A63$;]/1";VRN/,H*W-_>M]?PVORQM7BWJKY5 MR[5U?V^7U_5M]:Y>-[5OW]]\GOXY,=RNV32'DK"R* &PZS?0H:"J\-IFBFT[ MM>(=X'9O$!T#SA86JW=-@KCD.PKA!7GW5,4CRK=;5X^P9ENPV2\-W+]LRW37 M-YG%/'AQ Q]"SVEFHJX9B8"F:MWS\@@)6725UH_59CI?5C,]72WM>F1]A$I5 M-_/K^6:2$TP@D#F2.><$%$VYW\ZP$(SZJ&D$N5TG6F=!P"U*,WQ M+*'MR9/[ J6-R*RCVSQ\7DV7Z^EUDX-:J_GZ>E&O[U?5Y^K/C5@TV2>60R4D MY#D0G,."FUPK"D')E)($:*_DMH]=:')*2L6@IHI )IJ3 A3IG.::4P%3/ZJV M@YJU6+-CL'Y:%I5J-UF[%,M^"G>:X.P -/MG S5KL0Z\V>[!XMFU8_R^&(A07I:*?_@=(.F,E MZ21\(Z52EA1!.N" V0>#F<',\#__U[>[R4]?\]E\7$S__C/\&_CYIWPZ+$;C MZBG MO\:+VY_^._SKRV">__1M M/O[W^? VOQN\+X:#Q>K=MXO%_;__^NM??_WUMV]?9I._%;.;7Q$ ^-=MJYU/ MQ-]^*1_[)7[T"T2_8/BW;_/1SS^%&4[GJW=7>$GY^+=7S_^%5T]#*>6OJV^W MC\[';ST8NH6__I_?WG]:S?.7\72^&$R'^<__\6\__;0FQZR8Y!_SZY_BOW]\ M?/>LDUE^LYPLY[-O?QL6=[_&)W[5@_EX?G7]89;/ _E75%/3T:?EW=U@]G!U M_6E\,QU?CX>#Z4(-A\5RN@@\_%!,QL-Q/@]C7;WR=I9?__WGV3Z^NY\$,O[:R3S=]74^7%Q=_Y[_]>3+V7@Z'(=1V7PQ M&$\:)<91 ^@#Q7X?S&:AQ=>QOU>S8/@QF@7:W^2+0:7+:0-_LHO91?PH,SN,6 M'SAN!O-;/RG^JD[9O:T;'>O5?3Y;07,>L&F*N_M9?AL>"O+F?3$_;0+5NJQK M5J5J%=[EPA):/+R;7A>SN]4 #@V_2MNZQND'X]E_#2;+_+=\,%_.UL0Z-,"] MC1H=V?;#_QP';LZ&MP^^F*GY/"RH0*WWX\&7\62\"))JTVBD%MLF5]./^7 Y M"QOXS4H&KG>ND^;:W# :I5ZU#:)"T[I&^6[Z-9\O*F'NC4<;&,7C-GA;S!:? M\]G=DR^K >:TWAJ82S5N[VQ0UXA^SQ=1P'[(9Y]NPYYW:#P['F]H--58NK=1 M72/[F$^B#1[T@L7#Y]E@.A\,5[O5H<$=:M?T^*J1L%KKNL;Z:5$,_[PM)J-\ M-G?_6H8M]-#X=K=H;DQAPUC>W:_(\$=05CX7;KX8AVT^?]PKKE>MKNY+O25 M<*4*1#4R?A-5A#"PXB%?__YA&3:CP3S_$#3-:HSI>%C-43>H>'?%=/7YQV#J MS+[FH[!)^^4B;&GOPA3C8$\ET?%]-S?/U2=!D\A72FW0:%=ZHOL6?\S59++Q MRITZU9.Z;WBV:^ %D'V<+U60(U_#%TGS.]QAGWQ>"@)?WRN;K?7Y$J.QZO>S3K_6?CH1Y,/@P>[HY@W7&] MU#WV:E+P[:=/&LO3,R.Y'LLTOXDZZOO!E_R%H'BKW60V>]8L'E;)>%@%V6JL M;_56\TBC75+K8%]V6/-X@YHX+D9N6C.)W^ZVD;%_6@0#IHG1O^ZXYO&'I3// MZQWYZR[K'G.Q&$QJ'O.K+NL;\PG 6+P>9D44W#\YOWD?/M@\'_MMX_1Y/:[\ MVR*?CO+1ZB2\'%DP"=XBP6KZUX/YEQ4-EO-?;@:#^U^C>/\UGRSFY2&B'-(DTNWO/X?79X<;95(B0Z0#$EI(H9#2.>P@ M]IIKBK1QSR>Z,G.*V88#S<[T:G8SF([_>\47$Q3.,/)1R:2G/+NZ]N-IT%'' M@\GC.8<=SX>3(KIM/P?FZ##"/_?0I^Y795!R(I14SF-&#>.:<&$Y==8JA[Q$ M5:CZ%-EJ-ORIF 6CY^\_PY]_"M];#VEOF[Z7@1,*CN[\/( M5YQ<*S=F>;>%V._M]R<^3EB]D+V5%,PX_#M0A5W\;S?4OU MF'XRC!UP&ALH"*06$:VYP59XPZ$URHK+PF);P"G:8TE;\/P%;CV=(&A"X)@RE@AJL)0/ :HTP<31,55X6V!KB>E$[H5N3<-OY M!WUP.AK,1O,_[H/JF(?G"9 ',56I?68M,]PZ*)UG89%RP1RA O"P<#U4I)(^ M'#A@&@!DHE MP _U#WX=;:BM\*:_R+7%W6 \K16[ZRZSL.5(&^QOK#VE/*QM$#1RJ;0RE!#) M[64)SZ9AE(S:D[C2%F[-8#)_SIG6;*3[=.R4U':GKP-;*2*ZC^PQ"J"G6&!L9*&>!E)2$'5(28*A" M(,4\[Z$VT3JF.^!16^@^63-[/Y[F[Q;YW3[=.+WSC DEP@:J+=>0,DXUI0C# ML($2+2 7*7HR[A^R.]*36^=3:[I',5VYD/\Y7MR:Y7Q1W.6S,L'E89]ZL:]= MA@4!$$%@/6+4<9/ FQ&RU6&4'$=BY $I7#XUCGQSF>S8/%H;KCB$D%(K0"88,,D9MH# MJR"X+!NU#J85]9*TVEXQ+U$^SX=_NRF^_CK*QVN AQ]>XCI\E*TSHG]?1H/@ MZKK,,GI+A=[S= 8-)\A29;Q#4O"@W(6?F41&*A $4-,&N)XFUA<,^1]-7,W ZF-T$W>R."[5!X5%*_F<.&,P4]MY@1)A V M@I5,D5:GN'')=X'.-LG?GKCEC;6$BU>RLCX.M(6V%T,]>-SZYO.9%-8;3CW0T$IBE5(:;N86K%-, M+@M=-?&YJ)^RK84W%=<6TA1 !IXSWQ4C%I2YHQ*T"*"[F'OKUN=MFV MN708V3N.JV)UW+"\XC]1+?XZF,0QAD]^&\S^S%<*[*=8]7-5%'37.=91G604 M6\"]-]XJ@BQ@UC.VG5G8;RY+*+:(A*(EEK06P?/B=']7NO2[333 X]ZS+[SG MY$XS:J71S"BDN;.8<\>E+ZFD65)NV@69)Z<#MW46]3\BX_*JERB#@[JF$#.6 M $:T=RHF&*6$""5M1.<)H23BMARK[P-!WHJ+K2ZECNLH\T(PK@SR+*P3 M8;A CAN*(&4^IK2E0"W)6#Q/J#5*_-8.VF,I^5>%E;>5B-\%+7$:E;=8,WNM MP.P+MS^AMPQYYPF4GGJ-*8-&.,H0$D') UHHD&)!)L5_G"$2/[6V7(.$4\TE)Z2RED4C(GK NC%M1" Q- POIGZ=>-BUJ)VP.? M_;&&X+%=93$'-?X? >:IA$8ACK6"RG,15TZ*2#HN7*LTSRSW3!G!I(74 $BF8"@HQ=M " &&E"+2&1.KZ M0M *8O39@QGRP!*A" ?"$"@%YPAO9@2%PYU5+6Y!CZV7XR]CH5+(W%I$W6J0 M9CF+Y*J,G1?/9Z%O";5%U.A &@XQI-NY2<4Z"PYIPQ0ZD!Z9. M!L.K^F[UD[N]4XO7-QGO/99X_7AFL7$48J4M),0(B[5EFYDA['"KA5N?5U\Y M.RC50-^60\6C@GVUN(UE#8=YP'XT>G_/%QN"'+8U][?/)/=<$H$]]Q(Y!X6E MV[E[:#HK=G9VR&J"W&U![;GG_#"TWGP^XT8Z8;#%A D/G&'!T"OG1H/M> D MF9R=V&A5;;,,<62,A5HZIT@P60$$)5F0-M5B-FL[#7UR#>+9R9,4LK:W!17W M^6SQ$*,]%F$/C8K^?53/PN:Y=R?:W2Q3&#(GH<.(0$&T"U23Y4R%DRD;4N_C M%>LQZFLD;UM >A>8-;T9![UK38,P4O=MDR;_CZ(8_36>3/8 JDKS3$-OB16YZ$T)P.K 3)WH/'$"@O'*#V/SV>0B+!:+ E3E)@8 MJY@I"8M:?16.+ZIVD2&C@@G 8Y"'H%1)313?+@2G*M6> M/5/EI]%#L888T $$JY^9[6Z48<\\P (C&>B)-,?4F7*6V/+.@BQ:@%G]2-@- MM32RM^VR_C!XB([/ZC[JYPTRJK1AUHV"ZF2> M[_!,)Q&Y10C%X/[79-B/HK?;9)Q!K@1@1"D&L+>..5?.$4O0666OLP52+71N M"TMEI>V/^>KZA*,P=;!MYA@/^J6SQ& #D:)C4(!28EZZ*'5:0;@,KIQ&PMOFC?%4*' MT5*E>::LLU!!!RR@! N"F=3ES!'5*?9=#P_.&H!1 U1NU05YU':VHT5&&;5, M8Z\1],8P3N,!TWI^"AJ?DF??PXS#!E!4#V&[L_Z/LOHS"A"$3A,'F*/<0J"V M3I.@^2499L=G#+;KGVP .\D$[L5^5ND0I&(/,54%FD!')QE4"D&&O-_.'Y!+ M]EHV[DYJA@"$])\HP4SHW- JZX04?U38N MDVHC>P<:5#75*9,>2LH@ ?%$4EJ/ 2\U04VI:3?"L3.=J?$3DB/IW)[J='['SYY6L4H^Y-@&E1,80071'JCMNN!)46W]-MF:THKJ(G5K M*46GQ WLH1P36" GD=;QD@7G! /R4= FU=KK>QF8QM%5&]G;E%?%=#7L@UF0 M+Q[-N($ZUC=%7!G'!+=AAEL)S))BVA(OJ6\EZ"2=TV^(I@0"MW9D.QJM0FL& MDP^#\>C=U SNQT'->#+Z?6>W!QMGB $ 69BY(PI;0SU1)?F,!;[5R^=;CV2J M'52U$[S%R(!U@?9\G6 7JT;.\MM\.A]_S=]-A\5=_KZ8QTCBJ^O/@V_[XP6. MZ2GS*J@ 3D%#N102@* .@)(>S(H4#;[O)[U- +!1ZK>%QH_Y8C">YB,WF$V# MPCA_,BN;7X^'XWW*V.'&&:&80F (,D0I"D0,92YGK752O="^.QT:P%SM!.]. MUS]*Q\^DPX0H L-?1A**F&5;48Z92@E2Z;OSH0$8)1.X+X'F"0'FF0EVL*!. M J$=P1)9O(W,-\2*%/_#\24;+]>?50?Q'^'6?@VU#RN*WN:+\7 P>3ZL2RNH M9BP!G'*#*?6.2\V"1,%(>*&AA[I2U>;&C?G CJO9:CJCE2WY(9^M"K!7L^]W MM"9A!PC%&!. 0J;:#EW 8.#(*7,<4*00UL:,N%3JJ+WW_YO!V.)-.\,6^_F\^5QN%JW MR+015E*$-&8"QGDI+#?S"Q/E* %3_3?IV\342?3N#$]7R\4\7OL;;,1C0/6D M618LR*CM4:2(5P(19I4N9ZJ=[RR\^^*0=3K16U:+MV297UW'&H9^4OS5BQ+# MV\$A2SPLR)#$GT"GA"&%8 M$,JP+RFH%4HQJL](CTY UJO+.#I@2UO;5IC\#.]A(^ Q""9AL)%WZ> MY)M+:]1=C([^[\&!>^"K- ]L(,1:1@45VH#PDP&XG+DF\J*KT7>*I%>9IK4S MJ[6#PS=OU]RGX+_9(*,^AO=#B3B5%&.*@9*;V2'+DB[HZKM,[144:V%/FT4\ MUFOER4*YNK;C^;9&]H=9?C=>WLVKE<4_K.Z58LIP9;#$WC!M2NHPVE*) M!KD&[S2_614V^#[AVPH#6TTP>DNUVIBO6XOV4+Y1E3XR(0CREF(D-(4(88ND M*FF@N>NL4N1W@-JFF-064 /-9GG8,VR^_O<)E39AGQ5,M>J=9,8BS;PWQ%DO M/'.*2+#=C<+_6XTV^HZ5A<98UAUP]URO<11V]_23"0"\@Q1"1ZP61FH1BZ.M M:0$!2=%UJYM=7:D+36#F("SKXT9WR'Q^6\=18'S>-..*06X]B9D=4A" C"_I MBIU,NO"@NJWU)OXN"'))-.]PXWZNBARJ)UVM@XQXAADWRGDN<; 7/0'E\0I6 M$*7HEJ<:2)\;5S$[@5T-Y.]^\]U4$#UIP]VTS9!SA'/@J(FJ#=,:D>V"(TJG M'$/U/3ZBTRWV-/IWBKD7Q4:/A=V+YAF3&CH85 D%"88>62]A.7.KDVH+]=TZ MZ0IY:2SH#GR[JY$>!<+=W62$!0IPH2E 7C$O-9&EXQ9C8U(J$R=5<;A4,-;& MBNY N;=^UU&XW-M3YBV4AB +O4,.*B>\*0^!L=&PW2)_EZD-ULF [@!I2TZ> M*![?:)_%^& ND,!*>L20QPZ7BY%H@D4"^([/+OL.Y&(Z#UJ,>JOH/ZTE7#.# M3C!+( W6&<0:, ]H26/BI6FWD."3/,>+#"!JC"\=HW-]F-E@H/&1+P@,4H1: MKU788IR0U#&!2NI%=EUP/$>;@<;-LJ4M4'\8/&Q.M-3P7\OQ+/]T6\P6G_/9 M7;6PC4KMP]P==T 0;8B04 751Y>.?F*@:R8K&:TJ([9TWO-!+%< >B1T(P8Y!%B MI>)$G9;_S,1A]V38+<^0H*/I$(L$$UMJBTFM,$>7M%.#^ M ZP6FRN+5BA"6M*PAPA)I/)DNRXY%BDGZ7TOM-4Q0AMC4L=0W:30 M-^$(P@%KS8! @KTL&4?G=U,QHW'70+%NZ,,YB#9!8&"P0KU)- MX(-M,\FDP-QR)!#T7#@E8;GG,&V3,CW[GB#7-FKV&%IU\*839T$M(7'C_G] M1K.^NEY?@E-,;Z+?+=YNN@>+>]MEP'((+5+!)O0&,J11+$<*N,7"""_:V:); MC"#N&'QU,N,P\';V]#J9;/&6F FK.K-I20?&4LZ(S-;/;DG6- M,:FU8G]A]/$X(/P3W:E?!Y,HN#_D@7.CEW$Q>\!Z3#<9=5 B S5&G"O+&"%$ MEY2 E*2$TATO0-LNO]Z R=P@\;N%H0J+:S9[".OHX*U+5=IGU >=5P"L",>( M(:$=*Q/G&=$\I0KET7+R?L6>@(?9XB+AET;[R$="@:5H(@C%1/? 32/Q/9EQ0X#W,6?#**)C*ODV:IX+K=N)K+UP^*10O#672#$=ALD_GC]/1ULC M^5V0TY5.;*OVD7GNB8.:,N4Y<@!*;TOOMK!07'*^3#.'L@U1OF7T7#.)IYG! _C$C>,LN(%=@)Q@P4E@?Z;_,S!+:XLU+F M#7GEZL?+VXALD >/V&S]/H0G#LKIZ-E-H$]KF[=^2<)ZI]D.M%J5M+=:!"U' M&,:H@4:;0'_L-3?KFRFD9H)5 XXI M+F?$C6VG2E9G&9II3'YUGV0"94_<4>:SQ1.,A-]>XB-\%(^C1LOAXFKV*9]] M'0]S]6W\U@'.KD+.=$?3RN[AGZP3^OHI[2R)KRT!9Q52]47#'?1M.EJ---<;PW^CSX-MA M+!W36P:($!9!BJBPVGK'$0(E73!)"E?J.]Q.Q\C;8&N0[FWA<5O-9%-\MHH$ MV]DF P)QC("%CFM@L=1.HNWBM3+EJ/UL=KQT4587?=N3:?,\O"L&!-BP,";% M*BWXTR8K5DSBE*M*(J6B6XU D= ^Z2KW&O 0"O!%9]I&X+5O_(IX$, MDWBWU>AN/!U'$BS&7_/#P#K0,JBC1 N$N7;&537$))-5A.TL I9*W=6L DEW*/8=-DVH1R=3ML6#[^+Y8#<0KQ9NL;]M M%L0H,Y!0;K10BGAB8.E4<9#1E#"+OE>MKQ%-==.Y[6C"\IJ:]=@KQ!4^;Y!A M@R#!A,FP9"2RW%!=TLUKWM(%0QVE"=?'^AU!A4FT;AM)56X+>O9DK%*.H&;4 M&2E1F(Z"/2<1N9VHU+C[ENZP5[F]^G\NHC%F;81DNY; M($Q@\'@ZF#VLQ':,'8H.M&(R69%Q/?&#,2V-O#73D# 5E$Y#8Q P$01C7=*9 M8YI2TZOOB9PU;JC]X5#K\=F;!:N#17P]/HSB5RTRX &1P7JB&FJCN?44EH:/ M1]JEY&963U7J-EZ[;B"F$KG%K/5*=N6SYS(.*;76(8 T9,AZ -4F=D,!3V"* M)^OX#*.S%5DI-&W-^Q#UR&?1J(]##N._N@Y ?SOIN,J)3G+G6;PT#M)@>@ML MO'#4 (&V5%,\!8EG$_1?@V^C;49T#=\_IF'TD_%_YZ/_+";QR/0?@_$TSO9J M^BD?QGK)\?+AV7@>OK+AU^G->OHE,4X =>HK,^<\A!9@"(4V%%I!,=A2^&D> MQ^69S&WBL^+2:)F=K>7&OYYI!&NL4"2V_ M'UVA/@JWA20WF$T#ZF-)DD^W@5QZ,!\/XT'P>+)<["TR>*!EYA&E!F%BA">8 M4LD *.<;U@U-BHP%_0F-;0!%]5*V+23],Q_?W(;AJ:_!E+_)?U_&X-UX@T&8 MP=5R,5\,IE$ 5P?8:1UF"F/+*8!4&4F= 01A5U+'A@TE!7<]"LEN '>M$+R= MW#U;#)>KC*?IR$T78?]XDM;]?#R5DO1VY!GL>\L>PZIRVXPXRJ#!FI"@@V@O M W$W*]W'NSXK.1W?6NWS+O#PT7:TG\.+WIC1 MRT# MMTIVOGHFDQ(P@((\XLX*0P$E0<=?#UL:HR\Q +194*20MR%4E'/]4-:RLF%[ M.B QGCV;.:H1M"Q7J"'_.;57#Z M=/'[X,U(N5V/9@ KA:G25AHE% +<4U5.@C-UB74['RXMF, ^N$X(IYZK2&U L@RFG$ZJ<7>!#:!EC2R-P06LQR-GNF M1.VWAG8]GA$<_V<9PD@'TPYP23;^-:^Y=BF;T/%',Y> F9HHW:B0\>-)/C.Q M0D8QVR]BGCV9A6V464F@@T@B"P'BU)13[&SW>9+9R MU,^?>.KW;TU[&F:&0F0\=QYH30 %(#M2A!6IZ2/I!VBG#F,:B1ZHZCZ=#>8 M3/1R/I[F;P8<[G@RXSKLM))#*VQ,8D#8L^@AD(Q0J91+BGY)\O&>'U12"-LH M-MQ=/KN)H32SXJ_%;0QY&$SW;U%OMLB$QEX3*2"F6 *#E7 Q7EL*XHQG/.4X M "9Y>L\/*W40N)V#63\8SU;W/_R6#^;+V;JLZ@DGLO7$+&Q'8X,N."GB@*K4 M.-G7+,,,0:9P1(BCUC"!B%2&0VHMY\)7,O':F^WG0&T]V7^][=YV&7>(AAD; MZ#2C6AC!K-'86(#B149)YDE?-85Z<5 T1^T.U_3VP_\3!%[--V>?I MZ/UX\&4\645?;AJ-U&+;Y&KZ,09GSC;!)G.;+P;CR45)"48A#QMWK(=@*+%4 M&<&E,Q(3::CWE;R&#<]6/^C!)%9F_'2;YXNPM2SO T,.%5^NTCRSVD!.@!>: M^1C*IKC0W@ DI:+A&_R]RHS*J-@E,^HC>EMA@T^&OI(.9C*8SW>4;S[8)L-8 M",6*MHVJ]XY1[S,N-Y8]I\66> MS[Y&VKR;WB\7X>MB.@P[TXK[3R>[LWQTTZ_,*,080@J%YHHR[93QQ'A$.114 M$WW)MSZO7>YS, >&0Q_@@3@%B&@H32 T-H]XB MG9+[?C8([ PO;URNF,JAUJ3P^F*9># 7%)RU ^3 SOYVBTPQXP"DG)&@%3$( M=/C;*^UH^,2P['ZM%7+\QB7D,C9Z_ M_=7!S;O.UV1,^&#\*\+BY0G1D>@-*]H"=1A< MO'QK:(K9?;SL(+?YE\5C/NK!7;I2^TQ;39@*TZ1(TR BA'$,FR M8-@-;(KF&=.:JIC/%N/K<4!!)([-[XOY>'%88=S=*G,<*$>QT=P+:I05S%EO M/?< ,N%>WF=_[IMV+P!8'SO:@MT?GS[/5DKUPQ$"<'>C+-A^2,!8MH<$PQ!A MZ1TE.NXX ,;@TJ[21RX8=+5QHRW,_5;,%C>#FUP/AG_FH\=!OYO/E_E(/_SQ MZ1_%UWPVC<3Y=%],YT7@N(MUQH+%.:^ SWI>D E@I8;>((M=L.JI9^,L+#@&Q"W;)Q.\29.@DD&U:9= &JE%'C+&(AI\UBQ5N@31 0<9- M9X;U18/L-.)W"3)\$L@VK3)L!:=*0DP@IF&'D,P!RK%D-,S;P910BK-1XEH' MV6G$;]]^>$.UW1ICVXI49G"_*NG]OL(-N:E=9U8PH2&AQ@M$)2-A&T#""464 M$ 8E7<3K4R+RO[ 1)(;=CXC&=!23)($L2H5M!):+V ME5339F;[:7B;CY:3_.KZ14S/V^'H+R-\5KRJDBU1ZWLR PA&6CC,!:0!Q$): M(BS3VFDFO+[$0GKUXNSEI?$=W#\N5PXZ!R Z),+#DJ(=422, \)A@[B0"EOE)Z^B#.*@7N+)Z=DX T]#4MKQ35&BOLA#;$6X@--NMZ$=QI7-$KW% HVK, I9=3.93L5:%UQK"S\;)? M:XGU"@@>UDPY=^!@9_FAG0F.RF!X&5Q6.['/+P[<:6E\E&@T9K+'6N/,;^9G M&."=Y7B.QV7;RO$,!Q5#^9ME@8Z ACU"C(+!.N9(4%FJ7D)O8P M-:Q).[Y)NA_&X(Z+T7X;+.*K']970+SM\GT#2Y7;9F'U6@^,$P@[Q(APSK-R M'@3AE$N"^GXTT1##BV99T%I*'VY [=<\1A2TSH"2R'P^7=VDF] ' C MG.D[JN,%[$VB^EG_&7588P*#G, MZQ3>=(7KQWD]G^5)00'/N\B"PD\YCA?30$M7> ."> "9_H0*[Q[&L\K_)T0'GQ: MUYGE0DIN L6PH5QYK8+=I:B $'IG?$KR7]]-WSHQ=8(;I4:VM"-*?L\7<;L- M9OSJLIG.!(D;S*;CZ $1;#I35%'BJML)9(Q8P)K$PE7;Z&(_&D^5B_/6)P'??AI-E(+,/ M$(V7ZBS7_+RZ?C7#NV(YW:L-U=%_AI +T >64P]I_)D @KC"4L5LSJ24[!Z& M\J3#Z*59T $3VA$9'_.5J?UA,%L\K(Y, YEBEF5G4F/7@"I(CT--,X6](5 2 M)6/82C *&3%<4JPQYXB3#LV&74,_+I_GB%XRZ FCTG+HF*51VR7:,Q0L9N(4 MT["S4L,M: GUX:1HB_[="H..%8DF18*)=SPK3:$VA'JFE& ,.&VI=UJ(:EFR M37L2=DU"/SS[YD#&S4G]9= 8''9-;2T,FK-DRF@O5P0"Q%N5=)WKN8N)RMC9 MZ3%HCA-M.;RKS>! SD[U3C(*+:( *NJ\IEQ3B:3#7EO(N!<,?!_A&XW IN)> MELR3+I!Y,'WG]<.95\HAJ044P-!8]":8#!1I*P33*FS7%XRT)GB_!UXG$?SD M"+-/@VEQ/=X9=/OJF4P!BI%7PG(3C$:HXSWM(KI_@&?&Z$M.9D_A4E$//3O> MR-Y7"& ]U#334&&H(&-4>THX50 +13D$RA ;3(L+SF/IQ:9U*B>4NR?X\7MTR;'0[-JSYGD!BI&/59"4&^$9@)QR$2P6)DDWXWL2\-2 M-9 VQ)-V/ >?%L7PS]MB$C@[7Q2?JP"IBHX$M(ZSAC0@)%#>=,$6HU4U0HR1W!6!$$JFT"#7D:7C'O]V*1 M'^=ZK-Q'9JWFW',*J, 48J*4451;)J55CB9=3=%WD=(6@E[Z&QKB35>B1 W^]:G6U?DA-1Q_RV74QNUN5F8S?A(_,C7OW]8SH:W@>@?)H-IQ][.OLHOJ0 BV@4M'S+*+5=!@W>0,@BQ!YQ5"O&N M:J+%4>@XBJ?C5+.P*]ZLZE_JA\='-@-5?PUFHZ>5^4J(_)8O;HO1"B@[/*2- MOS.S$&'FI/'$@Q@M* 5#V$I!-(%4\DNN\MH6ZHI^\K*UP.,X_)C(>L#5^NRY MS KLC0: :"8ID5J+6%H%6 >$8A)ES$'-74ZUJ^ P6;RFA'+,:?2(&>TNV1A?"+$7NJ3W7.E M+;P_4Q+7ZN3!<@T[VV1(..^ AM0P1Z736FEDJ,*$"P&QN^C#JTXQ\S*JLR8. MM87"I]9+I-'ADB$[6F3&*VZH!AAJ034'@H4EKV-%"TBP3WZRR_S\6@\F#W$M(:-<7U T=S9)H->(\44%F%)A6V'2^K]%IT/A);CJIGQS5R/5]BMM)E#X];*09Z;TOOJ"5]V:18DAZ)(TRE#,EXZW7AC%&8-A/^"5> MN=R_[;B/K.Z-3^F8:<VW9\P'-5XP3RD7%)$@B(U"W#N(41#-,&7!]=67\]TMN%I8?]9+SHZ_ MCD?Y=-3%@GOZ[LQ@92V%PD$(J7)00>P)84Y[K@!!*:4]^FJK?;?++8'QK2ZV M+X?G_>68><=JP?#0*FODI9G#EA@J UFYI0K#(-V\-$QHC"!R,B4?6!XUT%O(9IWQ73U>SK_G(%S._7"QG>;Q*(!XC_HA:?3-^,&!+:JQ% M0!F@U"(9.&R@D=HB08GO,NI^FQEU^LET]9S_Q'=D-KK3,1?"24)!L*T4I5!* MXC0S1*.40]N^6]9M(7!GE8!V>7>>006,QQ,EXQ!PA&+%PNR4(1!*#2W'U4K[ MG"D^.P!*Y2""X]AR*4$$DB.L@GJC%#-40RF4"RJ/]0P( 3F^Y C3&J!P?!#! M'U5LW"HSXZGT_<$:" *H L5II1#YDR(ORK 1$&N[ 0+ME#6#^8 MZJ-T[_W?^P*1ZNL\0\H1P+A2AD'JB-<4(LH1()!X 2\R^+='>GK;_.L]ZC<9 MXE?+Q7PQF([&TYO?EP>D;NWORCB'5GCI2=B"@E3B4C-,&.'4.R>]3Z[ MG4] 9%V+H28^]GYM_%Y,UU-=.Z&?W(K;RG(YXO49M!XQHKUD%H5-60I A948 M>PP1\TDU1?JH-9_AHFF.F_U?1ZM9;7;]9W?X_B.T;20V]< K,\9)%%#6(2&H M55H2'G/,6)!7X0OR(XZ@9XNG5G:VM6">G%J:P?UX,9BLQ[_S"'//2CBZK\QS M;H!P03L6B KIA&"0"*"EQPX9\^,LOQ&(-\VGKD[@5Y^\(NFF9)^:K. 3W0P_ M#N'?.@(ETJJ@'&M&B*,86.6=@]0ZIHA!%V4,=^:2+Y7H&#A%4TSJ&(P'3^WWMLNLA\8Z*0RRG&HWG6KIB.;?\TGQ7T<^D;#.W@45Z%UQBWF$AB+@784 M>2\!5XYQ'.,BD-/N^P/9L8!X54B[;J*?'!%0#F7P;"B?PH^S:.5LM)']P0'' M])%AYJP4'"J"85B?6&#/$&!.0P"13+J7J8<>SWKQTS2UVQ)9_\BG8;"3 '\U MNAM/QU&GC3=45A5:E=IG$BK**!!(.T"A%AIP+;45(.C+@/,4I/7=5]B,V&J" M["<+KLU@!B\'3?'/G@*+F MZ=UZL%.2 50E;J7F-V5*$!R4!R@($=13+(AE&EL#9#SYA95NHS[[()8^V*_= M,K:MA;*90#YZ>WZ;?6,/_JMUD!%@HQ/>8X0D9< J2EVL1 EDF#NFEQR'TAF0 M7M8 ;X)3G1Z:K$_]@[+S<;Y4P[!)A2]^').\G2F&,49$6($5\H9R"AV3-BA[ MP62%$E32M)L^)CF'7$6!,.+&>P: ":3$'H5UMZ:C]V%?N:P4B[9 UUAZXG'L M:FW3/>E"#4$@XP83@0A'G@=KRY;4]%R;S@I0]3VBN3(&]MZ9<1SU>Q,X=@YW M9@A+ #3:>,>0HU@B2TK* JHZNRBF&5R?B*I6KLDXBA&=Y"TE7Y-!E!+">ZM- MT):=I=H:)2UDVM!8+*2S&MP=16LU"I/*-V,_+"S!,K7+!OE<+><(,\]+*DKF XQ7_?=T=GF]AL+N'N=&:>X5+I(",5$NPT M#!*/:*&9,PH:N*$I-)2VZL:X7_G7/RT&L\49+).:L-IXKNIQ'#Z75;-*AYJ_ MFZ[/9!I<,L]?E$G%*,?".N.4%DI2Z$1)36949U5;?JR45AG;VC*)IE',H,I' M=CD+E%N/=IUJ]<1TG[MO^6PX#C/=MQ2.[BS#SBD#"?6(:.0\<%:YDBJ D10' M3?60,+F&^S2_B<<>24-,Q #Q2U4WFRX@@C'*4E+%VO9],I5U@RC+VSY=;_F,BA M0(H43%/A& ?( 5K2'S"1LKU]=RZWVC'?S?(\$A.]69,[C]7>]+$TM2[K&T5F MI!8 )L5F8YRUJ?38*B-TLTU??4D9J;-*Y,<,"]0HXX AQD M'@4^E;S2R*9LL!=;K*^'"[A'&#F7]7P^!BKE6#$KG7= T$!])['>T!][I5." MIKXS_VO?UVDSB.C]BGQ=F7IQF\\^WPXVE:OGOQ?3K_D\4*/AX,63!I(Q@S % MW@,,E;$,<2I*DP2'/Z K);AGR[%#YVP;?+V@5=;<&>.Q8\AHP ;W4&I.**.> M$*U!R0-H2,?.V9ZML(9AWOYJ/ D$Y[\0FP^F/'((F06,2TBMI= ;!B%7$)4< M ,I?6-&[[WX!)G'__-???ZU8U.GZ>SZ$C(*@+CD:K!+-C HB3^$RK DCB[N( M^_S\8QGV&@3GOPPW7JN.5^*K462$*HF)= AZR("D3HO2OXVQL"DZZ:D1I3\6 M8^]Q6^\I<>,-./,4^.QES0PU1H6[Y O^0F,[NQ(LF?+^2S< MJ0TR_GM:R#U?O1FRDGD+&49,2^T8=P)O.>=E2A;N]^RE;6;U]% *' F@\U_Z M>P,>>[+^CQQC)N-5+Y(+B"00&#I =;D-$0.2KJOX/GW$9[[\F\7/^8 2-9L \5%@:CH'UZ2,H$=Z(H2G&-75(HQ'!F?T4 M ,<,,,, @RAX\IC[@C71I;"",Y M090PHBQR$@!&+3<(^DK7$[RDV(X+$U^4%Y['>T1G7_-16 1^&3>96(LK7L&W M8M7GP!P=>O[SC;FG=)=YI:$F89MB\4928;3E$%#$+#:6&MU9C?P6,C':PDK1 M.IM:4R<.E,A^6C:NO+/K()SKZSPH82+PQ$LG# ]["9,*2*"1H,$L0Q:DW#;2 M]WS[EL'=&=.ZA/I3%>+IQ*(BL,9+6,QWZ\^28'_ZBS)IE.24(048IIQP 8'Q MG,0[%# F*B6BI.\I[3U: JTQL/WE4-/UK4>MC)K?F5F".0YJNW-64 ^X1-YB M"J3FP@HD4Q9)W]/&.U\DW?*R+?MK%HAY,QZ&>8RC=A?SUDVP> =?BDWJ>F>F MV-7L9A"HN1J%"0,I)N/1FN;3T805[%(JNE_\PZ;:6V M!&(/*4$XLA82J[RST-MJVU@S]'O"QJ_Y$U_#X\*J(MN.Z"4C89U92$U88I)B M@[6$4*"P""$"SJL4!U7?3;:6P52TQ:3>B*&.;U0^#V'$(0;010^_=HR$_XC8 M)' *K*BIM ";5LMV836R_/=B.MSQ]>?PTSS,<:N(5M+'ZGI9IBC7,JP6X9"E M&D+$@2TI"Y%1/T1;7=#J0\T7=G*D113OO1][[?-CWK5>*QK)23$MI%>:^'"]G M22['OB*I%O;MA\))Q*T1#(.7>M+.BV&/ZR"#@20<8 N,]M!P303<9/L(HF12 M)8(>75%<$U?W8Z0>$I\.FL&TN!X?P,639S+H%-<($DDII\AR3"DJQV6!2KD; MKZ^'$TW@X'22MN4KC1<;7UT_V3%W*"A[G\]8(( I0HAKQ4WY=R,2G+D M]Q4N/5)1ZN1-6[A[39_!VR0Y>,OYD3UED!-@ 06.4NN(HC8F\FWHX9QN-8&J M9:PF J1HD_ G[W6FN+O;G.5^6,Z&MX-YKFYF^6I4^W? PRTSCBTAL2BK\9Y; M'RQ:7 IQ"I&[9!] 8^PNFF3!R3#Z,"N*ZR((]: $W(?YC0>3_>C9V2 30B"+ MH-, 8T&=4^&#6SOKN+!60'DXW# M[+?Q))\OBFE^P# [KI?,0ART4001E XSQ(D5K)R;LCK%F.][\$0KJ&J4':?O M;N&1\?"0+'K^5"80UE9;2"WRE!&FJ2ZM3&JPAA<<0M#.KI5"[K8T[AC-&=YU M&ZA@\Z_YI+A?:8"/U CR<^6G_UQ\R&?7Q>S.%[-5K/E7'WO>[('N^#(&: YSFRG [W6_C-D':) A.6O #2. M&R=*2< <4Y<".'R4?8PDVJ$6//L^ M \Y:11&B3 FN+=9LJQT'XJ!+#F+M@4*0PHO&\;-3G+UX(F-(,\L8\- 4(1:M5F M[)R"RV;^L>PKZB%BHP 8?#L,@*?/9"),7FIHJ-#*,82<%68[=BDN\8BQ%@ D M$+&U?)WEE_EX-![,'CX-5JE)T?U_P-NPLTUFC'-A2@AAR[%3W,2L_,TAKT(#F9*FQ?H.H.XWR3IYTRC>\IN7(]RY%^Y]/E/<.86\"THK M]R"L2\#+)2D0M.0"!59-3"[J)^]QD)GGP[_=%%]_'1;+Z6+V$%'#RU\B:/@3 MT&P^SO[X] 9"'K_,+ \0@Q4)!#BGAA ;> ME'0A"*9 O?KNO+UTK]FK1;H!U*MHA::9E!!-_XP ^6!]UT#^UBU7^QMDR! C MO?(0!0,=$>PTQ>6(E2$I-F=?-_A>H*Q6MK3G*2N&>3Z:K]=$.?9BMF^_W]DF M$\!:2[&R4&+ML0#8EN<>B@EPR87F>B'@ZN),0HC5FD,;26O"C^-%U$3435"U MYXMU?=/'H.[=T57']9,Q1H.93QFW7EBHF<"F5'24="XE K"'=?J[EW,-,Z@] M"^FU&O!^//@RG@1IL9G;8ZVYO3;0,1UEQGB!G7(&\QC(YKT'V^5H*+CDP]-> M",I&V=4>>+=)?.M"TK%N] &4OMDB$X1H@@Q6W#OKN3+<;><'F$\I?=/W8XJ> MP+$.OIR\:Y?UQE?5/[=YH;/Q,/^0SU8#VK5/'VZ92>8AT ("'&-@B(-0\>W: M(3+E2*+O#IWNM^G:^=.!;#MT8U@G=[5"HUSP""P! L(6 :KVYWH:5'2%.F M4P2:_ &O@_Z5)IC4"W/C5.LB0X9!!90)_$2$"*K,-KQ+FR#=4_S(X '\ZAX9;#[G< MKB7D=%+^Y(_#C4/ ;)-WIZ.V>!A,%@]AJ0PCEV_6%TE<37_/%S&F=:?+^5"[ MS&GMF(*(PF"16^N08^4!CI9!PTW!WH_3C8/8JY<]C_!JM-C^\LL\_]CZ'%FOHO!U*A3/ZN)AEA48&FT#*OJ0-!GPG[$.9* 2V0Z?(:CI=#KG2A MT*XVF87:>:>H@A)0XZ#4B"H58 69E)1=6,0T%DJB2-M_*+ _>//'&XYD/=CX( M]JS*PQ1C*J MR]DYA3M;LRTOT\I,WK],3Z%I6ZZ4>@HJ4^XPPEK2H"-0ZKPQ7(2Y!8II;!@! M%XV7(]E;J0KR<01M"RS=54%V2&N&C.3&46A\)YI':EC)*9& -19CDXS"&F,ISOJ/262 MNRT!9?,OBW?3L'LO*VQEKQ_.@L1VA >9C:RUP@-'G-T(<:4Q3P%1DEOL#/:Q M9&IV@Y&8E'VP8,*N)AD46'EML$!<4^2U,\B5,\167)B>G,+BO6@YF:(G;SZ? M\]G=^V(PW;_?/'\J0\9RJQW7T'H4K )&!2K'9J#I[#ZJ-KA]"HN*NDAY,IM] ML9PM;E68P.AP*TR((L)(S&="<'.8<&D'4+F<.VE M76TRRCSW$E+#7##Q(&$*L7*.&'97VDOG:)F6-YO!\U)U&U(\2\KU!18%>3C (2M"P C! R M2&K'M"A7F5$4I"@U/4SS:G*+.I6FK:$FAGC>%I/ F[G[UW*\>/B]6.3K%(G[ MR3A6"_\:OHK!GY&3'SDP^!AY5OX:S ;7=VO/)CN6RPT M/X^+]I_Y^.9VD8]4F/?@)M]\DZ\2,?8!MYT19%88J\(^!)0%6@J,1.#$AOZ0 M^LYNH3T7O/>232?['C[,\OOU(#\&,HUGJRD4U]$)$O/*-[4&!;5":N(".1@MQR1L M4NY64M[].:#A9#*>S-K-K0IF,+^-_EU3A%D,IF^%O>U[/ -(8J:$Y\[ZL(OCN8#Z.5,(IB9S4Z=1?+=.[61JKW MD5&$B0::0\R 0LA0^KA1&N=3G)E)V>KG@)4&"9V0$[Q]__K%9G _7@PFJ_E6 M$2J5.\B\9AX1XP@B G%AN76E%>NO#PC[BQ /%+( MCN?#23%?SO(*X>%O-\B8\XZ%75U@'A:D%H(2)B$1.AB=TK!*-Z@W,\/WQ?0F MDCD.O$I:QYO/9XY+!PE1V$)/E6$J %(@I %U# "?Y.@48S]MFC@)LD6>$X6!66LR!P.4\E$]*\^[AX6<; $DB<#- MT0E T>6UL HJ3S5T@4H> $$8*44JQ0BGU$'JX5%EBT YC=)Q$R;;P\;Z8CHKINVF@[9?!],^K MZ\"/?!2'_?Z=OOIX,'JZ4OL,*L22N4(QAX!*$'1"'G>#D_"""Z9,6F3M_*J11M31B%\5U= MKZ_J\(/AJCKI;X-O\5!6%[-9\5?0SC#S4$FNM)-:(00T M]UR6I@,S!J84*NZ].GPZ&&HA9ELRYND-5(^7#UPM;O/9T_/#/>*E8@^9XAXB MP9V$@G!K"*:4E//'D*4H/4?O6E^#_E"<"9R:I7,WVL]*@\OGBZBYK>X"'SW6 M":VL$.WK),-40D*M)4![CY1G3&ZIH#5/.:;L81AQW5AKC-#=P$T/YN/YI\"T MP>AJ^M0%5K6+3$!,C&+$\/"'2>.#R5%2P,,DIU$/8Y2;A5IM9#X]@G55 MLOVZF'V8C:?#\?U@,IB.RA6P":G>G4A3I7%&I$ <&!#K6DE&E',0;&;"%8;>W#R40S8_S@8KRZQGMWD.\.;][7)0%#[(&54(BL MMYE4FK"'$(&;#%L]%)1^9)-V"= 2YJIFTSV/C\5W$2-D*[+.CL0$G+ 342&!/D'I-; M62?2SB*2+J,Z=W <3]RD4 KW;3&>WBS'\]L#V95O/IPA8QP(>C22D@K*C8>R M%'%"49I4<@Y6UT!Y' 9[2RH2"L8=L%^ MX!IHV;UWSEU?Y\-X2U"B@^Z-?C*KXS7)2CJ/@'.&!XM^2XNP8I*VGMX?9#;I MI$LG=KMY/WZY6,[RK4E6VF&7D@X$K8:((*$\U)1SK7BP*85FP7A0&E:KF=+7 M=""L)//8!JU&:$JI5-($D]E!!(.J$W!]>>?%*0RND YT'$'/)1U(>?1V1_'$?C\@B>1QD0YRA$WC'*)%,<.2:*9(U$3ONCTH3IWHE,IVH6CX[=! ML"_&BW$^_U@Z[.97UUM[XV,>UU1@X=6U#\K=8/)_\\&!(.^DKC/J*3:,"XZ5 MH! 3C61@AP2,<&UUFK.M[Q@\ 3=[_"DMD+^'@'TWC?-XV^N?TETFD==,0&B! M]C001RM$ '6">Z(-1RD>F=X+QU:!>2K)^PO&\/9]OH/3.LQ,H'Y0>H,AC2%5 M*IC3S@;%V%+(E-$^)1S]C#R$[0'R!*+W^>3" X288DPK("D40E C8/C-.IH4@B#C'22BL%#1(= M5G/[% S$T7*27UT_BI&KZV<%QB(+JA1Z.[:KC&,$"?6<$4*HX$!9"DPLLX2D M4CHI;Z"GRG(*-%Z6NF^6VA66^>:+^->7P3S_CW_[_P%02P$"% ,4 " #W MC&A-B?/ZV_GQ >9PP $0 @ $ _P &UL M4$L! A0#% @ ]XQH35'3"6:R- K'0" !4 ( !/10! M ')G;',M,C Q.# Y,S!?9&5F+GAM;%!+ 0(4 Q0 ( />,:$VIMBN8)(D M "+2!@ 5 " 2)) 0!R9VQS+3(P,3@P.3,P7VQA8BYX;6Q0 M2P$"% ,4 " #WC&A-3CCN#3-. "0S@, %0 @ %YT@$ K&UL4$L%!@ & 8 B@$ -\@ @ $! end

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2018	Nov. 02, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3
Trading Symbol	RGLS
Entity Registrant Name	REGULUS THERAPEUTICS INC.
Entity Central Index Key	0001505512
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		8,750,343
Entity Small Business	false
Entity Emerging Growth Company	false

Condensed Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 14,084	$ 13,519
Short-term investments	6,433	46,555
Contract and other receivables	13	373
Prepaid materials, net	4,194	4,783
Prepaid expenses and other current assets	717	1,506
Total current assets	25,441	66,736
Property and equipment, net	8,324	9,708
Intangibles, net	676	775
Other assets	327	590
Total assets	34,768	77,809
Current liabilities:
Accounts payable	1,235	5,743
Accrued liabilities	1,856	2,995
Accrued compensation	1,292	1,985
Current portion of term loan, less debt issuance costs	19,069	19,859
Current portion of contract liabilities	72	0
Other current liabilities	2,130	2,018
Total current liabilities	25,654	32,600
Contract liabilities, less current portion	24	1,921
Deferred rent, less current portion	7,139	8,072
Other long-term liabilities	373	0
Total liabilities	33,190	42,593
Commitments and Contingencies
Stockholders’ equity:
Common stock, $0.001 par value; 200,000,000 shares authorized, 8,750,343 and 8,662,435 shares issued and outstanding at September 30, 2018 (unaudited) and December 31, 2017, respectively	9	9
Additional paid-in capital	385,793	381,199
Accumulated other comprehensive loss	(63)	(134)
Accumulated deficit	(384,161)	(345,858)
Total stockholders’ equity	1,578	35,216
Total liabilities and stockholders’ equity	$ 34,768	$ 77,809

Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (shares)	200,000,000	200,000,000
Common stock, shares issued (shares)	8,750,343	8,662,435
Common stock, shares outstanding (shares)	8,750,343	8,662,435

Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues:
Total revenues	$ 18	$ 18	$ 54	$ 54
Operating expenses:
Research and development	6,879	12,697	28,720	42,727
General and administrative	2,993	2,736	10,115	13,752
Total operating expenses	9,872	15,433	38,835	56,479
Loss from operations	(9,854)	(15,415)	(38,781)	(56,425)
Other income (expense):
Interest and other income	201	160	483	559
Interest and other expense	(620)	(580)	(1,848)	(1,730)
Loss before income taxes	(10,273)	(15,835)	(40,146)	(57,596)
Income tax benefit	0	7	0	139
Net loss	(10,273)	(15,828)	(40,146)	(57,457)
Other comprehensive loss:
Unrealized gain (loss) on short-term investments, net	16	(16)	70	19
Comprehensive loss	$ (10,257)	$ (15,844)	$ (40,076)	$ (57,438)
Net loss per share, basic and diluted (in dollars per share)	$ (1.18)	$ (2.11)	$ (4.62)	$ (10.52)
Weighted average shares used to compute basic and diluted net loss per share (in shares)	8,703,626	7,506,529	8,688,831	5,463,096
Revenue under strategic alliances and collaborations
Revenues:
Total revenues	$ 18	$ 18	$ 54	$ 54

Condensed Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
Condensed Statements of Cash Flows - USD ($) $ in Thousands	Sep. 30, 2018	Sep. 30, 2017
Operating activities
Net loss	$ (40,146)	$ (57,457)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization expense	1,672	1,942
Stock-based compensation	4,374	6,531
Amortization of premium on investments, net	92	271
Other	182	206
Change in operating assets and liabilities:
Contracts and other receivables	360	1,124
Prepaid materials	589	(360)
Prepaid expenses and other assets	1,050	2,405
Accounts payable	(4,509)	(579)
Accrued liabilities	(1,138)	(652)
Accrued compensation	(693)	(631)
Contract liabilities	(54)	(54)
Deferred rent and other liabilities	(1,035)	(418)
Net cash used in operating activities	(39,256)	(47,672)
Investing activities
Purchases of short-term investments	0	(48,539)
Sales and maturities of short-term investments	40,101	58,310
Purchases of property and equipment	(22)	(217)
Acquisition of intangibles	0	(16)
Net cash provided by investing activities	40,079	9,538
Financing activities
Proceeds from issuance of common stock, net	219	43,411
Proceeds from exercise of common stock options	2	4
Principal payments on other long-term obligations	(833)	0
Proceeds from capital lease financing	354	0
Net cash used in financing activities	(258)	43,415
Net increase in cash and cash equivalents	565	5,281
Cash and cash equivalents at beginning of period	13,519	14,941
Cash and cash equivalents at end of period	14,084	20,222
Supplemental disclosure of cash flow information
Interest paid	(1,573)	(1,444)
Income taxes paid	(1)	(1)
Supplemental disclosure of non-cash investing and financing activities
Non-cash acquisition of property and equipment	$ 306	$ 0

Net Loss Per Share	9 Months Ended
Net Loss Per Share	Sep. 30, 2018
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share Basic net loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of options outstanding under our stock option plans. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted net loss per share. Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive consisted of zero and 575,256 shares attributable to common stock options and restricted stock units ("RSUs") for the three and nine months ended September 30, 2018, respectively, compared to 106,597 and 210,816 shares attributable to common stock options for the three and nine months ended September 30, 2017, respectively.

Strategic Alliances and Collaborations	9 Months Ended
Strategic Alliances and Collaborations	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Strategic Alliances and Collaborations	Strategic Alliances and Collaborations Revenue recognized from our strategic alliances and collaborations was less than $0.1 million for each of the three and nine months ended September 30, 2018 and 2017. Sanofi In July 2012, we amended and restated our collaboration and license agreement with Sanofi to expand the potential therapeutic applications of the microRNA alliance targets to be developed under such agreement. We determined that the elements within the strategic alliance agreement with Sanofi should be treated as a single unit of accounting because the delivered elements did not have stand-alone value to Sanofi. The following elements were delivered as part of the strategic alliance with Sanofi: (1) a license for up to four microRNA targets; and (2) a research license under our technology alliance. In June 2013, the original research term expired, upon which we and Sanofi entered into an option agreement pursuant to which Sanofi was granted an exclusive right to negotiate the co-development and commercialization of certain of our unencumbered microRNA programs and we were granted the exclusive right to negotiate with Sanofi for co-development and commercialization of certain miR-21 anti-miRs in oncology and Alport syndrome. In July 2013, we received an upfront payment of $2.5 million, of which $1.25 million is creditable against future amounts payable by Sanofi to us under any future co-development and commercialization agreement we enter pursuant to the option agreement. Revenue associated with the creditable portion of this option payment was deferred as of December 31, 2017 and recorded as an adjustment to accumulated deficit upon our adoption of ASC 606 on January 1, 2018. The non-creditable portion of this payment, $1.25 million, was recognized as revenue over the option period from the effective date of the option agreement in June 2013 through the expiration of the option period in January 2014. In February 2014, we and Sanofi entered into a second amended and restated collaboration and license agreement (the “2014 Sanofi Amendment”) to renew our strategic alliance to discover, develop and commercialize microRNA therapeutics to focus on specific orphan disease and oncology targets. Under the terms of our renewed alliance, Sanofi has opt-in rights to our clinical fibrosis program targeting miR-21 for the treatment of Alport syndrome, our preclinical program targeting miR-21 for oncology indications, and our preclinical program targeting miR-221/222 for hepatocellular carcinoma (“HCC”). We are responsible for developing each of these programs to proof-of-concept, at which time Sanofi has an exclusive option on each program. If Sanofi chooses to exercise its option on any of these programs, Sanofi will reimburse us for a significant portion of our preclinical and clinical development costs and will also pay us an option exercise fee for any such program, provided that $1.25 million of the $2.5 million upfront option fee paid to us by Sanofi in connection with the June 2013 option agreement will be creditable against such option exercise fee. We are eligible to receive royalties on microRNA therapeutic products commercialized by Sanofi and will have the right to co-promote these products. In connection with the 2014 Sanofi Amendment, we entered into a Common Stock Purchase Agreement (the “Purchase Agreement”), pursuant to which we sold 1,303,780 shares of our common stock to Aventisub LLC (“Aventis”), an entity affiliated with Sanofi, in a private placement at a price per share of $7.67 for an aggregate purchase price of $10.0 million. Under the terms of the Purchase Agreement, Aventis was not permitted to sell, transfer, make any short sale of, or grant any option for the sale of any common stock for the 12-month period following its effective date. The Purchase Agreement and the 2014 Sanofi Amendment were negotiated concurrently and were therefore evaluated as a single agreement. Based upon restricted stock studies of similar duration and a Black-Scholes valuation to measure the discount for lack of marketability, approximately $0.4 million of the proceeds from the Purchase Agreement was attributed to the 2014 Sanofi Amendment, and represents consideration for the value of the program targeting miR-221/222 for HCC. We are recognizing the $0.4 million allocated consideration into revenue ratably over the estimated period of performance of the miR-221/222 program. As of September 30, 2018, contract liabilities associated with the Purchase Agreement and the 2014 Sanofi Amendment was $0.1 million, which we are expecting to recognize over the remaining estimated period of performance of approximately one year. We are eligible to receive milestone payments of up to $101.8 million for proof-of-concept option exercise fees (net of $1.25 million creditable, as noted above), $15.0 million for clinical milestones and up to $300.0 million for regulatory and commercial milestones. In addition, we are entitled to receive royalties based on a percentage of net sales of any products from the miR-21 and miR-221/222 programs which, in the case of sales in the United States, will be in the middle of the 10 to 20% range, and, in the case of sales outside of the United States, will range from the low end to the middle of the 10 to 20% range, depending upon the volume of sales. If we exercise our option to co-promote a product, we will continue to be eligible to receive royalties on net sales of each product in the United States at the same rate, unless we elect to share a portion of Sanofi’s profits from sales of such product in the United States in lieu of royalties.

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions We have entered into certain agreements with related parties in the ordinary course of business to license intellectual property and to procure research and development support services. In September 2014, we entered into an agreement with Sanofi-Aventis Deutschland GmbH (“Sanofi Deutschland”), a contract manufacturing subsidiary of Sanofi, for the manufacture of certain drug substance requirements and other services to support our preclinical and clinical activities associated with the RG-012 program. Pursuant to this agreement, we engaged Sanofi Deutschland to manufacture RG-012 drug product and perform stability studies on our behalf. Expenses incurred under the agreement for services performed or out-of-pocket expenses were less than $0.1 million for each of the three and nine months ended September 30, 2018 and 2017.

Basis of Presentation and Summary of Significant Accounting Policies (Narrative) (Details) $ in Millions	1 Months Ended
	Jul. 31, 2018	May 31, 2017 employee	Sep. 30, 2018 USD ($) employee	Jan. 01, 2018 USD ($)
Accounting Policies [Abstract]
Reduction of workforce	60.00%	30.00%
Number of employees \| employee		65	25
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents and marketable securities			$ 20.5
AOCI Including Portion Attributable to Noncontrolling Interest \| Accounting Standards Update 2014-09
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of new accounting principle in period of adoption				$ (1.8)

Basis of Presentation and Summary of Significant Accounting Policies (Effect of New Accounting Principle) (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Jan. 01, 2018	Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Deferred revenue (contract liabilities), non-current		$ 77
Accumulated deficit	$ (384,161)	(344,014)	$ (345,858)
Calculated under Revenue Guidance in Effect before Topic 606
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Deferred revenue (contract liabilities), non-current			1,921
Accumulated deficit			$ (345,858)
Accounting Standards Update 2014-09 \| Difference between Revenue Guidance in Effect before and after Topic 606
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Deferred revenue (contract liabilities), non-current		(1,844)
Accumulated deficit		$ 1,844

Net Loss Per Share (Detail) - shares	3 Months Ended		9 Months Ended
Net Loss Per Share (Detail) - shares	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Earnings Per Share [Abstract]
Potentially dilutive securities not included in calculation of diluted net loss per share (in shares)	0	106,597	575,256	210,816

Investments (Summary of Short-Term Investments) (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Debt Securities, Available-for-sale [Line Items]
Amortized cost	$ 6,439	$ 46,632
Unrealized Gains	1	0
Unrealized Losses	(7)	(77)
Estimated fair value	$ 6,433	$ 46,555
Corporate debt securities
Debt Securities, Available-for-sale [Line Items]
Maturity (or less) (in years)		1 year
Amortized cost		$ 32,922
Unrealized Gains		0
Unrealized Losses		(55)
Estimated fair value		$ 32,867
Certificates of deposit
Debt Securities, Available-for-sale [Line Items]
Maturity (or less) (in years)	1 year	1 year
Amortized cost	$ 2,440	$ 8,216
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated fair value	$ 2,440	$ 8,216
U.S. Treasury securities
Debt Securities, Available-for-sale [Line Items]
Maturity (or less) (in years)	1 year	1 year
Amortized cost	$ 3,999	$ 3,996
Unrealized Gains	1	0
Unrealized Losses	(7)	(18)
Estimated fair value	$ 3,993	$ 3,978
Debt securities of U.S. government-sponsored agencies
Debt Securities, Available-for-sale [Line Items]
Maturity (or less) (in years)		1 year
Amortized cost		$ 1,498
Unrealized Gains		0
Unrealized Losses		(4)
Estimated fair value		$ 1,494

Fair Value Measurements (Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis) (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	$ 20,064	$ 57,402
Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	13,631	10,847
Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	6,433	46,555
Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	0	0
Corporate debt securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis		32,867
Corporate debt securities \| Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis		0
Corporate debt securities \| Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis		32,867
Corporate debt securities \| Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis		0
Certificates of deposit
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	2,440	8,216
Certificates of deposit \| Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	0	0
Certificates of deposit \| Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	2,440	8,216
Certificates of deposit \| Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	0	0
U.S. Treasury securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	3,993	3,978
U.S. Treasury securities \| Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	0	0
U.S. Treasury securities \| Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	3,993	3,978
U.S. Treasury securities \| Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	0	0
Debt securities of U.S. government-sponsored agencies
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis		1,494
Debt securities of U.S. government-sponsored agencies \| Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis		0
Debt securities of U.S. government-sponsored agencies \| Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis		1,494
Debt securities of U.S. government-sponsored agencies \| Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis		0
Cash equivalents
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	13,631	10,847
Cash equivalents \| Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	13,631	10,847
Cash equivalents \| Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	0	0
Cash equivalents \| Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	$ 0	$ 0

Term Loan (Details)			1 Months Ended
Term Loan (Details)	Jun. 22, 2016 USD ($)	Jun. 17, 2016 USD ($) loan	Mar. 31, 2018	Sep. 30, 2018 USD ($)
Debt Financing Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 30,000,000.0
Number of term loans \| loan		2
Stated interest rate, percentage		8.51%
Period for principal and interest payments		24 months
Amended period for principal and interest payments			15 months
Unrestricted cash raised target				$ 30,000,000
Prepayment fee, option one				2.00%
Prepayment fee, option two				1.00%
Debt extinguishment fee				5.50%
Term loan, less debt issuance costs				$ 19,100,000
Debt instrument effective rate				8.98%
Debt Financing Agreement \| London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Basis spread on variable rate, percentage		0.44%
Debt Financing Agreement Tranche A
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 20,000,000.0
Proceeds from borrowing under term loan	$ 20,000,000
Term loan, less debt issuance costs				$ 19,167,000
Debt Financing Agreement Tranche B
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 10,000,000.0

Term Loan (Future Principal Payments) (Details) - Debt Financing Agreement Tranche A $ in Thousands	Sep. 30, 2018 USD ($)
Debt Instrument [Line Items]
Future Repayments of Principal, 2018	$ 1,917
Future Repayments of Principal, 2019	11,500
Future Repayments of Principal, 2020	5,750
Long-term Debt	$ 19,167

Stockholders' Equity (Common Stock Reserved for Future Issuance) (Detail) shares in Thousands	Sep. 30, 2018 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock options outstanding	1,134
Total common shares reserved for future issuance	1,419
Common stock available for future grant under 2012 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSUs outstanding	66
Common stock available for future grant	61
Common stock available for future grant under 2015 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock available for future grant	3
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock available for future grant	155

Stockholders' Equity (Stock Option and RSU Activity) (Detail) shares in Thousands	9 Months Ended
	Sep. 30, 2018 $ / shares shares
Number of options
Number of options, ending outstanding number (in shares)	1,134
Stock options
Number of options
Number of options, beginning outstanding number (in shares)	887
Number of options, Granted (in shares)	603
Number of options, Exercised (in shares)	(1)
Number of options, Canceled/forfeited/expired (in shares)	(355)
Number of options, ending outstanding number (in shares)	1,134
Weighted average exercise price
Weighted average exercise price, beginning balance (in dollars per share) \| $ / shares	$ 53.24
Weighted average exercise price, Granted (in dollars per share) \| $ / shares	11.70
Weighted average exercise price, Exercised (in dollars per share) \| $ / shares	4.56
Weighted average exercise price, Canceled/forfeited/expired (in dollars per share) \| $ / shares	$ 58.59
Restricted Stock Units (RSUs)
Number of RSUs
Shares outstanding (in shares)	35
Shares granted (in shares)	102
Shares vested in period (in shares)	(57)
Shares canceled in period (in shares)	(8)
Shares outstanding (in shares)	72
Weighted average grant date fair value
Beginning balance (usd per share) \| $ / shares	$ 10.68
Granted (usd per share) \| $ / shares	3.88
Exercised (usd per share) \| $ / shares	6.25
Canceled/forfeited/expired (usd per share) \| $ / shares	$ 7.57

Strategic Alliances and Collaborations (Detail)	1 Months Ended			3 Months Ended		8 Months Ended	9 Months Ended
Strategic Alliances and Collaborations (Detail)	Feb. 28, 2014 USD ($) $ / shares shares	Jul. 31, 2013 USD ($)	Jul. 31, 2012 target	Sep. 30, 2018 USD ($) shares	Sep. 30, 2017 USD ($)	Jan. 31, 2014 USD ($)	Sep. 30, 2018 USD ($) shares	Sep. 30, 2017 USD ($)	Jan. 01, 2018 USD ($)	Dec. 31, 2017 USD ($) shares
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues (less than)				$ 18,000	$ 18,000		$ 54,000	$ 54,000
Common stock, shares issued (shares) \| shares				8,750,343			8,750,343			8,662,435
Common stock value				$ 9,000			$ 9,000			$ 9,000
Deferred revenue									$ 77,000
Revenue under strategic alliances and collaborations
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues (less than)				100,000	$ 100,000		$ 100,000	$ 100,000
Sanofi
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of collaborative areas granted \| target			4
Deferred revenue	$ 400,000
Sanofi \| Private Placement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Common stock, shares issued (shares) \| shares	1,303,780
Price per share (in dollars per share) \| $ / shares	$ 7.67
Common stock value	$ 10,000,000
Restriction period in which Alliances could not sell, transfer, make any short sale of, or grant any option for the sale of any common stock	12 months
Sanofi \| Minimum \| United States
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalties based on percentage of net sales							10.00%
Sanofi \| Minimum \| Outside of the United States
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalties based on percentage of net sales							10.00%
Sanofi \| Maximum \| United States
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalties based on percentage of net sales							20.00%
Sanofi \| Maximum \| Outside of the United States
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalties based on percentage of net sales							20.00%
Sanofi \| Development Commercialization And License Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Initial upfront option payment		$ 2,500,000
Deferred revenue creditable against future milestones	$ 1,250,000	$ 1,250,000					$ 1,250,000
Upfront payment non-creditable portion recognized						$ 1,250,000
Sanofi \| Common Stock Purchase Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue				100,000			$ 100,000
Deferred revenue recognition period							1 year
Sanofi \| Proof-of-Concept Trial
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential revenue through milestone payments				101,800,000.0			$ 101,800,000.0
Sanofi \| Regulatory and Commercialization Milestones
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential revenue through milestone payments				300,000,000.0			300,000,000.0
Sanofi \| Clinical
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential revenue through milestone payments				$ 15,000,000.0			$ 15,000,000.0

Related Party Transactions (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Related Party Transactions (Detail) - USD ($) $ in Millions	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Sanofi
Related Party Transaction [Line Items]
Expenses incurred for services performed or out-of-pocket expenses under the Sanofi agreement (less than)	$ 0.1	$ 0.1	$ 0.1	$ 0.1

Subsequent Events (Details) - Subsequent Event	Oct. 02, 2018	Nov. 05, 2018 USD ($)	Oct. 15, 2018 $ / shares
Subsequent Event [Line Items]
Conversion ratio for reverse stock split	0.0833
Exercise price (usd per share) \| $ / shares			$ 4.56
Term Loan
Subsequent Event [Line Items]
Potential revenue through milestone payments		$ 6,800,000
Fourth Amendment
Subsequent Event [Line Items]
Prepayment requirement of loan from license fees		25.00%
Potential revenue through milestone payments		$ 10,000,000.0
Payment fee		5.50%
Minimum cash, debt covenant		$ 10,000,000.0
Proceeds debt covenant, conditional minimum amount		15,000,000
Conditional amount, capital event, debt covenant		5,000,000
Development Milestones \| Term Loan
Subsequent Event [Line Items]
Potential revenue through milestone payments		$ 40,000,000